<SEC-DOCUMENT>0000950123-19-009056.txt : 20190930
<SEC-HEADER>0000950123-19-009056.hdr.sgml : 20190930
<ACCEPTANCE-DATETIME>20190920172003
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-19-009056
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20190920
<PUBLIC-REL-DATE>20190930
DATE AS OF CHANGE:		20190920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02766
		FILM NUMBER:		191105436

	BUSINESS ADDRESS:	
		STREET 1:		501 NORTHWICK LANE
		CITY:			VILLANOVA
		STATE:			PA
		ZIP:			19085
		BUSINESS PHONE:		(610) 659-0200

	MAIL ADDRESS:	
		STREET 1:		501 NORTHWICK LANE
		CITY:			VILLANOVA
		STATE:			PA
		ZIP:			19085
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on
September&nbsp;20, 2019 as Amendment No.&nbsp;2 to the draft registration statement. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333&#150;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>The
Securities Act of 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-1685768</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Cabaletta Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>2929 Arch Street, Suite 600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Philadelphia, PA 19104 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">759-3100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Steven Nichtberger, M.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer and President </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>2929 Arch Street, Suite 600 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Philadelphia, PA 19104 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">759-3100</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell S. Bloom, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Michael J. Minahan, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Goodwin&nbsp;Procter LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>100 Northern Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02210</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Patrick O&#146;Brien, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Benjamin Kozik, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Ropes&nbsp;&amp; Gray LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>800 Boylston Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02199</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">951-7000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration
statement</B>. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to
Rule&nbsp;415 under the Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Accelerated</FONT> Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>TITLE&nbsp;OF&nbsp;EACH&nbsp;CLASS&nbsp;OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES&nbsp;TO&nbsp;BE&nbsp;REGISTERED</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>PROPOSED<BR>MAXIMUM<BR>AGGREGATE<BR>OFFERING&nbsp;PRICE(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT OF<BR>REGISTRATION&nbsp;FEE(2)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, par value $0.00001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. Includes the aggregate offering price of shares that the underwriters have the option to purchase to cover over-allotments, if any. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Registration fee will be paid when registration statement is first publicly filed under the Securities Act of
1933, as amended. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration
statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Arial Narrow"><FONT COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#cc062a"><I>SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2019 </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I>PRELIMINARY PROSPECTUS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </I></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g45x09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. This is our initial
public offering. Prior to this offering, there has been no public market for our common stock. We expect the initial public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. We have applied to list our common stock on The Nasdaq Global Market under the symbol &#147;CABA.&#148; </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>We are an &#147;emerging growth company&#148; under the federal securities laws and, as such, we have elected to comply with certain reduced public company
reporting requirements for this prospectus and future filings. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company.&#148; </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>Investing in our common stock involves a high degree of risk. Before buying any shares, you should carefully read the discussion of the material risks of
investing in our common stock under the heading &#147;<A HREF="#rom686907_2">Risk Factors</A>&#148; beginning on page&nbsp;12 of this prospectus. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities that may be
offered under this prospectus, nor have any of these organizations determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense</I></B><I>. </I></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>PER&nbsp;SHARE</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>TOTAL</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Public offering price</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Underwriting discounts and commissions (1)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Proceeds, before expenses, to Cabaletta Bio, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See &#147;Underwriters&#148; beginning on page&nbsp;191 of this prospectus for additional information
regarding the compensation payable to the underwriters. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We have granted the underwriters an option for a period of 30&nbsp;days
to purchase an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delivery of the shares of common stock is expected to be made on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" NOWRAP><I>MORGAN&nbsp;STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><I>COWEN</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><I>EVERCORE&nbsp;ISI</I></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </I></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_8">SELECTED&nbsp;FINANCIAL&nbsp;INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_13">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_18">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_19">UNDERWRITERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_20">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_21">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_22">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom686907_23">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor
the underwriters have authorized anyone to provide you with information different from, or in addition to, that contained in this prospectus, any amendment or supplement to this prospectus and any related free writing prospectus prepared by or on
behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurances as to the reliability of, any information that others may give you. This prospectus is not an offer to sell, nor is it
seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus or in any free writing prospectus is only accurate as of its date, regardless of its time of
delivery or the time of any sale of our common stock. Our business, financial condition, results of operations and future growth prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This
prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#146; trademarks, service marks, trade names or products in this
prospectus is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may appear without the&nbsp;&reg;,
&#153; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service
marks and trade names. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We have not, and the underwriters have not, done anything that would
permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must
inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerical figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in
various tables may not be arithmetic aggregations of the figures that precede them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in greater detail elsewhere in this prospectus. This summary does not contain all of the
information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto and the information set
forth under the sections titled &#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case
included in this prospectus. As used in this prospectus, unless the context otherwise requires, references to the &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Cabaletta Bio, Inc. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
focused on the discovery and development of engineered T&nbsp;cell therapies for B&nbsp;cell-mediated autoimmune diseases. Our proprietary technology utilizes <U>c</U>himeric <U>a</U>uto<U>a</U>ntibody <U>r</U>eceptor, or CAAR, T&nbsp;cells that are
designed to selectively bind and eliminate B&nbsp;cells that produce disease-causing autoantibodies, or pathogenic B&nbsp;cells, while sparing normal B&nbsp;cells. Our lead CAAR&nbsp;T cell product candidate was designed based on chimeric antigen
receptor, or CAR, T&nbsp;cell technology that has been successfully developed and is marketed for the treatment of B cell cancers. We believe our technology, in combination with our proprietary <U>C</U>abaletta <U>A</U>pproach for selective
<U>B</U>&nbsp;cell <U>A</U>blation platform, called our CABA platform, has applicability across over two dozen B&nbsp;cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. During the past two years, using our CABA
platform, we have discovered and developed four product candidates, including our lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris, or mPV, and three additional product candidates that have demonstrated specific
and selective target engagement <I>in vitro</I>. In order to accelerate product development for our lead program and to access a proven cell therapy manufacturing platform, we have entered into a collaboration with the University of Pennsylvania, or
Penn. We hold multiple agreements with Penn to develop CAAR&nbsp;T cell therapies for the treatment of these diseases. Our goal is to leverage our team&#146;s expertise in autoimmunity and engineered T cell therapy and our Penn collaboration to
rapidly discover and develop our portfolio of CAAR&nbsp;T product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial focus is on pemphigus vulgaris, or PV, which is
an autoimmune blistering skin disease. We submitted an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or the FDA, in August 2019 and, if our IND is accepted, plan to advance our lead product candidate,
DSG3-CAART, into a Phase&nbsp;1 trial for the treatment of mPV in 2020. We are also advancing additional product candidates currently in discovery-stage or preclinical development for the treatment of muscle-specific kinase myasthenia gravis, or
MuSK MG, mucocutaneous PV, or mcPV, and Hemophilia&nbsp;A with Factor&nbsp;VIII, or FVIII, alloantibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B&nbsp;cell-mediated
autoimmune diseases occur when certain populations of B&nbsp;cells mistakenly produce autoantibodies, which are directed against specific healthy tissue or cells in the body. The presence of autoantibodies can manifest in a variety of autoimmune
diseases and result in the destruction of healthy tissue in the body. Current treatment options for B&nbsp;cell-mediated autoimmune diseases are generally limited to corticosteroids and other generalized immunosuppressants that offer only temporary
disease suppression, may require chronic, <FONT STYLE="white-space:nowrap">in-hospital</FONT> administration and are associated with potentially life-threatening side effects. We believe the ideal therapy for B&nbsp;cell-mediated autoimmune diseases
would selectively and completely eliminate the pathogenic B&nbsp;cells while sparing the body&#146;s normal B&nbsp;cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
pioneering the development of a new class of engineered T&nbsp;cell therapies that express CAARs to selectively engage and eliminate pathogenic B&nbsp;cells. By harnessing the power of targeted cell therapy, we believe our CABA platform, as
developed by our team, has the potential to be a one-time curative therapy that may be a safer and more effective therapy option than current treatments. These efforts have attracted the support of many
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
leading investors, including Adage Capital Partners, 5AM Ventures, Boxer Capital, LLC of Tavistock Group, Cormorant Asset Management, Deerfield Management and RedMile Group as well Penn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a portfolio
of CAAR T cell product candidates for the treatment of B cell-mediated autoimmune diseases. Our lead product candidate, DSG3-CAART, targets B cells that express pathogenic autoantibodies against the DSG3 protein, which cause mPV. The publication of
the first <I>in vivo</I> evaluation of activity and toxicity of the product candidate in an animal model was followed by additional preclinical studies to support our planned IND submission. Upon acceptance of our IND, we plan to open the first
clinical trial site for our DSG3-CAART product candidate. Our next <FONT STYLE="white-space:nowrap">PV-directed</FONT> product candidate, <FONT STYLE="white-space:nowrap">DSG3/1-CAART,</FONT> is being designed to target B cells that give rise to
pathogenic autoantibodies against either the DSG3 or DSG1 protein, which cause mcPV, and could address a broader PV population. Our second product candidate, MuSK-CAART, is being designed to target B&nbsp;cells that give rise to pathogenic
autoantibodies against the MuSK receptor in patients with MG. An additional product candidate, FVIII-CAART, targets B&nbsp;cells that produce alloantibodies against exogenous FVIII in Hemophilia&nbsp;A patients who consequently require repeated and
increased exogenous FVIII administration. We are exploring additional CAAR&nbsp;T cell product candidates that will focus on patients with B cell-mediated autoimmune diseases with well-defined antibody targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below shows our CAAR T cell product candidates currently under development: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g63t24.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>May not be required if Phase&nbsp;2 is a registrational clinical trial. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing
engineered T cell therapy candidates that express CAARs, which serve as &#147;decoys&#148; for antibodies expressed on the surface of B cells. Our CAAR T platform is based on the foundation of established CAR T therapeutics, differing primarily in
their use of the antigen rather than an antibody fragment to target pathogenic B cells. We believe these CAARs enable the T cells to specifically engage and eliminate pathogenic B&nbsp;cells while sparing normal B&nbsp;cells. By harnessing the power
of cell therapy, our technology has the potential to overcome the ability of these B&nbsp;cells to evade elimination and thus lead to durable responses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast to currently available therapies for B cell-mediated autoimmune diseases, we believe our CAAR&nbsp;T cells can recognize the
specific autoantibodies that are responsible for causing an underlying disease </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and kill the cells that express the autoantibodies on their surface while preserving the rest of the humoral immune system. As a result, we believe CAAR&nbsp;T cell therapy used in B
cell-mediated autoimmune diseases has the potential for durable elimination of pathogenic B cells and an associated elimination of clinical recurrences with an improved adverse event, or tolerability, profile relative to the current standard of
care. We believe our technology has broad applicability, and we are building a portfolio of product candidates for B cell-mediated autoimmune diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our CABA Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed our
CABA platform to inform product candidate development from indication selection through preclinical studies. Using our CABA platform, our team has identified our highest priority target indications following a rigorous analysis of B cell-mediated
autoimmune diseases. A deep understanding of the antigenic epitopes targeted in these diseases is required to design and construct a successful CAAR, a competency that we believe we are uniquely positioned to utilize in product candidate
development. Finally, we evaluate preclinical activity and toxicity of our optimized CAAR constructs through <I>in vitro</I> and <I>in vivo</I> studies. We leverage the experience and insight gained from the development of each product candidate to
improve the efficiency of our CABA platform in evaluating additional potential product candidates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our History and Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientific <FONT STYLE="white-space:nowrap">co-founders,</FONT> Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., began partnering
at Penn in 2013 to combine Dr.&nbsp;Payne&#146;s expertise in B cell-mediated autoimmune diseases with Dr.&nbsp;Milone&#146;s deep and experienced insights into the design and implementation of CAR&nbsp;T products. Dr.&nbsp;Payne is a worldwide
leader in characterizing B cell-mediated autoantibody repertoires in PV and other autoimmune diseases. Dr.&nbsp;Milone is a renowned scientist in CAR&nbsp;T therapy and was a <FONT STYLE="white-space:nowrap">co-inventor</FONT> of and a key driver in
the preclinical discovery and development efforts that yielded Kymriah, the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> CAR&nbsp;T cell therapy for the treatment of B cell cancers. Dr.&nbsp;Payne&#146;s laboratory surmised that by
incorporating an antigen instead of an antibody fragment as the extracellular domain of the CAAR, specific pathogenic B cells could be targeted. This resulted in a collaboration between the two investigators to apply the scientific foundation of
CAR&nbsp;T technology in B cell-mediated autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D., our Chief Executive Officer and President, is an
adjunct professor at the Wharton School at the University of Pennsylvania and has experience creating and building companies, including a novel cellular therapy company, which required transferring technology from an academic institution,
establishing a </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development organization, hiring of manufacturing and quality teams, creating novel manufacturing processes, reaching agreement with the FDA on novel clinical development pathways
and constructing a commercial-scale Good Manufacturing Practices, or GMP, facility that manufactured autologous cell therapy products for clinical trials. In 2017, based on over a year of interaction and strategic discussions regarding development
of a commercial cell therapy product portfolio that could offer potentially curative treatment options to patients, Drs. Payne, Milone and Nichtberger decided to launch Cabaletta Bio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gwendolyn Binder, Ph.D., our Executive Vice President, Science and Technology, was an early member of the Translational Research Operations
team at Penn for over five years and participated in the submission and acceptance of multiple INDs for novel engineered T&nbsp;cell therapy products. In partnership with Dr.&nbsp;Milone, the two collaborated along with other members of the team at
Penn to drive the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> translational studies that facilitated the initial CAR&nbsp;T clinical trial in B&nbsp;cell cancers at Penn. Dr.&nbsp;Binder also built and led a clinical stage biotechnology
company&#146;s manufacturing operations and quality teams, including creation of a fully functioning commercial grade GMP facility. Dr.&nbsp;Binder also built the translational research program and ultimately led the company&#146;s research
organization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Research and Manufacturing Collaboration with Penn </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CABA platform has already produced multiple product candidates through our sponsored research agreements, or SRAs, with Penn for the
laboratories of our scientific <FONT STYLE="white-space:nowrap">co-founders,</FONT> Drs.&nbsp;Payne and Milone. Our contractual relationship with Penn through ongoing licensing and research arrangements also provides important services around
manufacturing supply. In July 2019, we amended and restated our worldwide license agreement with Penn to develop our CAAR&nbsp;T technology to treat B&nbsp;cell-mediated autoimmune and alloimmune diseases. This license agreement provides us with
access to multiple patent families covering CAAR&nbsp;T cell therapy as applied to the field of B cell-mediated autoimmune and alloimmune diseases and to the robust IP portfolio created by Penn under these SRAs in this field. Our ongoing
collaboration with Penn is also based on a Master Translational Research Services Agreement, or Services Agreement, that we entered into in October 2018, along with multiple additional agreements under the Services Agreement to engage and partner
with individual Penn entities, including cell product manufacturing, correlative research, vector manufacturing, clinical trial operations and protocol development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Penn is uniquely suited to be our partner in our efforts to develop product candidates leveraging our CAAR&nbsp;T technology based
on a decade of experience, including manufacturing and clinical support for approximately a dozen active cell therapy clinical trials. The original manufacturing process for the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> CAR&nbsp;T
cell therapy was developed at Penn before being transferred to Novartis Pharmaceuticals Corporation during late-stage clinical trials. We currently plan to leverage Penn&#146;s experience, validated standard operating procedures, manufacturing
facilities and staffing to accelerate initial development efforts for our lead product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to build upon our first mover advantage and expertise in cell therapies for B&nbsp;cell-mediated autoimmune diseases to accelerate
the discovery, development and commercialization of our CAAR&nbsp;T cell therapies, with a focus on reliable manufacturing. We believe achieving this goal could result in potentially curative therapies for patients with unmet medical needs who
suffer from certain B&nbsp;cell-mediated autoimmune diseases. To achieve this goal, key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Achieving clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> </I></B><B><I>for our lead product candidate, DSG3-CAART </I></B><B><I>in mPV, the first in a series of well-understood and validated B cell-mediated
autoimmune diseases for which we are</I></B> <B><I>developing CAAR&nbsp;T cell product candidates. </I></B>We believe our biologic understanding coupled with the </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
well-understood clinical signs, symptoms and natural course of the disease, identify mPV as a model disease to evaluate our CAAR&nbsp;T approach. In addition, we have designed and developed
DSG3-CAART, our lead product candidate that has demonstrated robust target engagement and no <FONT STYLE="white-space:nowrap">off-target</FONT> toxicities in preclinical studies. We believe our planned Phase&nbsp;1 clinical trial evaluating
DSG3-CAART for the treatment of mPV represents an optimal first opportunity to establish initial clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of our CABA platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging our CABA platform to identify optimal targets for the CAAR&nbsp;T approach and apply learnings
from DSG3-CAART to advance additional product candidates</I></B><B><I>.</I></B> Shortly after inception, we undertook a comprehensive review of all known B&nbsp;cell-mediated autoimmune diseases in order to evaluate and prioritize the opportunity
for selective destruction of B&nbsp;cells in an effort to cure B&nbsp;cell-mediated autoimmune diseases. We intend to continue to apply our proprietary learnings from DSG3-CAART, including scientific and regulatory learnings, to most effectively
advance these additional opportunities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expanding upon our established IP position and first mover advantage in CAAR&nbsp;T therapy targeted
towards B&nbsp;cell-mediated </I></B><B><I>autoimmune </I></B><B><I>diseases</I></B>. We believe there is a particularly high value to the first mover advantage including, but not limited to, experience in discovery, preclinical development,
regulatory efforts, intellectual property and insights from clinical trials that can be translated across programs. We are focused on protecting our intellectual property as we continue pursuing the development of future product candidates. We
believe the issued U.S. patent on our initial CAAR constructs is the first patent covering cells engineered to express the known pathogenic epitopes recognized by DSG3 and DSG1 autoantibodies, which we are continuing to supplement with additional
patent filings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging our cellular therapy experience and knowledge in addition to knowledge gained through our Penn
collaboration to rapidly build our own fully-integrated internal infrastructure.</I></B> We have differentiated expertise that we believe is uniquely suited for the continued buildout of our CABA platform specializing in B&nbsp;cell-mediated
autoimmune diseases. In combination with a management team possessing significant experience in executing on manufacturing strategies for cell therapy products, our partnership with Penn allows us to utilize their existing infrastructure to
accelerate our ability to submit our first IND. In parallel, we continue to build out an experienced team to develop and continue implementing a path to our manufacturing independence. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the section of this prospectus entitled &#147;Risk Factors&#148; beginning on page&nbsp;12. These
risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a preclinical-stage company with a limited operating history, have incurred significant losses since our
inception, and anticipate that we will continue to incur significant losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are highly dependent on our relationship with Penn for our preclinical research and development activities,
key technology and our current manufacturing needs for our Phase&nbsp;1 clinical trial of <FONT STYLE="white-space:nowrap">DSG3-CAART.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are reliant on intellectual property licensed to us by Penn and termination of our license agreement with Penn
would result in the loss of significant rights, which would have a material adverse effect on our business. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain sufficient intellectual property protection for DSG3-CAART, our other
product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will need to raise substantial additional funding before we can expect to
complete development of any of our product candidates or generate any revenues from product sales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to successfully develop our current programs into a portfolio of product candidates, or
experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could
be delayed or otherwise adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to advance our product candidates through clinical development, obtain regulatory approval and
ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results of earlier studies may not be predictive of future study or trial results, and we may fail to establish
an adequate safety and efficacy profile to conduct clinical trials or obtain regulatory approval for our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the
development of any of our product candidates, we may need to delay, abandon or limit our further clinical development of those product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manufacturing and administering our product candidates is complex and we may encounter difficulties in technology
transfer from Penn to a contract manufacturing organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products
before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may establish our own manufacturing facility and infrastructure in addition to or in lieu of relying on third
parties for the manufacture of our product candidates, which will be costly and time-consuming, and which may not be successful. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends in part upon our ability to retain our key employees, consultants and advisors and to
attract, retain and motivate other qualified personnel. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in April 2017 under the name Tycho Therapeutics, Inc. In August 2018, our
corporate name was changed to Cabaletta Bio, Inc. Our principal executive offices are located at 2929 Arch Street, Suite&nbsp;600, Philadelphia, PA 19104 and our telephone number is <FONT STYLE="white-space:nowrap">(267)&nbsp;759-3100.</FONT> Our
website address is www.cabalettabio.com. We do not incorporate the information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website to be part of this
prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended. As an emerging
growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements in addition to any required unaudited
interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any
golden parachute arrangements not previously approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from new or revised financial accounting standards until they would apply to private companies and
from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would
cease to be an emerging growth company on the date that is the earliest of: (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following the
fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a
large accelerated filer under the rules of the Securities and Exchange Commission. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly,
the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common&nbsp;stock&nbsp;offered&nbsp;by&nbsp;us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares in full)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to
purchase up to an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock from us at the public offering price, less underwriting discounts and
commissions on the same terms as set forth in this prospectus.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from the sale of shares of our common stock in this
offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase
additional shares in full, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after
deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, for: the
advancement of DSG3-CAART, our lead product candidate; the advancement of our other product candidates; establishment of our planned manufacturing facility; and working capital and other general corporate purposes. For a more complete description of
our intended use of the proceeds from this offering, see &#147;Use of Proceeds.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in our common stock involves substantial risks. You should read this prospectus
carefully, including the section entitled &#147;Risk Factors&#148; and the financial statements and the related notes to those statements included in this prospectus, before investing in our common stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;CABA&#148;</P></TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on
5,772,484 shares of our common stock outstanding as of June&nbsp;30, 2019, and gives effect to the conversion of all of our outstanding preferred stock into 19,356,835 shares of our common stock upon the completion of this offering, and excludes:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,435,545 shares of common stock issuable upon the exercise of stock options outstanding under our 2018 Stock
Option and Grant Plan, or 2018 Plan, as of June&nbsp;30, 2019, at a weighted average exercise price of $1.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">291,454 shares of common stock reserved for issuance under our 2018 Plan as of June&nbsp;30, 2019;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be reserved for
future issuance under our 2019 Stock Option and Incentive Plan to be effective upon the effectiveness of the registration statement of which this prospectus forms a part; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to be reserved for
future issuance under our 2019 Employee Stock Purchase Plan to be effective upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">gives effect to
a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reverse stock split of our common stock effected
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes no exercise of the underwriters&#146; option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock in this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">gives effect to the automatic conversion upon the completion of this offering of all of our outstanding shares of
preferred stock into an aggregate of 19,356,835 shares of common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes the filing of our amended and restated certificate of incorporation and the effectiveness of our amended
and restated bylaws, which will occur upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following tables summarize our financial and operating data for the periods indicated. The summary statements of operations and
comprehensive loss data for the period from April 3, 2017 (inception) to December&nbsp;31, 2017 and for the year ended December 31, 2018 have been derived from our audited financial statements included elsewhere in this prospectus. The summary
statements of operations and comprehensive loss data for the six months ended June&nbsp;30, 2018 and June&nbsp;30, 2019 and the summary balance sheet data as of June&nbsp;30, 2019 have been derived from our unaudited financial statements included
elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the interim data reflect all normal recurring adjustments necessary for the fair presentation of the financial
information in those statements. The summary financial information below should be read in conjunction with the information contained in &#147;Selected Financial Information,&#148; &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations,&#148; our financial statements and notes thereto, and other financial information included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected
in the future, and results for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2019 are not necessarily indicative of the results to be expected for the full year ending December&nbsp;31, 2019. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,663,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,548,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,448,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing pro forma net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447,398</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,768,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Notes&nbsp;2 and 10 to our audited financial statements and Notes&nbsp;2 and 10 to our unaudited interim
financial statements included elsewhere in this prospectus for a description of how we compute basic and diluted net loss per share and basic and diluted pro forma net loss per share, and the weighted-average number of shares used in the computation
of these per share amounts. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our financial statements and related
notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma amounts give effect to the automatic conversion of all of our outstanding shares of preferred stock
into an aggregate of 19,356,835 shares of common stock upon the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pro forma as adjusted amounts reflect the pro forma adjustments described in footnote&nbsp;2 above as well as
the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information discussed above is illustrative only and will change based on the actual
initial public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price
range set forth on the cover of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted
amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price
remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of
the other information in this prospectus, including our financial statements and the related notes, before you make an investment decision. The occurrence of any of the events or developments described below could harm our business, financial
condition, results of operations and growth prospects. As a result, the market price of our common stock could decline, and you may lose all or part of your investment in our common stock. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses over the next
several years, and may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly
speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become
commercially viable. We have only recently acquired rights to license the patents underlying our product candidates and do not plan to initiate our first clinical trial until 2020. We have no products licensed for commercial sale, and we will
continue to incur significant research and development and other expenses related to our ongoing operations. Our net losses may fluctuate significantly from quarter to quarter and year to year. We have to date financed our operations primarily
through private placements of our preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we are not profitable and have incurred net losses in each period since
our inception. For the years ended December&nbsp;31, 2017 and December&nbsp;31, 2018, we recorded net losses of $0.3&nbsp;million and $12.2&nbsp;million, respectively, and for the period ended June&nbsp;30, 2019, we recorded net losses of
$6.9&nbsp;million. As of June&nbsp;30, 2019, we had an accumulated deficit of $22.0&nbsp;million. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if, and as, we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and development efforts and submit Investigational New Drug applications, or INDs, for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct preclinical studies and clinical trials for our current and future product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further develop our product candidate platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional clinical, scientific manufacturing and commercial personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial
quantities of any product candidates for which we may obtain regulatory approval, whether through a contract manufacturing organization, or CMO, or through a manufacturing facility that we establish; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies,
including advanced manufacturing and translational capabilities that we will need for the further development and possible commercialization of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for any product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to support the sales and marketing of any product
candidates for which we may obtain marketing approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts, as well as to support our transition to a public company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing, and eventually
commercializing, a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of our
product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the
preliminary stages of most of these activities and have not yet demonstrated our ability to successfully develop any product candidate, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our
behalf, or conduct sales and marketing activities necessary for successful product commercialization. We may never be able to develop, manufacture or commercialize a marketable product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to succeed in these activities, we may never generate revenues that are significant enough to achieve profitability.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses
will increase if, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are any delays in completing our clinical trials or the development of any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are required by the U.S. Food and Drug Administration, or the FDA, or other regulatory authorities to perform
trials or studies in addition to, or different than, those expected; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are any third-party challenges to our intellectual property or we need to defend against any intellectual
property-related claim. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we
will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other
unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had
and will continue to have an adverse effect on our stockholders&#146; equity and working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating
history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability, and we may face significant challenges and expense as we test our product candidates and build our capabilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are early in our development efforts and we have not initiated clinical trials for any of our product candidates. We were
incorporated in 2017 and initially acquired rights to license certain patent rights from the University of Pennsylvania, or Penn, in August 2018. We have a limited operating history and are subject to the risks inherent to any newly-formed
organization, including, among others, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have <FONT STYLE="white-space:nowrap">in-house</FONT> resources sufficient to enable our <U>c</U>himeric
<U>a</U>uto<U>a</U>ntibody <U>r</U>eceptor, or CAAR, T cell platform. We are reliant on several manufacturing and support services from Penn through a Master Translational Research Services Agreement, or the Services Agreement, as well as certain
research and development and general and administrative services through two sponsored research agreements. We also rely on Penn for access to key technologies for current manufacturing of our product candidates. As we build our own capabilities, we
expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein. Our ability to rely on services from Penn is limited to a specified
period of time, to specific capabilities, and is subject to Penn&#146;s right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminate these services with or without cause. If we are unable to establish necessary relationships with third party partners and build our own capabilities, our operating and financial results
could differ materially from our expectations, and our business could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our programs require additional preclinical research
and development, clinical development, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we
generate any revenue from product sales. Other programs of ours require additional discovery research and then preclinical and clinical development. In addition, our product candidates must be licensed for marketing by the FDA before we may
commercialize any product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our limited operating history, particularly in light of the rapidly evolving cell therapy field, may make it
difficult to evaluate our technology and industry and predict our future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and
difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will fluctuate
significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our shareholders should not rely upon the results of any quarterly or annual period as an indicator of future
operating performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as an early-stage company, we have encountered and may continue to encounter unforeseen expenses,
difficulties, complications, delays and other known and unknown circumstances. As we advance our product candidates, we will need to transition from a company with a research focus to a company capable of supporting clinical development and if
successful, commercial activities. We may not be successful in such a transition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have not generated any revenue from our
product candidates and may never be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we or any potential future collaborator must
develop and eventually commercialize products with significant market potential at an adequate profit margin after cost of goods sold and other expenses. All of our product candidates are in the early stages of development and we will require
additional preclinical studies, clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product
sales. DSG3-CAART, our most advanced product candidate, targeting pathogenic B&nbsp;cells in patients with mucosal pemphigus vulgaris, or mPV, has not yet been evaluated in clinical trials. Our other product candidates, which include <FONT
STYLE="white-space:nowrap">DSG3/1-CAART,</FONT> targeting pathogenic B cells in patients with mucocutaneous pemphigus vulgaris, or mcPV, MuSK-CAART, targeting pathogenic B cells in a subset of patients with myasthenia gravis, or MG, and FVIII-CAART,
for potential use as an adjunctive therapy targeting a subset of patients with Hemophilia A who develop alloantibody resistance to Factor VIII, or FVIII, replacement therapy, have yet to complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT>
studies. We have not yet administered any of our product candidates in humans and, as such, we face significant translational risk as our product candidates advance to the clinical stage. Our ability to generate revenue depends on a number of
factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more
than we currently anticipate and will depend substantially upon the performance of third-party academic and commercial contractors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies and successfully submit INDs
or comparable applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we are required by the FDA to conduct additional clinical trials or other studies beyond those planned to
support the licensure and commercialization of our product candidates or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate to the satisfaction of the FDA the safety, potency, purity and acceptable risk to
benefit profile of our product candidates or any future product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence, duration and severity of potential side effects or other safety issues experienced with our
product candidates or future product candidates, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing and processing our product candidates being greater than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timely receipt of necessary marketing approvals from the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product
candidates or future product candidates to treat B cell-mediated autoimmune diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and
commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with current Good
Manufacturing Practices, or cGMP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully develop a commercial and competitive strategy and thereafter commercialize our
product candidates or any future product candidates in the United States, if licensed for marketing, reimbursement, sale and distribution, whether alone or in collaboration with others; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient demand for our product candidates and any future product candidates, if licensed; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and enforce intellectual property rights in and to our product candidates or any future
product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the factors listed above are beyond our control and could cause us to experience
significant delays or prevent us from obtaining regulatory approvals or commercialize our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever.
If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Additionally, even if
we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to research, develop and market additional product candidates. Our failure to become and
remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could
cause you to lose all or part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen expenses, difficulties, complications, delays and other
unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had
and will continue to have an adverse effect on our stockholders&#146; equity and working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial
additional financing to develop and commercialize our product candidates and implement our operating plans. If we fail to obtain additional financing or cannot obtain financing at the levels we require, we may be delayed in our plans or unable to
complete the development and commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash
since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates, including our planned Phase 1 clinical trial of DSG3-CAART, our initial <I>in vitro</I> studies and
expected <I>in vivo</I> studies of MuSK-CAART, and our planned studies for <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> as well as research and development, preclinical studies and clinical trials for FVIII-CAART and any future product
candidates, to seek regulatory approvals for our product candidates, to enable commercial production of our products, if licensed, and to initiate and complete registration trials for multiple products. Further, if licensed, we will require
significant additional amounts of cash to launch and commercialize our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, we had approximately $75.3&nbsp;million of cash and cash
equivalents. We estimate that our net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that the net proceeds from this offering together with our existing cash,
cash equivalents and marketable securities will be sufficient to fund our operations for at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, we have based this estimate on assumptions
that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our
control. We may require substantial additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities, and may need to raise additional funds sooner if we choose
to expand more rapidly than we presently anticipate. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and
any approved marketing and commercialization activities. Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical development plans we establish for these product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of product candidates that we may develop or
<FONT STYLE="white-space:nowrap">in-license;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any collaboration agreements we may choose to conclude; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third
parties against us or our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of establishing and maintaining a supply chain for the development and manufacture of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of establishing, expanding and scaling manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of maintaining the amount patient data for which we would be responsible following commercialization of
one or more of our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we
may receive regulatory approval in regions where we choose to commercialize our products on our own. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be
certain that additional funding will be available on acceptable terms, or at all. Until we are able to generate sufficient revenue to finance our cash requirements, we will need to finance our future cash needs through a combination of public or
private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us,
we may have to significantly delay, scale back or discontinue our research and development initiatives. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are
less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the above events could significantly harm our business, prospects, financial
condition and results of operations and cause the price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business, Technology and Industry
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are very early in our development efforts. All of our product candidates are still in preclinical development. If we are
unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are very early in our development efforts. None of our product candidates have entered clinical development. Our ability to generate product
revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Even if we are able to develop and commercialize a
marketable product, we may face challenges generating revenue from product sales. The success of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies resulting in data that is supportive of advancing to an IND
submission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful submission of INDs or comparable applications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful initiation of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of adequate safety to progress to a therapeutic dose level; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt and related terms of regulatory and marketing approvals and licensures from applicable regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers for
clinical supply and commercial manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with various medical divisions across hospitals for administration of our product candidates,
including with cancer treatment centers to conduct leukapheresis and with the relevant hospital divisions to perform infusion; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical
and commercial supplies of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution and patient administration capabilities and launching commercial
sales of our products, if and when licensed, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if and when licensed, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies targeting the same indications as our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining third-party coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of our products following licensure. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or be unable to
successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our engineered CAAR T product candidates represent a novel approach to the treatment
of B cell-mediated autoimmune diseases, which creates significant challenges for us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline of CAAR T
product candidates that are intended for use in treating individuals with B cell-mediated autoimmune disease. Advancing these novel product candidates creates significant challenges for us, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing our product candidates to our specifications and in a timely manner to support our clinical trials,
and, if licensed, commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sourcing clinical and, if licensed, commercial supplies for the materials used to manufacture our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">understanding and addressing variability in the quality and quantity of a subject&#146;s T cells, which could
ultimately affect our ability to manufacture clinical supply and, if licensed, commercial supply of our product candidates in a reliable and consistent manner; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">educating medical personnel regarding the potential side effect profile of our product candidates, if licensed,
such as the potential adverse side effects related to pemphigus flare from infusion of activated T cells or medication taper, cytokine release syndrome, or CRS, or other unexpected adverse effects of therapy with our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating patient access to the limited number of facilities able to administer our product candidates, if
licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">using medicines to manage adverse side effects of our product candidates that may not adequately control the side
effects and/or may have a detrimental impact on the efficacy of the treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially utilizing preconditioning agents in patients to enhance engraftment in advance of administering our
product candidates, which may increase the risk of adverse side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining regulatory approval for our product candidates, as the FDA and other regulatory
authorities have limited or no experience with development of engineered T cell therapies for the treatment of B cell-mediated autoimmune diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of
a novel therapy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing costs of inputs and other supplies while scaling production. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, preclinical murine and other animal models may not exist or be adequate for some or all of the B cell-mediated autoimmune
diseases we choose to pursue in our programs, and because we have not commenced clinical trials of any of our product candidates, we are unable to predict whether there may be short-term or long-term effects from treatment with any product
candidates that we develop. In developing our product candidates, we have not exhaustively explored different options in the method for manufacturing CAAR T cells. We may find our existing manufacturing process may be substantially improved with
future design or process changes, necessitating further clinical testing, delaying commercial launch of our first products, and causing us to incur additional expenses. For example, while we have used a lentiviral vector in our manufacturing
process, we may in the future find that another viral vector or <FONT STYLE="white-space:nowrap">non-viral</FONT> vector-based process offers advantages. Switching from one lentiviral vector to another or switching from lentiviral to another
delivery system would necessitate additional process development and clinical testing, and this may delay the development of existing product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not know the doses to be evaluated in pivotal trials or, if licensed, commercially. Finding a suitable dose may delay our
anticipated clinical development timelines. Our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors. We may experience delays in
developing a sustainable, reproducible and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our product candidates on a timely
or profitable basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our product candidates may not perform successfully in clinical trials or may be associated
with adverse events that distinguish them from the chimeric antigen receptor T, or CAR T, therapies that have previously been licensed. For instance, subjects in our clinical trials will be infused with our proposed therapies, and may possess
strongly activating soluble antibodies, which, when they interact with our infused product candidates, could result in potential adverse side effects, such as CRS, which are not experienced with CAR T cell products for cancer. Unexpected side
effects or clinical outcomes would significantly impact our business. Adverse side effects caused by even one of our product candidates could negatively affect our ability to develop future product candidates based on our CABA platform. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Two of our current product candidates, <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> and FVIII-CAART, will and certain of our
future product candidates may require introducing large transgenes into T cells, and lentiviral vectors may have too limited a genome capacity to accomplish this process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently use lentiviral vector transduction for transgene delivery. However, lentiviral vectors have a limited genome capacity that
restricts the size of the transgene that can be delivered using this vector system. For example, designing a lentiviral vector that will have sufficient capacity to introduce DSG3 CAAR and DSG1 CAAR together into T&nbsp;cells may not be possible. In
addition to reducing lentiviral vector titers that may substantially increase the cost of gene transfer, it may be entirely unsuccessful, thus necessitating use of alternative strategies for transfer of these larger transgenes into T cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may have serious and potentially fatal targeting of cells within the body due to unexpected protein interactions
with the CAAR. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have completed multiple preclinical studies designed to screen for toxicity caused by unintended <FONT
STYLE="white-space:nowrap">off-target</FONT> recognition by the cell binding domain of the DSG3 CAAR, our product candidates may still recognize and react with one or more proteins unrelated to the intended surface immunoglobin target protein to
which it is designed to link. If unexpected binding occurs in normal tissue, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse events, undesirable side effects, toxicities or
unexpected characteristics. Detection of any unexpected targeting may halt or delay any ongoing clinical trials for our product candidates and prevent or delay regulatory approval. While we have developed a preclinical screening process to identify
cross-reactivity of our product candidates, we cannot be certain that this process will identify all potential tissue that our product candidates may target. For example, a membrane protein array with DSG3-CAART yielded one weak signal against a
protein that is designed to bind to glycoproteins and which was detected in both the test and control conditions. Further analysis of this protein in confirmatory cell-based assays repeatedly demonstrated that DSG3-CAART does not recognize nor
activate against this protein. However, this further analysis may prove to be inaccurate. Any unexpected targeting that impacts patient safety could materially impact our ability to advance our product candidates into clinical trials or to proceed
to marketing approval and commercialization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patients receiving T cell-based immunotherapies, such as our product candidates, may
experience serious adverse events, including neurotoxicity, CRS and killing of cells other than the intended B cells that express the autoantibodies. If our product candidates are revealed to have high and unacceptable severity and/or prevalence of
side effects or unexpected characteristics, their clinical development, regulatory approval, and commercial potential will be negatively impacted, which will significantly harm our business, financial condition and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates are CAAR T cell-based immunotherapies. There is a possibility that our product candidates could have adverse side
effects, such as neurotoxicity and CRS. In other similarly designed cellular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immunotherapies to treat cancer, there have been life threatening events related to severe neurotoxicity and CRS requiring intense medical intervention, such as intubation or medications to
support blood pressure, and in several cases, resulted in death. Severe neurotoxicity is a condition that is currently defined clinically by cerebral edema, confusion, drowsiness, speech impairment, tremors, seizures or other central nervous system
side effects, when such side effects are serious enough to lead to intensive care. CRS is a condition that is currently defined clinically by certain symptoms related to the release of cytokines, which can include fever, chills and low blood
pressure, when such side effects are serious enough to lead to intensive care with mechanical ventilation or significant medications to support blood pressure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results of our studies could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA. In some cases,
side effects such as neurotoxicity or CRS have resulted in clinical holds of ongoing clinical trials and/or discontinuation of the development of the product candidate. Given that the autoimmune and alloimmune diseases we are seeking to treat are,
in some cases, less serious than the later stage cancers being treated with other immunotherapy products, we believe the FDA and other regulatory authorities likely will apply a different benefit-risk assessment thresholds such that even if our
product candidate demonstrated a similar safety profile as current CAR T therapies, the FDA may ultimately determine that the harmful side effects outweigh the benefits and require us to cease clinical trials or deny approval of our product
candidates. We believe tolerance for adverse events in the patient population being pursued with CAAR T cell therapies will be lower than it is in oncology, and the risks of negative impact from these toxicities may therefore be higher for us than
for CAR T programs in oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, treatment-related side effects could also affect patient recruitment or the ability of
enrolled patients to complete the studies or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell-based
immunotherapies are not normally encountered in routine medical care. Medical personnel may need additional training regarding T cell-based immunotherapy product candidates to understand their side effects. Inadequate training in recognizing or
failure to effectively manage the potential side effects of T cell-based immunotherapy product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to side effects caused by our product candidates, the preconditioning, administration process or related procedures, which we
evaluate from time to time as part of our process improvement and optimization efforts, may also cause adverse side effects. For example, severe neurotoxicity has been noted to be associated with the use of certain lymphodepleting regimens. While we
believe there are sufficient data from other CAR T programs to suggest that it is reasonable for us to initiate our first clinical trial of DSG3-CAART without a preconditioning regimen, we cannot be certain that a preconditioning regimen, with or
without lymphodepleting agents, will not be required. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Although we plan to infuse DSG3-CAART without preconditioning initially in
our planned Phase&nbsp;1 clinical trial of DSG3-CAART, we may in the future use a preconditioning regimen for our CAAR T cell product candidates, which may increase the risk of adverse side effects and impact our ability to accurately assess the
efficacy of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In oncology patients receiving CAR T cell therapy, a lymphodepleting preconditioning regimen
is typically used to condition the patient prior to CAR T cell infusion in order to improve tumor immunogenicity and to promote the expansion of the infused CAR T cells. Together, these effects have been shown to enhance the clinical activity of CAR
T cells in oncology patients. These regimens often include cyclophosphamide and fludarabine and are usually administered within the week prior to infusion of CAR T cells. Serious adverse events have been observed in some patients following CAR T
cell infusion, and these include infection, cytokine release syndrome and neurotoxicity. The preconditioning regimen may contribute to the occurrence and severity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of these adverse events due to its role in inducing lymphopenia, or low levels of lymphocytes in the blood, and enhanced CAR T cell activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lymphodepleting preconditioning may not be required in all oncology settings for CAR T cell activity. A recent clinical trial in multiple
myeloma patients published in 2019 in <I>The Journal of Clinical Investigation </I>showed similar clinical activity of CAR T cell infusions in patients with or without a lymphodepleting preconditioning regimen. Furthermore, the requirement for
lymphodepleting preconditioning for potentiating engineered T cell therapy outside of oncology has not been well established. Specifically, the effect on tumor immunogenicity is not relevant in settings outside oncology, and therefore the
contribution of this aspect to the potential enhancing effect of preconditioning would not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there is evidence to suggest
that our CAAR T product candidates may be functional in target autoimmune patient populations without a preconditioning regimen. First, CAR T cells are functional in the absence of preconditioning as described above. Second, long term-term
persistence of engineered T cell therapy in the setting of HIV patients without conditioning across three independent studies was reported in 2012 in <I>Science Translational Medicine</I>, where CAR T cells were detected in 98% of samples tested for
at least 11&nbsp;years after infusion. Third, our CAARs differ from CARs used in oncology in that they are designed to target antibodies rather than tumor antigens. Also, the profile of the autoimmune patients we intend to treat will differ from
oncology patients in many ways, including the presence of circulating autoantibodies capable of binding to and driving expansion of the CAAR T cells. Finally, we believe there are multiple approaches to improve persistence of engineered T cells
which may be safer for autoimmune patients including multiple infusions, and incorporation of <I>in vivo</I> cytokine support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, a lymphodepleting regimen may eliminate pathogenic B cells targeted by our CAAR T cell product candidates. As a result, any lymphodepleting regimen for preconditioning that we use may adversely affect our ability to use DSG3 autoantibody
titers, a standard clinical assay, to assess the activity of DSG3-CAART. An inability to use DSG3 autoantibody levels to demonstrate the specific activity of our CAAR T cell product candidates may require us to rely on the objective measurement of
blister formation in patients, which can be a less sensitive and accurate measurement of CAAR T cell activity. This therefore could delay efficient clinical development. As a result of these factors, including the concern that lymphodepletion may
confer a potential increased safety risk to an autoimmune patient population, we believe the inclusion of such a regimen must be justified by clinical data demonstrating the need for it in the setting of autoimmune patients and is therefore
difficult to justify in our first-in-human studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We therefore plan to initiate our Phase&nbsp;1 trial of DSG3-CAART without a
preconditioning regimen, subject to FDA feedback on our proposed clinical trial design and our IND becoming effective. If clinical data suggest that a preconditioning regimen is advisable, or if FDA requires that we employ a preconditioning regimen,
we may employ such a regimen. If we ultimately use a preconditioning regimen, with or without lymphodepleting agents, prior to infusing patients with our CAAR T cell product candidates, our clinical patients may experience increased or more severe
adverse effects specifically related to the preconditioning regimen, some of which may result in death. These undesirable side effects, whether associated with the preconditioning regimen alone or in combination with our CAAR T cell product
candidates, could cause delays in patient enrollment in our clinical trials, could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a change to our clinical trial design, a more restrictive label or
the delay or denial of regulatory approval by the FDA. Any of the foregoing may increase the duration and expense of the clinical development of our product candidates or limit market acceptance of such product candidates, if approved, any of which
could have a material adverse effect on our business and financial condition. Even if we do not use a preconditioning regimen, patients may experience adverse effects related to our CAAR T cell product candidates, and our decision to design our
clinical trials without preconditioning does not eliminate the risk of those side effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cellular therapies are a novel approach and negative perception or increased
regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cellular therapies in general, and CAAR T cell therapies in particular, remain novel therapies, with no immunotherapies licensed to date in the
United States or the European Union to treat autoimmune diseases or alloimmune responses. CAAR T cell therapies may not gain the acceptance of the public or the medical community. For example, CAR Ts and other cellular therapies have in some cases
caused severe side effects, including death, and their broader use may therefore be limited. Even if CAR Ts and other cellular therapies are accepted by the public and medical community in the short term, long-term adverse events observed in these
therapies may increase negative perception and regulatory scrutiny. Although our CAAR Ts are different from CAR Ts and other cellular therapies, they may be viewed in the same vein, limiting their market acceptance. Public perception may be
influenced by claims that gene therapy, including the insertion of a transgene, is unsafe, and products incorporating gene therapy may not gain the acceptance of the public or the medical community. The patient populations targeted by our product
candidates are also typically not at risk of near-term death, even if they may suffer life-threatening symptoms, so patients will need to deem the benefits of cell therapy to be worth the risk of unknown potential adverse side effects. Our success
will depend upon physicians who specialize in the treatment of B cell-mediated autoimmune diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing
treatments with which they are more familiar and for which greater clinical data may be available. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity,
as well as any other adverse events in the field of cellular therapies, could result in a decrease in demand for any product that we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, responses by agencies at the federal and state level to negative public perception or ethical concerns may result in new
legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. The FDA has expressed interest in further regulating biotechnology
products, such as cellular therapies. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other government entities or governing agencies have also expressed interest in further
regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of cellular therapy products conducted by others may cause the FDA or other
oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us
to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval
limitations or restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the clinical study requirements of the FDA and other regulatory agencies and the criteria they use
to determine the safety, potency and purity of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as
ours is less clear, and can be more complex and consequently have higher development risk, be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the FDA for
existing cell therapies treating B cell-mediated diseases, such as Kymriah (Novartis Pharmaceuticals Corporation) and Yescarta (Gilead Sciences, Inc.), may not be indicative of what the FDA may require for approval of our therapies. Approvals by any
regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. As we advance our product candidates, we will
be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may
result in a review and approval process that is longer than we otherwise would have expected. More restrictive statutory regimes, government regulations or negative public opinion would have an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any
products we may develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business is highly dependent on the success of our initial product candidates targeting B
cell-mediated autoimmune diseases, particularly DSG3-CAART. All of our product candidates will require significant additional preclinical and clinical development before we can seek regulatory approval for and launch a product commercially.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and future success depend on our ability to obtain regulatory approval of, and then successfully launch and
commercialize our initial product candidates targeting B cell-mediated autoimmune diseases, including DSG3-CAART, MuSK-CAART, <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> and others that may be selected from preclinical programs. Our product
candidates are in the early stages of development and will require additional preclinical studies, clinical trials, regulatory review and licensure, substantial investment, access to sufficient commercial manufacturing capacity and significant
marketing efforts before we can generate any revenue from product sales. There is no guarantee that we will be able to advance our product candidates through clinical development or obtain marketing approval for any of our product candidates. The
process for obtaining marketing approval for any product candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval as planned, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to initiate a Phase 1 clinical trial for DSG3-CAART in 2020, if our planned IND is accepted by the FDA. DSG3-CAART has only been
administered in murine models to date, and such results may not be predictive of the results of our planned clinical trial or any future clinical trials. Because DSG3-CAART is the first product candidate that we plan to test in the clinic, we may
experience preliminary complications surrounding regulatory acceptance of our planned IND, trial design, protocol establishment and execution, establishing trial protocols, patient recruitment and enrollment, quality and supply of clinical doses, or
safety issues. For example, while the majority of oncology CAR T clinical trials have been conducted with a lymphodepleting or other preconditioning regimen prior to infusion, we do not intend to use
<FONT STYLE="white-space:nowrap">pre-infusion</FONT> lymphodepletion or other preconditioning regimen initially in our planned Phase&nbsp;1 trial. However, we may determine that use of a lymphodepleting or other preconditioning regimen is necessary
for our product candidates to be successful, which could result in delays in clinical development and will expose patients to the associated risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a failure of our planned clinical trial of DSG3-CAART could influence physicians&#146; and regulators&#146; opinions with regard
to the viability of our CABA platform more broadly, particularly if treatment-related side effects are observed. The occurrence of any of these risks could significantly harm our development plans and business prospects. If treatment-related side
effects are observed with the administration of DSG3-CAART, or if it is viewed as less safe, potent or pure than other therapies, our ability to develop other CAAR T cell therapies may be significantly harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent
their regulatory approval, limit their commercial potential or result in significant negative consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable or
unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA.
Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a
significantly larger number of patients exposed to the drug. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of
our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensed CAR T cell therapies and those under development have shown frequent rates of CRS
and neurotoxicity, and adverse events have resulted in the death of patients. Similar adverse events could occur during treatment with our CAAR T cell product candidates. For example, activation of CAAR T cells by patient autoantibodies or
alloantibodies could stimulate CRS. When CAAR&nbsp;T cells are infused and the CAAR binds to soluble antibodies in the blood or tissues of treated patients, these soluble antibodies may trigger the CAAR, resulting in an activation of the immune
system that is too high, leading to CRS. Further, it is possible that patients will exhibit acute rejection of the CAAR T cells because of preexisting immunity to the antigen within the CAAR. This could render our product candidates ineffective.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If unacceptable toxicities or health risks, including risks inferred from other unrelated immunotherapy trials, arise in the development
of our product candidates, we could suspend or terminate our trials or the FDA, the Data Safety Monitoring Board, or DSMB, or local regulatory authorities such as institutional review board, or IRBs, could order us to cease clinical trials.
Competent national health authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects
to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally
encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using CAAR T cell product candidates to understand the side effect profile of our product candidates for both our preclinical
studies and clinical trials and upon any commercialization of any of our product candidates, if licensed. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of
these occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our planned preclinical studies and
clinical trials may fail to demonstrate the safety, potency and purity of any of our product candidates, which would prevent or delay regulatory approval and commercialization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex
and expensive preclinical testing and clinical trials that our product candidates are safe, potent and pure for use in each target indication. Clinical trials are expensive and can take many years to complete, and their outcomes are inherently
uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any
post-approval studies of our product candidates. In addition, initial success in any clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of
product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency and purity profile despite having progressed through preclinical studies and initial clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to
lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been
caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to
obtain FDA or EMA approval. Most product candidates that commence clinical trials are never approved as products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any preclinical studies
or clinical trials that we may conduct may not demonstrate the safety, potency and purity necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are
inconclusive with respect to the safety, potency and purity of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some
instances, there can be significant variability in safety, potency or purity results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in
protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. For example, because our CAAR&nbsp;T cell product candidates
only target approximately 0.01% to 1% of the B cells in a patient, they may not engage enough of the target to achieve adequate engraftment necessary for elimination of all pathogenic B cells. Insufficient safety or potency in clinical trials may
delay product development to enable time to modify the product candidate for next generation approaches or make manufacturing changes or may lead us to discontinue development of the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, for DSG3-CAART, <FONT STYLE="white-space:nowrap">MuSK-CAART</FONT> and any future trials that may be completed, we cannot
guarantee that the FDA will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA to support a marketing
application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline or preliminary data from any preclinical studies or clinical trials that we conduct may change
as more data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on a pre-IND interaction with the FDA, we expect our initial clinical trial for our lead product candidate will be open-label. From time
to time, we may publicly disclose preliminary or topline or data from our preclinical studies and clinical trials, which will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject
to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the
opportunity to fully and carefully evaluate all data. Additionally, we expect that in our planned Phase 1 clinical trial of DSG3-CAART, the product candidate will be administered by intravenous infusion, using a fractionated-dose infusion scheme of
escalating numbers of DSG3-CAART cells. Because of the fractionated-dose infusion scheme, if we release topline results from our planned Phase&nbsp;1 clinical trial, they may differ from the final data we observe once all dose levels have been
administered within the initial cohort. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the topline results&nbsp;that we report may differ from future results of the same
studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being
materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from planned interim analyses in
our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse
differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock after this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory agencies, including the FDA, may not accept or agree with our assumptions, estimates, calculations, conclusions or
analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain approval for, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience as a company in conducting clinical trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our key employees have significant experience in leading clinical development programs, we have no experience as a company in
conducting clinical trials. In part because of this lack of experience, we cannot be certain that our ongoing preclinical studies will be completed on time or that our planned preclinical studies and clinical trials will begin or be completed on
time, if at all. Any clinical trial that we conduct, including our planned Phase 1 clinical trial of DSG3-CAART, will require significant financial and management resources and reliance on third-party clinical investigators, contract research
organizations, or CROs, and consultants. For example, the coordination of the clinical trial sites for our Phase 1 clinical trial of DSG3-CAART will be conducted by a CRO. Relying on third-party clinical investigators, CROs and consultants may force
us to encounter delays and expenses that are outside of our control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to file INDs to commence clinical trials on
the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We submitted an IND to the FDA to
initiate a clinical trial of DSG3-CAART targeting mPV in August 2019. The timing of submissions on future product candidates will be dependent on further preclinical and manufacturing success. We cannot be sure that submission of an IND or IND
amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that would cause us or the FDA to suspend or terminate such clinical trials. Additionally, even if such regulatory authorities
agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect or at
all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical trials will
be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing,
and our future clinical trials may not be successful. Events that may prevent successful or timely completion of clinical development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology or other <I>in vivo</I> or <I>in vitro</I> data to
support the initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in developing suitable assays for screening patients for eligibility for clinical trials with respect to
certain product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with the FDA and other regulatory agencies on trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical study sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining required institutional review board, or IRB, approval at each clinical trial site;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including
after review of an IND submission or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to
patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in treating one or more patients, once enrolled, due to their inability to accommodate parts of the
complex study procedures schedule; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties or us to adhere to clinical trial requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on our recourse in our CRO relationship with Penn as compared to a CRO that is not an academic
institution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s good clinical practice, or GCP, requirements or applicable
regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development
or commercialization partner for the manufacture of product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a trial or return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers
to meet our quantity or quality requirements for necessary raw materials; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of
our product candidates for use in clinical trials or the inability to do any of the foregoing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to
successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required
to, or we may elect to, conduct additional trials to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our product candidates and products, if licensed, have patent
protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the DSMB for such trial or by the FDA or other
regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a
clinical trial due to a number of factors, including failure to conduct </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities
resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the initiation, conduct or completion of any clinical trial of our product candidates
will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a
delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. In the event we identify any additional product candidates to pursue, we cannot be sure that
submission of an IND will result in the FDA allowing clinical trials to begin in a timely manner, if at all. Any of these occurrences may significantly harm our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Monitoring safety of patients receiving our product candidates will be challenging, which could adversely affect our ability to obtain
regulatory approval and commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our planned clinical trials of DSG3-CAART and our other product
candidates, we expect to continue to contract with Penn and other academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. In the future, we may also contract with <FONT
STYLE="white-space:nowrap">non-academic</FONT> medical centers and hospitals with similar capabilities. Nonetheless, these centers and hospitals may have difficulty observing patients, including due to failure by patients to comply with
post-clinical trial <FONT STYLE="white-space:nowrap">follow-up</FONT> programs, and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to
more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using
DSG3-CAART and our other product candidates, if licensed, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of DSG3-CAART and our other product candidates
may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter
difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials
in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting an adequate number of suitable patients to participate in a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining IRB approval at each clinical trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial and whether the FDA agrees to the design and implementation of the trial;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate
being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of dose-limiting toxicity in the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product
candidates or trial completion; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of patients to meet the complex <FONT STYLE="white-space:nowrap">follow-up</FONT> requirements of the
clinical trial. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that
are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial
being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites may also be used by some of our competitors, which may reduce the number of patients who are available for
our clinical trials in that clinical trial site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because our product candidates represent a departure from more commonly used
methods for B cell-mediated autoimmune disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as corticosteroids or systemic immunosuppressive medications, rather than enroll patients in our
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our planned clinical
trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials are expensive, time-consuming and difficult to design and implement. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory
requirements. Failure or delay can occur at any time during the clinical trial process. Because our CAAR T cell product candidates are based on new technologies, we expect that they will require extensive research and development and have
substantial manufacturing and processing costs. In addition, costs to treat patients with PV and other B cell-mediated autoimmune diseases and to treat potential side effects that may result from our product candidates can be significant.
Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our planned initial Phase 1 clinical trials for each of our product candidates will be pilot dose escalation studies with a limited
number of patients. The activity and toxicity data from these clinical trials of our product candidates may differ from future results of Phase 2 and/or Phase 3 clinical trials that enroll a larger number of patients. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the number of patients that we plan to dose in our planned Phase 1 clinical trial of DSG3-CAART is small, the results from such clinical
trial, once completed, may be less reliable than results achieved in larger </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates.<B><I><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></I></B>In our planned Phase 1
clinical trial of DSG3-CAART, we plan to evaluate the toxicity profile of DSG3-CAART and establish the recommended dose for the next clinical trial. The preliminary results of clinical trials with smaller sample sizes, such as our planned Phase 1
clinical trial of DSG3-CAART, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader
patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty
that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of DSG3-CAART, we may not achieve a statistically significant result or the same level of
statistical significance, if any, that we might have anticipated based on the results observed in our initial Phase 1 clinical trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior
treatments and may be small. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our projections of both the number of people who have the B cell-mediated autoimmune diseases we are
targeting, as well as the subset of people with these diseases in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These
estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence
of these B cell-mediated autoimmune diseases. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment
with our product candidates. For instance, we expect our lead product candidate, DSG3-CAART, to initially target a small patient population that suffers from mPV. Even if we obtain significant market share for our product candidates, because the
potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital,
we must prioritize development of certain product candidates, which may prove to be wrong and may adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may
fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new
product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product
candidates, yet fail to yield results for clinical development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential indications and/or product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other
characteristics that indicate they are unlikely to be effective drugs; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources than we will possess to identify additional therapeutic
opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and human resources, we intend to initially focus on
research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a
greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates
or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other
potential programs that ultimately prove to be unsuccessful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to develop additional product candidates, our commercial
opportunity will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our core strategies is to pursue clinical development of additional product candidates beyond
DSG3-CAART, MuSK-CAART, <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> and FVIII-CAART. Developing, obtaining regulatory approval and commercializing additional CAAR T cell product candidates will require substantial additional funding beyond
the net proceeds of this offering and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the
development process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive FDA approval to market additional product candidates for the treatment of B cell-mediated
autoimmune diseases, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully
develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any
other, or result in losing approval of any approved, product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The product candidates we plan to develop and commercialize
are premised on offering a potential cure for B cell-mediated autoimmune diseases, which may result in a high degree of uncertainty related to pricing and long-term demand for our product. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our target patient populations are relatively small. Because of this pricing and demand for our product candidates, if licensed, may not be
adequate to support an extended period of commercial viability, which could adversely affect our continued ability to successfully produce and market our product or any <FONT STYLE="white-space:nowrap">follow-on</FONT> products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely upon Penn for our manufacturing needs, and we intend to rely on other third parties for our future manufacturing needs
prior to establishing our own manufacturing facility. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently reliant upon Penn for our cell product manufacturing for
our lead product candidate, DSG3-CAART. In parallel with initiating our first clinical trial, we plan to establish a relationship with a CMO to help secure the manufacturing supply chain for future product candidates. We will need to develop
relationships with suppliers, increase the scale of production and demonstrate comparability of the material produced at these facilities to the material that was previously produced. Transferring manufacturing processes and <FONT
STYLE="white-space:nowrap">know-how</FONT> is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific
requirements of a given facility. We would expect additional comparability work will also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant <FONT
STYLE="white-space:nowrap">know-how</FONT> and data has been adequately incorporated into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the manufacturing process until the completion of studies (and the related evaluations) intended to demonstrate the comparability of material previously produced with that generated by any CMO
that we engage for our manufacturing needs. If we are not able to successfully transfer and produce comparable product candidates, our ability to further develop and manufacture our product candidates may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to eventually establish our own manufacturing facility. While the addition of our own manufacturing facility would provide us with
future flexibility within our manufacturing network, we still may need to identify additional CMOs for continued production of supply for some or all of our product candidates. Given the nature of our manufacturing processes, the number of CMOs who
possess the requisite skill and capability to manufacture our CAAR T cell immunotherapy product candidates is limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we may
not be able to achieve clinical manufacturing and cell processing through Penn on a timely basis, on our own or at any future CMO. While our current manufacturing process is based off the validated process developed at Penn for CD19 CAR T, or
CART19, we have limited experience as an organization in managing the CAAR T engineering process. Finally, because clinical manufacturing and cell processing is highly complex, we cannot be sure that the manufacturing processes employed by Penn, any
CMO that we engage in the future, or by us at a manufacturing facility that we establish will consistently result in T cells that will be safe and effective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are to operate our own manufacturing facility, significant resources will be required and we may fail to successfully operate our
facility, which could adversely affect our clinical trials and the commercial viability of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we establish
our own manufacturing facility, our operations will be subject to review and oversight by the FDA and the FDA could object to our use of our manufacturing facility. We must first receive approval from the FDA prior to licensure to manufacture our
product candidates, which we may never obtain. Even if licensed, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMPs and other government regulations. Our
license to manufacture product candidates will be subject to continued regulatory review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cost of goods development is at an early
stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biopharmaceutical products is complex and requires significant expertise, and can be impacted by resource
constraints, labor disputes and workforce limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of biopharmaceutical products is complex and requires
significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial
production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified
personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities upon which we currently or will rely,
such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates, whether by
Penn, by a third-party CMO, or at any manufacturing facility that we may establish, will not occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penn, third-party CMOs
that we engage or we may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in
loss of usable product or prevent or delay the delivery of product candidates to patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penn, third-party CMOs that we engage, or we may also experience manufacturing difficulties
due to resource constraints, labor disputes or workforce limitations arising from the expanding need for manufacturing in the cell therapy field and the limited number of training programs for technical staff. If we were to encounter any of these
difficulties, our ability to provide our product candidates to patients would be jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing and
sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to
generate product revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or distribution capabilities and as a company have no experience
in marketing pharmaceutical products. We intend to develop an <FONT STYLE="white-space:nowrap">in-house</FONT> marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have
to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Additionally, there are risks involved with establishing our own sales, marketing and distribution capabilities. For
example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or
does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will need to pursue collaborative
arrangements regarding the sales and marketing of our products, if licensed. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective
sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. Our product revenues and profitability, if any, are likely to be lower than if we were to market, sell and distribute any products
that we develop ourselves. In addition, we may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We
also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
can be no assurance that we will be able to develop <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United
States or overseas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition from other biotechnology and pharmaceutical companies, and our operating
results will suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical and pharmaceutical industries are characterized by
rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research
organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as novel therapies that may gain regulatory approval in the future. Many of our
competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources
being concentrated in our competitors. We believe we are the first and only company developing CAAR T drug candidates for the treatment of B cell-mediated autoimmune diseases. However, despite the significant differences in discovery, development
and target populations between oncology and autoimmune targets, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recognize that companies with an investment and expertise in CAR T cell development for oncology indications could attempt to leverage their expertise into B cell-mediated autoimmune disease
affected populations. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with
collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop
proprietary technologies or secure patent protection that we may need for the development of our technologies and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically,
while rituximab is the first drug for the treatment of PV, the target indication of our lead product candidate, DSG3-CAART, to have received regulatory approval in the United States in over 60&nbsp;years, we are aware that multiple biopharmaceutical
companies have therapies in clinical development. We are aware that Affibody AB, Alexion Pharmaceuticals, Inc., argenx SE, Immunovant, Inc., Momenta Pharmaceuticals, Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., Principia Biopharma Inc. and
Rubius Therapeutics, Inc., among others, are developing treatments for PV. We are also aware of other biopharmaceutical companies developing therapies for muscle-specific kinase myasthenia gravis, or MuSK MG, and Hemophilia&nbsp;A patients who
develop alloantibodies against FVIII. While we do not expect these product candidates to be directly competitive to our product candidates, even if we obtain regulatory approval of our product candidates, the availability and price of these other
products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of
physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional
information regarding our competition, see &#147;Business&#151;Competition&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive biotechnology and
pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific, and medical personnel, including our Chief Executive
Officer and President, our Scientific Advisory Board members, our Chief Medical Officer, our Executive Vice President, Science and Technology, and our Chief Financial Officer. The loss of the services of any of our executive officers, other key
employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on
acceptable terms or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be
significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our
management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for
<FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#147;key person&#148; insurance policies on the lives of these
individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior managers as well as
junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior scientific and medical personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to grow the size of our organization, and we may experience difficulties in
managing this growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, we had 12 full-time employees and no part-time employees and were reliant on
services provided to us by Penn and certain Penn-affiliated entities under the Services Agreement. As our development and commercialization plans and strategies develop, and as we continue to transition into operating as a public company, we expect
to rapidly expand our employee base and continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of
management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical and FDA review process for our
product candidates, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our
ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order
to devote a substantial amount of time to managing these growth activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will
continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including certain research and development as well as general and administrative support, pursuant to agreements which
expire after a certain period of time. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements.
In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may
not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on
economically reasonable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by hiring new employees and expanding
our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization
goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the benefits of acquired assets or other strategic transactions, including any transactions whereby we
acquire or license manufacturing and other advanced technologies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, we entered into a License Agreement with Penn
and the Children&#146;s Hospital of Pennsylvania, or CHOP, which was amended and restated in July 2019, or the License Agreement, pursuant to which we were granted licenses to certain patent rights for the research and development of products, as
well as an exclusive license under those same patent rights to make, use, sell and import such products, in the autoimmune disease and alloimmune response subfields, in each case, for the treatment of humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as
pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including the License Agreement, and any future strategic transactions depends on the risks and uncertainties involved including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated liabilities related to acquired companies or joint ventures; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties integrating acquired personnel, technologies and operations into our existing business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management time and focus from operating our business to management of strategic alliances or joint
ventures or acquisition integration challenges; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increases in our expenses and reductions in our cash available for operations and other uses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">possible write-offs or impairment charges relating to acquired businesses or joint ventures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or
strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax
consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt,
contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, Penn&#146;s operations and those of any CMOs, CROs and other contractors and consultants that we may engage could be subject to
earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or
business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We currently rely on Penn to
produce and process our first product candidate and anticipate that in the future we will rely on a third-party CMO for the same. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these
suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval of our product candidates, the products may not gain the market acceptance among physicians,
patients, hospitals, treatment centers and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of engineered
T cells as a potential treatment for B cell-mediated autoimmune diseases is a recent development and may not become broadly accepted by physicians, patients, hospitals, treatment centers and others in the medical community. We expect physicians to
be particularly influential and we may not be able to convince them to use our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which our product candidates are licensed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">physicians, hospitals, treatment centers and patients considering our product candidates as a safe and effective
treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages of our product candidates over alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA or other regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling approved by the FDA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our product candidates as well as competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate reimbursement and pricing by third-party payors and government
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive
therapies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, treatment centers or
others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that
are more favorably received than our products, are more cost effective or render our products obsolete. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If product liability
lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk
if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer
protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant
financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to bring our product candidates to the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in our share price. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we have not yet commenced marketing of any products, we do not yet hold product liability insurance for commercialization of our product
candidates. Our inability to obtain sufficient product liability insurance at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our
insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a
court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate
collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several
years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further
deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and
unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on
favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current
service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, the Tax Cuts and Jobs Act, or the TCJA, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The TCJA
includes, among other things, a reduction of the corporate tax rate from a top marginal tax rate of 35% to a flat rate of 21%, a limitation of the tax deduction for net interest expense to 30% of adjusted earnings (except for certain small
businesses), a limitation of the deduction for net operating losses to 80% of annual taxable income for losses arising in taxable years beginning after December&nbsp;31, 2017 and an elimination of net operating loss carrybacks for losses arising in
taxable years ending after December&nbsp;31, 2017 (though any such net operating losses may be carried forward indefinitely) and the modification and repeal of many business deductions and credits, including the reduction of the business tax credit
for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#147;orphan drugs.&#148; We continue to examine the impact this tax reform legislation may have on our business.
Prospective investors in our common stock should consult with their legal and tax advisors with respect to the TCJA and potential tax consequences of investing in or holding our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating losses and certain other tax attributes to offset future taxable income may be subject to
certain limitations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had U.S. federal and state net operating loss carryforwards of
$4.0&nbsp;million, which begin to expire in 2038. Approximately $3.8&nbsp;million of the federal net operating losses can be carried forward indefinitely. These net operating loss carryforwards could expire unused and be unavailable to offset future
taxable income or tax liabilities, respectively. In addition, in general, under Sections 382 and 383 of the Code and corresponding provisions of state law, a corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its
ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards or tax credits, or NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where
the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#146;s stock increases its ownership by more than 50 percentage points over its lowest ownership
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in
connection with or after this offering, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result
in an ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our
NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#147;&#151;Risks Related to Our Financial Condition and Capital Requirements&#148;, we have incurred
significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary
to utilize our NOLs or credits that are subject to limitation by Sections 382 and 383 of the Code. Under the TCJA, net operating loss carryforwards generated after December&nbsp;31, 2017 will not be subject to expiration. However, any NOLs generated
after December&nbsp;31, 2017 may only offset 80% of our annual taxable income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are reliant on a research services agreement with Penn for our nonclinical research and development activities and current
manufacturing activities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, we had 12 employees, and we have limited clinical research and development,
regulatory support and validation and manufacturing capabilities. We are reliant on the Services Agreement with Penn and certain Penn-affiliated entities, pursuant to which Penn and these affiliated entities provide us with these services. For more
information, see &#147;Business&#151;Our Material Agreements&#148;. While we intend to eventually build out these functions internally, we are currently significantly reliant on Penn for these critical business functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also dependent on Penn to enroll patients and conduct the DSG3-CAART Phase 1 clinical trial at the first clinical trial site, to be
located at Penn, in a timely and appropriate manner. If Penn does not conduct the trial on the timeline we expect or otherwise fails to support the trial, our clinical trial results could be significantly delayed, thereby adversely impacting our
leadership position in the CAAR T industry and our ability to progress additional product candidates. Further, although we intend to transition our manufacturing needs to a CMO and eventually secure our own clinical manufacturing facility,<B><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B>we must currently rely on Penn to manufacture supplies and process our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Penn and its affiliated entities were to fail to perform their obligations in accordance with the terms of the Services Agreement or
terminate the Services Agreement with little notice, we may have difficulty continuing our normal business operations and our business prospects, financial condition and results of operations could be harmed. In addition, the termination of our
relationship with Penn and the Services Agreement and any delay in appointing or finding a suitable replacement provider, if one exists, could make it difficult for us to operate our business for that period. Moreover, we will be reliant on Penn to
assist us with any necessary technology transfer. Any delays or inadequacies in such technology transfer, or disputes regarding the scope of such technology transfer, could delay our operations, including our clinical trials, require us to expend
additional resources and otherwise have an adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, over time we will need to transition from
receiving the services that Penn currently provides to performing such services internally. The Services Agreement is scheduled to expire on the later of October&nbsp;19, 2021 or completion of all research and development projects, and unless the
Services Agreement is amended, Penn will not be obligated to provide any further services under the Services Agreement after that time. In addition, Penn has the right to terminate the Services Agreement in whole at any time with 90 days&#146;
notice and to terminate any research and development project being performed under the Services Agreement if the Penn service provider appointed to lead such project is unavailable and Penn is unavailable to find a replacement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within 60 days for such service provider. Penn also has the right to terminate certain manufacturing services being performed under the Services Agreement with 180 days&#146; written notice. From
time to time, we may enter into further addenda to the Services Agreement that provide Penn with the right to terminate such addenda with limited notice periods. If we do not have adequate personnel and capabilities at the time that we assume
responsibilities for such services, we may not be successful in effectively or efficiently transitioning these services from Penn, which could disrupt our business and have a material adverse effect on our financial condition and results of
operations. Further, we will incur costs relating to establishing our own financial, administrative, information technology and other support functions as well as running and maintaining such functions on a going-forward basis. In addition, the
process of establishing such functions may distract our management from focusing on business and strategic opportunities and could result in disruptions to our business. Even if we are able to successfully transition these services, they may be more
expensive or less efficient than the services we are receiving from Penn during the transition period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will rely on third
parties, including Penn, to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend and will continue to depend upon third parties, including independent investigators and collaborators, such
as universities, medical institutions, CROs and strategic partners, to conduct our preclinical studies and clinical trials under agreements with us. Specifically, we depend on our collaborator, Penn, pursuant to the terms of the Services Agreement,
to operate the first trial site for our planned Phase&nbsp;1 clinical trial of DSG3-CAART. As we open additional clinical trial sites, we expect to have to negotiate budgets and contracts with CROs and study sites, which may result in delays to our
development timelines and increased costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will rely heavily on these third parties, including Penn, to conduct our preclinical
studies and clinical trials, and as a result, will have limited control over the clinical investigators and limited visibility into their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities,
including with respect to their compliance with the approved clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with applicable protocol, legal, regulatory and scientific standards,
and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with Good Clinical Practices, or GCPs, which are regulations and guidelines enforced by the FDA for product
candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP
requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. We cannot provide assurance that, upon
inspection, such regulatory authorities will not determine that some or all of our clinical trials do not fully comply with the GCP requirements. For any violations of laws and regulations during the conduct of our clinical trials, we could be
subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a
large number of test patients. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse
publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or these third parties do not successfully carry out their contractual duties, meet
expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and
will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. Our failure or the failure of these third parties to comply with applicable regulatory requirements or our stated protocols could also subject us to
enforcement action. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any third parties conducting our clinical trials will not be our employees and, except for
remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. These third parties may also have relationships with
other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry
out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory
requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our
financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into
arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition,
there is often a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships
with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the
part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We intend to rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and
process our product candidates, if licensed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we may eventually secure our own clinical manufacturing facility for any
late phase clinical development that we undertake, we currently rely on Penn to supply raw materials and other important components that are used to manufacture our product candidates and intend in the future to rely on CMOs. In the case of any
manufacturing performed for us by Penn, the services performed for us risk being delayed because of the competing priorities that Penn has for utilization of its manufacturing resources and any capacity issues that thereby arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not yet have sufficient information to reliably estimate the cost of the manufacturing and processing of our product candidates in
clinical quantity or commercial quantity, and the actual cost to manufacture and process our product candidates could ultimately materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to
develop a commercially viable product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us
to the following risks: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential
manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent
processes for, production of our products after receipt of FDA questions, if any. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the
quantity and quality required to meet our clinical and commercial needs, if any. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any contract manufacturers that we engage may not perform as agreed or may not remain in the contract
manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies
to ensure strict compliance with cGMP and other government regulations. We do not have control over third-party manufacturers&#146; compliance with these regulations and standards. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our
third-party manufacturers in the manufacturing process for our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our third-party manufacturers could breach or terminate their agreement with us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such
companies, which exposes our manufacturers to regulatory risks related to the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may affect the
regulatory clearance of our contract manufacturers&#146; facilities generally. If the FDA does not approve these facilities for the manufacture of our product candidates or if any agency withdraws its approval in the future, we may need to find
alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described
above. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In
addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information, see &#147;Risk Factors&#151;Risks Related to Manufacturing and Supply&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the
benefits of such alliances or licensing arrangements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may form or seek strategic alliances, create joint ventures or
collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that
we may develop. Any of these relationships may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or
disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a
strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the
requisite potential to demonstrate safety, potency and purity. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain
geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we
license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our License Agreement with Penn and CHOP
requires significant research and development commitments that may not result in the development and commercialization of our product candidates, including DSG3-CAART and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent upon the availability of specialty raw materials and the production capabilities of small manufacturers to source the
components of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates require many specialty raw materials, some of which are manufactured
by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In addition, those suppliers generally do not have the capacity to support
commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be <FONT STYLE="white-space:nowrap">ill-equipped</FONT> to support our needs, especially in <FONT STYLE="white-space:nowrap">non-routine</FONT> circumstances
like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays
in receiving key raw materials to support clinical or commercial manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, some raw materials are currently available
from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce
these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and
effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new
supplier on commercially reasonable terms, which could have a material adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are
uniquely manufactured. If we, Penn or any of our third-party manufacturers encounter difficulties in manufacturing our product candidates, our ability to provide supply of our product candidates for clinical trials or, if licensed, for commercial
sale, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing process
used to produce our product candidates is complex and novel and it has not yet been validated for commercial production. Among the complex processes used in the manufacture of our product candidates is the manufacture of the lentiviral delivery
vector used to deliver the applicable CAAR gene into the T cells. For example, the manufacture of our product candidates includes harvesting white blood cells from each patient, stimulating certain T cells from the white blood cells and thereby
causing them to activate and proliferate, combining patient T cells with our lentiviral delivery vector through a process known as transduction, expanding the transduced T cells to obtain the desired dose, and ultimately infusing the modified T
cells back into the patient&#146;s body. Notably, the manufacture of both <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> and FVIII-CAART will likely involve particularly complex processes due to the need to deliver large transgenes in a vector
delivery system with limited capacity. Because of these complexities, the cost to manufacture our product candidates is higher than traditional small molecule chemical compounds and monoclonal antibodies, and the manufacturing process is less
reliable and is more difficult to reproduce. Furthermore, our manufacturing process development and <FONT STYLE="white-space:nowrap">scale-up</FONT> is at an early stage. The actual cost to manufacture and process our product candidates could be
greater than we expect and could materially and adversely affect the commercial viability of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing
process may be susceptible to logistical issues associated with the collection of white blood cells from patients&#146; blood, variability in the quality of white blood cells collected from patients&#146; blood, procurement of lentiviral vectors and
shipment to the product candidate manufacturing site as well as shipment of the final product to clinical centers, manufacturing issues associated with interruptions in the manufacturing process, contamination, concentration and purity of batches of
lentiviral vectors, equipment or reagent failure, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improper installation or operation of equipment, vendor or operator error, inconsistency in cell growth, and variability in product characteristics due to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">patient-to-patient</FONT></FONT> variability. Even minor deviations from normal manufacturing processes could result in reduced production yields, lot failures, product defects, product recalls, product liability claims
and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, production at such manufacturing facilities may be
interrupted for an extended period of time to investigate and remedy the contamination. Further, as product candidates are developed through preclinical studies to late-stage clinical trials toward approval and commercialization, it is common that
various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Penn has informed us that it will be unable provide clinical supply for any late-phase clinical
trials of our product candidates that we may conduct. Therefore, we will need to enter into new agreements with CMOs to produce clinical supply of our product candidates for late-phase clinical trials. We cannot guarantee that we will be able to
enter into such agreements on commercially acceptable terms, if at all. We will need to transfer the technology to manufacture our product candidates to these CMOs, and these CMOs may decide or be required to adopt different manufacturing protocols
or processes, which may require us to amend any ongoing or proposed clinical trial protocols or perform additional preclinical studies to demonstrate the comparability of any such new manufacturing protocols or processes. We cannot provide any
assurance that Penn will provide adequate support to efficiently and effectively transfer the technology or that disputes will not arise between us and Penn regarding the necessary scope of technology transfer, that the technology transfer will be
successful, or that any CMO will be successful in producing our product candidates in sufficient quantities or of acceptable quality, if at all. Such changes carry the risk that they will not achieve these intended objectives, and any of these
changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we continue to optimize our manufacturing process for our product candidates, doing so is a difficult and uncertain task, and there
are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process
reproducibility, stability issues, lot consistency and timely availability of reagents and/or raw materials. We ultimately may not be successful in transferring our production system from our contract manufacturer to any manufacturing facilities we
may establish ourselves, or our contract manufacturer may not have the necessary capabilities to complete the implementation and development process. If we are unable to adequately validate or <FONT STYLE="white-space:nowrap">scale-up</FONT> the
manufacturing process for our product candidates with our current manufacturer, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and <FONT
STYLE="white-space:nowrap">scale-up</FONT> the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we
will be able to come to agreement on terms acceptable to us. As a result, we may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product
candidates are commercialized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The manufacturing process for any products that we may develop is subject to the FDA approval
process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis. If we or our CMOs are unable to
reliably produce products to specifications acceptable to the FDA, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance
that either we or our CMOs will be able to manufacture the approved product in accordance with requirements from the FDA, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential
future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, result in sanctions being imposed on us, including
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production or recalls of the product candidates or marketed
biologics, operating restriction and criminal prosecutions, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of
operations and growth prospects. Our future success depends on our ability to manufacture our products, if licensed, on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality control and complying with
applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, and results of operations. In addition, we could incur higher manufacturing costs if manufacturing processes or
standards change, and we could need to replace, modify, design, or build and install equipment, all of which would require additional capital expenditures. Specifically, because our product candidates may have a higher cost of goods than
conventional therapies, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of viral vectors is complex and variable, and there are a limited number of manufacturers able to supply us with viral
vectors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our DSG3-CAART and MuSK-CAART product candidates utilize a lentiviral delivery vector and some or all of our other
product candidates may require a lentiviral delivery vector, a key drug substance that delivers the CAAR to the target T cells. We do not have the capability to manufacture lentiviral vector and plan to obtain the vector we require from third
parties. The manufacturing process for lentiviral vector is variable and still evolving. It is not uncommon for manufacturing runs to fail, whether due to contamination, supplier error, or equipment failure, or to be delayed. To the extent our
product candidates use a lentiviral delivery vector, a lack of vector supply will cause us to be unable to manufacture our CAAR T cells as well as a delay in patient enrollment, which may have a negative impact on our ability to successfully develop
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there are a limited number of manufacturers capable of producing lentiviral vectors. It can be
challenging to secure a relationship with any of these manufacturers, and the manufacturing and release process can take a significant amount of time. We have secured a supply of lentiviral vector from CHOP sufficient for a portion of the patients
we plan to enroll in our Phase&nbsp;1 clinical trial of our DSG3-CAART product candidate. We have also reserved additional vector manufacturing capacity at Penn and we are in discussions with other CMOs for additional supply. There is no assurance
that we will be able to secure adequate and timely supply of lentiviral vector. Moreover, we cannot be certain that our CAAR&nbsp;T&nbsp;cell product candidates produced with lentiviral vector from different manufacturers will be comparable or that
results of clinical trials will be consistent if conducted with lentiviral vector from different manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Vector production also
requires the production of high-quality DNA plasmids, for which there is also a limited number of suppliers. Although we have established relationships with multiple suppliers for lentiviral vector and plasmids, we do not yet have our own
clinical-scale manufacturing facility established, and are therefore highly dependent on the ability of these suppliers to manufacture necessary materials and to deliver these materials to us on a timely and reliable basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing
capabilities. If we encounter such difficulties, our ability to provide supply of our CAAR T cells for clinical trials or for commercial purposes could be delayed or stopped. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Establishing clinical and commercial manufacturing and supply is a difficult and uncertain task, and there are risks associated with scaling to
the level required for advanced clinical trials or commercialization, including, among others, increased costs, potential problems with process <FONT STYLE="white-space:nowrap">scale-out,</FONT> process reproducibility, stability issues, lot
consistency, and timely availability of reagents or raw materials. For example, we may find it difficult to establish a manufacturing process that is consistent. If this occurs, we may need to complete more than one manufacturing run for each
treated patient, which would impact the availability of adequate coverage and reimbursement from third-party payors. Competitors that have developed CAR T cell therapies have had </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
difficulty reliably producing engineered T cell therapies in the commercial setting. If we experience similar challenges manufacturing product candidates to approved specifications, this may
limit our product candidates&#146; utilization and our ability to receive payment for these product candidates once licensed. Alternatively, these challenges may require changes to our manufacturing processes, which could require us to perform
additional clinical studies, incurring significant expense. We may ultimately be unable to reduce the expenses associated with our product candidates to levels that will allow us to achieve a profitable return on investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our third-party suppliers use hazardous, <FONT STYLE="white-space:nowrap">non-hazardous,</FONT> biological or other materials
in a manner that causes injury or violates applicable law, we may be liable for damages. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities
involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture,
storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#146; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our
suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail
the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities
arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm
our business, prospects, financial condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in product candidate manufacturing or formulation
may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is
common that various aspects of the development program, such as manufacturing methods or formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform
differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials or with materials made with the altered methods. Such changes may also require additional testing, or notification to,
or approval by the FDA or other regulatory authorities. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs,
delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Government
Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the
clinical development and regulatory approval of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval,
selling, import, export, marketing and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug
product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar licensure filings to comparable foreign authorities. A BLA must include
extensive preclinical and clinical data and supporting information to establish the product candidate&#146;s safety, potency and purity for each desired indication. The BLA must also include significant information regarding the chemistry,
manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has not previously reviewed regulatory applications for the commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development of CAAR T cells for treatment of pemphigus, and there is no therapy currently approved by the FDA for the treatment of mPV. Because of this, we have little guidance as to which
endpoints will be accepted, how many clinical trials we may expect to conduct, and whether open-label clinical trials will be deemed acceptable, among other things. We may also request regulatory approval of future CAAR T cell-based product
candidates by target, regardless of disease type or origin, which the FDA may have difficulty accepting if our clinical trials only involved diseases of certain origins. The FDA may also require a panel of experts, referred to as an Advisory
Committee, to deliberate on the adequacy of the safety, potency and purity data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product
candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#146;s recommendations. Further, given the rapidly evolving landscape of cell therapy, we could encounter a significant change in the regulatory
environment for our product candidates once we have already begun one or more lengthy and expensive clinical trials for our product candidates. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex,
expensive and lengthy, and approval may not be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also experience delays in completing planned clinical trials for a
variety of reasons, including delays related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory authorization to begin a trial, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of financial resources to commence and complete the planned trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval at each clinical trial site by an independent IRB; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting suitable patients to participate in a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial
before the product candidate is manufactured and returned to the site, or return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any patient safety concerns that arise during a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding new clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient
basis for use in clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if physicians encounter unresolved ethical issues
associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs
for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical
protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from
using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the DSMB. If we experience termination of, or delays in the completion
of, any future clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will
increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical
trials may ultimately lead to the denial of regulatory approval of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect the product candidates we develop will be regulated as biological products,
or biologics, and therefore they may be subject to competition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009, or
BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, to establish an abbreviated pathway for the approval of biosimilar and
interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity
to a licensed biologic. Under the BPCIA, an application for a biosimilar product cannot be licensed by the FDA until 12 years after the reference product was licensed under a BLA. The law is complex and is still being interpreted and implemented by
the FDA. In addition, as discussed more fully below, since the BPCIA was enacted as part of the ACA, if the ACA is invalidated in its entirety as unconstitutional, then the BPCIA could be considered invalid as well. While it is uncertain when such
processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any of the product candidates we develop that is licensed in the United States as a biological product under a BLA should
qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product
candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of the
reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still
developing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established
cell therapies and other therapies for B cell-mediated autoimmune diseases are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in
obtaining regulatory approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we are developing novel CAAR T cell product candidates that are unique biological entities,
the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For
example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible
for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies, formerly known as the Office of Cellular, Tissue and Gene Therapies,
within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical
trials are also subject to review and oversight by an institutional biosafety committee, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although
the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its
initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each
institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory
approvals for our product candidates, further complicating the regulatory landscape. For example, in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal
products, or ATMPs, to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. These various
regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to
changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAAR T cell
product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such
approvals may later be withdrawn because of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a
potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are
not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate
revenue will be materially impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates and the activities associated with their development and
commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other
regulatory agencies in the United States. Before we can commercialize any of our product candidates, we must obtain marketing approval. We have not received approval to market any of our product candidates from regulatory authorities in any
jurisdiction and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. We, as a company, have no experience in filing and supporting the applications
necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting
information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#146;s safety, potency and purity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of
manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may
preclude our obtaining marketing approval or prevent or limit commercial use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals is expensive,
may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in
marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted IND, BLA or equivalent application types, may cause delays in the
approval or rejection of an application. The FDA has substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or
other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA that a drug candidate is safe, potent and pure for
its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA for
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of an BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA may fail to approve the manufacturing processes, test procedures and specifications, or facilities that
we may establish or of third-party manufacturers with which we may contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data
insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete
the FDA approval process and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would
significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the novel nature of our product candidates to create
further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted. For example, the general approach for FDA approval of a new biologic or drug is
for sponsors to seek licensure or approval based on dispositive data from well-controlled, Phase&nbsp;3 clinical trials of the relevant product candidate in the relevant patient population. Phase&nbsp;3 clinical trials typically involve hundreds of
patients, have significant costs and take years to complete. We believe that we may be able to utilize the FDA&#146;s Regenerative Medicine Advanced Therapy designation for our product candidates given the limited alternatives for treatments for
certain rare diseases and B cell-mediated autoimmune diseases, but the FDA may not agree with our plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, approval of genetic or
biomarker diagnostic tests may be necessary to advance some of our product candidates to clinical trials or potential commercialization. In the future, regulatory agencies may require the development and approval of such tests. Accordingly, the
regulatory approval pathway for such product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, if licensed, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our
product candidates may be harmed and our ability to generate revenues will be materially impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek orphan drug designation for DSG3-CAART,
<FONT STYLE="white-space:nowrap">MuSK-CAART</FONT> and some or all of our future product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation,
including market exclusivity, which may cause our revenue, if any, to be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or more in the United
States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug
designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and <FONT
STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage
in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently
receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to
market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug
exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug
was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or
disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant
demonstrates clinical superiority over our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek orphan drug designation for some or all of our product candidates in
specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication
broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with
the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if licensed. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such
designations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for
expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe there may be an opportunity to accelerate the development of certain of our product candidates through one or more of the
FDA&#146;s expedited programs, such as fast track, breakthrough therapy, accelerated approval or priority review, we cannot be assured that any of our product candidates will qualify for such programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, a drug may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with one or
more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Although
breakthrough designation or access to any other expedited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program may expedite the development or approval process, it does not change the standards for approval. If we apply for breakthrough therapy designation or any other expedited program for our
product candidates, the FDA may determine that our proposed target indication or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining a breakthrough therapy designation or
access to any other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. Access to an expedited program may also be withdrawn by the FDA if it believes
that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and
continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety, potency and purity of the
product candidate. We believe it is likely that the FDA will require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication
plans or additional elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA approves our product candidates, the manufacturing processes, labeling,
packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions
of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to
continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue
to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#146;s approved uses (known as <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously
unknown problems with our product candidates through <FONT STYLE="white-space:nowrap">follow-up</FONT> programs with our clinical trial patients, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or
imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the
market or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government regulation that may arise from future legislation or administrative or executive action. For example, certain policies of the current U.S. President&#146;s administration may impact
our business and industry. Namely, the current U.S. President&#146;s administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay,
FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented,
and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our
business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained, and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement may be limited or
unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if licensed, profitably. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful commercialization of our product candidates, if licensed, will depend in part on the extent to which reimbursement for those drug
products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations,
decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug
products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by
government health administration authorities, private health coverage insurers and other third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory
approval. Any product candidate for which we seek regulatory approval and reimbursement will need to meet or surpass our target product profile, or TPP, to be deemed a viable alternative to currently approved therapies. In addition, because our
product candidates represent new approaches to the treatment of B cell-mediated autoimmune diseases, we cannot accurately estimate the potential revenue from our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may
depend upon a number of factors, including, but not limited to, the third-party payor&#146;s determination that use of a product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that
could require us to provide the payor with supporting scientific, clinical and cost-effectiveness data for the use of our products, if licensed. In the United States, the principal decisions about reimbursement for new drug products are typically
made by the Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and
private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly
from payor to payor. Further, one payor&#146;s determination to provide coverage for a product does not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an
appropriate return on our investment in product development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain coverage for a given product, if the resulting
reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients are unlikely
to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the
hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including
the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates.
Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other
third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable
coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been a number of legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain regulatory approval.
We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and
in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2010,
President Obama signed into law the ACA. Among the provisions of the ACA of potential importance to our business and our product candidates are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee on any entity that manufactures or imports
specified branded prescription products and biologic products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for products that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback
Statute, new government investigative powers and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50%
(increased to 70% as of January&nbsp;1, 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand products to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturer&#146;s outpatient products to be covered under Medicare Part&nbsp;D; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability to individuals enrolled in Medicaid managed care
organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report certain financial arrangements with physicians and teaching hospitals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new requirement to annually report product samples that manufacturers and distributors provide to physicians;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the
Medicare program to reduce expenditures by the program that could result in reduced payments for prescription products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service
delivery models. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been a number of significant changes to the ACA and its implementation. The Tax Cuts and
Jobs Act of 2017, or Tax Act, includes a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge,
ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA, including the BPCIA, are invalid as well. The U.S. President
Administration and CMS have both stated that the ruling will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal. On July&nbsp;9, 2019, a Fifth Circuit U.S. Court
of Appeals held a hearing to determine whether certain states and the House of Representatives have standing to appeal the lower court decision, but it is unclear when the Court will render its decision on this hearing, and what effect it will have
on the status of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. We will continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2017, the U.S. President signed an Executive Order directing federal agencies with authorities and responsibilities
under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health
insurers, or manufacturers of pharmaceuticals or medical devices. On October&nbsp;13, 2017, the U.S. President signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the ACA. The U.S. President administration
has concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the ACA have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those
appropriations are made. The loss of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the
subsidies, but their request for a restraining order was denied by a federal judge in California on October&nbsp;25, 2017. On June&nbsp;14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay
more than $12&nbsp;billion in ACA risk corridor payments to third-party payors who argued were owed to them. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our
business, are not yet known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, on January&nbsp;22, 2018, the U.S. President signed a continuing resolution on appropriations for
fiscal year 2018 that delayed the implementation of certain Affordable Care <FONT STYLE="white-space:nowrap">Act-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise
tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Moreover, the Bipartisan Budget Act of 2018, among other things, amended the Affordable Care Act, effective January&nbsp;1, 2019, to increase the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount (from 50% under the ACA to 70%) that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closed the coverage gap in most
Medicare drug plans, commonly referred to as the &#147;donut hole&#148;. More recently, in July 2018, CMS announced that it is suspending further collections and payments to and from certain Affordable Care Act qualified health plans and health
insurance issuers under the Affordable Care Act risk adjustment program pending the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, CMS has recently published a final rule
that would give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans
sold through such marketplaces. Congress is continuing to consider legislation that would alter other aspects of the Affordable Care Act. The ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is
unclear. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations.
Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things included aggregate reductions
to Medicare payments to providers of 2% per fiscal year, which went into effect in April&nbsp;2013 and will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was
signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and treatment centers, and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. These new laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which
we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and
likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates. Such reforms could have an adverse effect on anticipated revenue from product candidates that we
may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between
pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President&#146;s administration&#146;s budget for fiscal year 2019 contains further drug price
control measures that could be enacted during the 2019 legislative session or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some
states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Further, the current U.S. President&#146;s administration released a
&#147;Blueprint&#148;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs,
incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is
immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January&nbsp;1, 2019.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additionally, on May&nbsp;10, 2019, CMS announced a new pricing transparency rule, which was set to go into effect on July&nbsp;9, 2019, but on July&nbsp;8, 2019, a federal judge struck down the
rule concluding that HHS did not have the statutory authority to implement such regulations on drug companies. This final rule would have required <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT>
television advertisements for prescription drugs and biological products for which reimbursement is available, directly or indirectly, through or under Medicare or Medicaid to include the list price of that product, except for a prescription drug or
biological product that has a list price of less than $35 per month for a <FONT STYLE="white-space:nowrap">30-day</FONT> supply or typical course of treatment. If it goes into effect, the pricing transparency rule could have had a negative effect on
our business. Although a number of these, and other proposed measures will require authorization through additional legislation to become effective, Congress and the current U.S. President&#146;s administration have each indicated that it will
continue to seek new legislative and/or administrative measures to control drug costs. While some proposed measures will require authorization through additional legislation to become effective, Congress and the current U.S. President&#146;s
administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and
implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be,
legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to
generate revenue, attain profitability, or commercialize our product. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may
affect our overall financial condition and ability to develop product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the initiatives that may be adopted
in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to set a price that we believe is fair for our products, if licensed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors,
which may adversely affect our future profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and
regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third
parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business
operations, environmental damage resulting in costly <FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste
products. Although we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and
regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources
and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more
stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Breach of certain environmental, health and safety laws and regulations could also in certain circumstances constitute a breach of our License
Agreement with Penn. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or
production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers
compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or
other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA,
provide true, complete and accurate information to the FDA, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial
information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will
increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed
and future sales, marketing and education programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers, healthcare providers, physicians, and third-party
payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent
contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws may
impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws
and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial
arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of individual identifiable health information and other personally identifiable information. The U.S.
healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting,
receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease,
order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating
the statute without actual knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the False Claims Act, or FCA. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a
number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit,
among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing
to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an
obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims.
The FCA also permits a private individual acting as a &#147;whistleblower&#148; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (<I>e.g.</I>, public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact
or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty
of violating HIPAA without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their respective implementing regulations, which impose, among other things, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the
use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the
federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act, created under the Patient Protection and Affordable Care Act, and its
implementing regulations, which require manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report
annually to the HHS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment
interests held by physicians and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, and may be broader in scope than their
federal equivalents; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or
otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or
marketing expenditures; and state and foreign laws governing the privacy and security of individually identifiable health information and other personally identifiable information in certain circumstances, many of which differ from each other in
significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of
pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of
investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and
resource-consuming and can divert a company&#146;s attention from the business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or
regulatory requirements subjects entities to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines,
disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restructuring of our operations, as well as additional reporting obligations and
oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Any action for violation of these laws, even if successfully
defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#146;s attention from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that
some of our business activities, or our arrangements with physicians, some of who receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants,
commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. Effective upon the completion of this offering, we will adopt a code of business conduct and ethics, but it is
not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may
involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or
other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition
of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and
future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and
curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal
information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The collection and processing of personal data &#150; including health data &#150; is governed by the European
Union-wide General Data Protection Regulation, or GDPR, which became applicable on May&nbsp;25, 2018. The GDPR applies to any business, regardless of its location, that provides goods or services to residents in the EU or monitors the behavior of
individuals within the European Union. The GDPR imposes more stringent operational requirements for processors and controllers of personal data, including, for example, special protections for &#147;sensitive information&#148; which includes health
and genetic information of data subjects residing in the European Union, expanded disclosures about how personal information is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized
(<I>i.e.</I>, <FONT STYLE="white-space:nowrap">key-coded)</FONT> data, mandatory data breach notification requirements and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities.
GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal
remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the European Union to the United States and other jurisdictions that have not been
deemed to offer &#147;adequate&#148; privacy protections. The GDPR provides that European Union Member States may make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result in
differences between Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. Our clinical trial activity conducted within the member states of the European
Union is regulated by the GDPR. In addition, we are subject to evolving and strict rules on the transfer of personal data out of the European Union to the United States. Furthermore, the current main data transfer mechanisms (Privacy Shield and
Standard Contractual Clauses) are the subject of a legal challenge before the European Court of Justice, raising the possibility of future uncertainty about mechanisms that may be used to legitimize cross-border transfers of personal data. Failure
to comply with European Union data protection laws may result in fines (for example, of up to &#128;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year (whichever is higher) under the GDPR) and other
administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
penalties, which may be onerous and adversely affect our business, financial condition, results of operations and prospects. As a result of the implementation of the GDPR, we may be required to
put in place additional mechanisms ensuring compliance with the new data protection rules. There is significant uncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR is not yet clear.
Enforcement uncertainty and the costs associated with ensuring GDPR compliance be onerous and adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our security measures are breached or unauthorized access to individually identifiable health information or other personally
identifiable information is otherwise obtained, our reputation may be harmed, and we may incur significant liabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unauthorized access to, or security breaches of, our systems and databases could result in unauthorized access to data and information and
loss, compromise or corruption of such data and information. The systems of Penn, any CMOs that we may engage in the future, and present and future CROs, contractors and consultants also could experience breaches of security leading to the exposure
of confidential and sensitive information. Such breaches of security could be caused by computer hacking, phishing attacks, ransomware, dissemination of computer viruses, worms and other destructive or disruptive software, denial of service attacks,
and other malicious activity, which may be heretofore unknown. The number and complexity of these threats continue to increase over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a security breach, our company could suffer loss of business, severe reputational damage adversely affecting investor
confidence, regulatory investigations and orders, litigation, indemnity obligations, damages for contract breach, penalties for violation of applicable laws or regulations, significant costs for remediation and other liabilities. For example, the
loss of preclinical study or clinical trial data from completed or future preclinical studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the
extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and
commercialization of our product candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred and expect to incur significant expenses to prevent
security breaches, including costs related to deploying additional personnel and protection technologies, training employees, and engaging third-party solution providers and consultants. Although we expend significant resources to create security
protections that shield our customer data against potential theft and security breaches, such measures cannot provide absolute security. Moreover, as we outsource more of our information systems to vendors and rely more on cloud-based information
systems, the related security risks will increase, and we will need to expend additional resources to protect our technology and information systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have in the past experienced breaches of our security measures. For example, in 2019, we believe a phishing incident led to certain
employee email accounts being accessed by an unauthorized third party. We initiated an investigation to determine whether further action was required under applicable law. The incident did not have a material impact on our business or financial
condition. While we believe we responded appropriately, including implementing remedial measures with the goal of preventing similar such events in the future, there can be no assurance that we will be successful in these remedial and preventative
measures or in successfully mitigating the effects of potential future incidents or cyber-attacks. We thus remain at risk for future breaches, including, without limitation, breaches that may occur as a result of third-party action, or employee,
vendor or contractor error or malfeasance and other causes. If, in the future, we experience a data breach or security incident, we would be likely to experience harm to our reputation, financial performance, and customer and vendor relationships,
and the possibility of litigation or regulatory investigations or actions by state and federal governmental authorities and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We rely heavily on certain <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent and other intellectual property rights in
connection with our development of our product candidates and, if we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to develop and commercialize our product candidates is heavily dependent on
<FONT STYLE="white-space:nowrap">in-licenses</FONT> to patent rights and other intellectual property granted to us by third parties. For example, we depend heavily on our License Agreement with Penn and CHOP, pursuant to which we obtained (a)&nbsp;a
non-exclusive, non-sublicensable, worldwide research license to make, have made and use products in two subfields of use, (b)&nbsp;effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under
certain of the intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and (c)&nbsp;effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to
sublicense, under certain of Penn&#146;s know-how to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. We may enter into additional license agreements in the future. Our license agreement
with Penn and CHOP imposes, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under these licenses, our
licensors, including Penn and CHOP, may have the right to terminate these license agreements, in which event we might not be able to market our product candidates. Termination of any of our license agreements or reduction or elimination of our
licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to obtain
additional licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if
at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could
harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or,
with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore,
in many cases, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we <FONT STYLE="white-space:nowrap">in-license</FONT> from third parties. For
example, pursuant to our License Agreement with Penn and CHOP, Penn controls such activities for the patent rights licensed to us under such agreement. Therefore, although we provide input to Penn and CHOP on these activities, we cannot be certain
that these patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our current or future licensors or collaboration partners fail to obtain, maintain or protect any patents or patent
applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license
agreement, including those related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the License Agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we have breached the License Agreement and whether any such breach is subject to a cure period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, disputes may arise
between us and our current or future licensors regarding the ownership of intellectual property developed by us, such that we may be required to assign or otherwise transfer such intellectual property to such licensor. In the event that the assigned
or transferred intellectual property is covered by an existing license agreement with such licensor we may be required to make additional royalty or milestone payments, or both, to such licensor. If the assigned or transferred intellectual property
is not covered by an existing license agreement, then we may be required to enter into an additional license agreement to advance our research or allow commercialization of our product candidates, which may not be available on commercially
reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our
ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our efforts to protect the proprietary nature of the intellectual property related to our current and any future product candidates
are not adequate, we may not be able to compete effectively in our market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to
obtain and maintain intellectual property protection in the United States and other countries with respect to our product candidates. If we do not adequately protect or enforce our intellectual property rights, competitors may be able to erode or
negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights in the United States and
abroad relating to the product candidates that are important to our business. The patent application and approval process is expensive, complex and time-consuming. Our licensors may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is
highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights
with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial
value of our patent rights are highly uncertain. Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other
requirements for patentability are met, currently, the first to file&nbsp;a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States, the first to invent was entitled to the patent.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases
not at all. Therefore, we cannot be certain that our licensors were the first to make the inventions claimed in the patents or pending patent applications we <FONT STYLE="white-space:nowrap">in-license,</FONT> or that our licensors were the first to
file for patent protection of such inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because the issuance of a patent is not conclusive as to its inventorship,
scope, validity or enforceability, the patents or pending patent applications we <FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to
a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in post-grant review procedures, derivation proceedings, reexaminations, or<I>&nbsp;inter partes</I>&nbsp;review in the United
States, or oppositions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other comparable proceedings in foreign jurisdictions, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of
exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of
the patent protection of our technology and product candidates. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or
shortly after such candidates are commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United
States and other countries may diminish the value of the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same
extent or in the same manner as the laws of the United States. For example, European patent law is more restrictive than U.S. patent law in connection with the patentability of methods of treatment of the human body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether the patent applications we <FONT STYLE="white-space:nowrap">in-license</FONT> currently being pursued will issue as
patents, whether the claims of any patent that has or may issue will provide us with a competitive advantage or prevent competitors from designing around the claims to develop competing technologies in
<FONT STYLE="white-space:nowrap">a&nbsp;non-infringing&nbsp;manner,</FONT> or whether we or our licensors will be able to successfully pursue patent applications in the future relating to our current product candidates or future products and product
candidates. Moreover, the patent application and approval process is expensive and time-consuming. We or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.
Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them.
Therefore, we may miss potential opportunities to seek additional patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the
preparation or filing of patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect
such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution or enforcement of the patents or patent applications we
<FONT STYLE="white-space:nowrap">in-license,</FONT> such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the patent applications we
<FONT STYLE="white-space:nowrap">in-license</FONT> issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage.
Our competitors may be able to circumvent our patent rights by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our competitors may also seek approval to market their own
products similar to or otherwise competitive with our product candidates. Alternatively, our competitors may seek to market generic versions of any approved products by submitting abbreviated BLAs to the FDA during which process they may claim that
patents licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our intellectual property rights, or both, including by filing lawsuits alleging patent infringement. In any of these types
of proceedings, a court or other agency with jurisdiction may find the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> invalid or unenforceable, or that our competitors are competing in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Thus, even if we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> valid and enforceable patents, these patents still may not provide protection against competing products or
processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we likely will need to expand our patent portfolio to pursue patent coverage for new product candidates that we wish to
develop. The patent prosecution process is competitive, and other companies, some which may have greater resources than we do in this area, may also be pursuing intellectual property rights that we may consider necessary or attractive in order to
develop and commercialize future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, maintaining, defending and enforcing patents on our product candidates in all countries throughout the world
would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. The deadline to pursue protection in foreign jurisdictions for many of the
patent families licensed under the License Agreement with Penn has not yet expired. Prior to applicable deadlines, we and Penn will need to decide where to pursue protection, and we will not have the opportunity to pursue protection unless we do so
in applicable jurisdictions prior to the deadlines. Although our License Agreement grants us worldwide rights, there can be no assurance that we will obtain or maintain patent rights in or outside the United States under any future license
agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection.
Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or
importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own
products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates
and the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make
it difficult for us to stop the infringement of the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights, even if
obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> at risk of being invalidated or
interpreted narrowly and the patent applications we <FONT STYLE="white-space:nowrap">in-license</FONT> at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the
damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We or our licensors may be subject to claims challenging the inventorship or ownership of the
patents and other intellectual property that we own or license. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former
employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we <FONT STYLE="white-space:nowrap">in-license</FONT> or that we may own or <FONT STYLE="white-space:nowrap">in-license</FONT>
in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such
an agreement with each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may be breached. Our licensors may face similar obstacles. We or our licensors could be subject to
ownership disputes arising, for example, from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. For example, our scientific co-founders, Drs. Payne and Milone, are members of our
scientific advisory board and are also employed by and subject to Penn&#146;s intellectual property policy. Litigation may be necessary to defend against any claims challenging inventorship or ownership. If we or our licensors fail in defending any
such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and
financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Some intellectual property which we
<FONT STYLE="white-space:nowrap">have&nbsp;in-licensed&nbsp;was</FONT> discovered through government funded programs and thus is subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain
reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the intellectual property rights we have licensed, including rights licensed to us by Penn relating to our DSG3-CAART and <FONT
STYLE="white-space:nowrap">DSG3/1-CAART</FONT> product candidates, was generated through the use of U.S. government funding and may therefore be subject to certain federal laws and regulations. As a result, the U.S. government has certain rights to
intellectual property embodied in our DSG3-CAART and <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> product candidates and may have rights in future product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in
certain inventions developed under a government-funded program include <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;non-exclusive,&nbsp;non-transferable,&nbsp;irrevocable</FONT></FONT> worldwide license to use inventions
for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, <FONT STYLE="white-space:nowrap">or&nbsp;non-exclusive&nbsp;licenses</FONT> to any of these inventions to a third
party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public health or safety needs; or (iii)&nbsp;government action is necessary to meet
requirements for public use under federal regulations, also referred to <FONT STYLE="white-space:nowrap">as&nbsp;&#147;march-in&nbsp;rights&#148;.</FONT> The U.S. government also has the right to take title to these inventions if we, or the
applicable licensor, such as Penn, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program
is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that products embodying the subject invention or produced
through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been
made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S.
manufacturers may limit our ability to contract <FONT STYLE="white-space:nowrap">with&nbsp;non-U.S.&nbsp;product</FONT> manufacturers for product candidates covered by such intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patent rights or other intellectual property rights, which could be
expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe, misappropriate or otherwise violate patents, trademarks,
copyrights or other intellectual property that we own <FONT STYLE="white-space:nowrap">or&nbsp;in-license.&nbsp;To</FONT> counter infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and
time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived violators could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or
otherwise violate their intellectual property, in addition to counterclaims asserting that the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> are invalid or unenforceable, or both. In any patent infringement proceeding, there is a
risk that a court will decide that a patent we <FONT STYLE="white-space:nowrap">in-license</FONT> is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is
also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that the
patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving the patents we <FONT STYLE="white-space:nowrap">in-license</FONT> could limit our ability to assert the patent we
<FONT STYLE="white-space:nowrap">in-license</FONT> against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could
adversely affect our competitive business position, business prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement,
misappropriation or another violation of our intellectual property rights, the court may decide not to grant an injunction against the offender and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and
pursue such claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could
outweigh any benefit we receive as a result of the proceedings. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or the interpretation of the patent laws in the
United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or
the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act
also included provisions that switched the United States from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;&#147;first-to-invent&#148;&nbsp;system</FONT></FONT> to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;&#147;first-to-file&#148;&nbsp;system,</FONT></FONT> allowed third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the
USPTO administered post grant proceedings. Under <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;first-to-file&nbsp;system,</FONT></FONT> assuming the other requirements for patentability are met, the first inventor to file
a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith
Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&nbsp;16, 2013. It remains unclear what impact, if any, the Leahy-Smith Act
will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of the patent applications we <FONT STYLE="white-space:nowrap">in-license</FONT>
and the enforcement or defense of the issued patents we <FONT STYLE="white-space:nowrap">in-license,</FONT> all of which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of companies engaged in the development and commercialization of biologics are particularly uncertain. For example, the
Supreme Court of the United States issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1
and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA, which is an artificial construct that may be
created from RNA transcripts of genes, may be patent-eligible. Thereafter, the USPTO issued a guidance memorandum instructing USPTO examiners on the ramifications of the Prometheus and Myriad rulings and apply the Myriad ruling to natural products
and principles including all naturally occurring nucleic acids. Certain claims of <FONT STYLE="white-space:nowrap">our&nbsp;in-licensed&nbsp;patent</FONT> applications contain, and any future patents we may obtain may contain, claims that relate to
specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that our efforts to seek patent protection for one or more of our product candidates will not be negatively impacted by
this Supreme Court decision, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#146;s decisions in Myriad may have on the ability of life science companies to
obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent
rights and our ability to protect and enforce our intellectual property in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of trade secrets, our business and
competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and
confidentiality agreements to protect certain <FONT STYLE="white-space:nowrap">proprietary&nbsp;know-how&nbsp;that</FONT> is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements
of our product candidate discovery and development processes that involve <FONT STYLE="white-space:nowrap">proprietary&nbsp;know-how,&nbsp;information</FONT> or technology that is not covered by patents. However, trade secrets can be difficult to
protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our
employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We also seek to
preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals,
organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could infringe, misappropriate or otherwise violate our intellectual property rights, design around our
protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we
would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors,
our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade
secrets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims that we are infringing certain third-party patents or other third party intellectual
property rights, any of which may prevent or delay our development and commercialization efforts and have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on avoiding infringing, misappropriating and otherwise violating the patents and other intellectual
property and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries,
including patent infringement lawsuits, and administrative proceedings such as interferences,<I>&nbsp;inter partes</I>&nbsp;review and post grant review proceedings before the USPTO and opposition proceedings before foreign patent offices. Numerous
U.S. and foreign issued patents and pending patent applications, which are owned or controlled by third parties, including our competitors, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical
industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we or our licensors are employing their proprietary technology without authorization. There may be third-party
patents or patent applications with claims to materials, methods of manufacture or methods for treatment relating to our product candidates and, because patent applications can take many years to issue, there may be currently pending third party
patent applications which may later result in issued patents, in each case that our product candidates, their manufacture or use may infringe or be alleged to infringe. We may fail to identify potentially relevant patents or patent applications,
incorrectly conclude that a patent is invalid or does not cover our activities, or incorrectly conclude that a patent application is unlikely to issue in a form of relevance to our activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making patent infringement claims against us may obtain injunctive or other
equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, including demonstrating <FONT STYLE="white-space:nowrap">non-infringement,</FONT>
invalidity or unenforceability of the respective patent rights in question, regardless of their merit, is time-consuming, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. For
example, in order to successfully challenge the validity of any U.S. patent in federal court, we would need to overcome a presumption of validity. This is a high burden requiring us to present clear and convincing evidence as to the invalidity of
any such U.S. patent claim, and we can provide no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We may not have sufficient resources to bring these actions to a successful conclusion. There
could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of
our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a holder of any such patents seeks to enforce its patent rights against us with respect to one or more of
our product candidates, and our defenses against the infringement of such patent rights are unsuccessful, we may be precluded from commercializing our product candidates, even if approved, without first obtaining a license to some or all of these
patents, which may not be available on commercially reasonable terms or at all. Moreover, we may be required to pay significant fees and royalties to secure a license to the applicable patents. Such a license may only
<FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;in</FONT> which case our ability to stop others from using or commercializing technology and products similar or identical to ours may be limited. Furthermore, we could be liable for
damages to the holder of these patents, which may be significant and could include treble damages if we are found to have willfully infringed such patents. In the event that a challenge to these patents were to be unsuccessful or we were to become
subject to litigation or unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware of third-party issued U.S. patents relating to the lentiviral vectors which may be used in the manufacture or use of our product
candidates. If these patent rights were enforced against us, we believe that we have defenses against any such action, including that these patents would not be infringed by our product candidates and/or that these patents are not valid. However, if
these patents were enforced against us and defenses to such enforcement were unsuccessful, unless we obtain a license to these patents, which may not be available on commercially reasonable terms, or at all, we could be liable for damages and
precluded from commercializing any product candidates that were ultimately held to infringe these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even in the absence of a finding of infringement, we may need or may choose to obtain licenses from third parties to advance our research or
allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would be unable to further develop and commercialize our product candidates.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing could materially adversely affect our business, results of operations and
financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent term may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years
beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, a patent term extension cannot extend the remaining term of a patent beyond a
total of 14 years from the date of the product&#146;s approval by the FDA, only one patent applicable to an approved drug is eligible for the extension, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. In the future, if and when our product candidates receive FDA approval,
we plan to apply for patent term extensions on patents covering those product candidates in any jurisdiction where these are available. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent
regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to the patents we <FONT STYLE="white-space:nowrap">in-license,</FONT> or may grant more limited
extensions than we request. Moreover, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable
requirements. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade
secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information
<FONT STYLE="white-space:nowrap">or&nbsp;know-how&nbsp;of</FONT> others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Our licensors may face similar risks, which could have an adverse impact on
intellectual property that is licensed to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights
have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to our product candidates or utilize similar cell therapy
technology but that are not covered by the claims of our current or future patent portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions
covered by the issued patent or pending patent application that we license now or that we may license or own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our current or future licensed patent applications will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do
not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent application in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent application covering such intellectual property; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party patents may issue with claims covering our activities; we may have infringement liability exposure
arising from such patents. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our
common stock will be and as a result it may be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering
there has been no public market for shares of our common stock. An active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares quickly or at the market price if trading in
shares of our common stock is not active. The initial public offering price for our common stock will be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of the common stock
after the offering. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. Further, an inactive market may also impair our ability to raise capital by
selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The price of our stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in
response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment or results of our planned preclinical studies or clinical trials of our product
candidates or any preclinical studies or future clinical trials we may conduct, or changes in the development status of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical
trial or to terminate an existing preclinical study or clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays in preclinical studies or clinical trials of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse
development with respect to the applicable regulatory authority&#146;s review of such filings, including, without limitation, the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to our product candidates, including, but not limited to, clinical
trial requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse developments concerning our manufacturers or suppliers; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable
prices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to establish collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">introduction of new products or services offered by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth of our initial target markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully treat additional types of B cell-mediated autoimmune diseases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of
research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and The Nasdaq Global Market and biopharmaceutical companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual
operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#146;s securities. If the market price of our common stock after this
offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against
companies following periods of volatility in the market price of a company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#146;s attention and resources, which would harm
our business, operating results or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you will incur immediate and
substantial dilution in the book value of your shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price is substantially higher than the net
tangible book value per share of our common stock, which gives effect to the automatic conversion of all of our outstanding shares of convertible preferred stock into common stock. Investors purchasing common stock in this offering will pay a price
per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, based on the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the
price range set forth on the cover page of this prospectus. Further, investors purchasing common stock in this offering will contribute approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total amount invested by stockholders since our inception but
will own only approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding after giving effect to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This dilution is due to our investors who purchased shares prior to this offering, including upon the exercise of options to purchase common
stock, having paid substantially less when they purchased their shares than the price offered to the public in this offering. In addition, we have, in the past, issued options to acquire our common stock at prices significantly below the initial
public offering price. If all of these outstanding options to purchase shares of common stock as of June 30, 2019 were exercised, our pro forma as-adjusted net tangible book value would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an immediate increase in our pro forma as-adjusted net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share to our existing stockholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing shares in this offering. As a result of the dilution to investors
purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately
after this offering, see &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends on our common stock, so any returns will be
limited to the value of our stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently anticipate that we will retain future earnings for the development, operation and
expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over
matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, our executive officers, directors, and 5% stockholders
beneficially owned, in the aggregate, approximately 88.7% of our voting stock as of June&nbsp;30, 2019, and, upon the closing of this offering, that same group will beneficially own &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock.
Accordingly, even after this offering, these stockholders will have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may
be able to significantly affect the outcome of elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited
acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are
an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an
emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor
attestation requirements of Section&nbsp;404 of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements
and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years
following the year in which we complete this offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the
fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our
common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700&nbsp;million as of the prior June 30th, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth
companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that
have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the
JOBS Act. As a result, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies and our financial statements may not be comparable to other public companies that comply
with new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, even after we no longer qualify as an
emerging growth company, we may still qualify as a &#147;smaller reporting company&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor
attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our
common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our
ability to operate our business could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that we have adequate internal financial and accounting controls and
procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be <FONT STYLE="white-space:nowrap">re-evaluated</FONT> frequently. Our internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this
offering, we intend to begin the process of documenting, reviewing, and improving our internal controls and procedures for compliance with Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the
effectiveness of our internal control over financial reporting. We have begun recruiting additional finance and accounting personnel with certain skill sets that we will need as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our
existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate
financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a
timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased costs as a result of operating as a public
company, and our management will be required to devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we
will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require,
among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition<B><I>. </I></B>In addition, the Sarbanes-Oxley Act, as well as rules
subsequently adopted by the SEC and the Nasdaq Global Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and
financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive
compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Emerging growth companies are permitted to implement many of these
requirements over a longer period and up to five years from the pricing of this offering. We intend to take advantage of this legislation for as long as we are permitted to do so. Once we become required to implement these requirements, we will
incur additional compliance-related expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations,
which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to continue to increase our legal and financial compliance costs and to
make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results
of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and
regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount
or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees
or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders in the public
market could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial
amounts of our common stock in the public market after the <FONT STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on
shares of common stock outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, upon the closing of this offering we will have outstanding a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. Of these shares, only the shares of common stock sold in this offering by us, plus any shares sold upon exercise of
the underwriters&#146; option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering. The underwriters, however, may, in their sole discretion, permit our officers,
directors and other stockholders who are subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180 days from the date
of this prospectus. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under the 2019 Stock Option and Incentive Plan, or the 2019 Plan, will become eligible for sale in the public
market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to
the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See &#147;Description of Capital Stock&#151;Registration Rights&#148;. Registration of these shares under the Securities
Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a
material adverse effect on the trading price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to
purchase common stock, including pursuant to the 2019 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical
trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more
transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material
dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock, including shares of common stock sold in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2019 Plan, certain amendments of which became effective on the business day prior to the public trading date of our common
stock, our management is authorized to grant stock options to our employees, directors and consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the aggregate number
of shares of our common stock that may be issued pursuant to stock awards under the 2019 Plan is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. Additionally, the number of shares of our common stock
reserved for issuance under the 2019 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2020 and continuing through and including January&nbsp;1, 2029, by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number
of shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for
future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that
adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt,
limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances
and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes
described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of
the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. The failure by our
management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable
return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the
market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws, which are to become effective at or prior to the closing
of this offering, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of
the board will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken
at a meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the
chief executive officer, or by a majority of the total number of authorized directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for
cause and, in addition to any other vote required by law, upon the approval of the holders of not less than 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws
by stockholder action or to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors
without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate
Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and
restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger,
tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you
desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our bylaws to be effective upon the consummation of this offering designate certain
courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers, or employees. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our amended and restated bylaws, to be effective upon the completion of this
offering, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware or other
state courts of the State of Delaware) will be the sole and exclusive forum for state law claims for: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty or other
wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of
incorporation or bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v)&nbsp;any action asserting a claim governed by the internal affairs doctrine. This exclusive
forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. In addition, our amended and restated bylaws will provide that any person or entity purchasing or otherwise acquiring any interest in shares
of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims, particularly if
the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#146; ability to bring a claim in a forum that they find favorable for disputes
with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. The Court of Chancery of the State of
Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable
to us than our stockholders. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock
price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend in part on the research and reports
that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the
trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about
our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to
decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion
and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently
available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and
unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
Forward-looking statements in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of our planned IND submission for DSG3-CAART; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost and timing and conduct of our clinical trial program, initially our planned Phase 1 clinical
trial of DSG3-CAART, and our other product candidates, including statements regarding the timing of initiation and completion of the clinical trials and the period during which the results of the clinical trials will become available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approval of our product candidates, including
DSG3-CAART, MuSK-CAART and <FONT STYLE="white-space:nowrap">DSG3/1-CAART,</FONT> in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to pursue research and development of other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plan to infuse our DSG3-CAART product candidate without lymphodepletion or other preconditioning agents
initially in our planned Phase 1 clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages of our CABA platform and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our scientific approach and CABA platform may potentially address a broad range of diseases;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits and success of our arrangements with Penn and CHOP and our scientific <FONT
STYLE="white-space:nowrap">co-founders,</FONT> Drs. Milone and Payne; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates, including DSG3-CAART and our other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential receipt of revenue from future sales of DSG3-CAART and our other product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of DSG3-CAART and our other product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market opportunity for DSG3-CAART and our other product candidates, and our
ability to serve those markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our sales, marketing and distribution capabilities and strategy, whether alone or with potential future
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain arrangements or a facility for manufacture of DSG3-CAART and our other
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to initiate and complete our
planned Phase 1 clinical trial of DSG3-CAART and our ongoing preclinical studies of MuSK-CAART, <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> and FVIII-CAART; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential achievement of milestones and receipt of payments under our collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into additional collaborations with existing collaborators or other third parties;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product
candidates and our ability to operate our business without infringing on the intellectual property rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or become available, and our competitive position;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional
financing </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations in the United States and foreign countries; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific or management personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, forward-looking statements can be identified by terminology such as &#147;may,&#148; &#147;should,&#148; &#147;expects,&#148;
&#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue&#148; or the negative of these terms or other comparable terminology. These
statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially
affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled &#147;Risk Factors&#148; and elsewhere in this prospectus. If one or more of
these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a
guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement, of which this prospectus is
a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events
and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should
therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and
studies conducted by third parties. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events
and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies,
and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented
in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section
titled &#147;Risk Factors&#148; and elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale of shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise in full their option to purchase additional shares,
assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this
offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our net
proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. We do not expect that a change in the offering price or the number of shares by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the
amount of time prior to which we may need to seek additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, we had cash and cash equivalents of
$75.3&nbsp;million. We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the
advancement of DSG3-CAART, our lead product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the
advancement of our other product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for establishment
of our planned manufacturing facility; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder, if any, to fund working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe our existing cash, together with the net proceeds from this offering, will be sufficient to fund our
operations through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from
this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. For example, we may use a portion of the net proceeds for the acquisition of
businesses or technologies to continue to build our pipeline, our research and development capabilities and our intellectual property position, although we currently have no agreements, commitments or understandings with respect to any such
transaction. We cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our
actual expenditures may vary significantly depending on numerous factors, including the progress of our research and development, the status of and results from <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies or clinical trials we may
commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our management will retain
broad discretion over the allocation of the net proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of proceeds from this offering, we intend to
invest the net proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future
earnings to support our operations and finance the growth and development of our business, and therefore do not intend to pay cash dividends on our common stock for the foreseeable future. Any future determination related to dividend policy will be
made at the discretion of our board of directors and will depend on, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may
deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and restricted cash and total capitalization as of June&nbsp;30, 2019: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i)&nbsp;the automatic conversion of all outstanding shares of our
preferred stock into an aggregate of 19,356,835 shares of common stock upon the completion of this offering and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our sale and issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering, at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information below is illustrative only, and our
capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with &#147;Use of Proceeds,&#148; &#147;Selected Financial Information,&#148; &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in&nbsp;thousands,&nbsp;except&nbsp;shares&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (Series&nbsp;A, <FONT STYLE="white-space:nowrap">A-1,</FONT> <FONT
STYLE="white-space:nowrap">A-2</FONT> and B), $0.00001 par value; 20,762,168 shares authorized, 19,356,835 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00001 par value; 29,000,000 shares authorized, 5,772,484 shares issued and
outstanding, actual; pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of cash and restricted
cash, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
(decrease) of 1.0&nbsp;million shares in the number of shares offered by us in this offering would increase (decrease) the pro forma as adjusted amount of cash and restricted cash, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital,
total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above excludes the following shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,435,545 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30,
2019, at a weighted average exercise price of $1.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">291,454 shares of common stock available for future issuance under our 2018 Stock Option and Grant Plan, or 2018
Plan, as of June&nbsp;30, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that will be made
available for future issuance under our 2019 Stock Option and Grant Plan, or 2019 Plan, upon the effectiveness of the registration statement of which this prospectus forms a part; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that will be made
available for future issuance under our 2019 Employee Stock Purchase Plan, or 2019 ESPP, upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, our historical net tangible book value (deficit) was $(23.1)&nbsp;million, or $(3.99)&nbsp;per share of our common
stock. Net tangible book value (deficit) per share represents our total tangible assets (total assets less intangible assets) less total liabilities and preferred stock, divided by the total number of our outstanding shares of common stock as of
June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of June&nbsp;30, 2019 was approximately $74.9&nbsp;million, or $2.98 per
share of pro forma common stock. Pro forma net tangible book value (deficit) per share represents the amount of our total tangible assets (total assets less intangible assets) less total liabilities, divided by the total number of outstanding shares
of our common stock as of June&nbsp;30, 2019, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred stock as of June&nbsp;30, 2019 into an aggregate of 19,356,835 shares of common stock upon the
completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;the sale and
issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering, at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2019 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. This represents an immediate increase in pro forma net tangible book value of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to investors participating in this offering is determined by subtracting pro forma as adjusted net tangible book value per
share after this offering from the initial public offering price per share paid by investors participating in this offering. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to
purchase additional shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to pro forma adjustments described
above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to investors participating in
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma as adjusted net tangible book value per share to new investors participating
in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative and will change based on the actual initial public
offering price and other terms of this offering determined at pricing. If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after this offering would be
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and the dilution in pro forma as adjusted net tangible book value per share to new investors participating in this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjusted net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution to investors participating in this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting
discounts and commissions and estimated expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, each increase (decrease) of 1.0&nbsp;million shares in the
number of shares offered by us in this offering would increase (decrease) the pro forma as adjusted net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to investors
participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and
commissions and estimated expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on a pro forma as adjusted basis as of June&nbsp;30,
2019, the differences between the number of shares of common stock purchased from us, the total cash consideration and the average price per share paid to us by existing stockholders and by new investors purchasing shares in this offering, at the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover of this prospectus before deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing shares of common stock in this offering will pay an average price per share substantially higher than our existing investors paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARES<BR>PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares in full, the number of shares of
common stock held by existing stockholders will be reduced to&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock to be outstanding after this offering, and the number of shares of common stock held by investors participating in
this offering will be further increased to &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock to be outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and tables are based on 5,772,484 shares of common stock issued and outstanding as of June&nbsp;30, 2019 and gives effect
to the conversion of all of our outstanding preferred stock into shares of our common stock upon the completion of this offering and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,435,545 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30,
2019, with a weighted average exercise price of $1.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">291,454 shares of common stock available for future issuance under our 2018 Plan as of June&nbsp;30, 2019;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that will be made
available for future issuance under our 2019 Plan upon the effectiveness of the registration statement of which this prospectus forms a part; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that will be made
available for future issuance under our 2019 ESPP upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by investors in this offering
by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1.0&nbsp;million shares in the number of shares offered by us in this offering would increase (decrease) the total consideration paid by investors in this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price
range set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options are exercised or shares are issued under our equity incentive plans, you will experience further
dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is
raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_8"></A>SELECTED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The statements of operations and comprehensive loss data for the period from April 3, 2017 (inception) to December&nbsp;31, 2017 and for
the year ended December&nbsp;31, 2018 and the balance sheet data as of December&nbsp;31, 2017 and 2018 have been derived from our audited financial statements included elsewhere in this prospectus. The statements of operations and comprehensive loss
data for the six months ended June&nbsp;30, 2018 and 2019 and the balance sheet data as of June&nbsp;30, 2019 have been derived from our unaudited financial statements included elsewhere in this prospectus and have been prepared on the same basis as
the audited financial statements. In the opinion of management, the interim data reflect all normal recurring adjustments necessary for the fair presentation of the financial information in those statements. You should read this data together with
our financial statements and related notes included elsewhere in this prospectus and in the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical
results are not necessarily indicative of the results to be expected in the future, and results for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2019 are not necessarily indicative of the results to be expected
for the full year ending December&nbsp;31, 2019. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements&nbsp;of&nbsp;Operations&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,663,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,548,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,448,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing pro forma net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447,398</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,768,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Notes&nbsp;2 and 10 to our audited financial statements and Notes&nbsp;2 and 10 to our unaudited interim
financial statements included elsewhere in this prospectus for a description of how we compute basic and diluted net loss per share and basic and diluted pro forma net loss per share, and the weighted-average number of shares used in the computation
of these per share amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of<BR>June&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our financial statements and related
notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of
operations together with the section entitled &#147;Selected Financial Information&#148; and our financial statements and related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set
forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including
those factors set forth in the section entitled &#147;Risk Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You
should carefully read the section entitled &#147;Risk Factors&#148; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled
&#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company focused on the discovery and development of engineered T&nbsp;cell therapies for B&nbsp;cell-mediated autoimmune
diseases. Our proprietary technology utilizes CAAR T&nbsp;cells that are designed to selectively bind and eliminate B&nbsp;cells that produce disease-causing autoantibodies, or pathogenic B&nbsp;cells, while sparing normal B&nbsp;cells. Our lead
CAAR&nbsp;T cell product candidate was designed based on or CAR T&nbsp;cell technology that has been successfully developed and is marketed for the treatment of B&nbsp;cell cancers. We believe our technology, in combination with our proprietary
Cabaletta Approach for selective B&nbsp;cell Ablation platform, called our CABA platform, has applicability across over two dozen B&nbsp;cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. In order to accelerate
product development for our lead program and to access a proven cell therapy manufacturing platform, we have entered into a collaboration with Penn. We hold multiple agreements with Penn to develop CAAR&nbsp;T cell therapies for the treatment of
these diseases. Our goal is to leverage our team&#146;s expertise in autoimmunity and engineered T cell therapy and our collaboration with Penn to rapidly discover and develop our portfolio of CAAR&nbsp;T product candidates. Our initial focus is on
pemphigus vulgaris, or PV, which is an autoimmune blistering skin disease. We submitted an IND to the FDA in August 2019 and, if our IND is accepted, plan to advance our lead product candidate, DSG3-CAART, into a Phase&nbsp;1 trial for the treatment
of mucosal pemphigus vulgaris, or mPV, in 2020. We are also advancing additional product candidates currently in discovery-stage or preclinical development for the treatment of MuSK MG, mucocutaneous PV, or mcPV, and Hemophilia&nbsp;A with FVIII
alloantibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in April 2017. In August 2018, we entered into multiple agreements with Penn to develop the
CAAR&nbsp;T technology to treat B&nbsp;cell-mediated autoimmune diseases. Our operations to date have been financed primarily by net proceeds of $86.4&nbsp;million from the sale of convertible notes and convertible preferred stock. As of
June&nbsp;30, 2019, we had $75.3&nbsp;million in cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have had significant operating losses,
much of which are attributable to research and development costs pursuant to sponsored research and research service agreements. Our net loss was $0.3&nbsp;million for the period from April&nbsp;3, 2017 (inception) through December&nbsp;31, 2017,
$12.2&nbsp;million for the year ended December&nbsp;31, 2018 and $6.9&nbsp;million for the six month period ended June&nbsp;30, 2019. As of June&nbsp;30, 2019, we had an accumulated deficit of $22.0&nbsp;million. Our primary use of cash is to fund
operating expenses, which consist primarily of research and development expenditures and, to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as
reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital
expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products, as well as hire
additional personnel, develop commercial infrastructure, pay fees to outside consultants, lawyers and accountants, and incur increased costs associated with being a public </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs. Our net losses may
fluctuate significantly
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;quarter-to-quarter&nbsp;and&nbsp;year-to-year,&nbsp;depending</FONT></FONT></FONT></FONT> on the timing of
our clinical trials and our expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon our current operating plan, we believe
that the net proceeds from this offering, together with our existing cash and cash equivalents as of June&nbsp;30, 2019, will enable us to fund our operating expenses and capital expenditure requirements
through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. To date, we have not had any products approved for sale and have not generated any product sales. We do not expect to generate any revenues from
product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product
candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance
our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when
needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we
will need to delay, reduce or terminate planned activities to reduce costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated License Agreement with The Trustees of the
University of Pennsylvania </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into the License Agreement with Penn and CHOP, which we refer to as the
Institutions, pursuant to which we obtained (a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> non-sublicensable, worldwide research license to make, have made and use products in two subfields of use, (b)&nbsp;effective as of October
2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain of the Institutions&#146; intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and
(c)&nbsp;effective as of October 2018, a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#146;s <FONT STYLE="white-space:nowrap">know-how</FONT> to
make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. Our rights are subject to the rights of the U.S. government and certain rights retained by the Institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the License Agreement will expire with respect to a product upon the later of (a)&nbsp;the expiration of the last
to expire patent or patent application covering such product or (b) 10 years after the first commercial sale of such product. We may terminate the License Agreement in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">subfield-by-subfield</FONT></FONT> basis at any time for convenience upon a certain number of days&#146; written notice. Penn may terminate the License Agreement in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">subfield-by-subfield</FONT></FONT> basis for our uncured material breach, including for our failure to meet certain diligence obligations and milestone events. We, however, may extend the achievement date of any milestone
event for an additional period of time by making a payment in a certain amount, subject to certain limitations in the number of times each event may be extended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Penn </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sponsored
research agreements with Penn for the laboratories of Drs.&nbsp;Payne and Milone, who are also our scientific co-founders and members of our scientific advisory board. Under these agreements, we are committed to funding a defined research plan for
three years through April 2021. The total estimated three-year cost of the two agreements is $8.5&nbsp;million, which satisfies the $2.0&nbsp;million annual obligation under the License Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Regents of the University of California </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we executed a research agreement with The Regents of the University of California. Under this agreement, we are committed to
funding scientific research through October 2020 in an immaterial amount. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Master Translational Research Service Agreements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into a Services Agreement with Penn pursuant to which Penn agreed to perform certain services related
to the research and development of the technology licensed to us under the License Agreement, as well as certain clinical, regulatory and manufacturing services. The research and development activities are detailed in Penn organization-specific
addenda that are separately executed. The Services Agreement will expire on the later of (i)&nbsp;October&nbsp;19, 2021 or (ii)&nbsp;completion of the services for which we have engaged Penn under the Services Agreement. As of December&nbsp;31,
2018, we had executed three project addenda and the three projects are anticipated to commence and conclude in 2019. In January 2019, we executed two additional project addenda under the Services Agreement for manufacturing and development work. The
two projects are anticipated to commence in 2019. The manufacturing addendum is expected to occur through June 2020. The development addendum is expected to occur through December 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date,
we have not generated any revenue from product sales and do not expect to generate any revenue from the sales of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result
in marketing approval, we may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining
regulatory approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also in the future enter into license or collaboration agreements for our
product candidates or intellectual property, and we may generate revenue in the future from payments as a result of such license or collaboration agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel costs, which include salaries, benefits and stock-based compensation expense; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with consultants, third-party contract organizations that conduct research and
development activities on our behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to sponsored research service agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies and equipment used for internal research and development activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not reported program costs since inception because historically we have not tracked or recorded our research and development expenses
on <FONT STYLE="white-space:nowrap">a&nbsp;pre-clinical</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program&nbsp;basis.</FONT></FONT> We use our personnel and infrastructure resources across the breadth of our
research and development activities, which are directed toward identifying and developing product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense all research and development costs in the periods in which they are incurred.
Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by Penn, our vendors and third-party service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and
development activities related to developing our product candidates, including investments in manufacturing, as our programs advance and we conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory
approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to
what extent we will generate revenue from the commercialization and sale of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks
and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues
from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product
candidates will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development of chemistry, manufacturing and controls, or CMC, processes and procedures for purposes of IND
applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful patient enrollment in, and the initiation and completion of, clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of regulatory approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing commercial manufacturing capabilities or arrangements with third-party manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection
<FONT STYLE="white-space:nowrap">and&nbsp;non-patent&nbsp;exclusivity;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration
with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies and treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a continued acceptable safety and efficacy profile following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enforcing and defending intellectual property and proprietary rights and claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving desirable medicinal properties for the intended indications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical
studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing
associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority, were to require us to conduct clinical trials beyond those that we currently anticipate
will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial
resources and time on the completion of preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property,
depreciation expense and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and
administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of operating as a public company and the potential commercialization of our
product candidates. We anticipate our general and administrative costs will increase and with respect to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased
costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Income and (Expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our other income and (expense) includes (i)&nbsp;interest income earned on cash reserves in our operating account; and (ii)&nbsp;fair value
adjustments on convertible notes for which we have elected the fair value option of accounting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the six months ended
June&nbsp;30, 2018 and 2019 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth our results of operations for the six months ended June&nbsp;30, 2018 and 2019:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $0.6&nbsp;million for the six months ended June&nbsp;30, 2018 as compared to $5.4&nbsp;million for the
six months ended June&nbsp;30, 2019. The increase of $4.8&nbsp;million in our research and development expenses <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-on-period</FONT></FONT> reflects that our principal operations
did not commence until April 2018 when we entered into two SRAs with Penn. Specific increases in our research and development expenses <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-on-period</FONT></FONT> include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.7&nbsp;million for manufacturing of preclinical and clinical supplies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.3&nbsp;million of personnel costs, including $0.5&nbsp;million of stock-based compensation expense;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.9&nbsp;million with respect to sponsored research activities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.9&nbsp;million of development services, including preclinical testing, clinical operations and regulatory.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months<BR>Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License of intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing of preclinical and clinical supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $0.4&nbsp;million for the six months ended June&nbsp;30, 2018 as compared to $2.4&nbsp;million for the
six months ended June&nbsp;30, 2019. The increase of $2.0&nbsp;million in our general and administrative expenses <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-on-period</FONT></FONT> includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.8&nbsp;million increased costs of services, including legal, audit and accounting, public relations,
recruiting and other consulting fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.9&nbsp;million of increased costs related to personnel, including $0.3&nbsp;million of stock-based
compensation expense; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.3&nbsp;million increase in other general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income and (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income or (expense) for the six month periods ended June&nbsp;30, 2018 and 2019 comprises interest income which has increased
$0.9&nbsp;million deriving from our increased cash resulting from proceeds received from our issuances of our convertible notes in May 2018 and convertible preferred stock in October 2018 and January 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the period from April&nbsp;3, 2017 (inception) to December&nbsp;31, 2017 and
year ended December&nbsp;31, 2018 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth our results of operations for the period from April&nbsp;3, 2017
(inception) to December&nbsp;31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $0 for the period from April&nbsp;3, 2017 (inception) to December&nbsp;31, 2017, as our principal
operations did not commence until April 2018 when we entered into two SRAs with Penn. Research and development expenses increased to $4.5&nbsp;million for the year ended December&nbsp;31, 2018 and include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$2.0&nbsp;million for sponsored research activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.2&nbsp;million for the license of intellectual property from Penn in exchange for shares of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.7&nbsp;million for manufacturing of preclinical and clinical supplies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.5&nbsp;million of personnel costs, including $0.5&nbsp;million of stock-based compensation expense; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.1&nbsp;million for services and other expenses. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from<BR>April&nbsp;3,&nbsp;2017<BR>(inception)&nbsp;to<BR>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsored research activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License of intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing of preclinical and clinical supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $0.3&nbsp;million for the period from April&nbsp;3, 2017 (inception) through December&nbsp;31, 2017
related to services to us, comprised of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.2&nbsp;million of legal fees; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.1&nbsp;million in consulting and other services. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased to $1.7&nbsp;million for the year ended December&nbsp;31, 2018, and were primarily comprised of:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$1.2&nbsp;million for legal, accounting, consulting, recruiting and other services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.4&nbsp;million of personnel costs, including $0.2&nbsp;million of stock-based compensation expense; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$0.1 million&nbsp;for other general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income and (Expense) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had no other income or (expense) for the period from April&nbsp;3, 2017 (inception) to December&nbsp;31, 2017. Our other income and
(expense) for the year ended December&nbsp;31, 2018 includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interest income of $0.2&nbsp;million earned on cash reserves in our operating account; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fair value adjustments on our convertible notes for which we have elected the fair value option of accounting.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in April 2017 through June&nbsp;30, 2019, our operations have been financed by proceeds of $86.4&nbsp;million from the sale
of convertible notes and our convertible preferred stock. As of June&nbsp;30, 2019, we had $75.3&nbsp;million in cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with
a view to liquidity and capital preservation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred losses since our inception and, as of June&nbsp;30, 2019, we had an
accumulated deficit of $22.0&nbsp;million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund
operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the
foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue,
we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect
will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to <FONT STYLE="white-space:nowrap">the&nbsp;build-out&nbsp;of</FONT> our headquarters, laboratories and
manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash
equivalents as of June&nbsp;30, 2019, will enable us to fund our operating expenses and capital expenditure requirements through at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from the date of this offering. We
have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire
<FONT STYLE="white-space:nowrap">or&nbsp;in-license&nbsp;other</FONT> potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources,
including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital
through public or private equity offerings, the ownership interest of our existing stockholders, including investors in this offering, will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect our stockholders&#146; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay,
reduce or terminate planned activities to reduce costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with research,
development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of researching, developing and manufacturing our lead product candidates
or any future product candidates, and conducting preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product
candidates or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of any additional product candidates we develop or acquire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of any cash milestone payments if we successfully achieve certain predetermined milestones;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our lead product candidate or any future product candidates and any products we
successfully commercialize, including costs associated <FONT STYLE="white-space:nowrap">with&nbsp;building-out&nbsp;our</FONT> manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial
terms of any such agreements that we may enter into; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and amount of sales of any future approved or cleared products, if any.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital
requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and
commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months</B><br><B>Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the period from April&nbsp;3, 2017 (inception) through December&nbsp;31, 2017, cash used in operating activities of $0 was attributable
to a net loss of $0.3&nbsp;million offset by a net change of $0.3&nbsp;million in our net operating assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2018, cash used in operating activities of $4.7&nbsp;million was attributable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our net loss of $12.2&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">largely offset by <FONT STYLE="white-space:nowrap">non-cash&nbsp;charges</FONT> of $8.0&nbsp;million for changes
in fair value of our convertible notes, common stock issued for the Penn license and stock-based compensation charges; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased by the net change of $0.5&nbsp;million in our net operating assets and liabilities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2018, cash used in operating activities of $1.7&nbsp;million was attributable
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our net loss of $1.0&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offset by <FONT STYLE="white-space:nowrap">non-cash&nbsp;charges</FONT> of $0.1&nbsp;million with respect to
stock-based compensation charges; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased by the net change of $0.8&nbsp;million in our net operating assets and liabilities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2019, cash used in operating activities of $6.1&nbsp;million was attributable
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our net loss of $6.9&nbsp;million; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offset by <FONT STYLE="white-space:nowrap">non-cash&nbsp;charges</FONT> of $0.9&nbsp;million for stock-based
compensation charges and depreciation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased by the net change of $0.1&nbsp;million in our net operating assets and liabilities.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had no investing activities during the period from April&nbsp;3, 2017 (inception) through December&nbsp;31, 2017, the year ended
December&nbsp;31, 2018 or the six months ended June&nbsp;30, 2018. For the six month period ended June&nbsp;30, 2019, we used $0.4&nbsp;million of cash and cash equivalents in investing activities consisting of purchases of property and equipment.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the period from April&nbsp;3, 2017 (inception) through December&nbsp;31, 2017, cash provided by financing activities amounted to
$1&nbsp;thousand in the issuance of vested and <FONT STYLE="white-space:nowrap">non-vested,</FONT> restricted common stock to our founders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, cash provided by financing activities amounted to $37.7&nbsp;million comprised of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$12.5&nbsp;million of proceeds upon the issuance of convertible notes in May 2018; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$12.6&nbsp;million of proceeds on the milestone closing of the convertible notes and issuance of our Series <FONT
STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock in October 2018; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$12.6&nbsp;million net proceeds upon the issuance of our Series A convertible preferred stock in October 2018.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2018, our financing activities provided $12.5&nbsp;million of proceeds upon the
issuance of convertible notes in May 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2019, our financing activities provided
$48.7&nbsp;million of proceeds upon the issuance of Series B convertible preferred stock in January 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant
Judgments and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on
our financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and
on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more
significant areas involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate costs of research and development activities conducted by service providers, which include activities under the License Agreement,
the conduct of sponsored research, preclinical studies and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and include
these costs in the accrued and other current liabilities or prepaid expenses on the balance sheets and within research and development expense on the statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements
established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we
adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize compensation costs related to stock-based awards, including stock options and <FONT STYLE="white-space:nowrap">non-vested</FONT>
stock, based on the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model, or Black-Scholes. The grant date fair value
of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Black-Scholes requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>&#151;Historically, for all periods prior to this initial public offering, the
fair value of the shares of common stock underlying our stock-based awards was estimated on each grant date by our board of directors. In order to determine the fair value of our common stock underlying option grants, our board of directors
considered, among other things, valuations of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice
Guide,<I></I><I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>, or the Practice Aid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I>&#151;The expected term represents the period that stock-based awards are expected to be
outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the expected term to be the midpoint between the vesting date and the contractual life of the stock-based awards.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected Volatility&#151;Since we have been a privately held company and do not have any trading history for our
common stock, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based
on their similar size, stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk-Free Interest Rate&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in
effect at the time of grant for periods corresponding with the expected term of option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected Dividend&#151;We have never paid dividends on our common stock and have no plans to pay dividends on our
common stock. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each of our awards for the
period from April&nbsp;3, 2017 (inception) through June&nbsp;30, 2019 has been estimated using Black-Scholes based on the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.82%&#151;2.96</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&#151;6.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.3%&#151;73.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to use judgment in evaluating the assumptions utilized for our stock-based compensation
expense calculations on a prospective basis. In addition to the assumptions used in Black-Scholes, the amount of stock-based compensation expense we recognize in our financial statements includes stock option forfeitures as they occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table details stock-based awards that we granted since inception: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type&nbsp;of&nbsp;Award</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Subject&nbsp;to&nbsp;Awards<BR>Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;share</B><br><B>Exercise&nbsp;Price</B><br><B>or&nbsp;Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimate&nbsp;of</B><br><B>Common&nbsp;Stock</B><br><B>Fair&nbsp;Value&nbsp;per</B><br><B>Share&nbsp;on&nbsp;Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2017&#150;January 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Restricted common stock and <FONT STYLE="white-space:nowrap">non-vested,</FONT> restricted common stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">694,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001&#151;0.262</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-vested,</FONT> restricted common stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,356,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,367,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">278,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>De minimis</I> value as principal operations had not yet commenced. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the issuance of convertible notes in May 2018, awards with respect to 4,356,000 shares of
common stock issued in August 2017 were amended to include vesting provisions that require continued service to us in order to vest in those shares. As such, the modified shares of common stock became compensatory upon such modification. The fair
value of each award on the modification date was determined to be $0.49 per share of common stock by calibrating to the recent convertible note issuance considering the maximum conversion price and the seniority of the convertible notes.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of measuring compensation for accounting purposes with respect to awards in October and November
2018 we performed a retrospective common stock valuation as of October&nbsp;28, 2018 with the assistance of an independent third-party valuation specialist. In this retrospective valuation, we employed an OPM framework and utilized the back-solve
method for inferring and allocating the equity value predicated on the sale of our Series A preferred stock. This method was selected as management concluded that the recent financing transaction was an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction. Furthermore, as of the valuation date we were at an early stage of development and future liquidity events were difficult to forecast. Application of the OPM back-solve method
involves making assumptions for the expected time to liquidity, volatility and risk-free rate and then solving for the value of equity such that value for the most recent financing equals the amount paid. In the October&nbsp;28, 2018 retrospective
valuation and for purposes of the OPM allocation of total equity value determined with reference to a recent financing transaction, we assumed a 71% volatility rate and a <FONT STYLE="white-space:nowrap">1.3-year</FONT> weighted average estimated
term. We then reflected a discount for lack of marketability of 35% to arrive at a $1.60 per share valuation of our common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of measuring compensation for accounting purposes with respect to awards in January 2019 we
performed a retrospective common stock valuation as of January&nbsp;2, 2019 with the assistance of an independent third-party valuation specialist. For our January 2019 valuation, the independent third-party valuation specialist used a hybrid
back-solve method considering two scenarios in a Probability Weighted Expected Return Method, or PWERM, framework and using the OPM to allocate value in one of the scenarios. The scenarios included: a trade-sale scenario predicated on the <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> capital raise that transpired just prior to the valuation date and an IPO scenario also based on the recent arm&#146;s length transaction. Under the hybrid method, the per share value calculated
under the two scenarios are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share value of the common stock before a discount for lack
of marketability is applied. For the January 2019 valuation we (i)&nbsp;assigned a 90% probability of occurrence to the trade-sale scenario, with a 75% volatility rate and a <FONT STYLE="white-space:nowrap">1.6-year</FONT> weighted average estimated
term applied within the OPM, then reflected a discount for lack of marketability of 30%; and (ii)&nbsp;we assigned a 10% probability of occurrence to the IPO scenario, with a 30% discount rate and a <FONT STYLE="white-space:nowrap">0.8-year</FONT>
estimated term to an IPO event, then reflected a discount for lack of marketability of 15%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For our February 2019 valuation, the independent third-party valuation specialist used a hybrid back-solve
method considering two scenarios in a PWERM framework and using the OPM to allocate value in one of the scenarios. The scenarios included: a trade-sale scenario predicated on the <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> capital
raise that transpired prior to the valuation date and an IPO scenario with reference to the same arms&#146; length capital transaction. Under the hybrid method, the per share value calculated under the two scenarios are weighted based on expected
exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share value of the common stock before a discount for lack of marketability is applied. For the February 2019
valuation, we: (i)&nbsp;assigned a 65% probability of occurrence to the trade-sale scenario, with a 76% volatility rate and a <FONT STYLE="white-space:nowrap">1.6-year</FONT> weighted average estimated term applied within the OPM, then reflected a
discount for lack of marketability of 30%; and (ii)&nbsp;we assigned a 35% probability of occurrence to the IPO scenario, with a 30% discount rate and a <FONT STYLE="white-space:nowrap">0.7-year</FONT> estimated term to an IPO event, then reflected
a discount for lack of marketability of 15%. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, for all periods prior to this offering, the fair values of
the shares of common stock underlying our stock-based awards were estimated on each grant date by our board of directors. In order to determine the fair value of our common stock, our board of directors considered, among other things,
contemporaneous valuations of our common stock prepared by an independent third-party valuation specialist in accordance with the Practice Aid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the absence of a public trading market for our common stock, our board of directors exercised their judgment and considered a number of
objective and subjective factors to determine the best estimate of the fair value of our common stock, including contemporaneous valuations performed by an independent third party, our stage of development, important developments in our operations,
the prices at which we sold shares of our preferred stock, the rights, preferences and privileges of our preferred stock relative to those of our common stock, actual operating results and financial performance, the conditions in the biotechnology
industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of our common stock, among other factors. After the closing of this offering, our board of directors will
determine the fair value of each share of underlying common stock based on the closing price of our common stock as reported on the date of the grant. Our board of directors intended all options granted to be exercisable at a price per share not
less than the per share fair value of our common stock underlying those options on the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conducting the retrospective
valuation, we and the independent third-party valuation specialist considered all objective and subjective factors that it believed to be relevant for each valuation conducted in accordance with the Practice Aid, including our best estimate of our
business condition, prospects and operating performance at each valuation date. Other significant factors included: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our preferred stock sold to outside investors in
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions, and the rights, preferences and privileges of our preferred stock as compared to those of our common stock, including the liquidation preferences of our preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of guideline companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations and financial position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the composition of, and changes to, our management team and board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any external market conditions affecting the life sciences and biotechnology industry sectors;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock and stock options, such as an
IPO, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the state of the IPO market for similarly situated privately held life sciences companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimates of fair value of our common stock are highly complex and subjective. There are significant judgments and estimates inherent in
the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event, the related valuations associated with
these events, and the determinations of the appropriate valuation methods at each valuation date. The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the application of
management judgment. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share applicable to common stockholders could have been materially different. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Estimated Offering Price </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our underwriters determined the estimated price range set forth on the cover of this preliminary prospectus, which is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. In comparison, our estimate of the fair value of our common stock was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share
at&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which was determined by our board of directors with the assistance of an independent third-party valuation of our common stock as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We note that, as is typical in
initial public offerings, the estimated price range for this offering was not derived using a formal determination of fair value but was determined based upon discussions between us and the underwriters. Among the factors considered in setting the
estimated range were prevailing market conditions, estimates of our business potential, progress in our clinical trials and developments in our business, the general condition of the securities market and the market prices of, and demand for,
publicly-traded common stock of generally comparable companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, the aggregate intrinsic value of options outstanding as of
June&nbsp;30, 2019 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, all of which related to unvested options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Determination of the Fair Value of Convertible Notes, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Convertible Preferred Stock and
Series A-2 Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected the fair value option for the accounting for our convertible notes issued
in 2018. Fair value adjustments to the convertible notes are included in our other income and (expenses). The fair value of the initial closing of our convertible notes in May 2018 was determined to be equal to the proceeds of $12.5&nbsp;million on
issuance. The fair value of the convertible notes on conversion and of the milestone-based closing in October 2018 was determined to be equal to the value of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock and
Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock into which the convertible notes were converted, which was determined to be $3.39 per share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred
stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, using an OPM framework and utilized the back-solve method for inferring and allocating the equity value predicated on the concurrent sale of Series A
convertible preferred stock. This method was selected as we concluded that the sale of the Series A convertible preferred stock was <FONT STYLE="white-space:nowrap">an&nbsp;arm&#146;s-length&nbsp;transaction.</FONT> Application of the OPM back-solve
method involves making assumptions for the expected time to liquidity, volatility and risk-free rate and then solving for the value of equity such that value for the most recent financing equals the amount paid. The OPM allocation of total equity
value was determined with reference to a recent financing transaction and we assumed a 71% volatility rate, a <FONT STYLE="white-space:nowrap">1.3-year</FONT> estimated term and a probability weighted average discount for lack of marketability of
35%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS&nbsp;Act. Under the JOBS&nbsp;Act, emerging growth companies can delay adopting new
or revised accounting standards issued subsequent to the enactment of the JOBS&nbsp;Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised
accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended
transition period provided in the JOBS&nbsp;Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-09,</FONT> <I>Compensation&#151;Stock Compensation</I> (Topic 718):
&#147;<I>Scope of Modification Accounting</I>,&#148; which provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this ASU
should be applied prospectively to an award modified on or after the adoption date. This guidance was effective for all entities for annual periods and interim periods within those annual periods, beginning after December&nbsp;15, 2017. We adopted
ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> effective January&nbsp;1, 2018, which did not impact our financial statements or financial statement disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I> (Topic 842), with guidance regarding the
accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12&nbsp;months on the balance sheet. This update also requires lessees and
lessors to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&nbsp;15, 2018. For all other entities, including emerging growth
companies, this standard is effective for annual reporting periods beginning after December&nbsp;15, 2019, and interim periods within annual periods beginning after December&nbsp;15, 2020. Early adoption is permitted. We have yet to evaluate the
effect that ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on our financial statements or financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share</I> (Topic&nbsp;260), Distinguishing
Liabilities from Equity (Topic&nbsp;480) and Derivatives and Hedging (Topic&nbsp;815): <I>I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial
Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. Part I of this update addresses the complexity of accounting for certain financial instruments with down round
features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and
complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part&nbsp;II of this update addresses
the difficulty of navigating Topic&nbsp;480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral
of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part&nbsp;II of this update do not have an accounting effect.
For public business entities, the amendments in Part&nbsp;I of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> are effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2018. For all other entities,
the amendments in Part&nbsp;I of this update are effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted for all entities,
including adoption in an interim period. We are currently assessing the potential impact of adopting ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> on our financial statements and financial statement disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, we entered into an operating lease agreement for new office space in Philadelphia, Pennsylvania. The lease term commenced in
May 2019 and will expire in July 2022. The initial annual base rent is $0.3&nbsp;million, and such amount will increase by 2% annually on each anniversary of the commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commitments include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The License Agreement. </I>Under the License Agreement, we are required to make milestone payments upon
successful completion of certain development, regulatory and sales milestones on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. The payment obligations under the License Agreement are contingent upon future events such as our achievement of specified development,
regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under the License Agreement. As of December&nbsp;31, 2018, we were unable to
estimate the timing or likelihood of achieving the milestones or making future product sales. We are also obligated to pay $2.0&nbsp;million annually for three years beginning August 2018 for funding to the laboratories of Drs.&nbsp;Payne and
Milone. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Under the License Agreement, we must use commercially reasonable efforts to develop and commercialize a product
in each subfield. During the term of the License Agreement until the first commercial sale of the first product, we are obligated to pay Penn a <FONT STYLE="white-space:nowrap">non-refundable,</FONT>
<FONT STYLE="white-space:nowrap">non-creditable</FONT> annual license maintenance fee of $10,000. We are required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced
by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that we are able to
successfully develop and launch multiple products under the License Agreement, total milestone payments could approach $20.0&nbsp;million. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an
annual minimum royalty, on annual worldwide net sales of any products that are commercialized by us or our sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by us. To the extent we sublicense our license
rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the <FONT STYLE="white-space:nowrap">mid-single</FONT> to low double-digits. We have also entered into a subscription and
technology transfer agreement with Penn, pursuant to which we will pay Penn an upfront subscription fee and a nominal <FONT STYLE="white-space:nowrap">non-refundable</FONT> royalty on net sales of products, a portion of which will be credited toward
milestone payments and royalties under this License Agreement.&nbsp;Technology transfer activities would be at our cost and subject to agreement as to the technology to be transferred. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Master Translational Research Services Agreement with Penn.</I> Under the Services Agreement, we have
contracted for additional research and development services from various laboratories within Penn. The Services Agreement will expire on the later of (i)&nbsp;October&nbsp;19, 2021 or (ii)&nbsp;completion of the services for which we have engaged
Penn under the Services Agreement. As of December&nbsp;31, 2018, we had executed three project addenda with work expected to commence and conclude in 2019. In January 2019, we executed two further project addenda with work expected to commence in
2019 and conclude in 2020. In July 2019, we executed an additional project addendum with work expected to commence in 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Sponsored Research Agreements. </I>We have SRAs with Drs.&nbsp;Payne and Milone. Under the SRAs, we have
committed to funding a defined research plan for three years through April 2021. We have estimated the three-year cost of the two SRAs to be $8.5&nbsp;million, which satisfies the $2.0&nbsp;million annual obligation under the License Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Research Agreement with The Regents of the University of California. </I>Under the research agreement, we have
committed to funding scientific research through October 2020 in an immaterial amount. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Research Service Agreement with the Children&#146;s Hospital of Philadelphia. </I>Under the research services
agreement, we contracted for the manufacturing of preclinical study and clinical trial material through April 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Off-Balance&nbsp;Sheet</FONT> Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not have, nor do we
currently have, <FONT STYLE="white-space:nowrap">any&nbsp;off-balance&nbsp;sheet</FONT> arrangements as defined under SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and
Qualitative Disclosures about Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash
and cash equivalents of $33.0&nbsp;million as of December&nbsp;31, 2018 and $75.3&nbsp;million as of June&nbsp;30, 2019. We generally hold our cash in interest-bearing money market treasury fund accounts. Our primary exposure to market risk is
interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in
interest rates would not have a material effect on the fair market value of our cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
focused on the discovery and development of engineered T&nbsp;cell therapies for B&nbsp;cell-mediated autoimmune diseases. Our proprietary technology utilizes <U>c</U>himeric <U>a</U>uto<U>a</U>ntibody <U>r</U>eceptor, or CAAR, T&nbsp;cells that are
designed to selectively bind and eliminate B&nbsp;cells that produce disease-causing autoantibodies, or pathogenic B&nbsp;cells, while sparing normal B&nbsp;cells. Our lead CAAR&nbsp;T cell product candidate was designed based on chimeric antigen
receptor, or CAR, T&nbsp;cell technology that has been successfully developed and is marketed for the treatment of B&nbsp;cell cancers. We believe our technology, in combination with our proprietary <U>C</U>abaletta <U>A</U>pproach for selective
<U>B</U>&nbsp;cell <U>A</U>blation platform, called our CABA platform, has applicability across over two dozen B&nbsp;cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. In order to accelerate product development for
our lead program and to access a proven cell therapy manufacturing platform, we have entered into a collaboration with the University of Pennsylvania, or Penn. We hold multiple agreements with Penn to develop CAAR&nbsp;T therapies for the treatment
of these diseases. Our goal is to leverage our team&#146;s expertise in autoimmunity and engineered T&nbsp;cell therapy and our collaboration with Penn to rapidly discover and develop our portfolio of CAAR&nbsp;T cell product candidates. Our initial
focus is on pemphigus vulgaris, or PV, which is an autoimmune blistering skin disease. We submitted an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or the FDA, in August 2019 and, if our IND is accepted,
plan to advance our lead product candidate, DSG3-CAART, into a Phase&nbsp;1 trial for the treatment of mucosal pemphigus vulgaris, or mPV, in 2020. We are also advancing additional product candidates currently in discovery-stage or preclinical
development for the treatment of muscle-specific kinase myasthenia gravis, or MuSK MG, mucocutaneous PV, or mcPV and Hemophilia A with factor VIII, or FVIII, alloantibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B&nbsp;cell-mediated autoimmune diseases occur when certain populations of B cells mistakenly produce autoantibodies, which are directed
against specific healthy tissue or cells in the body. The presence of autoantibodies can manifest in a variety of autoimmune diseases and result in the destruction of healthy tissue in the body. Current treatment options for B cell-mediated
autoimmune diseases are generally limited to corticosteroids and other generalized immunosuppressants that offer only temporary disease suppression, may require chronic, <FONT STYLE="white-space:nowrap">in-hospital</FONT> administration and are
associated with potentially life-threatening side effects. We believe the ideal therapy for B&nbsp;cell-mediated autoimmune diseases would selectively and completely eliminate the pathogenic B&nbsp;cells while sparing the body&#146;s normal
B&nbsp;cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are pioneering the development of a new class of engineered T&nbsp;cell therapies that express CAARs to selectively
engage and eliminate pathogenic B&nbsp;cells. Our CAARs build upon the scientific foundation of CARs, differing primarily in the use of the antigen rather than an antibody fragment, which enables the CAAR T cells to serve as a &#147;decoy&#148; for
specific autoantibodies expressed on the surface of B cells. This allows these pathogenic B cells to engage with the CAAR T cells instead of benign antigens, resulting in their elimination. By harnessing the power of targeted cell therapy, we
believe our CABA platform has the potential to be a one-time curative therapy that may be a more effective and safer therapy option than current treatments. We have developed our CABA platform to inform product candidate development from scientific,
clinical and commercial assessment through CAAR design. Using our CABA platform, we have identified and thoroughly evaluated over two dozen B&nbsp;cell-mediated autoimmune diseases that we believe will be amenable to treatment with the Cabaletta
approach and have advanced several of our highest priority targets into discovery and preclinical testing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current product candidate pipeline is illustrated below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g63t24.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>May not be required if Phase&nbsp;2 is a registrational clinical trial. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial therapeutic focus is on PV, a chronic, autoimmune blistering skin disease that affects over 17,000<B> </B>patients across the
United States and over 25,000 patients across the European Union. The affected PV population in Asia is recognized to be significantly higher than in each of the United States and the European Union. Despite a current standard of care that includes
corticosteroids and adjunctive immunosuppressive agents, PV remains associated with frequent recurrences as well as substantial morbidity and mortality. Our lead product candidate, DSG3-CAART, is being evaluated for the treatment of mPV, a subtype
of PV that affects mucosal surfaces. mPV is caused by autoantibodies against the cell adhesion protein desmoglein 3, or DSG3. DSG3-CAART is designed to selectively target B cells expressing autoantibodies specific for DSG3, which may prevent these
B&nbsp;cells from producing DSG3 antibodies that are the cause of mPV while preserving general B cell immune function. We are advancing DSG3-CAART towards an IND submission with the FDA. Our next <FONT STYLE="white-space:nowrap">PV-directed</FONT>
product candidate, <FONT STYLE="white-space:nowrap">DSG3/1-CAART,</FONT> is being designed to target B cells expressing autoantibodies against DSG3 and desmoglein 1, or DSG1. It is being developed for the treatment of mucocutaneous PV, or mcPV,
another subtype of PV that affects both mucosal and skin surfaces and is caused by autoantibodies against DSG3 and DSG1, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, MuSK-CAART, is designed to treat a subset of patients with myasthenia gravis, or MG. MG is an autoimmune disease
induced by autoantibodies targeting the neuromuscular junction, or NMJ, which can lead to life-threatening muscle weakness. Our product candidate targets B cells expressing autoantibodies against a transmembrane protein, muscle-specific kinase, or
MuSK, and is being developed for the treatment of MuSK MG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also pursuing development of an additional product candidate,
FVIII-CAART, which is being designed to treat a subset of patients with Hemophilia A, an <FONT STYLE="white-space:nowrap">X-linked</FONT> bleeding disorder caused by mutations in the FVIII gene. While our CABA platform is primarily focused on the
treatment of B cell-mediated autoimmune diseases, we believe our approach may be applicable in other instances where B cell antibody production is implicated in response to exogenous FVIII, which is administered for the treatment of Hemophilia A.
Specifically, we have identified an unmet need in cases where the immune system produces antibodies against exogenous antigens, which is known as an alloimmune response. Some patients receiving repeated administrations of exogenous FVIII will
develop alloantibodies against the treatment, also known as inhibitors, neutralizing its therapeutic potential. Patients with FVIII alloantibodies may often require high-dose FVIII, immune tolerance induction with FVIII, agents that mimic FVIII or
plasmapheresis to remove the FVIII alloantibodies. FVIII-CAART leverages a CAAR designed to target B&nbsp;cells expressing alloantibodies against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FVIII, and it is initially being developed as an adjunctive therapy for Hemophilia A patients who develop FVIII alloantibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to build upon our first mover advantage in the field of cell therapy for B cell-mediated autoimmune diseases and further
advance the discovery, development and commercialization of our CAAR T portfolio. Our scientific founders are leading experts in B cell-mediated autoimmune diseases and CAR T technology, and we are led by an experienced team with demonstrated
success in discovering, developing, manufacturing, and evaluating novel cell therapy products in clinical trials. In addition, we have partnered our discovery and initial development efforts with Penn, a pioneer in cell and gene therapy with a
proven track record of expertise in the translational research, clinical development and manufacturing of cell therapy products, in order to accelerate timelines for our first product candidate to enter clinical trials. To date, we have raised an
aggregate of $88&nbsp;million from leading investors including Adage Capital Partners, 5AM Ventures, Boxer Capital, LLC of Tavistock Group, Cormorant Asset Management, Deerfield Management and RedMile Group as well as Penn. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our History and Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientific <FONT
STYLE="white-space:nowrap">co-founders,</FONT> Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., began partnering at Penn in 2013 to combine Dr.&nbsp;Payne&#146;s expertise in B cell-mediated autoimmune diseases with Dr.&nbsp;Milone&#146;s
deep and experienced insights into the design and implementation of CAR T products. Dr.&nbsp;Payne is a worldwide leader in characterizing B cell-mediated autoantibody repertoires in PV and other autoimmune diseases. Dr.&nbsp;Milone is a renowned
scientist in CAR T therapy and was a <FONT STYLE="white-space:nowrap">co-inventor</FONT> of and a key driver in the preclinical discovery and development efforts that yielded Kymriah, the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
CAR T therapy for the treatment of B cell cancers. Dr.&nbsp;Payne&#146;s laboratory surmised that by incorporating an antigen instead of an antibody fragment as the extracellular domain of the CAAR, specific pathogenic B&nbsp;cells could be
targeted. This resulted in a collaboration between the two investigators to apply the scientific foundation of CAR T technology as it has been advanced by Drs. Payne and Milone in order to address B cell-mediated autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Their first scientific publication, &#147;Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease&#148;
(<I>Science</I>, July 2016), attracted the attention of a colleague, Steven Nichtberger, M.D., who is an adjunct professor at the Wharton School at the University of Pennsylvania, teaching a class on biotech company formation, financing and
leadership in the Vagelos Life Sciences&nbsp;&amp; Management Program. Additionally, Dr.&nbsp;Nichtberger has experience creating and building companies, including a novel cellular therapy company, which required transferring the technology from an
academic institution, establishing a research and development organization, hiring of manufacturing and quality teams, creating novel manufacturing processes, reaching agreement with the FDA on novel clinical development pathways and constructing a
commercial-scale Good Manufacturing Practices, or GMP, facility that manufactured autologous cell therapy products for clinical trials. In 2017, based on over a year of interaction and discussions regarding the optimal strategy to advance the
scientific opportunity into a commercially developed product portfolio that could offer potentially curative treatment options to patients, Drs. Payne, Milone and Nichtberger decided to launch Cabaletta Bio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The longstanding and highly productive partnership between our <FONT STYLE="white-space:nowrap">co-founders</FONT> has been complemented by
additional management experience that brings a successful history of translating academic cellular therapy research from Penn and elsewhere into commercially sponsored clinical trials and the establishment of a GMP manufacturing facility and
organization. Gwendolyn Binder, Ph.D., our Executive Vice President, Science and Technology, was an early member of the Translational Research Program Operations team at Penn for over five years and participated in the submission and acceptance of
multiple INDs for novel engineered T cell therapy products. As part of the cell therapy organization at Penn, Dr.&nbsp;Binder partnered with Dr.&nbsp;Milone and others to drive the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> translational
studies that facilitated the initial CAR T clinical trial in B cell cancers at Penn. Dr.&nbsp;Binder also built and led a clinical stage biotechnology company&#146;s manufacturing operations and quality teams, including creation of a fully
functioning commercial grade GMP facility. Dr.&nbsp;Binder also built the translational research program and ultimately led the company&#146;s research organization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Research and Manufacturing Collaboration with Penn </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CABA platform has already produced multiple product candidates through our sponsored research agreements, or SRAs, with Penn for the
laboratories of our scientific <FONT STYLE="white-space:nowrap">co-founders,</FONT> Drs. Payne and Milone. Our continuing relationship with our scientific <FONT STYLE="white-space:nowrap">co-founders</FONT> provides important guidance and insights
to us. Our contractual relationship with Penn through ongoing licensing and research arrangements also provides important services around manufacturing supply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we amended and restated our worldwide license agreement with Penn to develop our CAAR T technology to treat B cell-mediated
autoimmune and alloimmune diseases. This license agreement provides us with access to multiple patent families covering CAAR T therapy as applied to the field of B cell-mediated autoimmune and alloimmune diseases and to the robust intellectual
property portfolio created by Penn under these SRAs in this field. See &#147;&#151;Our Material Agreements&#151;Amended and Restated License Agreement with Penn.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ongoing collaboration with Penn is also based on a Master Translational Research Services Agreement, or Services Agreement, that we
entered into in October 2018, along with multiple additional agreements under the Services Agreement to engage and partner in individual Penn entities, including cell product manufacturing, correlative research, vector manufacturing, clinical trial
operations and protocol development. In addition to the Services Agreement, we have agreements in place with various functional areas and centers that provide additional resources to Penn as well as contractual commitments from Penn with the goal of
providing the capacity to manufacture our lead product candidate, DSG3-CAART. Penn has also agreed to manufacture vector product for use in our clinical trials. Penn&#146;s obligations are subject to certain limitations and termination rights. See
&#147;&#151;Our Material Agreements&#151;Master Translational Research Services Agreement with Penn&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Penn is uniquely
suited to be our partner in our efforts to develop product candidates leveraging our CAAR T technology based on a decade of experience, including manufacturing and clinical support for approximately a dozen active cell therapy clinical trials. The
original manufacturing process for the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> CAR T therapy was developed at Penn before being transferred to Novartis Pharmaceuticals Corporation during late-stage clinical trials. We currently
plan to leverage Penn&#146;s experience, validated standard operating procedures, manufacturing facilities and staffing to accelerate initial development efforts for our lead product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to build upon
our first mover advantage and expertise in cell therapies for B cell-mediated autoimmune diseases to accelerate the discovery, development and commercialization of our CAAR&nbsp;T cell therapies, with a focus on reliable manufacturing. We believe
achieving this goal could result in potentially curative therapies for patients with unmet medical needs who suffer from certain B cell-mediated autoimmune diseases. To achieve this goal, key elements of our strategy include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Achieving clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for our lead product candidate, DSG3-CAART in mPV, the first in a series of well-understood and validated B cell-mediated autoimmune diseases for which
we are developing CAAR&nbsp;T cell product candidates. </I></B>It is well-established that the presence of DSG3 autoantibodies and DSG3 autoantibody producing B cells in patients are both necessary and sufficient to cause mPV in the vast majority of
cases. We believe our biologic understanding coupled with the well-understood clinical signs, symptoms and natural course of the disease, identify mPV as a model disease to evaluate our CAAR T approach. In addition, we have made significant
investment in the design and development of DSG3-CAART, generating a lead candidate that has demonstrated robust target engagement and no <FONT STYLE="white-space:nowrap">off-target</FONT> toxicities in preclinical studies. Taken together, our Phase
1 clinical trial evaluating DSG3-CAART for the treatment of mPV represents an optimal first opportunity to establish initial clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> of our CABA
platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging our CABA platform to identify optimal targets for the CAAR T approach and apply learnings from
DSG3-CAART to advance additional product candidates.</I></B> Shortly after inception, we </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
undertook a comprehensive review of all known B cell-mediated autoimmune diseases in order to evaluate and prioritize the opportunity for selective destruction of B cells in an effort to cure B
cell- mediated autoimmune diseases. Central to this analysis were (i)&nbsp;scientific, clinical and commercial assessment, (ii)&nbsp;epitope mapping to determine regions targeted by autoantibodies, (iii)&nbsp;evaluation of the ability to optimize
the CAAR construct and design with the goal of selectively ablating reactive B cells, and (iv)&nbsp;evaluation of existing or required development of new preclinical models and <I>in vitro</I> and <I>in vivo</I> clinical testing. As we performed
this analysis of potential product candidates, we considered possible paths for clinical trial design and regulatory approval. This analysis incorporated the extensive learnings gleaned from years of effort devoted to development of DSG3-CAART. We
prioritized the targets and since then have been focused on being first to discover and develop a series of products with each providing the potential for cure of an important B cell-mediated autoimmune disease in patients. We intend to continue to
apply our proprietary learnings from DSG3-CAART, including scientific and regulatory learnings, to most effectively advance these additional opportunities. Preclinical studies that are generally similar to, and informed by, DSG3-CAART preclinical
studies are actively ongoing with other CAAR T cell product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Expanding upon our established IP position and first mover advantage in CAAR T therapy targeted towards B
cell-mediated autoimmune diseases</I></B>. We are focused on protecting our intellectual property as we continue to pursue the development of future product candidates. We believe the issued U.S. patent on our initial CAAR constructs is the first
patent covering cells engineered to express the known pathogenic epitopes recognized by DSG3 and DSG1 autoantibodies, which we are working to supplement with additional patent filings. The design of a broadly effective CAAR requires a deep
understanding of the location of immunogenic epitopes targeted by autoantibodies, a competency that we believe we are uniquely positioned to utilize in product candidate development. We believe there is a particularly high value to the first mover
advantage including, but not limited to, experience in discovery, preclinical development, regulatory efforts, intellectual property and insights from clinical trials that can be translated across programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leveraging our cellular therapy experience and knowledge in addition to knowledge gained through our Penn
collaboration to rapidly build our own fully-integrated internal infrastructure.</I></B> We have differentiated expertise that we believe is uniquely suited for the continued buildout of our CABA platform specializing in B cell-mediated autoimmune
diseases. Our scientific <FONT STYLE="white-space:nowrap">co-founders</FONT> who initially developed our technology continue to collaborate closely with us through SRAs. In addition, our management team has a successful history of building the
capabilities of cell therapy-based companies from the discovery and preclinical stage through Phase 3 readiness. In combination with our team, which possesses significant experience in executing on manufacturing strategies for cell therapy products,
our partnership with Penn allows us to utilize their existing infrastructure to accelerate our ability to submit our first IND. In parallel, we continue to build out an experienced team to manage the relationship with Penn while also developing and
continuing to implement a path to our manufacturing independence. Ultimately, we intend to prepare and build our own manufacturing facility upon achieving sufficient initial clinical trial data for DSG3-CAART. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B Cell-Mediated Autoimmune Diseases: Overview and Current Treatment Paradigm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The body&#146;s immune system, which is designed to protect the body from infection and cancer, includes B cells and T cells. B cells are
responsible for producing antibodies against antigens that the body perceives as foreign whereas T cells are responsible for cell-mediated immunity. In the case of B cell-mediated autoimmune diseases, certain populations of the patient&#146;s B
cells mistakenly produce antibodies directed against normal tissues and cells, leading to disease. While these autoantibodies are the major effectors of B cell-mediated autoimmune diseases, the underlying root cause of each B cell-mediated
autoimmune disease is the defective B cells that mistakenly make these pathogenic antibodies. These pathogenic B cells express autoantibodies on their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surface with the same antigen specificity as the circulating pathogenic autoantibodies, which can be used to distinguish them from the healthy B cell population, as shown in the figure below.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I><B><I>Antibodies are B cell receptors that drive B cell maturation.</I></B><I> CD19 serves as a B
cell marker throughout the na&iuml;ve B cell phase, while CD20 is a surface marker expressed later in B cell maturation. CAAR T is capable of eradicating antigen specific B cells and preventing their further development to antibody producing plasma
cells. IgM: immunoglobulin M; IgD: immunoglobulin D; IgA: immunoglobulin A; sIg: surface immunoglobulin, representing the autoantibody on the B cell surface. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current treatment options for autoimmune mediated diseases involve generalized immune suppression, achieved through corticosteroids,
immunosuppressive medications and biologics. Most commonly, corticosteroids are used on both a chronic and acute basis to control disease, and act via a variety of mechanisms to control or downregulate multiple inflammatory pathways. In many cases,
systemic immunosuppressive medications often used in chemotherapy such as mycophenolate, azathioprine and methotrexate, are added in an effort to minimize symptoms and manage the expected recurrences in patients. Biologic therapies have emerged as a
new class of therapies and have a variety of targets including cytokines, B cells, and <FONT STYLE="white-space:nowrap">co-stimulation</FONT> molecules. One particular biologic, rituximab, is an anti-CD20 antibody and is employed in multiple
autoimmune diseases. Rituximab was approved by the FDA in 2018 for treatment of moderate to severe PV. Currently existing treatment options target parts of the immune system in addition to disease-causing B cells, and in general require chronic
administration to reduce recurrence rates. We believe the ideal therapy in autoimmune diseases would completely and specifically eliminate the pathogenic B cells while sparing the immune cells that protect against infection, without requiring
chronic administration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using our CABA platform, we are developing engineered T cell therapy candidates that express CAARs, which serve as &#147;decoys&#148; for
antibodies expressed on the surface of B cells. We believe these CAARs enable the T cells to specifically engage and eliminate pathogenic B cells while sparing normal T cells. By harnessing the power of cell therapy, our technology has the potential
to overcome the ability of these B cells to evade elimination and thus lead to durable responses. Our CAAR T platform is based on the foundation of established CAR T therapeutics, differing primarily in their use of the antigen rather than an
antibody fragment to target pathogenic B cells. We believe our technology has broad applicability and we are building a portfolio of product candidates for B cell-mediated autoimmune diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Background: CAR T Cells </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Engineered T cell therapy is a type of immunotherapy in which human T cells are genetically modified to express specific receptors, enabling
the T cells to recognize and eliminate pathogenic cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key application of engineered cell therapy involves the use of CARs, which are engineered
molecules that enable T cells to identify specific antigens present on the surface of diseased cells. When expressed on the patient&#146;s T cells, the CAR directs the T cells to kill cells that express a particular antigen. These <FONT
STYLE="white-space:nowrap">CAR-expressing</FONT> T cells, or CAR T cells, can proliferate, generating memory CAR T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies
are using CAR T technology to develop therapies for the treatment of B cell cancers. Several drug candidates have demonstrated clinical success, leading to the first FDA regulatory approvals of CAR T therapies for certain B&nbsp;cell cancers. In
these B cell cancers, CAR T therapy has resulted in complete remission of disease in many patients, even in cancer patients with severe, refractory disease. Despite success in treating certain B&nbsp;cell cancers, we believe that CARs have not yet
been developed or evaluated as a treatment option for other types of B cell-mediated autoimmune diseases in patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our
Technology: CAARs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CAAR T platform builds upon the scientific foundation of CARs to enable targeted B cell elimination in an
autoimmune setting, which may lead to complete and durable remission of disease while sparing all other B&nbsp;cell populations that can provide beneficial immunity from infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> domain and the signaling domain of both a CAR T cell and CAAR T cell carry out the
same activation and cytotoxic functions once the engineered cell therapy engages a B cell. Our CAAR T cells differ from CAR T cells primarily in the extracellular targeting domain. Our CAAR T cells incorporate the relevant parts of the autoantigen
that is subject to attack in autoimmune disease, as shown in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I><B><I>Key differences between CAR T (left) vs. CAAR T therapy (right)</I></B><I>. A CAR T cell
typically contains a signaling domain and a <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> domain and incorporates antibody fragments that recognize CD19, a specific antigen present in both leukemia cells and healthy B cells. In contrast, a
CAAR T cell typically contains an antigen as its targeting domain rather than an antibody fragment. The antigen recognizes the specific, pathogenic antibody along with the limited population of B cells that produce the antibody. The model CAAR T
cell depicted here contains an identical signaling domain and a <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> domain. The primary difference between a CAR T cell and a CAAR T cell is the target domain expressed on the cell surface. The
example shown demonstrates the <FONT STYLE="white-space:nowrap">pan-B</FONT> cell ablation that happens when targeting the B cell lineage marker, CD19, and the highly selective pathologic B cell targeting approach of CAAR T. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Potential Advantages of CAAR T Cell Therapy in B Cell-Mediated Autoimmune Diseases
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast to currently available therapies for B cell-mediated autoimmune diseases, based on observations of CAR T activity in
refractory B cell cancers, we believe a single CAAR T treatment could potentially offer complete and durable remission of certain specific B cell-mediated autoimmune diseases while leaving the humoral, or bodily fluid, antibody-producing immune
system intact. We believe our CAAR T cells can recognize the specific autoantibodies that are responsible for causing an underlying disease and kill the cells that express the autoantibodies on their surface. As a result, we believe CAAR T cell
therapy used in B cell-mediated autoimmune disease has the potential for durable elimination of pathogenic B cells and an associated elimination of clinical recurrences with an improved adverse event, or tolerability, profile relative to the current
standard of care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Enhanced target specificity and preservation of humoral immune system </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preservation of the humoral immune system represents a potentially meaningful benefit over existing CD19- or CD20-targeting methods for B cell
ablation, as patients would be less susceptible to infection throughout the remainder of their lives and would not require chronic <FONT STYLE="white-space:nowrap">in-hospital</FONT> treatment with intravenous immunoglobulin, or IVIG, or other
prophylactic therapies. Additionally, because self-reactive B cells make up only 0.01% to 1% of the normal B cell population, we believe the risk of <FONT STYLE="white-space:nowrap">on-target</FONT> toxicity may be reduced compared to systemically
immunosuppressive medications that <FONT STYLE="white-space:nowrap">non-specifically</FONT> weaken the immune system. Continued use of these drugs poses significant risks, such as the potential for fatal infections due to the <FONT
STYLE="white-space:nowrap">non-specific</FONT> tempering of the immune system related to the complete depletion of CD20+ or CD19+ B cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Potential for complete, long-lasting elimination of pathogenic B cells </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current standard of care for B cell-mediated autoimmune disease displays limited and transient therapeutic benefit while also weakening the
humoral immune system. We believe our CAAR T cells have the potential to eliminate the reactive, antibody-producing B cells that are ultimately responsible for disease, while sparing normal B cells. The curative potential of CAAR T cells would be
consistent with clinical findings from use of CAR T products in B cell cancers and would be a significant improvement relative to the current standard of care for certain B cell-mediated autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While CAR T has demonstrated significant clinical success in B cell cancers, cancer cells employ a variety of mechanisms to evade detection by
targeting immune cells, and antigen escape poses a significant risk of failure for CAR T cell treatment in oncology. Antigen escape in CAR T treatment occurs when the antigen that the CAR T cell targets is lost from the malignant cell. Clinically,
this results in response rates that decline from an initial complete response level of about 80% to approximately 50% over a period of years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe this risk of antigen escape is reduced in our setting as mechanisms to evade CAAR T therapy would involve B cell receptor
down-regulation or mutation such that antigen specificity is lost. We believe that the implication of this is that the mutated B cell would no longer produce autoantibodies that recognize the antigen and therefore should no longer be pathogenic. We
also believe that a single infusion of CAAR T cells has the potential for curative effects due to either complete ablation of pathogenic cells or production of memory CAAR T cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our CABA Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team has developed
our CABA platform to inform product candidate development from indication selection through preclinical studies. Using our CABA platform, our team has identified our highest priority target indications following a rigorous analysis of B
cell-mediated autoimmune diseases. A deep understanding of the antigenic epitopes targeted in these diseases is required to design and construct a successful CAAR. Our scientific founders have studied B cell repertoires for many years in the context
of PV. Their expertise is essential to provide insights and guidance regarding our portfolio of products. We leverage the experience and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insight gained from the development of each product candidate to improve the efficiency of our CABA platform in evaluating additional potential product candidates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image6.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Scientific, Clinical and Commercial Assessment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through broad literature review and consultation with internal and external experts, we have identified and continue to monitor the universe of
diseases where pathogenic B cells are implicated in disease pathophysiology. From this set of possible indications, our team then evaluates each disease based on numerous criteria, which include, but are not limited to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Biologic Opportunity for Cure </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the presence of the antibody is well established in patients with the clinical manifestations of the disease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identified antibody has been shown to be necessary and sufficient in causing clinical disease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is a correlation between antibody titer and disease activity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">B cell-depleting therapies are shown or believed to be effective in treating the disease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the antibody repertoire has been or can be characterized for the disease; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Identifiable and Underserved Patient Populations </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a routine and established antibody test exists or can be developed for diagnosis and biomarker assessment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical course and severity of the disease warrant a cellular therapy despite current standard of care;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">products in development do not have the potential to materially improve outcomes versus the current standard of
care; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Evaluation of Preclinical and Clinical Development Pathway </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical <I>in vitro</I> and <I>in vivo</I> models exist or can be developed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential clinical trial designs and endpoints appear reasonable and achievable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to assessing the underlying biologic and clinical rationale for each potential target, we also assess commercial feasibility of
CAAR T therapy in various B cell-mediated indications. As part of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assessment, we evaluate the direct lifetime drug and overall healthcare costs due to the burden from the disease, including the costs of managing potential adverse effects from existing standard
of care compared to the potential CAAR T therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform this rigorous and detailed conceptual analysis to enable us to be thorough
and thoughtful before committing significant resources to a program. We believe this analysis allows us to prioritize and advance potential product candidates through the CABA platform with a higher degree of confidence and a higher probability of
success. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Epitope Mapping </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Epitope mapping involves identifying specific sites on the antigen that are responsible for binding to the antibody of interest. This step is
required in order to facilitate an understanding of CAAR design and feasibility. An understanding of the locations of the key immunogenic epitopes on the antigen heavily informs the potential feasibility of a CAAR. With an understanding of these
epitopes, we then leverage our cell therapy expertise to design the CAAR construct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CAAR Construct / Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our scientists and collaborators design and create multiple CAAR constructs following completion of epitope mapping, which are tested against
the antibody or antibodies of interest. The goal in CAAR design is to maximize the inclusion of known immunogenic epitopes on the antigen while also optimizing the size of the construct to improve the ability of the CAAR to bind to the antibody.
Determining the location of antigen expression and if there are other antigens that may unintentionally cross-react with the CAAR will also inform CAAR design and feasibility. The size of the antigen will also determine whether a CAAR can be
designed based on the size constraints of the delivery system. Once we have designed and developed optimal CAAR constructs, we test them in a variety of <I>in vitro</I> and <I>in vivo</I> studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Vitro <I>and</I> In Vivo <I>Testing</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>In vitro</I> preclinical testing is focused on establishing the specificity and activity of the potential CAAR T cell product candidate
against B cells expressing known pathogenic target antibodies. Specificity is evaluated against <FONT STYLE="white-space:nowrap">non-target</FONT> membrane proteins that may be expressed on other cells, with specific focus against any proteins that
are known to bind to the antigen presented on the CAAR. CAAR T function is tested in the presence and absence of soluble, or free, antibodies isolated from patients, since these antibodies may enhance or inhibit CAAR T cell function. Where relevant
animal models exist, the CAAR T cell product candidate is tested in one or more models to address specific questions around safety and the ability of the potential product candidate to reduce disease activity <I>in vivo</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a portfolio
of CAAR T cell product candidates for the treatment of B cell-mediated autoimmune diseases. Our lead product candidate, DSG3-CAART, targets B cells that express pathogenic autoantibodies against the DSG3 protein, which cause mPV. The publication of
the first <I>in&nbsp;vivo</I> evaluation of activity and toxicity of the candidate in an animal model was followed by additional preclinical studies to support our planned IND submission. Upon acceptance of our IND, we plan to open the first
clinical trial site for our DSG3-CAART product candidate. Our next <FONT STYLE="white-space:nowrap">PV-directed</FONT> product candidate, <FONT STYLE="white-space:nowrap">DSG3/1-CAART,</FONT> targets B&nbsp;cells that give rise to pathogenic
autoantibodies against either the DSG3 or DSG1 protein, which cause mcPV, and could address a broader PV population. Our second product candidate, MuSK-CAART, targets B cells that give rise to pathogenic autoantibodies against the MuSK receptor in
patients with MG. An additional product candidate, FVIII-CAART, targets B cells that produce alloantibodies against exogenous FVIII in Hemophilia&nbsp;A patients who consequently require repeated and increased exogenous FVIII administration. We are
exploring additional CAAR&nbsp;T cell product candidates that will focus on patients with B&nbsp;cell-mediated autoimmune diseases with well-defined antibody targets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below shows our CAAR T cell product candidates currently under development: </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g686907g63t24.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>May not be required if Phase&nbsp;2 is a registrational clinical trial. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>DSG3-CAART
for Mucosal PV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, DSG3-CAART, is a CAAR T cell therapy expressing DSG3 antigen epitopes as the
extracellular domain of a chimeric immunoreceptor, and is designed to enable specific cytotoxicity toward B cells with DSG3 autoantibody targeting abilities. We believe this strategy has the potential to enable direct elimination of DSG3
autoantibody memory B&nbsp;cells and indirect elimination of DSG3-specific short-lived plasma cells that produce the pathogenic autoantibodies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Scientific, Clinical and Commercial Assessment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PV is a potentially fatal, chronic autoimmune disease characterized by acantholysis, which is the loss of adhesion between cells of the skin or
mucous membranes. Desmosomes are a collection of proteins that provide the structure for epithelial cells to connect with each other. PV results when specific pathogenic autoantibodies disrupt desmosomes by targeting DSG3 and/or DSG1, which are
proteins that are part of the desmosomes. These autoantibodies cause the upper layer of the epidermis to split away from its base resulting in characteristic erosions and blisters. Widespread damage to the skin and mucous membranes increases
susceptibility to life-threatening systemic infections. PV has two major subtypes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mPV&#151;Characterized by DSG3 autoantibodies only, affecting only mucosal surfaces&#151;accounts for
approximately 25% of PV </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mcPV&#151;Characterized by DSG3 autoantibodies and DSG1 autoantibodies, affecting both mucosal and cutaneous
surfaces&#151;accounts for approximately 75% of PV </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence of <FONT STYLE="white-space:nowrap">DSG-specific</FONT>
antibodies is 98% to 100% sensitive and specific in identifying patients with PV. Based on a published consensus document, these antibodies have been deemed both necessary and sufficient to cause the disease. Thus, in the absence of DSG
autoantibodies, PV generally does not occur. In mPV, patients will typically develop painful skin blisters on their mucosal membrane surface, including mouth, nose, throat, genitals, and other orifices, often leading to an inability to eat, drink
and function normally. The pathogenic </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DSG3 autoantibody is made by a specific small number of aberrant B cells, which express the DSG3 autoantibody on their surface. An overview of mPV and mcPV is provided in the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g60p26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Visual evidence of clinical manifestations of PV. (Left panel) Inside of cheek of a patient with mPV,
showing sloughing mucosa and blistering. (Right panel) Back of a patient showing cutaneous skin blistering and sloughing in a patient with mcPV. Image credit: D@nderm. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Like most autoimmune diseases, the current standard of care for PV relies on general immune suppression, which is often transiently effective
but can lead to severe infection, potentially resulting in hospitalization and death. First-line therapy for PV typically consists of corticosteroids in moderate to high doses in combination with the anti-CD20 monoclonal antibody rituximab where
clinically appropriate. Second-line therapy focuses on the several systemically immunosuppressive medications such as mycophenolate, azathioprine and methotrexate. Additional options used in the acute setting with severe disease presentation include
plasmapheresis, or infusions of intravenous immunoglobulin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B cell depletion with rituximab was approved by the FDA for the treatment of
PV in 2018 and is playing an increasing role as part of the standard of care because it has proven to be one of the more effective therapies for PV. However, data suggest that a significant number of patients treated with rituximab will relapse with
or without chronic therapy. Despite the recent approval for use as an adjuvant therapy with corticosteroids in PV, rituximab has several limitations in terms of efficacy, safety and convenience. Rituximab treatment frequently results in relapse,
which is reduced but still occurs despite chronic treatment every six months in PV. It does not specifically target the pathogenic B cells, but rather it depletes all CD20-expressing B cells, which leads to an ongoing risk of severe infection and
death. As such, there remains not only an unmet medical need in PV, but also a need for safer therapies that can provide a reliable, durable and complete remission off of all other medications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several emerging therapies also being developed for the treatment of PV, which are being evaluated in late-stage clinical trials.
These therapies provide important alternative therapeutic options for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients; however, we believe based on early published data that these therapies are unlikely to be curative and do not specifically ablate autoantibody producing B cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Epitope Mapping </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DSG3
consists of five extracellular cadherin, or EC, domains as shown schematically in the figure below. Since T cell activation depends on the intermembrane distance of the immunologic synapse, we tested different combinations of ECs for expression in
primary human T cells using DSG3 fragments as the extracellular domain as shown in the figure below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image7.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Image showing the naturally occurring DSG3 protein and the five EC domains. (B)&nbsp;The CAAR constructs
that were evaluated in preclinical studies, containing the whole or subsets of the DSG3 protein. The transmembrane and intracellular signaling domains are identical to those in the CART19 studies published by Penn. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CAAR Construct / Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DSG3 <FONT STYLE="white-space:nowrap">EC1-5</FONT> CAAR was minimally functional, likely due to the extracellular domain being too large to
enable CAAR function or aggregation of the CAAR on the T cell surface. The CAAR designs with either DSG3 <FONT STYLE="white-space:nowrap">EC1-3</FONT> or DSG3 <FONT STYLE="white-space:nowrap">EC1-4</FONT> showed interferon-gamma production after
exposure to the target cells, demonstrating specific cytotoxic activity across targets. In addition, no cytokine production was detected after exposure to cells that did not express surface immunoglobulins or other
<FONT STYLE="white-space:nowrap">non-target</FONT> cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DSG3 <FONT STYLE="white-space:nowrap">EC1-3</FONT> was not effective against one target
cell known to bind to the DSG3 EC3-4 domain. Together, this data suggests that the DSG3 <FONT STYLE="white-space:nowrap">EC1-4</FONT> CAAR is the optimal construct to balance activity while retaining the ability to target locations of known
pathogenic antibodies, as shown in the figures below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image8.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cytotoxicity assay to assess killing activity of DSG3 CAART. Negative control is a CAR T with an antibody
fragment attached to the extracellular domain. * indicates construct that was selected for further development. E:T ratio = effector to target ratio. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Vitro <I>Studies</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A variety of <I>in vitro</I> studies were conducted to evaluate DSG3-CAART from a preclinical activity and toxicity perspective. These studies
included an evaluation of DSG3-CAART against proteins that are known to bind the DSG3 antigen, a screen of DSG3-CAART against an array of other membrane proteins and a set of studies designed to evaluate the potential effects of soluble DSG3
antibodies against DSG3-CAART. The results of these studies are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Evaluation of DSG3-CAART reactivity
against known DSG3 binding proteins. </B>The DSG3 antigen presented on the extracellular domain of DSG3-CAART may naturally bind proteins in the body. These proteins may bind to and activate DSG3-CAART, potentially causing toxicity. The native
binding proteins for DSG3 are the desmocollin proteins, which are important for cell adhesion in the skin and mucosa. We performed a variety of studies to test whether DSG3-CAART recognizes and activates the desmocollin proteins. Epithelial cells
isolated from various primary organ systems that express some level of desmocollin proteins were screened. Potential DSG3-CAART activity was evaluated through the detection of cytokines released against each cell type and cytotoxicity. The data
demonstrated an absence of inflammatory T cell cytokines after being exposed to these cells, indicating an absence of T cell activation. No cytotoxicity was detected except at very high, <FONT STYLE="white-space:nowrap">non-pharmacologically</FONT>
feasible doses. Collectively, we believe there is sufficient evidence to suggest that the DSG3 protein in the context of a CAAR does not interact with desmocollin proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Evaluation of DSG3-CAART off-target binding against membrane proteins.</B> A membrane protein array was utilized to screen
the DSG3-CAART extracellular domain against 5,300 membrane proteins, which encompass the approximate number of membrane proteins contained in the human genome. The confirmatory screen yielded no <FONT STYLE="white-space:nowrap">off-target</FONT>
signals, except for one weak signal against a protein that is designed to bind to glycoproteins, and which was detected in both the test and control conditions. Further evaluation of this protein in cell-based assays indicated that DSG3-CAART does
not recognize and activate against this protein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Evaluation of the effect of soluble antibodies on DSG3-CAART
function.</B> We expect that circulating antibodies may prompt an active immune response against treatment with CAAR T cell therapy. These antibodies can induce proliferation of DSG3 CAAR T cells but also could neutralize the cells. In our
preclinical <I>in vitro</I> studies, we observed that while DSG3 antibodies may have a variable effect on CAAR function, there was no systematic effect to enhance or reduce CAAR function. These dynamics were evaluated in a series of <I>in vitro</I>
studies as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Soluble DSG3 antibodies were added to CAAR T cell cytotoxicity assays, at a range of concentrations likely to
be encountered in patients, to assess the impact on CAAR function.</I> In all cases when the CAAR T cells were tested in the presence of soluble DSG3 antibodies, they retained their killing function. In addition, the presence of antibodies did not
demonstrate a systematic effect to enhance or reduce the CAAR T cells&#146; cytotoxic ability. Therefore, we believe that removal of circulating soluble DSG3 antibodies from patients prior to infusions may not be necessary to enable potential
benefit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Monoclonal DSG3 antibodies with an enhancing effect were evaluated in combination with PV patient serum to
assess their impact on DSG3 CAAR T cell division and stimulation of cytokine production.</I> Monoclonal DSG3 antibodies were capable of inducing DSG3 CAAR T cell division and stimulated production of moderate levels of cytokine production, as
measured by interferon gamma. Therefore, we believe the presence of DSG3 autoantibodies in patients may contribute to the DSG3 CAAR T cell population expansion post-infusion. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Antibodies purified from PV patients were added to DSG3 CAAR T cells at a range of concentrations known to
commonly occur in patients in order to evaluate the extent to which</I> <I>patient serum may activate CAAR T cells.</I> These antibodies induced a dose dependent increase in interferon gamma. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">Off-target</FONT> toxicity may also be seen due to antibody-mediated bridging
of DSG3 CAAR T cell cytotoxicity against hematopoietic cells that express receptors designed to bind to antibodies, known as Fc receptors. </I>To evaluate this, we loaded DSG3 antibodies onto cells expressing antibody-binding receptors, and
evaluated the ability of DSG3 CAAR T cells to bind and activate against these targets <I>in vitro.</I> No evidence of cytotoxicity was observed, suggesting the potentially low risk of off-target killing mediated by this mechanism.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Vivo<I> Studies</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To evaluate DSG3-CAART <I>in vivo</I>, three murine models were used. These models were designed to: directly compare the potency of
DSG3-CAART in comparison with CART19 cells; evaluate the potential for on-target skin toxicity; and measure the activity of DSG3-CAART in the presence of polyclonal soluble DSG3 antibodies. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Evaluation of potency of DSG3-CAART in a human B cell tumor line compared to CART19 cells.</I> This B cell
model contained genetically-modified B cells to express DSG3 antibodies on the cell surface in addition to luciferase, a bioluminescence marker, and allowed evaluation of DSG3-CAART&#146;s ability to engage and kill B cells that express the
pathogenic antibody. CART19 cells were used as a positive control in this model as the B cells express CD19 on their cell surface. In this model, DSG3-CAART was found to result in a similar reduction of B&nbsp;cells compared to the CART19 cells.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Evaluation of on-target skin toxicity mediated by DSG3-CAART.</I> A human skin-xenografted model was used to
evaluate the potential skin toxicity of DSG3-CAART by evaluating if the extracellular domain would react with desmocollin proteins, which are the known target for DSG3. These results were compared directly to a positive control CAR&nbsp;T expressing
a DSG3 specific antibody as an extracellular domain. In this model, we observed the absence of skin toxicity mediated by the DSG3-CAART cells compared to the positive control, which did demonstrate skin toxicity. </P></TD></TR></TABLE>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Evaluation of DSG3-CAART in the presence of soluble antibodies.</I> We also tested a model where mice have
circulating DSG3 antibodies to mimic the situation in PV patients. In this model, the DSG3 antibodies have well-defined and different epitopes with varying affinities, which may reflect the potential breadth of B cell targets that could be
encountered in PV patients. The mice were then treated with DSG3-CAART, which was compared to <FONT STYLE="white-space:nowrap">non-CAAR</FONT> expressing T&nbsp;cells. In this model, we observed amelioration of disease (see figure&nbsp;A below),
reduction of DSG3 antibody titers (see figure&nbsp;B below), as well as control of the pathogenic B&nbsp;cells (see figure&nbsp;C below), by DSG3-CAART. We believe these results show the functional activity of DSG3-CAART in the presence of soluble
antibody, which is further illustrated in the figures below. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g24a05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Histology showing DSG3 CAAR maintaining normal epithelial cell structure in treated animals. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g08a06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>OD450 is a proxy measure for serum DSG3-ELISA in this assay. * indicates statistically significant
reduction in DSG3 serum antibody level in DSG3-CAART treated mice. P value is &lt; 0.05. *** indicates statistically significant increase in DSG3 serum antibody level in the negative control CAR treated group. P value is &lt; 0.001. <FONT
STYLE="white-space:nowrap">p-value</FONT> is a statistical calculation that relates to the probability that the difference between groups happened by chance, with a <FONT STYLE="white-space:nowrap">p-value</FONT> of less than 0.05, or less than 5%
probability that the difference happened by chance, generally being used as the threshold to indicate statistical significance. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image9b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Total flux is a quantitative measure of cell bioluminescence, which approximates cell activity in this
assay. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to submit an IND to the FDA for a Phase 1 trial of DSG3-CAART. If accepted, subject to feedback from the FDA, we expect the
DSG3-CAART trial will be designed as a Phase 1, open-label trial to assess the safety and tolerability of various dosing regimens of DSG3-CAART in the treatment of subjects with active mPV. DSG3-CAART will be administered by intravenous infusion,
using a fractionated-dose infusion scheme of escalating numbers of DSG3-CAART cells for the initial cohorts in the first phase. This dosing scheme is designed to reduce the potential risks associated with acute infusion-related toxicities while
preserving potential benefit for subjects by allowing a total infused dose that we believe is large enough to be potentially therapeutic based on prior CAR T trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the trial will have three phases: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase A: Fractionated dose escalation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase B: Fractionation reduction at the selected dose </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase C: Expansion phase at the selected dose and administration scheme </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Phase A, the split dose uses dose fractionation to accommodate a low number of cells in the first infusion while still advancing the dose
within the cohort up towards and spanning the range of cell doses that have been therapeutic in past gene-engineered T cell therapy trials. In Phase B, the dose selected from Phase A will be delivered in a decreasing number of dose fractionations to
determine the dose fractionation strategy. In Phase C, subjects will be enrolled at the dose and fractionation, as determined in Phase A and B, to generate additional safety and outcome data to support the rationale for and design of future clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients are eligible to be enrolled if they have a confirmed diagnosis of mPV based on colon biopsy for histology and positive
DSG3 ELISA; active disease at screening; elevated DSG3 by ELISA; and previously been inadequately managed by, or refractory to, or relapsed after, or with contraindications to or intolerance of at least two prior systemic therapies. The primary
objective of the trial is to evaluate the safety of DSG3-CAART cells and initial signs of target engagement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the risk of
cytokine release syndrome, or CRS, a potentially life-threatening toxicity that has been observed&nbsp;after treatment with some types of immunotherapy, may be reduced with our CAAR T cells, due to its correlation with target burdens. In the context
of treating cancer, the target cell population consists of all B </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cells (healthy and cancerous), whereas our CAAR T cells only target the small subset of disease-causing reactive B cell population. In a clinical trial, while the possibility of cytokine release
resulting from strongly activating soluble antibody cannot be ruled out, to date we have not observed any evidence of it in preclinical studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> for mcPV </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Scientific and Commercial Assessment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next PV product candidate, <FONT STYLE="white-space:nowrap">DSG3/1-CAART,</FONT> is being designed to target DSG3 and/or DSG1
autoantibodies on pathogenic B cells that cause mcPV. mcPV is the most severe and most common subtype of PV and affects approximately 75% of PV patients. While mPV is caused by DSG3 autoantibodies, mcPV involves autoantibodies to both DSG3 and DSG1,
resulting in the additional involvement of skin erosion and blistering. Similar to mPV, mcPV is typically treated with immune suppression, which has a high rate of relapse and potential for hospitalizations and fatal infections. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Epitope Mapping </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DSG1
consists of five EC domains, with all known pathogenic epitopes occurring in the DSG1 <FONT STYLE="white-space:nowrap">EC1-4</FONT> domains. Similar to development of DSG3-CAART, we tested different combinations of DSG1 ECs for expression in primary
human T cells using DSG1 fragments as the DSG1 EC domains. Given prior development of DSG3 CAAR, we leveraged those findings in the design of our DSG1 CAAR. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CAAR Construct / Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also tested multiple combinations of EC domains of DSG1 CAAR administered alone and in combination with the DSG3 <FONT
STYLE="white-space:nowrap">EC1-4</FONT> CAAR to evaluate for cell-surface expression of the CAAR along with the potency and breadth of target cell killing. In this setting, the DSG1 <FONT STYLE="white-space:nowrap">EC1-4</FONT> CAAR showed robust
and specific cytotoxicity towards all known pathogenic epitopes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Vitro<I> Studies</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CAAR development for mcPV, based on the targeting of DSG3- and/or DSG1-specific B cells, has shown promising preclinical results. DSG1 CAAR T
cells specifically killed DSG1-specific B cells <I>in vitro</I>. In addition, we observed that with a 1:1 mixture of DSG3 and DSG1 CAAR T cells had killing capabilities without synergistic or antagonistic effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Vivo<I> Studies</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
activity and toxicity of DSG3 and DSG1-CAAR T cells was evaluated using human skin xenografts in comparison with anti-CART19 cells, which are known from human clinical trials not to cause direct skin toxicity. A 1:1 mixture of DSG3 and DSG1 CAAR T
cells did not show <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity <I>in vivo.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Development Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From a regulatory and clinical trial design perspective, we anticipate many of the elements incorporated into the planned DSG3-CAART trial will
carry over to <FONT STYLE="white-space:nowrap">DSG3/1-CAART.</FONT> We plan to evaluate the initial cohorts of patients from the planned DSG3-CAART trial to evaluate for safety and evidence of target engagement prior to proceeding with an IND
submission for <FONT STYLE="white-space:nowrap">DSG3/1-CAART.</FONT> We believe that, because mcPV is the most prevalent subset of PV and the patients are generally followed by the same subspecialists, it will allow for a wider patient pool eligible
for a clinical trial. We anticipate the <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> clinical trial protocol will have a significant amount of overlap with the DSG3-CAART protocol, but it will be informed by clinical data from the early
cohorts in the DSG3-CAART trial. We further anticipate being able to use the same centers from the DSG3-CAART Phase 1 clinical trial to enroll patients for the <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, we are evaluating advanced manufacturing technologies that would potentially
allow us to administer <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> as a single product rather than requiring separate administration. The size of the DSG3/1 product candidate will likely require us to incorporate additional technologies to
accommodate the size of the final CAAR construct. An evaluation of potential technologies to achieve this objective is ongoing. Upon completing the evaluation of these manufacturing technologies, we expect to conduct additional <I>in vitro</I> and
<I>in vivo</I> studies using the combined product. While a product that administers a DSG3 CAAR and DSG1 CAAR as two separate products may be feasible, we believe that there would be significant advantages to developing a combined product from a
regulatory and commercial perspective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>MuSK-CAART for MuSK Myasthenia Gravis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Scientific, Clinical and Commercial Assessment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MG is an autoimmune disease induced by autoantibodies targeting the neuromuscular junction, or NMJ, which can lead to life-threatening muscle
weakness. Generalized MG, or gMG, is characterized by profound muscle weakness throughout the body, resulting in motor impairment, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">gMG affects approximately 65,000 to 70,000 patients in the United States. The majority of patients who develop gMG have autoantibodies against
some part of the NMJ that are known to be pathogenic. 80% to 90% of patients with gMG have autoantibodies against the acetylcholine receptor, or AchR, detectable in their serum. Approximately 6% to 7.5% of patients with gMG have autoantibodies
against MuSK, which is a different target on the surface of the muscle membrane. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients diagnosed with MuSK MG have a different
recommended treatment course compared to patients with AchR MG. Importantly, many patients with MuSK MG respond poorly to cholinesterase inhibitors, which are often the first line of therapy in AchR MG. In that setting, patients with MuSK MG are
typically started on corticosteroids in addition to one or more steroid-sparing immunosuppressive agents. Corticosteroids are tapered to the extent possible to prevent disease relapse, though many remain dependent on corticosteroid despite
concomitant treatment with immunosuppressive medications. In the acute setting, plasmapheresis may be used to address severe disease. Rituximab is often considered as a second-line therapeutic option in patients with an inadequate response to
initial immunosuppressive medications. Importantly, complement is not thought to be meaningfully implicated in the pathophysiology of MuSK MG, and complement inhibitors are not indicated for treatment of disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Epitope Mapping </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MuSK protein has a similar structure and size as compared to DSG3. MuSK contains four extracellular domains, as shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Figure illustrating the extracellular domains of the wild-type MuSK protein. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies conducted in patients with MuSK MG have revealed that the autoantibodies may be against epitopes located in each of the extracellular
domains for MuSK. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CAAR Construct and Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With an understanding that pathogenic autoantibody epitopes may target any domain of MuSK, multiple MuSK CAAR candidates have been engineered
that incorporate all extracellular domains. Each CAAR construct is being or will be tested in preliminary <I>in vitro</I> and <I>in vivo</I> experiments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Development Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
initial <I>in vitro</I> studies with our MuSK-CAART product candidate are ongoing. We expect these studies to be followed by <I>in vivo</I> studies to evaluate toxicity of the MuSK-CAAR construct along with evaluation of target engagement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>FVIII-CAART for Hemophilia A with Factor VIII Alloantibodies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our CABA platform is primarily directed towards the treatment of B cell-mediated autoimmune diseases, we believe the approach may be
applicable in other instances where B cell antibody production is implicated. Specifically, we have identified an opportunity to apply the CABA platform to develop potential CAAR adjunctive therapies in cases where the immune system has or produces
antibodies against potential therapies, which is known as an alloimmune response. These alloantibodies can prevent a particular therapy from being delivered effectively because the therapy is degraded by the immune response due to alloantibody
binding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We believe our approach has the potential to address the alloantibody response by specifically ablating the B cells responsible for producing the alloantibodies through a similar mechanism seen
in autoimmune disease. With the alloantibody producing cells ablated, the treatment could then be provided. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Scientific, Clinical and
Commercial Assessment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hemophilia A is an <FONT STYLE="white-space:nowrap">X-linked</FONT> bleeding disorder caused by mutations in the
FVIII gene resulting in a deficiency of functional FVIII, a critical factor in blood coagulation. It affects about 1:5,000 male births. Severe Hemophilia A, where FVIII levels are less than 1% of normal, accounts for about 60% of all cases and is
characterized by frequent spontaneous bleeds. Currently, Hemophilia A is treated with FVIII replacement via intravenous administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main complication of FVIII replacement therapy is that 20% to 30% of patients with severe disease develop neutralizing alloantibodies
against the FVIII protein. These alloantibodies decrease the levels of FVIII and at high-titers, render attempts to replace or stimulate the production of FVIII ineffective. The risk of alloantibody development for patients with severe Hemophilia A
is highest during their initial FVIII exposures. The standard treatment to reverse alloantibody formation consists of repeated high-dose infusions of FVIII, which has limited efficacy, a high cost and is difficult to titrate to an appropriate
therapeutic level for the patient. We believe FVIII-CAART could be effective in addressing patients with Hemophilia A who have developed FVIII antibodies that require repeated, high-dose administrations of FVIII. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Epitope Mapping </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following image depicts FVIII, which is a large glycoprotein consisting of six domains that interact with each other to form the full complex. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907image11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies conducted in patients with Hemophilia A have revealed that acquired FVIII alloantibodies following
exogenous FVIII administration are typically directed against A2, C1 and C2 domains of FVIII. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>CAAR Construct and Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary FVIII CAAR and CAAR-like constructs have been engineered that target parts, but not all, of the FVIII domains. Dr.&nbsp;Milone, one
of our scientific <FONT STYLE="white-space:nowrap">co-founders,</FONT> has led the development of one such construct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Development Plan
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internally, we are conducting additional<I> </I>studies to optimize our FVIII-CAART development. The focus of these studies will be to
fully characterize any additional pathogenic epitopes and construct a FVIII-CAART that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
includes additional FVIII domains. Given the size of the FVIII protein, this will likely require us to incorporate additional technologies to reduce the size of the final CAAR construct. An
evaluation of potential technologies to achieve this objective is ongoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Vector Manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lentiviral vector that we plan to use in the initial subjects in our Phase 1 clinical trial for DSG3-CAART was manufactured at CHOP. We
have also reserved multiple vector manufacturing slots at Penn, which we may use in our DSG3-CAART or subsequent clinical trials. In parallel, we are in discussions with multiple CMOs to secure production slots for vector which may be used in our
DSG3-CAART or subsequent clinical trials. We believe these efforts will provide us with sufficient clinical-grade vector to move forward with our anticipated clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cell Manufacturing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a collaboration with the Clinical Cell and Vaccine Production Facility, or CVPF, at Penn, to provide focused scientific,
technical and regulatory support for CAAR T cell manufacture. CVPF is accredited by the Foundation for the Accreditation of Cell Therapy and is capable of and experienced at supporting manufacture for early-phase clinical trials of novel cell
therapy products in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-man</FONT></FONT> clinical trials. We expect to rely upon CVPF to provide initial Phase 1 clinical trial drug supply for DSG3-CAART. Penn&#146;s
manufacturing process for DSG3-CAART is directly related to the process developed at Penn for early clinical trials of the CART19, which subsequently became known commercially as Kymriah. The process was later transferred to Novartis Pharmaceuticals
Corporation and further modified for the Kymriah program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we scale our manufacturing of DSG3-CAART and our other product candidates to
meet our expected needs for further clinical trials, we may or may not rely on Penn, but we also expect to rely on contract manufacturing organizations, or CMOs, and other third parties for the manufacturing and processing of our clinical trial
materials. Any CMO that we select will be subject to cGMP requirements. We believe the use of contract manufacturing for our pipeline programs will be cost-effective and allow us to rapidly prepare for clinical trials in accordance with our
development plans. In preparation for this transition, we have engaged multiple third-party contractors to manufacture clinical grade viral vector used to deliver the applicable CAAR gene into the T cells. We have also initiated development work
with certain contractors for cGMP and commercial vector production. We expect third-party manufacturers will be capable of providing and processing sufficient quantities of our product candidates to meet anticipated clinical trial demands and
commercial need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once we have sufficient clinical data from subjects in our DSG3-CAART study, we intend to begin the process of
engineering and then establishing our own commercial scale <FONT STYLE="white-space:nowrap">GMP-compliant</FONT> manufacturing facility. We believe this will allow us to enhance supply chain control, increase supply capacity and help ensure clinical
and commercial demand for our pipeline programs is met in the event that DSG3-CAART receives marketing approval. Informed by our experience in building cell therapy facilities and creating supply chains, we plan to develop a robust supply chain with
alternative sources to maintain continuous supply. In parallel with these activities, we are evaluating and executing proof-of-concept studies to test advanced manufacturing and automation technologies to continuously improve the manufacturing
process and meet commercial and scalability targets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our aim is to become a fully integrated cellular therapy company in order to improve the lives of patients with B cell-mediated autoimmune
diseases. We have designed a strategic approach to move forward with our lead product candidate, DSG3-CAART, while at the same time having a number of product candidates in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development. The product candidates from our CABA platform address clinical indications where there is a compelling opportunity to improve clinical outcomes in comparison with the current
standard of care in an easily identified patient population. Our initial product candidates are focused on rare disease populations where we believe there is potential to commercialize independently. This is due to a concentration of treatment
paradigms and limited but easily identified patient populations. Our plan is to focus commercialization and launch efforts initially in the United States, and eventually in the European Union and Asia-Pacific geographies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and
biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as any novel therapies that may gain
regulatory approval in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Existing treatment options for PV are limited. Rituximab, marketed by Roche Holding AG, is the first
drug to have received approval for PV in the United States in over 60&nbsp;years. In Europe, the approved therapies for PV are corticosteroids, azathioprine and rituximab. Other standard of care treatments include various immunosuppressants and
intravenous immunoglobulin infusions given monthly or on another periodic chronic basis. Additionally, multiple biopharmaceutical companies have therapies in clinical development. We are aware that Affibody AB, Alexion Pharmaceuticals, Inc., argenx
SE, Immunovant, Inc., Momenta Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Ono Pharmaceutical Co., Ltd., Principia Biopharma Inc., Rubius Therapeutics, Inc., among others, are developing treatments for PV. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition in the MuSK MG autoimmune space is currently dominated by the current standard of care, rituximab. A second approved approach to
treating patients is IVIG, which is available through CSL Behring LLC, Grifols, S.A., and Mitsubishi Tanabe Pharma Corporation. Additionally, multiple biopharmaceutical companies have therapies in clinical development. We are aware that argenx SE,
BioMarin Pharmaceutical Inc., Catalyst Partners, Inc., CuraVac, Inc., GlaxoSmithKline PLC, Millennium Pharmaceuticals, Inc. (subsidiary of Takeda Pharmaceutical Company Limited), Novartis Pharmaceuticals Corporation, and Ra Pharmaceuticals, Inc.,
among others, are developing drugs that may have utility for the treatment of MuSK MG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Multiple therapies are approved or in development
for the treatment of Hemophilia A patients who develop alloantibodies against FVIII. Standard of care is typically immune tolerance induction, or ITI, therapy with higher doses of FVIII. Available treatments for those who do not respond to ITI
include anti-inhibitor coagulation complexes, recombinant factor VIIa, and bispecific factor <FONT STYLE="white-space:nowrap">IXa-</FONT> and factor <FONT STYLE="white-space:nowrap">X-directed</FONT> antibodies. Companies who market products or are
developing product candidates within these categories of medicine include Catalyst Pharmaceuticals, Inc., Novo Nordisk A/S, OPKO Health, Inc., Roche Holding AG and Takeda Pharmaceutical Company. In addition, we are aware that Alnylam
Pharmaceuticals, Inc., Apitope Technology Ltd., Bayer AG, GC Pharma (formerly known as Green Cross Corporation), Idogen AB, Novo Nordisk A/S and Pfizer Inc., Sanofi, Spark Therapeutics, Inc., and uniQure N.V. are developing product candidates with
other mechanisms that have the potential to treat Hemophilia A patients with FVIII alloantibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are the first and only
company developing CAAR T drug candidates for the treatment of B cell-mediated autoimmune diseases. However, despite the significant differences in discovery, development and target populations between oncology and autoimmune targets, we recognize
that companies with an investment and expertise in CAR T cell development for oncology indications could attempt to leverage their expertise into B cell-mediated autoimmune disease-affected populations. We are aware of biotechnology companies that
are exploring other methods of engineering T cells for the treatment of autoimmune conditions. Companies that are developing drug candidates for autoimmune diseases using either traditional CAR T or CAR T regulatory cell approaches include Atara
Biotherapeutics, Inc. and Sangamo Therapeutics, Inc. In addition, some biotechnology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies are engineering red blood cells to incorporate self-antigens with the goal of tolerizing the immune system to treat autoimmune and alloimmune conditions; these companies include Rubius
Therapeutics, Inc. and SQZ Biotechnologies Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our belief is that the majority of products currently under development will not be direct
competitors to our products. Current standard of care therapy, and other most products in development, require repeated administration of an oral or intravenous drug that often produces an incomplete response or is effective for a limited period of
time prior to patient relapse. While these products may be used prior to our products or used in addition to our products, we do not believe that the use will restrict the affected patient populations that we intend to target. Potential competition
may arise from other cell therapy approaches that are or may be explored as a potential cure for indications we are currently targeting, but we believe we are currently well-positioned compared to our competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and
biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in
acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property and Barriers to Entry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent
protection intended to cover our product candidates and their use, as well as other inventions that are important to our business. In addition to patent protection, we also rely on <FONT STYLE="white-space:nowrap">know-how,</FONT> confidentiality
agreements, invention assignment agreements and trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position. The
confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants or certain other third
parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our
agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially
important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid
and enforceable intellectual property rights of others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions for biotechnology companies like us are generally uncertain
and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As
a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular
jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;1, 2019, our patent estate (all of which has been <FONT
STYLE="white-space:nowrap">in-licensed)</FONT> included one issued U.S. patent, seven&nbsp;pending U.S. patent applications, and 13&nbsp;pending foreign patent applications. See &#147;&#151;Our Material Agreements&#151;Amended and Restated License
Agreement with Penn.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regard to our DSG3-CAART and <FONT STYLE="white-space:nowrap">DSG3/1-CAART</FONT> product candidates, we
have one issued U.S. patent with claims directed to a genetically modified cell containing a chimeric autoantibody receptor containing an extracellular domain containing DSG3, DSG1 or fragments thereof, which is scheduled to expire in 2035, without
taking a potential patent term extension into account. We also have four pending U.S. patent applications and counterpart patent applications pending in Canada, China and Europe, which if issued, would be expected to expire in 2035. This patent
family is owned by Penn and exclusively licensed to us in the field of the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regard to our MuSK-CAAR&nbsp;T cell product
candidate, we have one pending U.S. patent application and one pending International, or PCT, patent application, which if issued, would be expected to expire in 2039. This patent family is owned by Penn and exclusively licensed to us in the field
of the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regard to our FVIII-CAAR&nbsp;T cell product candidate, we have one pending U.S. patent application and counterpart
patent applications pending in Australia, Canada, China, Europe, Japan, Korea, Mexico, New Zealand, and Russia, which if issued, would be expected to expire in 2037. This patent family is <FONT STYLE="white-space:nowrap">co-owned</FONT> by Penn and
CHOP and is exclusively licensed to us in the field of the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the
patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20&nbsp;years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the term of a patent covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug may be eligible for a patent
term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term
of a patent beyond a total of 14&nbsp;years from the date of product approval. Only one patent among those eligible for an extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in
certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering each of our product candidates may be entitled to patent term extensions. If our product candidates receive FDA
approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however,
there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret protection for our
proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect
our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently
develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, and other
proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities,
and market exclusivities. See &#147;&#151;Government Regulation&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Material Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated License Agreement with Penn </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into an amended and restated license agreement, or the License Agreement, with Penn and the Children&#146;s Hospital
of Philadelphia, or CHOP, and together with Penn, the Institutions, pursuant to which we obtained (a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-sublicensable,</FONT> worldwide research license
to make, have made and use products in two subfields of use, (b)&nbsp;effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights of the Institution to make, use, sell,
offer for sale and import products in the same two subfields of use, and (c)&nbsp;effective as of October 2018, a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, royalty-bearing license, with limited rights to sublicense, under
certain of Penn&#146;s <FONT STYLE="white-space:nowrap">know-how,</FONT> which <FONT STYLE="white-space:nowrap">know-how</FONT> satisfies certain criteria and is listed on a mutually <FONT STYLE="white-space:nowrap">agreed-to</FONT> schedule, to
make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. As of July 2019, no such <FONT STYLE="white-space:nowrap">know-how</FONT> has been scheduled. Our rights are subject to the rights of the
U.S. government and certain rights retained by the Institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the License Agreement will expire with
respect to a product upon the later of (a)&nbsp;the expiration of the last to expire patent or patent application covering such product or (b) 10 years after the first commercial sale of such product.&nbsp;We may terminate the License Agreement in
its entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">subfield-by-subfield</FONT></FONT> basis at any time for convenience upon a certain number of days&#146; written notice.&nbsp;Penn may terminate the License
Agreement in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">subfield-by-subfield</FONT></FONT> basis for our uncured material breach, including for our failure to meet certain diligence obligations and
milestone events. We, however, may extend the achievement date of any milestone event for an additional period of time by making a payment in a certain amount, subject to certain limitations in the number of times each event may be extended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penn maintains control of all filing, prosecution and maintenance of the Institutions&#146; patent rights licensed by us, and we are
responsible for all ongoing patent costs during the term of the agreement. We also reimbursed Penn for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred prior to the effective date of
the agreement with respect to the filing, prosecution and maintenance of the patent rights licensed by us.&nbsp;Under the terms of the License Agreement, we are also obligated to pay $2.0&nbsp;million annually for three years beginning August 2018
for funding to the laboratories of each of Drs. Milone and Payne. See &#147;&#151;Sponsored Research Agreements with the Trustees of the University of Pennsylvania.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the License Agreement, we must use commercially reasonable efforts to develop and commercialize a product in each subfield.&nbsp;During
the term of the License Agreement until the first commercial sale of the first product, we are obligated to pay Penn a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> annual license
maintenance fee of $10,000. We are required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a
milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that we are able to successfully develop and launch multiple products under the
License Agreement, total milestone payments could approach $20.0&nbsp;million. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any
products that are commercialized by us, our affiliates or our sublicensees that contain, use, embody, result from the use of or incorporate, or are covered by, the intellectual property licensed by us. To the extent we sublicense our license rights
under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the <FONT STYLE="white-space:nowrap">mid-single</FONT> to low double-digits. We have also entered into a subscription and technology
transfer agreement with Penn, pursuant to which we will pay Penn an upfront subscription fee and a nominal <FONT STYLE="white-space:nowrap">non-refundable</FONT> royalty on the net sales of products, a portion of which will be credited toward
milestone payments and royalties under this License Agreement. Technology transfer activities would be at our cost and subject to agreement as to the technology to be transferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreements with Penn </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Michael Milone </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2018, we and Penn entered into a Sponsored Research Agreement for the laboratory of Dr.&nbsp;Milone, or the Milone SRA, pursuant to
which we agreed to sponsor certain research related to the development of (i)&nbsp;T&nbsp;cell based immunotherapies for autoimmune and alloimmune antibodies of pathologic significance and (ii)&nbsp;a clinical grade microfluidic device designed for
single step selection and activation of T cells from blood samples to be conducted in Dr.&nbsp;Milone&#146;s laboratory at Penn. Under the Milone SRA, Penn granted us a perpetual, irrevocable,
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use all intellectual property resulting from the research sponsored by us for internal research purposes. In addition, Penn
granted us an option to include, in exchange for a fee, any intellectual property resulting from the research sponsored by us that relates to CAAR T cell therapies for hemophilia and/or pemphigus within the scope of the License Agreement. Penn also
granted us an option to negotiate a license to all other intellectual property resulting from the research sponsored by us. Unless earlier terminated, the Milone SRA will expire on April&nbsp;23, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dr.&nbsp;Aimee Payne </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April 2018, we and Penn entered into a Sponsored Research Agreement for the laboratory of Dr.&nbsp;Payne, or the Payne SRA, pursuant to which we agreed to sponsor certain research related to the development of T cell based immunotherapies for
autoimmune and alloimmune antibodies of pathologic significance to be conducted in Dr.&nbsp;Payne&#146;s laboratory at Penn. Under the Payne SRA, Penn granted us a perpetual, irrevocable, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license to use all intellectual property resulting from the research sponsored by us for internal research purposes. In addition, Penn granted us an option to include, in exchange for a fee, any
intellectual property resulting from the research sponsored by us that relates to CAAR T cell therapies for hemophilia, MG and/or pemphigus within the scope of the License Agreement. Penn also granted us an option to negotiate a license to all other
intellectual property resulting from the research sponsored by us. Unless earlier terminated, the Payne SRA will expire on April&nbsp;23, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have committed to funding a defined research plan for three years through April 2021 under both the Milone SRA and Payne SRA. We have
estimated the three-year cost of the two SRAs to be $8.5&nbsp;million, which satisfies the $2.0&nbsp;million annual obligation under the License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Master Translational Research Services Agreement with Penn </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into a Master Translational Research Services Agreement with Penn, or the Services Agreement, pursuant to which
Penn agreed to perform certain services related to the research and development of the technology licensed to us under the License Agreement, as well as certain clinical, regulatory and manufacturing services. The Services Agreement will expire on
the later of (i)&nbsp;October&nbsp;19, 2021 or (ii)&nbsp;completion of the services for which we have engaged Penn under the Services Agreement. Either party may terminate this agreement with or without cause upon a certain number of days&#146;
written notice. The services encompassed by the Services Agreement are performed by different organizations at Penn pursuant to certain addenda to the Services Agreement, including the CAROT Addendum and the CVPF Addendum. In addition, in July 2019
we and Penn entered into an Alliance Agreement pursuant to which we will pay Penn a nominal annual fee in order for Penn to provide an adequate and consistent level of support to the services that it provides to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The CAROT Addendum </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Center for Advanced Retinal and Ocular Therapeutics, or CAROT, Addendum, Penn manufactures vector that is then to be used by the CVPF in the manufacture of our product candidates. In the event that certain materials owned by Penn are
incorporated into a product developed for us, Penn has agreed to grant us a limited license to use those materials. Further, Penn agreed to grant us an exclusive, <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, transferable,
irrevocable, perpetual exclusive license to any deliverables produced under the CAROT </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Addendum, except with respect to certain technical information of Penn that is contained or incorporated in the deliverables, to which Penn agreed to grant us a limited nonexclusive license.
However, any necessary technology transfer would be pursuant to the subscription and technology transfer agreement described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The CVPF Addendum </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the CVPF Addendum, Penn conducts process validation studies and large scale engineering runs for our product candidates. Under the CVPF Addendum, CVPF will contractually agree to manufacture agreed upon quantities of DSG3-CAART material for use in
connection with our Phase 1 clinical trial, unless the agreement is terminated by either party. Any necessary technology transfer would be pursuant to the subscription and technology transfer agreement described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research Agreement with The Regents of the University of California </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into a Research Agreement, or the UC Agreement, with The Regents of the University of California, or the UC
Regents, pursuant to which the UC Regents agreed to perform certain research projects relating to the toxicity and activity of MuSK CAAR T cells in various models of anti-MuSK MG, or the UC Research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The UC Agreement provides that the UC Regents will own all rights to any intellectual property developed solely by UC Regents employees in
conducting the UC Research, or developed solely by any of our employees that conduct the UC Research using the UC Regents&#146; facilities or resources. The UC Regents granted us an irrevocable, royalty-free, nonexclusive, worldwide,
nontransferable, perpetual license to use this <FONT STYLE="white-space:nowrap">UC-owned</FONT> intellectual property for internal research purposes only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the UC Regents jointly own the rights to any intellectual property jointly developed by our employees and UC Regents employees in
conducting the UC Research, provided that our employees did not use the UC Regents&#146; facilities or resources in the research. We were granted an option to acquire a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> or exclusive, worldwide,
transferable license, including the right to sublicense, to make, use sell, offer for sale, import and otherwise exploit products embodying these joint inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we exercise our option with respect to certain intellectual property under the UC Agreement, any license we enter into will require us to
diligently pursue timely commercial development and marketing of product candidates using such intellectual property, and will be subject to other terms and conditions to be negotiated at the time of entering into any such license. Unless earlier
terminated, the term of the UC Agreement will expire on October&nbsp;1, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Regulation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in
registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated
products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the
submission and approval of a BLA before we can market them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States (at the federal, state and local
level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products
such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries.
Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in
Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>U.S. Biological Product Development
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health
Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal,
state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or
after approval, may result in delays to the conduct of a study, regulatory review and approval or subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#146;s refusal to approve
pending applications, withdrawal of an approval, license suspension or revocation, refusal to allow an applicant to proceed with clinical trials, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals
from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations or penalties. Any agency or
judicial enforcement action could have a material adverse effect on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug product candidates must be approved by the FDA through
the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive nonclinical, sometimes referred to as preclinical, laboratory tests, animal studies and
formulation studies in accordance with applicable regulations, including the FDA&#146;s Good Laboratory Practice, or GLP, regulations and standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, representing each clinical site before each
clinical trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
good clinical practices, or GCPs, and other clinical trial-related regulations to establish the safety and efficacy of the proposed drug product candidate for its proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of a BLA, which includes not only the results of the clinical trials, but also, detailed
information on the chemistry, manufacture and quality controls for the product candidate and proposed labelling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#146;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the
product&#146;s identity, strength, quality, purity and potency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the preclinical trial sites and/or clinical trial sites that generated the data in support
of the BLA; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data required to support a BLA is generated in two distinct development stages: preclinical and clinical. The
preclinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the preclinical
studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical
protocol, as well as other information, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general
investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical
hold within that <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug
product candidate at any time before or during clinical trials due to safety concerns, <FONT STYLE="white-space:nowrap">non-compliance,</FONT> or other issues affecting the integrity of the trial. Accordingly, we cannot be sure that submission of an
IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials
involving recombinant or synthetic nucleic acid molecules had historically been subject to review by the Recombinant DNA Advisory Committee, or RAC, of the NIH Office of Biotechnology Activities, or the NIH Office of Biotechnology Activities, or
OBA, pursuant to the NIH Guideline. On August&nbsp;17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH
Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed
October&nbsp;16, 2018, the NIH announced that it will no longer accept new human gene transfer protocols for review as a part of the protocol registration process or convene the RAC to review individual clinical protocols. In April 2019, NIH
announced the updated guidelines, which reflect these proposed changes, and clarify that these trials will remain subject to the FDA&#146;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth
in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an Institutional Biosafety Committee, or IBC, a local institutional committee that reviews and oversees
research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay
before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research,
many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of
development involves the administration of the drug product candidate to healthy volunteers and patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance
with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the
clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as
part of the IND. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and
considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.
Sponsors of certain clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at
www.clinicaltrials.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and
may overlap. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the drug product candidate. The primary purpose of these clinical trials is to assess
the metabolism, pharmacologic action tolerability, adverse effects, and safety of the drug product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in disease-affected patients to
determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification of possible adverse effects and safety risks and preliminary
evaluation of efficacy. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries, and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its
safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of
treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA. In certain instances, FDA may condition approval of
a BLA on the sponsor&#146;s agreement to conduct additional clinical trials to further assess the biologic&#146;s safety and effectiveness after BLA approval. Such post-approval trials are sometimes referred to as Phase 4 clinical trials. These
trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document clinical benefit in the case of drugs approved under Accelerated Approval regulations. Failure to exhibit due
diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports
detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse
events, findings from other studies suggesting a significant risk to humans exposed to the biologic, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a
serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may
suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an
independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on
access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as interim data suggesting a lack of efficacy. We may also suspend or terminate a
clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical
characteristics of the drug product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the drug product candidate and, among other things, must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stability studies must be conducted to demonstrate that the drug product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BLA and FDA Review Process </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following trial completion, trial data are analyzed to assess safety and efficacy. The results of preclinical studies and clinical trials are
then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the
chemistry of the drug product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is
demonstrated by extensive preclinical and clinical testing. The application may include both negative or ambiguous results of preclinical and clinical trials as well as positive findings. Data may come from company-sponsored clinical trials intended
to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish
the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on
an annual basis. PDUFA also imposes an annual prescription drug product program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#146;s submission, the FDA&#146;s goal is to
review BLAs within 10 months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would
provide a significant improvement in safety or effectiveness. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval, and may require additional
preclinical, clinical or other studies before it accepts the filing. Additionally, the review process is often significantly extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed drug product
candidate is safe and effective for its intended use, and whether the drug product candidate is being manufactured in accordance with cGMP to assure and preserve the drug product candidate&#146;s identity, strength, quality, purity and potency. The
FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review,
evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
The FDA will likely <FONT STYLE="white-space:nowrap">re-analyze</FONT> the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive
and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before
approving a BLA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether the facilities comply with cGMPs. The FDA will not approve the product
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA
may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An
approval letter authorizes commercial marketing of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be
approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3
clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the
deficiencies identified in the letter, withdraw the application or request a hearing. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical
trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that
the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to
specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or
precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical
trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#146;s safety and effectiveness and may require testing and
surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe
use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication
plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,
prescription or dispensing of products. Product approvals may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or based on the results of post-market studies or surveillance programs. Additionally,
post-approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes and adding labeling claims, are subject to further testing requirements and FDA review and approval. Such post-approval
requirements can be costly and time-consuming and can affect the potential market and profitability of the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan Designation
and Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a
rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the
cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the
therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years from the date of such approval, except in
limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity on the basis of greater effectiveness or safety or providing a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for
a different indication but that could be used <FONT STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval
before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#146;s product for the same indication or disease. If we
pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and
benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expedited Development and Review Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that
meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to
address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the
drug or biologic as a Fast Track product concurrently with, or at any time after, submission of an IND, and the FDA must determine if the product qualifies for Fast Track designation within 60 days of receipt of the sponsor&#146;s request. Unique to
a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application,
the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review, or review within a <FONT STYLE="white-space:nowrap">six-month</FONT> timeframe from the date a complete BLA is
accepted for filing, if it has the potential to provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or
biological product designated for priority review in an effort to facilitate the review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a product may be eligible for
accelerated approval. An investigational drug may obtain accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate
endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit.
As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective
can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions as it deems necessary to assure safe use of the drug, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribution restricted to certain facilities or physicians with special training or experience; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribution conditioned on the performance of specified medical procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitations imposed would be commensurate with the specific safety concerns presented by the product. In addition, the FDA currently
requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review
and accelerated approval do not change the standards for approval but may expedite the development or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Breakthrough Designation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary
clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug product candidate be designated as a breakthrough therapy
concurrently with, or at any time after, the submission of an IND, and the FDA must determine if the drug product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. If so designated, the
FDA shall act to expedite the development and review of the product&#146;s marketing application, including by meeting with the sponsor throughout the product&#146;s development, providing timely advice to the sponsor to ensure that the development
program to gather preclinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate
an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accelerated Approval for Regenerative Advanced Therapies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the 21st Century Cures Act, Congress amended the FD&amp;C Act to create an accelerated approval program for regenerative advanced
therapies, which include cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Regenerative advanced therapies do not include those human cells,
tissues, and cellular and tissue-based products regulated solely under section 361 of the Public Health Service Act and 21 CFR Part 1271. The new program is intended to facilitate efficient development and expedite review of regenerative advanced
therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A drug sponsor may request that FDA designate a drug as a regenerative advanced therapy concurrently with or at any time after
submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or
life-threatening disease or condition. A new drug application or BLA for a regenerative advanced therapy may be eligible for priority review or accelerated approval through (1)&nbsp;surrogate or intermediate endpoints reasonably likely to predict
long-term clinical benefit or (2)&nbsp;reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to
support accelerated approval. A regenerative advanced therapy that is granted accelerated approval and is subject to postapproval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient
registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or postapproval monitoring of all patients treated with such therapy prior to its approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration
for each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication,
new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as
may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach,
or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA
and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. The FDA may, on its own
initiative or at the request of the applicant, grant deferrals for submission of data or full or partial waivers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-Marketing
Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the
FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy
information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling
(known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may
prescribe legally available drugs and biologics for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the
FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug
products and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing Act, or the PDMA, a part of the FDCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. We
rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance
as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are
required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must
continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and
quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms
and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such
facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among
other things, recall or withdrawal of the product from the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require post-approval testing, sometimes referred to
as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a
product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or
communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings and
contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be established, or the FDA&#146;s policies may change, which could delay or prevent regulatory approval of our products under development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Regulatory Matters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory
authorities in addition to the FDA, including, in the United States, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services (e.g., the Office of Inspector General, or OIG, and
Office for Civil Rights), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local
governments. In the United States, sales, marketing and scientific/educational programs must also comply with federal and state fraud and abuse laws, data privacy and security laws, transparency laws, and pricing and reimbursement requirements in
connection with governmental payor programs, among others. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant
packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping,
licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply
with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall
or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA
and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially
affect our business in an adverse way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulations, statutes or the interpretation of existing regulations could impact our
business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional
record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>U.S.
Patent Term Restoration and Marketing Exclusivity </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of the FDA approval of our drug
product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments
permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total
of 14 years from the product&#146;s approval date. The patent term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of a BLA plus the time between
the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the
extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we
may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an
<FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, which was part of the Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, or collectively the ACA. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference
product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency, can be shown through analytical
studies, animal studies, and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product
in any given patient and, for products administered multiple times, that the product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to
exclusive use of the reference biological product. However, complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, as well as the processes by which such products are
manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biological product is
granted twelve years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after first
licensure. &#147;First licensure&#148; typically means the initial date the particular product at issue was licensed in the United States. This does not include a supplement for the biological product or a subsequent application by the same sponsor
or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or
strength, unless that change is a modification to the structure of the biological product and such modification changes its safety, purity, or potency. Whether a subsequent application, if approved, warrants exclusivity as the &#147;first
licensure&#148; of a biological product is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis with data submitted by the sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six
months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which attaches to the twelve-year exclusivity period for reference biologics, may be granted based on the voluntary
completion of a pediatric trial in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>United States </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of
our products will depend, in part, on the extent to which our products, once approved, will be covered and reimbursed by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These
third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a third-party payor will provide coverage for a drug product, including a biologic, typically is separate from the
process for setting the price of a drug product or for establishing the reimbursement rate that a payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list,
also known as a formulary, which might not include all of the approved drugs for a particular indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and
reimbursement for any drug product candidate that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the drug product candidate, in addition
to the costs required to obtain FDA or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comparable regulatory approvals. Whether or not we conduct such studies, our drug product candidates may not be considered medically necessary or cost-effective. A third-party payor&#146;s
decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return
on our investment in product development. In the United States, the principal decisions about reimbursement for new drug products are typically made by the U.S. Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department
of Health and Human Services, or HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and
reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs, including biologics, have
been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for
substitution of generic products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower
than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced
compared with the United States. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in
third-party reimbursement for our drug product candidate or a decision by a third-party payor to not cover our drug product candidate could reduce physician usage of the drug product candidate and have a material adverse effect on our sales, results
of operations and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside of the United States, the pricing of pharmaceutical products is subject to governmental
control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been approved. Some
countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to
obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and
utilization of pharmaceutical products will likely continue as countries attempt to manage healthcare expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other
Healthcare Laws and Compliance Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians, and third party payors will play a primary role in
the recommendation and prescription of any products for which we obtain marketing approval.&nbsp;&nbsp;&nbsp;&nbsp;Our business operations in the United States and our current and future arrangements with clinical investigators, healthcare
providers, consultants, third-party payors and patients may expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal Anti-Kickback Statute, the False Claims Act, and HIPAA. The Anti-Kickback Statute makes it illegal
for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or
reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by
imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate
it. Moreover, the ACA provides </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we would not submit claims directly to payors, drug manufacturers can be held liable under the
federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be
presented to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services.
Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare
programs and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#147;caused&#148; the
submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product <FONT STYLE="white-space:nowrap">off-</FONT> label. Claims which include items or services resulting
from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act. Our future marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, if
approved, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our product candidates, are subject to
scrutiny under this law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created new federal criminal statutes that prohibit among other things, knowingly and willfully executing,
or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private
third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick,
scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The civil
monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or
service that was not provided as claimed or is false or fraudulent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to data privacy and security regulations by both
the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH, and their implementing regulations, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in
common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information.
Among other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities, which include certain health care providers, health plans, and healthcare
clearinghouses, that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered
entities and business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing
federal civil actions. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may
not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and criminal penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the
ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain
exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians,
certain other healthcare professionals, and teaching hospitals and to report annually certain ownership and investment interests held by physicians, certain other healthcare professionals, and their immediate family members. In addition, many states
also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted,</FONT> and may have a more prohibitive effect than the Sunshine
Act, thus further complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar federal, state and foreign fraud and abuse laws and regulations, such as state
anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have
similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to
comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers or marketing expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to distribute products commercially, we must comply with
state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers
or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers
and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance
programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare
entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to
federal and state consumer protection and unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and
subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between
healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices
may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment,
exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.
If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions
from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource- consuming and can divert a
company&#146;s attention from the business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Current and Future Legislation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory
changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are
expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical industry are that the ACA: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">1.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs to 23.1%
of average manufacturer price, or AMP, and adding a new rebate calculation for &#147;line extensions&#148; (<I>i.e.</I>, new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially
impacting their rebate liability by modifying the statutory definition of AMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">2.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposed a requirement on manufacturers of branded drugs to provide a 70% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount off the negotiated price of branded drugs
dispensed to Medicare Part D beneficiaries in the coverage gap (<I>i.e.</I>, &#147;donut hole&#148;) as a condition for a manufacturer&#146;s outpatient drugs being covered under Medicare Part D; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">3.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extended a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">4.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanded the entities eligible for discounts under the 340B Drug Discount Program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">5.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">6.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare
programs, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">7.</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by
the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to
lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation through 2019. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional
challenges. Further, on January&nbsp;20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA waive, defer, grant exemptions from, or delay the implementation of any provision
of the ACA that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. In addition, CMS has recently
finalized regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans
sold through such marketplaces. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on
certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the
<FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plan, the annual fee imposed on certain high cost employer- sponsored insurance plans, the annual fee imposed on certain
health insurance providers based on market share, and the medical device exercise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA,
effective January&nbsp;1, 2019, to reduce the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; In July 2018, CMS announced that it is suspending further collections and payments to and from certain ACA
qualified health plans and health insurance issuers under the ACA risk adjustment program pending the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December&nbsp;14, 2018, a U.S.
District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the
remaining provisions of the ACA are invalid as well. The Texas District Court Judge, as well as the Trump Administration and CMS, have stated that the ruling will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge
issued an order staying the judgment pending appeal. On July&nbsp;9, 2019, a Fifth Circuit U.S. Court of Appeals hearing was held to determine whether certain states and the House of Representatives have standing to appeal the lower court decision,
but it is unclear when a Court will render its decision on this hearing and what effect it will have on the status of the ACA. Litigation and legislation related to the ACA are likely to continue, with unpredictable and uncertain results. We will
continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress also could consider
additional legislation to repeal, replace, or further modify elements of the ACA. Thus, the full impact of the ACA, or any law replacing elements of it, and the political uncertainty regarding any repeal and replacement on the ACA, on our business
remains unclear. Many of the details regarding the implementation of the ACA are yet to be determined, and at this time, it remains unclear the full effect that the ACA would have on our business. There have been judicial and Congressional
challenges to the ACA, and we expect such challenges and amendments to continue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, in May 2018, the Trump
administration released its &#147;Blueprint to Lower Drug Prices and Reduce <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs,&#148; or the Blueprint. The Blueprint contains several potential
regulatory actions and legislative recommendations aimed at lowering prescription drug prices, including measures to promote innovation and competition for biologics, changes to Medicare Part D to give plan sponsors more leverage when negotiating
prices with manufacturers, and updating the Medicare drug-pricing dashboard to make price increases and generic competition more transparent. In addition, the Department of HHS released a Request for Information, or RFI, soliciting public input on
ways to lower drug pricing. Together, the recommendations in the Blueprint and RFI, if enacted by Congress and HHS, could lead to changes to Medicare Parts B and D, including the transition of certain drugs covered under Part B to Part D or the
offering of alternative purchasing options under the Competitive Acquisition Program that currently applies to selected drugs and biologics covered under Part B. In September 2018, CMS announced that it will allow Medicare Advantage Plans the option
to use step therapy for Part B drugs beginning January&nbsp;1, 2019. While most of the proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it
will continue to seek new legislative, administrative and/or additional measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have
been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked
with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes
aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013, following passage of the Bipartisan Budget Act of 2013, and will remain in effect through 2027 unless additional congressional
action is taken. Further, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer
treatment centers, and increased the statute of limitations period </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the government to recover overpayments to providers from three to five years. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in
payments from private payors, which may adversely affect our future profitability. Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try
Act, was signed into law. The law, among other things, provides a federal framework for certain patients to request access to certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing
investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and
regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and
ability to develop product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Foreign Corrupt Practices Act </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or
indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates
companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Additional
Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including
the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive
substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in
material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Europe / Rest of World Government Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions that we may in the future
select governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we would need to obtain the requisite approvals from regulatory authorities in
foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much
like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#146;s national health authority and an independent ethics committee, much like the FDA and IRB,
respectively. Once the clinical trial application is approved in accordance with a country&#146;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use
may be restricted in some countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of
Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit an
MAA. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that
have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our potential collaborators fail to comply with applicable foreign regulatory
requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>European Union General Data Protection Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#146;s General Data
Protection Regulation, or GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights
regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party
processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU
member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal
data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of
up to &#128;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to
the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, we
had 12 employees, all of whom were full-time. Of those, nine were engaged in research and development activities. All company employees are located in Philadelphia, PA, or the surrounding area. We do not have any employees that are represented by a
labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Philadelphia, PA, where we lease 7,672 square feet of office, research and development space subject
to a lease agreement that is in effect through 2022. We expect to expand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to a new space in 2022 that will both be adequate for near-term needs in addition to providing additional space to grow. We feel that suitable additional research and development, laboratory and
manufacturing space should be available in the region on commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, our company may become involved in litigation or legal proceedings. At present, we are not involved in any material
litigation or legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information about each of our executive officers and directors as of September&nbsp;15, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>AGE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>POSITION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer and Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anup Marda, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">42</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">45</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Science&nbsp;&amp; Technology</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Brian Stalter, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catherine Bollard, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Daniels, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Henriques, MBA<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">63</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Simon, MBA<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Steven
Nichtberger, M.D.</I> Dr.&nbsp;Nichtberger has served as our Chief Executive Officer, President and a member of our Board of Directors since its founding in 2017. Dr.&nbsp;Nichtberger also serves as managing partner of GBF Advisors, LLC, a company
that provides advisory services to healthcare companies, investors, and leading academic scientists, and is an adjunct professor at The Wharton School at the University of Pennsylvania. He is the chairman of the board of directors of ControlRad,
Inc., a medical device company developing and marketing products to reduce radiation exposure associated with medical procedures, a member of the board of directors of the BioAdvance Greenhouse Fund, which provides funding to startup life sciences
companies in southeastern Pennsylvania, and a member of the board of governors of Main Line Health, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> health system. Dr.&nbsp;Nichtberger is also a
venture advisor for the Israel Biotech Fund. Previously, he was the president, chief executive officer, and a member of the board of directors of Tengion, Inc. from 2004 to 2011 Earlier in his career, Dr.&nbsp;Nichtberger served in various
commercial leadership positions at Merck from 1995 to 2003. He has previously served as a member of the boards of directors of the Alliance for Regenerative Medicine (as a founding member), Pennsylvania Bio including as chairman, and Biotechnology
Industry Organization. He was also a member of the board of overseers for the School of Arts&nbsp;&amp; Sciences at the University of Pennsylvania for over a decade. Dr.&nbsp;Nichtberger received his M.D. from the State University of New York at
Buffalo, his B.S. from The Wharton School at the University of Pennsylvania and his B.A. from the University of Pennsylvania. He completed an internship, residency and fellowship in the Department of Medicine and the Division of Cardiology of the
Mount Sinai Medical Center. We believe Dr.&nbsp;Nichtberger is qualified to serve as a member of our board of directors because of his scientific background and corporate leadership experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anup Marda, MBA.</I> Mr.&nbsp;Marda joined our company in January 2019 as our Chief Financial Officer. From April 2001 to January 2019,
Mr.&nbsp;Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning&nbsp;&amp; Analysis, and previously as Head of Finance, R&amp;D Operations and Head of Finance, R&amp;D
Portfolio Management and Global Medical from 2014 to 2018. Prior to this, Mr.&nbsp;Marda held the role of Executive Director, U.S. Pharmaceuticals from 2012 to 2014 and Assistant Treasurer, Capital Markets from 2008 to 2012. Mr.&nbsp;Marda received
his MBA from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gwendolyn Binder, Ph.D.</I> Dr.&nbsp;Binder joined our company in February 2019 as our
Executive Vice President, Science and Technology. Prior to joining Cabaletta, Dr.&nbsp;Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she initially established and led capabilities in manufacturing, correlative
science, compliance, regulatory and clinical operations, to enable the transfer of certain T cell receptor clinical programs from the Translational Research Program at the University of Pennsylvania and vector and cell manufacturing. She later went
on to establish the internal translational sciences, and manufacturing and quality teams and oversaw the planning and execution of an onsite manufacturing facility. Once the manufacturing was secure, she assumed leadership of the research
organization. Earlier in her career, Dr.&nbsp;Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she participated in multiple engineered T cell therapy clinical programs in HIV and
oncology including the data generation and IND drafting for CART 19 under the leadership of Drs. Carl June and Michael Milone. Prior to that, she was the director of scientific affairs at VIRxSYS Corporation. Dr.&nbsp;Binder received her Ph.D. from
the Johns Hopkins University School of Medicine and her B.A. from Wells College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David J. Chang, M.D., M.P.H.</I> Dr.&nbsp;Chang
joined our company in June 2019 as our Chief Medical Officer. From June 2015 to May 2019, he was Senior Vice President and Head, Inflammation, Autoimmunity&nbsp;&amp; Neuroscience, or IA&amp;NS, Global Medicines Development at AstraZeneca
Pharmaceuticals LP, where he oversaw development projects of both biologics and small molecules in a variety of indications and led the late-stage clinical development organization for IA&amp;NS. From October 2007 to June 2015, Dr.&nbsp;Chang served
in various positions at GlaxoSmithKline plc, including VP and Head, Immuno-Inflammation, Clinical Development. Dr.&nbsp;Chang is an adjunct associate professor in the Division of Rheumatology at the Perelman School of Medicine of the University of
Pennsylvania. He received his M.D. from New York University School of Medicine, his M.P.H. from Emory University and his B.S. from Yale University. Dr.&nbsp;Chang completed his internship and residency in internal medicine at the New York
Hospital&#151;Cornell University Medical Center and fellowship in rheumatology at the Hospital for Special Surgery&#151;Cornell University Medical Center. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>J. Brian Stalter, J.D.</I> Mr. Stalter joined our company in September 2019 as our General Counsel. Prior to joining our company, Mr.
Stalter served as Vice President &amp; Assistant General Counsel, Business Development at Bristol-Myers Squibb. Previously, Mr. Stalter held the role of Assistant General Counsel, Transactional Practice Group at Bristol-Myers Squibb from September
2005 to July 2016. Earlier in his career, Mr. Stalter was Deputy General Counsel at Medarex, Inc. and Senior Counsel, Licensing at Schering-Plough Corporation. He began his career at Dewey Ballantine LLP in New York. Mr. Stalter received his J.D.
from Columbia University and his B.A. in History from the University of Notre Dame. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Catherine Bollard, M.D.</I>&nbsp;Dr.&nbsp;Bollard joined our board of directors in April 2019. She is the director of the Center
for Cancer and Immunology Research at the Children&#146;s Research Institute and the director of the Program for Cell Enhancement and Technologies for Immunotherapy at the Children&#146;s National Health System, or CNHS. She is also a member of the
Division of the Blood and Marrow Transplantation of CNHS. Since 2013, Dr.&nbsp;Bollard also serves as Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine at the George Washington University and is the associate center director
for translational research and innovation within the George Washington Cancer Center. Prior to her move in 2013, Dr.&nbsp;Bollard was Professor of Pediatrics, Medicine and Immunology at Baylor College of Medicine. She is the immediate past president
of the International Society for Cell Therapy, and she served on the Cellular, Tissues and Gene Therapy Advisory Committee of the FDA until 2019. Dr.&nbsp;Bollard has chaired the <FONT STYLE="white-space:nowrap">Non-Hodgkin&#146;s</FONT> Lymphoma
Committee of the Children&#146;s Oncology Group since 2012 and previously served as a member of the board of directors of the Foundation for the Accreditation of Cellular Therapy. Dr.&nbsp;Bollard received her medical degree from University of Otago
Medical School in New Zealand. We believe Dr.&nbsp;Bollard is qualified to serve as a member of our board of directors because of her scientific background and significant experience in clinical and research efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Brian Daniels, M.D.</I> Dr.&nbsp;Daniels joined our board of directors in October 2018. Since 2018, he has been a partner at 5AM Ventures,
where he was previously a venture partner from 2014 to 2018. From 2004 to 2014, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr.&nbsp;Daniels held positions at Bristol-Myers Squibb, serving as senior vice president, global development and medical affairs from 2004 to 2014. Dr.&nbsp;Daniels also serves on the boards of
directors of Spyryx Biosciences, Inc., Nohla Therapeutics Inc., RareCyte, Inc. and Novo Nordisk A/S and on the clinical advisory board of Aprea Therapeutics AB. He previously served on the board of directors of IDEAYA Biosciences, Inc.
Dr.&nbsp;Daniels received his M.D. from Washington University in St. Louis and his B.S. and M.S. from Massachusetts Institute of Technology. He completed his residency in internal medicine at New York Hospital and a fellowship in rheumatology and
immunology at University of California, San Francisco. We believe that Dr.&nbsp;Daniels is qualified to serve as a member of our board of directors because of his scientific background, experience in the venture capital industry, and corporate
leadership experience at numerous biopharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Richard Henriques, MBA.</I> Mr.&nbsp;Henriques joined our board of
directors in February 2019. Since 2015, he has been a senior fellow at the Center for High Impact Philanthropy at the University of Pennsylvania, with a focus on impact investing. From 2010 to 2014, Mr.&nbsp;Henriques was the chief financial officer
of the Bill&nbsp;&amp; Melinda Gates Foundation, where he was responsible for finance and accounting, financial planning and analysis, strategic planning, measurement and evaluation, program related investments and information technology. From 1981
to 2008, Mr.&nbsp;Henriques held positions at Merck&nbsp;&amp; Co., Inc., including as Senior Vice President of Finance for Global Human Health, Vice President and Corporate Controller, and Principal Accounting Officer. Mr.&nbsp;Henriques also
serves on the boards of directors of EMulate Therapeutics Inc. (formerly Nativis Inc.), Arbutus Biopharma Corporation, the Pennsylvania chapter of the Nature Conservancy and Episcopal Community Services, and on the board of trustees of the Franklin
Institute. We believe that Mr.&nbsp;Henriques is qualified to serve as a member of our board of directors because of his extensive corporate leadership experience and expertise in finance and investment management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mark Simon, MBA.</I> Mr.&nbsp;Simon joined our board of directors in October 2018. He is a partner and
<FONT STYLE="white-space:nowrap">co-founder</FONT> of Torreya Partners, LLC, a global investment banking firm serving companies in the life sciences industry. Prior to <FONT STYLE="white-space:nowrap">co-founding</FONT> Torreya, Mr.&nbsp;Simon was a
managing director and head of life sciences investment banking at Citigroup from 2002 to 2005, and a senior biotechnology research analyst at Robertson Stephens from 1989 to 2002. He began his career at Kidder Peabody. Mr.&nbsp;Simon serves on the
boards of directors of ControlRad, Inc. and Sun Pharma Advanced Research Company Limited. He received his MBA from Harvard Business School and his B.A. from Columbia College. We believe that Mr.&nbsp;Simon is qualified to serve on our board of
directors because of his extensive experience of over 30 years in the life sciences industry and biotechnology and specialty pharma transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of five members, each of whom is a member pursuant to the board composition provisions of our current
certificate of incorporation and agreements with our stockholders. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations
regarding the election of our directors. Our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our board of directors&#146; priority in selecting board members is
identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our
business, understanding of the competitive landscape, professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their
resignation or removal. Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering also provide that our directors may be removed only for cause by the
affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of
our board of directors, may be filled only by vote of a majority of our directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on The Nasdaq Global Market. Under the Nasdaq listing rules, independent directors must comprise a
majority of a listed company&#146;s board of directors within twelve months from the date of listing. In addition, the Nasdaq listing rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and
nominating and governance committees be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule
<FONT STYLE="white-space:nowrap">10C-1</FONT> under the Exchange Act. Under Nasdaq listing rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not
have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the
Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any
consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In order to be
considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining
whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of
compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, our board of directors
undertook a review of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations,
including family relationships, our board of directors has determined that all members of our board of directors, except Steven Nichtberger, are independent directors, including for purposes of Nasdaq and SEC rules. In making that determination, our
board of directors considered the relationships that each director has with us and all other facts and circumstances the board of directors deemed relevant in determining independence, including the potential deemed beneficial ownership of our
capital stock by each director, including non-employee directors that are affiliated with certain of our major stockholders. Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of
our committees will comply with all applicable requirements of Nasdaq and the rules and regulations of the SEC. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to adopt a policy, subject to and effective upon the effectiveness of the registration statement of which this prospectus forms a
part, that outlines a process for our securityholders to send communications to the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will
become effective upon the closing of this offering, our board of directors will be divided into three staggered classes of directors and each will be assigned to one of the three classes. At each annual meeting of the stockholders, a class of
directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of
stockholders to be held during the years 2020 for Class&nbsp;I directors, 2021 for Class&nbsp;II directors and 2022 for Class&nbsp;III directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;I director will be Brian Daniels; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;II directors will be Catherine Bollard and Richard Henriques; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;III directors will be Steven Nichtberger and Mark Simon. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this
offering will provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a
change of our management or a change in control. We expect that additional directorships resulting from an increase in the number of directors, if any, will be distributed among the three classes so that, as nearly as possible, each class shall
consist of one third of the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board&#146;s Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks,
including risks relating to our financial condition, development and commercialization activities, operations, strategic direction and intellectual property as more fully discussed in the section entitled &#147;Risk Factors&#148; appearing elsewhere
in this prospectus. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face, while our board of directors, as a whole and through its committees, has
responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning
as designed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of
the board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview
of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular
risk or risks, the chairman of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the
risk oversight role, particularly with respect to risk interrelationships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each
of which will operate pursuant to a charter to be adopted by our board of directors and will be effective upon the effectiveness of the registration statement of which this prospectus is a part. Upon the effectiveness of the registration statement
of which this prospectus is a part, the composition and functioning of all of our committees will comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, Nasdaq and SEC rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of this offering, the full text of our audit committee charter, compensation committee charter, and nominating and
corporate governance charter will be posted on the investor relations portion of our website at www.cabalettabio.com. We do not incorporate the information contained on, or accessible through, our corporate website into this prospectus, and you
should not consider it a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, Richard Henriques, Brian Daniels and Mark Simon will serve on the audit committee, which will be chaired by
Mr.&nbsp;Henriques. The audit committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public
accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and
quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent
registered public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as
they relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis</I>
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, to be provided to us by our independent registered public accounting firm must be approved in advance by our audit committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All members of our audit committee will meet the requirements for financial literacy under the applicable rules and regulations of the SEC and
the Nasdaq listing rules. Our board of directors has determined that Richard Henriques qualifies as an &#147;audit committee financial expert&#148; within the meaning of applicable SEC regulations. In making this determination, our board of
directors considered the nature and scope of experience that Mr.&nbsp;Henriques has previously had with public reporting companies, including service as Senior Vice President of Finance for Global Human Health, Vice President and Corporate
Controller, and Principal Accounting Officer at Merck &amp; Co. Inc. Our board of directors has determined that all of the directors that will become members of our audit committee upon the effectiveness of the registration statement of which this
prospectus forms a part satisfy the relevant independence requirements for service on the audit committee set forth in the rules of the SEC and the Nasdaq listing rules. Both our independent registered public accounting firm and management will
periodically meet privately with our audit committee. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, Catherine Bollard, Brian Daniels and Mark Simon&nbsp;will serve on the compensation committee, which will be
chaired by Dr.&nbsp;Daniels. The compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">annually reviewing and recommending to the board of directors the corporate goals and objectives relevant to the
compensation of our Chief Executive Officer; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and
based on such evaluation (i)&nbsp;recommending to the board of directors the cash compensation of our Chief Executive Officer and (ii)&nbsp;reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the cash compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence
standards identified in the applicable Nasdaq rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to the board of directors the compensation of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing our compensation committee report if and when required by SEC rules; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis,&#148; if and
when required, to be included in our annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the
evaluation of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that each member of the compensation
committee is &#147;independent&#148; as defined in the applicable Nasdaq rules. Each member of our compensation committee will be a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined in Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, Catherine Bollard, Richard Henriques and Mark Simon&nbsp;will serve on the nominating and corporate
governance committee, which will be chaired by Mr.&nbsp;Simon. The nominating and corporate governance committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees
recommended by stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the
appropriate skills and expertise to advise us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of
corporate governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee are, or has at any time during the prior three years been, one of our officers or employees.
None of our executive officers currently serve, or in the past fiscal year have served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or
compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the effectiveness of the registration statement of which this prospectus is a part, we will adopt a written code of business conduct
and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Following the
effectiveness of the registration statement of which this prospectus is a part, a current copy of the code will be posted on the investor relations section of our website, which is located at www.cabalettabio.com. If we make any substantive
amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an
emerging growth company, we have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller reporting companies,&#148; as such term is defined in the rules promulgated under the Securities Act. This section provides
an overview of the compensation awarded to, earned by, or paid to our principal executive officer for fiscal year 2018, and our next most highly compensated executive officer in respect of their service to our company for our fiscal year ended
December&nbsp;31, 2018. We refer to these individuals as our named executive officers. We did not have any other executive officers serving in 2018. Our named executive officers are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Steven Nichtberger, M.D., our Chief Executive Officer and President; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel E. Geffken, our former Interim Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive compensation program is based on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy. Compensation for our executive officers is composed primarily of the following main components: base salary; bonus; and equity incentives
in the form of stock options. Our executive officers, like all full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we intend to evaluate our
compensation values and philosophy and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 Summary Compensation Table
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to, earned by, or paid to our named executive officers for
services rendered to us in all capacities during the fiscal year ended December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>NAME&nbsp;AND&nbsp;PRINCIPAL<BR>POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SALARY<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BONUS<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STOCK<BR>AWARDS<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPTION<BR>AWARDS<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ALL&nbsp;OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer and President</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,204</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,399</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913,675</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel E. Geffken,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Interim CFO</I><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the grant date fair value of stock and option awards granted or modified in 2018 in accordance
with the Financial Accounting Standards Board&#146;s Accounting Standards Codification Topic 718, or ASC 718. Such grant date fair value does not take into account any estimated forfeitures related to service-vesting conditions. For information
regarding assumptions underlying the valuation of equity awards, see Note 8 to our financial statements and the discussion under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Critical
Accounting Policies and Significant Judgments and Estimates&#151;Stock-based Compensation&#148; included elsewhere in this prospectus. These amounts do not correspond to the actual value that may be recognized by the 2018 Named Executive Officers
upon vesting of applicable awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Nichtberger entered into a consulting agreement with us in August 2017 and became an employee on
October&nbsp;11, 2018. The 2018 salary reported reflects the compensation Dr.&nbsp;Nichtberger received both as a consultant and as an employee in 2018. Dr.&nbsp;Nichtberger also serves as a member of our board of directors but does not receive any
additional compensation for his service as a director. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Geffken was appointed to serve as our Interim Chief Financial Officer on August&nbsp;21, 2018 and
resigned effective as of February&nbsp;12, 2019. Mr.&nbsp;Geffken was compensated for his services in this position pursuant to a Consulting Agreement, as amended, effective as of May&nbsp;7, 2018, that we entered with Danforth Advisors,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
LLC, or Danforth. Mr.&nbsp;Geffken is a founder and managing director at Danforth and is paid a salary by Danforth. We paid an aggregate amount of $186,017 to Danforth during 2018 pursuant to the
terms of the Consulting Agreement. In addition, on November&nbsp;16, 2018, we granted 20,000 options to Mr.&nbsp;Geffken, which vest in eight equal quarterly installments over a <FONT STYLE="white-space:nowrap">two-year</FONT> period commencing on
November&nbsp;16, 2018. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to the 2018 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use
base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our executive officers. Base salaries are reviewed annually, typically in connection with our annual performance review
process, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Bonus </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
employees participate in our annual performance-based bonus plan. Our employment agreements with our named executive officers define a target bonus percentage of the executive&#146;s base salary, as described further below under the section entitled
&#147;Employment Arrangements and with our Named Executive Officers&#148;. Bonus targets may be modified up or down based on our board&#146;s assessment of company performance vs our annual goals, and further modified based on individual performance
vs annual objectives and assessed behaviors. The 2018 target bonus amount, expressed as a percentage of annual base salary, for Dr.&nbsp;Nichtberger was 40%. With respect to 2018 performance, our board of directors awarded a bonus of $98,466 to
Dr.&nbsp;Nichtberger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, or any formal equity
ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In
addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors
periodically reviews the equity incentive compensation of our named executive officers and from time to time may grant equity incentive awards to them in the form of stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We typically grant stock option awards at the start of employment to each executive and our other employees. We award our stock options on the
date our board of directors approves the grant. We set the option exercise price and grant date fair value based on our <FONT STYLE="white-space:nowrap">per-share</FONT> estimated valuation on the date of grant. For grants in connection with initial
employment, vesting begins on the initial date of employment. To date, we have not maintained a practice of granting additional equity on an annual basis, but we have retained discretion to provide additional targeted grants in certain
circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with our Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an offer letter with our Chief Executive Officer and President, Steven Nichtberger,&nbsp;M.D., which was amended on
January&nbsp;2, 2019, and a consulting agreement with Danforth, an entity controlled by Mr.&nbsp;Geffken. The terms and conditions of these agreements are summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Steven Nichtberger, M.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with Steven Nichtberger, M.D., our Chief Executive Officer and President, on October&nbsp;10, 2018, which was
amended in January 2019. Dr.&nbsp;Nichtberger&#146;s offer letter sets forth the initial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms and conditions of his employment with us, including base salary, target annual bonus opportunity and standard employee benefit plan participation. Dr.&nbsp;Nichtberger&#146;s offer letter
provides for &#147;at will&#148; employment. Under the terms of his offer letter, Dr.&nbsp;Nichtberger is entitled to receive an annual base salary of $425,000 and an annual target bonus of 40% of his annual base salary based upon our board of
directors&#146; assessment of Dr.&nbsp;Nichtberger performance and our attainment of targeted goals as set by the board of directors in their sole discretion. Pursuant to his offer letter, Dr.&nbsp;Nichtberger also entered into an Employee
Restrictive Covenant Agreement with us, pursuant to which he agreed to certain <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality and invention assignment terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Nichtberger&#146;s offer letter provides that, in the event that his employment is terminated by us without &#147;cause&#148; or by
Dr.&nbsp;Nichtberger with &#147;good reason&#148; (as defined in Dr.&nbsp;Nichtberger&#146;s offer letter), subject to the execution and effectiveness of a separation agreement and release, he will be entitled to receive (i)&nbsp;continuation of his
base salary for twelve (12)&nbsp;months, and (ii)&nbsp;reimbursement of COBRA premiums for health benefit coverage, up to an amount equal to the monthly employer contribution that we would have made to provide health insurance to
Dr.&nbsp;Nichtberger had he remained employed with us for up to twelve (12)&nbsp;months (the &#147;Termination Benefits&#148;). In addition, in the event that Dr.&nbsp;Nichtberger terminates his employment with &#147;good reason&#148; within six
months of a &#147;chairperson designation&#148; (as defined in the offer letter), other than during the period commencing 60 days prior to and ending 12 months following a &#147;change in control&#148; (as defined in the offer letter), subject to
the execution and effectiveness of a separation agreement and release, all stock options and other stock-based awards held by Dr.&nbsp;Nichtberger shall accelerate and become fully exercisable or
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> as of the date of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Dr.&nbsp;Nichtberger&#146;s
employment is terminated by us without &#147;cause&#148; or by Dr.&nbsp;Nichtberger with &#147;good reason&#148; during the period commencing 60 days prior to and ending 12 months following a &#147;change in control&#148;, subject to the execution
and effectiveness of a separation agreement and release, he will be entitled to receive the Termination Benefits and all stock options and other stock-based awards held by Dr.&nbsp;Nichtberger shall accelerate and become fully exercisable or <FONT
STYLE="white-space:nowrap">non-forfeitable</FONT> as of the date of termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Danforth Advisors, LLC Consulting Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, we entered into a consulting agreement with Danforth, which was amended in May 2019, pursuant to which we have
engaged Danforth as an independent consultant to provide us with certain strategic and financial advice and support services. Mr.&nbsp;Geffken, who was appointed to serve as our interim chief financial officer on August&nbsp;21, 2018 and served in
that capacity until he resigned effective as of February&nbsp;12, 2019, is a founder and managing director at Danforth. We paid Danforth approximately $186,017 during 2018. In addition, on November&nbsp;16, 2018, we granted an option to purchase
20,000 shares of common stock to Mr.&nbsp;Geffken, which vests in eight equal quarterly installments over a <FONT STYLE="white-space:nowrap">two-year</FONT> period commencing on November&nbsp;16, 2018. The consulting agreement may be terminated by
either party thereto with or without cause upon thirty days&#146; prior written notice and will expire on May&nbsp;7, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2018 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by our named executive officers as of December&nbsp;31,
2018. All equity awards set forth in the table below were granted under our Amended and Restated Stock Option and Grant Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPTION&nbsp;AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>STOCK&nbsp;AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>UNEXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>EQUITY<BR>INCENTIVE<BR>PLAN<BR>AWARDS:<BR>NUMBER<BR>OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>UNEARNED<BR>OPTIONS (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER<BR>OF<BR>SHARES<BR>OR UNITS<BR>OF<BR>STOCK<BR>THAT<BR>HAVE<BR>NOT<BR>VESTED<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MARKET<BR>VALUE<BR>OF<BR>SHARES<BR>OR<BR>UNITS<BR>OF<BR>STOCK<BR>THAT<BR>HAVE<BR>NOT<BR>VESTED<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>
</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief&nbsp;Executive&nbsp;Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,515</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;28,<BR>2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,515</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">October&nbsp;28,<BR>2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel E. Geffken,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Interim CFO</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">November&nbsp;16,<BR>2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market price of our common stock is based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option vests over four years, with 25% vesting on October&nbsp;11, 2019, and the remaining shares vesting
in 36 equal monthly installments thereafter, subject to a continued service relationship with us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">139,839 of the shares subject to this option will vest on the date that the first patient is dosed in a PV
Phase 1 clinical trial, 139,839 of the shares subject to this option will vest upon our first underwritten public offering of our common stock with gross proceeds to us of at least $50&nbsp;million and a price per share equal to or greater than
$8.10, and 139,837 of the shares will vest upon affirmative approval by our board of directors of a clinical candidate for treatment of MG with <I>in vivo</I> proof-of-concept to support a decision to move forward with
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> development of such clinical candidate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">174,240 of the shares subject to this stock award vested on May&nbsp;4, 2019 and the remaining shares vest in
eight quarterly installments over the two years following May&nbsp;4, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option vests over two years in eight equal quarterly installments commencing on November&nbsp;16, 2018.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Risk Assessment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our
executive compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both
short-term and long-term strategic goals. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2018 Plan was approved by our board of directors and our stockholders on September&nbsp;7, 2018. Under the 2018 Plan, as amended through
the date hereof, we have reserved for issuance an aggregate of 3,870,680 shares of our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock. The number of shares of common stock reserved for issuance is subject to adjustment in the event of any merger, consolidation, sale of all or substantially all of our assets,
reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
shares of common stock underlying awards that are forfeited, canceled, reacquired by us prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise) and shares of common stock that are withheld upon
exercise of an option or settlement of an award to cover the exercise price or tax withholding are added back to the shares of common stock available for issuance under the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has acted as administrator of the 2018 Plan. The administrator has full power to select, from among the individuals
eligible for awards, the individuals to whom awards will be granted, and to determine the specific terms and conditions of each award, subject to the provisions of the 2018 Plan. Persons eligible to participate in the 2018 Plan are those employees,
officers and directors of, and consultants and advisors to, our company as selected from time to time by the administrator in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Plan permits the granting of (1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under
Section&nbsp;422 of the Internal Revenue Code of 1986, as amended, or the Code and (2)&nbsp;options that do not so qualify. The per share option exercise price of each option will be determined by the administrator but may not be less than 100% of
the fair market value of the common stock on the date of grant. The term of each option will be fixed by the administrator. The administrator will determine at what time or times each option may be exercised. In addition, the 2018 Plan permits the
granting of restricted shares of common stock, unrestricted shares of common stock, and restricted stock units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Plan provides
that upon the occurrence of a &#147;sale event,&#148; as defined in the 2018 Plan, our board of directors may take one or more of the following actions as to some or all awards outstanding under the 2018 Plan: (i)&nbsp;provide that outstanding
options awards will be assumed or substituted by the acquiring or successor corporation, (ii)&nbsp;provide that all unexercised options will terminate immediately prior to the consummation of the sale event unless exercised by the optionee (to the
extent exercisable) within a specified period prior to the consummation of the sale event, (iii)&nbsp;make or provide for a cash payment to the optionees equal to the difference between the per share cash consideration in the sale event and the per
share exercise price of the outstanding award, (iv)&nbsp;provide that all restricted stock and unvested restricted stock unit awards (other than those becoming vested as a result of the sale event) will be assumed or substituted by the acquiring or
successor corporation (v)&nbsp;provide that all restricted stock and unvested restricted stock unit awards (other than those becoming vested as a result of the sale event) will terminate immediately prior to the effective time of any sale event
unless repurchased at a price per share equal to the lower of the original per share purchase price paid by the holder (subject to adjustment) or the current fair market value of such shares, determined immediately prior to the effective time of the
sale event, (vi)&nbsp;make or provide for a cash payment to the holders of restricted stock or restricted stock unit awards in an amount equal to the consideration payable per share of stock pursuant to the sale event times the number of shares
subject to such award. We may also make or provide for a cash payment to participants holding options in an amount equal to the difference between the per share cash consideration payable to stockholders in the sale event and the exercise price of
the options (to the extent then exercisable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The administrator may amend or discontinue the 2018 Plan at any time, subject to
stockholder approval where such approval is required by applicable law. The administrator of the 2018 Plan may also amend or cancel any outstanding award, provided that no amendment to an award may adversely affect a participant&#146;s rights
without his or her consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Plan will terminate automatically upon the earlier of 10 years from the date on which the 2018 Plan
was adopted by our board of directors or 10 years from the date the 2018 Plan is approved by our stockholders. As of June&nbsp;30, 2019, options to purchase 2,435,545 shares of common stock were outstanding under the 2018 Plan. Our board of
directors has determined not to make any further awards under the 2018 Plan following the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2019 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2019 Plan was adopted by our board of directors
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 and approved by our stockholders
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 and will become effective upon the effectiveness of the registration statement of which this prospectus is part. The 2019 Plan will
replace the 2018 Plan as our board of directors has determined not to make additional awards under the 2018 Plan following the closing of our initial public offering. The 2019 Plan allows the compensation committee to make equity-based and
cash-based incentive awards to our officers, employees, directors and other key persons (including consultants). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have initially
reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, or the Initial Limit, for the issuance of awards under the 2019 Plan, plus the shares of common stock
remaining available for issuance under our 2018 Plan. The 2019 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2020,
by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31, or such lesser number of shares as determined by our compensation committee, or the Annual Increase. This number
is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares we issue under
the 2019 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax
withholding, reacquired by us prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the 2019 Plan and the 2018 Plan will be added back to the shares of common stock available for
issuance under the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options and stock appreciation rights with respect to no more
than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of stock may be granted to any one individual in any one calendar year. The maximum aggregate number of shares that may be issued in the form of incentive stock
options shall not exceed the Initial Limit cumulatively increased on January&nbsp;1, 2020 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Plan will be
administered by our compensation committee. Our compensation committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and
to determine the specific terms and conditions of each award, subject to the provisions of the 2019 Plan. Persons eligible to participate in the 2019 Plan will be those full or part-time officers, employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and other key persons (including consultants) as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under
Section&nbsp;422 of the Code, and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of
grant. The term of each option will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock
appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right may not be less than 100% of the
fair market value of the common stock on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee may award restricted shares of common stock and
restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a
specified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vesting period. Our compensation committee may also grant shares of common stock that are free from any restrictions under the 2019 Plan. Unrestricted stock may be granted to participants in
recognition of past services or other valid consideration and may be issued in lieu of cash compensation due to such participant. Our compensation committee may grant cash bonuses under the 2019 Plan to participants, subject to the achievement of
certain performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Plan provides that in the case of, and subject to, the consummation of a &#147;sale event&#148; as
defined in the 2019 Plan, all outstanding awards may be assumed, substituted or otherwise continued by the successor entity. To the extent that the successor entity does not assume, substitute or otherwise continue such awards, then (i)&nbsp;all
stock options and stock appreciation rights will automatically become fully exercisable and the restrictions and conditions on all other awards with time-based conditions will automatically be deemed waived, and awards with conditions and
restrictions relating to the attainment of performance goals may become vested and <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> in connection with a sale event in the compensation committee&#146;s discretion and (ii)&nbsp;upon the
effectiveness of the sale event, the 2019 Plan and all awards will automatically terminate. In the event of such termination, (i)&nbsp;individuals holding options and stock appreciation rights will be permitted to exercise such options and stock
appreciation rights (to the extent exercisable) prior to the sale event; or (ii)&nbsp;we may make or provide for a cash payment to participants holding options and stock appreciation rights equal to the difference between the per share cash
consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights (to the extent then exercisable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may amend or discontinue the 2019 Plan and our compensation committee may amend the exercise price of options and amend
or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2019 Plan require the
approval of our stockholders. No awards may be granted under the 2019 Plan after the date that is 10&nbsp;years from the date of stockholder approval. No awards under the 2019 Plan have been made prior to the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, our board of
directors adopted the 2019 Employee Stock Purchase Plan, or 2019 ESPP, and in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019, our stockholders approved the 2019 ESPP.
The 2019 ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. The 2019 ESPP initially reserves and authorizes the issuance of up to a total
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will
automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2020 through January&nbsp;1, 2029, by the lesser of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock,
(ii)&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or (iii)&nbsp;such lesser number of shares as determined by the 2019 ESPP administrator. The number of shares
reserved under the 2019 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All employees whose customary employment is for more than 20&nbsp;hours per week are eligible to participate in the ESPP. However, any
participating employee who would own 5% or more of the total combined voting power or value of all classes of stock after an option were granted under the ESPP would not be eligible to purchase shares under the 2019 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will make one or more offerings each year to our employees to purchase shares under the ESPP. Offerings will usually begin on each
January&nbsp;1 and July&nbsp;1 and will continue for <FONT STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at
least 15 business days before the relevant offering date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each employee who is a participant in the 2019 ESPP may purchase shares by
authorizing payroll deductions of up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of his or her base compensation during an offering period. Unless the participating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares on the last business day of the offering period at a price equal to
85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of common stock,
valued at the start of the purchase period, under the ESPP in any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accumulated payroll deductions of any employee who
is not a participant on the last day of an offering period will be refunded. An employee&#146;s rights under the 2019 ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of common
stock authorized under the ESPP and certain other amendments require the approval of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Senior Executive Cash
Incentive Bonus Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan, or the Bonus Plan.
The Bonus Plan provides for cash bonus payments based upon the attainment of performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our
company, or Corporate Performance Goals, as well as individual performance objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee may select Corporate
Performance Goals from among the following: cash flow (including, but not limited to, operating cash flow and free cash flow); research and development, publication, clinical and/or regulatory milestones; earnings before interest, taxes,
depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of the Company&#146;s common stock; economic value-added; acquisitions or strategic
transactions, including licenses, collaborations, joint ventures or promotion arrangements; operating income (loss); return on capital, assets, equity, or investment; total stockholder returns; coverage decisions; productivity; expense efficiency;
margins; operating efficiency; working capital; earnings (loss) per share of the Company&#146;s common stock; sales or market shares; number of prescriptions or prescribing physicians; revenue; corporate revenue; operating income and/or net annual
recurring revenue, any of which may be measured in absolute terms or compared to any incremental increase, measured in terms of growth, compared to another company or companies or to results of a peer group, measured against the market as a whole
and/or as compared to applicable market indices and/or measured on a pre-tax or post-tax basis (if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each executive officer
who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive.
The Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and
individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its
sole discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We participate in a retirement savings plan, or 401(k) plan, that is intended to qualify for favorable tax treatment under Section&nbsp;401(a)
of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. U.S. employees who are at least 21 years of age are generally eligible to participate in the 401(k) plan, subject to
certain criteria. Participants may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> and certain <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for
<FONT STYLE="white-space:nowrap">catch-up</FONT> contributions. Participant contributions are held in trust as required by law. An employee&#146;s interest in his or her salary deferral contributions is 100% vested when contributed. We have the
ability to make discretionary contributions under the plan and contributed in 2019 based on 3% of salary earned in 2018. Effective for the 2019 plan year, all eligible employees will receive an Employer Safe Harbor nonelective contribution equal to
3% of eligible pay for the plan year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, provisions in our amended and restated certificate of incorporation and amended and restated bylaws, both of
which will become effective upon the closing of this offering, limit or eliminate the personal liability of directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the
corporation, a director exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of
fiduciary duty as a director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act related to unlawful stock repurchases, redemptions or other distributions or payments of dividends; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not limit or eliminate our rights or any stockholder&#146;s rights to seek
<FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, such as injunctive relief or rescission. These provisions will not alter a director&#146;s liability under other laws, such as the federal securities laws or other state or federal laws.
Our amended and restated certificate of incorporation that will become effective upon the closing of this offering also authorizes us to indemnify our directors to the fullest extent permitted under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, our amended and restated bylaws to be effective upon the closing of this offering will provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we must advance expenses to our directors and officers, and may advance expenses to our employees and other
agents, in connection with a legal proceeding to the fullest extent permitted by law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights provided in our amended and restated bylaws are not exclusive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then
the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director,
employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our bylaws permit such indemnification. We have obtained such insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification that will be provided for in our amended and restated certificate of incorporation and amended and restated
bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These
indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys&#146; fees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of his service as one of our directors or executive officers
or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated bylaws
and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to
our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is,
therefore, unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no pending litigation or proceeding naming any of our directors or officers as to which
indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_13"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation for each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT>
member of our board of directors and received compensation for such service during the fiscal year ended December&nbsp;31, 2018. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity
awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to, or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2018. We reimburse members of our board of
directors for reasonable travel expenses. Dr.&nbsp;Nichtberger, our Chief Executive Officer and President, did not receive any compensation for his service as a member of our board of directors in 2018. Dr.&nbsp;Nichtberger&#146;s compensation for
service as an employee for fiscal year 2018 is presented in &#147;Executive Compensation&#151;2018 Summary Compensation Table.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEES&nbsp;EARNED&nbsp;OR<BR>PAID&nbsp;IN&nbsp;CASH</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>OPTION&nbsp;AWARDS<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Simon<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Daniels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reflect the aggregate grant date fair value of option awards granted in 2018 in accordance with the
Financial Accounting Standards Board&#146;s Accounting Standards Codification Topic 718, or ASC 718. Such grant date fair value does not take into account any estimated forfeitures related to service-vesting conditions. For information regarding
assumptions underlying the valuation of equity awards, see Notes 8 to our financial statements and the discussion under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Critical Accounting
Policies and Significant Judgments and Estimates&#151;Stock-based Compensation&#148; included elsewhere in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2018, Mr.&nbsp;Simon held an unvested option to purchase 41,951 shares of our common
stock. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors expects to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, effective upon
effectiveness of the registration statement of which this prospectus forms a part, that is designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the
policy, each director who is not an employee will be paid cash compensation from and after the completion of this offering, as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>MEMBER<BR>ANNUAL<BR>FEE</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHAIRMAN<BR>ADDITIONAL<BR>ANNUAL</B><br><B>FEE</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director serving on our board of
directors upon completion of this offering and each <FONT STYLE="white-space:nowrap">non-employee</FONT> director elected or appointed to our board of directors following the completing of this offering will be
granted&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;on the date of such director&#146;s election or appointment to the board of directors, which will vest in the following manner, subject to continued service through
such vesting date(s):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. On the date of each annual meeting of stockholders of our company, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be
granted&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which will vest in the following manner, subject to continued service as a director through such vesting
date(s):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the compensation agreements and other arrangements described under &#147;Executive Compensation&#148; and &#147;Director
Compensation&#148; in this prospectus and the transactions described below, since our incorporation on April&nbsp;3, 2017, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or
will be, a party in which the amount involved exceeded, or will exceed, $120,000 and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities
affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements of Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we sold an aggregate of 3,146,551 shares of our Series A preferred stock at a purchase price of $4.05 per share, 7,372,719
shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock at a purchase price of $2.76 per share and 1,873,777 shares of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock at a purchase price of $2.76 per
share. The Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock was purchased with a mix of cash and the conversion of certain of our outstanding convertible
promissory notes. The following table summarizes purchases of our Series A and <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>STOCKHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARES&nbsp;OF<BR><FONT STYLE="white-space:nowrap">SERIES&nbsp;A&nbsp;/&nbsp;A-1</FONT><BR>PREFERRED<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>PURCHASE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5AM Ventures V, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,743,531.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,401.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners, LP<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,605,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,950,926.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,330,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,193,330.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Brian Daniels serves as a member of our board of directors and is a partner at 5AM Ventures V, LP. 5AM Ventures
V, LP holds more than 5% of our voting securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Steven Nichtberger is our chief executive officer and a member of our board of directors.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This entity holds, in the aggregate, more than 5% of our voting securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Series B Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, we sold an aggregate of 6,963,788 shares of our Series B preferred stock at a purchase price of $7.18 per share. In addition,
we issued a further 1,405,332 shares of Series B Preferred Stock in exchange for 1,405,332 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. The following table summarizes purchases of our Series B preferred stock by
related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>STOCKHOLDER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARES&nbsp;OF<BR>SERIES&nbsp;B<BR>PREFERRED<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL<BR>PURCHASE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5AM Ventures V, LP<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,248,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,964,904.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners, LP<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">712,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,116,030.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">658,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,726,529.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Brian Daniels serves as a member of our board of directors and is a partner at 5AM Ventures V, LP. 5AM Ventures
V, LP holds more than 5% of our voting securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This entity holds, in the aggregate, more than 5% of our voting securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our Series <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A/A-1/A-2</FONT></FONT> preferred stock
financing and our Series B preferred stock financing, we entered into investors&#146; rights, voting and right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, voting
rights and rights of first refusal, among other things, with certain holders of our preferred stock and certain holders of our common stock. These stockholder agreements will terminate upon the closing of this offering, except for the registration
rights granted under our investors&#146; rights agreement, as more fully described in &#147;Description of Capital Stock&#151;Registration Rights.&#148; In connection with these financings, we also entered into a side letter with certain investors
containing rights to participate in this offering. For more information regarding certain rights relating to this offering granted under our stockholder agreements and the side letter, see the section of this prospectus titled &#147;Principal
Stockholders.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Danforth Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, we engaged Danforth Advisors, LLC, or Danforth, a consulting firm specializing in providing financial and strategic support to
life sciences companies and a controlled affiliate of Daniel Geffken, who served as our interim Chief Financial Officer from August 2018 to February 2019. Pursuant to a consulting agreement effective May 2018, which was amended in May 2019, we paid
professional fees to Danforth of $186,017 in 2018 and $279,995 through June&nbsp;30, 2019. Mr.&nbsp;Geffken was granted options with an aggregate grant date fair value of $25,000, as computed in accordance with ASC Topic 718. <B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with this offering, we intend to enter into new agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees),
judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s
status as a member of our board of directors to the maximum extent allowed under Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies for Approval of Related Party Transactions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting
securities and their affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such
transaction, and the transaction is not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approve the transaction. Further, when our stockholders are entitled to vote on a
transaction with a related party, the material facts of the related party&#146;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we expect to adopt a written related party transactions policy that such transactions must be approved by
our audit committee. This policy will become effective on the date on which the registration statement of which this prospectus is part is declared effective by the SEC. Pursuant to this policy, the audit committee has the primary responsibility for
reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person
has or will have a direct or indirect material interest. For purposes of this policy, a related person will be defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common stock, in each case
since the beginning of the most recently completed year, and their immediate family members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information known to us regarding beneficial ownership of our common stock as of June&nbsp;30, 2019 by:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of
our capital stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The column entitled &#147;Percentage of Shares Beneficially Owned&#151;Before Offering&#148; is calculated based on 25,129,319 shares of
common stock outstanding as of June&nbsp;30, 2019, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 19,356,835 shares of our common stock upon the completion of this offering. The column
entitled &#147;Percentage of Shares Beneficially Owned&#151;After Offering&#148; is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to be outstanding
after this offering, including the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that we are selling in this offering, but not including any additional shares
issuable upon exercise of outstanding options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and the
information is not necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities as well as any shares of common stock that the person has the right to acquire within 60 days of June&nbsp;30, 2019 through the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by
the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the
persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Rights In Connection With This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a side letter that we entered into in connection with our Series A/Series <FONT STYLE="white-space:nowrap">A-1/Series</FONT> <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred stock financing, we must use commercially reasonable efforts to cause the underwriters of this offering to provide each of Baker Brothers Life Sciences, L.P., 667, L.P., 5AM Ventures V, L.P. and Adage
Capital Partners, LP, or the <FONT STYLE="white-space:nowrap">Series&nbsp;A/A-1</FONT> investors, the opportunity to participate in this offering in an amount equal to such investor&#146;s pro rata share of an aggregate of 32% of the total number
shares of common stock being offered by us. Despite our commercially reasonable efforts, the underwriters may, in their sole discretion, determine that the <FONT STYLE="white-space:nowrap">Series&nbsp;A/A-1</FONT> investors&#146; participation in
such proportion is not advisable and designate a reduced number of, or no, shares for purchase by the <FONT STYLE="white-space:nowrap">Series&nbsp;A/A-1</FONT> investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, each outstanding share of our Series A, Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT
STYLE="white-space:nowrap">A-2</FONT> and Series B preferred stock, or our preferred stock, will automatically convert into shares of common stock in accordance with the provisions of our second amended and restated certificate of incorporation, or
our current charter. Our current charter provides that upon thirty days&#146; written notice to us prior to the closing of this offering, if a holder of our preferred stock, together with its affiliates, would beneficially own shares of our common
stock in excess of 4.99% following such conversion, such holder may elect to instead convert part or all of its shares of preferred stock into shares of a new class of common stock that will be <FONT STYLE="white-space:nowrap">non-voting</FONT> but
otherwise have the same rights and preferences as our common stock. Any holder of shares of <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock may convert these shares into shares of our common stock, unless, immediately prior to or
following such conversion, the holder and its affiliates beneficially own, or would beneficially own, more than 4.99% of our issued and outstanding shares of common stock. Any such holder of shares of our preferred stock has the right to increase or
decrease this beneficial ownership limitation, in its sole discretion, by providing us with 61 days&#146; prior written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for persons listed in the table is c/o
Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES<BR>BENEFICIALLY&nbsp;OWNED<BR>PRIOR&nbsp;TO&nbsp;OFFERING</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PERCENTAGE&nbsp;OF<BR>SHARES<BR>BENEFICIALLY OWNED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>NAME&nbsp;AND&nbsp;ADDRESS&nbsp;OF&nbsp;BENEFICIAL OWNER</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>BEFORE<BR>OFFERING</B><br><B>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AFTER<BR>OFFERING</B><br><B>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5AM Ventures V, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,822,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.19</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adage Capital Partners, LP<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,807,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,807,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aimee Payne, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Milone, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,633,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Boxer Capital,
LLC<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Deerfield
Management<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers, Other Officers, and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Nichtberger, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,724,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gwendolyn Binder, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Chang, M.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anup Marda, MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Brian Stalter, J.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catherine Bollard, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Daniels, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard&nbsp;Henriques,&nbsp;MBA<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Simon, MBA<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All executive officers and directors as a group (9&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>&nbsp;</B></P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B>1,800,210<B></B></P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>7.15<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>%<B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"> Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,146,551 shares of common stock issuable upon conversion of shares of Series A preferred stock and
1,675,532 shares of common stock issuable upon conversion of shares of Series B preferred stock, in each case held by 5AM Ventures V, L.P. 5AM Partners V, LLC is the general partner of 5AM Ventures V, L.P. and may be deemed to have sole investment
and voting power over the shares held by 5AM Ventures V, L.P. Andrew Schwab, Kush Parmar and Scott Rocklage are the managing members of 5AM Partners V, LLC, and may be deemed to share voting and dispositive power over the shares held by 5AM Ventures
V, L.P. Dr. Brian Daniels is a member of our board of directors and a partner at 5AM Venture Management, LLC. However, Dr. Daniels does not have or share voting or dispositive power over the shares owned by 5AM Ventures V, L.P. The address of the
above persons and entities is 501 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Street, Suite 350, San Francisco, CA 94107. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,605,408 shares of common stock issuable upon conversion of shares of Series A preferred stock and
1,201,736 shares of common stock issuable upon conversion of shares of Series B preferred stock, in each case held by Adage Capital Partners, L.P. Adage Capital Advisors, L.L.C. is the managing member of Adage Capital Partners GP, L.L.C., the
general partner of Adage Capital Partners, L.P. As managing members of Adage Capital Advisors, L.L.C., managing members of Adage Capital Partners GP, L.L.C. and general partners of Adage Capital Partners, L.P., Robert Atchinson and Phillip Gross may
be deemed beneficial holders with shared voting and dispositive power over the shares held by Adage Capital Partners, L.P. The address of Adage Capital Partners L.P. is 200 Clarendon Street, Boston, Massachusetts 02110. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 3,330,917 shares of common stock issuable upon conversion of shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preferred stock and 1,110,244 shares of common stock issuable upon conversion of shares of Series B preferred stock, in each case held by Baker Brothers Life Sciences, L.P. (&#147;BBLS&#148;) and (ii) 274,490
shares of common stock issuable upon conversion of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock and 91,492 shares of common stock issuable upon conversion of shares of Series B preferred stock, in each case held by
667, L.P. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(together with BBLS, the &#147;BBA Funds&#148;). Baker Bros. Advisors LP (&#147;BBA&#148;), is the management company and investment adviser to the BBA Funds and has sole voting and investment
power with respect to the shares held by the BBA Funds. Baker Bros. Advisors (GP) LLC <FONT STYLE="white-space:nowrap">(&#147;BBA-GP&#148;),</FONT> is the sole general partner of BBA. The managing members of
<FONT STYLE="white-space:nowrap">BBA-GP</FONT> are Julian C. Baker and Felix J. Baker. The address for BBA, <FONT STYLE="white-space:nowrap">BBA-GP</FONT> and the BBA Funds is 860 Washington Street, 3rd Floor, New York, NY 10014. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,633,500 shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,633,500 shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,258,636 shares of common stock issuable upon conversion of shares of Series B preferred stock
held by Boxer Capital, LLC (&#147;Boxer Capital&#148;) and (ii) 134,122 shares of common stock issuable upon conversion of shares of Series B preferred stock held by MVA Investors, LLC (&#147;MVA&#148;). Boxer Management is the managing member and
majority owner of Boxer Capital. Joseph Lewis is the sole indirect owner and controls Boxer Management. MVA is the independent, personal investment vehicle of certain employees of Boxer Capital and Tavistock Life Sciences Company, which is a
Delaware corporation and an affiliate of Boxer Capital. The principal business address of Boxer Capital and MVA is 440 Stevens Avenue, Suite 100, Solana Beach, CA 92075. The principal business address of both Boxer Management and Joseph Lewis is c/o
Cay House P.O. Box <FONT STYLE="white-space:nowrap">N-7776</FONT> E.P. Taylor Drive Lyford Cay, New Providence, Bahamas. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 696,379 shares of common stock issuable upon conversion of shares of Series B preferred stock
held by Deerfield Private Design Fund IV, LP and (ii) 696,379 shares of common stock issuable upon conversion of shares of Series B preferred stock held by Deerfield Special Situations Fund, L.P. Deerfield Mgmt, L.P. is the general partner of
Deerfield Special Situations Fund, L.P., and Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (together with Deerfield Special Situations Fund, L.P., the &#147;Deerfield Funds&#148;). Deerfield Management
Company, L.P. is the investment manager of each of the Deerfield Funds. Mr. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Mgmt, L.P.,
and Deerfield Management Company, L.P. Mr. James E.&nbsp;Flynn may be deemed to beneficially own the securities held by Deerfield Special Situations Fund, L.P. Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P. and Mr. James E.&nbsp;Flynn
may be deemed to beneficially own the securities held by Deerfield Private Design Fund IV, L.P. The address of the Deerfield Funds is 780 Third Avenue, 37th Floor, New York, NY 10017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,089,000 shares of common stock, (ii) 90,725 shares of common stock issuable upon conversion
of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock, and (iii) 544,500 shares of common stock held by the 2017 Nichtberger Family Trust (the &#147;Trust Shares&#148;). Dr.&nbsp;Nichtberger may be deemed to beneficially
own the Trust Shares. Dr.&nbsp;Nichtberger disclaims beneficial ownership of the Trust Shares and this shall not be deemed an admission that he is the beneficial owner of the Trust Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Stalter joined the company on September 4, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 8,705 shares of common stock underlying options exercisable within 60 days of June&nbsp;30, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 17,410 shares of common stock underlying options exercisable within 60 days of June&nbsp;30, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 27,217 shares of common stock issuable upon conversion of shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> preferred stock and (ii) 22,653 shares of common stock underlying options exercisable within 60 days of June&nbsp;30, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes an aggregate of 48,768 shares of common stock underlying options exercisable within 60 days of
June&nbsp;30, 2019 held by three current directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and
restated bylaws, which will be effective upon the closing of this offering. The descriptions of the common stock and preferred stock give effect to changes to our capital structure that will occur upon the completion of this offering. We refer in
this section to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended and restated bylaws as our bylaws. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this
offering, our authorized capital stock will consist of&nbsp;150,000,000&nbsp;shares of common stock, par value $0.00001 per share, and&nbsp;10,000,000&nbsp;shares of preferred stock, par value $0.00001 per share, all of which shares of preferred
stock will be undesignated. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, 5,772,484 shares of our common stock, 3,146,551 shares of Series A preferred
stock, 7,372,719 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, 468,445 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock and 8,369,120 shares of Series B preferred stock were issued and
outstanding and held by 25 stockholders of record. This amount does not take into account the conversion of all outstanding shares of our preferred stock into common stock upon the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any
dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other
subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our
common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when
issued and paid for, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon the
consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights,
preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of
which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our
liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after consummation of this offering, no shares of
preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, there were outstanding options to purchase an aggregate of 2,435,545 shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of preferred stock, will be entitled to rights with respect to the
registration of these securities under the Securities Act. These rights are provided under the terms of an investors&#146; rights agreement between us, holders of our preferred stock. The investors&#146; rights agreement includes demand registration
rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling
commissions, will be borne by the holders of the shares being registered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning 180 days after the effective date of this registration statement, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, including those issuable upon the conversion of preferred stock upon the completion of this offering, are
entitled to demand registration rights. Under the terms of the investors&#146; rights agreement, we will be required, upon the written request of holders of at least 40% of these securities, to file a registration statement and use commercially
reasonable efforts to effect the registration of all or a portion of these shares for public resale. We are required to effect only two registrations pursuant to this provision of the investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Short-Form Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the investors&#146; rights agreement, if we are eligible to file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of holders of at least 20% of these securities at an aggregate offer price of at least $5.0&nbsp;million, we will be required to use commercially reasonable efforts to effect a
registration of such shares. We are required to effect only two registrations in any twelve month period pursuant to this provision of the investors&#146; rights agreement. The right to have such shares registered on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the investors&#146; rights agreement, if we register any of our securities either for our own account or for
the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the
number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand registration rights and short form registration rights granted under the investors&#146; rights agreement will terminate on the
earliest of (i)&nbsp;a deemed liquidation event, as defined in the investors&#146; rights agreement, (ii)&nbsp;the fifth anniversary of the completion of this offering and (iii)&nbsp;at such time after this offering when the holders&#146; shares may
be sold without restriction pursuant to Rule 144 within a three month period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and
Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and bylaws that will be in effect on the completion of this
offering will include a number of provisions that may have the effect of delaying, deferring or preventing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather
than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide for the division of our board of directors into three classes serving
staggered three-year terms, with one class being elected each year. Our amended and restated certificate of incorporation will also provide that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or
more of the outstanding shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by
the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more
difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of
our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Stockholders
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and bylaws will provide that only a majority of the members of our board of
directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws will limit the business that
may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice
Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws will establish advance notice procedures with regard to stockholder proposals relating to the nomination
of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting
at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year.
Our bylaws specify the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment of our amended and restated certificate of incorporation must first be approved by a majority of our board of directors, and if
required by law or our amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote
thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than 75% of the
outstanding shares entitled to vote on the amendment, and not less than 75% of the outstanding shares of each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and
may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of
the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred
Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide
for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to
discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not
in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of
the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred
stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights,
of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws that will become effective upon the closing of this offering will provide that, unless we consent in writing to
the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting
a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General
Corporation Law or our certificate of incorporation or bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws or (5)&nbsp;any action asserting a claim governed by the internal
affairs doctrine. The choice of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203
of the Delaware General Corporation Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of
the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the
time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless
it satisfies one of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
applied to list our common stock on The Nasdaq Global Market under the trading symbol &#147;CABA.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the
availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to
contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time
and our ability to raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding as of June&nbsp;30, 2019, upon the
completion of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase
additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the
Securities Act, may only be sold in compliance with the limitations described below, and&nbsp;shares of our common stock are restricted shares of common stock subject to time-based vesting terms. All remaining shares of common stock held by existing
stockholders immediately prior to the completion of this offering will be &#147;restricted securities&#148; as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private
transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person
who has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days
preceding, a sale and (ii)&nbsp;we are subject to the Securities Exchange Act of 1934, as amended, or the Exchange Act, periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for
at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number
of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares then outstanding, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares,
based on the number of shares outstanding as of June&nbsp;30, 2019; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we are subject to the Exchange
Act periodic reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and
notice provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon waiver or expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period described below, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be eligible for sale under
Rule 144. We cannot estimate the number of shares of our common stock that our existing stockholders will elect to sell under Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon
Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may
be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, substantially all Rule&nbsp;701 shares are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under the section titled &#147;Underwriters&#148; included elsewhere in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth
in those agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and each of our directors and executive officers and substantially all of our stockholders have signed a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that prevents them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the
date of this prospectus without the prior written consent of the representatives, subject to certain exceptions. See the section entitled &#147;Underwriters&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning 180 days
after the closing of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result
in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration Rights&#148; appearing
elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to
register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the
SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions
described above. As of&nbsp;the date of this prospectus, we estimate that such registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> will cover
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-U.S.&nbsp;HOLDERS</FONT> OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax considerations applicable to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax
purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for
U.S. federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax
advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing
and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly
with retroactive effect. Any such change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue
Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital
asset within the meaning of Section&nbsp;1221 of the Code, generally property held for investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address all
aspects of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it
address any aspects of any U.S. federal tax other than the income tax, U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, rules regarding qualified small business stock within the meaning of
Section&nbsp;1202 of the Code or the Medicare tax on net investment income. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address
the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension
fund&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax advice. Accordingly, all prospective
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase,
ownership and disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT>
return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in
&#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; Any such distributions will also be subject to the discussions below under the sections titled &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding
and Information Reporting Requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion in the following two paragraphs in this section,
dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the
United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends that are treated as effectively connected with a trade or business
conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United&nbsp;States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively
connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly
executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) to the applicable withholding agent and satisfy applicable certification
and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding and Information Reporting
Requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale or other taxable disposition of shares of our
common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct
of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed
on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax
described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may be
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income
tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale of other taxable disposition
(or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on
the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real
property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we
are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules
described above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on
our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is
not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to
withholding of U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other
requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is
effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of
a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax
advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a
payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim
is filed with the IRS in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding and Information Reporting Requirements&#151;FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends
on, or gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence,
reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is
otherwise exempt under FATCA. Under applicable U.S. Treasury regulations, withholding under FATCA currently applies to payments of dividends on our common stock, but will only apply to payments of gross proceeds from a sale or other disposition of
our common stock made after December&nbsp;31, 2018. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the
United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this
legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30%
withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_19"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley&nbsp;&amp; Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; over-allotment option described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the
cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share under the public offering price. After the initial offering of the shares
of common stock, the offering price and other selling terms may from time to time be varied by the representatives. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to
reject any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this
prospectus, to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and
commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised,
each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total
number of shares of common stock listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per
share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; over-allotment option to purchase up to
an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and
commissions, are approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary
accounts to exceed 5% of the total number of shares of common stock offered by them. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on The
Nasdaq Global Market under the symbol &#147;CABA.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all of our directors and executive officers and the holders of
substantially all of our outstanding stock and stock options have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters under which they have agreed that, without the prior written consent of Morgan
Stanley&nbsp;&amp; Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C., on behalf of the underwriters, we and they will not, during the period ending 180 days after the date of this prospectus (the &#147;restricted period&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the Securities and Exchange Commission relating to the offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of common
stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C., on behalf of the
underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable
for common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions relating to shares of common stock or other securities acquired in this offering or in open market transactions after this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of common stock or any security convertible into or exercisable or exchangeable for common stock as a bona fide gift or to a charitable organization or educational institution in a transaction not
involving a disposition for value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the signatory is an entity, distributions of shares of common stock or any security convertible into or exercisable or exchangeable for common stock to limited partners, general partners, members, stockholders or
trust beneficiaries of the signatory or the signatory&#146;s affiliates or to any investment fund or other entity controlled or managed by the signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">d)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of common stock or any security convertible into or exercisable or exchangeable for shares of common stock by will or other testamentary document or by intestacy to the legal
representative, heir, beneficiary or a member of the immediate family of the signatory upon the death of the signatory; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">e)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of common stock or any security convertible into or exercisable or exchangeable for shares of common stock to any trust for the direct or indirect benefit of the signatory or the
immediate family of the signatory in a transaction not involving a disposition for value; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">f)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of options to purchase shares of common stock granted under a stock incentive plan or stock purchase plan described in this prospectus and outstanding as of the date of this prospectus or the exercise of
warrants to purchase shares of common stock described in the prospectus and outstanding as of the date of the prospectus, provided that the underlying common stock continues to be subject to the restrictions set forth in the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement and, provided further that no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of common stock shall be required or shall be voluntarily
made during the restricted period (other than a filing on a Form 4 that reports such disposition under the transaction code &#147;F&#148;, in which case the filing or announcement shall clearly indicate in the footnotes thereto or comments section
thereof that the filing relates to the exercise of a stock option or warrant, as the case may be, that no shares of common stock were sold by the reporting person and that the shares of common stock received upon exercise of the stock option or
warrant are subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters of the this offering); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">g)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of common stock or any security convertible into or exercisable or exchangeable for shares of common stock that occur solely by operation of law pursuant to a qualified domestic order or in
connection with a divorce settlement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">h)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers or dispositions of shares of common stock or any security convertible into or exercisable or exchangeable for shares of common stock to the company pursuant to any contractual arrangement disclosed to the
underwriters that provides for the repurchase of the signatory&#146;s shares of common stock or such other securities by the company solely in connection with the termination of the signatory&#146;s employment with or service to the company provided
that the repurchase price for any such shares or securities shall not exceed the original purchase price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) paid by the
signatory to the company for such shares or securities and, provided further, that no filing under Section&nbsp;16(a) of the Exchange Act reporting a reduction in beneficial ownership of shares of common stock shall be required or shall be
voluntarily made during the restricted period in connection with any such transfers or dispositions (other than any Form 4 or Form 5 required to be filed under the Exchange Act if the signatory is subject to Section&nbsp;16 reporting with respect to
the company under the Exchange Act and indicating by footnote disclosure or otherwise that such transfer or disposition was made solely to the company pursuant to the circumstances described in this clause); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">i)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that such plan does not provide for the
transfer of shares of common stock during the restricted period and provided further that to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the signatory or the
company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">j)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of shares of common stock or securities convertible into or exercisable or exchangeable for common stock pursuant to a bona fide tender offer for shares of our capital stock, merger, consolidation or other
similar transaction made to all holders of the company&#146;s securities involving a change of control of the company (including without limitation, the entering into of any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar
agreement pursuant to which the holder may agree to transfer, sell, tender or otherwise dispose of shares or other securities in connection with such transaction) that has been approved by our board of directors; <I>provided</I>&nbsp;that, in the
event that such change of control transaction is not consummated, these requirements shall not be applicable and the holder&#146;s shares and other securities shall remain subject to the restrictions contained in the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that, in the case of any transfer or distribution as described in
(b)-(e) and (g)&nbsp;above, (i) the transferee, donee or distributee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement to the underwriters and (ii)&nbsp;no public announcement or public filing under
Section&nbsp;16(a) of the Exchange Act relating to such transfer or distribution shall be required or shall be voluntarily made during the restricted period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C., in
their sole discretion, may release the shares of common stock and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater
than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In determining
the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell shares in
excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are
concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the
underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or
retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. Certain of the underwriters and their respective affiliates may, from time to time, perform various financial advisory and investment banking services for us, for which they will receive customary fees and
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may
make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any
time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or
publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this
offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering
price are our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Canada
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited
investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions </I>or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to,
the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a &#147;Member State&#148;), no offer of shares may be made to the public
in that Member State other than: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of shares shall require us or any of our representatives to publish a prospectus pursuant to
Article&nbsp;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed to and with each of the representatives and us that it is a &#147;qualified investor&#148; as defined in the Prospectus Regulation. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article&nbsp;5 of the Prospectus Regulation, each such financial
intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a nondiscretionary basis on behalf of, nor have they been acquired with a view to their offer or resale
to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives
has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, an &#147;offer to the public&#148; in
relation to any shares of our common stock in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to
decide to purchase or subscribe for any shares of our common stock, and &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the
Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of the shares of our common stock in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in, from or otherwise involving the United Kingdom.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston,
Massachusetts. Certain partners of Goodwin Procter LLP have an interest in an aggregate of less than 1% of our capital stock. Certain legal matters relating to this offering will be passed upon for the underwriters by Ropes&nbsp;&amp; Gray LLP,
Boston, Massachusetts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Cabaletta Bio, Inc. at December&nbsp;31, 2018 and 2017, and for the year ended December&nbsp;31, 2018 and for the
period from April&nbsp;3, 2017 (inception) to December&nbsp;31, 2017, appearing in this Prospectus and Registration Statement have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their
report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File Number
333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus does not contain all of the information included in the
registration statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other
documents, the references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly
and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.cabalettabio.com. Upon
completion of the offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and any amendments to those reports, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom686907_23"></A>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Financial Statements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_2">Balance sheets as of December&nbsp;31, 2017 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_3">Statements of Operations for the Period from April&nbsp;
3, 2017 (inception) through December&nbsp;31, 2017 and for the Year Ended December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_4">Statements of Convertible Preferred Stock and Stockholders&#146; Deficit for the
 Period from April&nbsp;3, 2017 (inception) through December&nbsp;31, 2017 and for the Year Ended December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_5">Statements of Cash Flows for the Period from April&nbsp;
3, 2017 (inception) through December&nbsp;31, 2017 and for the Year Ended December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited&nbsp;Interim&nbsp;Financial&nbsp;Statements:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_8">Balance Sheets as of December&nbsp;31, 2018 and June&nbsp;30,
2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_7">Statements of Operations for the Six Months Ended June&nbsp;
30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_9">Statements of Convertible Preferred Stock and Stockholders&#146; Deficit for the
 Six Months Ended June&nbsp;30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_10">Statements of Cash Flows for the Six Months Ended June&nbsp;
30, 2018 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin686907_11">Notes to Unaudited Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying balance sheets of Cabaletta Bio, Inc. (the Company) as of December&nbsp;31, 2018 and 2017, the related statements of operations, convertible preferred stock and stockholders&#146; deficit and cash flows for the year ended
December&nbsp;31, 2018 and the period from April&nbsp;3, 2017 (inception) to December&nbsp;31, 2017, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company at December&nbsp;31, 2018 and 2017, and the results of its operations and its cash flows for the year ended December&nbsp;31, 2018 and the period from April&nbsp;3, 2017 (inception) to
December&nbsp;31, 2017 in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to
obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2018. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philadelphia, Pennsylvania </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;2, 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_2"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and Contingencies (see Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A, <FONT STYLE="white-space:nowrap">A-1</FONT> and
<FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, $0.00001 par value: no and 12,393,497 shares authorized as of December&nbsp;31, 2017 and 2018, respectively; no and 12,393,047 shares issued and outstanding at
December&nbsp;31, 2017 and 2018 respectively; aggregate liquidation preference of $38,256 at December&nbsp;31, 2018.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00001 par value: 10,000,000 and 21,147,115 shares authorized as of
December&nbsp;31, 2017 and 2018, respectively; 5,000,000 and 5,772,484 shares issued and outstanding at December&nbsp;31, 2017 and 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_3"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per share, basic and diluted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,663,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited) (see Note&nbsp;2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing pro forma net loss per share, basic and
diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_4"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;April&nbsp;3, 2017 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock in connection with license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred stock upon conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,693,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,910</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred stock upon milestone closing of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,553,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,436</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred stock, net of issuance costs of $169</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,575</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,393,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,772,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_5"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock issued for research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,661</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock on milestone closing of convertible
notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible notes into convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_6"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts.) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio,
Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The Company is headquartered in Pennsylvania. Cabaletta is a
biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal operations commenced in April 2018, when the Company executed two sponsored research agreements with the Trustees of the University
of Pennsylvania (Penn). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect to generate revenue from sales of engineered T cell therapies for B cell-mediated autoimmune diseases or any other
revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company
expects to incur significant commercialization expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has sustained annual operating losses and expects to continue to
generate operating losses for the foreseeable future. The Company&#146;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents of $33,017 as of December&nbsp;31, 2018. Through
December&nbsp;31, 2018, the Company has incurred cumulative net losses of $12,452. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement
its business plan and to fund its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends to raise such additional capital through a combination of public or
private equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable
terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that
its cash and cash equivalents as of December&nbsp;31, 2018, in addition to proceeds of $50,000 from the issuance of Series B convertible preferred stock (Series B Preferred) in January 2019 (Note 7), will be sufficient to fund its projected
operations for at least 12 months following the date that these financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common
to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional
financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is currently dependent on Penn for much of its
preclinical research, clinical research and development activities and expects to be dependent upon Penn for initial manufacturing activities (Note 6). Product candidates currently under development will require significant additional research and
development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become
profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the accompanying statements of operations, the unaudited pro forma basic and diluted net loss per share for the year ended December&nbsp;31,
2018 has been prepared to give effect to the automatic conversion of all outstanding shares of convertible preferred stock upon the closing of the proposed initial public offering into 12,393,047&nbsp;shares of common stock as if the conversion had
occurred on January&nbsp;1, 2018 or, if later, the issuance date of the convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses
during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation, the valuation allowance on the Company&#146;s
deferred tax assets, and the fair value of convertible debt. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and
circumstances dictate. Actual results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be
cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly <FONT
STYLE="white-space:nowrap">associated&nbsp;with&nbsp;in-process&nbsp;equity</FONT> financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in
stockholders&#146; deficit as a reduction <FONT STYLE="white-space:nowrap">of&nbsp;additional&nbsp;paid-in&nbsp;capital&nbsp;generated</FONT> as a result of the offering. Should <FONT STYLE="white-space:nowrap">the&nbsp;in-process&nbsp;equity</FONT>
financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment
associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market
for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The
authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs (other than quoted prices included in Level&nbsp;1) that are either
directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
assets or liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which
include activities under the Penn Agreement (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the
estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements
established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company
has not experienced any material differences between accrued costs and actual costs incurred since its inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs include costs incurred for internal and external research and development
activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well
as fees paid to entities that conduct certain research and development activities on the Company&#146;s behalf. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures its stock-based awards granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to
estimate the fair value of its stock-based awards. The Company uses the simplified method in accordance with guidance provided by the Securities and Exchange Commission and calculates the expected term as the midpoint between the vesting date and
the contractual term for certain awards with service or performance conditions. Stock-based compensation is recognized using the straight-line method. As stock-based compensation is based on awards ultimately expected to vest, it is reduced by
forfeitures. The Company accounts for forfeitures as they occur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the
estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to
the carrying amount of the Company&#146;s property and equipment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company
concludes that it is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">more-likely-than-not</FONT></FONT></FONT> that the deferred tax assets will not be realized. In evaluating its ability to recover
deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position
is considered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">more-likely-than-not</FONT></FONT></FONT> to be sustained on examination by a taxing authority, assuming they possess full knowledge of
the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the <FONT
STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers its convertible preferred stock and unvested shares of common stock held by the Company&#146;s founders to be participating securities
as, in the event a dividend is paid on common stock, the holders of convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. The net loss attributable
to common stockholders is not allocated to the convertible preferred stock nor to the unvested shares of common stock as the holders of those securities do not have a contractual obligation to share in losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the
weighted average number of shares of common stock, which excludes unvested shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the
effects of potentially dilutive securities are antidilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed
by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#146;s CODM is its Chief Executive Officer. The Company has determined it operates in a single
operating segment and has one reportable segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company engages a firm controlled by an executive of the Company as of December&nbsp;31, 2018 for professional services related to
accounting, finance and other administrative functions. For the year ended December&nbsp;31, 2018, the costs incurred under this arrangement totaled $186, which were recorded as general and administrative expense in the accompanying statements of
operations. As of December&nbsp;31, 2018, amounts owed under this arrangement totaled $50 and are included in accounts payable in the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company engaged the services of its current chief executive officer prior to his employment in October 2018. For the year ended
December&nbsp;31, 2018, the costs incurred under this arrangement totaled $180, which were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recorded as general and administrative expense in the accompanying statements of operations. As of December&nbsp;31, 2018, amounts owed under this arrangement totaled $60 and are included in
accrued and other current liabilities in the accompanying balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&nbsp;Act). Under the
JOBS&nbsp;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&nbsp;Act, until such time as those standards apply to private companies. The Company has elected to use
this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&nbsp;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-09,</FONT> <I>Compensation&#151;Stock Compensation</I> (Topic 718):
&#147;<I>Scope of Modification Accounting</I>,&#148; which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this ASU
should be applied prospectively to an award modified on or after the adoption date. This guidance was effective for all entities for annual periods and interim periods within those annual periods, beginning after December&nbsp;15, 2017. The Company
adopted ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> effective January&nbsp;1, 2018, which did not impact the Company&#146;s financial statements or financial statement disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I> (Topic 842), with guidance regarding the
accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors
to disclose key information about their leasing transactions. This guidance will be effective for public companies for annual and interim periods beginning after December&nbsp;15, 2018. For all other entities, this standard is effective for annual
reporting periods beginning after December&nbsp;15, 2019, and interim periods within annual periods beginning after December&nbsp;15, 2020. Early adoption is permitted. The Company has yet to evaluate the effect that ASU <FONT
STYLE="white-space:nowrap">2016-02</FONT> will have on its financial statements or financial statement disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the
FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per Share</I> (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): <I>I. Accounting for Certain Financial Instruments
with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. Part I of
this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced
on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair
value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
navigating Topic 480, <I>Distinguishing Liabilities from Equity</I>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is
the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update
do not have an accounting effect. For public business entities, the amendments in Part I of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> are effective for fiscal years and interim periods within those years beginning after December&nbsp;15,
2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted
for all entities, including adoption in an interim period. The Company is currently assessing the potential impact of adopting ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> on its financial statements and financial statement disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no
assets or liabilities carried at fair value on a recurring basis as of December&nbsp;31, 2017. As of December&nbsp;31, 2018, the Company had $33,017 of money market funds, which were valued by the Company based on quoted market prices, which
represent a Level&nbsp;1 measurement within the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents a roll-forward of the aggregate fair
values of the Company&#146;s convertible notes (Note 5) for which fair value is determined by Level&nbsp;3 inputs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;January&nbsp;1,&nbsp;2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion into convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers among Level&nbsp;categories in the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying value of cash, cash equivalents, accounts payable and accrued expenses that are reported on the balance sheets approximate their
fair value due to the short-term nature of these assets and liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Convertible Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, the Company issued convertible notes (the Notes) with aggregate proceeds to the Company in an initial closing of $12,535,
including $5,000 issued to Penn. The Notes carried a stated interest rate of 7.5% per annum. All unpaid principal, together with the then accrued interest, for the Notes was due and payable at the earlier of May&nbsp;4, 2021 or upon an event of
default. The terms of the Notes provided for an additional milestone-based closing of $12,567 upon the achievement of certain Company-specific events. The Notes contained a number of provisions addressing automatic and optional conversion, events of
default and prepayment provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes were amended in September 2018 to adjust the terms of the automatic and optional conversion
provisions. In October 2018, the Notes were amended again to reduce the qualified financing threshold, make a qualified financing a milestone event, revise the structure of a milestone-based closing and reallocate milestone closing purchase rights
to new purchasers and the existing noteholders. On the same day, immediately following the amendment of the Notes, the Company completed a qualified financing, issuing 3,146,551 shares of Series A convertible preferred stock for gross proceeds of
$12,744 (Note 7). At this time, the Company issued 4,553,452 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred in connection with the milestone-based closing resulting in $12,567 of proceeds ($2.76 per share) and the Notes
together with interest accrued thereon ($409) were converted into 2,819,267 shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> convertible preferred stock (Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred) and 1,873,777 shares
of Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock (Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred), reflecting a conversion price per share of $2.76. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On issuance, the Company elected to account for the Notes at fair value with any changes in fair value being recognized through the statements
of operations until the Notes settled. In this connection, the Company&#146;s policy is to report a single <FONT STYLE="white-space:nowrap">non-operating</FONT> income/(expense) line item to record fair value adjustments on convertible notes and
does not report interest expense as a separate line item in the statements of operations. The fair value of the Notes was determined to be $12,535 on issuance. On issuance, total debt issuance costs of $53 were expensed and recognized as general and
administrative expense in the accompanying statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On issuance, the fair value of the Notes was determined to be equal
to $12,535, which is the principal amount of the Notes. The fair value of the Notes upon settlement was determined based on the fair value of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred and Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred issued, which was determined to be $3.39 per share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, using an
option pricing method (OPM) framework and utilized the back-solve method for inferring and allocating the equity value predicated on the capital raise that transpired just prior to the valuation date. This method was selected as the Company
concluded that the contemporaneous financing transaction was <FONT STYLE="white-space:nowrap">an&nbsp;arm&#146;s-length&nbsp;transaction.</FONT> Application of the OPM back-solve method involves making assumptions for the expected time to liquidity,
volatility and risk-free rate and then solving for the value of equity such that value for the most recent financing equals the amount paid. The OPM allocation of total equity value was determined with reference to a recent financing transaction and
the Company assumed a 71% volatility rate, a <FONT STYLE="white-space:nowrap">1.3-year</FONT> estimated term and a probability weighted average discount for lack of marketability of 35%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, the Company recognized $6,244 in in the accompanying statements of operations as other
expense&#151;fair value adjustments on the convertible notes, which reflects (i)&nbsp;the difference between the conversion price per share of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred and Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred ($2.76) into which the Notes were converted, and the fair value of such Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred, (ii) the difference between the price per share paid for the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred ($2.76) in the milestone-based closing and the fair market value of such Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred and (iii) interest accrued on the Notes ($409). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Lease Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Company entered into an operating lease agreement for office space. The lease term expires in September 2019. The initial
annual base rent is approximately $14. Rent expense incurred in 2018 was $7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company entered into an operating
lease agreement for new office space in Philadelphia, Pennsylvania. The lease term commenced in May 2019 and will expire in July 2022. The initial annual base rent is $261, and such amount will increase by 2% annually on each anniversary of the
commencement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research Service Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Company entered into a research service agreement with the Children&#146;s Hospital of Philadelphia for the manufacturing
of preclinical study and clinical trial material, amounting to $543, expected to be incurred from August 2018 through April 2019. During the year ended December&nbsp;31, 2018, the Company recognized research and development expense of $342 related
to this agreement in the accompanying statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with the University of Pennsylvania </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Company entered into a license agreement with Penn (the Penn Agreement) and activated the license in October 2018 pursuant
to which the Company obtained (a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> non-sublicensable worldwide license to certain of Penn&#146;s intellectual property to conduct research, product development, clinical trials, cell
manufacturing and other activities, and (b)&nbsp;an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis,
under certain of Penn&#146;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the Penn Agreement expires on the expiration or abandonment or other termination of the last valid claim in
Penn&#146;s intellectual property licensed by the Company. The Company may terminate the Penn Agreement at any time for convenience upon 60 days written notice. In the event of an uncured, material breach, Penn may terminate the Penn Agreement upon
60 days written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Penn Agreement, the Company issued 721,978 shares of common stock, with a value of $1,155,
recorded as a research and development expense in the accompanying statements of operations for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also reimbursed Penn for its prior <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses with respect to the filing, prosecution and maintenance of Penn&#146;s intellectual property licensed by the Company. The payment, totaling $89, is included in general and administrative expense in the accompanying statements of operations
for the year ended December&nbsp;31, 2018. Under the terms of the Penn Agreement, Penn is obligated to pay $2,000 annually for three years beginning August 2018 for funding to the laboratories of each of Drs.&nbsp;Milone and Payne (see <I>Sponsored
Research Agreements</I><I>&#151;</I><I>Penn</I>). During the term of the Penn Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of
$10. The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
Commitments and Contingencies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the
event that the Company is able to successfully develop and launch multiple products under the Penn Agreement, total milestone payments could approach $20,000. Penn is also eligible to receive tiered royalties at percentage rates in the low
single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the
Company. To the extent the Company sublicenses its license rights under the Penn Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amounts were due under the Penn Agreement as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Penn </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
sponsored research agreements with two faculty members at Penn, who are also scientific co-founders of the Company and members of the Company&#146;s scientific advisory board. Under the agreements, the Company has committed to funding a defined
research plan for three years through April 2021. The total estimated three-year cost of $8,524 under the two agreements satisfies the Company&#146;s annual obligation under the Penn Agreement (see <I>License Agreement with the University of
Pennsylvania</I> above). For the year ended December&nbsp;31, 2018, the Company recognized research and development expense of $1,957 related to these agreements in the accompanying statements of operations. No amounts were due under the sponsored
research agreements as of December&nbsp;31, 2018. However, $884 of advance payments are included in prepaid expenses and other current assets as of December&nbsp;31, 2018 in the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Regents of the University of California </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company executed a research agreement with The Regents of the University of California. Under the agreement, the Company
has committed to funding scientific research through October 2020 in an immaterial amount. For the year ended December&nbsp;31, 2018, the Company recognized research and development expense of $23 related to this agreement in the accompanying
statements of operations. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Master Translational Research Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company entered into a services agreement (the Services Agreement) with Penn for additional research and development
services from various laboratories within Penn. The research and development activities will be detailed in Penn organization-specific addenda to be separately executed. In October and November 2018, the Company executed three project addenda under
this agreement for research and development work. The three projects are anticipated to commence and conclude in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019,
the Company executed two project addenda under the Services Agreement for manufacturing and development work. The two projects are anticipated to commence in 2019. The manufacturing addendum is expected to occur through June 2020. The development
addenda are expected to occur through December 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No amounts were due to Penn under the master translational research service
agreements as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
Commitments and Contingencies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties against claims from
third parties. These contracts primarily relate to (i)&nbsp;the Company&#146;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their
relationship, (ii)&nbsp;contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii)&nbsp;contracts under which the Company may be required to indemnify
partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv)&nbsp;procurement, consulting, or license agreements under which the Company may be
required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#146;s acts or omissions with respect to the supplied products, technology or services. From time
to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts
received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a
judgment or settlement, may cause a material adverse effect on the Company&#146;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited
history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Convertible Preferred Stock
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued Series A Preferred, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred, Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred, and Series B Preferred (collectively, the Convertible Preferred Stock). The Company classifies Convertible Preferred Stock outside of stockholders&#146; deficit because the shares contain deemed
liquidation rights that are a contingent redemption feature not solely within the control of the Company. The following table summarizes the Company&#146;s outstanding Convertible Preferred Stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-1&nbsp;Preferred</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-2&nbsp;Preferred</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance on conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,819,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,873,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,693,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance on milestone closing of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,553,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,553,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,372,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,873,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,393,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company&#146;s amended and restated certificate of incorporation authorized
the Company to issue 12,393,497 shares of $0.00001 par value Convertible Preferred Stock. In October 2018, the Company issued 3,146,551 shares of Series A Preferred, resulting in gross proceeds of $12,744. Series
<FONT STYLE="white-space:nowrap">A-1</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
Convertible Preferred Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred were issued October 2018 upon conversion of the Notes and in connection with the milestone closing of the Notes (Note
5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, the Company&#146;s certificate of incorporation was amended to increase the authorized shares of Convertible
Preferred Stock to 20,762,168 shares, and the Company issued 6,963,788 shares of Series B Preferred, resulting in gross proceeds of $50,000. In connection, the Company issued a further 1,405,332 shares of Series B Preferred in exchange for 1,405,332
shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Convertible Preferred Stock have various
rights, preferences and privileges as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred are <FONT STYLE="white-space:nowrap">non-voting</FONT> shares. Each share of
Series A Preferred, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred and Series B Preferred (the Voting Preferred Stock) shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which such
shares of Voting Preferred Stock are convertible as of the record date for determining stockholders entitled to vote on such matter holds a number of votes equal to the number of shares of common stock into which it is convertible. Generally,
holders of Voting Preferred Stock shall vote together with the holders of common stock as a single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> into common stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of Series A Preferred and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred, exclusively and as a separate class,
are entitled to elect three members of the board of directors. Holders of shares of common stock are entitled to elect one member of the board of directors. The holders of common stock and Convertible Preferred Stock, voting together as a single
class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, are entitled to elect the balance of the total number of directors of the Company (two). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of shares of Convertible Preferred Stock shall be entitled to receive, on a <I>pari passu </I>basis, dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend (other than
dividends on shares of common stock payable in shares of common stock) on the common stock, at a rate of (i) $0.24 per annum for each share of Series A Preferred, (ii) $0.1656 per annum for each share of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred, (iii) $0.1656 per annum for each share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock and (iv) $0.4308 per annum for each share of Series B Preferred, in each
case, as adjusted for any stock splits, stock dividends, combinations, subdivisions, or other similar recapitalization affecting such shares. Dividends are payable when, as and if declared by the board of directors, and such dividends shall not be
cumulative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of each series of Convertible Preferred Stock can waive any dividend preference that the holders of such series
of Convertible Preferred Stock shall be entitled to receive upon the affirmative vote or written consent of the holders of at least a majority of the shares of such series of Convertible Preferred Stock then outstanding, voting together as a
separate series, and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After payment of such dividends on
the shares of Convertible Preferred Stock, any additional dividends or distributions shall be distributed among all holders of common stock and Convertible Preferred Stock in proportion to the number of shares of common stock that would be held by
each such holder if all shares of Convertible Preferred Stock were converted to common stock at the then effective conversion price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
Convertible Preferred Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Optional Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Convertible Preferred Stock shall be convertible, at the option of the holder, at any time and from time to time, and without the
payment of additional consideration by the holder thereof, into such number of fully paid shares of common stock as is determined by dividing the applicable original issuance price by the conversion price in effect at the time of conversion. As of
December&nbsp;31, 2018, each share of Convertible Preferred Stock is convertible on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into common stock. The respective applicable conversion prices
for the Convertible Preferred Stock is subject to adjustment upon any future stock split, stock dividend, combination, reclassification or similar event affecting the Convertible Preferred Stock or any series thereof. Such applicable conversion
prices for the Convertible Preferred Stock and the rate at which the Convertible Preferred Stock may be converted into shares of common stock, shall be subject to adjustment as provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mandatory Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Convertible Preferred Stock automatically converts into the number of shares of common stock determined in accordance with the
conversion rate upon either: (a)&nbsp;the closing of a public offering of common stock at a price of at least $12.15 per share resulting in at least $50,000 of gross proceeds, or (b)&nbsp;written consent of a majority of the holders of the then
outstanding shares of Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a mandatory conversion of Preferred Stock as a result of a Qualified
IPO, each holder of Preferred Stock may elect to receive non-voting Common Stock in lieu of all or a portion of such holder&#146;s voting Common Stock. The non-voting shares of Common Stock shall have the same rights and preferences as the Common
Stock but shall be non-voting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Convertible Preferred Stock then outstanding shall be entitled to be paid (a)&nbsp;out of the consideration payable to
stockholders in the event of a merger, consolidation, or reorganization involving the Company or a subsidiary or on the sale, lease, transfer, exclusive license or other disposition by the Company or a subsidiary of all or substantially all assets
of the not elected otherwise by a requisite of holders of the Series A Preferred, or (b)&nbsp;out of the available proceeds the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of
Convertible Preferred Stock then outstanding shall be entitled to be paid, on a <I>pari passu </I>basis, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater
of (i)&nbsp;the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately
prior to such event. If upon any such event, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of the outstanding shares of Convertible Preferred Stock the full amount to which they
shall be entitled, the holders of shares of Convertible Preferred Stock shall share ratably, on a <I>pari passu </I>basis, in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Dilution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Convertible Preferred Stock are afforded certain anti-dilution protection with respect to corporate events such as stock splits and
recapitalizations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
Convertible Preferred Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Convertible Preferred Stock is not redeemable but does contain deemed liquidation rights in the event of a merger,
consolidation, or reorganization involving the Company or a subsidiary or on the sale, lease, transfer, exclusive license or other disposition by the Company or a subsidiary of all or substantially all assets of the Company, and unless elected
otherwise by a requisite of holders of the Series A Preferred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated Certificate of Incorporation filed in August 2018, the Company is authorized to issue a total of
21,147,115 shares of common stock, of which 5,772,484 shares were issued and outstanding at December&nbsp;31, 2018. In January 2019, the Company&#146;s certificate of incorporation was further amended to authorize the issuance of 29,000,000 shares
of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the Notes in May 2018 (Note 5), several of the Company&#146;s founders agreed to
modify their shares of common stock outstanding to include vesting provisions that require continued service to the Company in order to vest in those shares. As such, the 4,356,000 modified shares of common stock became compensatory upon such
modification. The fair value of the awards on the modification date was determined to be $0.49 per share of common stock, by calibrating to the recent Notes issuance considering the maximum conversion price and the seniority of the Notes. The total
compensation cost resulting from the modification was $2,126. The total compensation cost is being recognized over the three-year vesting term attendant to the founders&#146; common shares. During the year ended December&nbsp;31, 2018, the Company
recognized $399 and $118 of this amount in research and development expense and general and administrative expense, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders
of shares of common stock have the right to elect one member of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common stockholders are entitled to dividends, if
and when declared by the board of directors, subject to the prior rights of the Convertible Preferred Stockholders. As of December&nbsp;31, 2018, no dividends on common stock had been declared. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provides for the Company to sell or issue
common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The 2018 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the
board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than
100% of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than 10 years. The Company generally grants stock-based awards with service conditions only (service-based awards),
although there has been one grant with performance conditions. Stock options granted under the 2018 Plan generally vest over three to four years. There were 2,726,999 shares reserved under the 2018 Plan for the future issuance of equity awards and,
as of December&nbsp;31, 2018, 1,269,976 shares were available for grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
Common Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no option activity for the period from April&nbsp;3, 2017 (inception) to
December&nbsp;31, 2017. A summary of the stock option activity under the 2018 Plan is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options Exercisable at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of
the options and the estimated fair value of the Company&#146;s common stock. The weighted average grant-date fair value of stock options granted during the year ended December&nbsp;31, 2018 was $1.27. The aggregate grant-date fair value of options
vested during the year ended December&nbsp;31, 2018 was $26. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each award is estimated using Black-Scholes based on the
following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended</B><br><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.92%&#151;2.96%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&#151;6.2 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards.
These assumptions include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Fair value of common stock</I>&#151;Historically, because there has been no public market for the
Company&#146;s common stock, the fair value of the Company&#146;s common stock underlying stock-based awards was estimated on each grant date by the Company&#146;s board of directors. In order to determine the fair value of the Company&#146;s common
stock underlying stock-based awards, the Company&#146;s board of directors considered, among other things, a valuation of the Company&#146;s common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by
the American Institute of Certified Public Accountants Practice Guide,<I></I><I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Expected term</I>&#151;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for
option grants is determined using the simplified method. The simplified method deems the term to be the average of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-vesting</FONT></FONT> and the contractual life of the
stock-based awards. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Expected volatility</I>&#151;Since the Company is a privately held company and does not have any trading history
for its common stock, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock-based awards. The comparable companies were
chosen based on their similar size, stage in the life cycle or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
Common Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury
zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Expected
dividend</I>&#151;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has recorded stock-based compensation in the accompanying statements of operations as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended</B><br><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, there was $1,762 of unrecognized compensation cost related to unvested option
awards, including $527 with respect to one grant with performance-based vesting terms, which is expected to be recognized over a weighted-average period of 3.0 years. As of December&nbsp;31, 2018, there was $1,618 of unrecognized compensation cost
related to unvested Founder Stock awards, which is expected to be recognized over a weighted-average period of 2.3 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017 U.S. Tax Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the U.S. government signed into law the Tax Cuts and Jobs Act (the Tax Act) that significantly reforms the Internal
Revenue Code of 1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, effective as of
January&nbsp;1, 2018; limitation of the tax deduction for interest expense; limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net operating loss carrybacks, in each case, for losses arising in
taxable years beginning after December&nbsp;31, 2017 (though any such tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits, including reducing the business tax credit for certain clinical
testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as orphan drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
staff of the Securities and Exchange Commission issued Staff Accounting Bulletin No.&nbsp;118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared or analyzed (including
computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In connection with the initial analysis of the impact of the Tax Act, the Company remeasured its deferred tax assets and liabilities based
on the rates at which they are expected to reverse in the future, which is generally 21% for federal tax purposes. The remeasurement of the Company&#146;s deferred tax assets and liabilities was offset by a change in the valuation allowance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, the Company finished its analysis of the impact of the Tax Act. Where the Company made reasonable estimates in 2017 of the effects
related to the Tax Act, the Company recorded provisional amounts. After the completed analysis, the resulting impact to the Company&#146;s financial statements did not differ from the recorded provisional amounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.
Income Taxes&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation of federal statutory income tax rate to the Company&#146;s effective
income tax rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year<BR>Ended</B><br><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected income tax benefit at the federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax rate reduction due to the Tax Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company&#146;s deferred tax assets consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License fee deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share based Compensation deductions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company increased its valuation allowance by $1,540&nbsp;for the year ended December&nbsp;31, 2018 in
order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#146;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&nbsp;31, 2018. The Company
intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2018, the Company had federal and state net operating loss carryforwards of $4,026; $3,776 of the federal amounts do not expire, and the remaining $250 expire in 2038. The $4,026 of state net operating losses begin to expire in
2038. As of December&nbsp;31, 2018, the Company had federal research and development tax credit carryforwards of $69. The federal credits expire in 2038. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.
Income Taxes&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the provisions of Sections&nbsp;382 and 383 of the Internal Revenue Code (the IRC), net
operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts, including an initial public
offering, could result in limitations on net operating loss and credit carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S.
federal jurisdiction as well as in Pennsylvania. The tax year 2017 remains open to examination by the jurisdictions where the Company is subject to tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates tax positions for recognition using a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT></FONT></FONT> recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the
effective settlement with a taxing authority that has full knowledge of all relevant information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is
anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from</B><br><B>April&nbsp;3,&nbsp;2017</B><br><B>(inception)&nbsp;to</B><br><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year<BR>Ended</B><br><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,393,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> Founder Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">612,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent events have been evaluated through August&nbsp;2, 2019, which is the date that the financial statements were available to be issued.
In addition to the items described in Note 6, regarding the execution of a new facility lease, a manufacturing service agreement and research and development work with Penn, Note 7, regarding the amendment to the certificate of incorporation
authorizing an increase of convertible preferred shares and the issuance of Series B Preferred and Note 8, regarding the amendment to the certificate of incorporation authorizing an increase to issuable common shares, the following subsequent events
occurred that require disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company&#146;s board of directors and stockholders approved an amendment to the 2018 Plan to increase the total number of
shares of common stock reserved for future issuance of equity awards under the 2018 Plan to 3,870,680 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company
also entered into certain new and amendments to existing agreements with Penn, including the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Penn
License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into amended and restated license agreement with Penn and the Children&#146;s Hospital of
Philadelphia. There were no changes in the financial terms relative to the Penn Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.
Subsequent Events&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Subscription and Technology Transfer Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into a subscription and technology transfer agreement pursuant to which the Company will pay Penn an upfront subscription
fee and a nominal <FONT STYLE="white-space:nowrap">non-refundable</FONT> royalty on the net sales of products, a portion of which will be credited toward milestone payments and royalties, respectively, under the Amended License
Agreement.&nbsp;Technology transfer activities will be at the Company&#146;s cost and subject to agreement as to the technology to be transferred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreement Addendum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an additional addendum pursuant to the Services Agreement with Penn for the manufacture of the Company&#146;s clinical
supply of DSG3-CAART, the Company&#146;s lead product candidate, for its Phase 1 clinical trial. Pursuant to the addendum, the Company will pay Penn a fee for dedicated resources as well as the cost to manufacture the clinical supply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Alliance Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an alliance agreement with Penn pursuant to which the Company will pay Penn a nominal annual fee in order for Penn to
provide an adequate and consistent level of support to the services that it provides to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_8"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share amounts) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proforma</B><br><B>June&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and Contingencies (see Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A, <FONT STYLE="white-space:nowrap">A-1,</FONT> <FONT STYLE="white-space:nowrap">A-2</FONT>
and B convertible preferred stock, $0.00001 par value: 12,393,497 and 20,762,168 shares authorized as of December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively; 12,393,047, 19,356,835 and no shares issued and outstanding at December&nbsp;31,
2018, June&nbsp;30, 2019 and proforma June&nbsp;30, 2019, respectively; aggregate liquidation preference of $38,256 and $94,475 at December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00001 par value: 21,147,115 and 29,000,000 shares authorized as of
December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively; 5,772,484 shares issued and outstanding at both December&nbsp;31, 2018 and June&nbsp;30, 2019; 25,129,319 shares issued and outstanding proforma June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_7"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per share, basic and diluted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,548,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,448,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing pro forma net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,768,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_9"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,050,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,393,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,772,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred stock, net of issuance costs of $1,293</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of convertible preferred stock, including deemed dividend</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,652</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,356,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,772,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_10"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,890</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> financing
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of convertible preferred stock, including deemed dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs in accrued expenses at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin686907_11"></A>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts.) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Basis of Presentation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc.
and, in August 2018, changed its name to Cabaletta Bio, Inc. The Company is headquartered in Pennsylvania. Cabaletta is a biotechnology company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal operations commenced in April 2018, when the Company executed sponsored research agreements with the Trustees of the University
of Pennsylvania (Penn). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect to generate revenue from sales of T cell therapies for B cell-mediated autoimmune diseases or any other revenue
unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects
to incur significant commercialization expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has sustained annual operating losses and expects to continue to generate
operating losses for the foreseeable future. The Company&#146;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents of $75,258 as of June&nbsp;30, 2019. Through June&nbsp;30,
2019, the Company had an accumulated deficit of $21,994. Management expects to incur additional losses in the future as it continues its research and development activities and will need to raise additional capital to fully implement its business
plan and to fund its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends to raise such additional capital through a combination of public or private equity
offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at
all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. The Company expects that its cash and
cash equivalents as of June&nbsp;30, 2019, will be sufficient to fund its projected operations for at least 12 months following the date that these financial statements are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological
innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased
expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is currently dependent on Penn for much of its preclinical research, clinical research and development activities, and expects to be dependent
upon Penn for initial and manufacturing activities (Note 6). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory
approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain
profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim financial statements have been prepared in conformity with generally accepted accounting principles (GAAP).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of management, the accompanying unaudited interim financial statements include all normal and recurring adjustments (which
consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company&#146;s financial position as of June&nbsp;30, 2019 and the results of its operations and its cash flows for the six
months ended June&nbsp;30, 2019 and 2018. The results for the six months ended June&nbsp;30, 2019 are not necessarily indicative of results to be expected for the year ending December&nbsp;31, 2019, any other interim periods, or any future year or
period. The balance sheet as of December&nbsp;31, 2018 included herein was derived from the audited financial statements as of that date. The unaudited interim financial statements, presented herein, do not contain the required disclosures under
GAAP for annual financial statements. These unaudited financial statements should be read in conjunction with the Company&#146;s audited financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited pro forma balance sheet as of June&nbsp;30, 2019 has been prepared to give effect to the automatic conversion of all
outstanding shares of convertible preferred stock into 19,356,835&nbsp;shares of common stock as if the Company&#146;s proposed initial public offering had occurred on June&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the accompanying statements of operations, the unaudited pro forma basic and diluted net loss per share attributable to common stockholders
for the six months ended June&nbsp;30, 2019 has been prepared to give effect to the automatic conversion of all outstanding shares of convertible preferred stock upon the closing of the proposed initial public offering into 19,356,835&nbsp;shares of
common stock as if the conversion had occurred on January&nbsp;1, 2019 or, if later, the issuance date of the convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses
during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, stock-based compensation, the valuation allowance on the Company&#146;s
deferred tax assets, and the fair value of convertible debt. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and
circumstances dictate. Actual results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be
cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring
the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of
and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to
property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated useful lives for property and equipment are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Property and equipment</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Estimated useful life</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Three&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Three&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lesser of estimated useful life or remaining lease term</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity
financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction of additional paid-in capital generated as a result of the
offering. Should the <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing be abandoned the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Classified Preferred Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company takes into consideration the expected economics and the business purpose of exchange of or amendments to its equity-classified
preferred shares in evaluating and determining the accounting or any such exchange or amendment. Fundamental changes to the nature of a preferred share and significant changes, additions or deletions of substantive contractual terms that are
reasonably possible of being exercised are accounted for as an extinguishment of the preferred shares. An exchange of preferred shares or an amendment to a preferred share that does not meet these criteria is accounted for as a modification. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment
associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market
for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The
authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs (other than quoted prices included in Level&nbsp;1) that are either
directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
assets or liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which
include activities under the Penn Agreement (Note 6), the conduct of sponsored research, preclinical studies and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the
estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements
established with service providers. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company
has not experienced any material differences between accrued costs and actual costs incurred since its inception. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs include costs incurred for internal and external research and development
activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well
as fees paid to entities that conduct certain research and development activities on the Company&#146;s behalf. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures its stock-based awards granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> based on the estimated fair values of the awards and recognizes the compensation over the requisite service period. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to
estimate the fair value of its stock-based awards. The Company uses the simplified method in accordance with guidance provided by the Securities and Exchange Commission and calculates the expected term as the midpoint between the vesting date and
the contractual term for certain awards with service or performance conditions. As stock-based compensation is based on awards ultimately expected to vest, it is reduced by forfeitures. The Company accounts for forfeitures as they occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the <FONT
STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers its convertible preferred stock and unvested shares of common stock held by the Company&#146;s founders to be participating securities
as, in the event a dividend is paid on common stock, the holders of convertible preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. The net loss attributable to common stockholders is not
allocated to the convertible preferred stock nor to the unvested shares of common stock as the holders of those securities do not have a contractual obligation to share in losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the
weighted average number of shares of common stock, which excludes unvested shares of common stock. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share since the
effects of potentially dilutive securities are antidilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed
by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#146;s CODM is its Chief Executive Officer and President. The Company has determined it operates in
a single operating segment and has one reportable segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company engaged a firm controlled by a former executive (until February 2019) of the Company for professional services related to
accounting, finance and other administrative functions. For the six month periods ended June&nbsp;30, 2018 and 2019, the costs incurred under this arrangement totaled $11 and $280, respectively, which were recorded as general and administrative
expense in the accompanying statements of operations. As of June&nbsp;30, 2019, amounts owed under this arrangement totaled $60&nbsp;and are included in accounts payable in the accompanying balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company engaged the services of its current Chief Executive Officer and President prior to his employment in October 2018. For the six
month period ended June&nbsp;30, 2018, the costs incurred under this arrangement totaled $65, which were recorded as general and administrative expense in the accompanying statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS&nbsp;Act). Under the
JOBS&nbsp;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&nbsp;Act, until such time as those standards apply to private companies. The Company has elected to use
this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&nbsp;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I> (Topic 842), with guidance regarding the
accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.
Summary of Significant Accounting Policies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including operating leases, with a term greater than 12 months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions.
This guidance will be effective for public companies for annual and interim periods beginning after December&nbsp;15, 2018. For all other entities, this standard is effective for annual reporting periods beginning after December&nbsp;15, 2019, and
interim periods within annual periods beginning after December&nbsp;15, 2020. Early adoption is permitted. The Company has yet to evaluate the effect that ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> will have on its financial statements or
financial statement disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Earnings Per
Share</I> (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): <I>I. Accounting for Certain Financial</I> <I>Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for
Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>. Part I of this update addresses the complexity of accounting for certain financial
instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current
accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option.
Part II of this update addresses the difficulty of navigating Topic 480, <I>Distinguishing Liabilities from Equity</I>, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the
result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this update do
not have an accounting effect. For public business entities, the amendments in Part I of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> are effective for fiscal years and interim periods within those years beginning after December&nbsp;15,
2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years beginning after December&nbsp;15, 2020. Early adoption is permitted
for all entities, including adoption in an interim period. The Company is currently assessing the potential impact of adopting ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> on its financial statements and financial statement disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2018, the Company had $33,017 of money market funds, which were valued by the Company based on quoted market prices, which represent a Level&nbsp;1 measurement within the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents financial information about the Company&#146;s financial assets measured at fair value on a recurring basis as of
June&nbsp;30, 2019 and indicate the level of the fair value hierarchy utilized to determine such fair values: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active&nbsp;Markets</B><br><B>for&nbsp;Identical</B><br><B>Assets&nbsp;(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial&nbsp;assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.
Fair Value Measurements&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the convertible notes (Note 5) is a recurring Level 3 fair value
measurement; however, there were no changes in the estimated fair value between the date of issuance and June 30, 2018 that were recognized in the statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers among Level&nbsp;categories in the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying value of accounts payable and accrued expenses that are reported on the balance sheets approximate their fair value due to the
short-term nature of these assets and liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other current liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Convertible Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, the Company issued convertible notes (the Notes) with aggregate proceeds to the Company in an initial closing of $12,535,
including $5,000 issued to Penn. The Notes carried a stated interest rate of 7.5% per annum. All unpaid principal, together with the then accrued interest, for the Notes was due and payable at the earlier of May&nbsp;4, 2021 or upon an event of
default. The terms of the Notes provided for an additional milestone-based closing of $12,567 upon the achievement of certain Company-specific events. The Notes contained a number of provisions addressing automatic and optional conversion, events of
default and prepayment provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes were amended in September 2018 to adjust the terms of the automatic and optional conversion
provisions. In October 2018, the Notes were amended again to reduce the qualified financing threshold, make a qualified financing a milestone event, revise the structure of a milestone-based closing and reallocate milestone closing purchase rights
to new purchasers and the existing noteholders. On the same day, immediately following the amendment of the Notes, the Company completed a qualified financing, issuing 3,146,551 shares of Series&nbsp;A convertible preferred stock for gross proceeds
of $12,744 (Note&nbsp;7). At this time, the Company issued 4,553,452 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred in connection with the milestone-based closing resulting in $12,567 of proceeds ($2.76 per share) and
the Notes together with interest accrued thereon ($409) were converted into 2,819,267 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> convertible preferred stock <FONT STYLE="white-space:nowrap">(Series&nbsp;A-1</FONT> Preferred)
and 1,873,777 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred stock <FONT STYLE="white-space:nowrap">(Series&nbsp;A-2</FONT> Preferred), reflecting a conversion price per share of $2.76. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On issuance, the Company elected to account for the Notes at fair value with any changes in fair value being recognized through the statements
of operations until the Notes settled. The fair value of the Notes was determined to be $12,535 on issuance and as of June&nbsp;30, 2018 and, as a result, had no fair value adjustments on convertible notes recognized in other expense in the
accompanying statements of operations in the six months </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.
Convertible Notes&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ended June&nbsp;30, 2018. On issuance in May 2018, the fair value of the Notes was determined to be equal to $12,535, which is the principal amount of the Notes. The fair value of the Notes as of
June&nbsp;30, 2018 was determined to be the same as that on issuance ($12,535) based on management&#146;s determination of no material changes to the assumptions underlying the determination of the fair value of the Notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Lease Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Company entered into an operating lease agreement for office space. The lease term expires in September 2019. The initial
annual base rent is approximately $14. Rent expense related to this lease agreement recognized in the accompanying statements of operations for the six months ended June&nbsp;30, 2018 and 2019 was $0 and $7, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the Company entered into an operating lease agreement for new office space in Philadelphia, Pennsylvania. The lease term
commenced in May 2019 and will expire in July 2022. The initial annual base rent is $261, and such amount will increase by 2% annually on each anniversary of the commencement date. Rent expense related to this lease agreement recognized in the
accompanying statements of operations for the six months ended June&nbsp;30, 2019 was $43. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, the future minimum
payments for operating leases are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;1, 2019 to December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research Service Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Company entered into a research service agreement with the Children&#146;s Hospital of Philadelphia for the manufacturing
of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study and clinical trial material. Research and development expense related to this research service agreement with the Children&#146;s Hospital of Philadelphia recognized in the accompanying
statements of operations in the six months ended June&nbsp;30, 2018 and 2019 were $0 and $201, respectively. There were no amounts due under the research service agreement with the Children&#146;s Hospital of Philadelphia as of June&nbsp;30, 2019.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with the University of Pennsylvania </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the Company entered into a license agreement with Penn (the Penn Agreement) and activated the license in October 2018 pursuant
to which the Company obtained (a)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> non-sublicensable worldwide license to certain of Penn&#146;s intellectual property to conduct research, product development, clinical trials, cell
manufacturing and other activities, and (b)&nbsp;an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis,
under certain of Penn&#146;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
Commitments and Contingencies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the Penn Agreement expires on the expiration or abandonment or
other termination of the last valid claim in Penn&#146;s intellectual property licensed by the Company. The Company may terminate the Penn Agreement at any time for convenience upon 60&nbsp;days written notice. In the event of an uncured, material
breach, Penn may terminate the Penn Agreement upon 60&nbsp;days written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Penn Agreement, Penn is obligated
to pay $2,000 annually for three years beginning August 2018 for funding to the laboratories of each of Drs.&nbsp;Milone and Payne (see <I>Sponsored Research Agreements</I><I>&#151;</I><I>Penn</I>). During the term of the Penn Agreement until the
first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10. The Company is required to pay certain milestone payments upon the achievement of specified
clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent
product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the Penn Agreement, total milestone payments could approach $20,000. Penn is also eligible to receive tiered
royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by,
the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the Penn Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low
double-digits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no amounts due under the Penn Agreement as of June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sponsored Research Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Penn </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
sponsored research agreements with two faculty members at Penn, who are also founders of the Company and members of the Company&#146;s scientific advisory board. Under the agreements, the Company has committed to funding a defined research plan for
three years through April 2021. The total $8,500 under the two agreements satisfies the Company&#146;s annual obligation under the Penn Agreement (see <I>License Agreement</I> <I>with the University of Pennsylvania</I> above). Research and
development expense related to these Penn faculty member research agreements recognized in the accompanying statements of operations in the six months ended June&nbsp;30, 2018 and 2019 was $537 and $1,421, respectively. Advance payments under the
Penn faculty member sponsored research agreements included in prepaid expenses and other current assets in the accompanying balance sheets were $884 as of June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Regents of the University of California </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company executed a research agreement with The Regents of the University of California. Under the agreement, the Company
has committed to funding scientific research through October 2020 in an immaterial amount. Research and development expense related to this research agreement with The Regents of the University of California recognized in the accompanying statements
of operations in the six months ended June&nbsp;30, 2018 and 2019 was $0 and $46, respectively. There were no amounts were due under this research agreement with The Regents of the University of California as of June&nbsp;30, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.
Commitments and Contingencies&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Master Translational Research Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company entered into a service agreement (the Services Agreement) with Penn for additional research and development
services from various laboratories within Penn. The research and development activities will be detailed in Penn organization-specific addenda to be separately executed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October and November 2018, the Company executed three project addenda under this agreement for research and development work. The three
projects commenced in 2019 and are anticipated to conclude in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, the Company executed two project addenda under the
Services Agreement for manufacturing and preclinical work. The two projects are commenced in 2019. The manufacturing addendum is expected to occur through June 2020. The preclinical addenda concluded in the six months ended June&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense related to executed addenda under the master translational research service agreement with Penn recognized in
the accompanying statements of operations in the six months ended June&nbsp;30, 2018 and 2019 was $0 and $1,684, respectively. Amounts due under the master translational research service agreement with Penn were $616 as of June&nbsp;30, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company has issued Series&nbsp;A Preferred, <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred, <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred, and Series&nbsp;B Preferred (collectively, the Convertible Preferred
Stock). The Company classifies Convertible Preferred Stock outside of stockholders&#146; deficit because the shares contain deemed liquidation rights that are a contingent redemption feature not solely within the control of the Company. There was no
Convertible Preferred Stock issued during the six months ended June&nbsp;30, 2018 or outstanding as of June&nbsp;30, 2018. The following table summarizes the Company&#146;s Convertible Preferred Stock issued in the six months ended June&nbsp;30,
2019 and outstanding as of June&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A</B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT></B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT></B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B</B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,372,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,873,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,393,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,963,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exchange, including deemed dividend</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,405,332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,146,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,372,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">468,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,369,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,356,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company&#146;s amended and restated certificate of incorporation authorized
the Company to issue 12,393,497 shares of $0.00001 par value Convertible Preferred Stock. In January 2019, the Company&#146;s certificate of incorporation was amended to increase the authorized shares of Convertible Preferred Stock to 20,762,168
shares, and the Company issued 6,963,788 shares of Series&nbsp;B Preferred, resulting in gross proceeds of $50,000. In connection, the Company issued a further 1,405,332 shares of Series&nbsp;B Preferred in exchange for 1,405,332 shares of <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred. The Company determined the terms of the Series&nbsp;B Preferred to be materially, qualitatively different than the terms of the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT>
Preferred and, as such, applied extinguishment accounting with respect to the <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred received in the exchange resulting in removal of the carrying amount of the <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred received ($4,764), the addition of the Series&nbsp;B Preferred issued at fair value determined with reference to the contemporaneous issuance of Series&nbsp;B Preferred ($10,090)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
Convertible Preferred Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the difference ($5,326) determined to be a deemed dividend recorded to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital (to the extent of
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital) and accumulated deficit within stockholders&#146; deficit on the balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Convertible Preferred Stock have various rights, preferences and privileges as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred are <FONT STYLE="white-space:nowrap">non-voting</FONT> shares. Each share of Series&nbsp;A Preferred, <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred and Series&nbsp;B
Preferred (the Voting Preferred Stock) shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which such shares of Voting Preferred Stock are convertible as of the record date for determining
stockholders entitled to vote on such matter holds a number of votes equal to the number of shares of common stock into which it is convertible. Generally, holders of Voting Preferred Stock shall vote together with the holders of common stock as a
single class and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> into common stock basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of Series A
Preferred and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred, exclusively and as a separate class, are entitled to elect three members of the board of directors. Holders of shares of common stock are entitled to elect one member of the
board of directors. The holders of common stock and Convertible Preferred Stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, are entitled to elect the balance of the total number of directors
of the Company (two). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of shares of Convertible Preferred Stock shall be entitled to receive, on a <I>pari passu </I>basis, dividends, out of any assets
legally available therefor, prior and in preference to any declaration or payment of any dividend (other than dividends on shares of common stock payable in shares of common stock) on the common stock, at a rate of (i) $0.24 per annum for each share
of Series A Preferred, (ii) $0.1656 per annum for each share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred, (iii) $0.1656 per annum for each share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Convertible Preferred Stock
and (iv) $0.4308 per annum for each share of Series B Preferred, in each case, as adjusted for any stock splits, stock dividends, combinations, subdivisions, or other similar recapitalization affecting such shares. Dividends are payable when, as and
if declared by the board of directors, and such dividends shall not be cumulative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of each series of Convertible Preferred
Stock can waive any dividend preference that the holders of such series of Convertible Preferred Stock shall be entitled to receive upon the affirmative vote or written consent of the holders of at least a majority of the shares of such series of
Convertible Preferred Stock then outstanding, voting together as a separate series, and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After payment of such dividends on the shares of Convertible Preferred Stock, any additional dividends or distributions shall be distributed
among all holders of common stock and Convertible Preferred Stock in proportion to the number of shares of common stock that would be held by each such holder if all shares of Convertible Preferred Stock were converted to common stock at the then
effective conversion price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Optional Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Convertible Preferred Stock shall be convertible, at the option of the holder, at any time and from time to time, and without the
payment of additional consideration by the holder thereof, into such number </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
Convertible Preferred Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of fully paid shares of common stock as is determined by dividing the applicable original issuance price by the conversion price in effect at the time of conversion. As of December&nbsp;31, 2018,
each share of Convertible Preferred Stock is convertible on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into common stock. The respective applicable conversion prices for the Convertible
Preferred Stock is subject to adjustment upon any future stock split, stock dividend, combination, reclassification or similar event affecting the Convertible Preferred Stock or any series thereof. Such applicable conversion prices for the
Convertible Preferred Stock and the rate at which the Convertible Preferred Stock may be converted into shares of common stock, shall be subject to adjustment as provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mandatory Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Convertible Preferred Stock automatically converts into the number of shares of common stock determined in accordance with the
conversion rate upon either: (a)&nbsp;the closing of a public offering of common stock at a price of at least $12.15 per share resulting in at least $50,000 of gross proceeds, or (b)&nbsp;written consent of a majority of the holders of the then
outstanding shares of Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a mandatory conversion of Preferred Stock as a result of a Qualified
IPO, each holder of Preferred Stock may elect to receive non-voting Common Stock in lieu of all or a portion of such holder&#146;s voting Common Stock. The non-voting shares of Common Stock shall have the same rights and preferences as the Common
Stock but shall be non-voting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Convertible Preferred Stock then outstanding shall be entitled to be paid (a)&nbsp;out of the consideration payable to
stockholders in the event of a merger, consolidation, or reorganization involving the Company or a subsidiary or on the sale, lease, transfer, exclusive license or other disposition by the Company or a subsidiary of all or substantially all assets
of the not elected otherwise by a requisite of holders of the Series A Preferred, or (b)&nbsp;out of the available proceeds the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of
Convertible Preferred Stock then outstanding shall be entitled to be paid, on a <I>pari passu </I>basis, before any payment shall be made to the holders of common stock by reason of their ownership thereof, an amount per share equal to the greater
of (i)&nbsp;the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of Convertible Preferred Stock been converted into common stock immediately
prior to such event. If upon any such event, the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of the outstanding shares of Convertible Preferred Stock the full amount to which they
shall be entitled, the holders of shares of Convertible Preferred Stock shall share ratably, on a <I>pari passu </I>basis, in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Dilution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Convertible Preferred Stock are afforded certain anti-dilution protection with respect to corporate events such as stock splits and
recapitalizations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Convertible Preferred Stock is not redeemable but do contain deemed liquidation rights in the event of a merger,
consolidation, or reorganization involving the Company or a subsidiary or on the sale, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.
Convertible Preferred Stock&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lease, transfer, exclusive license or other disposition by the Company or a subsidiary of all or substantially all assets of the Company, and unless elected otherwise by a requisite of holders of
the Series A Preferred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. 2018 Stock Option and Grant Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, the Company adopted the 2018 stock option and grant plan (the 2018 Plan), which provides for the Company to sell or issue
common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The 2018 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the
board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or their committee if so delegated, except that the exercise price per share of stock options may not be less than
100% of the fair market value of the share of common stock on the date of grant and the term of stock option may not be greater than 10 years. The Company generally grants stock-based awards with service conditions only (service-based awards),
although there has been one grant with performance conditions. Stock options granted under the 2018 Plan generally vest over three to four years. There were 2,726,999 shares reserved under the 2018 Plan for the future issuance of equity awards and,
as of June&nbsp;30, 2019, 291,454 shares were available for grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no awards in the six months ended June&nbsp;30, 2018. A
summary of the stock option activity under the 2018 Plan is presented below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">978,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,435,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options Exercisable at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options granted is calculated as the difference between the exercise price of
the options and the estimated fair value of the Company&#146;s common stock. The weighted average grant-date fair value of stock options granted during the six months ended June&nbsp;30, 2019 was $2.65. The aggregate grant-date fair value of options
vested during the six months ended June&nbsp;30, 2019 was $276. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the Black-Scholes option pricing method to calculate the
grant-date fair value of an award. The fair values of options granted during the six months ended June&nbsp;30, 2019 were calculated using the following assumptions: risk-free interest rate of 1.82%&#151;2.59% percent; expected term of
5.6&#151;6.1&nbsp;years; expected volatility of 70.3%&#151;73.2% percent; and no expected dividend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
2018 Stock Option and Grant Plan&nbsp;(continued) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation with respect to equity awards under the 2018 Plan and with respect to vesting common stock
issued to founders. The Company has recorded stock-based compensation in the accompanying statements of operations as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, there was $3,916 of unrecognized compensation cost related to unvested option
awards, including $527 with respect to one grant with performance-based vesting terms, which is expected to be recognized over a weighted-average period of 2.9 years. As of June&nbsp;30, 2019, there was $1,265 of unrecognized compensation cost
related to unvested Founder Stock awards, which is expected to be recognized over a weighted-average period of 1.9 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not record an income tax benefit in its statement of operations for the six months ended June&nbsp;30, 2018 and 2019 as it is
more likely than not that the Company will not recognize the federal and state deferred tax benefits generated by its losses. The Company has provided a valuation allowance for the full amount of its net deferred tax assets and liabilities as of
December&nbsp;31, 2018 and June&nbsp;30, 2019, as management has determined it is more likely than not that any future benefit from deductible temporary differences and net operating loss and tax credit carryforwards would not be realized. The
Company has not recorded any amounts for unrecognized tax benefits as of December&nbsp;31, 2018 or June&nbsp;30, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is
anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,393,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,356,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,435,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> Founder Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,577,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,775,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,427,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,568,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent events have been evaluated through August&nbsp;2, 2019, which is the date that the financial statements were available to be issued.
The following subsequent events occurred that require disclosure: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company&#146;s board of directors and stockholders approved an amendment to the 2018 Plan to increase the total number of
shares of common stock reserved for future issuance of equity awards under the 2018 Plan to 3,870,680 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company
also entered into certain new and amendments to existing agreements with Penn, including the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Penn
License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into amended and restated license agreement with Penn and the Children&#146;s Hospital of
Philadelphia. There were no changes in the financial terms relative to the Penn Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Subscription and Technology Transfer
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into a subscription and technology transfer agreement pursuant to which the Company will pay Penn an
upfront subscription fee and a nominal <FONT STYLE="white-space:nowrap">non-refundable</FONT> royalty on the net sales of products, a portion of which will be credited toward milestone payments and royalties, respectively, under the Amended License
Agreement.&nbsp;Technology transfer activities will be at the Company&#146;s cost and subject to agreement as to the technology to be transferred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Services Agreement Addendum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an additional addendum pursuant to the Services Agreement with Penn for the manufacture of the Company&#146;s clinical
supply of DSG3-CAART, the Company&#146;s lead product candidate, for its Phase 1 clinical trial. Pursuant to the addendum, the Company will pay Penn a fee for dedicated resources as well as the cost to manufacture the clinical supply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Alliance Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company entered into an alliance agreement with Penn pursuant to which the Company will pay Penn a nominal annual fee in order for Penn to
provide an adequate and consistent level of support to the services that it provides to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;day after the date of this prospectus), all dealers effecting
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to each dealer&#146;s obligation to deliver a prospectus when acting as underwriter, and with respect to
its unsold allotments or subscriptions. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
</I></P> <P STYLE="font-size:65pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g686907g45x09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:65pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>Common Stock </I></P> <P STYLE="font-size:65pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>PRELIMINARY
PROSPECTUS </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:65pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><I>MORGAN STANLEY </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><I>COWEN
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><I>EVERCORE ISI </I></P>
<P STYLE="margin-top:65pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </I></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information Not Required in Prospectus </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the fees and expenses, other than underwriting discounts and commissions, payable in connection with the
registration of the common stock hereunder. All amounts are estimates except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc. filing fee and The Nasdaq Global Market listing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT&nbsp;TO<BR>BE&nbsp;PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Industry Regulatory Authority, Inc. filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the Delaware General Corporation Law, or the DGCL, permits a corporation to eliminate the personal liability of its
directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a
law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation that will be effective upon the completion of this offering
provides that no director shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL
prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL authorizes
a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a
director or officer to a corporation. The indemnity may cover expenses (including attorneys&#146; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action,
suit or proceeding. Section&nbsp;145 permits corporations to pay expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145
provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their
status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted provisions in our certificate of incorporation and bylaws to be in effect upon the closing of this offering that limit or
eliminate the personal liability of our directors to the fullest extent permitted by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a
director, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of
equitable remedies such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our bylaws provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to
the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, in the discretion of
our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive
officers. These agreements provide that we will indemnify each of our directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146;
fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action
or proceeding arising out of that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of
expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director referenced herein.
Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the
expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain general liability insurance which covers certain
liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended, or the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification, under certain conditions, of us
and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934 arising in connection with the offering being registered hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under
the Securities Act: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Issuances of Capital Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From August 2017 to January 2018, we issued and sold an aggregate of 5,050,506 shares of our restricted common stock to certain of our officers
and scientific advisory board members as consideration for service provided to our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we issued and sold to an
accredited investor an aggregate of 721,978 shares of our common stock in connection with a licensing transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we
issued and sold an aggregate of 3,146,551 shares of our Series A preferred stock, 7,372,719 shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred stock, and 1,873,777 shares of our Series
<FONT STYLE="white-space:nowrap">A-2</FONT> preferred stock to eleven investors for aggregate consideration of approximately $38.3&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, we issued and sold an aggregate of 6,963,788 shares of our Series B preferred stock to 16 investors for aggregate
consideration of approximately $50.0&nbsp;million. In addition, we issued a further 1,405,332 shares of Series B Preferred Stock in exchange for 1,405,332 shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing sales of securities. The sales of securities described above were deemed to be exempt from
registration pursuant to Section&nbsp;4(a)(2) of the Securities Act, including Regulation D and Rule 506 promulgated thereunder, as transactions by an issuer not involving a public offering. All of the purchasers in these transactions represented to
us in connection with their purchase that they were acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities for an indefinite period of time. Such purchasers
received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. All of the foregoing securities are
deemed restricted securities for the purposes of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Grants and Exercises of Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options to purchase an aggregate of 2,435,545 shares of our common stock, with exercise price ranging from $0.67 to $4.20
per share, to employees, directors and consultants pursuant to the 2018 Plan. No shares of common stock have been issued upon the exercise of stock options pursuant to the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuances of the securities described above were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2) of the Securities
Act or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans. The shares of common stock issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits to the registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by
reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the Underwriting Agreement certificates
in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement
as of the time it was declared effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under the Securities Act, each post-effective
amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NO.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;INDEX</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Third Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">By-laws</FONT> of the Registrant, as currently in effect</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> (to be effective upon the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Specimen Common Stock Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investors&#146; Rights Agreement among the Registrant and certain of its stockholders, dated as of January&nbsp;2, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2018 Stock Option and Incentive Plan, as amended, and forms of award agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2019 Stock Option and Grant Plan and forms of award agreements thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2019 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its directors and officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated License Agreement, dated as of July&nbsp;23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#146;s Hospital of Philadelphia</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sponsored Research Agreement, dated as of April&nbsp;23, 2018, between the Registrant and the Trustees of the University of Pennsylvania</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sponsored Research Agreement, dated as of April&nbsp;23, 2018, between the Registrant and the Trustees of the University of Pennsylvania</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Translational Research Services Agreement, dated as of October 2018, between the Registrant and the Trustees of the University of Pennsylvania</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CAROT Master Services Addendum to Master Translational Research Services Agreement, dated as of February&nbsp;4, 2019, between the Registrant and the Trustees of the University of Pennsylvania</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CVPF Master Services Addendum to Master Translational Research Services Agreement, dated as of October&nbsp;22, 2018, between the Registrant and the Trustees of the University of Pennsylvania</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Research Agreement <FONT STYLE="white-space:nowrap">A19-3095,</FONT> dated as of October&nbsp;31, 2018, between the Registrant and The Regents of the University of California</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease, dated as of February&nbsp;11, 2019, between the Registrant and Brandywine Cira, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consulting Agreement, dated as of May&nbsp;7, 2018, between the Registrant and Danforth Advisors, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No.&nbsp;1 to Consulting Agreement, dated as of May&nbsp;7, 2019, between the Registrant and Danforth Advisors, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Offer Letter between the Registrant and Steven Nichtberger</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Offer Letter between the Registrant and Anup Marda</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NO.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT&nbsp;INDEX</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Offer Letter between the Registrant and Gwendolyn Binder-Scholl</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Offer Letter between the Registrant and David Chang</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Offer Letter between the Registrant and Brian Stalter</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiaries of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young, Independent Registered Public Accounting Firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page to this registration statement)</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be included by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain portions of the exhibit have been omitted pursuant to Rule 406 promulgated under the Securities Act
because they are not material and would likely cause competitive harm to the Registrant if disclosed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Commonwealth of Pennsylvania, on the&nbsp;&nbsp;&nbsp;&nbsp;day
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>CABALETTA&nbsp;BIO,&nbsp;INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Steven Nichtberger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>Chief Executive Officer and President</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY AND SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each individual whose signature appears below hereby constitutes and appoints each of Steven Nichtberger and Anup Marda as such person&#146;s
true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent with full power of substitution and <FONT STYLE="white-space:nowrap">re-substitution,</FONT> for such person in such
person&#146;s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement (or any Registration Statement for the same offering that is to be effective upon
filing pursuant to Rule&nbsp;462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to
all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or any substitute or
substitutes of any of them, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of
1933, as amended, this Registration Statement and Power of Attorney has been signed by the following person in the capacities and on the date indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Steven Nichtberger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Director, Chief Executive Officer and President (Principal Executive Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Anup Marda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Chief Financial Officer <BR>(Principal&nbsp;Financial&nbsp;and&nbsp;Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Catherine Bollard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brian Daniels</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Richard Henriques</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mark Simon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Director</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIRD AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;Corporation&#148;),
hereby certifies as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the Corporation is Cabaletta Bio, Inc. The date of the filing of its original Certificate of
Incorporation with the Secretary of State of the State of Delaware was April&nbsp;3, 2017 (the &#147;Original Certificate&#148;). The name under which the Corporation filed the Original Certificate was Tycho Therapeutics, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Second Amended and Restated Certificate of Incorporation (the &#147;Certificate&#148;) amends, restates and integrates the provisions
of the Second Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on January&nbsp;2, 2019 (the &#147;Amended and Restated Certificate&#148;), and was duly adopted in accordance with
the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the &#147;DGCL&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The text of
the Amended and Restated Certificate is hereby amended and restated in its entirety to provide as herein set forth in full. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of the Corporation is Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE II </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the
Corporation&#146;s registered office in the State of Delaware is c/o The Corporation Trust Company, 1209 Orange Street in the City of Wilmington, County of New Castle. The name of its registered agent at such address is The Corporation Trust
Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE III </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IV </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>CAPITAL STOCK </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total
number of shares of capital stock which the Corporation shall have authority to issue is one hundred and sixty million (160,000,000), of which (i)&nbsp;one hundred and fifty million (150,000,000) shares shall be a class designated as common stock,
par value $0.0001 per share (the &#147;Common Stock&#148;), and (ii)&nbsp;ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#147;Undesignated Preferred Stock&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in any certificate of designations of any series of Undesignated Preferred Stock, the number of authorized shares
of the class of Common Stock or Undesignated Preferred Stock may from time to time be increased or decreased (but not below the number of shares of such class outstanding) by the affirmative vote of the holders of a majority in voting power of the
outstanding shares of capital stock of the Corporation irrespective of the provisions of Section&nbsp;242(b)(2) of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The powers,
preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance with, or as set forth below in, this Article&nbsp;IV. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A. <U>COMMON STOCK</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject
to all the rights, powers and preferences of the Undesignated Preferred Stock and except as provided by law or in this Certificate (or in any certificate of designations of any series of Undesignated Preferred Stock): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the holders of the Common Stock shall have the exclusive right to vote for the election of directors of the Corporation (the
&#147;Directors&#148;) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; <U>provided</U>,
<U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate (or on any amendment to a certificate of designations of any series of Undesignated
Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Undesignated Preferred Stock if the holders of such affected series of Undesignated Preferred Stock are entitled to vote,
either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (or pursuant to a certificate of designations of any series of Undesignated Preferred Stock) or pursuant to the DGCL;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) dividends may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation
legally available for the payment of dividends, but only when and as declared by the Board of Directors or any authorized committee thereof; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) upon the voluntary or involuntary liquidation, dissolution or winding up of the
Corporation, the net assets of the Corporation shall be distributed pro rata to the holders of the Common Stock. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B. <U>UNDESIGNATED
PREFERRED STOCK</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Board of Directors or any authorized committee thereof is expressly authorized, to the fullest extent permitted
by law, to provide by resolution or resolutions for, out of the unissued shares of Undesignated Preferred Stock, the issuance of the shares of Undesignated Preferred Stock in one or more series of such stock, and by filing a certificate of
designations pursuant to applicable law of the State of Delaware, to establish or change from time to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers,
preferences and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE V </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>STOCKHOLDER ACTION
</U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Action without Meeting</U>. Any action required or permitted to be taken by the stockholders of the Corporation at any annual or
special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by a written consent of stockholders in lieu thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Special Meetings</U>. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of
Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a majority of the Directors then in office, and
special meetings of stockholders may not be called by any other person or persons. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VI </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>DIRECTORS </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as
otherwise provided herein or required by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Election of Directors</U>. Election of Directors need not be by written ballot unless
the <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation (the <FONT STYLE="white-space:nowrap">&#147;By-laws&#148;)</FONT> shall so provide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Number of Directors; Term of Office</U>. The number of Directors of the Corporation
shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Undesignated Preferred Stock, shall be classified, with
respect to the term for which they severally hold office, into three classes. The initial Class&nbsp;I Director of the Corporation shall be Brian Daniels; the initial Class&nbsp;II Directors of the Corporation shall be Catherine Bollard and Richard
Henriques; and the initial Class&nbsp;III Directors of the Corporation shall be Steven Nichtberger and Mark Simon. The initial Class&nbsp;I Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2020, the
initial Class&nbsp;II Directors shall serve for a term expiring at the annual meeting of stockholders to be held in 2021, and the initial Class&nbsp;III Directors shall serve for a term expiring at the annual meeting of stockholders to be held in
2022. At each annual meeting of stockholders, Directors elected to succeed those Directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election.
Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, whenever, pursuant to the provisions of Article&nbsp;IV of this Certificate, the holders of any one or more
series of Undesignated Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect Directors at an annual or special meeting of stockholders, the election, term of office, filling of
vacancies and other features of such directorships shall be governed by the terms of this Certificate and any certificate of designations applicable to such series. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Vacancies</U>. Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors and to fill
vacancies in the Board of Directors relating thereto, any and all vacancies in the Board of Directors, however occurring, including, without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation,
disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining Directors then in office, even if less than a quorum of the Board of Directors, and not by the stockholders. Any
Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director&#146;s successor
shall have been duly elected and qualified or until his or her earlier resignation, death or removal. Subject to the rights, if any, of the holders of any series of Undesignated Preferred Stock to elect Directors, when the number of Directors is
increased or decreased, the Board of Directors shall, subject to Article VI.3 hereof, determine the class or classes to which the increased or decreased number of Directors shall be apportioned; <U>provided</U>, <U>however</U>, that no decrease in
the number of Directors shall shorten the term of any incumbent Director. In the event of a vacancy in the Board of Directors, the remaining Directors, except as otherwise provided by law, shall exercise the powers of the full Board of Directors
until the vacancy is filled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Removal</U>. Subject to the rights, if any, of any series of Undesignated Preferred
Stock to elect Directors and to remove any Director whom the holders of any such series have the right to elect, any Director (including persons elected by Directors to fill vacancies in the Board of Directors) may be removed from office
(i)&nbsp;only with cause and (ii)&nbsp;only by the affirmative vote of the holders of 75% or more of the outstanding shares of capital stock then entitled to vote at an election of Directors. At least forty-five (45)&nbsp;days prior to any annual or
special meeting of stockholders at which it is proposed that any Director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent to the Director whose removal will be considered at the meeting.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VII </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>LIMITATION
OF LIABILITY </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages
for breach of fiduciary duty as a Director, except for liability (a)&nbsp;for any breach of the Director&#146;s duty of loyalty to the Corporation or its stockholders, (b)&nbsp;for acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law, (c)&nbsp;under Section&nbsp;174 of the DGCL or (d)&nbsp;for any transaction from which the Director derived an improper personal benefit. If the DGCL is amended after the effective date of this Certificate
to authorize corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of this Article&nbsp;VII by either of (i)&nbsp;the stockholders of the Corporation or (ii)&nbsp;an
amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person
serving as a Director at the time of such amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE VIII </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF <FONT STYLE="white-space:nowrap">BY-LAWS</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Amendment by Directors</U>. Except as otherwise provided by law, the <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation
may be amended or repealed by the Board of Directors by the affirmative vote of a majority of the Directors then in office. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Amendment by Stockholders</U>. The <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Corporation may be amended or repealed at any annual meeting of stockholders, or special meeting of stockholders called for such purpose, by the affirmative
vote of at least 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; <U>provided</U>, <U>however</U>, that if the Board of Directors recommends that stockholders approve
such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a
single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE IX </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>AMENDMENT OF CERTIFICATE OF INCORPORATION </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter prescribed by statute and this
Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation. Whenever any vote of the holders of capital stock of the Corporation is required to amend or repeal any provision of this Certificate, and in
addition to any other vote of holders of capital stock that is required by this Certificate or by law, such amendment or repeal shall require the affirmative vote of the majority of the outstanding shares of capital stock entitled to vote on such
amendment or repeal, and the affirmative vote of the majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose; <U>provided</U>,
<U>however</U>, that the affirmative vote of not less than 75% of the outstanding shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of not less than 75% of the outstanding shares of each class entitled to
vote thereon as a class, shall be required to amend or repeal any provision of Article V, Article VI, Article VII, Article VIII or Article IX of this Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[End of Text] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this ____ day
of __________, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CABALETTA BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Steven Nichtberger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">BY-LAWS</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the
&#147;Corporation&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE I </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Stockholders </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Annual Meeting</U>. The annual meeting of stockholders (any such meeting being referred to in these <FONT STYLE="white-space:nowrap">By-laws</FONT> as an &#147;Annual Meeting&#148;) shall be held at the hour, date and place within or without the
United States which is fixed by the Board of Directors, which time, date and place may subsequently be changed at any time by vote of the Board of Directors. If no Annual Meeting has been held for a period of thirteen (13)&nbsp;months after the
Corporation&#146;s last Annual Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these <FONT STYLE="white-space:nowrap">By-laws</FONT> or otherwise, all the force and effect of an Annual
Meeting. Any and all references hereafter in these <FONT STYLE="white-space:nowrap">By-laws</FONT> to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Notice of Stockholder Business and Nominations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Meetings of Stockholders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Nominations of persons for election to the Board of Directors of the Corporation and the proposal of other business to be
considered by the stockholders may be brought before an Annual Meeting (i)&nbsp;by or at the direction of the Board of Directors or (ii)&nbsp;by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice
provided for in this <FONT STYLE="white-space:nowrap">By-law,</FONT> who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this <FONT
STYLE="white-space:nowrap">By-law</FONT> as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii)&nbsp;shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting
(other than matters properly brought under Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> (or any successor rule) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), and such stockholder must comply with the
notice and other procedures set forth in Article I, Section&nbsp;2(a)(2) and (3)&nbsp;of this <FONT STYLE="white-space:nowrap">By-law</FONT> to bring such nominations or business properly before an Annual Meeting. In addition to the other
requirements set forth in this <FONT STYLE="white-space:nowrap">By-law,</FONT> for any proposal of business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For nominations or other business to be properly brought before an Annual Meeting by a stockholder pursuant to clause
(ii)&nbsp;of Article I, Section&nbsp;2(a)(1) of this <FONT STYLE="white-space:nowrap">By-law,</FONT> the stockholder must (i)&nbsp;have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation, (ii)&nbsp;have
provided any updates or supplements to such notice at the times and in the forms required by this <FONT STYLE="white-space:nowrap">By-law</FONT> and (iii)&nbsp;together with the beneficial owner(s), if any, on whose behalf the nomination or business
proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this <FONT STYLE="white-space:nowrap">By-law.</FONT> To be timely, a stockholder&#146;s written notice shall
be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the preceding year&#146;s Annual Meeting; <U>provided</U>, <U>however</U>, that in the event the Annual Meeting is first convened more than thirty (30)&nbsp;days before or more than sixty
(60)&nbsp;days after such anniversary date, or if no Annual Meeting were held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than the close of business on the later of the
ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as
&#147;Timely Notice&#148;). Notwithstanding anything to the contrary provided herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder&#146;s notice shall be timely if received by
the Secretary at the principal executive offices of the Corporation not later than the close of business on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which
public announcement of the date of such Annual Meeting is first made or sent by the Corporation. Such stockholder&#146;s Timely Notice shall set forth: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) as to each person whom the stockholder proposes to nominate for election
or reelection as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A
under the Exchange Act (including such person&#146;s written consent to being named in the proxy statement as a nominee and to serving as a director if elected); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business
desired to be brought before the meeting, the reasons for conducting such business at the meeting, and any material interest in such business of each Proposing Person (as defined below); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) (i) the name and address of the stockholder giving the notice, as they appear on the Corporation&#146;s books, and the
names and addresses of the other Proposing Persons (if any) and (ii)&nbsp;as to each Proposing Person, the following information: (a)&nbsp;the class or series and number of all shares of capital stock of the Corporation which are, directly or
indirectly, owned beneficially or of record by such Proposing Person or any of its affiliates or associates (as such terms are defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Exchange Act), including any shares of
any class or series of capital stock of the Corporation as to which such Proposing Person or any of its affiliates or associates has a right to acquire beneficial ownership at any time in the future, (b)&nbsp;all Synthetic Equity Interests (as
defined below) in which such Proposing Person or any of its affiliates or associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including without limitation,
identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (x)&nbsp;whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in
such shares to such Proposing Person, (y)&nbsp;whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares and (z)&nbsp;whether or not such Proposing Person and/or, to the extent
known, the counterparty to such Synthetic Equity Interest has entered into other transactions that hedge or mitigate the economic effect of such Synthetic Equity Interest, (c)&nbsp;any proxy (other than a revocable proxy given in response to a
public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person has or shares a right to, directly or indirectly, vote any shares of
any class or series of capital stock of the Corporation, (d)&nbsp;any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing
Person that are separated or separable from the underlying shares of the Corporation, and (e)&nbsp;any performance-related fees (other than an asset based fee) that such Proposing Person, directly or indirectly, is entitled to based on any increase
or decrease in the value of shares of any class or series of capital stock of the Corporation or any Synthetic Equity Interests (the disclosures to be made pursuant to the foregoing clauses (a)&nbsp;through (e) are referred to, collectively, as
&#147;Material Ownership Interests&#148;) and (iii)&nbsp;a description of the material terms of all agreements, arrangements or understandings (whether or not in writing) entered into by any Proposing Person or any of its affiliates or associates
with any other person for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) (i) a description of all agreements, arrangements or understandings by
and among any of the Proposing Persons, or by and among any Proposing Persons and any other person (including with any proposed nominee(s)), pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders
(which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding), and (ii)&nbsp;identification of the names and addresses of other stockholders (including beneficial owners) known by
any of the Proposing Persons to support such nominations or other business proposal(s), and to the extent known the class and number of all shares of the Corporation&#146;s capital stock owned beneficially or of record by such other stockholder(s)
or other beneficial owner(s); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) a statement whether or not the stockholder giving the notice and/or the other
Proposing Person(s), if any, will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under
applicable law to approve the proposal or, in the case of a nomination or nominations, at least the percentage of voting power of all of the shares of capital stock of the Corporation reasonably believed by such Proposing Person to be sufficient to
elect the nominee or nominees proposed to be nominated by such stockholder (such statement, the &#147;Solicitation Statement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Article I of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the term &#147;Proposing Person&#148;
shall mean the following persons: (i)&nbsp;the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders&#146; meeting, and (ii)&nbsp;the beneficial owner(s), if different, on whose behalf the
nominations or business proposed to be brought before a stockholders&#146; meeting is made. For purposes of this Section&nbsp;2 of Article&nbsp;I of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the term &#147;Synthetic Equity
Interest&#148; shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or <FONT STYLE="white-space:nowrap">so-called</FONT>
&#147;stock borrowing&#148; agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a)&nbsp;give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock
of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit or avoid a loss from any increase or decrease in the value of any shares
of any class or series of capital stock of the Corporation, (b)&nbsp;mitigate loss to, reduce the economic risk of or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock
of the Corporation, (c)&nbsp;otherwise provide in any manner the opportunity to profit or avoid a loss from any decrease in the value of any shares of any class or series of capital stock of the Corporation, or (d)&nbsp;increase or decrease the
voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) A stockholder providing Timely Notice of nominations or business
proposed to be brought before an Annual Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided
in such notice pursuant to this <FONT STYLE="white-space:nowrap">By-law</FONT> shall be true and correct as of the record date for the meeting and as of the date that is ten (10)&nbsp;business days prior to such Annual Meeting, and such update and
supplement shall be received by the Secretary at the principal executive offices of the Corporation not later than the close of business on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and
supplement required to be made as of the record date), and not later than the close of business on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten
(10)&nbsp;business days prior to the meeting). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) Notwithstanding anything in the second sentence of Article I,
Section&nbsp;2(a)(2) of this <FONT STYLE="white-space:nowrap">By-law</FONT> to the contrary, in the event that the number of directors to be elected to the Board of Directors of the Corporation is increased and there is no public announcement naming
all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least ten (10)&nbsp;days before the last day a stockholder may deliver a notice of nomination in accordance with the second
sentence of Article I, Section&nbsp;2(a)(2), a stockholder&#146;s notice required by this <FONT STYLE="white-space:nowrap">By-law</FONT> shall also be considered timely, but only with respect to nominees for any new positions created by such
increase, if it shall be received by the Secretary of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>General</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) Only such persons who are nominated in accordance with the provisions of this
<FONT STYLE="white-space:nowrap">By-law</FONT> shall be eligible for election and to serve as directors and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of
this <FONT STYLE="white-space:nowrap">By-law</FONT> or in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a
nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law.</FONT> If neither the Board of Directors nor such designated committee makes a
determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law,</FONT> the presiding officer of the Annual Meeting shall have the power and duty to
determine whether the stockholder proposal or nomination was made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law.</FONT> If the Board of Directors or a designated committee thereof or the presiding officer, as
applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this <FONT STYLE="white-space:nowrap">By-law,</FONT> such proposal or nomination shall be disregarded and shall not be presented for
action at the Annual Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Except as otherwise required by law, nothing in this Article I,
Section&nbsp;2 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee
for director or any other matter of business submitted by a stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing provisions of
this Article I, Section&nbsp;2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be
disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I, Section&nbsp;2, to be considered a qualified representative of the proposing stockholder, a person must be
authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such written instrument or
electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the presiding officer at the meeting of stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) For purposes of this <FONT STYLE="white-space:nowrap">By-law,</FONT> &#147;public announcement&#148; shall mean disclosure
in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section&nbsp;13, 14 or 15(d)
of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) Notwithstanding the foregoing provisions of this <FONT STYLE="white-space:nowrap">By-law,</FONT>
a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this <FONT STYLE="white-space:nowrap">By-law.</FONT> Nothing in this <FONT
STYLE="white-space:nowrap">By-law</FONT> shall be deemed to affect any rights of (i)&nbsp;stockholders to have proposals included in the Corporation&#146;s proxy statement pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> (or any
successor rule), as applicable, under the Exchange Act and, to the extent required by such rule, have such proposals considered and voted on at an Annual Meeting or (ii)&nbsp;the holders of any series of Undesignated Preferred Stock to elect
directors under specified circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Special Meetings</U>. Except as otherwise required by statute and subject to the
rights, if any, of the holders of any series of Undesignated Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors acting pursuant to a resolution approved by the affirmative vote of a
majority of the Directors then in office. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon
at a special meeting of stockholders of the Corporation. Nominations of persons for election to the Board of Directors of the Corporation and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be
considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section&nbsp;1 of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> in which case such special meeting
in lieu thereof shall be deemed an Annual Meeting for purposes of these <FONT STYLE="white-space:nowrap">By-laws</FONT> and the provisions of Article I, Section&nbsp;2 of these <FONT STYLE="white-space:nowrap">By-laws</FONT> shall govern such
special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Notice of Meetings; Adjournments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting and the means of remote communication, if
any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given not less than ten (10)&nbsp;days nor more than sixty (60)&nbsp;days before the Annual Meeting, to each stockholder entitled to
vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation&#146;s stock transfer books. Without limiting the manner
by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section&nbsp;232 of the Delaware General Corporation Law (&#147;DGCL&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice of
all special meetings shall state the purpose or purposes for which the meeting has been called. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Notice of an Annual Meeting or special
meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting,
unless such attendance is for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Board of Directors may postpone and reschedule any previously scheduled Annual Meeting or special meeting of stockholders and any
record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section&nbsp;2 of this Article&nbsp;I of these <FONT STYLE="white-space:nowrap">By-laws</FONT>
or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder&#146;s notice under this Article I
of these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) When any meeting is convened, the presiding officer may adjourn the meeting
if (i)&nbsp;no quorum is present for the transaction of business, (ii)&nbsp;the Board of Directors determines that adjournment is necessary or appropriate to enable the stockholders to consider fully information which the Board of Directors
determines has not been made sufficiently or timely available to stockholders, or (iii)&nbsp;the Board of Directors determines that adjournment is otherwise in the best interests of the Corporation. When any Annual Meeting or special meeting of
stockholders is adjourned to another hour, date or place, notice need not be given of the adjourned meeting other than an announcement at the meeting at which the adjournment is taken of the hour, date and place, if any, to which the meeting is
adjourned and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting; provided, however, that if the adjournment is for more than thirty
(30)&nbsp;days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be
deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may
hereafter be amended and/or restated, the &#147;Certificate&#148;) or these <FONT STYLE="white-space:nowrap">By-laws,</FONT> is entitled to such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Quorum</U>. A majority of the shares entitled to vote, present in person or
represented by proxy, shall constitute a quorum at any meeting of stockholders. If less than a quorum is present at a meeting, the holders of voting stock representing a majority of the voting power present at the meeting or the presiding officer
may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as provided in Section&nbsp;4 of this Article&nbsp;I. At such adjourned meeting at which a quorum is present, any business may be
transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to
leave less than a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Voting and Proxies</U>. Stockholders shall have one vote for each share of stock entitled to vote
owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i)&nbsp;in person, (ii)&nbsp;by written proxy or (iii)&nbsp;by a
transmission permitted by Section&nbsp;212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section&nbsp;212(c) of the DGCL may be substituted for or used in lieu of the
original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire
original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. Except as otherwise limited therein or as otherwise provided by law, proxies authorizing a person to vote at a
specific meeting shall entitle the persons authorized thereby to vote at any adjournment of such meeting, but they shall not be valid after final adjournment of such meeting. A proxy with respect to stock held in the name of two or more persons
shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Action at Meeting</U>. When a quorum is present at any meeting of stockholders, any matter before any such meeting (other than
an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the Certificate or by these
<FONT STYLE="white-space:nowrap">By-laws.</FONT> Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Stockholder Lists</U>. The Secretary or an Assistant Secretary (or the Corporation&#146;s transfer agent or other person
authorized by these <FONT STYLE="white-space:nowrap">By-laws</FONT> or by law) shall prepare and make, at least ten (10)&nbsp;days before every Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote
at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for a period of at least
ten (10)&nbsp;days prior to the meeting in the manner provided by law. The list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Presiding Officer</U>. The Board of Directors shall designate a representative
to preside over all Annual Meetings or special meetings of stockholders, provide that if the Board of Directors does not so designate such a presiding officer, then the Chairman of the Board, if one is elected, shall preside over such meetings. If
the Board of Directors does not so designate such a presiding officer and there is no Chairman of the Board or the Chairman of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is elected, shall preside over
such meetings, provided further that if there is no Chief Executive Officer or the Chief Executive Officer is unable to so preside or is absent, then the President shall preside over such meetings. The presiding officer at any Annual Meeting or
special meeting of stockholders shall have the power, among other things, to adjourn such meeting at any time and from time to time, subject to Sections&nbsp;4 and&nbsp;5 of this Article&nbsp;I. The order of business and all other matters of
procedure at any meeting of the stockholders shall be determined by the presiding officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Inspectors of Elections</U>.
The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any
inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the presiding officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent
of the Corporation. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The
inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the
inspectors. The presiding officer may review all determinations made by the inspectors, and in so doing the presiding officer shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any
determinations made by the inspectors. All determinations by the inspectors and, if applicable, the presiding officer, shall be subject to further review by any court of competent jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE II </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Directors </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Powers</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided by the Certificate or required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Number and Terms</U>. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly
adopted from time to time by the Board of Directors. The directors shall hold office in the manner provided in the Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
3. <U>Qualification</U>. No director need be a stockholder of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Vacancies</U>. Vacancies in the Board of
Directors shall be filled in the manner provided in the Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Removal</U>. Directors may be removed from office only
in the manner provided in the Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Resignation</U>. A director may resign at any time by giving written notice to
the Chairman of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Regular Meetings</U>. The regular annual meeting of the Board of Directors shall be held, without notice other than this
Section&nbsp;7, on the same date and at the same place as the Annual Meeting following the close of such meeting of stockholders. Other regular meetings of the Board of Directors may be held at such hour, date and place as the Board of Directors may
by resolution from time to time determine and publicize by means of reasonable notice given to any director who is not present at the meeting at which such resolution is adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Special Meetings</U>. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a
majority of the directors, the Chairman of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Notice of Meetings</U>. Notice of the hour, date and place of all special meetings of the Board of Directors shall be given to
each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairman of the Board, if one is elected, or the President or such other officer designated by the Chairman of
the Board, if one is elected, or the President. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of electronic communication, sent to his
or her business or home address, at least twenty-four (24)&nbsp;hours in advance of the meeting, or by written notice mailed to his or her business or home address, at least forty-eight (48)&nbsp;hours in advance of the meeting. Such notice shall be
deemed to be delivered when hand-delivered to such address, read to such director by telephone, deposited in the mail so addressed, with postage thereon prepaid if mailed, dispatched or transmitted if sent by facsimile transmission or by electronic
mail or other form of electronic communications. A written waiver of notice signed before or after a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a
director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these <FONT
STYLE="white-space:nowrap">By-laws,</FONT> neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Quorum</U>. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for
the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business which might
have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this section, the total number of directors includes any unfilled vacancies on the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Action at Meeting</U>. At any meeting of the Board of Directors at which a quorum is present, the vote of a
majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 12. <U>Action by Consent</U>. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken
without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the records of the meetings of the Board of
Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the Board of Directors for
all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Manner of Participation</U>. Directors may participate in meetings of the Board of Directors by means of
conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall constitute presence in person at such meeting for
purposes of these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Presiding Director</U>. The Board of Directors shall
designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is absent,
then the Chairman of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chairman of the Board, if one is elected, are unable to preside
or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Committees</U>. The Board of Directors, by vote of a majority of the directors then in office, may elect one or more
committees, including, without limitation, a Compensation Committee, a Nominating&nbsp;&amp; Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers except those which by law, by the Certificate or
by these <FONT STYLE="white-space:nowrap">By-laws</FONT> may not be delegated. Except as the Board of Directors may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted
so far as possible in the same manner as is provided by these <FONT STYLE="white-space:nowrap">By-laws</FONT> for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of
Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings and shall report its action to the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 16. <U>Compensation of Directors</U>. Directors shall receive such compensation for their services as shall be determined by a
majority of the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees and who receive compensation for their services as such, shall not receive any salary or other compensation
for their services as directors of the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE III </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Officers </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1.
<U>Enumeration</U>. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other officers, including, without limitation, a Chairman of the Board of Directors, a Chief Executive Officer and one or more Vice
Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Election</U>. At the regular annual meeting of the Board of Directors following the Annual Meeting, the Board of Directors shall
elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors at such regular annual meeting of the Board of Directors or at any other regular or special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Qualification</U>. No officer need be a stockholder or a director. Any person may occupy more than one office of the Corporation
at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Tenure</U>. Except as otherwise provided by the Certificate or by these
<FONT STYLE="white-space:nowrap">By-laws,</FONT> each of the officers of the Corporation shall hold office until the regular annual meeting of the Board of Directors following the next Annual Meeting and until his or her successor is elected and
qualified or until his or her earlier resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resignation</U>. Any officer may resign by delivering his or
her written resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise provides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Removal</U>. Except as otherwise provided by law, the Board of Directors may remove any officer with or without cause by the
affirmative vote of a majority of the directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Absence or Disability</U>. In the event of the absence or disability of any
officer, the Board of Directors may designate another officer to act temporarily in place of such absent or disabled officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.
<U>Vacancies</U>. Any vacancy in any office may be filled for the unexpired portion of the term by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9.
<U>President</U>. The President shall, subject to the direction of the Board of Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Chairman of the Board</U>. The Chairman of the Board, if one is elected, shall have such powers and shall perform such duties
as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Chief Executive Officer</U>. The Chief Executive Officer, if
one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION
12. <U>Vice Presidents and Assistant Vice Presidents</U>. Any Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of
Directors or the Chief Executive Officer may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 13. <U>Treasurer and Assistant Treasurers</U>. The
Treasurer shall, subject to the direction of the Board of Directors and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept
accurate books of account. The Treasurer shall have custody of all funds, securities, and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or
the Chief Executive Officer. Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 14. <U>Secretary and Assistant Secretaries</U>. The Secretary shall record all the proceedings of the meetings of the stockholders and
the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary
shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The Secretary shall have custody of the seal of the Corporation, and the Secretary, or an Assistant Secretary shall have authority
to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the
Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of
Directors or the Chief Executive Officer may from time to time designate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 15. <U>Other Powers and Duties</U>. Subject to these
<FONT STYLE="white-space:nowrap">By-laws</FONT> and to such limitations as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective
offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief Executive Officer. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE IV </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Capital
Stock </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Certificates of Stock</U>. Each stockholder shall be entitled to a certificate of the capital stock of the
Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by the Chairman of the Board, the President or a Vice President and by the Treasurer or an Assistant Treasurer, or the
Secretary or an Assistant Secretary. The Corporation seal and the signatures by the Corporation&#146;s officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose
facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer,
transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of
stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these Bylaws, the Board of Directors of the Corporation may provide by resolution or resolutions that some or all of any
or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of
these Bylaws the Board of Directors has determined that all classes or series of the Corporation&#146;s stock may be uncertificated, whether upon original issuance, <FONT STYLE="white-space:nowrap">re-issuance,</FONT> or subsequent transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Transfers</U>. Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock
that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate theretofore properly endorsed or accompanied by a written assignment or power of
attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate
may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its transfer agent may require. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Record Holders</U>. Except as may otherwise be required by law, by the
Certificate or by these <FONT STYLE="white-space:nowrap">By-laws,</FONT> the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and
the right to vote with respect thereto, regardless of any transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these <FONT
STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Record Date</U>. In order that the Corporation may determine the stockholders
entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change,
conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of
Directors, and which record date: (a)&nbsp;in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days
before the date of such meeting and (b)&nbsp;in the case of any other action, shall not be more than sixty (60)&nbsp;days prior to such other action. If no record date is fixed: (i)&nbsp;the record date for determining stockholders entitled to
notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting
is held; and (ii)&nbsp;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Replacement of Certificates</U>. In case of the alleged loss, destruction or mutilation of a certificate of stock of the
Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE V
</U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Indemnification </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Definitions</U>. For purposes of this Article: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;Corporate Status&#148; describes the status of a person who is serving or has served (i)&nbsp;as a Director of the Corporation,
(ii)&nbsp;as an Officer of the Corporation, (iii)&nbsp;as a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation, or (iv)&nbsp;as a director, partner, trustee, officer, employee or agent of any other corporation,
partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the Corporation. For purposes of this
Section&nbsp;1(a), a Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a Subsidiary shall be deemed to be
serving at the request of the Corporation. Notwithstanding the foregoing, &#147;Corporate Status&#148; shall not include the status of a person who is serving or has served as a director, officer, employee or agent of a constituent corporation
absorbed in a merger or consolidation transaction with the Corporation with respect to such person&#146;s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders of the Corporation; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;Director&#148; means any person who serves or has served the Corporation as a
director on the Board of Directors of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;Disinterested Director&#148; means, with respect to each Proceeding in
respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
&#147;Expenses&#148; means all attorneys&#146; fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel
expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization,
telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a
witness in, settling or otherwise participating in, a Proceeding; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;Liabilities&#148; means judgments, damages, liabilities,
losses, penalties, excise taxes, fines and amounts paid in settlement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <FONT STYLE="white-space:nowrap">&#147;Non-Officer</FONT>
Employee&#148; means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;Officer&#148; means any person who serves or has served the Corporation as an officer of the Corporation appointed by the Board of
Directors of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;Proceeding&#148; means any threatened, pending or completed action, suit, arbitration, alternate
dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;Subsidiary&#148; shall mean any corporation, partnership, limited liability company, joint venture, trust or other entity of which
the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i)&nbsp;a general partner, managing member or other similar interest or (ii)&nbsp;(A) fifty percent (50%) or more of the voting power of
the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B)&nbsp;fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such
corporation, partnership, limited liability company, joint venture or other entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Indemnification of Directors and Officers</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the operation of Section&nbsp;4 of this Article V of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> each Director and
Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits
the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) <U>Actions, Suits and Proceedings Other than By or In the Right of the Corporation</U>. Each Director and Officer shall be
indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or any claim,
issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status,
if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to
believe his or her conduct was unlawful. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) <U>Actions, Suits and Proceedings By or In the Right of the Corporation</U>.
Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director&#146;s or Officer&#146;s behalf in connection with any Proceeding or
any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director&#146;s or Officer&#146;s Corporate Status, if such
Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this
Section&nbsp;2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court
of Chancery or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly and reasonably entitled
to indemnification for such Expenses that such court deems proper.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) <U>Survival of Rights</U>. The rights of indemnification provided by this Section&nbsp;2 shall continue as to a Director or
Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) <U>Actions by Directors or Officers</U>. Notwithstanding the foregoing, the Corporation shall indemnify any Director or
Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized in advance by the Board
of Directors of the Corporation, unless such Proceeding was brought to enforce such Officer&#146;s or Director&#146;s rights to indemnification or, in the case of Directors, advancement of Expenses under these
<FONT STYLE="white-space:nowrap">By-laws</FONT> in accordance with the provisions set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Indemnification of <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employees</U>. Subject to the operation of Section&nbsp;4 of this Article V of these <FONT STYLE="white-space:nowrap">By-laws,</FONT> each <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee may, in the discretion of the Board of Directors
of the Corporation, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee or on such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#146;s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter
therein, which such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is, or is threatened to be made, a party to or participant in by reason of such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee&#146;s Corporate Status, if
such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee acted in good faith and in a manner such <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee reasonably believed to be in or not opposed to the best interests of the
Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section&nbsp;3 shall exist as to a
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee after he or she has ceased to be a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and
administrators. Notwithstanding the foregoing, the Corporation may indemnify any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee seeking indemnification in connection with a Proceeding initiated by such
<FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee only if such Proceeding was authorized in advance by the Board of Directors of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Determination</U>. Unless ordered by a court, no indemnification shall be provided pursuant to this Article V to a Director, to
an Officer or to a <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best
interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a)&nbsp;a majority vote of the Disinterested Directors,
even though less than a quorum of the Board of Directors, (b)&nbsp;a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if
there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion, or (d)&nbsp;by the stockholders of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Advancement of Expenses to Directors Prior to Final Disposition</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such
Director is involved by reason of such Director&#146;s Corporate Status within thirty (30)&nbsp;days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time, whether prior
to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any
Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection
with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i)&nbsp;authorized by the Board of Directors of the Corporation, or (ii)&nbsp;brought to enforce such
Director&#146;s rights to indemnification or advancement of Expenses under these <FONT STYLE="white-space:nowrap">By-laws.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a
claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30)&nbsp;days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time
thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation
(including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action
brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be
on the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an
undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Advancement of Expenses to Officers and <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employees Prior to Final
Disposition</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Corporation may, at the discretion of the Board of Directors of the Corporation, advance any or all Expenses
incurred by or on behalf of any Officer or any <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee upon the receipt by the Corporation of a statement or statements from such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee requesting such advance or advances from time
to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee and shall be
preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee is not entitled to be
indemnified against such Expenses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms
of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee has not met any applicable standard for indemnification set
forth in the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Contractual Nature of Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The provisions of this Article&nbsp;V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to
the benefits hereof at any time while this Article&nbsp;V is in effect, in consideration of such person&#146;s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of
this Article&nbsp;V nor the adoption of any provision of the Certificate of Incorporation inconsistent with this Article&nbsp;V shall eliminate or reduce any right conferred by this Article&nbsp;V in respect of any act or omission occurring, or any
cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts
that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding
with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article&nbsp;V shall continue notwithstanding that the person has ceased to be a director or
officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributes of such person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60)&nbsp;days after
receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director
or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel, or stockholders) to make a determination
concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that
such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director or
Officer has not met any applicable standard for indemnification set forth in the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8.
<U><FONT STYLE="white-space:nowrap">Non-Exclusivity</FONT> of Rights</U>. The rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right which any Director, Officer, or <FONT
STYLE="white-space:nowrap">Non-Officer</FONT> Employee may have or hereafter acquire under any statute, provision of the Certificate or these <FONT STYLE="white-space:nowrap">By-laws,</FONT> agreement, vote of stockholders or Disinterested Directors
or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Insurance</U>. The Corporation may maintain insurance, at its expense, to protect itself and any Director,
Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT> Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or <FONT STYLE="white-space:nowrap">Non-Officer</FONT>
Employee, or arising out of any such person&#146;s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article&nbsp;V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Other Indemnification</U>. The Corporation&#146;s obligation, if any, to
indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit
plan or enterprise (the &#147;Primary Indemnitor&#148;). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee,
officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the
applicable Primary Indemnitor(s) and any applicable insurance policies. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>ARTICLE VI </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Miscellaneous Provisions </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 1. <U>Fiscal Year</U>. The fiscal year of the Corporation shall be determined by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 2. <U>Seal</U>. The Board of Directors shall have power to adopt and alter the seal of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 3. <U>Execution of Instruments</U>. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by
the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairman of the Board, if one is elected, the President or the Treasurer or any other officer, employee or agent of
the Corporation as the Board of Directors or the executive committee of the Board may authorize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 4. <U>Voting of Securities</U>.
Unless the Board of Directors otherwise provides, the Chairman of the Board, if one is elected, the President or the Treasurer may waive notice of and act on behalf of the Corporation, or appoint another person or persons to act as proxy or attorney
in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or shareholders of any other corporation or organization, any of whose securities are held by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 5. <U>Resident Agent</U>. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or
proceeding against the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 6. <U>Corporate Records</U>. The original or attested copies of the Certificate, <FONT
STYLE="white-space:nowrap">By-laws</FONT> and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the
amount of stock held by each, may be kept outside the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or at such other place or places as may be
designated from time to time by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 7. <U>Certificate</U>. All references in these <FONT
STYLE="white-space:nowrap">By-laws</FONT> to the Certificate shall be deemed to refer to the Third Amended and Restated<B> </B>Certificate of Incorporation of the Corporation, as amended and/or restated and in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 8. <U>Exclusive Jurisdiction of Delaware Courts</U>. Unless the Corporation consents in writing to the selection of an alternative
forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for state law claims for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach
of or based on a fiduciary duty owed by any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation or any
current or former director, officer or other employee or stockholder of the Corporation arising pursuant to any provision of the Delaware General Corporation Law or the Certificate or Bylaws, (iv)&nbsp;any action to interpret, apply, enforce or
determine the validity of the Certificate or Bylaws, or (v)&nbsp;any action asserting a claim against the Corporation or any current or former director, officer or other employee of the Corporation governed by the internal affairs doctrine.&nbsp;Any
person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 9. <U>Amendment of <FONT STYLE="white-space:nowrap">By-laws</FONT></U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment by Directors</U>. Except as provided otherwise by law, these <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended or
repealed by the Board of Directors by the affirmative vote of a majority of the directors then in office. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Amendment by
Stockholders</U>. These <FONT STYLE="white-space:nowrap">By-laws</FONT> may be amended or repealed at any Annual Meeting, or special meeting of stockholders called for such purpose in accordance with these
<FONT STYLE="white-space:nowrap">By-Laws,</FONT> by the affirmative vote of at least seventy-five percent (75%) of the outstanding shares entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the
Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of the outstanding shares entitled to vote on such
amendment or repeal, voting together as a single class. Notwithstanding the foregoing, stockholder approval shall not be required unless mandated by the Certificate, these <FONT STYLE="white-space:nowrap">By-laws,</FONT> or other applicable law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 10. <U>Notices</U>. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed
to the stockholder at such stockholder&#146;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic
transmission in the manner provided in Section&nbsp;232 of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECTION 11. <U>Waivers</U>. A written waiver of any notice, signed by a stockholder or
director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business to
be transacted at, nor the purpose of, any meeting need be specified in such a waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adopted September 10, 2019 and effective as of ___________, 2019.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF] OFFICER INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (&#147;<U>Agreement</U>&#148;) is made as of ________________ by and between Cabaletta Bio, Inc., a Delaware
corporation (the &#147;<U>Company</U>&#148;), and ____________ (&#147;<U>Indemnitee</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the
indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Amended and Restated
Certificate of Incorporation (as amended and in effect from time to time, the &#147;<U>Charter</U>&#148;) and the Amended and Restated Bylaws (as amended and in effect from time to time, the &#147;<U>Bylaws</U>&#148;) of the Company require
indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and
thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) has determined that the increased difficulty in attracting and
retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#146;s stockholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the
Charter or the Bylaws, so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions
adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree
as follows: </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Services to the Company</U>. Indemnitee agrees to [continue to] serve as
[a director and] an officer of the Company. Indemnitee may at any time and for any reason resign from [any] such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no
obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
&#147;<U>Change in Control</U>&#148; shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to
which the holders of the Company&#146;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or
successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any
other transaction in which the owners of the Company&#146;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon
completion of the transaction other than as a result of the acquisition of securities directly from the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Corporate
Status</U>&#148; describes the status of a person as a current or former [director or] officer of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was
serving at the request of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Enforcement Expenses</U>&#148; shall include all reasonable attorneys&#146; fees,
court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal
from such action. Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
&#147;<U>Enterprise</U>&#148; shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the
Company as a director, manager, partner, officer, employee, agent or trustee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Expenses</U>&#148; shall include all reasonable
attorneys&#146; fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or
otherwise participating in, a Proceeding or an appeal resulting from a Proceeding. Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or
benefits owed to Indemnitee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Independent Counsel</U>&#148; means a law firm, or a partner (or, if
applicable, member or shareholder) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company, any subsidiary of
the Company, any Enterprise or Indemnitee in any matter material to any such party; or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#147;Independent
Counsel&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#146;s
rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or
relating to this Agreement or its engagement pursuant hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The term &#147;<U>Proceeding</U>&#148; shall include any threatened,
pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise
and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was [a director
or] an officer of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action taken by Indemnitee or of any action taken on his or
her part while acting as [a director or] an officer of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such
capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; <U>provided</U>, <U>however</U>, that the term &#147;Proceeding&#148; shall not
include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#146;s rights under this Agreement as provided for in Section&nbsp;12(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Indemnity in Third-Party Proceedings</U>. The Company shall indemnify Indemnitee to the extent set forth in this
Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;3, Indemnitee
shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or
matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or
her conduct was unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Indemnity in Proceedings by or in the Right of the Company</U>. The
Company shall indemnify Indemnitee to the extent set forth in this Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.
Pursuant to this Section&nbsp;4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;4 in respect of any claim, issue or matter as to
which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#147;<U>Delaware Court</U>&#148;) shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</U>. Notwithstanding any other provisions of
this Agreement and except as provided in Section&nbsp;7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall
indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or
matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this
Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Reimbursement for Expenses of a Witness or in Response to a Subpoena</U>. Notwithstanding any other provision of this
Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i)&nbsp;is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii)&nbsp;receives a subpoena with respect to
any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Exclusions</U>. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under
this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to
the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
to indemnify for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or similar
provisions of state statutory law or common law, or from the purchase or sale by Indemnitee of such securities in violation of Section&nbsp;306 of the Sarbanes-Oxley Act of 2002 (&#147;<U>SOX</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to indemnify for any reimbursement of, or payment to, the Company by Indemnitee of any
bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company pursuant to Section&nbsp;304 of SOX or any formal policy of the Company adopted by the Board (or a
committee thereof), or any other remuneration paid to Indemnitee if it shall be determined by a final judgment or other final adjudication that such remuneration was in violation of law;<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it
controls, any director or officer thereof or any third party, unless (i)&nbsp;the Board has consented to the initiation of such Proceeding or part thereof and (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to
the powers vested in the Company under applicable law; <U>provided</U>, <U>however</U>, that this Section&nbsp;7(d) shall not apply to (A)&nbsp;counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or
(B)&nbsp;any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company in the suit for which
indemnification or advancement is being sought as described in Section&nbsp;12; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) to provide any indemnification or advancement of
expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Advancement of Expenses</U>. Subject to Section&nbsp;9(b), the Company shall advance, to the extent not prohibited by law,
the Expenses incurred by Indemnitee in connection with any Proceeding, [and such advancement shall be made as incurred,] and such advancement shall be made within thirty (30)&nbsp;days after the receipt by the Company of a statement or statements
requesting such advances (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition
of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#146;s (i)&nbsp;ability to repay the expenses, (ii)&nbsp;ultimate entitlement to indemnification under the other provisions of this
Agreement, and (iii)&nbsp;entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses of covered loss under the provisions of any applicable insurance policy (including , without
limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an
undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that
Indemnitee is not entitled to be indemnified by the Company. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section&nbsp;8 shall limit
Indemnitee&#146;s right to advancement pursuant to Section&nbsp;12(e) of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Procedure for Notification and Defense of Claim</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis for
the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect
to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to
Indemnitee of written notice of the Company&#146;s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this
Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; <U>provided</U> that (i)&nbsp;Indemnitee shall have the right to employ separate counsel in any such
Proceeding at Indemnitee&#146;s expense and (ii)&nbsp;if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee shall have reasonably concluded that there may be a conflict of interest
between the Company and Indemnitee in the conduct of such defense, or (C)&nbsp;the Company shall not continue to retain such counsel to defend such Proceeding, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to
his or her separate counsel shall be Expenses hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that the Company does not assume the defense in a Proceeding
pursuant to paragraph (b)&nbsp;above, then the Company will be entitled to participate in the Proceeding at its own expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The
Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). The Company shall
not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or delayed), enter into any settlement which (i)&nbsp;includes an admission of fault of Indemnitee, any
<FONT STYLE="white-space:nowrap">non-monetary</FONT> remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and actually indemnified hereunder or (ii)&nbsp;with respect to any Proceeding with respect to which
Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee from all liability in respect of such Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Procedure Upon Application for Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon written request by Indemnitee for indemnification pursuant to Section&nbsp;9(a), a determination, if such determination is required by
applicable law, with respect to Indemnitee&#146;s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: [(x) if a Change in Control shall have occurred and indemnification is being requested by
Indemnitee hereunder in his or her capacity as a director of the Company, by Independent Counsel in a written opinion to the Board; or (y)&nbsp;in any other case,] (i) by a majority </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vote of the disinterested directors, even though less than a quorum; (ii)&nbsp;by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though
less than a quorum; or (iii)&nbsp;if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board. For purposes hereof, disinterested directors are those members of the
Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought. In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#146;s written opinion shall be delivered to
Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30)&nbsp;days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company,
as applicable, in making such determination with respect to Indemnitee&#146;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not
privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs
or expenses (including reasonable attorneys&#146; fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination
as to Indemnitee&#146;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;10(a), the Independent
Counsel shall be selected by the Board[; <U>provided</U> that, if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, the Independent Counsel
shall be selected by Indemnitee]. Indemnitee [or the Company, as the case may be,] may, within ten (10)&nbsp;days after written notice of such selection, deliver to the Company [or Indemnitee, as the case may be,] a written objection to such
selection; <U>provided</U>, <U>however</U>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#147;Independent Counsel&#148; as defined in Section&nbsp;2 of this
Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and
substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20)&nbsp;days after
the later of (i)&nbsp;submission by Indemnitee of a written request for indemnification pursuant to Section&nbsp;9(a), and (ii)&nbsp;the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been
selected without objection, either Indemnitee or the Company may petition the Delaware Court for resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment
as Independent Counsel of a person selected by the court or by such other person as the court shall designate. The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under
Section&nbsp;10(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section&nbsp;12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity
(subject to the applicable standards of professional conduct then prevailing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Presumptions and Effect of Certain Proceedings</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be
presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;9(a) of this Agreement, and the Company shall have the burden of proof to overcome
that presumption in connection with the making of any determination contrary to that presumption. Neither (i)&nbsp;the failure of the Company or of Independent Counsel to have made a determination prior to the commencement of any action pursuant to
this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii)&nbsp;an actual determination by the Company or by Independent Counsel that Indemnitee has not met such
applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
guilty, <U>nolo</U> <U>contendere</U> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act
in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was
unlawful. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of
the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Remedies of Indemnitee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;12(f), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;10 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;8 of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made
pursuant to Section&nbsp;10(a) of this Agreement within sixty (60)&nbsp;days after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv)&nbsp;payment of
indemnification or reimbursement of expenses is not made pursuant to Section&nbsp;5 or 6 or the last sentence of Section&nbsp;10(a) of this Agreement within thirty (30)&nbsp;days after receipt by the Company of a written request therefor (including
any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3 or 4 of this Agreement is not
made within thirty (30)&nbsp;days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such indemnification or
advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the
right to commence such proceeding pursuant to this Section&nbsp;12(a); <U>provided</U>, <U>however</U>, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under
Section&nbsp;5 of this Agreement. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication or award in arbitration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee is not entitled to
indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse
determination. In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee is entitled to indemnification,
the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to
make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 that the
procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by
Indemnitee, shall (within thirty (30)&nbsp;days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with
any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company in the suit for which indemnification or
advancement is being sought. Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work
performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement
shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U><FONT STYLE="white-space:nowrap">Non-exclusivity;</FONT> Survival of
Rights; Insurance; Subrogation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The rights of indemnification and to receive advancement as provided by this Agreement shall not
be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or
repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration
or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Charter, Bylaws and this Agreement, it is the intent of the
parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be
cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent
assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent that the Company maintains an insurance policy or policies
providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the
maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has
director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of
recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company&#146;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the
Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Duration of Agreement</U>. This Agreement shall continue until and terminate upon the later of: (a)&nbsp;ten (10) years
after the date that Indemnitee shall have ceased to serve as [both a director and] an officer of the Company or (b)&nbsp;one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is
granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section&nbsp;12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns
and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the
Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had
taken place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Severability</U>. If any provision or provisions of this Agreement shall be held to be invalid, illegal
or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b)&nbsp;such provision or
provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement (including,
without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent
manifested thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>Enforcement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to serve or continue to serve as [a director and] an officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as [a director and] an officer of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; <U>provided</U>, <U>however</U>, that this Agreement is a supplement to and in furtherance of the Charter, the
Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Modification and Waiver</U>. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall
be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing
waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement,
modification or amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. <U>Notice by Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon
being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of
Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Notices</U>. All notices, requests, demands and other communications
under this Agreement shall be in writing and shall be deemed to have been duly given if (i)&nbsp;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii)&nbsp;mailed by certified or
registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii)&nbsp;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been
directed or (iv)&nbsp;sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If
to Indemnitee, at such address as Indemnitee shall provide to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2929 Arch Street, Suite 600 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: President </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to any
other address as may have been furnished to Indemnitee by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Contribution</U>. To the fullest extent
permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee,
whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order
to reflect (i)&nbsp;the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers,
employees and agents) and Indemnitee in connection with such event(s) and/or transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21. <U>Internal Revenue Code
Section</U><U></U><U>&nbsp;409A</U>. The Company intends for this Agreement to comply with the Indemnification exception under <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(10)</FONT> of the regulations promulgated under the Internal
Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee
with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity
as a service provider of the Company. The parties intend that this Agreement be interpreted and construed with such intent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Applicable Law and Consent to Jurisdiction</U>. This Agreement and the
legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee
pursuant to Section&nbsp;12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the
Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding
arising out of or in connection with this Agreement, (iii)&nbsp;consent to service of process at the address set forth in Section&nbsp;19 of this Agreement with the same legal force and validity as if served upon such party personally within the
State of Delaware, (iv)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the
Delaware Court has been brought in an improper or inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23. <U>Headings</U>. The headings of the paragraphs of
this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Identical Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CABALETTA BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Name of Indemnitee]</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CABALETTA BIO, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indemnification Agreement (&#147;<U>Agreement</U>&#148;) is made as of ________________ by and between Cabaletta Bio, Inc., a Delaware
corporation (the &#147;<U>Company</U>&#148;), and ________________ (&#147;<U>Indemnitee</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RECITALS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in order to induce Indemnitee to [provide or continue to provide] services to the Company, the Company wishes to provide for the
indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Amended and Restated
Certificate of Incorporation (as amended and in effect from time to time, the &#147;<U>Charter</U>&#148;) and the Amended and Restated Bylaws (as amended and in effect from time to time, the &#147;<U>Bylaws</U>&#148;) of the Company require
indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#147;<U>DGCL</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and
thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) has determined that the increased difficulty in attracting and
retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#146;s stockholders; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the
Charter or the Bylaws, so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions
adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[WHEREAS, Indemnitee has certain rights to indemnification and/or insurance provided by [ ] (&#147;[ ]&#148;) which Indemnitee and [ ] intend
to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided in this Agreement, with the Company&#146;s acknowledgment and agreement to the foregoing being a material condition to Indemnitee&#146;s willingness to
serve or continue to serve on the Board.] </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the
Company and Indemnitee do hereby covenant and agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Services to the Company</U>. Indemnitee agrees to
[continue to] serve as a director of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no
obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
&#147;<U>Change in Control</U>&#148; shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation pursuant to
which the holders of the Company&#146;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or
successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv)&nbsp;any
other transaction in which the owners of the Company&#146;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon
completion of the transaction other than as a result of the acquisition of securities directly from the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Corporate
Status</U>&#148; describes the status of a person as a current or former director of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the
request of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Enforcement Expenses</U>&#148; shall include all reasonable attorneys&#146; fees, court costs,
transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal
from such action. Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
&#147;<U>Enterprise</U>&#148; shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the
Company as a director, manager, partner, officer, employee, agent or trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Expenses</U>&#148; shall include all reasonable attorneys&#146; fees, court
costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating,
being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding. Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against
Indemnitee or fees, salaries, wages or benefits owed to Indemnitee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Independent Counsel</U>&#148; means a law firm, or a
partner (or, if applicable, member or shareholder) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5)&nbsp;years has been, retained to represent: (i)&nbsp;the Company,
any subsidiary of the Company, any Enterprise or Indemnitee in any matter material to any such party; or (ii)&nbsp;any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term
&#147;Independent Counsel&#148; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine
Indemnitee&#146;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages
arising out of or relating to this Agreement or its engagement pursuant hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The term &#147;<U>Proceeding</U>&#148; shall include
any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the
Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee
is or was a director of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action taken by Indemnitee or of any action taken on
his or her part while acting as a director of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such capacity at
the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; <U>provided</U>, <U>however</U>, that the term &#147;Proceeding&#148; shall not include any
action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#146;s rights under this Agreement as provided for in Section&nbsp;12(a) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Indemnity in Third-Party Proceedings</U>. The Company shall indemnify Indemnitee to the extent set forth in this
Section&nbsp;3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section&nbsp;3, Indemnitee
shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or
matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or
her conduct was unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Indemnity in Proceedings by or in the Right of the Company</U>. The
Company shall indemnify Indemnitee to the extent set forth in this Section&nbsp;4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.
Pursuant to this Section&nbsp;4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section&nbsp;4 in respect of any claim, issue or matter as to
which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#147;<U>Delaware Court</U>&#148;) shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</U>. Notwithstanding any other provisions of
this Agreement and except as provided in Section&nbsp;7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall
indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or
matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this
Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Reimbursement for Expenses of a Witness or in Response to a Subpoena</U>. Notwithstanding any other provision of this
Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i)&nbsp;is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii)&nbsp;receives a subpoena with respect to
any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Exclusions</U>. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under
this Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to
the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; <U>provided</U> that the foregoing shall not affect the rights of Indemnitee or the Secondary Indemnitors as set
forth in Section&nbsp;13(c); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) to indemnify for an accounting of profits made from the purchase and sale (or sale and
purchase) by Indemnitee of securities of the Company within the meaning of Section&nbsp;16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law, or from the purchase or sale by Indemnitee
of such securities in violation of Section&nbsp;306 of the Sarbanes Oxley Act of 2002 (&#147;<U>SOX</U>&#148;); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to indemnify with
respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i)&nbsp;the Board has consented to the initiation of such
Proceeding or part thereof and (ii)&nbsp;the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; <U>provided</U>, <U>however</U>, that this Section&nbsp;7(c) shall not
apply to (A)&nbsp;counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or (B)&nbsp;any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any
directors&#146; and officers&#146; liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought as described in Section&nbsp;12; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to provide any indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment
would otherwise be required pursuant to this Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Advancement of Expenses</U>. Subject to Section&nbsp;9(b),
the Company shall advance, to the extent not prohibited by law, the Expenses incurred by Indemnitee in connection with any Proceeding[, and such advancement shall be made as incurred,] and such advancement shall be made within [thirty (30)] days
after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law)
from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#146;s (i)&nbsp;ability to repay the expenses, (ii)&nbsp;ultimate
entitlement to indemnification under the other provisions of this Agreement, and (iii)&nbsp;entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses of covered loss under the
provisions of any applicable insurance policy (including , without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and
delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of
competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding,
including any appeal therein. Nothing in this Section&nbsp;8 shall limit Indemnitee&#146;s right to advancement pursuant to Section&nbsp;12(e) of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Procedure for Notification and Defense of Claim</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis for
the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect
to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to
Indemnitee of written notice of the Company&#146;s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this
Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; <U>provided</U> that (i)&nbsp;Indemnitee shall have the right to employ separate counsel in any such
Proceeding at Indemnitee&#146;s expense and (ii)&nbsp;if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B)&nbsp;Indemnitee shall have reasonably concluded that there may be a conflict of interest
between the Company and Indemnitee in the conduct of such defense, or (C)&nbsp;the Company shall not continue to retain such counsel to defend such Proceeding, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to
his or her separate counsel shall be Expenses hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the event that the Company does not assume the defense in a Proceeding
pursuant to paragraph (b)&nbsp;above, then the Company will be entitled to participate in the Proceeding at its own expense. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The
Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). The Company shall
not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or delayed), enter into any settlement which (i)&nbsp;includes an admission of fault of Indemnitee, any
<FONT STYLE="white-space:nowrap">non-monetary</FONT> remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and actually indemnified hereunder or (ii)&nbsp;with respect to any Proceeding with respect to which
Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee from all liability in respect of such Proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Procedure Upon Application for Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon written request by Indemnitee for indemnification pursuant to Section&nbsp;9(a), a determination, if such determination is required by
applicable law, with respect to Indemnitee&#146;s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: (x)&nbsp;if a Change in Control shall have occurred, by Independent Counsel in a written
opinion to the Board; or (y)&nbsp;if a Change in Control shall not have occurred: (i)&nbsp;by a majority vote of the disinterested directors, even though less than a quorum; (ii)&nbsp;by a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum; or (iii)&nbsp;if there are no disinterested directors or if the
disinterested directors so direct, by Independent Counsel in a written opinion to the Board. For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which
indemnification is sought. In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#146;s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to
indemnification, payment to Indemnitee shall be made within [thirty (30)] days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, in making such determination with respect to
Indemnitee&#146;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is
reasonably available to Indemnitee and reasonably necessary to such determination. Any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs or expenses (including reasonable attorneys&#146; fees and
disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#146;s entitlement to indemnification) and
the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the determination of entitlement to
indemnification is to be made by Independent Counsel pursuant to Section&nbsp;10(a), the Independent Counsel shall be selected by the Board if a Change in Control shall not have occurred or, if a Change in Control shall have occurred, by Indemnitee.
Indemnitee or the Company, as the case may be, may, within [ten (10)] days after written notice of such selection, deliver to the Company or Indemnitee, as the case may be, a written objection to such selection; <U>provided</U>, <U>however</U>, that
such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#147;Independent Counsel&#148; as defined in Section&nbsp;2 of this Agreement, and the objection shall set forth with
particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not
serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within [twenty (20)] days after the later of (i)&nbsp;submission by Indemnitee of a written
request for indemnification pursuant to Section&nbsp;9(a), and (ii)&nbsp;the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may
petition the Delaware Court for resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by
such other person as the court shall designate. The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section&nbsp;10(a) hereof. Upon the due commencement of any judicial
proceeding or arbitration pursuant to Section&nbsp;12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then
prevailing). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Presumptions and Effect of Certain Proceedings</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be
presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section&nbsp;9(a) of this Agreement, and the Company shall have the burden of proof to overcome
that presumption in connection with the making of any determination contrary to that presumption. Neither (i)&nbsp;the failure of the Company or of Independent Counsel to have made a determination prior to the commencement of any action pursuant to
this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii)&nbsp;an actual determination by the Company or by Independent Counsel that Indemnitee has not met such
applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of
guilty, <U>nolo</U> <U>contendere</U> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act
in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was
unlawful. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of
the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Remedies of Indemnitee</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;12(f), in the event that (i)&nbsp;a determination is made pursuant to Section&nbsp;10 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii)&nbsp;advancement of Expenses is not timely made pursuant to Section&nbsp;8 of this Agreement, (iii)&nbsp;no determination of entitlement to indemnification shall have been made
pursuant to Section&nbsp;10(a) of this Agreement within [sixty (60)&nbsp;days] after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv)&nbsp;payment of
indemnification or reimbursement of expenses is not made pursuant to Section&nbsp;5 or 6 or the last sentence of Section&nbsp;10(a) of this Agreement within [thirty (30)&nbsp;days] after receipt by the Company of a written request therefor
(including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v)&nbsp;payment of indemnification pursuant to Section&nbsp;3 or 4 of this
Agreement is not made within [thirty (30)&nbsp;days] after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such
indemnification or advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the
right to commence such proceeding pursuant to this Section&nbsp;12(a); <U>provided</U>, <U>however</U>, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under
Section&nbsp;5 of this Agreement. The Company shall not oppose Indemnitee&#146;s right to seek any such adjudication or award in arbitration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee is not entitled to
indemnification, any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse
determination. In any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If a determination shall have been made pursuant to Section&nbsp;10(a) of this Agreement that Indemnitee is entitled to indemnification,
the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12, absent (i)&nbsp;a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to
make Indemnitee&#146;s statement not materially misleading, in connection with the request for indemnification, or (ii)&nbsp;a prohibition of such indemnification under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;12 that the
procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by
Indemnitee, shall (within [thirty (30)&nbsp;days] after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with
any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#146; and officers&#146; liability insurance policies maintained by the Company in the suit for which indemnification or
advancement is being sought. Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work
performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement
shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U><FONT STYLE="white-space:nowrap">Non-exclusivity;</FONT> Survival of
Rights; Insurance; Primacy of Indemnification; Subrogation</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The rights of indemnification and to receive advancement as provided
by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No
amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to
such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Charter, Bylaws and this Agreement,
it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right
and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not
prevent the concurrent assertion or employment of any other right or remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent that the Company maintains an insurance
policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or
their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms
hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) [The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided
by [ ] and certain of its affiliates (collectively, the &#147;<U>Secondary Indemnitors</U>&#148;). The Company hereby agrees (i)&nbsp;that it is the indemnitor of first resort (<I>i.e.</I>, its obligations to Indemnitee are primary and any
obligation of the Secondary Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by
Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Charter and/or Bylaws (or any other
agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Secondary Indemnitors, and (iii)&nbsp;that it irrevocably waives, relinquishes and releases the Secondary Indemnitors from any and all claims
against the Secondary Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Secondary Indemnitors on behalf of Indemnitee with respect to any
claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Secondary Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights
of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Secondary Indemnitors are express third party beneficiaries of the terms of this Section&nbsp;13(c).] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) [Except as provided in paragraph (c)&nbsp;above,] in the event of any payment under this
Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee [(other than against the Secondary Indemnitors)], who shall execute all papers required and take all action necessary to secure
such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)
[Except as provided in paragraph (c)&nbsp;above,] the Company&#146;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee,
agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Duration of Agreement</U>. This Agreement shall continue until and terminate upon the later of: (a)&nbsp;ten (10) years
after the date that Indemnitee shall have ceased to serve as a director of the Company or (b)&nbsp;one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of
indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section&nbsp;12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to
the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial
part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be
required to perform if no such succession had taken place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Severability</U>. If any provision or provisions of this
Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section
of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest
extent permitted by law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent
possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or
unenforceable) shall be construed so as to give effect to the intent manifested thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>Enforcement</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order
to induce Indemnitee to serve or continue to serve as a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all
prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; <U>provided</U>, <U>however</U>, that this Agreement is a supplement to and in furtherance of the Charter, the
Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Modification and Waiver</U>. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall
be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing
waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement,
modification or amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18. <U>Notice by Indemnitee</U>. Indemnitee agrees promptly to notify the Company in writing upon
being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of
Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>Notices</U>. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be
deemed to have been duly given if (i)&nbsp;delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii)&nbsp;mailed by certified or registered mail with postage prepaid, on the third
business day after the date on which it is so mailed, (iii)&nbsp;mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv)&nbsp;sent by facsimile transmission,
with receipt of oral confirmation that such transmission has been received: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If to Indemnitee, at such address as Indemnitee shall
provide to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Cabaletta Bio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">2929 Arch
Street, Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19104 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attention: President </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to any other address as
may have been furnished to Indemnitee by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>Contribution</U>. To the fullest extent permissible under applicable
law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines,
penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i)&nbsp;the
relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii)&nbsp;the relative fault of the Company (and its directors, officers, employees and agents) and
Indemnitee in connection with such event(s) and/or transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21. <U>Internal Revenue Code
Section</U><U></U><U>&nbsp;409A</U>. The Company intends for this Agreement to comply with the Indemnification exception under <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(b)(10)</FONT> of the regulations promulgated under the Internal
Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee
with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity
as a service provider of the Company. The parties intend that this Agreement be interpreted and construed with such intent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Applicable Law and Consent to Jurisdiction</U>. This Agreement and the legal relations among the parties shall be governed
by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;12(a) of this Agreement, the
Company and Indemnitee hereby irrevocably and unconditionally (i)&nbsp;agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court
in the United States of America or any court in any other country, (ii)&nbsp;consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement,
(iii)&nbsp;consent to service of process at the address set forth in Section&nbsp;19 of this Agreement with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv)&nbsp;waive any objection to the
laying of venue of any such action or proceeding in the Delaware Court, and (v)&nbsp;waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient
forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;23. <U>Headings</U>. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not
be deemed to constitute part of this Agreement or to affect the construction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;24. <U>Identical Counterparts</U>.
This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against
whom enforceability is sought needs to be produced to evidence the existence of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left
Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CABALETTA BIO, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[Name of Indemnitee]</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSULTING AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Consulting
Agreement (the &#147;Agreement&#148;) is made effective as of May&nbsp;7, 2018 (the &#147;Effective Date&#148;), by and between Tycho Therapeutics, Inc., a Delaware corporation, with its principal place of business being [****] (the
&#147;Company&#148;) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being [****] (&#147;Danforth&#148;). The Company and Danforth are herein sometimes referred to individually as a
&#147;Party&#148; and collectively as the &#147;Parties.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company possesses
<FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology related to the discovery and development of therapeutics the utilize chimeric autoantibody/alloantibody receptor <FONT STYLE="white-space:nowrap">T-cells</FONT> <FONT
STYLE="white-space:nowrap">(CAAR-Ts);</FONT> and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Danforth has expertise in financial and corporate operations and strategy; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Danforth desires to serve as an independent consultant for the purpose of providing the Company with certain strategic and
financial advice and support services, as more fully described in <U>Exhibit</U> <U>A</U> attached hereto, (the &#147;Services&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company wishes to engage Danforth on the terms and conditions set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which are hereby acknowledged,
the Parties agree and covenant as follows. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Services of Consultant</U>. Danforth will assist the Company with matters relating to the Services. The
Services are more fully described in <U>Exhibit A</U> attached hereto. Danforth and the Company will review the Services on a monthly basis to prioritize and implement the tasks listed on <U>Exhibit</U> <U>A</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compensation for Services</U>. In full consideration of Danforth&#146;s full, prompt and faithful
performance of the Services, the Company shall compensate Danforth a consulting fee more fully described in <U>Exhibit</U> <U>A</U> (the &#147;Consulting Fee&#148;). Danforth shall, from time to time, but not more frequently than once per calendar
month, invoice the Company for Services rendered, and such invoice will be paid upon thirty (30)&nbsp;days of receipt. Each month the Parties shall evaluate jointly the current fee structure and scope of Services. Danforth reserves the right to an
annual increase in consultant rates of up to 4%, effective January&nbsp;1 of each year. Upon termination of this Agreement pursuant to Section&nbsp;3, no compensation or benefits of any kind as described in this Section&nbsp;2 shall be payable or
issuable to Danforth after the effective date of such termination. In addition, the Company will reimburse Danforth for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> business expenses,
including but not limited to travel and parking, incurred by Danforth in performing the Services hereunder, upon submission by Danforth of supporting documentation reasonably acceptable to the Company. Any such accrued expenses in any given three
(3) month period that exceed one thousand dollars ($1,000) shall be submitted to the Company for its prior written approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All Danforth invoices and billing matters should be addressed to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">Company Accounts Payable Contact:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Steven Nichtberger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All Company payments and billing inquiries should be addressed to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">Danforth Accounting:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Betsy Sherr</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term and Termination</U>. The term of this Agreement will commence on the Effective Date and will continue
through the anniversary of such date in the next calendar year (the &#147;Term&#148;). This Agreement may be extended for an additional period by mutual written agreement. This Agreement may be terminated by either Party with or without cause upon
thirty (30)&nbsp;days prior written notice to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Time Commitment</U>. Danforth will devote such time to perform the Services under this Agreement as may
reasonably be required. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Place of Performance</U>. Danforth will perform the Services at such locations upon which the Company and
Danforth may mutually agree. Danforth will not, without the prior written consent of the Company, perform any of the Services at any facility or in any manner that might give anyone other than the Company any rights to or allow for disclosure of any
Confidential Information (as defined below). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compliance with Policies and Guidelines</U>. Danforth will perform the Services in accordance with all rules
or policies adopted by the Company that the Company discloses in writing to Danforth. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Confidential Information</U>. Danforth acknowledges and agrees that during the course of performing the
Services, the Company may furnish, disclose or make available to Danforth information, including, but not limited to, material, compilations, data, formulae, models, patent disclosures, procedures, processes, business plans, projections, protocols,
results of experimentation and testing, specifications, strategies and techniques, and all tangible and intangible embodiments thereof of any kind whatsoever (including, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
but not limited to, any apparatus, biological or chemical materials, animals, cells, compositions, documents, drawings, machinery, patent applications, records and reports), which is owned or
controlled by the Company and is marked or designated as confidential at the time of disclosure or is of a type that is customarily considered to be confidential information (collectively the &#147;Confidential Information&#148;). Danforth
acknowledges that the Confidential Information or any part thereof is the exclusive property of the Company and shall not be disclosed to any third party without first obtaining the written consent of the Company. Danforth further agrees to ensure
that the Confidential Information, and part thereof, shall not be disclosed or issued to its affiliates, agents or employees, except on like terms of confidentiality memorialized in a written agreement with such affiliate, agent or employee as
applicable. The restrictions of this Section&nbsp;7 shall not apply to information that is or becomes generally known in the trade other than by breach of the Agreement by the Consultant. The above provisions of confidentiality shall apply for a
period of five (5)&nbsp;years following the Term. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Intellectual Property</U>. Danforth agrees that all ideas, inventions, discoveries, creations, manuscripts,
properties, innovations, improvements, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventions, designs, developments, apparatus, techniques, methods, and formulae that Danforth conceives, makes, develops or improves as a result of performing
the Services, whether or not reduced to practice and whether or not patentable, alone or in conjunction with any other party and whether or not at the request or upon the suggestion of the Company (all of the foregoing being hereinafter collectively
referred to as the &#147;Inventions&#148;), shall be the sole and exclusive property of the Company. Danforth hereby agrees in consideration of the Company&#146;s agreement to engage Danforth and pay compensation for the Services rendered to the
Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged that Danforth shall not, without the prior written consent of the Company, directly or indirectly, consult for, or become an employee
of, any company which conducts business in the Field of Interest anywhere in the world. As used herein, the term &#147;Field of Interest&#148; shall mean the research, development, manufacture and/or sale of the products resulting from or that would
directly compete with the commercialization of the Company&#146;s technology. The limitations on competition contained in this Section&nbsp;8 shall continue during the time that Danforth performs any Services for the Company, and for a period of
three (3)&nbsp;months following the termination of any such Services that Danforth performs for the Company. If any part of this section should be determined by a court of competent jurisdiction to be unreasonable in duration, geographic area, or
scope, then this Section&nbsp;8 is intended to and shall extend only for such period of time, in such area and with respect to such activity as is determined to be reasonable. Except as expressly provided herein, nothing in this Agreement shall
preclude Danforth from consulting for or being employed by any other person or entity. Danforth acknowledges that and agrees that the Company may require, as a condition to entering into this Agreement, that each representative of Danforth who will
be providing services to the Company under this Agreement execute an agreement with the Company governing invention assignment and confidentiality. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Non Solicitation</U>. All personnel representing Danforth are employees or contracted agents of Danforth. As
such, they are obligated to provide the Services to the Company and are obligated to Danforth under confidentiality, <FONT STYLE="white-space:nowrap">non-compete,</FONT> and <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements.
Accordingly, they are not retainable as employees or contractors by the Company and the Company hereby agrees not to solicit, hire or retain their services for so long as they are employees or contracted agents of Danforth and for two (2)&nbsp;years
thereafter. Should the Company violate this restriction, it agrees to pay Danforth liquidated damages equal to thirty percent (30%) of the employee&#146;s starting annual base salary and target annual bonus for each Danforth contracted agent hired
by the Company in violation of this Agreement, plus Danforth&#146;s reasonable attorneys&#146; fees and costs incurred in enforcing this agreement should the Company fail or refuse to pay the liquidated damages amount in full within thirty
(30)&nbsp;days following its violation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Placement Services</U>. In the event that Danforth refers a potential employee to the Company and that
individual is hired by the Company as a full-time employee as a result of Danforth&#146;s efforts within one (1)&nbsp;year of the date such applicant is submitted to the Company, and remains employed for at least sixty (60)&nbsp;days, Danforth shall
receive a payment equal to fifteen percent (15%) of the employee&#146;s starting annual base salary and target annual bonus, such payment due within thirty (30)&nbsp;days of the employee&#146;s start date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Implied Warranty</U>. Except for any express warranties stated herein, the Services are provided on an
&#147;as is&#148; basis, and the Company disclaims any and all other warranties, conditions, or representations (express, implied, oral or written), relating to the Services or any part thereof. Further, in performing the Services Danforth is not
engaged to disclose illegal acts, including fraud or defalcations, which may have taken place. The foregoing notwithstanding, Danforth will promptly notify the Company if Danforth becomes aware of any such illegal acts during the performance of the
Services. Because the Services do not constitute an examination in accordance with standards established by the American Institute of Certified Public Accountants (the &#147;AICPA&#148;), Danforth is precluded from expressing an opinion as to
whether financial statements provided by the Company are in conformity with generally accepted accounting principles or any other standards or guidelines promulgated by the AICPA, or whether the underlying financial and other data provide a
reasonable basis for the statements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification</U>. Each Party hereto agrees to indemnify and hold the other Party hereto, its directors,
officers, agents and employees harmless against any claim related to performance under this Agreement and based upon circumstances alleged to be inconsistent with such representations and/or warranties contained in this Agreement. Further, the
Company shall indemnify and hold harmless Danforth and any of its employees and subcontractors against any claims, losses, damages or liabilities (or actions in respect thereof) that arise out of or are based on the Services performed hereunder,
except for any such claims, losses, damages or liabilities arising out of the gross negligence or willful misconduct of Danforth or any of its representatives. The Company will endeavor to add Consultant and any applicable representative to its
insurance policies as additional insureds. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Independent Contractor</U>. Danforth is not, nor shall Danforth be deemed to be at any time during the term
of this Agreement, an employee of the Company, and therefore Danforth shall not be entitled to any benefits provided by the Company to its employees, if applicable. Danforth&#146;s status and relationship with the Company shall be that of an
independent contractor and consultant. Danforth shall not state or imply, directly or indirectly, that Danforth is empowered to bind the Company without the Company&#146;s prior written consent. Nothing herein shall create, expressly or by
implication, a partnership, joint venture or other association between the parties. Danforth will be solely responsible for payment of all charges and taxes arising from his or her relationship to the Company as a consultant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Records</U>. Upon termination of Danforth&#146;s relationship with the Company, Danforth shall deliver to
the Company any property or Confidential Information of the Company relating to the Services which may be in its possession including products, project plans, materials, memoranda, notes, records, reports, laboratory notebooks, or other documents or
photocopies and any such information stored using electronic medium. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. Any notice under this Agreement shall be in writing (except in the case of verbal
communications, emails and teleconferences updating either Party as to the status of work hereunder) and shall be deemed delivered upon personal delivery, one day after being sent via a reputable nationwide overnight courier service or two days
after deposit in the mail or on the next business day following transmittal via facsimile. Notices under this Agreement shall be sent to the following representatives of the Parties: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">If to the Company:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Steven Nichtberger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Phone:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">If to Danforth:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gregg Beloff</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman">Phone:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[****]</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignment and Successors</U>. This Agreement may not be assigned by a Party without the consent of the
other which consent shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all or substantially
all of its assets or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Force Majeure</U>. Neither Party shall be liable for failure of or delay in performing obligations set forth
in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of either Party. In the event of such force majeure, the Party affected
thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings</U>. The Section headings are intended for convenience of reference only and are not intended to be
a part of or to affect the meaning or interpretation of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Integration; Severability</U>. This Agreement is the sole agreement with respect to the subject matter
hereof and shall supersede all other agreements and understandings between the Parties with respect to the same. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, excluding choice of law principles. The Parties agree that any action or proceeding arising out of or related in any way to this Agreement shall be brought solely in a Federal or State court of competent jurisdiction
sitting in the Commonwealth of Massachusetts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in counterparts, each of which will be deemed an original,
but all of which together will constitute one agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are in agreement with the foregoing, please sign where indicated below,
whereupon this Agreement shall become effective as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DANFORTH ADVISORS, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">TYCHO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gregg Beloff</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven Nichtberger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name: Gregg Beloff</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name: Steven Nichtberger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Date: 5/7/18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Date: 5/7/18</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>EXHIBIT A </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Description of Services and Schedule of Fees </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Danforth will perform mutually agreed to finance and accounting functions which are necessary to support the management and operations of the Company, certain
of which are set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Senior Advisor Services: </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Participate in longer-term strategic planning process </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Participate in financing activities, including additional capital raises and/or debt and equity restructurings
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oversee the finance and accounting functions, including the Danforth engagement team </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Board, Audit, Compensation, and Corporate Governance committee meeting preparation, support and attendance
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Director Services: </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Start-up</FONT> Services </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Review budget and long-range plan </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Oversee establishment of insurance, banking, benefits and payroll </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Development of initial cap table </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investment policy </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">On-going</FONT> Services </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manage the accounting and finance function </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Participate in strategic business planning </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corporate and business development advisory work </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financial modeling, planning and analysis </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Capitalization table management </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">409(a) Valuation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manage and prepare for audit, as appropriate and necessary </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maintain and audit corporate records (minute book, stock records, and option agreements) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Board, Audit, Compensation, and Corporate Governance committee meeting preparation, support and attendance (as
requested by Company) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Controller Services </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Start-up</FONT> Services </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Create account/reporting structure in QB </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Set up GL/Chart of Accounts in QuickBooks </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prepare annual budget </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Input of budget in QuickBooks for variance analysis </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Insurance and banking <FONT STYLE="white-space:nowrap">set-up</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Payroll and benefits <FONT STYLE="white-space:nowrap">set-up</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish purchasing and signing authority matrix </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ongoing Maintenance </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maintain the accounting system and general ledger </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regular bookkeeping and accounting activities &#151; monthly close, monthly reporting, and general financial
administration </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish and perform procedures for setting up new vendors (contracts,
<FONT STYLE="white-space:nowrap">W-9s)</FONT> and paying monthly invoices; manage payables and cash disbursements </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reconcile cash accounts, track cash usage and prepare cash flow projections </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish/maintain internal controls </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manage insurance and banking </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Manage payroll and employee benefits </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Update and manage the Company&#146;s cap table </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Financing, audit, budget, payroll/workers comp set up or other special project(s), as required and requested
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Provide support for fundraising initiatives </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Assist with tax returns, as appropriate </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prepare monthly financial statements and reporting packages for management and the Board </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Prepare Board materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fees:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior&nbsp;Advisor:&nbsp;Daniel&nbsp;Geffken</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$325/hour</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Kathleen McGowan $275/hour</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Controller:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Debra Taylor $155/hour</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 TO CONSULTING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 to Consulting Agreement (&#147;Amendment&#148;) is made as of May&nbsp;7, 2019 (&#147;Effective Date&#148;), by and
between Cabaletta Bio, Inc. (formerly known as Tycho Therapeutics, Inc.), with a principal place of business being 2929 Arch Street, Suite 600, Philadelphia, PA 19104 (&#147;Company&#148;) and Danforth Advisors, LLC (&#147;Consultant&#148;), with a
principal place of business being [****] (&#147;Danforth&#148;). Capitalized terms used but not defined herein shall have the respective meanings set forth in the Consulting Agreement by and between Danforth Advisors and the Company dated as of
May&nbsp;7, 2018 (&#147;Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>Consultant is engaged by the company under the terms and conditions of the
Consulting Agreement and the parties hereto desire to revise the terms of the Consulting Agreement on the terms and conditions set forth more fully herein; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Company and Consultant mutually desire to amend the term and scope of the Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration of the premises and the mutual covenants and agreements herein contained and for the other good and
valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3. <U>Term and Termination</U> is hereby modified to extend the term of the Agreement until
May&nbsp;7, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified and shall
remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except as specifically provided for in this Amendment No.&nbsp;1, the terms of the
Agreement shall be unmodified and shall remain in full force and effect. For avoidance of doubt this Agreement remained in effect the entire time between May&nbsp;7, 2018 and the Effective Date of this Amendment No.&nbsp;1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This Amendment may be executed in one or more counterparts, each of which shall be considered an original instrument, but all of which shall be
considered one and the same Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Amendment has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above
written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******** </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>DANFORTH ADVISORS, LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>CABALETTA BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Gregg Beloff</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anup Marda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Gregg Beloff</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Anup Marda</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print Name</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Managing Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">5/27/19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">7/9/19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g686907g08a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907g08a06.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $, 0@# 1$
M A$! Q$!_\0 'P !  (" P$! 0$           @)!PH$!08# @L!_\0 01
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M@WW++4FW,FY$*RDFDDL)9ZO+>>]]/!;%I/A4> > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > > > > > > > > > > > > > > > > > > > > > > > > > > > >
M> > > C[U?,+EK_FJ\9MSQ%0,XO*+UG*S-51&3.DV@,_-V0M=4$.?[JD0Z;C
M19YC3*([<N(P5<ZHC/U4;]Y]Z@)6,K+PN]E(5!?+C(Z;A/2LI[(M0S.GE21>
ME3 VF;&Y>+<6=:1Z96M-%:WT!G8;.#_[CS=1$Y<]"IA+9$VDHRB3="0+SIYL
M-P&)NQ9QRURKKG&'S+"6>[?.SVQGP1)R'_-!7=I-J@!TOSW9URVS;-P7C1:=
M:UY8=!'6$?GM PF&V9-'6]M-[1VJ.10EW7,V%R\!+HU+R3<FVT5#:LDY/] ?
MA#BUG.V,=<]^WAGJL&61ORKU*2%5(62K:Q$TK>L_MNK0R2BD:_-%E>'(S:\G
MGA(G^$OG7(Z8-:E+MHEAKE9SHX*#?UE)@GAUNB'*\M96R3_5RX__ *1&5[\[
M,1$Q!W.S?%G3HN*L.:*>[1>%53E N-$.4;=/NHDPM?+9K;RKW=^VDK%V@.KY
M)MO,3(=+)Q<>%0U7;H">1YQE-\SCMGJL9[EX]>A*OY$[JZ&K^7</53SE949J
M8_T_TL^J.1SR2UJPM5$)'&E/6-8&J[&*$3L:0<NU"418H?C_ %EEMJ@LKG\>
M?I^7N(23YF^Y9V_$EX/Q*_IOW=\B(RL[EJP"-96!<7+W;PWGZ]KSYUYZWL^9
M$>?35.MK: 6U6O*IFR$L&;"3=G([%K"C J62YK%1>"DE$ C.F<X%"W*MF]E*
M+:3?>GC#>-D^J^"SWG:5U\A73U[1+C'GVI+YH\C>73ER=80>5=._N+GH;:LX
M)R@ '2\X'EG,-C.H8^B/3A@9*8D(/0@F8*P0%G!N1A'$@!NQ+IN#BO6>&DL;
M975^?>MGAX,G4UU;U5>W,=W8I_J^D;@L>A+FRSEUQ5]R/>:]JK4=O"%I>+!H
M\FRIA#&A#I(\4^R&BQ,?DY.OGD1>:$TMT9!LBCN(:2:V>Z[VL9SA[K;"^3ZG
MJ91WQ>^/@[+]]L5ZY&]$C^<U)V]_9YE@]!1-BAY'B,'QSD"]?OMF9 419D!T
MIB+LF]6BDI;%XVN]=*B-EU 44ZG+OC.//W_U6Q&X[W/V36/(/1-_/K6M*8RF
M!F>3PL587]\:\^XV!L<W'T? :YEKN.OIU)':5J9S$3QEHLB(U1UBKMP!,.]]
ML$V2"H**;2\I=&GT3?ACZEH/:_1-ET99W \5K]P%1%]"=<-:=L5$P/2=;/88
MK35LS;+4<^4_%L#>;'H>%WV*HI+JI--'*.$=]5ML>%4LJ7DL_P#[)?U*W>$.
M]>Q)?U1 J@[,G(>K999$9N(E(N=+2Y?EM,-!Y6"-]I")(<>]%@CD_K/H^#B8
MZV?NYD\ETN#G-XTWS+ *#O5N28#Q:2CC,>[&^5\X]5Y/IW'K?C0^5N7]>=9W
M!5\^.U<ZK"V8Q-;IXC1AQ 5M+F53U9<DSJ"3QJV&;=\X?M; DX-C KF BWJ#
M=?6%2AXZ;[.6C170<)E#"36<IXEX9:RL>75-OO7<7Z>&,> > > > > > > >
M > > > > > > > > > > Q7=]*UIT;4D_HVXHTA+ZSLV.O(O,(\NY>,?OACO
M.BFN[4@.<-"0PDP=HMB(HJ.=-B LFT:$&+A!TV25U!-IY6S1!!E\1?*S@#9H
M^P3_ $)=DKL^*U_"'-LW/?$XG5N0B+51-$;)K0164V<NFKN#)0VQ&S6;L' E
MOAX2D3?1W(W)M)1=!86YFL8PL>"77&-_A\/(S97G!E-U]*J5GV\FN6P)]1,I
MNB:1.:VE:9^='B4BOJ,,8?/G![<K_P !@;D -8LX]&XXPCL8CNZ&[H:&2=.W
MRSH1GJL+?'R_?>8B$?$SRF%L?6QVKNYU51TUZ*GT2A#VVY&\K2 '^K(=-(9>
MF\*A*WXA8EO,VL\/EOPKX?. YI1NJ%<L!R:HU<3SO\TDWWO&,?EC^^3MCWQ7
M<FR2!$*W)BIUM&27%=6<"NDT9H[1>YY[IT^2DL+'Z.\-,[:2Q$F5=[$9/C7+
MA^CE-'=OIC3&<AS2SG.^7+HNKZOY&;.J.-JOZY856WL"1VM#"U+3S>R:XE].
M6(8K*:QR6*1@W$%'S*3 ]?U)'50#(2K/?1!1'.V'.WUW_#]==A";6<=^SZ/O
M3[_-(P2Z^*3D_-8QZOPW[Y(K*8O<AOH83T''KJGR'3&;OE(3>+RVR2ETD"I*
M3GS<KBF^(K(&)W8E'2$>09#=@FB(T=]H)YG\L8PL87=CI_7._4_?\E-RAI44
M?JUII;PV01>XY/T0$Z"&7'.&/3+2^)NVV'36U][G0(ZR)W)I>&VT R1H]U<1
MHP%;L6#T JF.89;!S/Y8QA8PO+I_4XHSXI>:0L%-1H5+>D&=@2.W@U\'>CO]
M86Q7?1Q6UP$7=P47*'EEOR3O*J#>"OG<.Q%\A\0[8$KHGF/?>-FCUN',WX86
MV,+&/^]_>9A<\#\XJ\7DN"&L>D SGDQ#RL,*#&<I*JRT@UD,A<RZ3FWLQ)*$
M"[R3R>5OR<D.FW6ZR[XN4?N,ZIZK83T$<SSS9W\<+Z=##IKXM*;E]3V52EB7
MMV?:=?V>P@S(H+L[I^>S=6.+5U846LV+F(,N;V<XBAQI)H>%_-*CD\.5AB:X
M_P#%HFOG;5^^I/,T\[9W[DNJQW(]4'^-VFD7->NYY9O3-YK5;;+"Y85F_;VE
M=MZB96Q@TTKM1DGK*\.\?LP4C<]/)F0&GY;0F\PP=.<[;,M--G[ZY^I&7OYK
M#V73*?U1BF+_  W\E1/\AFRDG1Y*-1>O[9K.EX3).@)U)(=SA%KLBI2"S].A
M0QER[Q"R;Z%FRD6%&'BYTC'P[O9 *X9*(MUD7[ZD\S_/#>%U:WR_'??PSW&<
M8W\;?'<%D'-TNK2GXY5<OY8<:[5K+*U%AH?)28Y2 /JU* +#-BA21"P I^+D
M%DSB$C7=NGQ/1,M]XD__ #%E1',]]^O_ '\/@3K\('@'@'@'@'@'@'@'@'@'
M@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@'@*8?E?ZK[BYJ.4#CE&
MK65EQ<M(-IW9Z08583^5L(+4Y!L>LY.5.PU-VC%F%6%(F1%C":,=60OA^3>9
M4JN-290<41;"T4GG+]WO;]Z_KYF);AZ^^4*)=T<Z4_'Z<JTO5I:'P07:LGC;
M&^MZD$SV](['OT5>?&2'/1>;?;Q68U->K&OG\!),8R-%3B'_ .L>^K]T)U4?
M"4H\K;??MTSMG.V?<]\>6=SUG-'6GR)3GY);@I*TZDB OFEH\.1^-3O0=;PR
M([_N13-:SIS4[DO180F^EDF?V_1[*2DK4F3*L#*=?3!S0IN8)&7.X<0TN5-/
M+[UW]=N_Z?''?>9X5'@'@'@'@'@'@'@'@'@**?D9OGNGGN\8.6J3HFK]-;.M
M.AJVY2X9C]5"IQ/>D]7Q\5CI.0W#+S0S25UQ&H%&7I<^/F->&6<4C@(,/VF+
MYH7,(IK"\4GG.=DVWE+'ACWO;'Y$EOE2MSKRK:DIIGQA'K8)6+8/0<4B4XDE
M0T;'[]D<"J!*)3@_,)+K#IH_!0/1PL4$1D$+<S*5Q 0H_+Z-\R)@KOKG81'E
MR^;PVZK?;P_/HS'%&?*/S%5_&E"7!U9UX_D1*RC=I1/:Q9[S^9J68DYQ7TW,
M#Y=!9;3M6CIR+@$GK+58=#2S?4BNP-[B4Y"P(D$BWY^P.+SA+P?7N?>GWY+,
MZ2NVK>C:LB%UTK+F<\JZ?,79&(RX>S*CV9IDQ*/@SI=!F;8#"J&J),:^:;:O
M&#93.[?;?739+;3?85:P\/JC*G@'@.K(' @C=%,J8%C%'&-LH:$"#1ENOC7.
M-=LHZN5DME,:[;:XVSIC;&,[8QG^.<> ^S\F-%,'!4H08C1C1'+AT2?NT&;!
MLWQ]/JNX>.%$VZ*./KCZJJ*:Z?QQ_M?QQX#]MR#!XQ2)M'K1T-7;ZO$"#=RB
MNQ6:;I_FZ.DG:6^R"C?9+_>:KZ*92V3_ -O&V=?X^ XP<X$D++4D ,"S@[91
M5'4@'(-";+99#;\"R6KIDLNAE1'?_95TPI^)/;_9WQC/\/ <MF]9D&Z;M@[;
M/FJOX\).6:Z3ENI^7OLFI^6LCONGO^!33=/?\.V?P[Z[:9^FVN<8 X;LZ$8$
M1P=\9%,BQ?\ ._21;L@T;D2?V^OXW'Z<R66T<O?R-/\ ;6^V25_*U_VM_P .
M/X^ YV[ELDL@V4<()N'6%<MD-U4]%G&$-==U\H);;8W6PCIMKLK^7KM^7KMK
MMO\ 3&<9\ W<MDED&RCA!-PZPKELANJGHLXPAKKNOE!+;;&ZV$=-M=E?R]=O
MR]=M=M_IC.,^ ZU61QY!]^EKG@R)/\Q-'].5*,4WWYJV-=DDOM-U\./S%==]
M-D]/R_Q;XWUSKC.-L?4#N? / / 1CZHZECO)T' SN2U3T%;C,_*F\20 <YT_
M([HEP]RX$%S&I<S'8S_Q@V-II!U62YI?_A4B;T8QV_WKY+PE+/A\6E]6B!W\
MM'5'_1+\I?\ <+MGPGE?C']</^0_EHZH_P"B7Y2_[A=L^#E?C']</^0_EHZH
M_P"B7Y2_[A=L^#E?C']</^0_EHZH_P"B7Y2_[A=L^#E?C']</^0_EHZH_P"B
M7Y2_[A=L^#E?C']</^1*/E7O>%]9R^1PZ-<_=AU"ZC4;_:9P9Z.YOFM+1@FW
M_4V(O]+!'9-_PI8]^8^T=_I+?_B/T]!V\_\ TV^_A#37A\))_1LG5X0/ / /
M / / / / 556W\4L1M3L&1=M,>ONTJIMX_%8W 4&-6SFG!D2C->QU,:IM XD
MVE%%RV1@XM(3#!>32A@A)]U#,B+E2"SC359N@U%E+;'+%XWR\YS\&L_E@S+:
M7#&]F"7VJ76?7L)FC;H.1=!U_8L5LF+ZG:M<R2/MXTYI^+@B\"*04U1+$<FZ
M4%0*P(I,G3$@2?ODY!E91/\ *$9\EY]=_GE?#'U,S\K<Q5OR!2D:HRKEI*1C
MX)_)#Y.338NF?G$VF,UD)*63.;3,XBS'($Y))Y&7($R"S0<.'H?G)L18X>,:
M-&2 -Y>?VO!?!;$&?@D_FF^.?ZI3W_&.QO"9^W+\4OJSD?,]V%=G%'';:SZ'
MP'#R^67# *J(V7(02$E!4U&Y@WD+E[8Q$,_VU"NU=2041# N9%^./H2.9!W!
M1N]02^Q=<=J]Y<:?IE]>VMI4O[BVMZE6C:4L]I7G%;0CRQG)X]IJ$)3<8M0C
M*32?<_1SPUI/&/'/"W"^O<0VO"FCZYK%II^H<0WO9_9M+MZ\\3N*CK5:%".=
MJ5.=Q7HV].I4A.XK4J$:DXX8^#/NGHKM2K+[;]!G UFO*4LF.Q.,7M'XN$B+
M&PV\DBB4C+QPL+B:#6&*2ROG.[1(P]BS(4Q6%R2/).Q#4FW>.'NGPWJEYK&C
MVNH7]A4TVYK=HIVM1332A4E"-6,:D85(PK1BJD%.*:3V<X\LY=B]-G G#GHU
M](^O<'\*<76O&VBZ9]B=MKEI*VG&4[JRH7->RKU;*M<656ZT^M5G:W$[6M*F
MZE-J<+>NJMM1RMTO7O.ED?)M18?IB#TI/82RX.Z.)B!5Z1J"RF+-)(GT#S&U
M1(#F,_9/A*!Q,2[+MDG;9+1_J.<D4=%,-EG.NW.=Z]S_ *'E2;2>&UND\;=T
MB!@R(U?.XDUK&&6)2@VDHK\FEV8X+KWH>'F+-XNN:(1+G<*TF-0*K,# Z/,(
MY";LD]_F.=]VA8J) 'ZYU:06&R(9%VK,9)9O&^^7%<SR\IM_VQGSVRLG):%:
MPU"P^C+&JVLZ2YACWR<8A7;,8JJSEK XO*EY3R8]G]5@(X5?QN#"871L[OM]
M325K5"<B82.B[H++1^4(%&$\?O#8A+.<;OERLK?:6^-WEI)X[\;[8,Z+%N/X
M%TKTY1D[I.FN>:6G/*L@D]J2_G&_EDH7)JDA]Q0*O8D:NVFJJK&!)59,)D-M
M1XWTEVTCD"BU=B)=%C!PK$0BST:(W>&FVT^]>67CKGH22^/\"UK3I7O:G64>
MJB+#Q1KGJT <>YT9I J%CD;L*!2:+!0C:((M&Z,8NM1*K%I):V&N^6$AC<CJ
MF2,FK'4BHCL#Z)Y\5OY?]_)D98;#N()C4/?%F=XLJV=7/#.DNHV-V3R89%XO
M*I8+$;+E6_+36GY*MC:R(&@QH%*II50J5>KC7Y&3FM)!%D7DQ.$5G8EYV2SC
M"PNY[;OP>^4V_##Z&&.I[6M*=W[,>P*@H'H>UXA\;FU6!JLL$ ]J(8!:+!QK
M>P/D/%3>.V-<,#N,I))70,P T_N/B-52]R-LNO2+3\@D?8NPXX2DL)-K?.>N
MW\OEU6<MXP^JW8ZGO*>W!?TP[EH.E+CO&L_C]WJS:D[:J\U2F*Q>#4QJ%F]_
M:O1TSN>&6E(_VZYWG$=JL-I :QFR2$X@"FC7!8PT6%CP2VY6\<W7/-GO4>[Q
MW]SZF,[;BZMCO/EAZ"A7(7&O5U6+7S#WY"U;+ /)S>,5K<]PAQ\7)S2K(<UK
M-\M.HS 8E(-;3$1D-;T%E1QUB1MXJBC(MQ.3,8]WD.Z";:]5]-O]4O\ KI[V
MC8]YJ&" G.=!!8_92]S@@U+5:)#7 Z<ZO75JBQL'!LF%D.GFCEYJZ=3=J@E)
MG#C#MUA58GOO]PM^+\S:3&^K[O+I\C-G@'@'@'@'@'@'@'@*RNT/EUXDX-GX
M"JKTG,J=60;#-I0\AE:P*1V(:B<0>.5VK65S/0 U4:QX4Z5:N=FC9RZW./FZ
M&[QD'<L\Z.-]RST[4-1=6.GV-Y?.WI.O75G:U[ET:,?:K551A-TZ4>^I/E@N
M]E*E6E1476K4:*G+D@ZU6G24YOI"#J2CSR?\L<LG?45N5M?59PJXZ?EXF>UG
M8@%G)8;+@FZNP\R(>XVQHKJFY2;O63INLFLR)"R+5F4$$FSL649LR+1RV2TR
M[33P]FC(W@'@'@'@'@'@'@(G69W9Q[35RQ?GJTNBJO@USS+<$D!K\_(D6AE1
M:4NMF,7;DU,:;CX\XD[S7[:.-Y"]%KGEMD]!*;O95/&PE1;W2?Y>!D2_ND**
MY9@7[S^A;0BM4078R.CC8_*GN[=,E(2VKA0:!#L6R3HF;-/$&;YVB+$,GK[+
M%@_?Y0PS8NUT1&,]#WM?6#![7A,7LFM)8!G4!FP5E(HE+XP2;%P$@"D4L+,R
M(PBS440<(*Z9^F?P[?C25U406T36343U K ^"3^:;XY_JE/?\8[&\+3]N7XI
M?5EJLCC<=F (K%Y: "RF,G62PTW'9&*8FP1D>XU_"X8%1!-!T/(,E]?]E9J[
M;K(*Z_PWTVQX5.MA$!@M91H?#*WA<3KZ'B,*ZBHG"(X'B<:&8<*[N%\#P0%F
MP%LL++J*+*X;-4L**[[J;_BWVVVR!Y2QJ'HZXG0E[;E,U1:;T"BY;@W=C5W$
M)NZ"H/%$5GB EQ)@Y-4<BZ5;MU7*;/='1=1!'=77;9+3.H9:Z/!VLDJ2J9E!
M=:NE]95[*JSU:LF.M=R2%QLY!=6(W\'Z<SUB),:ZC^&K#\M/[)O@?^2U_!I^
M1HG^'7Z!G&ZV8!5)5,7@.:IC-95[':NRP>"\UL"AD<$0'(PCLIL0'9AP\:WC
MOV#[99;9XS_3OMW6RJF5T]\[[?4#J(%0E%U5'#L/J^EJFK>(RC#C631:!5S#
MX?')%J[;K-'6#H2/!APPOARU<.&SC!!JXPLW7614_$FKOKL&7XG=UQ5-74['
MLQ*HZV@-6139^Y*;1FN(='H/'MB;W">'A'(6,CA8W+]WA%'#EWEM]POA)/"J
MF^--?H&<]=SHY-0=%36= +1F5+5++;,BGVN8O8DFKF'GIU&\LE=EV60$N*AG
M<@#_ &B^^RS7].(-OMU=ME$OP;YSG(9?B>[%Q6+@QY(2%C8 .*,DCIDP-%AQ
MP\>5,2E^[*R8L29M&Z+9\2D11^^)'7SI-5T7?O';P@JX<.%E-P.LB%<U]7T6
M2@T"@D-A$)1P^U1AT0C 2-19+!155<GA*/AF+(2G@BNX76?8U:8P[5654<?F
M;J;YV _<0KZ!5\.<!X%"(A"!#O8?N[%Q"-!HT.=;B0 >)BMG#$,R9-EMAD6C
MP"-#]E$MLLP ,.&;93'#&39 #LXS%XU"P(N*PZ.@XG& ;75B%CD9$L ($0RT
MVVWT:"PXMNU'CVNNV^^VK=HW22UVVVSC3&=LYR!WG@'@'@'@'@'@'@'@-4+Y
M8?A<Z[O_ +,F/5?*)"J9D-O*.5V&L&(6?,2D()P&45W&&D'&'0CYN .LCD*(
M1T:->$Q:&[4ZT.ZD563)XD_RJGZ/P!Z1KS@%:M&VTVVU&&J0MVU7JSH3H5[5
M5U1GVE.$W5H__43[2@^1R:3IUJ3<W/@]:T&AKBM>VN:MM*UE4PZ<%44Z=5P<
MX\LI14)YIKEJ+*PVI0EB.+U/C6X_?\'<54IR\9EK6<R. #Y03EDE&H.6H-Y+
MI_-I)8<G;1IH[U2<H1D4;E+T2!RX;,G3P8R;D7S%F_>.FZ?GM>M.XKUKBHHJ
M=>K4K34(J$%.K-SDH16T8IR?+%;16$NAS:2C&,8YY81C".7EXA%17,^^32RW
MWO+)T^Q$CP#P#P#P#P#P&L-\E%JUA8W9A+C@O1=D5A14CDM 6AV[TG6O)MK6
M+->H9-4Y&+3"DZ$C$TK>O33-,-%D48]F96K)#:SJ-#&SN!QC5CN-,(D!DBGR
MN77JHIM;>+PVOAY[OIO)?Y ;9'';NX9Z51@ET%Z*X?[LM^ ]([LZ4LL\_ %W
MU#'(S%[3"0T+&BLFG-;!9/)QS%C8<1"F@NQ KLB/<JN-%-/"(KVEMF45C=?S
M1?PV3ZX.D^/?G3O@)\9/*</IJWHSQW,TI%?\\D<1NKGE:UC36O[1NV>3RJXP
MI&7LZ@#J"$Q$7/M"3\<YRZ<MM2Z(9RS'K"MT\B92BY-M<W3OQT27@\DBO@?P
MIK\2W&NJN^%%=8=.\*J:Z_@UW4Q<-BXWWUT^NWX,;;?7;&OUS^'&?I]<_3Z^
M%9^W+\4OJS,7R<][L_CMYN:W.G7ZEGS"8V/&*@K:&J&\QD(0F\J&2,\B[E,C
MT&F7 >.AX[$9&7>*,Q+]\1<LF01HFW7*:/FG)Z-I-WKNJV&CV'9?:]1N(6U!
MUZG948SGEN52?+)QA"*E.7+"<VHM0A.;47K7-S2L[:O=5W+L;>G*K4Y(\TW&
M/=".4G)MI++4=\RDHIM8N^*#Y,7/R-U_:RTMJYG4]K4?*H]'9R#C\C<RZ%F!
MTR#.3D2DL7-/Q ,FAJ_1'&&), 38;O!+D8FO@@]:DVVR6YQ/PWJ'">LW.B:G
M*WG=6T:,W4M*DJMO5IUZ4:U.=.4Z=*IAQFLQJ4J<U)-..,-X=/OZ&IVE*\MN
MT5*KSI1JQ4*D90FX2C)1E..S6SC*2:[\Y2\WVS=?2=/]K4K**@*'Y5557<MW
M)=-_\^BFVY)>V:V"6Q34,E1>&C=,_F*6Q64>E[ZPH,U:XR[EO[-E*X0RGO-=
M5DN -]8P\]<K#STZ_)_^3#L9^31]&E)>A##(VZMKU["O1K2,RD+VR3];1*A*
M]IRCYS^K,DZDKNT9N5%.W=BQ]G$@(F-LQRCF7O3!20"6HM1N0$N/R6_>^;+V
M^N?#!G".?(O=]K %%*@YICS::U]SZ?Z"NR)7-8$XK+5H.&VI<E11F*U:X?T\
MJ?D6MD&*"LJ6Q.:3:*0-@WA&8(2+@&SB:+HQH0XX>&^_"?=W/QVPFLGA;3^6
M*2U]'H9-VE;U03"+U#SE;4W@R-G3>1VY]A>8L$:.("H[7E33,+7XN#BS>C@+
M(;M.01E82[9WA!*, DFTG?!R[X]^'T6V>_X=%_X/A%^I>H5;2+ 9&+#S:0.O
MD&ZMI.CH]';+)Q"/NF-8\2W+:</A%DM$J[;-C<4<%XB";M=UEG;X=*3JTV>.
MWR\0&CSH86_E%-_%Q6V_GG][>LF7RU!&D&#3VNZNS*PQZM>5WJ:Q4Q)66L=N
M_K24E!T9J>6,HK!)I*&JE50V,2:=6YH#BYZ7#4-XK'P\2?%Y(GJU?O\ ?]1R
MX_-K\L?7.WGWDR..NG)!TG';(4ED <0J05C/M88J78B;('0.Q13V*QZ6"IM7
MZMJU_6LQV&_@/.8O(!96,Z* I?&CS%J3.B/THX2$-8QYK/AC=K^A%D?\@U\[
M<_Q?J]US7!R5'W?'((0Y\1"7:LA/-I%=UJUI5G.@"Y!ANOF3&-,;6<VF /R4
M_!59[^Z-%D3$%14KWPT*KAC?&=UG.WAUQO\ ET^!RIAWCT'7L\WYZD=$U.4Z
M+4M'G:("M 5ORI"GBL$Z9 7ZZA\^7DI"K,R\._B<FYVL$++(=F(E%W@M@,.!
M#*JL@1$C!.$]T]MWTWVQY^9AUYWKT^\N>O6SF%UI'0=9Q/Y&1M^0,1.C1<--
M)MR7O4:@$_#)&^K)D=3#O TU'O XTBF%R@\E<G9'TRBD1C90N\OWW?W#22>^
M?9QMXIMYW_O\#+U>=I=C6DI'8K%.<:!1LTISO$.MR@ ST!.&T<&5+:SDH-IV
MO\2)"CEG"UO2<O#K&9S!XD(5@,$;QP,]:EYCF3?;" PO%]<=/#K\/GY'O> ^
MF7G5,NZ.M <5DN]9REGR;854Q.2+XV6@T8M[DFJ+/=!$FB6ZC5DZ5+29V],Z
M,U%6RY=5VX15534U4V!K"7CNG\&8+H6.V+T+S5'>XIGV;:U'6?*S\@LK5=Y-
M$&_-%.PB.V:8'ITY**,?DXU7$AC@F'!/V)G<IF+W2RUI*H<DK"?QTBF-;BP>
MSQC*Z>;\\^?7'AL8BN7Y"-X;\A&QE&[' NB*7N*H>.Y_3VJ1',=E;^W )QW9
MEZN2&@Q85HM4%K3OG:$;/7+]MK'@<,OI!;.V7N-VXE+U>F^[SW;=WU?=EX1'
M:XKYLX=MVV<V-_(4VL,;V%:%$<[VS7]Q1**\G5O,BG[+@:2 V&WG]F,X1%X4
M,G9P<SEA":5T0CSUN6:A&GZX<*"A+H3CV>G196-WX]%G]OS-F*)IR5&+1I&9
MN1CR8)1\,G*W85)5$.ZDJ8YMJ=<B45]=5TABY3#I5@DMKJJFUV2U4UQOC./#
M&>@\ \!&6_\ L_DWE5[&!O1_1-14J3F>V^8N,L2;A(X3,MTE\-G!)H.?.M'O
MZ*T<[:MWIU5!,,Q7VU2=OD=]M=<B5%OHF\=<+)(<*:#R0.*D,=+##P Z.9&
MAP*_:E YD02;)O!Q0438JKLB Y^T61=,GS1=9LZ;*IKH*J);Z[9$'9^ > >
M> > > > > > > J0^"3^:;XY_JE/?\8[&\+3]N7XI?5D]^DN9J0ZZJ8Y2/0<
M%96!71]R.(KBG#XJ&(#309SAX&D,=D0!\+D,;D ESC*C$R#)L7R2:CEILLHR
M>/&R^2E5JT*M.M0J5*-:E.-2E5I3E3JTJD&I0J4ZD&I0G"24HRBU*+2:::*-
M*2E&2C*,HN,HR2E&49+$HRC)-2BULTTTULT>1Y*XNYQX>KLA67-T Q"H^</+
M2F4/R!V02Z5RZ2KM6S'8U*9=+"9B0F723%FV9,4')#[ 6S1U:BV;)#.Z>U[F
MZN;VO5NKRXKW=U6ESUKFYK5*]>K+"7-5K593J5)82692;PDLX1$(0IPC3I0A
M2IP6(4Z<(TZ<%EO$8048Q66WB*2RV^K9F!Q5,)=6X(O%8:OM8X*N9'5(TQ@B
M^U:HPF5R:+2\V-V$ZKX&++N3L,C[I,BJUV?-TVBC9!=-NZ<IJ8"Q%L/\<7*4
M2C6L:KB'R6I<,;GL&_(T>JJPIK Y/";%M5AJ)L%6&FP1ILX!Q&4"-=19&NTM
M5(#]DBR30C:.XD.H/$\S??W8^"_?7J1KZ3^.$W)!$<AO.@F!A(FC24\I8H9E
MM\]15S8R"4_DY:6'CT]E=:GCKKJ*+F9#(2TKD%86XL =$Y<Z.E$[/:-9U+![
MD2I?WZ+NZ>[WHS+GXO>9B4,4A,EWM$B'/U]4$)LH.!MRR8/$;0*4C XK74!G
MDMAL5E \(YE8>.0J+-45-4\CG&(['MRK$HY!#'+<1S/Q^2^7@9U#\=4<"MA2
MY1PJ4ZR[]\A6_F31S.Y>^B@:V)#44KHZ3RH%$GA=<$(4E%?3,VQ/CF+-$41*
M98GE&6I8<S=)!E_FL?!8?]$=(TX0Y@&U]:U9B*]< XU<=WO^D)<N!E<M!R5G
M=[H\!DS"Q(;+A1II)8(<C)R+Q][$,1$H'91C44V8AVC4;E=FJ&7U\%CNZ8Q]
M#+=,45!J*%29A#UI<8)S>4+36<S"P)K)K!F\QDZH@1'DB9V3RLD3(;I#X]'P
M8$,(8[L0000*:,1 MDCJIA001QU^-;DI1H4#%(=,)!$U@$IC$/@Y^U[-)PVG
MQ$SD0B6R#2CP2LKPWJ,AF21\ 5CQR$;"3D$_1!8VOR,6"LTAN!/,_P"N>_/O
M^/3IY'MHKP_0L7)L9*LSG<RG+2SH7;KFQ;$LR<3F>&)A7,8DT.@6I:1R$T\=
M+QF(QV8R9F#AJ&K:*M79PP;R(W/F"Q1\&7\L?O\ OU./(^$>=9,;VD;L%+!Y
MI:67?+W[T#8<U!Y+NNC0H8%<04R@--(-2D5F#6-QMPM''B*HP<1 "B I%DY;
M[;J!E_3Y=#[SOAZAYZT@[==*QX<Y@=5HT8P-5A;ED5G(3E,I(LDOW:S Y"I(
M&(RB.Z[,$G3%8JNL<!/W)5_&S 9V<-+$ R_S>>BZ_OKX]YEBJ.?ZFH]Y*W56
M1-K#T9BVKY@4%#'#O 1J-JVO@%6P06##JKJ, 0P!!XP$"-F(M%LWW39:KK:*
M.-U%=@;;ZO/7Y]3 !;X[>934H*F7HNQ]8?(;"S;4FHQI<EHL^=9-9:DA3E[F
M7':.;2I.O7JI.8))S$['LA4X=))?A24R*-E3SEV07#+_ *=%[NN#*N.3:+WH
M"P^9'<15)5#:^MM;6$&)FS3XO)W]XR63S&RC;^4.'V\B_7SDFEYLRW-H$DB0
M5XJSW"N&&!@[5L&7E/O6/#NZ?OO[S\#N2:)9U3<E*/8@M):YO\I-35N@Y:;-
M2529%+#"L ,N>OB)5\X(MW!1B-:*858N6JC(@G^IL-VS_/W& R\IYW73N,X0
M^,,85$XS#A;LR_&12/AXV.>R(R0D1]TP"#VXUFX-R NNZ+'2RK=LGN0,%'3H
MD3=Y5>OW+AVNJMN(/1> > TIOFS^.CM6<=_3GHNMN>YQU)5MU0&KXM#MX#H"
MD!*J'T)C6D:.U_( 1HFR= 8N?,INIWB1H([QW=U)B";YQ]\V723]3]&G&W#_
M  ?_ )W_ )YH<]5EJ-O1IVU6E1M*\X*DJ_:VE6-Y.$86MTZM-U9TN>6:45.A
M62@J?7N(-(OM6C9*ROE:?9JE252$YUH1DYN#C6A*C&3=6DHM0C))>L^6<&Y<
MVQY\27-5N<B?'MSG0%Z/$%;/A8.5/)"(:%DSS.%IS&?2J;!Z^:&D57#<FE @
MDA'Q3=RR=O!7W I=$&[7")#E,^8UZD*M>M5ITHT*=6K4J0H0;<:,)S<HTHM[
MN-.+4$WNTDV=A2:44Y.;48Q<VDG.48I2FTMDYM.32[V6.^Q > > > > > >
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MYQG&<?\ /&?KX)^W+\4OJRW+PJ/ / / / / / / / / / / / / / / / /
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MXMF?5O+E?R@[?UIT[S_-JRA4,K\G;9H08NXC7.S]RE"V+)XN?90F/R\P;?\
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M'A+/9LW+R,(QWT2<[N,JD$MM$=D]5MTQ#C*/5-$X_"IUY9XN.%$R#4>Z+.6
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M \ \!4A\$G\TWQS_ %2GO^,=C>%I^W+\4OJRV_PJ/ / / / / / / / / /
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M=11DX0E+/+&4TN6+EA\J;3>'CH.6&4N?>2;BL+F:C[34>;F:7>TL+/O+%,=
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MY5;LJ"G6<Y*I-2I0J4YQ5*FK9)*#A*65%**C&4HG]##WDQV(> > > > > >
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M-L_3XYM^@^>_D=MVH[$N"G.H*R[HY^#=JQ>X*$CRD1&+2&%N8I6>;?L"O!I
MS#82_P"BHR2%K.Y#"CCV'SJ20)L0!,V3Y:1)(B9<K@FEAQ?+A[Y[_?MY],XS
MT-C#PQCP#P#P%3/R!?)_7'*K"<0ZN)U6<BZ-IC>KK9LN@)DJ7"3:7\X+24>2
MMUQ32I'< !F=C"*N0D4F8# 962KA6XQPY+@%%MF35<6C%OR3V3\]\)^&7L3V
MG< HOL&A7\.G0",7%0MYP<:]58O=-G@&71"3CF9H <&NT=D'C-QELL-.QP^,
M<,C =\D.,"'K(BT:N41&Z>5LT92BL8"0F+QN&QIIN/CD2 AXS'V"CQ\149!
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M5)HS6WP)2;>%U(;=5_%]0W39B;77&3$CJ/K(V_KV:U7U-#"SI[-*GG-6QUZ
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M]Y79=PJY- 2 2>,-/$O&.,-86[2QC\MUU1?S\=G-D\Y!XQHOG"RID-G,NJT
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ME5F(Y$>*2DWC+RETV6<>;77IWDZO"H\ \ \ \ \ \ \ \ \ \ \ \ \ \ \
C\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g686907g24a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907g24a05.jpg
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M 0$! ?_  !$( 1T Y@,!$0 "$0$#$0'_Q  ?   ! P4! 0$
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MH\'1T>#HZ/!T='@Z.CP='6.+:IA),4YRQ,<O++&(2S\X_AG&/G_+QM$,C $
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M UN/(?)_)^_.C>W'D'?MD9 K&XV:_*!03AUD*]&"J*BRR*X@8CD[$@]A^_\
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MF?TZ]9QC&>W^N?\ CV_I_P ?C/QXP#GG]<?[_G_+! !ZV\*./W^OM[X]O?\
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M#GJ1&43S0D X" HNY1RP*LV=WO@<D'<.">L"SROJ.OW3_DUVFI\G"8GW4ZX
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M,*-SC:"6(!]"#[@9R1Z.84M0-N6S/&RCR;'W$'C)V1GE3Z^=/;  )'5R2ZT
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M98 \=S(''.,9/TYQUID:,N#'9)8Y?M@B1,#U&T;V''!&S@G!/5-LE=1C.]G
M3VQETUW&I@%YWY0G/RY)#$H"7&#U2-3F0PX+!F<LI0CB>985'GPG(C#DJN[<
M$SC\#GT"Y"G<0  3CK,EOL+N*E,*3E4V.^5&-B[@79O15'F/H,@<9<^G:=ME
M4%K8=?KSGGA?&&#@!D@CB\^1P]RO[A;/:4L^D0;A($'@48Y+'$/#*6)5FVJ
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M*]C;7AS&))18C3(9QLB 25H(AO$;J[#"/N"JY1LO9/N;34)R0BI6Y)8ML-6
M382N4<A%*6*,DLDJY2 R>2MG]ZPFFT%B(JB#;(VTX;(U6.K+*TQ[T9 1(S$&
M1MV%[P)20!D4M%VC(R[<S;5VR&976IG%FJNVPC1P(KF.0M&[9V8DBC>0';CA
M3W(RNYL*4?I0*:5P^UN"J.U(5=Y9'0G=5FO/ZY76 Z]:KP*L3R)\J<*A T8G
MD55!RQ<=+,;,@"&J$@A[XKFL+!W*L\T**W9EFBL2H9&G+2$LF_N$@IAW1%&T
MJ'W,RDPVI:G>^6EJHDB!NV#/O[<"NB.\R[MIL3++EMS)&BJ&7:,X/3LAJ-*N
M)A/3U-:CKUOEY&V-"BKJ[ [377@(G3L4.X+,T2&JA07<'5NIY653'[M94D(X
M9SMJ$18V+4C6(D26%#/*[-',K.'7@H&'<9G4O')EG8(64]16E7S#7["UGLR5
MW 4K,[U0MA&V-W'^S) ?':W*0X;N*S 9]65RM;YS0ELS+5K@S0!]LRRI;1#Z
MI1,-085!,2LH0P,<Y"-[H$(%Q*/IAP5IE 2DW<V(SJ5)#E7C)VA@K*0OXL 0
M=Q/KEL+9TTR=:KWC"I* B1G<&N2V&"?:,K/EM^U @3*H5)9]J6A=71T73OMN
MH#52K:FPR6=.FG(STG8F+BVC6UHULL/8;L7<N'" $%BPSZB@_=36'X==Z;4+
M0EG)>612O<D;RX6/;&LDC$!"%51EO-[-E Q.BIJM1I%DOP2!GA91(I>.N(I)
M5:":1P[;$BAC<(Q[DBDE7;:),5B\A:?H9$+O:HI%O1U;LD48?;063\$S)#?C
M0T<W?O#^9S83$ZM65S5GEH"\(5QC%A">^M3N7-T-<-VG=%E/F,<;L&[?>FV]
MN)?*Q5F9(P&8[\9Q'^(:PF@FBI7!!"S(PE[MB9BL@E?;-,L?;.PAC&7E$;(_
M#A5#=/%2[31[-KV',IB]A9*3L8,^W91B6N<G/TAQ"=5;"4X88]&(;!%)R)/-
M$F,'B>8F5B"2M.T9&QXB8V0$.1*BC)RK/W">6W(67_\ G&:@(+U:>O)%<DLR
M'8B*_;?MRJB@[SO:8*W;5FV,T8]SM*!\(RHJ2P2JG4K5RFM$FQE=<?4'5+"K
M2A%BLDC,_OCC;3.\+S1!$<H)BP>,LGRN5,6\(9DE[<T4BE%"R=PEP[%Q(!L&
MQECV@L"3(0I  82AMR,LX6M2+*PDG6.-6F>2;'F!V[,[U$K [QL=O8CJU-7
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M*X98TVE&[18N4F.%WD8&Q1T_)V)IU;5\I476P1C50@#6$YT\;*X0P.,V1?\
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M=_F!7JRU+@S<X:7=9V3D[<=TVN + 5/MBT7"W.K+V'NO=CU@ULK96P6&Y-E
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MA[W9+3(%J%9Q,J,SO!):5%D"=J2R&"MN:81HH6,-T[6=BK&J<:+*:NLV)$(
M6HP6*=K&O ,)<AI\-FRTI"< ,8P)5>3,1PS',>TH>3Q'VXF^<>1)6E'<+%V4
MQ;R!YG\H1\EAYF('F+$\'EAX5TJ_5I5I.S)?KK,SR3_+RPF4/*BFTT<7FV87
M.]E0/Z9.=W6$6V8E6D6;]@839DHY*DL63!927F2;.?<8%#RR"6)L2#Y(+!%(
M6,"[R_L] B#OA<$;R0[!5QG:. 6YR2#DY+'(]@3>GTZ*U(HBIH\<<KG?(I6,
M!E"C[,EG??E &(#DMQC&"SZ6Q:AR9.HL35-BR5-^U5J/OE.XEA=N."UCS6%7
M#4I9$9AB217&DG!L+%GD4<8+EDDC)\S1,E=9U57CC>3L21N"O$L8+Q]P<,!)
ML#@A@#@,,!VF@O56>>"*LL1426(E<*Z*WHHCDBEV*%(90#& I]<#9UD+-+92
M?M!]J4A>*KT2K%=2V*7V=9NW1*XPQZNQX<58G&U(6L6QF1UZVL]IDPR38:+/
M&(FKL(DE+0GO.LTZOW-L;JBKB':1]D.XQ'G>3<5.=HZW=R.AFU+,(I3+VZ\=
M?LSRQ1E>VK1US'(&8@,!O&]FP"J1J3UFZR+S-5:@HP IV'D@3KE23B_6*VT(
M8/"2V36!_40$_P!L&QBP&XV"*XX,KADS 6@"..1#)F6,2%6(RKF/[I.-H\Y3
ME1MVJV6(8A26VI R"G-=F9K48<SS*0DO:VJFVSV($RQ4 %5A[9&_*,=I965>
MGD5KXM["^LH0-,(]S8(UZ^7["N5[G:0J/5A**R!+#,W!R(UF:\C,$]J<C$!D
MUM*"Q6'+*9F$<;%BJO(/*S<_W@3R,1G.-N5 .V'M:RBVXQ1H-:MSNE>NLDK1
MP062 @FN$Y+D1Y58$C&0B NNUG"NT+:U")['?V:ZU3J.O59F,@DHH9F9G306
M1$)MW+39K!S(X*BF/":H_3!+*ILQD8F+, C2.($O8FD55)<\[02[%5 &Q,ER
M#N8DGS#C%-\6:19-_2=-JV)+VN:I;$2]N1TACC@3O2DQ1;4CKP@M)(7:60C/
MG3<45/L\A;%:BM=O$\Q5Z\O4NU"5,(?OROVSD2R6L,66*=9Q0M>FQ,DYA7*E
M(D0Q&IC,(L$6L%2.NL+)NLFPLIF)*!(QPR;&D=2'=0,$JP!;<QY W5_"GRNK
M4=)<PW3(%LVG.V,1)#+'NC[7S#++'.8RG;>1)<'U.XJ&TTK4==:OQ;CLVO1,
MKH*K-K$)F"P"](]>5=-"W;F+'O965@8#.$#1PI%D>#>QR),<9O&M6$ADK0R?
M_E$)R%++L;<98AE=O;57!;[^TD;U+9%J\8WK,5.GIFE:DU>]K<T=.*6!(Q\L
MKSCYHP1J2RQ0UU.9/.QQ&.Z9&W"YBSLW*>\I9:E*TM7'A(!A-H<*RN0(.9HJ
MUJ:T81 BFK#)R2$0OGPKG)RSR?.9MBL=2%SN$<*KO/E!9F& 6<G)+L3MP0 "
M>,#TD1^P_!'AFR(BM2*&LUF23ML]^]95MI:W-(9-\LTK*J1LL>SN@(GESU)3
M#BU5LEPO6K 9A"FS6C6P:0I&6J*T2!G"$G* P09' 0TQ^7!3'.;,22"$?GBN
MW++'&7)4,X;=C<09'+8"CU*EB3Z\ #'F..63,)M TE[<@@L&X;LLK(O#7;CV
M(J[,JF1VCWDS.#MCCB4$"1SB/%CS!IB^V(T*<QSV/:&T1.*:\CAPRS#=,\TJ
M[>L@%.*Z-FK4'$F^](<2Y$HNLNF(TI#GX=+M&JTSJW8K+)L:=^V'5941U@1F
MR9(GE5GC0,P&]G9]AZG4HOV SDMVT+B9RS[=TP$8W';]PR*A&QN27=Y#M'4F
M.F'3J79-WVOD2FMJFWT3:M=#95]>GB;GN;^TL5(N7#CTR%E+*U+2TE,A7"E%
M>N&!R<?,1^>!QFIV9:]6"A-%-'<K2E'D<[-L")E(4C"K@=Z6>5W;S.60'A!U
M0_%&M2U8J6GA98+T)D2SY=JJ:N8I F#@B:68R._JY4>50HSMT\5GJO='@Z.C
MP='1X.CH\'1T>#HZ/!T='@Z.M ?5ES6OI/.6VK0T4.YSK]BO17-C*P+5UE?+
MOD]2)BK\T)W'I *JB^=<48X=_MBP>#DAAW#3JBST3FQV6=(NS&4,C28&R7:^
M&$1W;V1#@,H?#*VT==E\&?#K5/$-*I9AU:31*=QE,)"Q3VF*KMFL1/L/:66>
M*0PJ\NY495VQ^A9>@W:OV2AN=GV#4:O00-G EI4J=YUYO8;=<#;=O!"JQ]H'
M7P3B_7B9L'K#V49V*^0G5(OB)-L]6,&O%!/)/*&=K'=1$CACQ&D1DD'<9]S*
MVU$CWXC;*LOI/VJ&O^'O$7[$JZC8\41UZZ6M1:1((&IU'D$:?,N_>0N[0RM7
MCC3N2]MPZ,&)7'CH/VF7I6Z5.5K8%8<_:G71GU@6Q:YF$#LY)9C#=20L X&N
M18PM:L=@.N4V.ZQHS.1;+1"(R[YX]L4:F&0"P8Y\E%(C+0[D89SF=88SMXD^
M[NLE;QD]!=NHZ5J6FT[G92E=NQS/I\V6"J[%=\D&^0JRM8BK;EVX"G -%/;%
M:/9=9I<7>R81<6:54IU:0=I7L69"1;DT[;A7CC62R[04@..<UKK))G;RQ8B#
M*2HJXEK6"(X6>$I*9'F,4JQX*E8HBV+&#AV RZ(HQL4G&S6-.L7'DO**48F=
M%F8RM'#VHD*QE\YGG&TLRLS1%<]M3L\O3@TE5INKW#^Z;H)FON;D[,%9B2!M
M.UCJV2KQ+&O<)%8JFNPPJ(6)1.@")E&%EU[/VYF%,FU-:B-*!QV4"[U8R01-
M*BD[I5#-OER[%<ALAAN$>X*U)FCU*5(8-)K?M&>N7D<M92EIU=&8]N-PJ%38
MD4[D3-F=4=)9)80Z"1;C<T>+@;I<5EO2  @KK1M*R#38U4Y5$G@5=_KQ7+YA
M=C85)^[I"$4KU?(G+RSF<@L$TR5YQ!L8]DR$E R&3O;2P+PR[(TS XQ,=Y)W
MK_AW%8VIJWB.W>FTQ5TS1KM8R31P6#)=DM#?VA+5M0_**R5W(2R ;+C+%E 3
MK$[$_J=(E2SH+1Z:.T6%@JM6VX\#=K+5"L);0D&5>4RIFH)*NL!82G"1H(M#
MDF2(6!PU103D3%D4_+1*TDB'(,;R+$VX,H(7=(@8,, NO/F#&YZ5JNHWKLM'
M6Z,,&I55B*35G,M34(9)&B>%&G2-\;D3,-A3(H99$D+%2U$=12TF9W1: )7V
M%<U8; U?(+V*/+ACY"6Q-B)"-99E.8X8,2$)3\_M<EG+,CNR,G9[K+'W.Z$#
M@1B5E WA>!Z8!)"G (SM ZDC9DU"9$2TJ211@V%#QOF:-2J1"%!*Z5CORY2-
M"2?)(<#K%-LU]&B)U)6P<)V"K!"EJ2-C!!YP2%="$5*XY,2E"<&+(BF8(! L
M0C+(<BSZNQ$DLOM9T)968O-,$)"AI')9I%YRK*,Y9BP"*X]$LTE>/8VVM7CE
M3:QE):0PH6<K$K^:)"=D7= ?+ABI))&=#KEH<+34K"D!%DF,5*!",JD$*(!9
MPF>;@W9SG-L;<H,C]L%498A&41,EE'2>TNP*)=R F0\."Y9@2OW0H$>P<[F)
M!;&"!TV;5C'(\+P36#&WVEBO"FY4R<2LD4J(^2\>003((RS1LH&:&GZP)2G7
MA.FL*?&2G9LJ^RMVFB5K>&V)Y7:V*&P6Y&)PC"95\@:*M[/,?(8+(I##OM-F
M<D212@%-KQQ"-90$'*1M%&%4$E6+*#OYPRD%F\FJ8A!,V9BK)&,0V.XI7:TD
M=2."(8D9EW"0I(K'#1@ 9S=95;#%2Q?4L:FF7*XP]3NU\;"\S*L7G(PH6(SK
M8:];(_60;B%A?&<LC*%@KXI8"?9I+$K1RRG8JRQ.%@\S#!,94X*CRR+Y?8Y
M0\P&IZO4GKF.5F>>/;5?<J1E&^S5V"I(\(D+@L0-Q$:[ JHZGKTS;TWVQ?D
M5L]9+6"<*^D"XU<)(-ED4MEG$*9[T8*B3]P(S]C-.%F*&55)]\&!@&#%,CM2
M:-(RC[Y-JQLZC C $J[F;(4JJ M&3N8?=8EQ0A^;MK4B@$=EHNY8D\KR)!Y(
MTGD*G:T\[QM'7@+LK'N/D!'#8^D@S=ZWMK4IE>N7T*\PHG8] ,J>-C,K9 ,M
M" @$<V$,*^U7*;TE,S)^\"6#$V%D$L,0PH1GR%4L=VT*H8+N)8[F;<Q!W#US
MZ/=9L0Z-JVB-+V:NFUI[2RV#M;&H?*_8B9$9[$I2.;YCNR1JAE94RKC9U<;@
MCL5/I%/6W8:K5-?&\S?/6+EO2$2=B (8IK,H>ZK7IRK<S< =>NKW<D,>!1D+
M/MY",02VB8F:>;MK$$[<P:,DG<%8!QB51&RNS*  1Z<F%T+6=*N^(-8U6$S:
MM>2(:=0BJU[;30QON:U<61HIXHULLL;1O-,@6*(AMBG;UB\:N[NVJ:_<Z7L$
M+*FUK%BWL.E*+(R?L+"TFO.IV%-E>5L6=7.N@-.*,@Y:%@N".""Q$V(I:>*%
MYH+%9X9Y)%6"S(Q"(D.X2Q%,J@8R$R;\CCA1GCK>NLKH_BFTFL"*(ZO1KQZ9
MJ<G>-4Q1#=+3DDDBIB*[6D+R2-'NKS9S')*FP]4=CJJFSK-?U$R3+#]=<XV
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MQY?4G*CR\%2N.G3:=--8=9IK-6%7#3"#LO9GRKLV)"?)"/*-U=)7WJ2)(UW
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MUVM+IM2HACFU!J\E""M#782J*A^5%AQ"K>554=R63*D@J-A)W2!T+7]JM8;
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MU* PV-:G,'9->E@.E55D3N-<N%=X655"QCNR-Y@'<K4^5MJ+:1$EKR>R9([
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M/[IQYS6*1EQMGY_O#3)D9F.?YS_:EG,GSG][YSX7W), =Q\ $ ;FP ?4 9P
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M]Q\G&<9.><9/[SUN&L:LK,ZZIJ*N^W>PNV0S;1A=S"7+;1PN2<#TZKBT#0P
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M+8+*[M,O>6QM&"I52@PQ O75%? N4ZU7&<%,7 <3*R2<",FE.,!"&@B.,1H
M!C[JY/N6)QR?0>BJ.<+ZDRVK:\MU:<-2M6I15(3'OK1LDUIRQW369FQ+*W'
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MQ$].^CP='1X.CH\'1T>#HZ/!T='@Z.CP='6JO@GF?7MVYCZL^/5I95V#CCJ
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M*7*%O8;"R5K+9F&;,QF\Y:6B4Y 3P%2J; ' Q1*F^S'$H%@$..V>'(HFT*C
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M:[/?*M*7#EH*=S>K4JR+L!*,4]Z"MUI9C&0,-06NK18<HDD/$W%>M9ENTHE
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MF+,F4ZZUIK067)66%0#]XG.J0F)"UK[ 5SBQCZ)'&I6]&I%X:L.<3A77RBX
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ME17(]2.?TY_'\!QC(]>HH.,_7@GV_KCUQ_OU6]?Y[Y[2QV^>W?/;&<8QCO\
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MD8F!@@5 S&.5FV@ +@8?'?H_"KZ;HLE;2T43_P#/77U+3IZT:B )((Y'A,)
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M]0D22D-%>$%1XA&$Q^H;)B9)F$@#\G>2W"G&TN2<\E=H&1Q@^OKZ?X?3#'.
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M/O!9BR),0B2L.TTV^5^6N3B<<4&N:QRIN6N(TV-=!,]!J59R)<N5ZTF$@KV
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MK-I+5X?KLVAU89/:(Y/5,^R3KC5]A5NAA*7O7KA>NE/O*) D(Q$NB71XW@E
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M=0JO(RJ!TT=;]('[O36NOL<]5 *T=D6S$-/AAL>6G"KQ28:O(GY?9!<-S"J
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+XE/F#XX^YDY'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g686907g45x09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907g45x09.jpg
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M2 ,!$0 "$0$#$0'_Q  =   " P # 0$            )"@ '" 0%!@,!_\0
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M_%40[U,@DKCKW7?ER?=R30+#[OK;>_STX.-_DW9(C'6>"+N.K,>[.0.)CK!
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MDS"Q\6C7=S%'8(D*Q/M#K4R]C#)+!T/,"^H,Y$%"GL88>44"&48_(09*NMB
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MFLT.IPU;G)_,0\I/N#?M]CGT#3/M]7'!*A$H;<;:?+;>HN$:<8KSW64&5Y3
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M6Q]NM,_*.JTLIB^ >-ZT*PSYK&]S/ML6DK3U:N4H*S #F-?TFVG,>K"11T"
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MO3>Q)7Q$,F7KJ*N)@D9*42Q'<1/)'_&+"K]:U-,YW+:W5_PD3J__ .W&V?\
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M0T)&QS.&TN/N82E9DD<]EZ0EY,C*S965*,DCGGC"WWEQB2Q)/4GJ=/    >
MU8GGFO=*"]@%1!X ]Y?#'DOJ)ANJU_E19*]'[6@HM.!8V5D[+<A-8[>.5'L?
M&(ZF?K5JKEN=8=:S\]]&*LKKGXB^@AJ7']) Z'Q3JONZ;C^T$?#4=_4E5A]K
MQ_7L?[-OOTWUY$U(TG)R?<NO2)VV&<R8JLS$[PPYG2$RC98L$-EY$-+VN0'L
M6PH-A&<M@#W"M7$9>T:,&_@%J=JDC-4V*-9P-8CP >WWF S)O!&:A>+=Z%^R
MSGFD7;P#HX[Z,';F0LBGHY&O^&12[:^RA.#I;,,'&?!L<)QC3MRF:&K&:^/F
M8]7:G9IL,9>=2Y@MQP7)4/-7CD;8U1MG6V\]?5?:NHKG [ U[<HUJ6KEIKAJ
M#8V0%=]<+;5Z82^%(!O)<#E(H]D64B)!@F-DPQ#QB!VS.&:*Q$DT$BR12#='
M4[@C\01X$$ @[@@$;:RAE<5D<)D+6+RU.>AD*<IBLU;"%)(W'@?S7C==GBEC
M+131LLD3O&RL;#\=U7ZP#V%]B>C>N_34EL39<F%.7V4"+9U5IP&6'$MVR;"A
M/QL,CMX:-(A:H 0IMRT7(F/(CH,/^A99DYTR'@Y2MR>3KXR RRD-(0>Y@!V>
M5_(>95 ?KN1LH]K$*3WL_P"SW.=H.8CQV-B>&C$Z'*9B2)GJ8VN3NS,=T6:U
M(H(JTUD62=^I:*!)IX@K<_)'D1VJ=*LSR-L_'1.DYNA;#@N16L=> VR1NUBN
M.I*A"3E8L=X)^[J53>BQ"ZO=+9;(6-P&4N7K-8#GA"'F9N*:719(V<Q@6M-5
M]':.1;440<R,\,:LCR=8TVW1W=1L>9$# ^L!KLW 4?#_ &6]L\/#M;B'YZ@O
M8^?AW)Y&2I'2KT\M<F@M5Z2\ENVLKK:I4ZDTO.O=6;+UW53!*=$_Z8N:]$YB
M<(=2,QLV"K:VD*54]2;@J2R&\3<7,T^&8K\):G@LJP\N%OT-$L6&-DF6\Q^9
M%R;@VGE'0,BRQ;8*_'>Q\.S#OJ\:03IOZP9%"JY'CRRJO.#X;\R@[H=N9=L?
M!=[@_C;+&2!QBLU=MY;#VPI[B6"W,UB:JK^'?4)IC7EC)[SNQ#.1W=B-F+1Y
M<ZY3I.7ZH;FG19N$U7P<I,V%.6VOW47<NX\1I#9"*BX!6YJ!H-0DG65.(1,S
M MLFK/)Q+N6BXR/#JQSS:FIL?*0?BV_&RPX^-@SK()Y]COR;(RQQG;[3!V=@
M=B $/VNFO_DQ\&7H9\IQO=A>"I8I/A\/WBE3;$EF&>_;C# 'N86J0U8Y1NDL
MCVD!WA;3"/'_ %B/NSJDTEIDPI((FW.O;6VL2C5I4M 8]]XWPM5?*4A/JI:1
MVI93JDIQE2L(SC'ZY\):L0L8:O 3L)L9#$3[!)55"?\ [M< S^3;"]J>:S*+
MSOB>T#(Y-$!V+M0XCFM*H)Z#F,0&_OT#KZ<+D@+I<_D!UE[TPF@;PI.W+7<J
M77K ZV&3.G#1T96-ETB,6[EMHN6K!M0&M0 @^7R9N$FIR7 P]&01+K=!PO:$
M!LXJQ]'/',[QJW0L0 DJ#?Q9"@< =65F(Z+KMORBN''S*8#M*P>]_"7<34IW
M;%<%U@1I)+.-NR@;E(K26VJR.VRP3PPPR<LLZ@MG>&6LI:$5W5\UJ+Q!X.;;
MCCYL'&V-\4JV:?U'4T$-9FI"0N,.]7K);6P\*R^U#4. EBIPN4=9S'XF<0$&
M\Y@N=";=I<]?CHX^8%AWUB-X(4W',2Z\K/M^;&I+$[;;\J^+#76NQC@R]Q=Q
MOB9(X'^:L%=J9?+6BI[F..G,MBO4+[<IFO3Q+ D0/>=UW\X') Y'@_I^^-MF
MXX]<% S<XTF%LV\[A9M_&PQK2V38Z)N,?7:]3/NFUXPMMR6HM-K-APRO"7!V
MYE [Z$$-/(2WPW5>KBXN<%7L.]DJ>A D"JF_QCC1OZVIW;YQ'6XB[1<AZ'(L
MU;"5*V!29"&226G)8L7.0CH1%>N6:^_4,82RDJ5.A&<.-BQ?5AW?\L^/^\R6
MJ9J;EU/R$OKJ[S"TQ]>95;KE*7W34D=*D90+B$4W8K;J^5E,>P0&[IPDYT$&
M/DG1Z2C*N(S]VM8/=PW6+12-T7UY#) 23TY3S/$3Y2="0 QUUGC#'2]J'8GP
MGG\&IN97A*O'#D:4([RP14IQ4,Q&D2[OWP-:IDXHNK/2.Z!W>,,Y)X<ZQ]K/
MO*3DQJWB%HN_[^W!-CP]1HL,08@51#+4I:9];+F("F5MAY6,GV2SR*6HR*%1
MC*4..K-,4/'!FECQK=J&E7DLSMRI&N^V_5V^RB^UG.P ^\] =7_#'#>4XMSE
M# XB!IK=Z94+!6,56 $=_<LLH^CK58]Y97/78<B!I'164T^F6ODQM/F?SLV?
M8L-8L&QZ<W?)W#'N^#$Q;]K'6&3PS[\Y5\6#9%_X_=G*O9Z>N?7U\#>%)&FO
M9&9_K2H)&V_.>8L?[2=:K^4K0AQ7!W N,K\QKXZTU" MMS&&GBXJ\7-MTYN2
M-=]NF^KWY@?WF[A5_#FB_P"0[N\D7O\ .RA_11_\-C5)PA_JT\:?[QO?W^$T
M1+ZA+C19^1O73;CJ5&DS-GT#=Z]OIJ( 94^?)5RM1%EK%W0,VA*E.)B*C<)>
MV$M)_?=8K2T,X<(RRTY9\2U'M8MS&"SUI%L\HZDHBNDG_LH[.?T-<]^3_P 2
MU>'>T.HEV58:N>HV,"9I"%CBL69JUFD6).P[ZW3AJ*W@K606V7F(\!U P77%
MS=X8ZNGL<4N(LSN36-4K>N-[0TGH'3IML&NU<BVHA-QF$DU)T\H'9(L;^;HZ
M:6I\8LLV6BU%N2T)+CBMX1<7D*,3>ATFGB1(K -: N)%7;G;=-R)0.<-X$EA
MONI G=KD_:)P5QEE*_\ "KBR'#Y*U9R.#FCSV72JU*Q*9?1(2ML(KXYI/1)(
M0%9%2*7D$4T+,4O_ & .!_\ W)^(_P#[;M-__C/+?YMQW_8*7_PL'_X]<P_A
M[QS_ .FG%G_U'F/_ -S0A.=N^>L;AOOO3_%RH]:G&GDAO_;)D:'^SJA:6T+"
MGU$BS24;$44&>)-UY*H1+W(LX@B.B<M,$APX:)N2R-'2D0\;29"QB:-F"FF*
MJVK,Q [J.O74H7*B,,3$WK2;[@>(4<QV!7?K? V"[2^,,#F.*+?:1Q)PY@,2
MDC_.-_,YV:.VM:.26\\"ID(B8J:HJR2[LKS.8(^:2*8(0WL\J\97>K/EQ4JI
M6X>LP59XP6N)A*I5H\6.KU:@*[76FAH:!C(\, &/@H&*!P-'B!@!"!QH;;;
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M]#HRU/))9$;2WE&4.N*SE"7Z[A&8G?JOE\1[QIF92P&WD?V:&@# =^T8 '&
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M\C].8#Q'3IX>/@/=IIOKJZV-&]<FKC*=K;)-MV!;?L"MH;=G@AQ+'=I !#N
MPA0F'"6:W48APDM4%5Q2S,"9)?*DY*9EB"9-Z-)*TAW/0#P7R'^)]^GD0(.G
*4^9T1#QO7WK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g686907g60p26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907g60p26.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Z ?H# 1$
M A$! Q$!_\0 'P !  (" @,! 0            8'!0@$"0,*"P(!_\0 9Q
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M0;3YS\0?A:;_ "II]C?@/^"EE_(T4];[/]_)'\H-I\Y^(/PM-_E33[&_ ?\
M!2R_D:*>M]G^_DC^4&T^<_$'X6F_RII]C?@/^"EE_(T4];[/]_)'\H-I\Y^(
M/PM-_E33[&_ ?\%++^1HIZWV?[^2/Y0;3YS\0?A:;_*FGV-^ _X*67\C13UO
ML_W\D?R@VGSGX@_"TW^5-/L;\!_P4LOY&BGK?9_OY(_E!M/G/Q!^%IO\J:?8
MWX#_ (*67\C13UOL_P!_)'\H-I\Y^(/PM-_E33[&_ ?\%++^1HIZWV?[^2/Y
M0;3YS\0?A:;_ "II]C?@/^"EE_(T4];[/]_)'\H-I\Y^(/PM-_E33[&_ ?\
M!2R_D:*>M]G^_DC^4&T^<_$'X6F_RII]C?@/^"EE_(T4];[/]_)'\H-I\Y^(
M/PM-_E33[&_ ?\%++^1HIZWV?[^2/Y0;3YS\0?A:;_*FGV-^ _X*67\C13UO
ML_W\D?R@VGSGX@_"TW^5-/L;\!_P4LOY&BGK?9_OY(_E!M/G/Q!^%IO\J:?8
MWX#_ (*67\C13UOL_P!_)'\H-I\Y^(/PM-_E33[&_ ?\%++^1HIZWV?[^2/Y
M0;3YS\0?A:;_ "II]C?@/^"EE_(T4];[/]_)'\H-I\Y^(/PM-_E33[&_ ?\
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M]H)VSEEADW& ^I4P"6):V8S?FXT(BI6P$ J4M*RIQI24#2T6QN221L1:</\
M!'&%H99X6<7PTKA:+<K]+%[(E2>(I$2\*FNMLM178J&(%R9=F*#EQ;G.CDH0
ME#:\*2Y8V7?*9;3VCS>7G/!L+G^S9WWV?!H6XXRS1#4I/#^'$ZC;ZY=;,+2R
M0EMEYG*"BLE7B0V.17JU/"LU]ZLH]$KA L:YR/7:&#.DQQ)7)N'*ULOI1R&
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M.4HSE0-4H\J2W>*[]P[%M-M?:L2[HTI1X@2U>[B[:K0+B^BW6,VQ7G),E0A
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M(WBK/DOLA0&W[>AFG<0YGL33NU1Y4JG'8WCU<4S,U;;K<ZQ(6Z-?R;N;RQ6
M;8[+"&JTC%V6F-+R\R#&V=P]QG'6U6K3;$+!%H=3&GR))4RJ'H0&@65*6XX@
MK!.IY&&M.@A2.87$K*FDKT$5I,GRFV]^_P#!UFX>2Q=6.*$RI3MQ<%U99B0H
M<EN(XAM#%JDZK@7Q*;<CS%0D0'8R47)R()3*ZHZ*V?,Y+ >TS-8WYRBMN9W(
M7O CJNA7$CI4YO3'>-FQ+.A)^FB'G%I +\H<\0HPBB-O19"A(K^=F%O'$$&-
M"D<PYERG(Q3IV1RRV-8.KTL\SZ.!C'7?:[=XO6U?>*[-Y@DIX:X=A7Y,CSD@
MS%2T7%9C*:Y)# ;\Q #H6Z5<PGEC1Z4SJ>PMO;O*4V#R?:.66<*UA,WY4Q&E
ME27K[=)>41QD%L7(O'5%2R-&CBUW,M6"&J=64MC9"0M<W$0QYQ)-P+LN1%M#
MEU5;0\$A,AYGG*2,J#.OZ*-0!6YHPA&L96H)U=M0Y?'2HGDX8X^-J4\MZRVN
M[&UM2%%+1N1BI*7)8C+6F+#,KG2I(B*4W%9=>#!*=%1O?/M*INU.;QY'U>U9
MH5D+I%V1W8<9;B< 3V <P8X<5Z71BF3B7C%9NWTFVUFZ(**2U3LM&N<R@9LT
M>LYAK&N46IW_ %N,%N&6@A;^7 HJ:E1E1GVBDX!*2I:%H7U0IM:NGI8VS(X(
MXLF<4LW!R3%LX;A.1D,7+A^_,7VT7$2&E.K2TX&8DV))A$!J7&G0V5:EH4RM
MQ)4&ZMP!LWW%[H(>UV+"M%C[)7*+.5"MW&Q3F0,:X\@*W-7X)HM-9RLUDBX5
M*-;>L3FOR4=&N#.1:K3'H^%\8LO,PS)_AC094P+4PVE26U(0M:G6FDH4YJY8
M*G5H U%) /35A.<J2#:7_C#A[AEZ+'O,YR-(G,2Y$..Q;[E<'Y+,'D^>+:9M
MT.6XKS=,AMQQ(3K2SS']/)9>6W.8GR=.\^9B\B2K;!TPT^"ZT7RE6>&G++1:
MW;7UMQ?$#8,B5ZB4FPVB,N&4Y2F07$S8&V,8.WFCXLZ3Y;ANNB=3(+7/4EU0
MCJ'*6XVM*EMI65M)U.I;;4L+>*$[J#25X&]07?*'P:R[;VE7ME?RG%@S8SS$
M:=)B(BW-[S>WOSIL>*[$M;<Q_P"TQU7-^)S'04#T@0)/!>2\WOV*FPV0(_$4
M(A49VE8_R6TE9G,^":X+/&F48U*5HV2+!'V#)D9*57'\TV6*@:YV9E$5R+E4
MW4',2+":8O6#?LFT7!2$N!E(0I#3N5/QTX:>3J;=6%.@H:4-M:PE(5Z*B%#%
M1G_*;P5'F/0'+N\J6Q,GVU;3-FODC7<K8Z6IMNCKCVUUN5/94-0AQENR'6BA
M]EMQA:'%?NO^2VWV66;N%=C\&>:R]#RLZP;96]AR9A^IIH9=0@8BS-:!%O+3
MD"'962PS\%/1$C4&U:<2Z=T1>D"IK3*B3@B)-GN*U+2(^[;QCJU.L('."4K#
M:2MQ(4I25)* G.O/H9P<)'E.X'C,PY#E[UM3[6B]QE1[;=Y15:5/NQE3W41H
M#JXT=A]AUN6J2EDPR@^=)9!3F:R/DM\_/]MN&<\X[BG%NF+Q5MR%GR7C26?T
M>CV_'A-N&2+%2;7'5RMVJ[1UTRE*,8BM2%FM,33:D\F*DBF#:1CCE6:.7.4V
M>28C$EH%:G$2E/,DMMK:\U=4VL(2MP./$)05K2V@J1C!&XS";\I]A;XCO-BN
M#J8C,*5P[&MMR:;G38EP/$5MCSHKDB1%A.0[8VMV2W&BNS)2&I9])MP86E,/
MDO)SYYGG\ CB*H3MDBS[;< ;@;K8,B36(L45^MHY]@$9&IQ3&R3^5W-9DT;1
M*'6B\;1[Z:ALBW?P%><=P\@BZC&_15JD*4D,(4L>:QI+BG5,LI1YRG*$A2GM
M!UGT6@5!Q?\ DTG(J6WY0[%'1(5=Y;$9P<1WZP0V+>Q=[H_(587RW+=<CL6I
M,EM49K2[<7&V7K="U)_]8/-J2XJ!3GD_-W]:M,929S#;V.M$QN$B=JL?$*V[
M'QUE\_3M;K=NB\>F61MBC5NZ=5ZW5Z0&=<KHU5OZ1!JYG47K9XV;X56R<E80
MI@A:I0A@<QK_  E2$K#7T\ Z5I.HG0,X*L@@3V./N$I,5R:Q>$.1F>'W>*7'
M1$N ";"Q)D1';@$F(%J2F1$D-\A*3*5R]:6%(4A2N ]V*;HHS%LOF.3Q[$QE
M(A6-SEW!9+)V)V%S?5_'=M=T2\6FO8R=7E+)=JJ%7M[!Y 2UMK-2EJX@^:N.
MF3.BW753X-NEI94^II*6TZR<NLAPI:66W%I:+G-6A"P4J6A"D@@[X!-=T<<\
M,.W1FSM7!UV:^N&TGEVVZKAH?N$1,Z#%D7),$VZ++E1%I?:BR9;4A2%)RV%*
M ,"Q[M=SSE:LTNX8[QX^ME>R#F^%VX5-[%RU<,M(YIL<4VFX&DN8U>81E(9:
M7BG/GT?-SC*-K3I%I*BE,F-#2Y66-J')>0VMIHK2Y(3%00I&[ZP%);(*LIU
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M4H:+?3IU[33I&49J>,7?8[4F2XS&+FJ5*<2\AT,\]M]/+ >"F%N$(3E30"T
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MNB/=%VB8JWYS'>AV2W2)#X3(ENNN).OK&K_]Q6G]KYO]ZQFLME_P3B'^)O\
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MFV1;E#E6^:RVP4H9><CJC2HS;>F+(0ZMM 6I+L9]. .95M[L_ Y$W&YOD:)
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M2);Z^)T\41YB);[CT1E]F2VVTEAYM,9\H^V/QD.$MSC+._W:+MSC-KV/=O=
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M/L\^3+?_ ->N;=?_ %?,V]?VFGZ'COFXY^*5N'X^[\#N0N/_ %]7=/F7?O\
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M/[(XZA$"^!%O5>H2B(& /#0-R(" @(![A 0'W:Z?-*[]]O\ YRA?KJE)\L?
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M043<< (ZQ_($D_\ XVR[=?\ UW;-O_[FN3Y5N$TC4H7U*3T)X<O0!^LP\5C
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MX('(J&(!>L3+<CTC[P >!JW[NM>4I)&3G *B ,;X))/7X=*]6L?D\CP@A3B
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M?5L=[TCHEJR4;]3585>$P3*5%18O2/64%% 'DI@.<.#=@,0?E(/?4H(QC .
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M=.0HG2<=<$[#Z^_M[<S-Q4$FJ2*#9F)$@.";Q<Q1$3G3$.I(.D.HY0)QP!!
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M&"!X=>W;U?54P<6&31:KJLDTC'\,O!A;K'3[&.D<Q4B' 2%$P@DB'("<YAY
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M*:4II2FE*:4II2FE*:4II2FE*:4KYM/]4HHG5\I]D<")@?G&^*0Y[=A" /\
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MCHH-8F/9J'B!='Y.@5_)F#Q'#CP3B;E4!; <!$H=92ZLVE2&]*RPH8<!)UG
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MZ<A.#JP5$ =I.3G8'U^Z*42'\XE4W#M8QE5EB@"/M"!! Q>HY2<%#J.)2<\
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M_)L$@ AR##U)9<5@G',<*U*/7!"E;XK9Q!8QVA>KH-T$-T'-T$!9$1,  !@
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MMZN><#=*3L1TZXQC.W3])JB9LRSQ?L1NFBF4HK*J%44ZE^D!*J?@IS&*MTE
MAC"F;M[0 7@1P.H'T=MP#UZ=0:W". PTI9.5'("!LHITC! ]?O&=S7"<'2C@
M,/B-EP%%,O9<&Z9DBBF8 (00'Q$B%'PSF*"A@,8 Z>=5#F6UJ &=)]7<>H]?
M<.AWKJ5\U PE20<X21N/#W_FJ(5>>=3+P%VD>LW5(L\2.Q,=,'IVC<_"RR9
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M$#N_;J:F*0J+)UI!PE"1UZD')^/=C?K4:EX,S0BA% .F0IO$!3@!$!+R('
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MSLJ$0I20C PHZ<J&^H=AWR.AW.QWWK-M5TW9.A5(O08@"4JG282D.)1#_"*
MD$WM)J /)#")3]/81L&76GPEMQ*5!*1NI0)[NISV[=XZ;&JYUM;*B4*.<_<@
MXR.P#&=O80"1MTDD 4$GAD"ATID3-P01 1 >2" ^\>0#D.X"(?\ IJY@>BZI
M"?H:<CN^._Z/559<3K9"\DJ4XG<CJ!D$_MOMT[IIJWJFKYB_]4DH"MY8?*?<
MH@&.L0B(F^U  K/( (_B^UX#W=PUC=_<U8ZX./75Y80#-;ST"AUZ?7GU8_;;
M0/&8M%/-V9>?&+X2W6)@ # /3R)>KI]DAP,   \\!SQQ[M7='I*5]9\3G?&_
M3.!V>JO2\$E.G?*ML9SC \<8VZ?L>PG&S4C=3Q!,/2IR=11,"B<#& A"C_A"
M(=)>1$O</D#[D5P;9':G]'3&^WJ^%3TME12<XP-P>O7IWX]F^QK:J-?)KLTT
MR&]LO"0%,("(&X,)0Y'MP(FX'J$P<]S=N>*F:/1;R-ST(SUZ#OQ\.E6C:%(4
M.ASCIOW]^/K]GKKGS9L$DG!2'F?A.70'<(F.9,OA.!\%,#&(DH*9A.8!543,
M)B' IP.(%*)>T1X<M84E)*"$ZE;;XZ X[L;=F.E;$N0E5N6@Z<G*0GN.E78!
MC&W4]>W;(K=FM2'FD-4VZCI,LC%P1VKYX81*X=K@IUD<G70'J7.! ;F4,J;E
M80.?H.)C!JV9*"@$')V[#TQG;<=O78]>\;TD&,E2'2\"4I)4"/2(_P!7<9ZC
MN\/&8RL\NU&.1E2*"WC7C9\D"!/-2 +IZV#Q0! HG-XY#)*F5Y ON%8P  $+
MCED(963C7MI[P.FY'0]QR=L=*W7AZ"RTVXX'-16,@=B=]AC'<-QL.TGOS=UK
M2-NR-7X(H&.T5?-E'+543"NJV,Q5565.<0.<ID3D*L D4X4*42@)"@8H86D:
MHY4K",@@ [*Z'<=>I[,_4.E+N\F/"0O4 E+SBO1S@@[ ;@;Y!!"@-CU[]OJS
M08>J1Q'$O"/)-'SUFNX301<*IROFG'FK<[5DN)^ER0%$#+. \W+XO()* 0!'
M)$A:R05%04O??.1GLV(/9M[:UR9<)$IA*(LOD^AZ2@5!:1OG3I!&>P;_ *:E
M3.92?2TJQCXR<0D))O&-X](K=1NNP*R07;L&G4DN1NWZEBJD7=-#>&=5%119
M-14Y2EG?;$.MM:%>B=L=,93IW&#V'LQTZY-8HRXRRREQ1YB1EUQ71T@9"E$]
M#]+UDD9V-;J4^O.SPL<:1X1D"()DD!,<JJJ:RH%(<JAQ.=/QU!+P8A1\%,/8
M  X#6SZ-;;842% #/0CI@>[K[JU>[S4MS'"RKT0HD=V_0CIGO[O$]M49%P-$
MV)P\:R .5FCM3TFV>I.G#24B01^S^*R71$@ME$3$33(4I^LW08! X&X#'(A1
MY$1YAS4>9@@$ @$?62,=AP? ;[2HE\+K"65%(U#2=6-B-LCJ.\^'?@US\34M
M.MM[9,@SCVB<BX*9D"2*+95\R:M",$)%Z0Y!6(Y*""A5""N')$RJ@!5UU!&'
M!93!2I(QA0TY[0A)]$;C[X=-\>-=[K<7I APM1*4)5C&X TYZY&#]7J.XK-V
MQPF];JL5U$W"C9/P4TP[E,)^DR8J<E#H+T]!N>3%$1X$1'D==UNZ4$ Y).PZ
M]0=SN!O^>LUOCJ:4C22E)*=2M\#&=S@;=>M:V/Y$R*<FN9FH=!#Q%?!+XB8"
M"1>A3GI.'(+*)"5,0+R'//VG28*TR',[]3DIQW#L[#^Q&_0;PF,E9:.OJVG;
M) .Y[,;YZ'Q'3&:J";F#3+-0[4_!'"G]AE5,J"S(%ND!((F-V3*4A"@GV .Q
M^.L>H,J0I8"\#<9WV/:!V8S[, BIJFDQ0%E .>_I@8W'A_;N3O5E8MK[\%F?
MFCMNC))KD*H\;)JE7,)03%5$6SCSADN@<AE2G%14BI?&'J.;I#B<8W+96A(R
M2K5K'TB#UU'8;=WO[],N,A3RBLJ.D9.-\* ';V[YZ]V.F];LP5;,Z9%A^%"-
MD71E&[0 51.W$!*[68<)J&!1(A>56?2=1,6YBIB1,>2E A:$LZDC?5DYW &,
M$[]^^=ABM'EW!+,DK3L1G)P#C;'7.1V9V'9OV"=2%+GF[.*.Q:F&'*HHI((L
MQ33G&AE!*=20C05<-B'<= +D*F*Y2>%T)N"G(!R*68$7S=+2P%JQ])(!&1G!
M.2,>S';UZZ['N=N??F(D\XR=*O-R%89"SGZ8"B2._;.!T.]21Q&G.W*T,=TL
MV=I^;M%C@9DZ%RF3K*UE6*!4V(. ,42E<,B%27Z3>&"8B0@U\AE 4G=('AG
M'HCNS[COD#QCQWT\TE26P4_2TE6CI]QL#DC))Q@G.V*BKNIMW+:+(X*BU2D;
M*R(_5:@8BC8C)B^!PNCP3VC@W! 2 *I#DY]L"F,'*0I3;+02-7IH"@-_1)_H
MXSX8[.ZQ3<")#BECG);BNE)=],H(;)2$;C&,;=W7?&*D=2J?F4C-E<DZW!54
M%2*"@FDFJF)5@ZP(4I2E%90IE%.D>DRO)AYZ"B:,"RJ0]R@H9"2YJ  !S]SA
M2L]-]AUV/?FFW+SEB$Z%A/VM2< X((3G?&>X=O9C -;/8/B$HNQ3(D3(D9:(
M_M*74":8&>MSB %'@H!]KT"0O<H<CP/;4J.G"U8[ ,_^]G&/5C?..H[ZU6]O
M%V-'*BHDNDC/3"48(]X^KKO6SNIM:S32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI7H$^7Y@ D/*.7]T8I3 :@8Z3'J H![$&8.>1Y^X/'/XM3F4)6P
M4D;ZCOM[NT$?6-Z]<X/MP?L[+ZDDI4\[N 2 ,@ 'U8)\<X';GI@1J$8W)UBJ
M55P ]0E*!1('/(B4P"'OY'_^/Q8"RTPE64I*E*/7(SD]?KR=AMMMC-;<BWMA
M83HPG'TL''N.>[.^,'NKSJQC4A"E\(#&$1]P ' C[NX=OE[#^/\ %QJ-( T%
M(2 !C;OW!Z=_?[?"M@BQ$%*@EH* .Z@,>O;L[=C[MJ_@17*!R$3*41[ )P#D
M YY#CO[Q'_)VY[]M8N6KEZ4K SX'H>WL]6,^-2Q!2<:F\=@';GNV]8[N\>'A
MCH%%=P7K*!CBJ5, $0Y*83%Y, !P <>[GG_('W>D:,-922%J!R%CL&-DX.>[
MKL#FN56Q.DJ"!G? QOMOV[=N=NAV\:W3J5>8M8-NU50:' 4DP%-5$BJ9S= =
MQ*<! !YY^0/EX]^MD;2D@:E ;=/';8C]NO9UJN7$4C.E(R,YR,G/M_37.D$O
M1+A(C4C<$52^'YL5(B;<.W44 1('04.?E#WC[Q[ZB25\I13NI*AZ.-@.SIN3
MU&PW/05+BPRLI"@ 4D:0!VY'9TV[M]CZZX$=..22?FQ4A0.0W2($3Y2 X<#[
M/(\%+]T ^[SSVU#0^MLY&#UP<=F>_. >SZQXULJ+<E32=2>A&WC@_HW_ $$5
M,9:*1LC-,SD 5*FF<%3 4O*9C (&$!XY 3<#P8/=^+4I:%.(#J5C40<]".S'
M:1V]WA69$=" II;>0<:3IVQN#D$^([3W[56MNHQ"(H&*R,= S8O@GZ.L!Z@X
M+[0<=2@ ' \\<_*(@'>E??=;?"'/H #TCT(/3 QZNG=VU=Q;9'?C+PA)5N"@
MIZ'I[SD],9\>D QX5;'-^2E2(E.S>H'8R2'O 4UQ*8BH$Z^ 4(8G'8.GGN''
MNU*CZ=6H(!))4G';DC"CW#<$XZ]U:Q.M"H2W'F5NZ5)])D?N:2-U9&Q.#V9V
MW[.N\>.1:O;":70-U(I<AR<I *3Q#E-T@!1$>HG/;CN8>/\ !UG;;4ITJ6GT
M?2)V[2#@?4>N.SZ@)S4LB$A 7Z92G ZGH._M&^#VCVC>%DD#IFD(FX$>CH((
M  ]!$PY'CY1#CGCL <@(>_7! U$9QO\ 2WQV8'@!WU&CR"A.Y.0HG.<]Y'@,
M'/J/OLK%%7QZ\OU51RN_=1>.G,P4UM>L$G2KP(Q!%==1LD#)-5X15\H@FT*J
MV3.=(KDQQZ! #ZZD@'T3D@[$#N_,?^^:PW>XW0VV8JSI#UP#/+90X0$A2_1U
M$'K@['<;8'C6F^^&*Q/\(<Z[P8WL;?'C-)FA$*V<X+22S@PF!^L43D!=)@9P
M<@,VZZ@N020$Z@\FXU$FX6V.;G2,8[\#._3?KX].W-;[Y/G;PFV,(OQ:-T6I
MSGI93H0A*@DH0-R"M&/25G!]=:3T:?%0Y$%3!U)<$.7CH-R!A#DQ>>_/ CV^
MYQQJ(PY@A"NG0'/M&>[/<>[KBO29T8%LE(WQU)\?S=GL[B:M272(\23$HE#D
M>>@_!@Z>_(B'5P8 ]X /81'GW@''=[259![/'V;=OB,5+LJU-+3U[NN,[@_'
M.WAWBN=CF$2>7VH-RJ^;N']BC&B*Y3I-3H*O7230JR:BO6B@5$JIEC*G2,4@
M)B8Q?9$=05)WV/177'9T/4]?#;OK;;G-Y5IN3BPDH:M\EYM"^<H*=CM><I04
MM9R'.44@$*U+TIPD$FNX+9#C=TPWCXJ=V=0'3Z)V_/YLSA204E5'@@\L%*AY
M@\AYVX,=LYB"(+1QQ(T0;QP(-B()$13$:BY84A"2-*>;M@]S(!\=U9ZXP"=M
MJ^:_*-?&I7!/$#$%: T[Q6AAMD-\DM))@7&2RMHI3H=#RG]2!J)<!5DY.?8W
M8++)$+]D, %(*9NK^UF%("")1'@#]7'<@@;@0 #E[CQJ(TXIM(4%**-(]$X(
M(&-N\C'49\>ZOE&0VTZ5>BG4%=1D$:ALKMZ=<8]O6LLHV1=_90)]C$#*+E(8
M"F()@#N4  P@4PAU<% /$*(@4!$"ZRAAIXC2-E^DXWJ (SVCZ]_4*C!YQG8J
M]). A6,CP"L^&Q)/7!/8:\"39RU'I$Q#I"43H."%]I$X](")@Z^Z/2( 8!]@
MP#R'!N0UA\V<8*@M> 4Y8<022E9."E9^Z21V#OSG%=UO-/@E(*%@A+B2=EC3
MU3MLK5V[]W96=0%N!BI',!CIB '1)R4R?6(AXH" \"W5_P 41$$S=/VH"/$A
MI$?F!HZN9J2E;: 1H*T@ES/:A9(43]QJJO=+J05Z<(.0A:O2"L$@(/:%  Y/
M: <GMJ:0)#$>=)PY$$3=)A !'I]GL)@#N8 #L(CWY#WZV& @H=2"#LVK<GKW
M;=V.E4EP(4V"D[)6 4]RNA.?<1^8;5,M754U?,:_JDTY4_*^9:Z_M?@YQ (F
M_P 7FKCP;L'^#R'_ //;6-P$C [O5^G?H1ZLU>6-0#JR>SU[$9P=O5ZN^NKG
M'$KYI(12KU17S15P9%;CKZR N)6X+(@0>HQ"F\-8@%]Q3&-QQR(ZW(* XIOM
MSV=QWZ>KJ,^/K]3@EM<4N']TTA0!]9 W^K/UUVA8SET%X5P90@(.XR2-&K)C
MP1)TF9(%$G*1P$1Z5C=A/P'A"(@?@>VL)0=*E$# R-^W&_OV_P"]&W\+"5]2
M<YZD^P^&#T]E; P8NW@#X(=(*'*/M>T"9A ?9)T_;& .2@(>R(\?Y=4L@A0(
M&XVP>N""-]\=@[]ML9J_C**RE1QG('8#C\WCCPVV-<>9<-$WY#R[(ZAFZB!D
MC$.HFLZ#QDE@**Q1$XF14+T']D *!A[<]PB,X'-1_P#M$YVWZ'U^[?IZJVA$
M%$E2&6@%+4G4.[4-MP>O7;.W=WUMK1)2.LA8LR1S.$"E\202.00%H!DRD,U*
MH)""LDDL )F,3[() *?D?;$;IM26VM:$:B$Z<$] 1U]^XZ'KOFH$F'(B.EA3
M9WTI(3G'7.>T:L=!G] JYJTHM*3KAM.$068 *1(UJW%0?.&#44S) JH!4S H
MY43 ZJ(F%,C<@IB4P@&H3KB-)UO#*\^@HXQU'CW>&QS6WQ(PC00IL:5Z$Y)V
M(W)\3VC [J_$)99![F)F\*J8IVKI5@X221ZO1L(1KYHZ=$)[70Y;D%)9(54U
M14347]D2G$-22@.MMA*]PI.0,?1!\,X\-LXK7;\RHM,(TZT'T^4#U4,$CO.H
MYVQG?MKLNI2B+MA$-&[A-R@S#A*04<$<O%FA&HIJ.'B2OAD34*H"Q#( !C@
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MW4;#W=;),5 W.I1Z8.,9[/N<]?'/7&,UBXYPD#ML4 $JI53"I[A()N0^VYY
M.X"(@' _C]P:@1I*?.U GZ77![<^O;PP<=XW-=^4D^BH=QSV8[,[9SV]:V,@
M[0<QVR(J)="9!X'K'VS)E O2 <CR/ <]A]WW!U;*>(7Z*B1V@] <=G3WC&YK
MJJ E0)Y:2=CD#.?K\.G3L .]2QVLG*-U13-UG2$I@,7DHD, ]0CU&*!@#M[N
M_P @:.OAT# .KZ\ #MZ]O;X=371N$I"LZ%#'WH_8'Q]7U5_(0C$RYE5CF([#
MCDIR_;>X.L!'O\@FYY#\7OU&.=L 8VSV;=I&=\[;'V]:NH[*BD H)QN-N[^P
M[^[;K/4')6[M%H@'B)*D$JH?_+*H;IYY#GN4@&ZC#SP &  X'GG.EQ2%:$+&
MDX R,'<YQD8R"#ML,=_2I_F*5MEPI4%]@[,#(Z8R<X!._N.UO03!K*,0CY-H
MFXZ2%.BL0 Y*FF)C"CW'@ '_ !A 1,'8!#Y9!C-O@:\'N&WP)_-]=4<EYZ&O
M4RHIU[+Z]F.FG3I)\=7JVQ4!MU,A'3HSEI'))+D*0IDR)J&X,(\$Z2AP'?D
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M2TJ>)22#A(PL;]YR?9T[JMHC)V01MD[?7TVS[.WMW&VP-5=*/F(]728P@?\
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MFC.@R6D/M++\1A;[?]Z!_F *AATJT(",I)T G"L>SC&F2(4I>L.H@E("G<1
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MK>9:PP468-7BL>@W*1T5R(+$.4H%55!8I"B'L]8](\@/'(A]VRYB)#*4'J"
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M4E2*K '680,')B!TCT&#D3!P ^\=2DR H*R=BUC)[3C)'KSL1VGI7GTGAR7
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M\';MZ=3ZLU[-9TI6IJ7DA"&?M?>E9W SWXSL!MV=:X558)BD0P)E$@%1*F'
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M$%'^3V[<9&_;OM7Q5)!25H4G2\RM04DI"<.()WQV;I.W3LZ58K50A2"D(*F
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MS\D*#<CUI-2+63@UW8*N6T1XOCD<IRYV2:"1?,R^<*L2]16HI+(NEW":A55
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ML>P;C??&*V]^Y0#<46Q;O]_E@O%H K 2-BDE.<*]>-LYQVZ\U4$2F #_ -K
M>"G QN>HW(<%#I[B(CQQQ[N>_P NN(@U-)P201G([,#._3KTV!W]53&%!IS1
MC;LSL!L>IZ].ZK3=^"UB_.!2$JG &(!C!UB7[8.KY>_ =N1__P":[)4K7L5
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MA!1BK]Z9J=-1!8JB*")R>;!U 4%5U4R="@< ( 4!P*;+B%-A*EA?5*>H^K8
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M+CA,Y@ _B)J$$G614@E.35KPVT%O+<6XL:R2,=02-DG(P=MM]^GU6WE*2&K
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M$55>$6>2*I2)*MRLP.F82O"K)ATN4U_%2*8@I@JJ!^@P@;@8C"7%.O( )WV
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M)VT.8!QVD#./K'2NJJX[LKQ;MN3#;A,OO'KL'8$Y")3*R2171;(B)B-WSP@
M+ULD)U2M"*%$Q"' O(](#KMYP5Q5Q59T@Z0D=H&W7V=#V?76[M<.6]F]N7Z/
MS43)$4LK47E*;2IP%2W V?1U*).!T'9WG56L1T@1P55,@JM 7*(B4. *(F$"
M]0#W#J]GCCG@.  =88K3C.I!.E*\Z1OMMN.P>/?MV5::$Z]1W&_L&=_SY[>V
MIS<"N$6[83@8"<D$1#L'LAQ[@_'_ .0C_D#6=*2TE>L#<8!!'81TZ#??Q[ZD
M )4VH@;@G.=]O#??Z\;=>VLO18\%4"+'4*'B*#V]QBAST\!P//N[<CQ_Z=]5
MKJ3S1@[*WW[-]L#.2-@0,8\=M[J&0$))!V3CV^OV_"KG3BTFQ.@ [K%$.>1Y
M, %$1,/(<C[^P=@$1X#[NIZ&0$ :RG(&<8R.W&Y]6XZ#MWWE<X*&D).,[D9Z
M]_0]>_&]<ZKLU6KP2)*F\)0X'(4X&+P?GI,0##V$2C[74'(" <!K IOT\A6%
M$:=O7MG/@ >_/9G!J3H44*P"#@XZ9!QV^&<?GZ9JWG+1Q,\-%N5$A1 @)&X$
M!$1 H!S[^H![FX'GW?)[NSF5;*5D8(P?=X;;XP?8:FP@B,G6VD-N9UJ42=\X
M)V]G<3XYKA8]CK1B^WO):,:M'C"23!C*,'!C%0>-3GY B1OMD720=1TE^# 0
MP=^ -J$&%H6<+PGN5MD;#LV^&1X5S?C!O=O2PZL)DL%2V'<##;FDC)SL<X![
M2 ,5OUCW</"UVP046RBYEPX?'5:J-%D0Z(])4 %8YW9U@*X32 O4GT@)C!ST
ME]X:SQP67#H.HG?U=XWQWG/7PKQB_<%39,)QY^1#0AI!<$E.0'EI5I2C2@>B
MH]Y&,]-MZQ>5+G6)1"W3S1X@XD2-9-ND'B%,0K=P3H6% @=1>Y1'Q"CP<HD(
M80]_'?*0^M2B-:@4@], _<GZMLX/MK-P_;Y\<6V(IE]#04TXITD<O4G0=)[>
MH'0X(WZ5USJ/T7,691FJJ+)-R<W)1["(#X1 /P''<I^P<@'4(#[@#4^(C4TX
MA'HI ^)[3[_7M6[W]26GD:BG6I"-AG)]($[G;.WK SCPFF/+2^9J^ 5V8A$@
M "_X1P/U#TD >>2^[@#!VX[!W[ZB!:0I2<Y*>NV,G)SCO/Z/#>H)BHDH1Z.0
M=R,=<C8#WGL\<5MHQN(*MF@KK$1223(NJ<ZO J"(  B80^V$O(F[' >.D![
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M@''W@&N/V_;^S-4FA)1J<2 YG?  3CM.#O\ 7D^JOU)' I"JG IETEE4DP$
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M^@Y0X  #@0Y[<<CW'W%$/\@=AU7NA9T.*SL-M\=">[&=]O'LJUBE"<)QD?1
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M$*5S$IP0HD!1 WWSCZ1\ DX!]W3C$A) C0J@@0L<4"D*_.J*:Q$6X *YDR&
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M40.N-L;9S7K\@!F#&8(W0VRWOUPVA*>G9C';ZS5;SXG(]32.<BRB"**91*4
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MWU-HT9.,XR<]OLR:I*.8FFKPSBS**%;OGC;Q3(@1<R"2IRG4.03B4I0*F(=
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M'6MWCXU+6&C%%RFGY^Z;E,*93 "A!'I,)5. $3 /'?N(#VX 0YXB.,*9 )4
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M1UU#Q&1L<;;9KD4&HVVJ71_.HS+B1KT_(*.CLE^L?,C'3!$$6WAE,D)05$3
MMU$*''1P4W5J>%E8!/7N'9W]._N_16&X7*VRK<F*IE"7D( UCKD]^=O=TR:V
MY3='(T$AB>U[S#WZC=?0GU&X)R!O<!Q+U&Z2]OQ*\]V*D) P YJ&/!6V_P!6
M2>\G!J".),$7 )$*?H;*=P(4P^<G[]0 8P$$01ZP'VAX,8.D0]PASM^?']OY
MJN4 N("CI&^V_=CM_/V^NHU/6 2(G'@R *@<Q"E-TJ*D*EUF#J*'/6)0.  4
M>_ !S[^>/J\/5X]?VSTZ8F16COC<$X/38;#.PP/#KX5=6TR0(ZMML23$#)#
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M;&#6T170&VPG8I(40>N% #&_NW[?JK]JNS) F'6/B&3Y/UCU" B8>X\@(=A
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M6EP^C@8/HJQMXGNZ9^.>DP(PCY3S1Y$10D5<D*JZ4<'X\V<I.4?&.1(RQFY
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M[\!SR/'8;9B.VTDJ)4?2) [0?#N[>WMWJAD\4V)Y[)O-M4>],Z.0=AG3ETX
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MI2M)3RE$$=N1W'H>O3&_U5K$F]P'CK$^*E0^CAY&!V]^1]6?54Z88VRH@5-
MV-K?X (D0$I:U(HIE+X0 3PDRM4DTB)"'(ATATF'H*!N#"&-.L (2TL8R=1&
MWJW[\_#;-53TV"YA7GL52RH9R^CH0<[E7J[2/5BI&AC?)ABIE/2KP@BS5,JD
MDC"R:(K=)%"%24$C43';G,;Q%D^LHJ=) *(@/2/5045#+:SUP=)Q^VYZ_P!M
M5[LN("K#T-6>A#J".O@3V_FST.\I;4W(YC&5-3+H!/! A$35^11%,X',<YP,
M+<#J>(4P$ !#D +P   !KOI40"$*'3J#D'/CO]8P*BJG1P, QCJ/8XDX!_\
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M_G"_R=_]73^Y_P#*C^ XO\]6C^N4_KB'R5'SZVW^!3+W]#M/G-9_\X7^3O\
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MJ9'1K&'8,W<:4DNA,O)*6E7O9=W<4 D-9 \[])QYUYP^=QE15ZG'"20A)RV
M  1OG))QP_)M#BO<]5P"5%7#1Y%OM5LM,%M/"_$#/$$,,Q(3*$H5)?:4S,<<
M<><6ES+*F4-M-(I6,WBRR.)1PW.8ZK<_5@VIO]KR2YI:>C)1! NZ*U[LJQD-
M-RQ<E2-/5S(EF3CCPJZ"T%-5R-(S>H)NG2KPD<3SR.0IE*D>9F)G4I*L>=KF
M(<R/NDNJQIQI4D '!)-7+O![2KM\L,7"0Q*^=*.)B.2PZT2>&8G"LJWE*TYY
M$FWQBX'PH/LR'2M!*4!)O>:\II+6&]HY;EL 8X<Y9JFX#-NY7$EU+8KP@&.\
MEYIM,=<%%G,"A,)Q5RAZ%88>(GZ5'RZ;=1&=C&[B9=2\.XE(&1DJNQ4X'C%:
M+S<A^4PYK<^UNOK"]T@A+B6U *;!P=0R24DI-$SY-6F()M+5_N*+5*L-EX<N
MT+S>"KY0MMFBN1 $OJ9+L-Z='>=8FN,E04PX4LI9=2V^W5)-\\\VK_I.-QA4
MH[/2F"JYML<9[;S-H-,&Q35:Q!4"(.WIBLB>KML@!C*M0N,7EQ\-5HXI[950
ME;0MKI:U&P?**@G(9;$GS=,7SG4O/)0A+8^UYT<SE)2T5XQH'T-?IU:G@=A4
MCEN7.6Y81?)/$:;"IF*&?E27)?GO!4T-B4J!\I27KDB'D*3+4 9"HJ$Q1,I;
M>@TRJ_F(2/J.-ML=HS%N6Q?N:RKN"9R&5K(E%97QRVRF=K9(BI1+>Y/ZU4CS
MV5K%:TZM5*[.24?.KBBT>+0*45$P60SP\5)"&HBGY3,MZ3EY>EYKFD+2A(64
MHU/*7H0A1"CL=. F&UP:NUH9?<EW+B6+9^'+GPU:K MNUQE.VJXJM@7&>ENJ
MAMR98CVN/%,J7(8;<93J6E+ZG77J2WOY^B-RNYK)>3JG&(0..U9)O6<6UYG&
MC",8;'%3:I0=8!O BZ?!!KS;9HI:IF+*]>^!8I^8.H^?+JJNUX]PDIERW7FQ
MI:R$,I TA+2!I1A.3IU :U)R<*4K<]:NN";"[PWPU;;9*<+]P#:I-TD+<YRW
MKC+47Y.I_2CGI84H1672A&J/'9 0A("$ZG:A5M=-*5]*"9^V@_VDX]_D)7->
MXQO\'8_V2/Z(K\D+Q^^UT_C&;_S+M8?6>JZFE*:4II2FE*:4II2M?;CMNQQD
MS*"^1LJ0%;R4T94F,IE.I]PJL1.0=.XF92:M4\P+*D?E6FK@HM7&+YP5LT\T
MCJG'-DO%\X='-"=@L/R"_(0V^ TEIIIUM"T->FI;BTZ@<J=^UA1P,!I('4UM
M=OXPN]FLJ+18Y4RS..7)^X7"X6^=(C2;CF.Q'@Q7>06BF/;PF8XT@K7K=GO+
M5ITH%5[3-H<52HFUUYA=GZU?E\47K#-5C3P;9+U+HUJN-KM,#$M5B2 A)-Z.
MRM 5:$2.BR!6#AHQ-82+$4.?"S;4LI<0'5%"H[L5M.@#E,K==<0@'/I!H.<M
M&P]!"<[U:W#CY^XOP);MM:3+CWVV<13GA)6KY1N<*WP(4I]:2T.2JYN0?/I*
M@IS3)D/E.4E('C0VC-DIM-RO>C/JR-EPM;WE;=U1JJH\G,/T=GCX2'E1F?#]
M#6BOQK#SR,5BUU&#TKI9-\[0<@U1X%M 7DNY;*XCBD%L9*XK09^EKQH<0E.4
MZ20<G40<#E7'JU1BA-L#<WS/B* W,;G+ ;BW^YN7;(8\WSYQ"EO.\MX/)#K1
M;26FU(*UY2<VJ0<')8[E=O3JD[?5L?R-ZDB1E?Q;#RE;F7=_A8""F'CR!CYB
MIH)R16-<CDB2 ++*J)HHI*%$B"8!V7;D(4PJ$6H18+RM*(Z5-K+Z4(42@*;
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M7R;9HB[<-3R:#6/%R+)'"U:F4I0B1HE-MQFXJ6W64Z=#+BUM*4"5@K2%!).
M"1J 3G2+2Y^46Y2'Y4NRIE\.S9M[F7Y^7 NCX?$JXPH\6>RRXTU&<;BO.,J>
M;:*W%-H6&%K>T<U61<;9[M$67)SG%V:4\54K**E6\_K%>QC O9FJMJOC6J8O
M:MZ19)&:/%PGAP-28JQGG%/DF\2Y/]B:KD12#78P'4./F/+\V9D%O+;<=!6V
M&X[4<!EQ2BE'H-)TY:4$GL.*PIXQMLB'9D7KAU5[N5E3-Y4V7>I3<><N;>9U
MZ6NY0V8X?DYE3W4O:+@RM] ]):2HUE5MNMKJ2$3#X/RXMCJF,<=5/&*]!MU-
M1RK44(.E,'41"RM9CI*QUU2NV1>(=BPGW*KB8@;$#.-=RU<<OFR[EWV,%QO2
MF))+#08;8+#K0DM:6@4H4VE3B"VX4G2LY4A>E)4@D$G"GBV#/4^_Q+84W>XN
MW>?>DW6!<56.>N5<G$/R6)KK,.8F7#2^V'8J$HCRHG,>0Q+2TM*$8..VF*X]
M859/".2%*1(0V*ZGAVS)W.FQ>2:MD.I4D)0:R[M%83DJ:="R0ZD_82,I& F8
M>-&/FW,0^A'T6RAFL7T3;>0&_-'^4I,=N*YS6DOMOM-:N67&PIHA:=:\%"T)
MTK*2@I" F2]QTF[.SCQ)9TW)F1>YW$$,VZX/6>;:9]R+'GJ(4U3-Q"H<@18I
M<9EQY#W-CHD-26GG)*W\C5MM]TQS!1R.-\V/(:T*6._V>XO9ZAPTO1K=(Y&<
M13N45''-=E:4SA%JTO"L0H;AC.*J0C5:5:306=*7?>)V;@.L(2&)92X5O+=*
MV4J9=4^4E1Y#:V4IY>@!DA7H J"N9J.<4WB^W7:2\;QPXW(A"):H=N;BW.1'
MN=O:M"'VV$B[RV+DY)3,3)<-S0[&"9+B6'(WF1CM!-YXGQQ$8AQO3<:03Q_(
MQ=-@VL,WD906_I"1.EU*.I!V1F@U8H+/GBJ[HS5@U:L&GB@U8M6[1%%$DR,P
MF,PTP@J4EI 0%*QJ5CJHX &2<G"0$C.$@  5K-]N[]_N]PO,IMII^X25R%M,
MZ^4T%8"&FRXI;BDMMI2@+=6MUS3K=6MQ2E',TRFPF/ZG#TRJH*,X2 9F912#
MI==\H@B*JJX JNNKX[CA58YAZU0.)1Z0.7@!#LTTAEM+38PA PD$DX&2>IW/
M7M-1[C<9-UGR+C.4'),IP.OJ0E+04K2E)TI2G0C*4CHG .^.RM4VFQS%L=4*
MP2-;0;+-E<N,%DE7<*E2X,,A3>0F=S2NUGGI9R0R;UTPNSI:;@YN#6F5FX5F
M<<PZ;@Z2""A:X6B.EIO2$"6AU#YF\I'/6^ET/.+4=B0\=:%H*\<M90#@"MX<
M\I=[>GS><N2YPW+M\FT)X35<9)M,:U.6Y5MA16$'+:';:A,:3&DICI69L9$@
MI"E*%2PFUJ(]7<>5M>VR*C6A6#.$X"Z48V17E2YMCLD1L@T'J=+)LA@4LC.5
M&;@"._/#Q:'C((E<J ED%N3RV&RXHAE<M>=(!5YVF0DCKMH#YP=\Z1L,[03Q
MM(\[NTQ,!D+ND3AJ,4J>6I+!X;>L[S3@PA)<\Z5:$!Q!*.6'E:5** 58>H;.
M:"2/<1^96U0SHW6JF):TDPMN/(@L&T<X@B;G7X"PM(:3D+(BA,/(*XN&+Q=-
M8O09-VHV%)"2.T;]&K6SITR@U,'*C-X<83H!BI=0AP(4IP!10Z03G;?&RL"1
M/\H-U+J'>'EW#AE29]]FEV!=I'G3B+^_;I4J(Y)9:AJ5';E6]#K:2G<*;"PI
M3(<7PY':Q='1<M5>+SDZK&*\S6F?G[75*_CR&1MC:.M,+$UZP5^!OC^:D$HE
MN^B(HK)*11J9I*-(Z66C5FCU-LZ0X5;G3YRVF86X\MQ:W6T,(YF'4)0XA#Q6
M0D*2G (;U)!.G!P1D9XWMR#89S_#2)M\X=@Q8L"=*NTA4!;L&2_+BRY5K:C,
MJ?6T^^7"RJ>&75(2EY+C16VO-73;?<99*Z5FD9F<5'%N1(-C7['CNQ46/R,T
MKT>UJD=27"6+G\Y.L6]+;/Z_$L#+0TO#7*MHSQ7M@;0B3V6E =]W8#J@ZVS*
M+4=]*4.,.,I?"$AL-'S=2EI#6I"4DI4AUL+!6$ J5F-;N+[>P;=,N7#R9][M
M$EV5#NT2YO6A<MU<YZY(-[:C175W%;4I]T)D,2;?,5%+<5<E3;#!;_+W;+,5
MV0DW>&,E-Z)'VFOTV!N]8N]"C\L5BQ+T*N1U0K=K19O9RKR,=<DZM#PD))2"
MTM)PLJU@819Y73O6)G3@;>ILJ,61R4N-M(=;>93);666TM-N@*6VI+H;0A"C
MJ4A00@E&4Y)OC*/,99;XBLZ[F["E7"5;9MMNCMBFQ$W26]/F05.-Q9K+MO5-
MD29++*6&9#"Y4E+<L-NA"+FPUBV,PQCF!QU%2LC.MX=Q89)S,RJ$6T>R<Q;+
M-,W"P/C,81A&1$<W<3T])*L8V.8MVD:Q,W8HE.1N"AY46.F*PAA*E+"2XHJ4
M$@J4ZXMU9PD)2 5K5A*0 D8 Z5KW$-Z>XAN\J[/L-1ER$1&41V%ON-LQX,./
M BMAV2Z](>6B-%9#CSSJW'G MU1!7@<G'>.T,?*7]1"46D_7W(]AR(N"K4C;
MT:O/M8EJ>+2$BRWG*+8(HIR.C^$=05C *).@!-RPP&.?A15SGUOG(QI*PD:1
MN<@:>OCTKI=KLNZBU!3*6?DNT1;2G2LKYR(KCZP\K*4Z%+YY!0-0&D>D<[6/
MK/5132E-*58.)_\ O-H?[:X3^/HZX/0^H_FKD=1ZQ^>NV_6"L]?.U\I7O*IU
M(W\;LJB^V);'\@NZ]FJX1;B[7VG9W>W.S*MG@%-+V1W7MPM;A'$LZ^W=*QD#
M$M#'[I,D0[:\RNLY#=QFH-OM[I3(<!<<;D%Q>_593)2DD^"0/"OT!\G'!TN=
MP)PK+1QQQM;T2+/%<3"@3+(W#C!23AJ,A^P2'DM)^Y#C[J^]9-:/_'SH?['#
MY/'Z";D/^J'5?\HM_@NV?R4G^MUNWS$G?Z1/*#^7\/?^6J?'SH?['#Y/'Z";
MD/\ JAT^46_P7;/Y*3_6Z?,2=_I$\H/Y?P]_Y:I\?.A_L</D\?H)N0_ZH=/E
M%O\ !=L_DI/];I\Q)W^D3R@_E_#W_EJGQ\Z'^QP^3Q^@FY#_ *H=/E%O\%VS
M^2D_UNGS$G?Z1/*#^7\/?^6J?'SH?['#Y/'Z";D/^J'3Y1;_  7;/Y*3_6Z?
M,2=_I$\H/Y?P]_Y:I\?.A_L</D\?H)N0_P"J'3Y1;_!=L_DI/];I\Q)W^D3R
M@_E_#W_EJGQ\Z'^QP^3Q^@FY#_JAT^46_P %VS^2D_UNGS$G?Z1/*#^7\/?^
M6J?'SH?['#Y/'Z";D/\ JAT^46_P7;/Y*3_6Z?,2=_I$\H/Y?P]_Y:I\?.A_
ML</D\?H)N0_ZH=/E%O\ !=L_DI/];I\Q)W^D3R@_E_#W_EJGQ\Z'^QP^3Q^@
MFY#_ *H=/E%O\%VS^2D_UNGS$G?Z1/*#^7\/?^6J?'SH?['#Y/'Z";D/^J'3
MY1;_  7;/Y*3_6Z?,2=_I$\H/Y?P]_Y:I\?.A_L</D\?H)N0_P"J'3Y1;_!=
ML_DI/];I\Q)W^D3R@_E_#W_EJGQ\Z'^QP^3Q^@FY#_JAT^46_P %VS^2D_UN
MGS$G?Z1/*#^7\/?^6J^B;%1]0F("JRKR@5$7,C3::\4(FC-%10!>K1"B;5N4
MTV8Y6K1,Q&K4JBBJI6Z*15EEE0.J?UZ/NPR?HY;0=*>@RD;#.3@=F2?77YH7
M0<NY7!LJ+I1-E)+CFDN.%+ZP5N%(2DK4?244I2"HG"0-JYOJ[1OF^J?[E-?7
M6LV#WGW?"H.K\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:
M8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y
M]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"
MFK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ
M4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*
M>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT
M;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^
MJ?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N
M4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37U
MUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#
MWGW?"FK\5/LJ20$'4$FEG*WI-::D6KJB3HB*<KTO&PRT2<6KCQ)5010%8B*X
M@D*2GBH)""@% Q#]59VW/TAW?"N0<YV&R3TV[NM1OU=HWS?5/]RFOKK7;![S
M[OA7&K\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\
M*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_
M%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/L
MIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[
M1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;
MZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^
MY37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?
M76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8
M/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"FK\5/LIZNT;YOJG^Y37UUI@]Y]
MWPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4^RGJ[1OF^J?[E-?76F#WGW?"F
MK\5/LIZNT;YOJG^Y37UUI@]Y]WPIJ_%3[*>KM&^;ZI_N4U]=:8/>?=\*:OQ4
M^RL_58*GH66"69TBM,G24JR.W=MDY8'#98JY!361%6652!1,P 8@J)*%Z@#D
MA@[:X(V.YZ'N^%<A62-D]1V>-;8ZPUEKY:OE:/[Y5O6_T@+U_'PUY%>?WUG_
M .\N?GK]-_)3_BXX-_B*'_1-=>.JRO0::4II2FE*:4II2FE*:4II2FE*:4II
M2FE*^JY5?TFT7]H-$_DA"Z]QC?X.Q_LD?T17Y(WG]][I_&$S_F'*SFL]5M=4
MNX9_8)S>E9:6K7-X.0:U#[6</V>%J>V+.,IB6/@;3/Y7W Q,K/V9J7.F%X20
M?3\?78"-:/7YYTJ2$ "3T&+1-,7%#,*UW);6FX.H3!CN(;A2E1PEQ3\M*EK
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M+:_:[Q?;N[.\QM,FTP!%MO(3+DS+P+BXP2_)2ZU'C,,6J6MUPL/*<>,:.E*
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MBOS9,>'%;+TF6^U&CM)*0IU]Y:6VFP5%*05K4E(*B "=R!O6: 0, "'<! !
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M<<7^ZM=*9>'%S8UE\C*KT2TN\=W!$8U^S",LC"'AYUU!F-(LFJ<@BC$V6)=
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MY<W[4_-X@;N#4:V.6:YQVF8J[=P_ ^:T5^4_;S:V9F7;-<XT::J#&C,RWG;
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MU;O32E-*4TI7TH)G[:#_ &DX]_D)7->XQO\ !V/]DC^B*_)"\?OM=/XQF_\
M,NUA]9ZKJ:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*LF@?]DY0_\ #IQ_*VI:X/4>O]!KLG[K_5-5MKFNM-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI5@XG_[S:'^VN$_
MCZ.N#T/J/YJY'4>L?GKMOU@K/7RU?*T?WRK>M_I 7K^/AKR*\_OK/_WES\]?
MIOY*?\7'!O\ $4/^B:Z\=5E>@TTI32E;28+W'06)\<98Q-=<*4W-=&RU9<66
M^3BK59\A5->'G\2-,DL:\\C)+'EFK,@HFY:Y0GTY!H]<.&ZHI,CD3(=(3#,C
MRDLM/,N1VY#;RV5E*UNHTJ9#H206EH.X>5D$XV&U:O?.'7[K<;3=H5YF6:=:
M8UTB-.Q8T"6EZ/=E6Y<A#C=PC26P4JMC!;6A*5#*P<@[62]WZW5X[F&OP3X=
M1H"M1PUCJHX?]#V>1QE2\<X6RRVS)%TIO'SEJEK)9(RXW T^_P @R%KM,O8;
M(\N%FDO3+-\\;*L\QN3A*AR6 T4,-(8PLM-M1WN>E "EE2@M>HN%:U*45J.0
M2,5J.!(:$LK^5KP9XEWBX2[OSHK=SFW"\VI5G=FJ<9BM1HSL.(&$0&XL5J/&
M1$C-<E3:%!=FK^4^R01S5H>,HS=+&L#CO)F+W]0G,J9EM-IE:CE6Q8^M\S$L
M<N3%V4R%5XVIVG%="L&-8:ORC2$JTI$2#B2CK*%KMQ)W,;P[E"4MX:2TZTI"
MGGUK4AY32R ^I?-0$+9;4TE*@E!2<A6M>JM'DRMQ3*>=G*-R?N%MN;<MBUV>
M+%9EVJ//B,NJM#,(6^2Y*BW2='N3LAM;TIIUM+;D;S6)R,.R\HY:6C7(\'\%
M-?3J5Z'%!V\+%Y*S7 S*1,/PMOAH.)NU]A\@-+UDVKVL]WG9_(5<LD\FSF+,
M+"3K*E-1CFK%/H+JL<U/)3H<Y.$AZ0E7VA+B4AQQ+@<>0LN*4XE2@%*P4:
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ML0E#:8A<]#DMO*D-1U*QS%Q6I"E2&HJUJCM/J+S;273JI2,-XNQM*3$S1*/
M5B3G4P;R#N+:>$?S('KJ3"+8$.<Z41"A)/7DB$+$$8Q(/W*[P&7G*AE!Y:BQ
MV%*4RTAM2]E%(QMDJTI[$IU$JT)PG42<9.:7+B"]WAEB/<[E*FLQE:VFWW-0
MYI;0SSW2 %/R.2VVUYR^7'^4A+?,T)":LO6>J>FE*:4II2FE*:4II2K!Q/\
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MYR:?[4NNJ_HGZOSBN1U'K'YZVBUAK/7RU?*T?WRK>M_I 7K^/AKR*\_OK/\
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M[P8Q@Z!M(,>SDYQY/*6EIEIQQ+C_ )LPVVMTI)])6-(44ZE%" 4-ZCG ZC'
MX1A6AX7"*_<[G<(4&1"LXOMXFS8]O:>2WJ88+@>+*7S'C-2)BFI4XL-!'-6D
MK;<J3<!EI?.>8;QD\\6$ PL,@R:5FN Y%Z%6H]8B(ZI4"I^?"FB9_P"JU(@J
M_7O/S(HF?>C?.S(I&6%,N"4_YP^X]C2%$!"<YT-H2$-(SVZ&TI3GMQFK:P6I
M-DM$*V!WGN1VUKDR-.CSJ=)><ESY6C)T>=37Y$CE@D(YF@$@9JG-8*N*:4II
M2OJN57])M%_:#1/Y(0NO<8W^#L?[)']$5^2-Y_?>Z?QA,_YARLYK/5;32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4B@?[FLO[
M7U?]YQ>N#U'K_0:Y'0^K](J.ZYKBFE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4K/5?],<)_G)I_M2ZZK^B?J_.*Y'4>L?
MGK:+6&L]4I.[:]N=IF)&Q6; .%+%8)ATJ^EYV=Q719>8E'JP\K/)&3D(%P]?
M.E1[JN'*ZJR@]S'$=8%18JU%2XS"U*.5*4RVI1/>24DD^NKECB/B&,RW'C7V
M\QV&4A#3#%TFM,M('1#;;;Z4(2.Q*4@#L%8GXIFU;];/M^_@:QS_ $;UU\SA
M_P":1OY!K_IK+\ZN)_X1W[^>+A_6*?%,VK?K9]OW\#6.?Z-Z>9P_\TC?R#7_
M $T^=7$_\([]_/%P_K%/BF;5OUL^W[^!K'/]&]/,X?\ FD;^0:_Z:?.KB?\
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MV?;]_ UCG^C>GF</_-(W\@U_TT^=7$_\([]_/%P_K%/BF;5OUL^W[^!K'/\
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MO2F!W#V"OV6.CR <",&9 4+T* 5J@4#DZBFZ#@! ZB]12FZ3<AU%*/'(!I3
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0(" @/NTI@=P]E<W2N:__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g686907g63t24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907g63t24.jpg
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M&;2LWUX-6,Q<P%.EZ_:&\G)!%.I)+T%A7BA6JCDWH H&,74:L8\V"S/LA:]
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M\^^0N"^<J#U*]6;/E%CN)W$$!BQ7)BSS+,4*Q+%M0*0N/*(_SCA5QY(4;0,
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MK%=L\V#]K%HB\>(;.^,<MK#SY%@:3:R*\SQ0-,8F81S31==B^4PPRAV1<$]
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M:M&S=OXTD$B%M555=JJJKU\E0 O4DGH.G4DD^DDFJEBQR22>G4DD]!@=3UZ
M #T"J\WV7L=H_&5:[ NS:4&SA=ADF]KG47XW,$ED MPO$WY7'RG!!PX1"?\
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MWABJ\R3##>^'.6&YL,?2PS@GWSFJ3,WV]6*!@:K8+I;)VL54ADJQ7)FQS$G
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M@3SLG7B\[5;T%\J!TS^DOJ[!MEFU9E5O'>EKD X9K<$9&<$<CH1W$>FH)CL
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M/&1NY_-V+6\U'5K,1GQG9W/,+#%LMO(4VX]O]!& <]/3@U2WM+"X+#L,\.T
M_1C,F[.?:_13G&.OHR*HO*_A/TON*MSKM-6Z:W+3>(V&L$LP6'0\MO*\5R)
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M?EG=YJ*@MOUT*'<YJ3C;![=%&800<1*\S3G2\8U,V]T623]GX/TJ?4>&-,B
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M?EF-S?NR+;WJW%I;75B]N5+3R-:20LH;D-*ZE*NDTX(ZCF.(]DTCN\0'T.$
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M9)KU) L=G'>OR=,=D*$R+?7 :)3OCY8&\[_:A'9,\,\A;8\194C*Y,C1#=,
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M*A>@'FK0:^D2ZOJKE+4L^KZN6,[7(8[=1N%&T0L%P!TZ]<UNE^I)Q =7\Q1
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ME7K:,L4VP36!I*/45I;:;ISQ)"]C:-%'"]M'&UO$42WD:-Y(44KA8W>*)F0
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M:999!F8XE*?N@^:1JK5PGV.'W1)4Y._<._<H]J")F 8% #Z74'XB<U7(_P
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M%VU5YZ49Q#)E;DW3Y04D3OZ998YF4P$.H(KO7D:BU;D])! #K*D*)O27OW,
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MUPZG?(6Y*/4XEM/H&8$0.N,U79F"*8' JE3!N:59M2N3 *)_(5$3BD D$X%
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MQ:3?27%_'J;36=U>:5IMQ;3Z-?\ BS4=,A-[>QP:CJ\5TL@BL+*:1IX569)
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M*<73-<"30TN9UN=#D2XB[#;W9CGWVLH65"#<,1PI^+5]LV)L:MHW"T7_ %M
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MLN)N5%D?KP62_11)1K0=CTVI[&8U>]/G]LK+;8=<L:C-^]<0\DYF*;XJLE]
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M^*6O5\)$$%NFJ0P(G?E76[]D$E# (!EN>(O"'9Q&:XXIXGCC#!2WLDU!^K=
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M4-3ZTWDZL-]ODRA 5:$/JW;\.62E7)3G1;&E)RA1L0R Y4SCYW[YJW+V[&5
M1 !ES:+J4$3S2VX6.-2SMSH&PH[SA9"3Z@":CQZE9RNL:2DNYVJ.7(,D]PR5
M 'PU+?D'R+T_Q:UN\VWO*UJ4R@1\I%0SN<3@+)93)24VX%K&-_A=4B)N7.#A
M<!(*R; R"/\ VEU$R_;9#MK:>[E$-NF^0AF"[E3HHR3EV5>@]^I,T\=NG,E;
M:F0,X+=3W=%!/\U0WU[UB.GAM2^4O6=%WPZFKKL&TP-+J40;5&Y8PLI9+/*-
M8:$CS2,MK]C%L >2+QNW%Y(O&C%L"GF=.442'4+.ET34X8Y)9+<+'$C2.W.@
M.%0%F.!(2< 'H 2?,*BIJ5G(ZQI*2SL%4<N099C@#)4 =?2<5-C>V]]6\:M7
MV+<VY[*>HZYJBD*C/3Z<+/V$[)2PSL;6XDH1%8C)B:=>ZF99@T$6D<N" +BX
M<"DV2663U]O;S74RP0+OE?=M7<JYVJ7;RG*J,*I/4]>X=:ES31P1M+*VU%QD
MX+>V(4=%!/>1YJ@Q4>LWTX[U:ZQ2:OOYW)6:XV&%JM=CC:DW4R!_.V&2;1,0
MR%X_UXV8M =2#MN@+EZY;M$ 4\KA=)$AU"[%]"U2-'D>V 2-6=CSH#A5!9C@
M2DG !Z $GS5$74[)V5%E)9F"J.7(,EC@#)3'>:GON7<>N^/^LK7N';,\>L:\
MI#1H^LT\2)F9T\<U?2;&&:J!$UZ/E9EYY)&29M_0QCW*A 5\JA2HIJJ$UT$$
MMS*D$*[Y9"0B[E7) +'JQ"CH#WD5+EE2&-I9#M1,%C@G&2!W $GJ1W"M?$1U
ML.FK.RT7!Q?(1XYDYF1914<V'3^[T </Y%RDT9H"LXUPD@CY7"R:?E75313]
M7K44(0#&#9-H.JJK,UL %!8GGV_<!D_][Z*AKJEDQ"B8Y8@#Z'+WDX'^96Q?
M:>SZ1I;7=PVMLB8-7Z)0X1W8K5-$C927-&0[$"F<NRQD(RD99Z*8& ?;Q[%T
MY/W^YHFS5PPR3RI#$NZ21@J+D+ECW#+$*/A(%39)%B1I'.$0%F."< >\ 2?@
M%:V"]</ICF,!2\BG@F,(% /K-[T#N(CV /GUKV_C_P"_-K[']6]S#[_;_K:@
M^-;']^/WJ7]"MF]_O57U?1+ILN[R1H:EZ]J=BN]NERLG\D:+K-4B'D[.R)8Z
M*:O9-^9E%L'3D&<<S=OG(I^%HV77.FD;4QQO+)'%&-TDKK&BY R[L%49) &2
M0,D@#SG%3W=8T:1SA44LQP3A5&2<#)/3T#-:Q_LXO3&^D6\_N:WK^[7-M[']
M6]S#[_;_ *VH'C6Q_?C]ZE_0K9U*WBL0E%DMDR<B9O3(BIO+Q(2P,WRQD*PP
MAU)YU(A'H-E)-4R44DHY]FBS4?'$O@3;&<""0ZE8W:01 ?1&<1A<CVY;:!G.
M._IG./?Q4\LH4N3Y(4L3U]J!G.._N^&M8OV<7IC?2+>?W-;U_=KFV]C^K>YA
M]_M_UM0/&MC^_'[U+^A6SB(O57G:'%[+BY(SFES-197J.EQ9/T3+U>0ADI]I
M)#'+MDI-(RL2LFY]DLS3?IB;P*-B. %(-2T;K(T+#$BN8RN1[<-M(SG'MNF<
MX\^<5/#JR!P<JRAP<'JI&0<$9[O-C/O5K'^SB],;Z1;S^YK>O[M<VWL?U;W,
M/O\ ;_K:@>-;']^/WJ7]"MF^OKY5MI4.E[,HTD:9I>PJK7[M4I<S)_&FE*U:
M(IK-P<B:.E6K*38"\C'K9P+.19M'S85/"Z;(+D.F74RQO#))%(-LD3M&ZY!P
MR$JPR"0<$'J"0?,:GHZR(LB'*NH93@C*L,@X.".GI&:UDFZX?3'*82FY%/ ,
M41*(?6;WH/80'L(?-K7M_'_W9MO8_JWN8??[?];4#QK8_OQ^]2_H5LGU9L^D
M;IUW3]K:WF#6"B7R$:6*JS1XV4B#2<.^ QFSLT9-LHZ69"H!1'V\@Q:N2=ON
MB)<U4T,D$KPRKMDC8JZY#88=XRI*GX"14Z.19461#E' 93@C(/O$ CX16NB7
MZV'35@I:4@Y3D(\;2<-(O8J1;!I_=ZX-W\<Y5:/$ 6;ZX506\3A%1/RH*J(J
M>GUIJ'()3#M%T'56566V!# ,#S[?N(R/^]]%0FU2R4E3,<J2#]#E[P<'_,K8
M/IK<>N^0&LJIN'4T\>SZ\N[1V^K,\>)F8(\BU8R;Z&=*#$V&/BIEGXY&->-_
M0^CVRAP2\J93(J)*'UL\$MM*\$R[)8R Z[E;!(##JI*GH1W$U,BE2:-98SN1
M\E3@C."1W$ CJ#WBH$V_K-=..B6RT4>T[^=QMFIMBFJI8XXNI-U/083M>DG,
M1+L@>,->.F+L&L@S<( Y9.7#1<$_*V751.10VQ30M4D1)$M@4D574\Z 95@&
M4X,H(R".A (\]1&U.R1F1I2&5BK#ER'!4X(R$QWBIS:)WOJWDKJ^N[FTQ93V
M[7-K4FD8&?4A9^O'>J5Z=DJW+%&(L\9#S37VLS$OV@"[CD 7! '#<56RJ*RF
MNN+>:UF:"==DJ;=R[E;&Y0Z^4A93E6!Z'IW'K4N&:.>-98FW(V<'!7VI*GHP
M![P?-4*-B=8;IXZJOMSUE>]\.H6ZZ^M$[3+;#EU1N63+%V.MR3F(F8\LC$Z_
M?1;X&D@T<( [CGKMDX GE;.%D3$4-/BT34IHXY8[<-'(BNC<Z 95AD'#2 C(
M/<0#Z:B/J5G&[1O*0R,58<N0X93@C(4@]?0<5,;CYR,T]RFUPTVUHRUJ7.@O
MI65A&LXI 62M&4DX18K>2;_"[7$0DN0&ZQRD!91@5!;OZD%%"@(Y"N;6>SE,
M-PG+D"ABNY'Z-U!RC,O7UYJ5#/'<()(FW(21G#+U'?T8 _S5$G:W5SZ?^D]B
MV_4^R]Y.J]?:',KP%IA":MV_,%C95L4AUFQ92#H4E$/0(50@^=@^=-S=^Q51
M$! )D.BZE/$DT5N&CD4,C<Z!<J>XX:0$>H@&HTFI6<3M&\I#H=K#ER'!'>,A
M2#\%2GXW\H-(\MJ [V?H&XJ7BD,;+(U%S,*UNTU<R=@BF,7(OV/PVWPL#*'!
M!G-1JH.B,C,U?<"FDX.HBN1.)=6EQ92"*Y3ER% X7<C^220#E&8=ZGIG/2I$
M$\5PG,A;<FXKG:R]1@D88 ^<>:HT;HZK_ SCWLZUZ<VWNQS5]B4ERP:66!3U
MCMJ=)'.).(CYUD0):NT:6AGGFBY1BY$S&0<D3%8453$7352)*@T?4;F%)X8
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M<"HZ1'U2%TN:^5<D#7-VPA'1B&<DB--5R-*X,D!@2,N5G<405,F!S@05 ,)
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MHH<QCG.83&$1$1R\2RCH)) !T #MT_GJW8OV*_$/S5<,=&1L.S2CXF/8Q;!
M5!08QS1!DS1%50ZRHI-FR:2*8J*J'54]! ]:ASG-W,81&PDL<L2Q/>222?-W
MFJ@ =  ![W2J ZH-$?.5WCVE5)V\=+*.'3IU7(=PY<N%CBHLNNNJS.JLLJH8
MQU%5#&.<YA,8PB(CEPED  $C@#H '8 >H9JFU?L5^(578R)BH5J5C#1D?$L2
MG.H5G&,FS!J510>ZBA6[5-)$#J#\YS 3U&'YS"(Y:6+'+$L?222?C-5  Z
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M?8>.IQ]#'<?]6Q/_ #?'B/5O<$_Q+^E3Y[G@V_A?I/RYOU-/L/'4X^ACN/\
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M"TNTP4M4D<?]Y/\ 1FSZ0'RBG^(BUX=Q!X7_  A<1\Q+OB*[L[5\CL>D8TJ
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MQX\>+K.G;MUHS6#ARZ<N%#*KN7*ZM7.JNNNJ<ZJRRIS***&,<YC&,(C(%_?
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M"M.'TC(OG2JKEX]>+K.73A119=4ZAS&'.M[>(JHEW=*J@*JK/*JJH& % <
M#H !@"L9M[=B6:"$DDDDQ(22>I))7))/4D]]95HVO:#K& 2JNM:/3]>U=%RY
M>HUNC5J%J< D\>G!1X[2AX!E'QR;EVH '<KD;@JN< ,J<Q@[Y@DEDF;?+(\K
MD ;Y'9VP.X;F).!YNO2LB(D8VHJHO?M10HZ]_0 "L8V7BAQ:N<]*6FX<:] V
MNSSCL[^:L=ETYKN=GIA\H  H\E)>4KCJ0D':@%*!W#MPLL8"@!CCV#,R7EY&
MH1+NY1%&%1)Y551Z H8 #W@*QM;V[$LT$+,>I9HD))]))7)^&LD4'6FN-4PB
MM9U=K^DZVKBT@O++5^@U2"I\(K*ND6S=S)JQ5>81S!20<MV;1!=X9 7*R+5L
MDHH8B"12XI)99FWS222O@#=([.V!W#<Q)P,G SCK5Z1I&-L:(@)R0BA03T&<
M* ,X &?>%8^MO%KC'?K%)6^]\<]$76V3*B*LQ9[;J'7UCL4LJV:H,6ZDE-3%
M>>23Y1!DU;,T3NG*IDFK=!N02I))D+D2\NXU"1W5Q&B^U1)Y45<DDX56 &22
M>@[R35K00.Q9X8F8][-&C,>F.I()/3IZJOK7VJM7ZDBGD%JK6]"UE"2,@:6D
M(;7U/KU,BGTJ=LW9GDWD?7(Z-:.9 [1FT:F>K(G<F;-6Z J"D@F4N.6::8AI
MI9)6 VAI7:0@9)P"Y) R2<=V2:N2..,$1HB G)"*%!/=DA0!G '6K,NG&/C9
MLBQ/;?L3CWH^^VR2(T3D;1=-3T*TV)^FP:(L&*;V;G(!]).B,F+9NR:%7<J%
M;M$$6Z($12(0N2.[NHE"17-Q&@SA(YI$49.3A58 9))/3J>M6M! [%GAB=CW
MLT:,QP,#)()Z#IZJNS7FH=3:B9R,=J?5^N]81\PY1>R['7E*K5*9RCQND*"#
MN1;5N,C$7SE!$QD45W)%54TA%,ARD$0RR6>:<@S32S%1A3+(\A /> 7)P#[U
M7)'''D1QI&#U(157/KV@9JVKSQMXZ[/GCVK9>@]+;#LZK5LQ4L=YU91K;/*,
MF93%:,SS$_!2$@=JU*<Y6S<S@4D"F,"1"@8>]\=U=0KLBN;B),D[(YI$7)[S
MM5@,GSG%6O!#(=SPQ.W=N>-&.!W#)!-5_76F-/:?)+I:EU/K75R<^9D>=3UU
M1*O2231XP'18T\N2M14862-'E?/BLC/ 6%H#QT" I@X6]=DL\\^WG32S;<[>
M;(\FW.,[=Y.,X&<=^!Z*JD44>>7'''NQG8BKG&<9V@9QDXSW9-4:_P#';C]M
M>:1LNTM%Z<V58V\<A$-Y^_ZRI5QFD(EJNZ=-HM&5L4)(ODHYNZ?/7*#(BY6R
M2[QTLFD51PJ8]T5U<PKLAN)XE)W%8I9(U+$ $X5@,D #.,X ]%'AAD.Z2*-V
MQC+QJQQZ,L"<=3T]^JCKO1VE-0+2KG4VG]6ZN<3J31";7UWK^ITE:818'748
MHRJM:B(P\@DR.Z=':)NS+$;G<KF1 @K*":DMQ<3X$T\TP7)42RO)MSWXWL<9
MP,X[\42**//+CCCSW[$5<X[L[0,XKB["T!H?;<FRF]K:3U'LV9C6 1<=+["U
MO3;I)L(P'"[L(YD_LD-).FK '3ERY!F@JFW!PX76!/R*J&,BN;B %8;B:%2<
ME8I9(P3C&2$8 G  R>N*/##(09(HW(& 716('?@%@3C)/2OIKS0FB]1OW\KJ
MC2^I]8RDJS)'RDEKS7-/I;^28)K%<IL7[RMP\:X>,R."$7(V<**(E6*54I .
M4# EN;B< 33S3!3E1+*\@![L@.Q ./.*)#%&28XHXR>A*(JDCT$J!FOWL31.
MD-O.XU_MC3>JMGOH9NNTAWFQ->5&ZNXIHY4(LY:QKBRQ$FLQ;N%DR*KHM3I)
MJJ$(=0IC% 017%Q "(9YH0V"PBE>,,1W$A&&<>;-'BBDP9(HY".@+HK8]6X'
M%<77W'O0>I9AU8=5:/U!K.??1JL,]G-?:TI=,F'D.NZ:/EXIU)UR%C7KB-6>
MQ[!XJQ57.U4=,FC@Z0JMD3DK+<W,RA9KB>50=P666210V",@.Q ."1GOP2//
M1(88R3'%&A(P2B*I([\$J <9 Z54=BZ2TSN T0;;>H]8[2-7P?E@#;%H-5NY
MH,LH+,9,L0-FB9,8T)$8Z/%^#+P@\%BS%QY/;(^BD5Q/!NY,\T.[&[E2/'NQ
MG&[8PSC)QGNR<=]'BBDQS(XY,9QO16QGOQN!QG SCT51Z'QRX]:LG#6?6.A]
M,ZXLIF+B,-8:'J^D5"<-&NSHJ.H\TM7X..?BQ<J-FZCAH+CP+'01,HF8R1!+
M62ZN9EV37,\J9!VR32.N1W':S$9&3@XSUJB0PQG='%$C8QN2-%./1D '%5_8
MFG-1;?;Q;3;.J]<;0:P:SEQ"MMB4>LW9O$.'I$4WB\6C98N33CUG:;=!-RJT
M*D=<B")53'*D0"VQ3SP$F&:6$M@,8I'C+ =P)0C./-FKGBCDQS(TDQW;T5L9
M[\;@<9JV:1QHXXZSL#>V:XX_Z2U_:FB#ILULU(U51*I8&S9ZB9N];MYF!@6$
MBB@[;G,@Z23<E3<(F,DJ4Y!$HWR7=U*I26YN)4."4DFD=21U!*LQ'0]W3I5J
M00QG<D,2-W;DC13U[^H -7;L+4VJ]N1["(VOK/7^SHJ+>&D8R,V%3*Y=(^.D
M#(';&?L&5DC9)LS>&;*JMS.FZ2:XH*'2$_C.8HV1330$M#++"2,$Q2/&2._!
M*$$C/7!JYXXY !(B2 '(#JK 'T@,#UJRZ=Q>XSZ[L<=<=?\ '?1=&MT/[L8B
MU4[4E K-CBA?L7,6^&.G(6OLI-C[V->O(YW[9TE[EB[<M%O6W753/?)=W<J&
M.6ZN)$;&Y))I'0X((RK,0<$ C(Z$ ]XJU8($8,D,2,,X98T5AD8." ",@D'W
MCBKZV!J_6FV89M7-J:[HNS*\RDT9MG [ J4!<X9I,MFKUBWEVT78X^28H2:#
M&2D6:+]) CI)J_>MR*E1=+D4QQ32PL6AEDB8C:6B=HV*D@E25()!(!QW9 /F
MJYXTD&V1$< Y =0P!ZC.&!&<$C/OFL?5;BKQ?HU@C+92>-^A*?:81<SJ&LM6
MT_KVOV"(<F24;F<1DS$UUI(L%S(++(F6:N4E!2543$WH.8!RO>7<BE)+JY=&
MZ,CSRLK#OP59B#U](JQ;>!"&2&%6'<RQHI'J(4$5DB]ZXUYM*"^2^S:'3-C5
MGWC>1^3M[J\';H+X@T*J5H_^$6!C(1_O&I5UBMW7M_.B594$SE!0_?%'++"V
M^&22)\$;HW9&P>\;E(.#YQFLCHD@VNBNO?M=0PR.XX((K&->XF<5JC.15GJG
M&?C]6++!/F\G!V&O:9US"SD-)-#@JUD(J6C:VV?QSYLH4%&[MHX1<(G #IJ%
M, #F5KV\=2CW=RZ,,,K3RLK ]X*ER"/>(K&MO;J0RP0JP.0RQ("#Z00N0?56
M5;M0J+LNO.JEL:EU._U5ZLU</*S=JY#VJO.UV*Y'3)=U"SK-_&KK,W2:;EJH
MJV.=NNF19(Q%"%,&&.22)@\4CQN,@/&S(PR,'#*01D=#UZBLC(CC:ZJZGO5E
M# X[NA!'2L1PW$+B;79>*L%?XO\ '>"GX*28S,)-PVE-:QDO#2\8Z2>QLK%2
M3*LH/8Z2CGJ"+MB^:+(NFCI%)PW5353(<,[7UZRE6N[IE8%65KB4JRD8((+X
M((Z$'H1T-8Q;6X((@A!!!!$2 @CJ""%R"#W&LQV^F4_85<DJ??JI6KQ4IDK8
MLO5K?!1=EKDJ5D];2+,LE"335[&/BM)!FT?M@=-500>M6SI+T+H)'+@21XF#
MQN\;KG:Z,489!!PRD$9!(.#U!(K(RJZE7574XRK ,IP<C(.0<$ CWQFL*L.'
M/$2*?LI2+XK\<(V3C7;9_'2+#1^LF;]@_9K$<-'K)VWK";AJ[:N$TUVSE!1-
M9!9,BJ1RG*4P9S?7K JUY=$$$$&XE((/0@@O@@CH0>^L8MK<$$6\((Z@B*,$
M$=Q!VUG&T56KW> E*I=*W V^K3;?VDU6K1#Q\_ 2[3R$5]K*0\JW=QS]OY4D
MU?"[;*I^1,A_3ZB%$(Z.\;!XV9'4Y5T8JRGTAE((/J-9656!5E#*>A5@"#ZP
M>AK Z/"_AVW5270XG\:4%T%"+(K(Z)U<FJBJF8#IJI*$JQ3IJ)G*!R'((&*8
M ,40$ '))O[X]#>79!Z$&XFZ_P#^]8>RVWN>#[U'^C6?K!7H"V0DK6;3!P]E
MK<\P<Q4Y7[!&LIF$F8MZD9!Y&RL3(HN6$BP=HG.BY9O&ZS==(QDU4SD,(#&5
MF1E=&9'4AE92592.H*L,$$'N(.168@,"K ,I!!! ((/>"#T(/G!J/O\ H4\-
MOHE<9?[AM6?LKDGM]][MN_PF;].L/9;;W/!]ZC_1J2Z:::*9$DB$222(5---
M,I2)IID*!2$(0H 4A"% "E*4 *4H    !D2L]?O%*8I73<ZQ?W]NP_R4UM_P
M7%9XQQE]7[G[E;?U"5^1GS6WU[N(/]6<._V-:5JZSEJ^:J8I6;M=<==M;5J\
MC=:;"U]2J14^G5GL[9=B:WH3 MA5C@EDXE!2^VVM&>NS1HB\ C(K@/"50PF
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MFM48V8ET95AO/2J->9W%-DG&IVQK#)NBQS>RDCDDF!)U)L24*R33:E= @0I
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M5DTKV?&G%=JT\,5O,;?B'5XC+!!%/!;PR;+M=\=O#<W$=NC96!)Y5B""1LT
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M+++*[22222,6>21V)9W=B6=V)9F))))KN8](3[P;3_\ 2VS_ -)]NSVG@_\
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/%*8I3%*8I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g686907image10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image10.jpg
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M>?1SZ/O<9$9%\T+)W',F+JN>9=,R\'>TNT7DID%GAG*6H+9:++F9SO2P4?\
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M2^)SU>W6[^0IG[3IOF1&5/3RU^]V'P?93]!MW]+[OZPL7>LHL3SSY=C & ,
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MJ:)<>_SR100OOSR 12A)!9B;ZC[TGE94)&XM+^P]WPH7 DZ[J*.RUCL::O\
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MXI$F.;##*B3<"K1\\B='R%/OW,I]^U4M_P"3K_\ ?/L7VT9/^NUC^,_H=/\
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MV 5.K!(\3#VI&SI&%"#2,+BDK%/I<VM&GO>F6.MTS=&#W].&.-+4L%(P!@#
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MF;MO\2?OX@%K^8ROXVBG\B%8]'#NXDL\+@C@@:&:_)JN-*;3*M&]FJXOY]+
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M+H=&FSUL*^<BU0P."M)49VX(/'#PL49_ \.G#E0.,"IO'R+H*U\F2>P0, 8
MP#3]M7UD7DX_IPI7]%.E<UI\W#U:9&?!>T>%K29W\RCU)Y2=GY?>$@]UF$9E
M2, E_P!'YM,:Z]SY0"85_)24.F J-V:F%DX?5CL5"JE>V4Y#.7H[Y29D&.KS
M1B0=:-U7#)QHBIOJKJGSOIKSQOUN7I-=/8RP=ZRC3S>W3:\NR%K[XC);VEV
MLKI3>.M8MYO,.RT8L>I(F;A\9M<W%QQNL[CF_:B@^K=8#CUGQB#,R;"JK5.W
MVZ-DGTL S4_'$J<FCN([%4UOFNW[,Z]+.X*:M])-O!O2DN6N+6_VIQW>OO:T
M$.MHRF*G=7\A=QRG"Q)Y:TK:4ZFT0ZS,NSL>F[,PUK(E,>5'T:?:1@O"',<3
M("Y"FF[2//(Z08F=PS<*UPXL=--%?I.I5]Y)IU((7%YI8M5UO5S*X^N4,OVD
M]-+#L"Q'"SF469 ZFXK:7AH=3BTL,3DM)K/@OS""5I&Y8^F98RI#DFXYZV0.
M/P:TT=:.FCCX=&&-:4,;D/)3+M W%O;U88;2B#]>.]1,_5[J<26,PDM,^L7:
MZ@Z+VW= I+ 1<G'OI-I)7!L&5DP(9(:^8$3<3) #"[]T31"G[/=5=98MUXNN
MQ+"F5^5;;42AD9GU%3"'"'3RO)(;DL0D<>L&O(_8$??M7$CCT:,L2PO8L3CA
MAHN/5:N]P[4\S<-M#6X0,(=,*:L>!DI\$# & , 8 P#UY<N)CXDF>/$QX0&$
M'O2YDR7>MAHD0)&ME7A$F3(O%46; >P9HK.WKUVLDV:MDE5UU4TD]MN)2<34
M,*<4432AA2;;;=$DEBVW@DL6P1;^GUT4_?J=2_\ Y&T]_?++KSA;OS*U_)IW
M[A-'J?:8^GUT4_?J=2__ )&T]_?+'G"W?F5K^33OW!1ZGVF:E=O]M^KC/R$>
M122+=AJ9VCDQN2I",2D+:QHH]!2<>*ZU5& )/@!AF47'%VC X-(B';E@Y710
M(L7;-3?5=NKIKKWYL+(#+C*G*_)6?DWDEE#?DFQY.S[-:YMUW3;;;!9K1%>4
M^;#)GQ2),:ES7+BAF*".D3@B45*-&9O,U96Y,9.Y,W_9[^R@NBYY\^^H)TF3
M>5X6:QS)LI6*5 YDN"?,@BC@4<+A<4*:SDUI/T^FGU'_ 'R5+_E"C?\ 7\Q!
M]!?=;]K;+7]7;S^K&2/HF[G?LWR6_P!;N_\ CCZ:?4?]\E2_Y0HW_7\>@ONM
M^UMEK^KMY_5AZ)NYW[-\EO\ 6[O_ (Y:=XG.PO0N0^)*B:,O_L7UG8LS JWA
M4VKJ=7M7\/-ZLWG8"S#3%(D-=3 )(Q"BZ&XTN.<:_$G/*"K(@S6^#506VW9W
M+8+=]A[KA\YVJL%WV.7%2SS7FQR[/+ES('2!K.@CAB@B6F&*%IXIFK"](E,O
M.\)DMJ.".VVF.".'TT,4,4Z.*&*%JJ<,2:::P:=2?(2QO$* B,]A#2]^D#\!
M:;5BSLSYS=B*JF1RP&PK53@(E,Y9+I\;E<EUCW*JJL;Y,&G>T<74W<@]AZ^W
M*G/9^<+=^96OY-._<+"D6I]IGNX3=/BAKKYMJ0[L5TJ#O(E*9'. I?Z1=5$)
M!K-)?'%8A)Y<3D12>/CL@DQN*J_-P@=D!$F47"(M!G+KAFQ9HH/.%N_,K7\F
MG?N$TBU/M,S'%:9Z47S6,8TKT#3-JU5&HNVK"%F*YD0J41R/1^)RV*3,?'HK
M*H<9=:AWL4F\'ATE&NPY5L<CLDC88FR>,B#%!76WF2IDJ+,FRXY4:H\R9!%!
M%1XIYL23QWG0AUWZJO)Y;YW0;U&ZS" .\8'TG $ *H6?1U8;L$270<!;3EH"
M>V0/<[.=EE7*,YFL6CTKE'*ZBBAD^):%7NZKS797:@5>M_\ 6CM&91,,BH*0
M2N5A@ P;))TN'=3 VT:Z(D9(XCXI(&$6+.->/?NU!8=!$<SV4YYY1:)Z):_J
M>,$'9L 8 P!@# & >,\9LR+-T/(-6SY@^;+LWS%X@DZ9O&;I+9!RU=-E]=T7
M#9PCONBN@MINDJEOLFIKMIMSQS*;333::=4U@TUH:>\T#$_T>* _<-I[\F<+
M_L3.3G\_\M-^,C\9-7K?;8^CQ0'[AM/?DSA?]B8Y_/\ RTWXR/QBKUOMLTW7
M-)4P>\BGE)''*BK R/CO8B$,(^Q*P&*$68)BO5P9RNS#-7@E9 8U6<<\KJMV
M6B"*BW/*N^G._/OLY)7I\Z*/T\3>+B],]&MU8G11*&51M5A>AM;Z,T?1KZY_
MN TI^2N"_P!@YRYD'J8?T5XC@SX_51?I/QG';K7UT][M_F!I3ZO/^RN"_L?R
M%C,@]3#^BO$,^/U47Z3\98[[GLIFGY5X?^H9Z3U36LC./];Z^/&CT%BY@L\^
M*]G;I9MOC9$@+</''Q=FW;M$/AEM_@6R"*"?O4DM-=;2";-AAS89LR%)Q42C
MB27IGH2="YC;SGB][?>I%S_T>* _<-I[\F<+_L3*N?S_ ,M-^,C\935ZWVV/
MH\4!^X;3WY,X7_8F.?S_ ,M-^,C\8J];[;,AQR+1B'#- D1C@&*ADEEG"8B.
M"!X,8FNXV]^X6T8#&[5IHLOO^J64U2XW5V_5;[;<_?RB***-UBBBB>BL3;?;
M=616ND]]E(& , 8 P!@# & , 8 P#3+9>LA\L7XR4#]E 7+F1HBXUL$_H97N
M7M1(3.<MSCO]3;[.WYN< GY[G.]35TX^SV"_2FN_.N6CE>UEU'T3Y-B+MLDI
M& , 8 P!@# & , 8 P!@# & :9;+UD/EB_&2@?LH"Y<R-$7&M@G]#*]R]J)"
M9SEN<=_J;?9V_-S@$_/<YWJ:NG'V>P7Z4UWYURT<KVLNH^B?)L1=MDE(P!@#
M & , 8 P!@# & , 8 P#3+9>LA\L7XR4#]E 7+F1HBXUL$_H97N7M1(3.<MS
MCO\ 4V^SM^;G )^>YSO4U=./L]@OTIKOSKEHY7M9=1]$^38B[;)*1@# & ,
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MD>MU[6]:76>K^*5O +BZ0M.PM/L2T;E,Z86I=FO6^PNPDOJ-I:L;F @17KJ
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MG;\W. 3\]SG>IJZ<?9[!?I37?G7+1RO:RZCZ)\FQ%VV24C & , 8 P!@# &
M, 8 P!@# -,MEZR'RQ?C)0/V4!<N9&B+C6P3^AE>Y>U$A,YRW.._U-OL[?FY
MP"?GN<[U-73C[/8+]*:[\ZY:.5[674?1/DV(NVR2D8 P!@# & , 8 P!@# &
M , 8!IELO60^6+\9*!^R@+ES(T1<:V"?T,KW+VHD)G.6YQW^IM]G;\W. 3\]
MSG>IJZ<?9[!?I37?G7+1RO:RZCZ)\FQ%VV24C & , 8 P!@# & , 8 P!@#
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L]3_W.3ZF;IK_ !5__I27=D+1RO:RRF='%QEW.24# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g686907image11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image11.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ]P"* P$1  (1 0,1 ?_$ !X
M 0 " @,! 0$            ("@8) P4'! (!_\0 6A    8#   "! ,+%!$%
M     @,$!08'  $("1$2$Q05"A8A%Q@9(C8X5W6TM=0C-#4W.4%55EES=Y.4
MEIBQTM76UQHD,3)14E-46'%V>(&1E;;1)D*(E[?_Q  > 0$  00# 0$
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M'Y6@7F/=HN:,2F'/L<%IO:FP(/1.VM-5 MD1N29I?;^LY-_(;D<'$8 P!@#
M& 15Y2YX=>=FV^D+K)&^2BN'JJ^NAT!C>A4H0LK5<,L^,:"-K J33=JG!E*_
MM98N)V6F5&?BA)18?I<%5^9.XECS;OWD&6];5Q$$%56B71]S5])7];";7TSG
M/2ECC-E5Y,*;MEE*1IUB$PPUZKJ>O2YBV:<8C0SM@A3ZK3'@90AT#5LNJ_\
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MOH>[E/I^:8A2\/0Z7FNF=+2T_P#H/@Z%M'1\FJZ6E==6K1SUH"1>>8# & ,
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M<LHZ?6+&WHUU"F(:#GU_?$TT=CH^8L>VPDDQO5K11>O?G^<DE@H, 8 P!@#
M*NOC!_FJ?A__ .[7TM]]([G9"\L;V_@J5=Y2[]MO>4QG/8>88!G/@IB/!XAG
MBY#2E%'J@P[A828@X\28DX\-<6?LDHU2 A2-.489H(##PIE B@;V8$@W8=%B
M\<7RQW:^"AZ4\JA]=_?0VQPOK*PI;)>@X5?G/5?PVNZ.E#14]J.43M">=!N4
M@D,^J>N+.9&6,U6R\T,;M-(^[QFV&%G>Q&C2JDK@6\I_<+FUIP+E765M:UEU
MYIJ3:J:[[T.ZLKNJ'QI/%7"L2X59<;EJOC<QA=6V9+4JU7&^JNNHKR\:]:8
M14TE&@B!3ZO?DHSWW3BXR)G70]U8H]M$<ZC%+?/W$N3S5)4JY*H1+4Q"Q&L(
M.2JTBHDM0E5)E!8BCTZ@@X(RCR#BAB+.)- (LPL0@#"(.]ZV*'/@# & , 8
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* & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g686907image2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image2.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X7/C:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^:6UA9V4R/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!I;6%G93(N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(Q,#<P,C$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#(Y+4IU;"TR,#$Y(#$R.C(V.C$X)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#(Y+4IU;"TR,#$Y(#$U.C(V.C$X)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.^* HB Q($--64L@8FQA8VL@;V)J96-T<R!C:&%N9V5D('1O(&=R87ES
M8V%L92XF(WA!.R8C>$$[XH"B(#(S(&AA:7)L:6YE(')U;&5S(&-H86YG960@
M=&\@,"XR-2XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L+4)O;&1-5"8C
M>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!I;6%G93(N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M<G(Q,#<P,C$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#(Y+4IU;"TR
M,#$Y(#$R.C(V.C,V)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#(Y+4IU
M;"TR,#$Y(#$U.C(V.C,V)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R
M+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,R8C>$$[1W)A
M<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P
M<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N
M=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[
M)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R8C>$$[07)I86PM0F]L9$U4)B-X03M!<FEA;$U4)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&EM86=E
M,BYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$Y,C$P-"8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,S$M2G5L+3(P,3D@,3,Z-3,Z,S8F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,S$M2G5L+3(P,3D@,38Z-3,Z
M,S8F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L350F(WA!.R8C>$$[+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X
M03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+V1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(Q,#<P
M,C$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+V1C.F-R96%T;W(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP-RTS
M,50Q,SHU,SHT,2TP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S
M*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C Q.2TP-RTS,50Q,SHU,SHT,2TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,3DM,#<M,S%4,3,Z-3,Z-#$M
M,#<Z,# \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N
M86EL<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XQ,#@\+WAM<$=);6<Z:&5I
M9VAT/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO
M>&UP1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM
M86=E/B\Y:B\T04%14VM:2E)G04)!9T5":T%'44%!1"\W44%S54=H=F1'.7IA
M1SEW241-=4U!0311:VQ.02LP04%!04%!0D%":T%!04%!14$F(WA!.T%11U%!
M04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G
M549"9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!
M-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P
M645"05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!
M8D%%04%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!
M04%!04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F
M(WA!.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!
M9TU20D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A-
M>%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO
M34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD
M6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI
M-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH
M26=:>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I
M63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F
M(WA!.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q
M=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I7
M5VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T51
M35)!1#A!.54T<3=&6%EQ;$]Q95IT4'-,:U<F(WA!.U-P3&4V:59$+U5R5E$X
M:7%A,&%2;4M2>$)Q2&E:2%=V875236UC645I*U%1+W=$:6TT+S9S9"\O04U&
M6F8Y;$].;G589TAE4'0O53<F(WA!.R]&3G@O=T)73R\X02M#<W8K>6Y'>C-,
M=T1V2#(O<60O:6TT+S9S9"\O=T%&6F8X05I4:EHW;#1",VHW9C%/+WA48V8Y
M5T\O+T%/0W,F(WA!.W8K>6Y'>C-,=T1V2#(O<60O:6TT+W=#<DAF.$$O0E=8
M+UI4:EHW;#1",VHW9C%/+WA48V8Y5T\O+W=#0W-V.$%S<'AS.7DX03=X.78F
M(WA!.S9N9C1P=5 K<DAF+T%00E=8+UI4:EHW;#1",VHW9C%/+W=!53-(+U9J
M=CA!+V=R3"]S<'AS.7DX03=X.78V;F8T<'50*W)(9B]W1$(F(WA!.U=8+UI4
M:EHW;#1",VHW9C%,-V)Z8EI09'@R;#=B6$]M>E1S<5=X=6Q4,#5'8EE+<W-,
M>E)":61G<G-'4%E(2&DW,"M(=%E.<#-K;70F(WA!.U-U-3)G='!:,6AE-&%*
M0S1G:31M4C9#=D9/4E9A;G15:D98;#EZ*UA6-65)3&U+-CAY5W,W=6)P1DYZ
M849%;FM*:TQ'4#%K-D]Z1V<F(WA!.V]D.'A4;W@O3TQU369B0FIS8V-#2W)L
M,%8W4#AV.55I=#55;C%(>DQ.3E!!24=K5S=T55930717:E$S1#AA;&4U4'IW
M:E,O,&EI9F$F(WA!.W=*1EES64%..'9V55IV>3%V-W$S358S<5!M851M1CE2
M5G4W35)K:&UB-%5A9#9$-'1H5310>6TR.&EZ:C)Z=VUX:7@O2D=W*U)*22\F
M(WA!.S!8>6)8-41P5'I00DDY>EI'42MV1$A&>$QE='-%.4MQ,#A4:W9Y;S(Y
M6$IP4&%P4$8V265U=6YC4V8P<4=N*U)*8E!Z3' Q+TIC*UHF(WA!.TI*96-3
M8S5R:3)K9T-10E<T>CA*2&(P,SE09C4K3TUD2T%B-'543$HR<UI9>D1W-$%'
M*VYE.4EV;6Y3>75'9UI%;E=.>D4X;C)!-%4F(WA!.SA3,C0R<C%Y*UA,6C X
M-V\Q>E-64$XY;F%A0TYC,31X-E)9>7%R,C1L9FQ)>71(>D$T2TML,D%*5D4U
M3E0S,D99>2MN:6QS>C!/3$PF(WA!.W%A14EM>G98;#4Y>4DX=F5C4$QF;4\P
M:W5D0W9O-SE99C<R2TTX6FMQ5T,X-'!/1'!Z2TYX-6=6-FIB2E)M2D-W,V%N
M4S5-2C1:>$DF(WA!.TM(=#0O359V<&0O2F1G3DI-='A.1&(R-T\X-G9+4S!C
M87531BM"5'@R,G)V6$E!4T%.=79I36=I8C@K6%!Y0UIA4$AQ.&1M:39O.$PF
M(WA!.WIG2T%)435P4E%$>61Z.%I*,W)X6#5:3T%L5S=B:45Q.598*U!X,%%U
M;V5A=$]T3'1R2TM/82]V:TMI5S)T135M4&QU4%9K67!&1V$F(WA!.V(P9'=A
M8C!P:$UM.%EY4EHR0VPO:6UF+T%+<VPO=T0X1EIF.6Q/3FYU6&=(95!T+U4W
M+T9-+SA!,5I,+T%0-$MY+S=+8V)08W9!3S@F(WA!.V9B*W S*TM:+W=$<7E8
M+R]!059L+W=";$].;G589TAE4'0O571B>EA-:6QM,%,O-&IC,$YO>"LU8F=K
M+U%-94DY>65!9#0K,SE366$F(WA!.U)R;6UA=$A).6Q+5V5%:&)I0U)':6UI
M63=G4U)30EA3;S-&4G5.>'1H0G1J2T)J>E(K1FDW1E9+-W5&=')783191FQH
M4G!'039K24,F(WA!.U14-W-"2U%,3DU4.'57-WAA5$).35$Y-V5Q3'4O;$@K
M-TQI6E$P:F9,.6Q2,E5!9$)G9TYM954S3'E#-715=D)D>G=,<&0P.&-82&@F
M(WA!.V-+,75%:S5#<$LX<%9/,W5-<W!Q6&9P2S@O-G16,2]W5G(O,5AX<$QV
M,&QE9CE7<38O-$LQ+S9R-#!R1G1C.'!(5G13;'8S5%=,6G F(WA!.RM0<5%W
M5#)Q>&Q544I4:C9V96Q4-#5I-4Y+2D<W9&QP*S U66]#4$)%,3-J9%%4>6AC
M43-D;F-V*VYB>#=38UA#<DIC5V)!<TDQ43$F(WA!.S543%%-5C5';4DP9W-(
M:4]Z2UAA<$U30D-!-&A7=S@Q3TAY<&5X5$=5:GI"2DIY9UI7:W5R1FEV;TYY
M;W!-*W=F;S)),&<O;D9:9'$F(WA!.VMI=D1H,39D+W=#<&PS-EDQ2"]Q>#,S
M+T%!9&PO=T)L3UI696)Q<EAX-G)F<V%.;S$T;G5Z,F8O04)R8TA'=DY7<#E7
M=EEO2DI2<$8F(WA!.S(U4E-W4E=T:5=O2S!!17A.5&I3;W T6611,#AX6&1U
M4D9C>#!M=%IU4$E">'5R8U-W<5!9-45H;$5K1W=J+TM-.3%.;T9U3'%5>GHF
M(WA!.S(W>E=R,T1F86LK<7IV04I(+WEN169*=F9)>#5-<VQC5WE*='1:<W)V
M54QQ=W1P565E,6I2,TE91VAD;EAI5D)R.%!P-R]-64)-16LF(WA!.T)O:FQ"
M:UEJ;45S,#-Z3F-J4W!.4S%L27)31DQH3$E"5T905E=95S P:%IM;T4Y8FQ1
M9&Q7<$\K,$DU1%9Y84UE<%!">%0R,W(W944F(WA!.R]B.6I)27!9<&]L;&ED
M6DEN05I*14E:5T(V145B2$Q18F-O14AC3'-+6%EQ-T9814%I:#-"-FI&6'HU
M+WIK;"MM8F)7=$<Q540Q9DPF(WA!.S!-1%<X6E9E4U$S9VM*;$5L0E)E84--
M044O<TAB8DU(5G=-<3=N<E!:;E91>&E1-B]O+UEX:B]N2&Q.8W8O>E5&.7!J
M0F1,=$Q/9&0F(WA!.V%M-%9J94M51#!O1F9I>7))6GA(24)65'A2="MO3'!)
M,&HR:C%-8VQ6>G0Y5EIN4$M+1B]C=&$R1GIC<4%Z45)0249046Q&3%4O1$$F
M(WA!.U-M27,P.#EI.'9A>DQP5VQF;S-6,W-'5T=35RMK.4U34&,S1GEG3%1/
M5TY+*V]Z4# V*S)5>7AY249';DYX86I(17DT-&-D,5<Y5E,F(WA!.UA2959F
M>DM7-&Q5*V$Q5S)C<39Y0T)897934E%J9VA196\K32],2WAH>2]Z;DY/=#!D
M1#EZ=C<O04IF:6M48RM7=GI%935,465A,6DF(WA!.V=+:6<K<5)-43160E-N
M46=K365V-CEJ-%=7+W%A-&%V4T-/*T=Z+U=0;79T9DMF;D-+45-3*V%:<#)9
M=#8T8491:%4Q;W%+1%)+95 F(WA!.UA(=TUN.#5J4%<V8VEH:4$K2W@O2VYN
M;CE(5VQR1C5R84]31T8T-VU9,C9U,'-J3S=#5&MZ8VAX5FQ8<C)W;D1K;T1I
M6D17-F)J36HF(WA!.V@R2C(S-6)$8CAD-E P1W<Q5%)T5#!$.4DV9V12,4LV
M;75,0S1V4%174#%B8S(X,3!I3T%457AV8FII,V%R1#EO-4]%5$=R3FQX9%(F
M(WA!.VQH:TUJ0U!"2%DQ9#<W0C9&;'IH3WA60C8Q+WAX<B\O04IH-68K24A"
M3&MY:#E14TQ39BM/5EIF.%E)=BM)1$=02EHX>6DX3$8R2W4F(WA!.WA6,DMU
M=W$P0T13;3EE;$U69%56<#-W2S-H5G!75F=#<'%$=4-/-$]!8F]T,TE6<%AC
M8FMF4$<P=&57-5AH.'1817%#<G@S3W!/;S0F(WA!.W,K-C-K-4AW;T-X*U-I
M=5%U9V9I>7I'="])9F,X;2]0:GI:-6A44W1#4S0P>6)38F4X861B>68Q1DIC
M8T5!="]5:F%O4U%/>%I*14@F(WA!.TQI3G9H3UEE;VQ)>#55-W(R5C1*-510
M3$-P4D%Q-E!0;EAY2&-W1#AO=&-V-%!Z6#!M,3!W0C0W.%A(<E=-:D%2>4-'
M,&UK:4I:;&8F(WA!.VEY35!H9%)Y<%5D1UE'1VQ"1'1F86U/3U5"24%'435F
M<&95*V@S97%85G9/*W R=W1,:$IM45%$9%%G04ML6DLP;$)R6&M!4$-G24\F
M(WA!.UHK36LX.6YI8TUP14AI1D<O=T%E.4AY4WAX<GEK64MU.5=044%#<$I0
M8EE9>GE29TQK84@T3&-):SAL=TE)0DA1-S<W6DU&0T,Q6%<F(WA!.TQ$4S1&
M;'5N4$M6=E1T-$DQ3'I44T560U)2<E9N8F)T,$<U,GA606%28V%X3&5Z6#)P
M6&-.=&%Y<C9D=&\V96TW47-J,%IP6G=F:6LF(WA!.S-#<VDO0W93<F1C2W%6
M<'!';%-A;'%C,3%,0F-X6$5O.4]Y3&E32D5U26\Q8FY'9F@U>G-P3SEA:G Q
M3F%2:3-*3%9H9UE437=A3C<F(WA!.U8P-69B86AP;6U71G!Q8EA&;F4R9&A9
M.$%L<G Y:7-#>&U#3C)D,DY2<UAL;%!09T(R,W)V:4U217(U2FXT:SAH;DM2
M2E!X-65:6DDF(WA!.TQM,DI)17%%<EAL.%$R<%-T9G9'5W1I0S%7-70U.48Q
M2#!:56PT5SAO8F=W86A-6D\Y345U5$M(,4)H='AR<S)L5T=M;C T-4E*3% F
M(WA!.VLS3FI(>$UA>&MU.&A"4DDQ46UV56MK549!>'DS5%E:6D18.$YF1R]C
M-#)Q,4AH>3AT+V8O6BMX05=F-6YA6&5Y>7!A26PQ.5="3GDF(WA!.VM-:$UG
M6&-C;S%D27A+3U9+;%<R0BM13V)L-U!L0TXW,S X+W0R*TQH>#=20C9-=VIK
M4V4S5U-+449*5C52>7AK34-'1E%Y;F-(>$<F(WA!.V$T9SAJ<UA:8W=X=E9F
M3U@V2G5,=4\X:6E3,G1$5#8Q2DPV45ES;G%H1E-K:%EH0T(Q<7I6;W5:=6XP
M4FY%1RMF8S1'8E=E1U1'<E(F(WA!.V5G*UHT.6)H:FQS;S!C5C54=7-N2TY9
M,G)W2W1X<7IT,U%Q3TY'-54K2&Q4<7103$9)1'8O2#0V96)D9S%0:40P:CAF
M:CAC<D8V:"\F(WA!.W@S+TQ(+V)2;"\W<'0U;4Y,;4A/:'EL-W8P:&U'4V$S
M:EAN>GIV-6AH.'@S5FQA,TQ7,%9O+T)21U11,#-'>#(W+T]V96Q!3TLQ;7 F
M(WA!.WEZ>7E*;$E!4TE!0DE'>')O969M.7@R5C)8:$]#37!$:4UH,5I,;R]N
M0RMV+TIT,4QC5TYZ9%,K:$EP:V=534%#<G(X5%--=&%C2VXF(WA!.W(Q2'IZ
M9&1J-FUE5$A+37IF065F94LK.%!0.$%A=6IJ9WI!4C5%.'9L*W1)-R]Z6G%#
M9FPQ6F%P8E=D>%EZ>7%K4G0W;%-K=U99>5,F(WA!.S8X5W%&4$1L6')X<C V
M:F].4$%324)D1'%P;4E*1'HS>3DU=#%Q,#%72U=.,5EM<7-!:7)T.6]L*T%5
M<V]P5G$Y=D$W:EE:35%)9%@F(WA!.VAZ>45N<V5S*UIP=$YK5D4P82]V43 P
M8U!/,FI2:%-19V-X5G=E2S%Q,6%B5GI63S991"MA6&U85EED6B]2.%)#,C!0
M1FM*6&MP2E$F(WA!.TU15F)K<%EC*W1/;$]M.61H<&-936)D8G)-<V=A0TXO
M2R]Z4'%K.%8Q87IX=&-1,CAB4WAP1V\U37=D9FAJ1E91534O15!L-S%R,5<F
M(WA!.TU$8TYM:GEM5WA:65!.33 X5W-Q,FM89'%.3G1Z37,Q-&EP0DY7379W
M5FQ:<3!P.%=9,D]!;DE24%5U6$]64DHX;FM(;DAZ5'$R;6$F(WA!.W,Q:EI"
M265#25IB<&\P9#5Y>4$Q*TY3<6]O*T96555&4$199$YP9%!(9TAD,$AC.#%K
M>6TR969L-7(S<E<P9#!T<5-B>3!K;4YR0U$F(WA!.WA6<F%F,&U%2W13:7E.
M2U<T.'%!*S5*3W W43 T:51,<F18-6,O<V1N,F9K2C4Y>DEX-7!L;6@Q;C%.
M275R5F1-9TUO:W9%5DE:=C,F(WA!.UAQ8U991C8P-DXQ<"M'82M%0DM1:65P
M<#)74U922CAN:TAN2'I0<3)L-G$Q:EI"24]#4G1*9$Y':G9.>5%D3V$X5E)2
M.$-Q;V]+538F(WA!.V)$<'1,<#1C03=U9S=N;7-M53)Z+W=$3&I7>&-W4GIR
M8FA0<FQP3$]B94DQ-$YA>F5M>7A+44M,2S!P8FIY;T0W:VY.5#)H<'A%;5@F
M(WA!.U<V=GEQ+W-D;C)F:TUJ.$=795$O36LQ>DI*<$QA4F97-D-3.7529GEX
M<4QE<E@Y=T1%5T1(-'A4;TLY*VTQ9%A(:S=J2GHK02LU2"LF(WA!.UE02TYN
M<G-S:T]V2S)P-DEQ3DMM;G5&0VEA=$%615E2>593;T974%A+<%DW3RLT83A7
M5$II>6-C6DAB.&9(-#)X<GE,*U8K;&%*6G0F(WA!.V1A8G!Z-D9R:E1G6$YW
M<W)/>C)R3UI&:55U6FMO:U5G56IJ475M+U%.;&--4G)U3$-7;S%'94$X56M3
M16HS8VHW=&I1,CDT*TPP9%,F(WA!.TEK:E-35&LU;V=D*TE:,D%R,$%55DY#
M9&AM45I!54-E9DQZ8D%$5'IR5U!0.3EF-FYE,D]J6#)I5V1R<'0U2EHS16UR
M4U-'4U-A,D4F(WA!.V)-5FA":#1+:W!D2VMN:U8R27I#,4=14SE*-&%S8R])
M9W4X,#-:.%)J-#5J3$EM3FIG07%J63-/+W=#>&M8:V9Z;$(U:3!U-6QK93,F
M(WA!.RMT861E4'!T-4YA>4(W5U=A34E22F)S5%AH27-Q:TLR-%!W,6%N2351
M>E)Q>5%.-F18;G='17%!4$LY*V9X5'%,4C=#4%4U=%4Y4&XF(WA!.V9Z2TDO
M6&M*8W!'04(V8UA+=G!Q>%AK=U=L5'5C=&-D9V9N=GEC2'8T6DY/,$XY62MV
M.$$Q9S9G1&-'3#!L9&]Y5$5Z3456>7I->6<F(WA!.S%&4C!P;'-*96)%:&DX
M,VQE5%1T3%<T=B]+8U,S549X8GA)8FY60U!R0W@K;T]966U'34]P:6HV3'5R
M2&E",FQX6#%26&MO4S9$;S F(WA!.S)Q3&)2-D1B,SET4$)!>75M<DE$=$=G
M;5=-0G9I5E-S;3=F>44Q<'-$6C<Q<$576&QZ5C15;'5%.&AE;7-S3&UQ86A*
M2B]V=55%2T@F(WA!.V)M5V5.5S)O869$=5)G36@S<4(U4%199DQ':2M8=DQ7
M;U=M:W=F5C1$8E-66&MZ5C1X='9U5&Q%-45J9'-X:6E'0BMA.4<K=#9017@F
M(WA!.VYE1DQV5%DT2DAJ-GA#14=4,4=P6#DP9E4T>64R,V9.:#)F<4EX<4HU
M,UDX,U<Y<#1I5%DX,D-E52]*;"]P*W51,V=U24PV4TI(34XF(WA!.W):;#58
M8WE,-E%*<7%"14)K,V1T:#,R,WIC86Y59W=/>"](-EA667-%:61H8C(O4F]K
M:#!E>&E2+U533S-I4EI/2FHU0E5!1&-$=70F(WA!.V9!.4TU;5=15$IK3U(S
M96EX+U-08W=(.'=02D]P*UHP3C%P9G%G*W-#<TTU14MS9E173FY+3T992T%G
M0VQV:7)Y,DMS1T=Z-T\W46@F(WA!.T%63%EE-SAF:C=D8G%D36-X-&\O8G0K
M4'@P4E@U8V569&8X04Q/9UA":U)*<GDV;6IL5S Y5&=O5W!J4$YM5G%!25)*
M.$DU9'4Q36\F(WA!.S=4,5EZ14=(5#1F=%HV8D)K>%%*0752<F)L."]V6F1F
M+W=$2&8X<V8Y=$=8+W5M,VUA*UA2,BM0;$PS9G!$34UK,7-A,6XX=E!,3W(F
M(WA!.UAZ,W1Z07EZ>4%C+U19;T-A-W-1=C=2>E9A:G-J1FMM6EA+2E!/<7(S
M-V<W+VIM-U149'-:.$U/0THR2&5J2#!I=S!J>7AD,DYJ1TDF(WA!.S1)-V%8
M-7,S<&UR35(Q63DX>DU';6AH>#A-9C=F375*;#%%.#)4:FUB2U57=&YB6&UH
M5W1V8W!Z:&5#3&MT4T]I<5)U0T0R>DIH26DF(WA!.VE(1WEX<VQ+.4PO3#-Y
M.7 Q,G0Q16IV2W1#3V9!1&M#0T0X0THT9$]N=&QX>GE)<'@T-F5)3G-L>6QY
M16TQ-WEL;RMU1E=V56)M=$(F(WA!.WI1:7!!<G129W<O839G5CDX<VAL3654
M5E!$1UA.6#!0>3=P=6EW3D1:25)Z*S(W57%A16MB2T9557(R2'IW5'E'6$Y/
M4$=).&MZ>4PF(WA!.UEW,F8X=DQA5DEJ2V)E-61),%0O045M,E=D;$E9;6E/
M-W$S<$Q86E=Q9D5S5&UD:C=1;D5B."]),#8R6%HT4%@W4'AT.# U,$QY*TXF
M(WA!.TTT4TI-,WAW<DA0059654)53#99:E9#5FI74#1W1D9F=&)K,$=9;6)+
M8VMU3&M/-SAD92]V8VI"<'AJ3F<Y3B\P9DQF.$%*>FM(2UDF(WA!.V)0.$%L
M-6)3<D=:1&)81$I'<4%83G-S-59G4V%)-T]R96MT9&QA<#A3835N43=1;D5B
M."]),#8R6%HT4%@W4'AS;D=G*UAX<&YP>4HF(WA!.TUW-7=R2%!B;%56059#
M*VU),5%L63%J*TU"450Y<C=2;TUX33)75U-8161H,V9J<C,Y+W=C:D)P=D1.
M9SE.>#DS>3,K9FMN,VLO.$$F(WA!.S0T<F8X>&PO+W="4C R57AC,TIZ*T$K
M-6]E6DE0,&AE5W0T2# R,VAG37-6,6-R-E%B,'DO<G5R=E=-<D=G4G9K86YB
M241*=5%D;D<F(WA!.W@U1%!*=T%'*VTS33<X=2]O:VUH961O-4Q#85=45F)8
M5C=W6&-D<DAB5T)76GA#2E!385EX=V,S<DEK8VLQ3VQ/;5%J;#(S3C<O:CDF
M(WA!.V)#8V,K0U W-DI%:DMG3T5J839*<7(O<$US:V$S=7)*2G!92DAJ240O
M5C-29S%4,F5-.6%6-DAV=F<Q14E4:#8T.%$W<78W3W9X.2\F(WA!.U)Y.$UJ
M9&<Q9G<O<V5:>2M2<BMZ=C=R571&,')2<C-2.51V;G5P8E!5,6MJ=4),8VQ)
M>6]L4DQH5$0V-#E89U4R<5%+6F=9.'-4:D<F(WA!.U1H<4A%26=D9'E)1#-#
M*VYC-W(X>G1W1V-X3TUE;DQA>C-J971K*R]+:CAT53AK955',&$V=69R,35D
M>G1E-FA-=G=X:60P4D]-3W<F(WA!.V-+9VE8:7A.4V9I*T=V16)(=TEM2$1)
M8F9J-45(:V59-75U,5=Q3U1)6FAK8F598F$S,4PV:'%%5#),4T]%<S=I5VXQ
M931*,E95;$(F(WA!.TMI42\W-V5J2'-#3CAV8U).8U93=E=V3"MM879*8F98
M0S1E,S5T14DS36)&5S1H>%5F1E1:96Q0>'A%-DYD5G)Q:T9V-4,X:S(Q,',F
M(WA!.W%E=$AC-F5"1D9),7A)4V=#9VAL0EEG,#5*,4A64C1:4B]+1T\U4DI!
M341V.&=F;'8X,GIW2F)'=68T+U%Y>7=S;V)'>'0W2T-V;U<F(WA!.W-347AC
M:E4X23%#<E4Y>E%:95,Q<4]T+SAC6%50*UEA8B]K,F-%=51+2#%"271*02]2
M9&MA8FDS:D%0>E%9>#5,4#9I:5!Q.% Q:C8F(WA!.WA1:5AJ=TQ!:T%R54@T
M:%=H<#)R,'%A9%1J=VDW82M!6&9657E42C)+<4YT85%7>4UK2VQ66FDU0EIM
M*TIV=$AC;C=2,U!I86LW:S4F(WA!.T5205EX9TEI9V<Y42]W0T\O=T-74"LR
M:DPO,U1B>D),;4<V2$M8=2]31U57*W!A9&-+1W0W<4=:5W!X84]25T(U9$M5
M2C8U2G)B:G8F(WA!.S='4E,P9'A%-FET4W)Q4G17=E$Y=4IX5D$V>G%7;DA3
M-WE)6%5*;&5#9%5J.5)E5$UI34=!1F%K<5)V9VQY6E$K;TI.6EA6=&$V2&$F
M(WA!.S-&,4UK145D=D5:2G!70TEO-&=63$Y11$=02EHX>7)Z86QP,$-).#$Q
M1$5K:FE+3FYK5E$P:F9:4E-4=7AP<TUK>%)/2W%$,SEI;'DF(WA!.TQ6-VE*
M8F]P-F]G6C%%;D-V2&YX2G)X<G181EA1,S%L4%!.8G<S16-S.79X.65*2%9N
M:C5#<3@Q0G%T4C!R:7%P2DQ&16Y/5C%22V<F(WA!.V-M24%Q>&]"52M*3DU6
M5TYE5V%Q5V%E34MO2EII-F=!1'%4=FEQ.4HT6$Y%:U9J,6]#0V9(1E9+-#%(
M5#=A4EER:35I:&QC5E)*2%8F(WA!.U=)<E-O0DE06$96.&0S87E"5$A-:FAW
M0W!69V%G;6=);V-682MU,F114%AJ<5%30GI88TQ3<#8Y=5%X5E4X="MT+VAQ
M-#E(;#8S,6XF(WA!.U5V4SE0:'HU9EA**U!(,5!G<EAP>3(X8W)(22]&;&YV
M<#-$-VYK2#4Y,VYN<5!Y+V]%=717.75M;')/>EAH=#(U9C94-EDY1#%G4C@F
M(WA!.T(T;55F=3-:82\W2$U054-::4%88RMY95EW>4=765)%<4959FXU9#-5
M<T4O2GDV,5<W+TYV4U@P56U/<5A0,3925FME,U-&<F519U0F(WA!.W)'>69#
M6D98:4=A;DU,,WE';&E16&(K,"ME13A904DT=6Y8.50V;3AV3')I,G,V-C!Y
M=F5#9#934CAF4V%-,$M'2E(X4W%"=%(O:34F(WA!.U8W57I0>#A697)M.$YP
M+T5O*THY5B]$-&9T-G!I64E31D)284E3549"445G:6\K9VY"-%5D=&AT>6-N
M:5!E=GEX:7 S3G)B6%9V2F(F(WA!.UA52U0R.'%L6EE:5D1O>6YQ1U9Q9VHU
M-'%L5VUA1F8V8G%**W(V:S<V2#925U!3<# Y5C1P95%O,%9Y>F-X1T9"2'!S
M1S8W14%!67$F(WA!.V=V3C)V5W5J6$9G5T5L,W%M;U-',3!N5$EP16A-<VA(
M2FDW35%214-%1'1V>'%.:EA-1%590C1G>45Y<V)!03%Z-2]/:#5/>#!7134F
M(WA!.T))0VA%8GEK4F1$,V0O3VMV,$Q7+W)L,49P5W,V3V1&=DQU4U%W96QC
M<&1#8W=Q<W)+.'EH6D9C.&DS5#EN-UAB2UEA3$1/4$1W.$8F(WA!.VUZ4C-L
M,3-L.5A0>G9Z6C9K94=B:%!J1F0Q5C=H>5IP1D5K56%X<%5+=E-P2E S;7!Z
M6EDX66A%4DA)3W1L26LR54IR9B](1C%$+VTF(WA!.T=M+S5.;DI3-4Q$-F<X
M62]-4%)V3'-Q95=B,U9T6C%F4W W,#)U;#)(-DMK5TYF6&M"6DAK<7!.4&E)
M<FAJ>5=F,49J3VPR+VMV560F(WA!.V1T+TMU:V5F=DUT>G)5-S-19V%786)H
M2$I$135*:TI71&M&-$9L1F%%:F9B8D-X939Y,'1R1BM-9U%1>$AJ3$LQ44]+
M+V%D:CAT>FDF(WA!.W)X.&5B=GIA=#50<3!E<F%&96M+1V4T=7)A.6=)3&]S
M649)-"M&1FY$-S$S558K14$P5E124$](-6E2-DY&9%AM;V5825IR=TUB0C(F
M(WA!.V$U4EI05'0R16YW34$T-%A01&QT<W1A,'A64"]!0VIQ1W18.&9L2S0Q
M<3AS<C=59C!R9$Q,4'!P63)X07-,,VAW3$)4.6EH<C,V-4<F(WA!.UA-3FU0
M;$PS9G!#1#@S+VQ$-60P>5!36B],9FQ%879C5VIO16IE+VUG4T)B4DI:;UA)
M3"]!3'=M4FEV6&-T=C=383)(,D@U5WI81G(F(WA!.TQC6&8U5WDR<SEH1D9$
M65=+-C)V1S176G5-;UIW9F=+0G5D5#,V,3-X5FLO:WHX;CE),6948C8Y.'=E
M5D0U93%/5GET<F%I*VUU1D,F(WA!.T)2-F)-4DMW<4-",D9E*T%P0F]S<W1T
M4#!Z>D(U4W1R2%5R8U17:SA-4UAD;SE24C133V-4.4162DDK3$0R24]#2C):
M6D)5:6LX=C4F(WA!.T]F;#5*8V971'!F1U4S558X>DI.36=-.$YE3&M+-$@W
M4G(T.3AK=UIR:7)(9&8X07DO.$%+5W8S<C,R<E=#,TXR.75,47I&;E9H078F
M(WA!.W%%27!5:FIV3WA.3W!P+TM+2W4X<BM14$LS;&4T=7)J4F)2<F%7.&ET
M-%IY6EI*055T53E/24%333%+3#DK2W!L<C)H85IR,FM83VLF(WA!.V%P15IR
M0S=52F-20FU1<V]93E1K:%9H=4]X>%8T=G)N-54V3' K<UA';394-49M,4MW
M:T5C34TO-E%U-&ME2E1&8U1)>DY*=U5C;5 F(WA!.T-P04Q$=6-66C,U1"],
M<E%,0DQ06%ID24]N95E)-4QL-49-,'-N1G!+,C=F861L6E=I:E5R,DAB1E5B
M*UE8-69E5U!-,6I.939P<&HF(WA!.V%L9E=6<DM,2TI:6F]Y>$$Y45(P:61+
M.&Y567$X.#AT9FPW86I614TO:TIR2S-H;6I*=2]R8WA+6$5$>4UV<%)L,4EI
M858P3E5Q;D4F(WA!.W0T8DM&*VEF;&HU9G5B=C!B=GEI,7!P3C%*3DAE4$I*
M9%)L0VY-96]$2DE+23-(;79W:%)T46YK355V8G9)34554&Q/>45#1DQ74G F
M(WA!.S5R345K;C9V3F-34W=%.'0Y-&Y5-S<U0U!*<WEI<%8W=G58,S-L:7IN
M,4-A*VYI1V]2;4(Q5%0W<&UM:4UR<T=*5EII.&-F3&E&*T8F(WA!.U)K1&HS
M=FTT<V-::&LX4TI014)T=65F;#-F0DDO3'8U8C9D6C9-3$LT,"MZ<W)T8G!B
M:5,V<UDQ:DUY.&I*=UHP16-N=VEA4TID.6@F(WA!.W8W6EA(1#9A3%AW6F-S
M0DA.27E-6EAD:S@Y*W4O=T12.7<K1$XT-#%J:E=.4U-Q04M#>D9M;T)49&U*
M66XS2GI*1&MG575X4S=&6%DF(WA!.W$W1EAN;C5T95)D4SAW>C9$<2MN,C8V
M:DIO53AJ>F%-.'8Q9C8Q1$]9*V%P4%5"1U@P45)863<W.6I2;GAC64A6,FY:
M;70X17E&.% F(WA!.T5/9D]V9WAJ>58U1#%#.3@O=T-I*V)J;S S;&%W,#)/
M-F5A=W9*1FQL=6)U-44P25-*4DEZ2VM55&-I-W%P86=O<$AX0W)"0TU31#DF
M(WA!.TXO="]1,V$O5GEL07=L3&I/,C0W=C=F93EQ>DUD2W S345D>&)Y,CAL
M9E1M4F\S<'-E3$-H+UAI56<P.&%V=$PX-GI8:T=K2%<T3DXF(WA!.W5O2G)D
M2DQA8FMH;'0T26=J>5=L1D)F,3)8-U5B2S!F33=H:V]9>&PP4$YS>5%S.%$U
M2G!Q4&Q8>GI.9#9A,6QR,%9N0D9B*VIQ56\F(WA!.VDU>5-34DUZ4GEO<F0U
M=5$Y6#1X4VA(>%8R;3!S<7-,3V1D2FAT3E)C6$TS;VE/-5DQ64]3=$=Q5%%T
M.'HQ>%-G;#AL*U9&4$PY1E<F(WA!.WAF-&%U,%E::G=B;7!::E5K:'0V;D97
M<C=Y:#54;G-0<3$S<#A(,4]*1U9!,W=#2EA4,#)-5$%G>$5R*S!H0CDX8E=L
M;FQF5#E,;C$F(WA!.TMX:C!+1E8P5%-(:W57=3!Q.%5T>$I%.75S54UJ13@K
M2U-/6%IA:&%+=FE"6&1N6G0T94=*=FU795I.<61I<G-662]F959P9G)S;#DF
M(WA!.V\Y-$Y0;75'-3-C16M8<C(P<C!O6D1'2&E:6DMD5U)W1"LP0V-J=SEZ
M64IG:6E,5R]O3'I,+S%D3$PO<$)L+S=+.&0P6$AU4'HO63<F(WA!.SE"95IF
M*W)P6F8X05-$3"]!3FQE3S8S2'50>B]!1T\O45AM6"]Q-E=8+U-$3"\R5C0W
M<F-E-"]0.6IV,$8U;"\V=6QL+W="24UV.$$F(WA!.S)6-#=R8V4T+U X05DW
M.4)E6F8K<G!:9CE)378O6EAJ=71X-VHX+S)/+U%8;5@O<3976"]!16=Y+W=$
M6EAJ=71X-VHX+W=":G8P1C4F(WA!.VPO-G5L;"\P9WDO.6QE3S8S2'50>B]9
M-SE"95IF*W)P6F8X05-$3"]!3FQE3S8S2'50>B]!1T\O45AM6"]Q-E=8+U-$
M3"\R5C0W<F,F(WA!.V4T+U Y:7AV2U8W9DXV97,V:6QZ<"\W9&IA=T<R4V(O
M04-:,F%79#)4+TI5<40P87$Q1U!#5'I:0UE(26)S;$%!04%&04]G>515-T8F
M(WA!.UAM974R=FTW>3-B4F%J<3-N5V(V;4IO;R]G<UEM<7A,3E)L1SE',D<S
M,UIA2U!)351T,5-C*UDW*UA367(K-#@S6$5&:$900GEM14LF(WA!.V@V<6Y+
M475S4C4K:WE.1WEH:E5N;4=!-U,T9"M33%0W4CE+.#1A-G1T<FQJ-7AK*V]T
M25=J9TYQ<6),2U$V4TE'<%=G<%$O4E1R:U,F(WA!.U%.<51U.4=Y<&LW1EA9
M<6@W.6)T;T]&<E%3<WEJ;51X0W%$56YX-U5Z1C%G>6U&62]Q2D<Y,5$V+W$K
M3&)H35)+-6-K0G%%9#=,9#(F(WA!.UDY3U-1>&AN;$5*36%#;TLO=T(T4W98
M=T)R5#4U<F1B1$Q03&I&4VQW,E1W*VMD,S%%:C5!,U8W8FAY8TUO0TUT=TPU
M6'8X05EM*V(F(WA!.WAW6%EQ;S-L:EI8<TIG=DQE3S5G2D)-57E,26A)-DAI
M=TEW15=K16IK;"\K169+;B]6;'-0*VMA2"]M;D)W1'5:94Q,=DQV.$DK5E F
M(WA!.RMR3%EF.4DP4"].3U!!3S5F1FPS;#,K169+;B]!1EIB1"]P1V@O-7!X
M-$(S3#1S=3AT<C54.'%Q=UID1W-1=TY14F)19V=J+T%'3U F(WA!.T%/-69&
M;#-L3D965E5+;T%50V=!,D%!>51"=D9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<6M8;DQ13'989$LF(WA!.VIS24I9,&EA9$AU-#5G
M,T-A1E$S2TDX4&E!6G%D0T0W:DI23DE)679D9FQL<CEY-5=45S$K<G9-6EI9
M,FEE4EA54VE32E1(2DDP6CDF(WA!.TYQ=4%14EAB<%A*.%DW:U5Z5%%,2%4W
M3%1H8C9L9698<FM34TXY64E#:W%Z:W)504-M>')4;T]G,D9C<DI:2FIG5E$Q
M0WI3.7-:-U(F(WA!.S)+2F-2=$=Z3#%!654R>4TT.%%)-S)E3V9$24AU64HU
M;3!E4'EZ<#ER95%487)Q1$-E2TM'>G0U05-8-4=8;'@T;&8R3U!4=FU01%(F
M(WA!.T,O<4QL4S%X3BMM3R]K9W1$9%AV-$9I<R]-9U-X2F5+1S4T0EI6:6%&
M>'E6;55F2#8S3VI'=7@O,6-K3D5),&5)-V5A2F$T>4)(1$@F(WA!.V9Y674Q
M;V)',7-R:E5:9DY#:3=G1GAQ16QT25-S9G!E<D-3-$E(-T5:9'%K,$9/=6)$
M-4]!>6YY-S596'I(<$5T=$QF-C=P-'-B>58F(WA!.UA3-VU!;F9K251W:S0Q
M1D8Y2%IA+W1C="M744UQ4%))1G,T.'(K6%DO3"ML:E1O-WDU=F\Q8FMK=#(O
M<5-!8U%V14=G,BM'=$UH23(F(WA!.VM#:S)Y2UA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ*U10>D(O3C,X>#E/.#AA-UE75W5445=D<F94=S(X2W)&4D52>495
M5E%N641-1U<F(WA!.U-6;F0V:E,V2$1,1D5M3S5$2"\K5C(O;7 O,4U-+SA!
M=T50+T%$4FMF16PS="\X04HK1"MA2&8X<G0O3E0O<5E:+SA!9TEF*V%-9D4F
M(WA!.VPS<B]!0V9G+VUH;%!L6'I4*V1F;65Y5V)44$Y+0S9L=51A5S%H33!-
M8S!Z<D=*6$U9361#15$Q63EV=7))4VME4F-B3F@P*TTW=S(F(WA!.W$W4C%X
M<5 U.3)L:').,60K6E9H9E)6:F%E1&Q#-U V:G9'46A737)65VE92&9T-&(T
M.%5T.2M405(P<$U122]5<7I3+W=$3U%T=' F(WA!.VPQ<48W-6=&<D1B1E)X
M6F]76C9Z2D%E25-.<6-7;%@W5DMJ<%A(:6Y6;T$P:$E!:F8T=%)L;B\U>4E.
M=%HS6#9A:T%U=G)::&ED-&\F(WA!.UI0.$%1:DE*=5-326TQ2651<G12:&IC
M,&=A4WE/2&Q8,G$R<4XO>FMJ<%5C,'0O<D)H:G0K0FQF,4Q6<4Q*26M3<TM+
M82]&24YH=C<F(WA!.V1+<VI-8S!1+TM3-5(K.4A83VUF.#5(=U1-<#AX4FU#
M3U=/0V$V371U:V%V33120CAA2U18:W94>$=(,7-"4%-(*T@W,&UV9%@O-7DF
M(WA!.T%S6G)+2SDQ-S9U*V]34E(R,TXT4#DS5$Q!<E!X:E!!0C-(3&Q1:DDX
M8W4Y=6I$4WEU;SAV-U5X4U@X.#5)-T]34'IC2UAP:D5+4W<F(WA!.WE13U1.
M3SA#1&A,8DMX87-,37=(,E)4*UIA;FEN,W1D86)F,&-V-V4Y:%=T9FUX*V)E
M:V%V93968V59-5AU3$=E4S-L84Y9:6AA2FDF(WA!.W!+;C!X='1G335D-VU9
M.49G;$53165A0R]W0U8R+VUP+W="5$10.$$X0D0O04TP65!%;#-S=C50=V9Z
M43<O;&1V-7%F.51$4"]W04(F(WA!.T0O>E)J-&MU.68U4'=F>E$Y=CA!*V-C
M=D]N;6IZ4&%A-C)V86<Y*S%R2F)#,TUI;T]!:U=4;%1G<3EE27I)=U-*=3-4
M9'$V94=->#0F(WA!.U)6,CEK>DED4S=&6%EQ>&)Z0C5#=#EA,5DV:DYE>4E2
M2$A':TA#3U)"-F)L.3%K1$1I,V1A0W4T2DE.0DU4;TE)43)M9FQP839D9% F
M(WA!.V,R*W S5$\X,$5R*W!W4$U15&EB:3E!<$I92T%4-#%9,4Q'<5HR=$UY
M>4-867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ.#0Q=C@F(WA!.V=F>3@Q
M;E8W>E9B>4LV*W0S,')Z>FQ*>7%L,TY7249$5&9+5&=I5&)S369A95=%4D56
M45%8+U%T6#59+S<U=E K:V<O,'=F;#1S+S4F(WA!.U=Z95AY9"\P3%8K5U K
M*V)Z+W!)4#E-9GDX5B]L8DXU9DIC=B]/3G8U84M15FIV5DDS0D9Y=V]4.4=0
M-65+4#57>F58>6)0+T%$:F@F(WA!.RM7-59L2S,S1B]T:C8P,411,3,R,S-X
M+TQX6"M68S-L.&Y(+T%*>'<O3%EI:%<K25!51S9B*VU0-65++WER;3AV:S%*
M+W=!-#,O;#$F(WA!.TDT6FTQ1&%V2697:65127!1,55N-W-(-65+:G183#5F
M2C0O-7HQ5#AU.48Q;3@X<C-/:V%V9E<R:U1Y4E%Q,G)/26=X24Q-:U12344F
M(WA!.S5%0W1->#551%AD-2]S9'1G:&QN151":41)9GI513!N:V1B3T,U4&MJ
M5R]Q;#!/5G9+3E%C<$E&4%933&5H,W=B9#,T*U1/<VPQ-&LF(WA!.V)(;"LQ
M6E!*-4-J=$QA-FTX:V%Y3%<X3&DQ;&)51S1Y1D0X654K:'91<G8X<V1U-S=F
M,DM";'-G5&I9.'8R=64X.&AE9W1Y+VMZ5V8F(WA!.U(T=$MS<F%I,TAJ53AM
M0DU(:74U=UA(=2LS.6DX3U<V-#0O-E@Y<6Q03BM88TYW.$4O:VI7175&67$X
M8C,W0F=W-59Q1&(Q+UEB-VHF(WA!.VAS9#,R+W-30FU)<UI)+TPY<F-%;C5D
M,T5O:6<X:C9X3$M595%)="MX2E-.4%5D9T)B.494-&HW63)/-S=F,DMF1TA0
M2D@U9G18>DPF(WA!.S5!9VMN:FTX:6%Z2$IA;&AC2S$X=TUF1G5$8W$R*S%'
M,GAS9#,R+W-52$MF.'!(9GDO87EV.'9F>E P9GER2F-74&QR>5)Q5'IA:U8F
M(WA!.VME2C=P<%AB,$%D,4AO1'!Z,WEE4$M).&@K4&LT=7$P8W-T1V533S-L
M*S%M,'8U."M:;U5M95@X=G144DQB:UHS3'9X5&=+='E0;U4F(WA!.T9/*U<O
M;40S9FHU3T=/>EE(+TM2+TAX6F0K5G8U;%$K9F1+=DY1:7-',#A7:S1G36)3
M:5AL5D$O2V]62V9A>7I(:S1N1C%M:SA#448F(WA!.S-B3DUT8TYB2S=*13=Q
M:&M:45-%2%4P-T-U47E335EK9U=2,#<R55):<FMK3W(K961",&1B4CE4:V4S
M4RM,+U8R-$9V9U-N>'-&<58F(WA!.U9U47!K3DQL.&%(1T%11'EV<4\O-'!Y
M=S1$4D\V5&HX-79):&=75F)M6FEY96]):$,O24-T3CEQ9F%.3W1+-6QE1U=R
M:4,W+T%*6$@F(WA!.S5'.50P;75::$M*0D1*2#9%:$M-9D=G3F4S,F$Y9FY2
M.$UR>$)E;C5T*U1J9FUW85=D3&M/-FQ':&%L27E63#%&4GAQ<$AJ=#!W94<F
M(WA!.U4X45=N.#1F25E25V$X;$%:=49$8GI!.'525"M8>$@T+U!(=WEJ:411
M+T],>4QY26$U;E1U0S%V3'5V179Y,E5K0VDY.&9$2SA15E4F(WA!.R].:GEC
M,7AD,C=Z5'A45V%3>7EQ,$5H+V1W;FEZ2U5$1&-G,"M2>#A-<GA"4F(X-5!)
M,T-6;V)M861O=CDQ<$))0S-4-TIC278W63<F(WA!.S1F1$LX45I:<$]Q,E=R
M861$<4YK-64Q=4%7:6-G<5-!4W91-SE2:T-+6DEV07)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER=TAZ="\F(WA!.WIJ:#5G.'=E8DY5,7%$5G)31T<O;F%:
M27!&:TQ+1S='9W!M3$Q!4U-896%F=%='4$=):TA92FAO+W=#568U=V%065-7
M1F@U=719-U,F(WA!.U,S1F])5VE:,5-)8W1O*V%.-EI0<45K<E%N=C!X1T=9
M-G--;74P.'I:9V)U,FTO2T@X,FU&:T<X,%="5W=E-&MT;$YV54)R<W5:<6<F
M(WA!.W!1.'958B]-1$(T174Y9GHR1&8P2&5U=F,Q<4@U3R]M='%.,&)R55!-
M=6TS8W!J.49X3F%H;%I/2E-J3#9F13=(131*13)3<V1F9VDF(WA!.TM%6D0T
M<&EN-69F;F5M<%-A:5!/1FHY8FQA3C5(3G%T0UEO,VE4-&94-&="6E<R038W
M.6-L-&,W=3)V.#%P<7)G3F4Y,F]F;#$K8U8F(WA!.S%Q54=O4F5:3DUS<$Q6
M-4I927)E,F-X<DI.0TE:2'!-2E-3-FIE<'!5;6Q-2&A4=3=73W$P-$9C36IF
M;6Q8;DA49GI3,$=X:#%0>D@F(WA!.S4W<TQ3>D5H=#0U4'%,37!L;%E40W%2
M44Y69S!(2E=)*TAT,7=4:DEC>BM0:S(T2C1*;FAH:DI0=B]B-7908G4Y=$QZ
M5D@Q3S<O34PF(WA!.U1,:39L1&E8,61.=6Y2>$IW3$LP8E=X46IL1W)5<#$S
M>6MJ>BLO.$%5-3A9:U(T4FIL6#E99G)40V9Z4DQ.8C-D=2\U:39323<T=6(F
M(WA!.VM,<%9W<&(Q2&%6='AA-V9V;F%88F\U2C<U26TK=C0K5%=-3D5(=S5B
M9C!H*W9U,F5G+S@T-DAY>G!T;'%E:#9D<C!'<S-S:VXQ,6@F(WA!.T)$8WA"
M26=Q4F)M94]-9F%P,'DW05)U3&-(=%AJ:U))>#12>3906F-Y6%5.3S92;WIU
M=U)&1E=::E%!1'538U9*634U<VTQ<U<Q=$(F(WA!.S5F;3 R3FMC:3E7+U!W
M<F)Q041X5F8U4WDY92](2$A'249$:T\U17!%-W-5,#8U+TTV4VE.2F],5W<K
M05A:2VQ*:3%+2VYP2"M9.$<F(WA!.W%O.7$U865(>E)U;4I0;7DU*W-W,TUU
M:$))>311>#!A5#8P6G$R-F9V07E)46]:;$Q+5'EP=#ER0G0U<G5O>5<O=T-:
M1G=75TA5=$<F(WA!.VI:6&5J<59K:U4Q,U9Q=SA396-F>%5P6&ME;D599E-U
M-DLQ<7<X>E1I4WIG;3!M.&IN;&QM360V:U1S<T%U531C54-+<#1+6#-92#0F
M(WA!.VIU4V-!25-54$=V-6Q,87=V2DPU9FMU0V\K<U,P8T9Q56]W3WDW<7IF
M-6Y(,"MA3C%+4V8X>55T-WDU834P1DI!06EI4G%W<5=L550F(WA!.T(R059T
M.7%G;G8S3DU0<#@Q,V)T-"]Z3U%)254P0S-T,4QX>'A"5W!22D]+8V5";T9+
M,#EX-%8R>#E0;74W33E'=CA!+U%R3S(Q0S0F(WA!.W12<3=12SEZ1&)U=D5V
M46,R:E5N;'A,3BM/5FM-:WIW2S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$X<"\F(WA!.S5Y445:.&QA64I/2'!N5TQ54#9V.3-4
M:$Q8;G50:#AD.'@Y5#E0>&1N,E8O94@K<5=+,TUU:#)W:78U1#5,=C553C%,
M97-71&976D\F(WA!.U,S2$-*3TQE:UA32F=R1FY7<#0P2#)45'-0-7)L05-/
M,S<P8W9H,%,R>3$K5WHQ;35S-V5(>59(3%HR,#AR,U555&-*=E1L42MJ1S$F
M(WA!.U9%:GEH=T959%)8=F=%=C9R6DQ(8U%4-'4U5%0X;')/-G-V>FPX,%=D
M,T9A45A.=EE,2$Q&<#9L3%I75C1!9E16<45E.64Y8W-W:7 F(WA!.W18845G
M9%!!:2MF6&XQ92]:;'5J5WI24E124$1+;V5+4E-K:4YU0W)#:$(K67=%5V=I
M>%)98G%V-64V3"MG0UIB1G16,4MZ=%A32E(F(WA!.TY,0UIN*T]3:$EF<3AJ
M,4Q(971$,D=(0T]!04Y73$5)4D58;E8Q-5,Q3T]C;S-K3UE46%!.-%I)8C4S
M.4]6:TQS6&-E<$=$>4IO4T$F(WA!.W1D=#9J36II.#)695-D,U!L5R](,4)K
M.&MC-VE)=S-)2S9H>%='94]29W%K+W1):6IN,#8W9#AJ>&5A83AL1U0X=6UI
M=3=I84AY:C8F(WA!.WI2=35H8C8R5G%05E5G3'EN,R]C;S%(*T@T=4]W*TDT
M95!Z6&A2,7 U2'9K:E153'9Y-4,Y,#%T-F,Q;$1026Q8*W5X=',U;65G-$0F
M(WA!.S%$<V0Q-C<P=V-8;6UK;FDO3"]50F%12"]":%$R-G!/;'1(<4E(36E4
M94)Z2TA&1T5R3V%C96A!-U902#5O<GE68E1Y5&1#-6IT4C4F(WA!.T=-5FYC
M:U%8:W-L.%I/34%M:&-"5'I$9$E$=B]!1G!I6F5A,35+3G@U53%/-&=T8F,K
M45=1,E13,VE);6]%4G,Y,$)Z579X0B]9<'@F(WA!.T)Q3G4S5C1V3F$X;5=E
M4R]).6=*,&YV+T%#-C)J>39627)A83,Q='!W,C5*3WA(.&<V:G8Y,$I3.#!G
M4%$X<EI/>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMS6"]-5"]!9C9":B]!36)E;"MI4')#96XV,W%C9E@T=G<O=79I<G@U
M6EAK-&$Y5&LF(WA!.S98>&5,.3,Y5E!.=BMS5B\K6$@O04MF37 O9&9I,UEF
M-&(U+UDW+W)&9CA!-6-F*VYZ2#DQ*TQ8+T1F4#='6&9L=CA!.'%A+U-T,2\F
M(WA!.V=B-G8K:V91+W="2CE(,2M8;V,Q-BMR=%1N>#9:6FHT3#E03GAD6"M9
M-%(T=#$X2&]E6$]!-T9867$W1EA9<3=&6%EQ-T9867$W1E@F(WA!.UEQ+R\R
M43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA
M:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV0T8X0D4T.4)"
M0C-%.3$Q.#=#-#A#.3 X0D(V0D5#1#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HV0T8X0D4T.4)"0C-%
M.3$Q.#=#-#A#.3 X0D(V0D5#1#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C<P,#8X86,V+3,X
M96$M-&$X-"UA,#)D+61D9C@V9F9D-30R93PO>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-D)&.$)%-#E"0D(S13DQ,3@W
M0S0X0SDP.$)"-D)%0T0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-D)&.$)%-#E"0D(S13DQ,3@W
M0S0X0SDP.$)"-D)%0T0\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HW,# V.&%C-BTS.&5A
M+31A.#0M83 R9"UD9&8X-F9F9#4T,F4\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E
M<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z134P,#=%-D4P.$(R13DQ,3A#130X
M-$,U-#8R,49!,#$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,3DM,#<M,CE4,#<Z,34Z,#0M,#<Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.C9#1CA"130Y0D)",T4Y,3$X-T,T.$,Y,#A"0C9"14-$/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#$Y+3 W+3,Q5#$S.C4S.C0Q+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @
M/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/E1R=64\+WAM<%109SI(87-6
M:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^
M"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S
M=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XW.3(N,# P,# P/"]S=$1I
M;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N
M:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \
M>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA;$U4/"]S=$9N=#IF
M;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^
M07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/E9E<G-I;VX@-2XR,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M
M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE
M/F%R:6%L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M3F%M93Y!<FEA;"U";VQD350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B U+C(P/"]S=$9N
M=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M
M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86QB9"YT=&8\+W-T1FYT.F9O
M;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @
M(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'
M<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS
M:7,N8V]M+VUE=&$O1F]N=%-E;G-E+R(^"B @(" @(" @(#Q%>'1E;G-I<T9O
M;G1396YS93IS;'5G/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N
M5'EP92 M(%14/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @
M(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO
M17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/C \+T5X=&5N<VES
M1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H
M>3PO17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3X*(" @(" @(" @(" @(" @
M(" @/$5X=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX^-2XR,#PO17AT96YS:7-&
M;VYT4V5N<V4Z5F5R<VEO;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES
M1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS
M93I+97)N:6YG0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I
M<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/C(S-38S-#,T.38\
M+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @
M(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR
M,S4V,S0S-#DV/"]%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*(" @(" @
M(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE
M/D%R:6%L350\+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP92 M(%14/"]%
M>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y!<FEA;#PO17AT96YS:7-&;VYT
M4V5N<V4Z1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z3W5T;&EN949I;&53:7IE/C \+T5X=&5N<VES1F]N=%-E;G-E.D]U
M=&QI;F5&:6QE4VEZ93X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N
M=%-E;G-E.D9O=6YD<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO17AT96YS:7-&
M;VYT4V5N<V4Z1F]U;F1R>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES
M1F]N=%-E;G-E.E9E<G-I;VX^-2XR,#PO17AT96YS:7-&;VYT4V5N<V4Z5F5R
M<VEO;CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.DME
M<FYI;F=#:&5C:W-U;3XP/"]%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE
M8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&
M;VYT4V5N<V5?,2XR7T-H96-K<W5M/C,V,S8Q-SDW-S0\+T5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @(" @(" @(" @
M(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XS-C,V,3<Y-S<T/"]%
M>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/D%R:6%L+4)O;&1-
M5#PO17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @
M(" @(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .D"
M-P,!$0 "$0$#$0'_Q  ?  $  @(" P$!            !P@&"00% @,*"P'_
MQ !7$  !! ("  ,$!00.!@<' @<% @,$!@$'  @1$A,)%!4A%AI8E]<7(C%7
M"A@C.$%156%WDIBWUM@9)#=Q>+@E,C96@9&V)B<S.4*AL=/P*%)BEK+2U/_$
M !T! 0  !P$!               ! @,$!08'" G_Q !?$0 " @$# @(% @X-
M"04' @<! @,$!0 1$@8A$S$'%")!42-A%188,E-4<8&1DY73U-4(,S0U0E)5
M5G-UE+/1%R2AL;2UP=+P0V)R=-8W8W:"@Y+A)?$)-H2BH[+#_]H # ,!  (1
M Q$ /P#[^.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--
M.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--4S[O"^
MPEPU<&UGUM^D >[; ML*&:V"!M/T&D:\I]<@SK60*-6W \PX-GV P' TR/&8
M$3W2$&PEF_",TT[+9PN<3(35%JXWQ$GL3*KV(Y? ->&,-*SB;BY5I'1(0 C%
MED?RVY#J?HDL]$XOJ&UG^O!2MXG"XR:6KA+N.^BZ9O*7IH<;!6;&>/56>&E5
MM7,J\CVH5@FHUCO([I$]5K[L#VC5NU_8Y59IA"B&3.M#M>:K(^HBGK%7]@.=
M1MCVZ38P-LDG,L.IB]F:O4M?5)]8[$%T?<439*'UN#I K%6+'4DU>0Q0M!(]
M:2/PEA7Q([!P]J8R1S,^WLY2*&M">/$K-R._LLO1<-A?07C,W0BR&6AS%2KG
MJ=YLA/DK*4;N%7TFX+&1T;F-CIAU,OH_R&2S>3C$_C)/BS%&4"SQV,&M7:#L
MWJ"_42EFI2A6-G[6K+--'W$1%GW'8@FS[GTK1+ EZMV:^MGZ0,$T.U6(\-'T
M@#,'B[(N4Q*%#X@M48A0ERF4IV*\#G@;5J/P5F0--966[2KOO%+8\2!4@ED=
M5@C*I*2"BA>+9;&^C[H'J?"YC+54]9/3W3F1?*SXNS)#B\)9QW2O5F8HE;^/
MPK4\M8M9G'4J<\^7N13V*"QO%9FELB2#+!FUO:@%==GB<[7=<KMW&!=GGXXB
M-1GS'O-MJVK?I-6]:Q4D9X&/+KYW9;+%,"VP8^;28$3R#<.R$9L:'9&ZR6NJ
M6K2,U>*.=4M2!%@+[RQ5/%BJCDT8,<EH"!)4+\XV;:1F E&-L=.?L?:V<I5X
M<Y?O8BQ;Z?I26I,LE7AC,CU%ZA>S\A@ANO%=J=/N^5MXVPE0U;4$)EH0122T
M&GK;6T^ZM9VW160FJJHG5$@M8HIYZIFBUWD.U1J7';%W:TF#.OZF/J96"(7*
M+FM?H*1(XQ,+"JSL+;929]#H%]<M9N*W (ZD/JI>02&%WG)A! 2>5WKPK"ZI
MN[U^0"\?DK-QF\%=.Z:Z=]%&0Z9S#V^H\E],D=6C)33)5*V)C7)-&[6,3CJM
M7-9*?)UYK(CK5,T:\CV#+MD,)TU7B^BDU8:!V+]H]>*5J"WUO7(D]7+TW1+!
M.M1V@/U>0_+LNOM;6";66Z\(*6F0WK-1\[=V(.RGL"$JC"8*'K#';;:F'L97
MR/4D\%.:.LDD4_J\C2O7,1)EK59&C\-&F/JOB23A;/L=D4>+L 9.@9KH?T%8
MC+=3XR_G;5.]AVS%*''4\RF11(J&:SU*+(&]:KXY&Z@%.GB'FP"^M'Q+,S+2
M<LT5/*-DV/OC>=>66&,!;#K=_AE=T--?1NIXIHZKR5=>>U,6F#:78Q&S9*MI
M"G;O T@R&L%IJK8H?:;4*/")I&S1FHVLJMF3/SUY B6(K"O='R4/@K$?H=EA
M"L$B6CZVAG6@$DEAX++,DB,\@VJV& H^AS$9RA+9N82_A9:W2C,+^1.4GR*#
MKCT<R96?+4;73\?TNV5P\W5S6Z6.R1LS8[&V*=J&"A(TG4&>:K(=O=?7>FZ\
M,B=A$M;L7.2,7<R(0GMDY;X<0O0P<B1<[)?]L-%*!6TU%5EMD2P1"$]4DTU/
MP/"6,K!9I]PKU6S%>>"LZ6&K>,5,[(UQY0'KQGQY;%OG7C$)EE$@9MW#<4E9
M?!FPO44/HSS>)RN;JV<+7SKXJ.P,5!:@Z;J8N62KF+B)BJ.%Z;-?-7SDQ1QD
MM*6"$1U&@,]NA6F?*8O' @+M7&[]F#JV]Q3-0/;S(^:-*.[!9UFWI:1UA'#X
MLB,V7V9.U"H5 W5AZ8U7*]IX=L^1:?\ I16P4UC! +)IQQY8=0.^UQJ9OMV,
ME@512.*500'LM3X+>W/A14UM&7VS8\+E&;^W<]',GH8JTP>EXNIUZ0AV>.GA
M7S[=5IZ0IYY$D:M@(>IA8FZ3*Q->N]43]/ICO\V&$.1\"W'DNS]K][1<[;#-
M(H)&2X+V.@6#:SK6'*K835*;-[H"N%0ML*S6&P;"MEDK689&SUJ/K4XS5GY)
M;U5!G0L(<=JVK>>1K0@KL2MD(G^:@Q)4\4!)H9EEDDL2R1$-+&*L@B)?ZPQA
M9,?T_P!.>A^Q#TX^6S4,8L8,V+;#/2QW[?49Q_BW,7D\9-CZ5+"8VA?$L&/O
MOGJC9%8ZW'UI+<L]*)YQ7VAP.P6R\PP=FR:E5ZTRLUMQZP']:#31L;[/)N7$
MK !GZ73XL86_"[0HI<Z'3;P0!/XN9)FI6)TC/@%[-GZC266=4DYF*8F/Y22J
MLCKTX"L48\9@%*Y00L(;#1GQW$4I9E?98:_H0MT<;B);=#U5+V-C%\)3I9^>
MG4G].#1RY"XWT,@DDL"7T>'+0RY7$07$.*@;)T4@AGJ[4]0F;I8M5ZY.[' O
M5?8!>DUHA=:](1$;>#VB4(B/'(#C4&7.BLY8(JD)PPU+>]#'@TO*7$*0G;*;
MSR5:TEF/PK#PQ-/&=O8E* NO8D#9M^VYV\O/7G7J:KBJ/46<IX*XF1PM7+7X
M,5>0RLEK'1VI5IS!IHH9'YP!#S:).9]H#B03(O+C6#UBY.[5,-::O2BIX</M
M=UCGI52!RWO1G6)FKQX<NP_"4+QA$QT1$GQ9DV.TO,AJ(XJ5Z66&GG&Z331)
M+% \BK+,)#$A.S2"(*9.'Q*!@6 [@'?;8$C'6,OC:N1Q^(LW8(,EEH[LN,IR
MOPFO)CDBDO>K ]I6K131RRHI+K$QDX\%=ERCE761TXTTXTTXTU6;;6R;<&WW
MU<U34);$9C8!S:-KV%ZD)B:IW7.NM?2VG8F,NIRY ]\OMQH7HSXSD=]+T;#/
MJ/17)D.3C+=F9,ABJD) %A[<UC=0V]:M7((\O9WL3U]F!!W&VY!(//NIL_DZ
MG6GHZZ:Q<J1IF[G4>2SG*))F; X+!RJT7M#E!XN:RN%XS(4<-'QY/&989+(L
MRXLE<AN/)COKB/>[RT,O-NKC2/30[Z$A*%*RR]Z3K;GI.82OTW$+\OE6G.<D
M"#N 0=CL=B#L?/8_ ['R.M^22.0N$D1S$_AR!&5C&_%6X. 24?BRMQ;8\64[
M;$:KU1=OF3.\^R^N;'D&/JNG8>H30$MG"X,E R^TXL5-Y/39,Q4%<: 3K\M^
M)*2Q"RQ&D/-REO(9:<1CH+CO>R=:7PUBIK3>-_K3QL0NS^(2VQ"O&2&V78$@
M[[;ZT;#=4VK?6/I P-\TX<=TK%TO;IV?:AD%?-8JS9M^NS22F$QPV*,KQ2!(
MN$;LLC.%4K,M/N],V&#9L]!ME;NU;DR)D2-8*F<&V$+(DCI+D*='8*"9,N$Z
M]#ELNQY#;;ZE-/-J0O&%8\.7L,\-A!+!+'-&2RB2)UD0E258!D)4D$$'OV.M
MKQ67Q.<IID<+D\?E\?(\L<=[&7*]ZH\D$C13(EBM)+"S12HT<@5R592#L=91
MRKK(Z<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<
M::<::P38NS:)J:N+M>PK)"K8;WN.,AK?;ES21HS-PY\.KU9 BX\X]:K.54TX
MT'K%;&E3YA]&8XP;+?\ W/DKND8Y.=AY#WDGW*H&Y9C[E4%CY '5Q5J6+LO@
MUHFE?B7;NJI'&NW.::5RL4$,>X,DTSI%&/:=U'?58Y?9G;UB5F1K3KRS$">/
M@P5WKLU&L"A)AS\Z.5$5"CTC<IEJ$ZQE+JAMY=U]:(SN<Q"( ?(0[ANEXDS=
MT@"CW&:3@3\"%1)B!M[G*,#V*CW7YIXN#V;65:27WIBZ7KD:,.QCDL6K..C+
M ]N=46X&'M)*XVWX?Y:>TWZM] ?>EL7\)N-[/\6#\9)^;U#A@OMC+?V.G^G:
M?EI[3?JWT!]Z.Q?PFXWL_P 6#\9)^;TX8+[8RW]CI_IVGY:>TWZM] ?>CL7\
M)N-[/\6#\9)^;TX8+[8RW]CI_IVGY:>TWZM] ?>CL7\)N-[/\6#\9)^;TX8+
M[8RW]CI_IVGY:>TWZM] ?>CL7\)N-[/\6#\9)^;TX8+[8RW]CI_IVGY:>TWZ
MM] ?>CL7\)N-[/\ %@_&2?F].&"^V,M_8Z?Z=I^6GM-^K?0'WH[%_";C>S_%
M@_&2?F].&"^V,M_8Z?Z=I^6GM-^K?0'WH[%_";C>S_%@_&2?F].&"^V,M_8Z
M?Z=I^6GM-^K?0'WH[%_";C>S_%@_&2?F].&"^V,M_8Z?Z=I^6GM-^K?0'WH[
M%_";C>S_ !8/QDGYO3A@OMC+?V.G^G:?EI[3?JWT!]Z.Q?PFXWL_Q8/QDGYO
M3A@OMC+?V.G^G:?EI[3?JWT!]Z.Q?PFXWL_Q8/QDGYO3A@OMC+?V.G^G:?EI
M[3?JWT!]Z.Q?PFXWL_Q8/QDGYO3A@OMC+?V.G^G:?EI[3?JWT!]Z.Q?PFXWL
M_P 6#\9)^;TX8+[8RW]CI_IVGY:>TWZM] ?>CL7\)N-[/\6#\9)^;TX8+[8R
MW]CI_IVGY:>TWZM] ?>CL7\)N-[/\6#\9)^;TX8+[8RW]CI_IVGY:>TWZM]
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M)28F9&D@R=\PXNG85?X5=[TD+V$;N%EAC>%B"!)N-=GUR]IKTE[4GH]/U%O
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M9LZ&)C8\,R)4X).G4.^$DL)\<I@TVF6TS*5C+<08^O*<*AXD@^O@;;XQND@
M^.Q*.?N*K$^X:F%"A-VK9BN'/UL=ZO8IEV]RK*BVJJ;G^'9LUXE'=I -]K(:
MZV=0MLU[Z4:\LT"RB&YL@5/S'3)ADP9N$EI1"NV<"38A'JI9Q?KLI+UFR#11
M\2ZXADD.BNJPCE1'21>2'<;['S!!'FK*=F5A[U8 CWC5C:IV:4O@VHFB<J'0
M[J\<L;;\9H)8RT4\+['PYH7>*0#='8=]9YR?5MIQIIQIIQIIQIIQIIQIK$[Y
M=ZYK6E6O8-OG*'5>EU\K93LQ##TM]H8'ANS96(D*,AV60G/-LY9@#H;3TTC-
M<8A0V'I3[32Y78(K.W954L?>=@-^P'<GX =R>PU7K5Y;=B&K O.:Q*D4:DA0
M7=@HY,Q"HHWW9V(5%!9B%!.J#U(!9KC9/RW[ABI5LPQ#DLUBJNR&2 C1E,)^
MFZUKVJ>BMZ!FQ28[<1S:=YAJ7/OEG84RW-:H@"BUFN4HXR3XLH^58=AYB%#_
M -FONW\O$<=W;W\ BKD+]R)(_H9CVVH1,#+, 4?*64W!N6-P'\($L*-5MDJ0
M'?B;4MJ::7.5]8C3C33C33C33C33C33C33C36KFW=TMG:ZW79JG;0 ;\FP[:
MNV& %JCCRONTJC:BZL73:]PJECFC81N4&L8^XPJ,8%%H0<M*/UDT?@C@<N56
MIF'M/GS]NKD)H)XH_5%NW1%,%?9JU'#6+L\,C(LACE6=:[HZQR-+"\JI&S1-
MOZ>Q/H:Z9ZAZ,QN5Q-^Y],=CI;I22_BY+%7Q(LWU;Z3\/TKB,KCH;,]**[CK
M&(FS=2U5GMU(:&3IT)K%V*+(Q%?6)]H24?B$K^5H#2J%51<E^\#*A8DW.0*1
MG8]DUF-/5HK&K(R9;8,T\(KKGN:A )U@;;9,YW]SK><%R=3N5>T]7_-H58V$
M@D\=DVM2U%DA=8E:=6ECB[>'&0DY<]HMGC;] %5):^!JYYAG<I:C3"6LMCSA
MX[3#I['=26:.1JRY*Q#BIH:%O(+XPMWDDLXJ*!-FR/\ FD_:<[6&=I[&V1J\
MQK)FB6#7->G3BZ<WF'9)\ Z)P!BD1I@"H  FPA9">;=DT>PQ7"<*V5\5),3&
M:T]*@#)&3HYB2Y:M5)*@K258F:3_ #E9621/#5TDC\*,JC-(37E4NLT4;2,(
M2RH="ZO]%E/I?IWISJ:GU*^<Q_460@@J$82;'03T;?KTE>S4O"_?@GLP04EC
MS6/D6M-BK]J.I$^12*>S' W3'N+L+;=.V%9;]*!7SZ(Z&UIMQ$+7<>K$2R;(
M>#W@A<J0]]"[59APLHV[7PK%<J%K0 O\5Z7/R=%X95&]#&X'.V;T%F:R8['@
M8VI>XU1$[B65++SUCX$TRHX\*,103>%9!9_$3;;;>_3'Z(.G^D\QT_C<%%>P
M7T7ZZZDZ4,_4,F3KU&QM&WA:^'S:?1G&8VQ:JLM^Y)D<MBFOX"1(JXHVB_B<
M\G']_L$3>JZ]'HE+*O[,E(BX.4S<D6T5R(J87K =J-5"L^BUF-?+#6_I,T5V
M#6FE )-9'P'VATJRE'XPYRLO4G.2E$*]=S;8+XD%\2Q+S>% (7>M"+,L7C![
M,0\,Q(IX-,Y"'&S^@3U>GU1?DSF9JQ]-Q&3U+,='RXS(R^%4R5MI,I5@S>2D
MP>/R7T-:K@,BPOQ9*Q8C:Q'CJT<MA8_UAW]N.&=:Q=B5JLF5;(M6HZYD]$/9
MK#E?S=^O74>^3\CZ>."6ZR7.7.NV^;,]#0/B#A(8?!&#3IP:W)C$,VE/J6?:
MHMJ&%S:EHQ&02^"8O6<7@[+<:Z1SS3LUG)S%>*I'&BHDLJ;JQSW4_H%P_/J2
M3I[)9&FO3F,ZMR I34OHDN0^@GI ]+&"K^L9>Q=Q6.P\4.%Z%QJ2F>6Q;N6;
M%FS1HV&CDKZVO<W37E;3C33C33C33C33C33C33C3467JEG'"L#9^KIT*L;JJ
M,-3-<.2LOL!;<&;>7-DZQV4B&TZ^9UY8GE.M.X7'FD:<4DMW.HHBV,<RM^E)
M&6V>,A95'LL?)AY^')MW,;>_S*GVUV8#63H7DA#4[BM/C+# SPKL9('("B[3
MY$".Y"-B-F1+"+ZM8+0N0+I:AV<&W%KJM[#"PYPIHTS.C%:^5]#!FIVH 3FU
MVYTL[B*Z_$P=IML$FJN:]RD28*B8F4N#*E0U,279HW$B!P"-]P5/FK*2K(?G
M5@5.W;<=B1WU;WJCT;4M9V63AP:.6/?PYX)46:O8BY -X5B"2.:/DJMPD7DJ
MMN!)/)]6FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FL#OFM*
M;LM%0;N8M99NBWNM;*K3:2!&$U#N-1>?D5\I(9@RHS1-L?(DN26QY-$L=F6B
M-,5%S+APWV*$]:&SX/C)S\">*S%[3+QFA),;D*1RXD[A6W7?8[;@$87,]/XK
MJ 8M<M6:RN&S./Z@QZB>>%8LKBV=Z-AUADC6PL#R,ZP6!+ 9!'*8S+%$Z:?/
M;I]X;3U(ZVU>D:R.O5O:?8>PDJ>+L,)W+!6LT<)!9EWHX%DH6ER&:=P2!5T?
M.;3Z\#!^42A.QR,&'(:U;K3*SXW%E*K%+%PO$)%.SQ1!=Y&3;N&.X17'=>1(
M(;8Z]5_L7_1UBNO?2)%-U#!':P/3L<.1LTYEY5[UUYUCH5+"D%9*Y99;$T+;
MI,L"Q.&B>13\=^NJU6;$))$#Q;W=_"%N(PMSS/O.J3YUON*7E2EJ4K/BMQ><
MY4KQ\<YSG'/,UN5A9823^$!N0>[-(S%CMW!!V/GL0Q)/??8Z^].-*U,3BDQN
M+BLPS+'&ZJH2&O'&@C6-%0J$XH!L-CQ   4#;52MJJE@9GQJK&9X<V!GLDZ_
M8 \R0-*BBHV2F4+*#2$1QJ6/GPI;#$J++BNMOQWVT.M+2M"<XVO V)E,,OM1
ML.+;CLRD;;D;;$'O[CV^.N >F?"X^W#DJKQPSUYXI8I(9%66,B52&B<,"K#<
M;'L5([_-K[\?86=];5W^Z* +SLR2B=N+4-O+:.VH8QA"'+6?J@@ 8$79]EO"
M4-S+35;&#FF<M-,17+(@ZJ&PQ$PRPWZ-Q5IK=&"9_KVC4,=]]R /:[^\^_Y]
M?#/KS!Q=/=59C&5U*5H;<QKIN"$B:1N* @ ;(!L-AL!L!OMK<GS(ZU#3C33C
M33C34*;]VI,U+KYXP &PSU]LA<71]95N>Z\U".WVRN.,BL%%Q<^^HK5=A,$[
MK=Y(Y#Q$=1:Q9BD&-*E0FH[M.5RB^R-W9@D:GWNWEO[^*@%WV[A%8@$C;5]C
MJB6[!$SM%5@BDM7)E +1UH0"_A@^R9IG*5JRN0CVIX4=E5BPJ&("5?2M3NNP
M;M9'2AA0V=>MS;=LC7G.69T +D32ATMB(V^J "!#F93-8IX5I(*G@6F*]5QD
M6#':8738Q4X)9YI-DCC>:Q.X[\8U+N[<03Q50>*J-E4!4&P U?0QY+J?+8S#
MXNH9;-ZY6Q6#Q%9@$%B]8CKU:L'B,B&:Q/)&)K,S!YYF,UB0DEAW0#;FLK-7
MZ=:!%XKB@VP!(TW3GB!%D),/#R\;,J"J*(-Y'EVY2VD.I?&R8+!*%(CRH<V)
M'EQ9+#4L5VI-%!-'8B\.TB20%F$;2JXY+Q23@_(C?="H=2"K*""!5O\ 2?4N
M,OYC&6\)D!<P%JS2S"UZ[W8:-BI((IQ+;I"Q4:(,5*68YWK31R130RR12QNW
M4US?&GK8)18 6P:[)KST8%*B6.5)<$UT@W9?BOP9L4>+M01!:7*4$*H=@#9D
MJ=!<AN-$(\5Q3:5R19&C.@ECLQ&(B-EE)*1.)>?AA)'"H[-X;[JC%EX[,!VW
MN\CT+U?BK1H7L!D(\@DMZ&7'11K;R-=L;ZKZXUJA4:>W4BC%VJR3V88H9UE#
M022J&*Y=(O\ 1(:2JY=UJ45 )41)Q<BR!V$AE$(JYT!)53LQ.!RIL%MR9$Q+
MRSF3%;7(9\[*5+Q6:S67GRL0+X?'Q.4L8\/DO)>>[>SR4%EY;;KW';6)CP&=
ME-58L+EI6O"4TA'CKCFX()1!.:H6$FP(9F6&4Q<_#E81OLY US2%LJPF$+)%
M;+7Q@XY(A1 I @9'0H1B62;RZ.BBY4F2VP0D3VL9<A,Q''G)3>,K82XGY\G:
M:%%1WEC19"JQLTBJLC.-T"$D!BP[J%)+#RWU0KXK*6YK5:KC;]FQ2CFENP5Z
M=B::I%6;A8EM11QL]>.!O9F>546)NSE3VUP'=@T)AHV^_=Z@RQ6GF8]C>=LH
M9MJOR)$MV!'8-N+FX0*>?G1WX3+4_+"W9;+L9"5/-K0F0V:P$A-B "(@2DRQ
M[1$L5 D/+V"6!4!MMV!'F-7"8#/2/2C3"9=WR2/)CD3&W&>^D<23R/240DVD
M2!TF=H!(%B=)&(1@3QSFR:)7')$<K:!;<R'-JL">.ANJ+%1KEV.C:W691,2)
M1.)#!)$L7@-K.3XL<,/AN/%B<^$)AS)T>$ENM$2'F3DK0JR*>;IZQ(D,+.B!
MG1'=U'B,HC527=E1685*/3>=R*QO5QEIH9H<I/!8F05*ME<+1LY')15;5LPU
M[-NO5J3LM&"62Y8F5*E:":W+#"^$T+L9IC9=?1:ZI>(;E:?<&-0SIX<:IXHF
MLV0,C Z!$^W#0<4PX3F "B(C(MV6\M++3BFT(EQ,OV];*T+<0GAL*824"RR+
M) CF1G2/PVG2-9.;1OQX%B=@?X2[YK/>COK+IN^<7E<),N21;+34:,]/+VJR
MTH*=FXUN#$V+LM1:T5^J97LK$@+LH8M%*$\[?V%U11+Y%UM9SAN%:I,>BRW4
MQ:%L$S71+&S;65HU 79;L#JQ&E53Z66X(4 !DV:PB5RB$7+>$I2]'6ZGRE*M
M96I-)(LQ%=CQK6I(D%N9Z];Q;$<+UX?'GC>*,32H68;>\;RXCT?]59S!2]1X
MRE2GQ<4F<C7Q<[@*>1MOTUBZN;SPQN%NY.OF<K]"L3=K7[AQM"T(J\G(DE'"
MR9-M58&$%B"-C CRS0B38'!DTP/B$&P,+*TS#:X3\AN2@1$4VXF224UB&QE"
M\.O(RG/A>--"C%'EC5Q&92C.JL(E[-(5)!\-2#N^W$>\ZUN#%Y.S76W6QU^Q
M5:W'06S!3L2UVO3 &&DLT<;1FW*&4QUPWC.".*'<:C^3OK4,2U"*8[>!BSQZ
M+7)PA,5@E-$38-M [7L]?G-V:'!D5I,*>!T?M$CF8Z7;C1&JOEN<[&?,U]HM
M:G)45FCKFPGBRK$R;!V1EGBNS1,)E4P\6BQUQ^1<!1#LQ!DB#Y^+H3JV;%V\
MRF$LBC1ER,%LR/7AMPSXF_TKC,A V-FF3)&>"_UMTQ7\%:C22MD^4"R)3OM5
MZPVJ2)EQ>QVAGH-AN T>RHV+JY*!*![]U^(>?41U\6D17U"2=BB,_$W-3VM^
M2W,I5V4B$LFW2+%?Z]8JI*R*+-9DD.VX:-E9)XP3NG)258_7>&V_L/[^)=6L
M8UL4YY,!GZ]FB@DXF*_!-7M8:Y,JF.V(9D2:&-MXC?KE.-JI[?AFS%3GAV+T
M^V5^^U*KWFID6C%6N=="VNM%F$N(9* +"-C%PY%I#R&WD-S1\R/)0AUMMU*7
M,)<0E>,IQ75@ZJZG=64,I^(8;@_?!UA)X):T\U:=#'-7ED@F0[;I+$YCD0[;
MC=74@[$CMVUD7)M4M.--.--.--.--.--4][>R5$&= Z_<RI0F^;] OV..WXI
M<=%ZLI-\W8#7AWQQY&&]CZWH&)K>/-[W"<D0EH4Q)>RFA-W:!/<TP+?<B1YE
M_!)&G^K67Q?R<67M#M)7Q<B0GW<[UJKC9@1L=R:5RWQ\N+<6!W4:]/*^L1IQ
MIJL^Y>RC&GMA:KU\[J;;=S5L\S\*3<*C5'2-'K&<1YS_ +N;.H<5G!Z5B%XC
M0+47U)S*G'\S&$L^5R]KT_6(II?6*\?@KR\.1]I'[@>RO\4;]V\A\-6\MCPG
MB3PI7\1MN:KNB^?US?QCMV7;O\1K/?RN1_U>;;__ + *?_[\I^K?^_K?CA_A
MJIXG_<D_^W_\Z?E>A_\ <#;?W<GO_P!+DO@'[+!^-&GB#^+)^+?_  T_*]#_
M .X&V_NY/?\ Z7'@'[+!^-&GB#^+)^+?_#7CC<(_/CXT+;J?#^/6EFSX_P"[
MR15?H_\ #]/R\>1]7/V6N?\ ZR?\2-/$'\63\6_^&O+\KX[_ +B[;^[.T_\
M_%R'@-]D@_'1_P#-IX@_BR?BW_PUX9W$-Q\OH)M[Y?Q:OMF?_OB!X9_WXX\!
MOLD'XZ/_ )M/$'\63\6_^&O/\L K./G2-M?/'SQG5MQ_A_@S_P!&9Q_^<<>
MWV2#\='_ ,VGB#^+)^+?_#7CC<(A.,)Q2-N8PG&$XPG5-T\N,8^6,8\HGP\,
M8^6/#Y>'Z./5V^R0?CH_^;3Q0>Y60D^9,;[D_@U_,;A#^;*OH1MM*E8QYE?D
MHNWBK"?'RXSG C.<^'CGP\?ECQSX?IX]7/V2#\='_P VH^+V VEV&^PX/L-_
M/8;=M]AO\=?Q6Y@R<^&:5M_Q_P#Z=27U6/ZR0F<9_P##/(^KM]DK_CXO^;4O
MBC^++^*D_P"77AC<@+'E\*/M['ESE2?#4%]QY5*\?-E/_07RRKS*\<X^>?-G
MQ_3GCU9OLE?\?%_S:CX_GVF[[ _)R]P-M@?9[[;#;?X#X:\L[E 9\N5TS;OF
M3GS)\=.[%7E"O!2?-A2:ZO&%>52D^*5>/E5G'Z,YQQZLWV2O_:(O^;03[;@"
M8 C8@12#<;[['V>XW /?WC7]_+0!_P"Y^W_N<V1_ASCU9OLE?^T1?\VH>*O\
M67\5)_RZ\<[J 8SC&:?N''C_  XTSLQ>,?[_ "5E7_E^G^;CU9OLE?\ M$7_
M #:>*O\ %E_%2?\ +KR_+37?^Z>W_N6VE_A3CU9OLE?^T1?\VGBK_%E_%2?\
MNO'.ZZXG]-3W#_X:4VHK_P#QJ6?#D?5G^RUO[3"/];Z>*O\ %E_%2?\ +K^I
MW76L_IJNX$_S*TCMG_S_ #:>K'_WY#U9_LE<_P#]3!_QDU'Q5_BR#_Z4O_!#
MHK=E83X>-7W!\_\ ^71VWE?^?EI>?#_QX]6?^/7_ +37_.:>*OPD_$R_\FHB
MVYW)I6HXU%E3=9[]L^+QL$7KZ+!KNE=A-EX\PL$L1ADA&'G@(7XXB/@ M$H2
M&?EG<Q'GR$$;.;'R6>5X,?).90)JJ>%$TI+V8>.RLB[$J[<=^?9FV7?L2-QJ
MC-:2$(2DS\Y!& L3[[E6(.S*N_UOD"6[[@'8ZMM%D(F18TMI#[;<IAF0VW*C
M2(4I"'VTNH1)ARVF941]*58P]&DLM2&',*:>:;<0I.+$C8D=NQ([$$=O@1V(
M^!'8^[5T._?X_$;?Z#W'W#KW\AIKA]9I"@6WNR% 85A0V;G4^\(S6/!#8V=L
ML3;=<&1D5A/@AF-)GZ$5:I"D(3F4;M1J:\IR3)?7FA'[,TZ#R(BF^X9 \9 _
M$\C\2Q.LO</C8O$66^OC:_BR?>Z4WKW8W8^;,%RO@#?ZV*")![*C5U.5]8C3
MC34::FV3%VK5)EFCBI(-T==]E44@'F2&Y,R"4UKL.SZ_GYD.,H;;3F>_6U%&
M6T86EN+.82EZ0G"9#MM4LBW$TH4IQGM0,A.Y5JUF6NV_8?7&+EM[@P&Y\SK_
M $SGX^I,;+D$K24V@S'4&&GJRNLDL-C 9W(X2;Q"H"@S/0-E5&X6.9 'D&SM
M5_MO<]D]=Y@+LU4U6"\T*N#54?:VFXQ1EB.2@V,FU&I-ZJ39!]$.%:PEUGBP
MAWP\<&*@;E+>QZU>@YSALU-;QK1Y>OXEB&*,5KE#Q.,<B2/M#/"#NJ3I,Z(Y
M"DO$Q&WLG?2/21FLYT0U/KRCZ[E\%0KMB>I>EXIHQXT>0L(F(S6+$SQQQY*G
MEI:]&XI;C:Q-Z61AXF/AY3CUQIFSJAKB,[N>WS;=M&W$B%TNWFG.RJ]5C!]:
M'\4:CQEK<;'U"H0T10@UME6<$'XLPV[A+Y1U",CC*]JO5'KL[6+<SM/88L6C
MCDDVWAKJ?K((5"HBCL2&?MRVUM/1..Z@Q^"B?JO(OD.H<E8GRN457Y4<98NE
M7&%Q*@D)C<3$(Z<#;EK+QRW7(>RR+FFN]F!=E+OV D,C':U_L:QZS(29S;"(
MY,U5V!BRTP0ME]Y3PZ/,(N"5N2$1GT%!A-CT,M,M2'[BM:2SZQP# 5[,E5BP
M&S/$%+E""=U!;AN=CS5AMVW.0P74%3/G-"I%.BX3/7NGYY)E01V+>.2NUF6J
M4=B\"2SFL6<1N+->PG#BBN\C<N=9[3C33C33C33C33C33C33C33C33C33C37
MRK_LHK2=NL.INLO8.O0I9()J"YW2I7!F,TX]@?"V*.!S0Q>0EO&?2B))TQ0M
MQ]?@CWPH.C^/J/M8SHO7-5IJE68(66-Y(I&'\#QO#,9;S]DLA7?RW('OUZP_
M8G]15\7U1G,7(ZQV;].I?IANQG;&/8\>!/C((K7C!/>D4C]N&OD>KFQ&Y<9E
MA$I#2E)\JD9<\JOGX?)6,*Q^C^+&,_+^;G&+&.V<L4WV[@_>\^X['R'NW\]N
M^OJQ@/2'(:L=5;0B!'$H7*GO\0"#_I\CVW[:BC=-R0-&N->\-./R?'#:,*_Z
MWF^7RQXYSG'\>?#P_G_3G.3Q-0R2+[) !\R/+W^[8_\ 78#W<U])W545>K.7
MLQ2,0S[!P>XW[>??<[#W>>WF!M]N'[%1T3<]6^SVO.R[D-F"&^P^_+'?Z9$E
MH6TJ71P%6JE''G&V5Y\4-%3P&RXC+RG&)4")#F-J<CR&%9[UAXQ'1B4;[ ;#
M<>8  W^^=]O=KX_^DFZ;W5=^=MA(S%I5!!\-Y'=_#)!/=$*;_ DCW:^G#F4U
MH.G&FG&FG&FJ2]BW<D>P77"N2_%T8-HW839\)C/AE#5NK#^F-<"B>/']#T:J
M[EO8Y"L?/#1A]/CC"E850?O8@!\A'/(/_$IAC!_^V5Q]_67K>QA<M*O9Y+F)
MI,?C7F7)7'0_,9\=5?[L8/N&L W)JP9NFA$=<'C!H/73I*O/6/-?EK'$RX,*
M?&G9];2394B8-A6- W 8M,'NL$4B9DUJ#)BR'6Y+5*_33(5FJ2221Q2/$9?"
M;B[QQR)(T7,;,BRA/#=E(;@S!2"=QD.C^J+/1F>K]14:E.WD:-?()CO7XA8K
M5+MRA9HP9$UG!ALS8YK)N58;"O6:U#"T\<L:M$]<!G137HIV$AFU6R</!'@I
MBIQCSD2PD*W$$[_JO8I\/'L)EN8;GQB=SKDJ#*ED)C\_X(;D1?>%N0XCJ<4G
M3M5.($TS)'+')")"LCQ*F3ARIC$L@:1E>Q$59F8MX<A&Y*J==&L^G'J"TL[-
MBL5!9O4+E/*RT1+0KY&6UT'E/1ZEQ\?3:&E!)6P^1BGBBKPI!Z[2CD\-5FE4
MP=L7V>1EK7XVMZIN TD?BUAS7F9=\6+ !XE,5K[9E 8D)A0-<W^(3/-#;]'Q
M*>P*"S)CPY^?$/"')\Z+-QUKI>055BI3H\@A-7>SPB00>JVZP.RU;0>3C97D
M?#C9BI82H696W7I[]D%3;/V<EU3B+-:C+DUZ@$6#%J];ES(S_3>>9#-/U#@9
M:U%K&!?PD-J[#"EE():-M8()89>J70;7U9L[MFDVNQGEKO0:_-BR[46<-:(P
M[82O14;EB:J6RH1/LY-Q\?'8CQ%AQ[+$7"YTKUB+M_!TW5AF,IFEEWL)9X2!
M60.)GLNFS<MT:9R4  ,:@+NS;N=1RWIWS^3QBXV/%8ZB!A+F":U4>6"PT$V*
MKX.K9#PB)Q;@QM94L2/)*+EAWE(@BX5U]EBZ$4(UKO7%%@W_ &8#EZ[KM*J\
M.SQ;;89,K(^DTA-$@RZ\ DFLU>BDY8M")19%3$#Z_:9R$?3^NW2$A$-*7IJK
M)5JUELW(VJQ5X5F$\K-QKU_5E,4;/X-=F3NXA1(IF_=45A?9U#'^G?/4NH>H
MLY/@>F[L74&0S.3FQDN*Q\<7K&:S1SL\60OQTAD\W6BLDQ5&RMN?(8N GZ Y
M##S$S'!/]'D/L;=A)W38A.%996Q=FVVL*IL.$.%AQ=UW?L3:$2*=D18(,];Y
MKHFY0X,O!,DVD 18FL YLB!E#TFW^EA91*T]IUE:U;GA\ !$C2QD+5Q1(0L<
ML[%)PIYN/"8,(V*]SG#^R!GQS4*V&Z>K3XZ+I[IK$Y(9B::Q9MVL-T5T_P!,
MRR48Y)KM#$PI;Q$T\1K5V-^N\,EZ&.QND4G!ND-/ R$1QUS-_1J-9]86Z"$E
MUNCS"3176MMTI:FF)-S=K_TNDA2Z]&UL>Z":*Q!C$<J56_'(J@5--:NTZ?@C
M.RV)/"$U.=8VBK,XDJ3X^< V##XYCD..A4QAU0!WW#<8/!UJWZ:\O>C,EC#4
MOHE)C.IL3-=AR6;AK-5ZCQ/6>*>2/#)D/H3'=J+UMD;"7FJRV7DJU0DE<3Y4
MY'HX_06F#!U8B@KV<&RZM5JK3X4F95:)9ASXD!1[G0B#\RL6@ 7K,PJ:%W8C
M/][G"Y<>&58:R[!(BII<21ICIJNB0K'8D1H888%9H:TRE(J\]9RT,T4D+/(D
M[-R9&"N!NKHTB/>OZ>,Q9L9*6]@Z5J+*9/*9:>.+*YS&V4M7LWA\[72')XR_
M4R4-6G:PU>#PH+44DU5V"S5[4-2U7S/;?3>I;<W((W&5L\T48%"-5B6DPJO3
MYAP>G4U]LVP \RI7,J(F6*CS39&SRAEED5F1!=)AXL6+A;*VT.HKWL%#>O1W
MGF9)$2D@XPP-(GJ5F6TC03NC2UVD:5DF,14O& NX.Q&'Z3],&6Z2Z/M](5<9
M#:J6K?5%IS-D\O#1L'JK!X[ VX<KAJMN''YN&E!C8K.-CR:3I7MR22%75F5O
M=MGJ!6]LV78!LC=#P:#LD!#&V 8/!T^7/8+":R1J@@H#MA8%.LU?'L#IZ9!
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M+AMR71PEB$.Q,<DS$14RIDIUZC6J5Z:.E:)84DE:9HTW""1PH8JOUJ!N()5
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MJ,=T[B1(NTC10F4_$B7YLB=OC\=:FWI-+"O18B*]E:<86F+9"4I29^$J3B1
M%21SV'(TZ0A77/1=@Z-GZ+]0Y*&*Q!C%BHTJ]B,30O=M+)XDTL,FZ.8J[*(E
M=6 $X<;% =<K]*F<>ABX<37*DYCQ([1;8\J07A- T1#!TG8O'(&]@JA1U=92
MHT]]PNU;W5B#7]):0ACQ=P>!M%RIZ2PT4;IX>>[(P-@"81'WMAXU-PV]+4LF
MS(B"QBX.(\5]<QI0_O7HXZ Q]^DDL\3P8''R/5QF-AFG\-^!Y2*SN[21U8&D
M:&*&&15/$HOAQ0HA\PW[T/3]:IBL5$D+1UH^)/MBK">92&!9&D!W#>(%=2D*
M-&L:G<%=8H3NUVI!FT'6MU7 B\E[U7!YN1&- W\?/S,K"$HTD6TRO&<IRF+%
MCK0G/BRMI>$K3U^?H?I.:%X?H)3B#+L)(5:*9/\ O"9&60M[]V8[GNX8ZUN+
M-YJ.2-VR<\H0[F.0*\;#B5 $;\T4#?W+V V7COK<7J+9P?MYJ6'M&#&Q3MS:
MO*+COR ,N6Q]'K2PW#)C+$$QEY7^H%6HC:XK9#$AZ&\P6$^M)BI=D3.$=1=&
M8S"]4XV/+5DRE!(;9Q#WB9$2*_"M2ZCUB16-J.)5A6T(S,L4[M$8A8E5MWQE
MVO<DQN?BCC7+86=_!D#L_J=F2)4]9K)R54DEA5XP\@>6+:1$?8\SO$Z_[-5N
M'3U&V!(93'*&!;L6PQFT^1F/9P4^77[,U&3XYSB'@\+(*A95X*5#4PI6$JSG
M'/,G5F$/3W4.4Q2GE!6L;UW))8UK")9J\]_-Q7FC$C D<]^YWWU[(P.1&6P]
M#(#CO8KH9.'UHE4O'(!Y;>U&3MM[._$[;=\[TF2'!^RG9$N7GPA0D7UUZOD2
M9,E*8@CQP^%?NXDF9.GS93C4:)#B1VG)$F5(=;889;6ZZM"$*5C55_=,O]!7
M_O+6MNF_>'&_UOF_]CZ?U>U"T.H0XVM+C;B4K;<0K"T+0O&%)6A2<Y2I*DYP
MI*DYSC.,XSC.<9Y7UB-81L$-?#H%,#7=W%:_.*GQW'SY6F)O*,"TI>Q+B0A#
MMAKL:.0?6IA4<E+>(QHN&G$N"9?K)4S0L)/)'QKSI7DY#>1X?']CON%0R1@,
M>VS,6 V/L'?MA\Y5S5RD(<%EZV$N&:-GNV<4,P!7 ?Q8H:K7J$:3N2A2Q*\\
M<85@U:7F"E,]):XE7OL!O(]MR['-[IT:5KNJM?3KR&IT$!6;!9M=!;KM*17J
ME4JX K;<V<*O%7K#Q@M#-V>,.A%0WQ]0\E-B.8:E6-B_>>Y,]\46CJ5VGC@6
M..26LDULQPPQQQ[LL\41=P\@4,GB<68:Y?T/BKMSK_JG,YO/9/J>UT+?QF"Z
M9R%^+'4HL-E;6$I9K/6L32P]+'U(+9AR^,HB_*EG*0106*R7_!GEC-)._?0O
MV=0.T=>SULT=K>OD-B]BZ<$NR8SY\&-G:V?C&<7&7*%!2L017@4(K,JZ"E@A
MQ!+(A<^&APA%;F*PY@<YA.GZD^-D]7CK-9R<*SK'/8AB:J5D\8F*.58HHU=H
M>3HJ!-Q[0!.N]^D#]EEZ7NA:O0E"'TB"M!D^M,/C+\N8PW3N:MMTZ8K,>4DF
MR.7P]^[!5ADDQZV,E+90U#+ &M1"7VMJ- ZA=9-7:N.:5U_HW6]4U;9XCT2R
MT\/6H3$"Q(D-I:7(/2<H61-$$I0WE@J2F22<9QIEV/+:<896C<(\90BK/3CJ
M0K6D4K)%QW5P?/F6W9C\&+%@>X(/?5#K/(7?2&EZ'K:S)U+!D:\E2Y7RA$U>
M2O+]="E<!8*\>_M*M>.((X61.+HK""NH&I;U&U[KRSS.P?8',FL%+52KQ0K>
M:JMSK5C):RN%DUV4Q[U>J2<O0.&3)5?))I=?N ]&(3^&1RF(SK#C6-P]2P*U
M:5LCD"8FE@G@E>&:*5JLTM9_:G@>PBL\18>',IV.PV&VW!?1=TSF(\'@\A+U
MQUN9,?9R6)R^%REO'9;'W['3V4OX&R#)F<1;S-.*Q8QQG4T<I77PGXU^$;(5
MV"<V#7;M.--4H[D]^>O/2&M0BNWK#,E6<^T\NHZWJC$8M>K0F/E:'I4(8],@
MQAPAAU/HR3QN<,$-O>$1J6_/6S#=P>:ZBQF!A$EV;Y1P?"K1;//+MOY*2 J\
ME*EW95W[ D@C75_13Z%NO?3)EGQG1V,5X*[(,AFK\CU</CN6Q46;"QS2/*R^
MT*U6">R4W?PN&[#0?=_V1&,+W.D&?VHYUJN4JTR#;#Z-R0'CI6'(!%0:F%!E
M:V:@196$E,RTM?2"4TMV.F/EY.'/>&^#]59BKUAU-Z.<T8FI1] ]4W.HQ#NM
MF7*"WTUG.G?5%?> 42OT9%HS\;7/U?P!$OB&5?:J_L#^INF.G<^).N<?;NYO
M$1T&A. L0TZDD-^EDO$6X^3>692:9AW-2$@2F38<1&^]GI=[1;K/WGK\B;IV
MQE(-Q$-07K7JNY"70FPZHR3A>_#B)$4VN9#FUPFPEQ0FUAB!&N$5-KC,$??V
MGX;/=*?4N*MM1A229+&0D>*O U:TY,D=9[;B26.)X85\"*1TDGDBCEX%8RS^
MSKPAUMZ-NJ.@LA8I9RK!X<1?P\A4LPS4K0CG]7?P'Y+(98Y2JRUGC6Q%R!DC
M";,;W<V#6A:C7;NLH6XJ"9UT4ME]IH>Q.BFS9;6=JF4>WR@L(M"(%:]"MPI&
M#U?@6F#$?KATC69H:SM R9'%?/@BJHI6*TUW.O\ 7M&U33:]KS6M2K]%HU4'
MMBJY5*N+B!P8> VI2_0A0(3;3#>77G'9,E[*5/RY;S\N4Z])?>=6TUF/&FJY
MV'5/7C7HFML-Z4UPEJ9<ZJ"K(071ZNSA-@-$80N)*A1LP6F([ 6 VX;)K83E
M<8&!E2&8\AV%&CJNEFLRLQ\>7M&[.QD?ZU020>_\(GB/BS >_5$QPH%VB3ZY
M0H"CS) W';L !R/P"[^[5<;$;Z<=@]4QG;DV'H%<15:65+#'@%9CD&:19:3<
M28P'/>DUJQ0(HT17[;L1^=,K3T<Q069%AL<(]6HA)PK-N56]6F(CY2MRD53R
M<@R(\8+ !U)8LD0 8%9#P0JY 44&-:>/V]D7BI(V4'@RN0">)  !<DC8I[3!
M@#N;$B=I]<=CW0 ,A)$V*^NQ)<:!'):ZLB;%7(<:#9A*XMD49JS$NAMS1A:T
MP!<:VK _'!YT@P);GQCGEF6QALQHQ.ZQ@]R)5XL25.Z;/M(050L4Y<2HY;<>
MU<20NP [M[MXV!78,NS;J.'9F #;;ACMN#J+(%_ZDDC-C&6+658K:M=SR.D(
MDFP:G=6.CU,)B?K>%"5,CU64&K%#/$9EJUOKUHQ.@#+CE)^L51$UZ45#)JF.
MX I65V\4+.>,W?FWRN_=PS2* LLO$$I[+OML&U3#UR2&15X$Q#E'V"CV-MPN
MR(Q)2/<@-W51W(U[=E$.IX_5>L99:ALDZ##+V+:NO-<B]7F(\,T^0B&ZA9K0
M8I9"KQD#0$Q_<4F>6L=MAA LXS;!!6:6D.G8F22(7#-*%D*R%5BEE,PW78JZ
M()%<[L!" $0LP5& 4!3L<U_#CW3= 3(B",C?L59BI7LORFY9@!NP)/M#?G.6
MCI)99[LU57UW9"JED8^?2T^1.$I@FS?38@5M4>(S3)<LCKT[@WL)^=LJ,S(H
M)!!VUX>LKJ3)-,J'&^J[<Y57L>\X4!E\,!-S( )5XQ[1'Y0<4]CV1LY56/UJ
M,>X[1DG9N6[=E/L-R?>0>R>3^UW;7"L6V.H.O:U<LQ*<'F2:*!L=@G4D-J X
MW8)PJ& O+T\Y%'2ZE%P[5#,*TWH6[LF6XW09#US.QR-K3BQSO?)DANRNF[L/
M$9%$C3+Q!+1[*2'/MJ4C/A#Y3Y-=D]D;&DK(K^R/8#,5$9W(V?<@<1NIY..?
MUAY'VNYUWPK973FMF+'@!"I4 [8C$NEV% #5YAPC;'3\R[%2+&$"JBZ_:ZH4
M(U#8!0D?@X)TY\@*LL^83S*7.>>D,5Y@G(R%542+RF&R!1&JGN^R. \2A3M)
MLR #RU$/60L%"@LQ4\8SNQ8N3Y+[2DI(21NNX8D^>LXJ&KNOMMA$,0],:ZB.
MU(Y<J#.&3*16%/CW(\TO )1U)1!<0L=91)R2=@I=SYY(&WK<D,1G2I"-FF\M
ME"-YY2'5) 1(VQ[#8^?FI7B?@R;=P =3K'"P/R2>R60@J-QY@_>93R'S-[MS
MJ=Q8@4$BK@AAL$5#<G%2CD4=%8AQUDCA28;-3ULQT-MJF%C)">5)2<IR]-(S
M94R0MR0^ZXJW+%CNQ+'8#<DD[* JC<^Y5  'N  '8:J@ #8  =SL!L-R=R?O
MDDGXD[ZICOW]]#U__H$[3?WA]0N6[?NF+^@L?WE768A_>')?UOA/]CZ@U0WN
MN(D@K7I[:N49R"@/G*!8Y6,+4@<NRN#9];F/^7Y,Q')PPA =D*_-Q+FCV/'S
MR&\9[?Z)[D<U?J+I_P 0+9LQU\E2C([RFF9%M(I+ %B)(751LW!)7^M&XX-Z
M6\9)+0H92*.204K#PS!2O%5L*IC<@J25W0AP&&[<5!W.QT>^TPZ^VZQ& G8.
ME"9=B LU6%7+S&&MNS9P-T,]->''W8S#;KGP6; E(A29B$>@.DP$+FK;;G-.
M8])>B_J&E6AGZ;NSBM8%M[%)I]HTF$RQB6$,Q53-%(I8+V9UD]D'B1KS+U5C
MYW*9BHAL10U!%:B57\5&A5V0[!3MXP!0,?95D'(>V#K3LU'E276XT6,])E/+
M2TU'8;6ZZMU6<)PVAI"<N.+SG/D2A"<K4K*<8QXY\.=E+(HY,ZK&.Y=B NWQ
MY$[#?SW)VVUISNX798RTOD8Q[14@;L"JDEBO<;+N2?+?W[XNE.KIG6+25QOV
MV<YJ-BVK(%K&ULVZS (0@@(>7F!F941Y27HYPOD@4FO"W4^^Q8,.'[PRQ)S*
MCL^>?2%U/BLMU!A\9%D*D=:&PV/ALO/&B7LK<XMZM5>0A9#'%48Q%.0F;Q5C
M#>R3OV$KC%TE:](M:3)SQ1PP3&."3FYF9(@C$,UF5.1$9)D^3[J2W%=YG3*E
MEZ7U^J2+!'<A&[7,L-_G0'4Y;>@-70W,-B(<AE?@XQ+C@I(MN;'<2ER/,Q(8
M<2E;:L8\P^DK*0Y7K#)R5I!)6J"OC8G!!60T((H9Y(R-PR&SXX5_)TX,NX))
M]B]%8Z?%=-XRK8!61X3993YJ)R)(U8=MF$;KS7;L_(=M6FYHFMJU@VSJ3&V3
MKN[T&6[B.U;ZP8 IE91Y_<Y!"$ZS$G81C&<J5!EJ9EMXQ\_.RGPYD<-D7Q&9
MQ6516<XZ]!;*#L)%BD5FB+>0$J<E/Q7EMJSR--,AC[M%V5!;KRP\VWV3FC*'
M.W?9&*L0/</@#KYA^^>L]@7W5=.9P(FIOW7LG9@^Q*2PR^^4P*/Q@:4V@=%0
MTIXF'B9KD>8F=&2I#PHHR6;_ -28DNM^Z.@<OC(,E:M1S(^,ZD@J3XZ^"/!6
M:!IN5:5]@(I)/6&41N>0DCDB(#D+KQ/U[@,E#M69)$EQ<EGUB @*TT;I$\<J
M*Q)/#PW]HGV7>)P3%N=:5U*PGQRK/AX9QC.<_+YY_1C/C_\ 5G^#'Z<_P<[.
M!OY=_?V[ZYNTJ1@&1T7?8;\@1R/DNX.W(GL!YGW#MKZ#_8[:9O-?M,FRD(#X
M>7*C$;>F*4BRO3'#8]8LE0K+Y6-CT7H3]A(76=.A#W5QYLX, ?(QU8C9;<SY
ME_9"9RG)T_-1KV(6ED:.C!(2&22SZS7O3@<3RDBK1T LIC.RR2B+ES\O0OH.
MP]^&Y-D'B:)WK32PB56\.,&&Q'6FE4;,4DDG4F/=7:!)"C*QC;6\K6F^:[8Y
M"Z+?"E;I6Z 9%5?LM!EF(L25-*-(95'+U"*0D-D#=9L4=Y@F ELMNOJBR<1)
M*4S8LE&/"V)Z@KV?\QR4M>AG*\GJUS'O*L9:=> $M(2-SL5K'(20.O(\7"]^
M(=^W].];4,C(V$S4^.P_6%&P:.1P4EV*.>:RBJR7,3!/*+-W%9")X[F/LHC,
M8)1#,$G@E!L!S8];QKM.EG^QP_\ \07:G_F3VIRA7^L?^GL?W\FLMF?W57_J
MG"?[GI:MIROK$Z<::TF>UJHE@+"(QX?'=?AX!B):4LH4M3^:H6,NEXWE3CYK
MCCK)'+H;SX^>- FNH2O,97A\[_V6.%M8_P!*?1W5<T;?0K,=*V.FXK)+&*+*
M4;]J\(&[E4:>M<1DW"\A'*02$;;W?^PTZBQM'(2XZU*B6#D+\&[D*(ES-*BM
M*9B2 $EMXJ2D7_@S6JT9(\8;_/'GY_/^/Y_I\?T\X/KZ8ZYHT;-+SX@L=&<F
M3R,AF%#C,IRMU^3)<2TTTVG'Z5+4K"?']"<9RI6<8QG/*<LT=>-YYG6.*%6D
MD=CLJHH)))^8=_N]MCY&A:M5Z-:>Y:E2"M5BDL3S2,%2.*)2[NQ/8!5!/SD
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MGMKU=OX4BO;DU+>9.%) GZX9H+TSR_N$(W"GX/BXSSN?S&W"T2847&1YO%S
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MIY^S=M1X^K;!EXTM:5JHRI0[#,U,.M%)<:">L3BH!KUXH]K0%/\ G$HV':&
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M&F<^&,YS_!\_X_\ [8^?![=_A\!O_H'<_<&FL*@;#I91TE%B6(>W.$2,Q",
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M1ES"$Q8TV1'R?3%18K4,?)?'=6D"!U#B*,IXK[ [\4YQJQ'UK2(IV9P-<O\
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M>Z<::<::\5H0YC&%I2O&%(7C"L85C"VU86A6,9_^I"TI4G/Z4JQA6/#.,9Y
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M,8SJCBJJ26(4 L=MVV&Q)  &Y\SL /@-M;<HXA1N3Q '([ G8 ;G8  G;<[
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M?E&TRL3/P"(T:EQ(Y5./M%@O?658SXXQG'Z,X\<>.,X_3_-GYX_W9^?-P!!
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ML)RU$ GRUEU!V%4=GUU=KHY7)H"W9+O45SLP"0W.+#KF[6'7=Q@>ZEH<&9G
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MP+N&CH^ID4=]0PC%("#(*1*TQ3Y-GJY)E8,K%D'J^-B JQ,&A@[3F=QVVVW
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M-)@N0$32D^Y-NMQ&U= WM$[PH=W)<A]^?$#V@GA>&4XC<'?8"EZO-R[RMQ[
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MFH)V-DHX1EF$K*BK(3RW9RTAW4M#$S *!N7!*[J@=U VN80R\E,912Q9!VV
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MP8S.?$&)#[S&&$RG?>0Q1E^7!=LJE>R ]N).&#PD[3VW9@82PJ*+$2NR^J)
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M:=YKFF+T+IU5"7W?$6E6O8D;L;I2NT6XI#Q=[V:SMF)>A+3LBV)#/;)6,DI
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MI2Y TB\\-.Q!GO3/;8*L]9@-4UQV8T[U8V**W]L"T]DRFUJDW:GML:(*Z]H
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MNVQ*CL$FWBRZRN/+<#I@,@1M\FW8QMVE(#-&BJ XX>U$Q7=HR=R.W/<<M/5
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M.XMQQFSD DLHP38.UPL&@DXQ/XJ,CIBTQ?;?Y2(N/$:4 R%2 ZQ\%!*M["\
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M&1.;!2%YNJ[^9 U\<WU5KM_]HGK;_7V?_@/FC?2?>^V:GX9OS6O7/U3O2?\
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MGU5KM_\ :)ZV_P!?9_\ @/CZ3[WVS4_#-^:T^J=Z3_F_U%^#&_IVGU5KM_\
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MCRY!5>:&P"EGK["IBV+" E%*,K9:)7<VKC1Q\>4JSV GM+&W;F4;L)8PQX[
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M9B7[VY.ELQX3STUQ#N23Q&*1HQ!+CB.?%0Y( ;<D*I[#VB1ML._;6X-Q 9V
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M=QN  OM)RE$M5 $V4>'Q(4IW4[)L>XW#;,A+';MW)]EMIPUO?NO5TNING4$
M#;M<(:(V4<91K[-??1FY0Z/=89LFY+#09$<Z4;(T@RX\31'(3R@W"&7)9>E'
M60%O+'92-7D9N!)B7Y3D/8,D?$;,1Q7:11MV"GW*Z\JR/"S%44<@ Y]CC]=Q
M8'R'<^R=_>1VW*G:;P].J->G3"@"JUP&3(PQ@\@1#@Q@R=/'A(J8(:#,EPHK
M$B5#$PD(AC(S[BV8$5"8\5#32<(Q;L[N &=F )(#,2 6.[$ GL6/<D>9\]5
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M+HO5<6L/4]5521!2KC7-@3FCQFPV0@2N51(UPG6SY0[8"Q,\4F"7ZC6H\;!
MG)8R*#0@;K+@5"H"I38F+\^>S<'C'%50!'#!U"J H#!WWV [L6^N[ZCX,?$K
MQW!8.=RS$LI4@EB2Q(XKYGR 'EVUCJ>KNA4#AX9O7(QH&-KCM39K[)$\S79
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M+(2[G@Q*;L3QW[ZG,49).Q[[;[,Z]QMLPV8;-[('(;-L-M]NVO=3M(ZPH!F
M?J59R))":LW2Q&?C=BG01%:3$J\%X>)$$R\P0+60C4JJ),3X$&.2-N@H$DO,
MG26U.J//+(I5VW!<N?94$L2YW+!0QV+OQ!)"\B% &BQ1H0RKL0O =V.R^SV
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K.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--.--?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g686907image3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image3.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1N<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %<< 5H  QLE1QP"   "   < E  "')R,3 W,#(Q' (% #9-:6-R;W-O
M9G0@4&]W97)0;VEN=" M($EM86=E(#,@+2!#05(@5"!V<RX@0T%!4B!4+G!P
M='@ .$))300E       00/^DPNZ+8J[>_=*KMB>>UCA"24T$.@     !%0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!QZ[(P        "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 \     !  $#P     $  3A"24T$)@      #@             _@
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              QT   <0
M          $                          0             '$    QT
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   QT
M    4F=H=&QO;F<   <0    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
M!3A"24T$#      0Y@    $   "@    1P   >   (4@   0R@ 8  '_V/_M
M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+
M"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ 1P"@ P$B  (1 0,1
M ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04!
M 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1
M P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2
M!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+2
M1)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]50LG)HQ:'Y&38*J:QN>]Q@
M(JQ?K:PV]'^S20,G(QJG.;RUINJ=:]O]6MKDE-7ZK=6NNR,[%S\SU[[,FRS
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M1GHWY68=M[!61OKI<[$IK_2VX]>ZJMMGO<QGJL_1?F>JKG4.N?5[&KL86[[
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M=8CCG527RJD@I^JDE\JI)*?_V3A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@ *\!N   G$  KP&X  "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.3HP-SHR.2 Q,CHS-SHS-@!R<C$P-S R,0
M     Z !  ,    !__\  * "  0    !   '$* #  0    !   #'0
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              $@    !
M2     $X0DE- _T       @      0   /_A 4A-30 J    "  ( 1(  P
M  $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$Y.C W.C(Y(#$R.C,W.C,V ')R,3 W,#(Q       #H $  P
M  '__P  H ( !     $   <0H , !     $   ,=          8! P #
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M & W^XR_'5)W2\9VNKV9D%=G1@"K8FI+L2C'5X=>5J8JIV5J#C3&M@!#N+H
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MI]U6^MMA%R-G[R1PWE459VU5-9JJ,\N]CWU5/0CU2ASC@X/H>W.>*OC^N#W
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MX_-<7P9^[TTP?.V#L=E!F,\1<1,.'$Y.Y(XN?6%58$RQW4A)/'!AB?[WE:Z
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M'NIU95E@E@,41W>\V<76BBZGN?\ JZKL$F]KC 9CW]'\1>$Q(^D1Z);V8_\
MM-/"DKVM]:7B75T GT?K-T;2ZNC;G5O]?=UG]W,4=@2T2 ''+P+S?N;7'\PX
MG=:37'<D5F3S7+]2=?9;58FR "WU6+%M\7FX-?G\N;85'%W)X6@IJJR&"^1#
MRVEP]<XN0B*56SZ->2S&>WNI)'N%6"['5AF@95N4'O$$8FCB:2.TNUEC1PFT
M0R6ZY)!K7^--&M;1+#4M,M[6"P:6\T=Q9WEG?*\NFS,;&_N'LKFZCBN-6TF2
MUGEC>7>]Y;:A*%52,Y?XX^SDW9]1$W8UE;5YZ6>ZI]W;5EH=/86!X'Y/6= H
M=M=D.KV"BZ 2T,8?],<7\L&V!; 4ET.]K@J[=A43.Y*J:YNAU<5?99G5Z$D&
M'1V<0J6%=?9$<-L$+9T; '#!<'1(%'Z1UC?&US%2*/TJ5V^2 R/30'B76@K)
M2]7CJ B*JNCJ\62OM=&*&=Y&'E;%\S*,7+$A2-]]C6Q>EZ+$Q454?P/[!FJ
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M LC0W<%TUO(P5+J.'<&A+GRJYWAT+^0E"I(W9K"O(9+B+;'@E9$DV,<*Y4G
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M<M;K>1]*X CADWILEC!4S1R&&5(YYDCGA,<\:RR".1=[9J>A[=I-7>56EO\
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M![TY$L\LKW*5=/YN=O\ P</_ /@_SW2E/S<[?^#A_P#\'^>Z4I^;G;_P</\
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M#,+O.RR(6&0B0D?G8,:"-BO=*9,9PXV*&-K?*NDE<YK&,1/+E\(GGJUOU?\
MF%2)Z_=_&I ^(A20X"U[#NV*Q-!AHL/V<;JOYC82Z5TDF*R=1Q:*/+2QCSBS
M)H9M1QU(ZHDEG01'I/\ -Q2"?,HEWY^7\JM[Y/KD?#OS^S_*L$!W#D\>:YU>
MW(W?;S2YGY3#4EW?'TI7Y6_4J>V=>Z.VGK"K#-Z>N*L!G6ZA5\I#ZCUU%6%8
M0E&3E:O5=8L](BBDNC(SW$ABMK>!.K<7$B(TC"*/(!V*N69F4*609);B">XB
MMU#RLP+,50(I=G90"0 OKC&#V)/<=ZRI^&'G=AS(#\3/A'=@Y\+5<X]LV&%X
MW;G)E.R[L.-B^5.+L]/F"R'/,(KZF2[HJ^>8US++ZI :EI# >D\75^FZG9ZK
M;M<VCDHLCPRI(ACEAFC/GCE0DA6 *MP2"K*<\X%T4T4Z"2(E@K%3D8*MA6P1
MW'!!Q_'-4']C45,B[WN_98@>$!S?$(A0QHR*\8[ZSR*GLRQRL7VYXOER8WL5
MK7M5'HOZT3.3U^W\\_Y5._85ZS?I57_:T#^)C_S?5]1T^E5?]K0/XF/_ #?2
ME/I57_:T#^)C_P WTI3Z55_VM _B8_\ -]*4^E5?]K0/XF/_ #?2E<# Z.26
M2",6IDGA_P"%A9 &Z6+]RO[9&UJO9^Z;^Z1/W3?WTZ4KG^E5?]K0/XF/_-]*
M4^E5?]K0/XF/_-]*4^E5?]K0/XF/_-]*4^E5?]K0/XF/_-]*4^E5?]K0/XF/
M_-]*4^E5?]K0/XF/_-]*4^E5?]K0/XF/_-]*4^E5?]K0/XF/_-]*4^E5?]K0
M/XF/_-]*4^E5?]K0/XF/_-]*4^E5?]K0/XF/_-]*4^E5?]K0/XF/_-]*5&O+
M5>%#B3WC!"Q3?-UC6N@&B9)^F="U6M=&Q'?I>?'A%^_GQ]^E*UG?$AX[LZ'X
M<7=+I2)2@KY_']:T08::4>8&K*V.8@N&%.A>Q[I+"FE."+$<JQ( 20.2R1TT
MD<5&['[*N7ZPK2/VI48_&/P'N^KDS0P2C_G?Y+K<EG?P:ZS!"MN,,;5DCJ[[
M210:BYU,9"-3RV.J+_6U?%@X0_//W\?G]]7G.\8]/R?V5YX>HZOK.3X:&I"Q
MW?[VD75@JM%DYMQV?5R*C?1-L#%R CW*OV2-A5["^3_^FCD\IY\I<GUA]]4;
ML?LK9WRKQI8<>_LAO+5\<$T0VK[D>,.2ZN=S%8TVOV5#2Z>ZGA7PGKAAMY-#
M72/3RBR@D,<Y5:[J[]<>OQ^7IZ?=5HY3X<?]_P!G[:]H/4E15P%?UL1_@)?]
M&[I2HA[??[#V+_Q:U_U]:]*J>_W#]PJ9>E4KQT_LA_)WFT[U^VC)44+BK;9\
M-YO)Y\5/O\Q>77+&RJPQV)_[\Q=D#'^^JO:GZDZC?NOY_P JD0X!^7-=SXV?
M'N<V_>/V_P#"T=U+2U?%/:*%::.T&&;8G_0J?1;1@%7452RC(1<F,I1HXFRE
M+'!%:,.DBEB#?$1J=>U-M)L1=1PK<2M/#;Q0N_3C=YVV@R2<%40!I&(.?+MX
M#9&+<W)M(&E558[E0!CQDYY/V?+FM6^3X!XHASMIRA3!WW(8;:>R'SO&>EE4
M2V=I:8_.NM[4V?/K62W^?KZ:^%+4.MB&)')EF0Z,P4*7SPMUXMUB=$LQT;";
MJQM=WD*]6&*VFBD,* RK*D$\CQN06.TH-P(['7RZE<D=,[8V4[I9HQD!&'Z-
M3D<'N#D\X]*W)=JO&62V?PV/B-\,8>E=G=?9\9T7-UWQ]\P2:ZBO1*G3GT%;
M7Q'/)M!H=(SA42WK@SYYBATO!W-<P243QU7A34+W4;&X:\=9Q!>2V\-V%V^]
M1+'$V_ZJJS1.[0LZ*$8H2"<UF6,TDT>Z7)"RLJ.>-ZC'F[#]8D>O;OZU+7[&
MPK4-X*[H6G0M)J3^3\@%[$S?7!++#D")#&^E?T?4L)8/J5/#D\1N\HJ-5.G3
MM]_Y_=6=)Z??6_.CX](R7(0)H22$4!4-DD$R^7R RO$E5!"G?BJ?94'(7[2M
M3T/5)D_3OJ.ISZ4ITI3I2G2E.E*=*4Z4K$SFSOG[4^W/D7-<4<T\P4^$WFLI
MQ=!34I]-JCHUI#;$ZI#L[.WIJ*RI*(,FPK+ >*6\L:]'?)SS+X@8LO6MO-7T
MW3Y8X+R[C@EE4,BNLARI8J&+*C*BEE89=E'!]!74:'X+\4>)+2ZOM#T>XU&V
MLY#%.\#0!A*L:RM''%)*DL\@C=&*0)(WF48R0*U$_&%Y_P"X:'D/B[C[MVYO
M,XUR2<0&<NGW>'VD>>+U9)&CL80GNNJ^9LUO7!U.3G;0TU840MX;>%N^G6#1
M8Y@>/\7:S=VUS:VUG>+;QFR:^9TF5#*O4<## Y<;86$:+GJ,[8#!"5]O]BG@
M'2-9TK5=6US0[C4Y8]?@\/QPR6,EPEK(UM$SJZ' @<RWL37-Q<"..TB@4M-$
MTJI+O [;]CI.0^WO@[>;&06;6[+B3CS3:><)(FADW]WE*JQMRAHX61Q0P%'D
M3D1CLC8@[)$@]#5C5J=MIT[W6GV-S)MZEQ9VT[[?JEY84=BO_"2QP/0<5X)X
MGTZ+1_$GB#2;<2"#3-;U73X1+GJK%9WT]O&LN23U%2,*YR<L"?6IIZS*T=.E
M*\COQ+.,91^_7D_D,LO7,U01?"^TXY/!F$#A"7/T.>&]8)DWO$BQUI8)CP7A
MPRMFMXIUG01!I7$^1^*+N"T\07/5>Y6X1=.O+0+L5'"NL3[7P6V+@D#G]*&R
M !D_=_L3\.'7_9CI*PQZ4UC<2>)=*UEI][SJTDMQ+'OC#A6=XVB63>8S';-&
MR=4L-F:?=3\:#6\<RC6G;]Q#7['CNCN(J33\A\@_71!;Z]9$PR?/9&JIYZ_Y
M5\]?ZC!+FXL'221-)FDSL, XC[7H[SQG$NV2QMVGM([@6]S=2K(JF3:K=* *
MOG=@Z,K_ %-I)QZUY-I7_AYNTB:'Q1JOT9KUU8C4;'0[,V\\UO8F0Q&[U"5R
M0.G("DMO"I*,-HN'?J+'O8XSUQ?(''&!W9^;M,<=M,9F-69DKQ8UNLP3H:4*
MVFH+98D;']2IY"W '>AK$^9'D_09^X3MHV+QHY4H716*-C<I8 E3CC(S@X]:
M^<KRW%I=W5JLR7"VUS/;B>+/3F$,K1]6/=SLDV[ESZ$5>_5]8U.E*=*4Z4KQ
M(<^FVG(7[(+IHYA8[!]?W9]O]2P28>.>%M-A ..AIGNA<U6*V"MHR#ED<U7,
M>BSJJO;Y6/\ \S\_"I?U/N_C\OG_ )U'_P 1M-*;\53NVH:BBUV@K](/BZ30
M0X\0D\^LK".)>-7"7CA8IQ15BKCXA6/4\P.%8"2!HRX2"(W=:S5KFRM(4GO+
MBUM0)#T9+IU0;BBAQ'P7)V@;]@/&,Y &,W3=1M=+N4N;O_9&.:,[<"11(JJS
M(<@EO+@\CRG!) Q4-XKC<42DQ<\>@U5"5A]II(<W7;RN@Q-EL=-,)1N(S-0.
M9I3RZ:GC(##$+L[D%E<XB=KH")XZXE%YB\\0Z=:M$F[WT/&)WDT^+WI((6P4
MDF8;-H8 L N]@!YE!XKI9/%^A0+$L37URT8:1(TB"QK'(F%5GZV%0G._L<;L
MKEL5EUWI9>T9\%'L.M+2CBK[7)<^<F9>YBE$;]0H3+&^YL0RH:0YBRBC?.YU
M(31VR)$20!7O?[SAH'M[:.2.:W@FB82130Q2Q.H(5XY(U='&0" RL" 0#SR.
M"*XQ765VD7 60LZA>P#MN 'R&<#Y"O1!\&W3V&L^&SVQ'V4BRD5M!L<O$]?Q
M^G9'DK99JHC\?O#U56$.W]]L**OW5>IU[#[*M;ZQK9SU6K:=*4Z4ITI3I2G2
ME.E*=*4Z4ITI3I2G2E.E*\AWQ?.[P#>_$=[9>"QL+6W.?[5.7./+"W*L%G*F
MW.EWUSQOI+V@CA'F;$V@KZNNI:98?2XTF^^M1S^!QQX9+"1N48]?W\?Y_=^$
MBCRL?B#^?S_&KT^(]KK6Y^)5RJ161B"%\6]J^/XWRNVNRQ0<UB=OLC2=EX+/
M,EAA$MM'F-!=4E<L:RE1K-(2Z)HC""AL"_U?3M,DMTOKJ*W:Z9D@#YRQ0;G)
M"@E4 QESA02 3S4+RQQ!0[8+L0J]RVT#/'H!GDGC^&%&@EO-R558/E*YGML[
MDN,]V1S1<U1$[UGOZB7-;+'U.>D;) );[L2NT-;+<7+!3J@C&W 4$\Y\V<&#
M!P=1TRR\0QV-W#=IFUFDDMKNWZ-PK(X:"YA.6>,[MO!(W1R(#M^,$T278AEB
MF*;'+(R#N&\KJ<\ $#&1@Y^%9U_"C+KZ+O-XJUV-GMHN-N4NWWEKA.KS]N,Z
M0W-:?#Z'(\R31'WD4; KAVC".N;JKF9"%+ Z&^K6#/BJI"9LS2]*MM(BGAM3
M(RW%S)=R/(4W-+(J)P(T1554C1%4 X5 <\X$L,"0(RJ6+,^]RV,EB I[<8PJ
M_/[JB3X/G=N%Q[\2#N5X:L,75TE%W9\J;H@&<)Q([L%JL)?\FZC-YZ)A,LK7
MT%B)>W>;0=[4,9=KG$AD8/\ ,PNV*GDC&/P].#^>?XUDN.,\\?'\]Z]@G5]1
M4Z4ITI5#T9I5?4%%!JUDS%A8DKT1S86RS,B=*J*U[4]*/\(][)(XG*DTD4L<
M;HW*5#PW*A4+[:K+;(22X2=E.:R,=SX[-[9(AQ3/E/VAT3I_;1D\4:^VYKFR
MNE:[W(GY_/[*5T.-8[UUZ&A36I"DUB63,YRNG>C1'"JUWK:KGM>1-$]SG/54
MD>KG(KO#W4_/<^GY^P\D_-61G5:4Z4JW;;35]07 #,P@@J9GNK$,D"K#$J2J
MU\OOSP?\)[$OH;'[CO+/TT8CXU>I5>AFC(AB(A>DD,\<<T3T141\<K4>QZ(J
M(J(YKD5$5$7[_=$7I2N3I2G2E.E*=*4Z4ITI3I2G2E<,P\!*,:1#',V.6*>-
MLK&O:R:%Z20RM1R*B212(CXW?BQ[6N:J.1%12M(WQX.ZZ/@3M)=Q"!G1+[2=
MT+='@XB;-7K79K(T8]07KM R&"6.8F\ADN*"OH(W.8&*;8NMBWS_ $R&KL[6
M.!^?SVJY!D_9S_*M-7<%R2P/]C^]EV2KJ\:BDVG/.IIK$(/W60V]7BMESK9V
M-P])I9)99S]"/GK YWEP[;&65(&#0M%'CH>$'V"KQ]<_GX5H'J*6UORI@:<*
M4\L>JO+N:"'T>N.IS5+8:.].7UO8GLUE'56%D1X57_+B2^VQ[_2QT7>KZK&!
MUA>!W6*W5>YS#\5KLWK@7M5$<PW-7(5R*]JJBHCFSA1N:JHJ(J)Y14ZJ.X^V
ME>D3XO/<I)V]_%@[7.=Z3#56EFXKX:X[TZ"$/+&DW-3=:SE& H9AD$OMP$B5
M5F:/GK!!9_DKCT$'P6@0\5<DC'!'SX_:/SC^=1K]4_?^X5ZS,9JZ?>8_*;C/
M3.(H-GFZ/5T9#T:U\]/HJL6WK9GM8^1C72!&0O<UKWM155$>Y/NM]1U72OZV
M(_P$O^C=TI40]OO]A[%_XM:_Z^M>E5/?[A^X5,O2J5X[>[SN\K>=/C8]L5 %
MAJLW+]N?</QWPA73&>^38:J]=RA7 Z/2$)!/\O%#F=861+DA(D>U)*-EE9OF
M2REJP;"<N!\/Y9_/^0J0#R'YY-6+\2[GFNL.^GNHR=7M:WCS44NOXCI!=78R
MF");9'*\89WZOE1;L" E:MU5KK&]M)0B&LBMUL5;$Y+"NB8[A/%VDWU[=6MQ
M%:W.H6D5K+&UI;E2Z3M+&RSB,NF[*>0G/E4 CD\ZF^@FEEB=8Y)HU0J(T[AR
M22Q&0#QCOVP?CQKYT<4W/')!O(-GJ=%6\3XC(79%'>YF.&F-U&FP=9QS7\@R
MXVO<-$53'7VCVM)H[2WM*J>Q6G/B+,ADD@0&OQHHY/"_AN&/W&W>^U"]Z,PN
M")(E,PE:'WC*L'$%O&T012H#$X(.0;8O_L^SC5H@T]Q*0ROR%4[BBR=P63L1
MD#FMPWP79Z#C7E[FNVS+M+I,YS'VS;;=OR>R(AM[TG2\+:O.#F4Q-G"$,/?B
MVU3R;$\(IP<<[7&65>3&7\HTN?<^%=8FU%;RTN8K2*>P:#_[FHC@>&X61HRL
M09NF4,15QN.6/%36-PTW6C9(T,#JN8@5#!QNR5QP<@YQ^ JD_L=3NJ%J=_RM
MVG6.9K:X/D@BWYHQ][7R%1N$T--64M1=XB:$PHE2:^7,@1W.>>QR' I0Z!+"
M>S8>,^LZM3R1\.WX\ULG'8_=7KBZOJ.G2E.E*=*4Z4ITI3I2G2E:>^_KX9LG
M<+RC4=S7%)U"_EK/4U/7W/'>Y$:7A^2&9LOW*:9YKYXI,]?#UDQ53)*U8@[F
M""E'FL<]\B39%\AXB\.RZC(E_9-$;R%%'NURNZVN@C94,<@QN%++D85_(I:+
M!<^U>R[VEV/AB&;P[XABO4T'4)Y"VKZ1)TM7T@7$>R9H4*LEU TBQ2-&P9H1
M[PZ0W32) ->-9V&<C<=46+O.XVL,XOXP'V V#N+2ON*/7'XBDT8UBYVC^3"L
MK@$#'R7LZ"DS26K):H^R+O9 +.,MX\_G#>%M1MEM;C7E>ST\78M)GBGCN'LH
M+A7VS[4>6-+0W!5)"9 T+2-.R.K,#]>+[:/"NJ3:OIGLUFM/$/B9M#&NV5O?
M:7>Z5%XBU+2;FU8Z2LDD%A<7&NQZ;'+<VZI9.FIP6EOI4,UK/#'*/2EQ69Q\
M5QWCHN*KBEO./JJ@K*#*GT%D-;5GTB@$BIQ!8C19)(WR!1!M$(8YR30SPR1S
ML9,U[4]LL6M&M+;W&2*6S6%(K=X9!+&8HE$2JKJ6!V!-AYR"I!Y!%?GGXC@U
MR#7=6'B6TO+'7IKZXN]4M[^UDL[M;R]D:[FDEMY$C:/K--UDP@1DD5X\HRDZ
ML?BZ<_\ +O%%%PG@N*-I>\>D\IVNR;8Z'+EMK-%839^+, UF<K;E%815,+EU
M4QQ) 4X9;IP:]&FPC-*CG]J]DOA_0M8FUN[UJ.*X^CH;/W:WG3JQ?IS=232M
M$0RR,J6H2,,K*-[^7<5(^?/;#XCU_1(=!L]$DFMQJ4UZUW<6[M#-BV]RCAB6
M92&CC=KMFD*LK$K'YMH<'(SX://&KY][6Z/2;FW)T>FRNGT.!.TQWI2ST<%"
MRN,K;6V1K(E=9I66X8!I<K$FM)@EMYE?(>Z1_.^TG1+#0O%$]MIB&&RN;>"]
MB@VE5@:5I8I8XP>T9E@>1%'E19!&@"(HKI?9?KNI:_X4@N-6?K7]K=7%C+.2
M&:X2)89X7=A]:18+B.&1V)>1XFED)=V-8U]XG*?;KS=SAQWV[S! RZV+DW-Y
M#;\I1U TY.=JI+*1]AQ_G;QJ$&K<V-TVNK;.9PBT] \DULDZGM,AB^?_ !#J
M6B:AJEEH<BJUX;Z"VFNNFIZ,3D226T4H\YEE98XWX*0AF+'< *^]O9+X6]HO
M@[P7XC]HD#W4>C-X9U35]&\/K?3*NH7D<!MH?$%_IY46[6%C:>^74"&5;J],
M$+K&UL$D>:.&?A==OG&&R'WFC2SY5N*MS),V#M!*=^;HGPEQ'!',HA!$@LKD
M2>*)\!]I*4/#/&AHP YS8B8MKHW@[3-'GDN5>:[E8CI>\"/IP $$&-(U53)P
M/TK[G(]0:X/Q[_X@_&GCK34TIH;#0K9QF_ETPW7OFH/TVB99;J:9C!;O&S(U
MO:I$I0[':120=EK4\-1/")X1$\)^"?W$ZZVO":_>E*=*4Z4ITI7E?[>L!B.4
M?V0]W!ZZJTF<O:GBBLU/(=<^NM!#8+'7Q\?8;C.ZJ14B>]I5CE[W9W_U=D2O
M^EVM!-%.K"(D1+?UOL&/Q_#M]_XU(3^CY_./\A6!7<1<9O9]R'<'/<;'0(7W
M0\_ZTNJN,R*+,S,93C'D/<<88$<XETLA%^,17U[;*RK09*AX<$0$$9R+"9*G
MDWBW47N-5E,=O&\6A12QL9FD;J27,4,LCQQ1E>D5CC,<4S;B=SJH&^M!J$NZ
M9AM7_5%(PX!#LP#Y (PI!RH)&<?;6,EYR==\FZF+'T_#]YRD%P9#'F*;1IH_
MR;],P+IP"7; IT5G3.K+.T#(_)X5MK6VT]<(V#YXF9\C [%\/6VGV45Y>:S#
MI3ZJ$GE@,#W"].94<>[)_M0;:)P7D*%(V.<Y'-39PP1*9;I+=[K+.I!<8< L
M(Q^J5'![#]];1\O'9=P_P+NZFHY.>/0<A<!<^;';N@OF+3K3Z--9F^1BZV$8
MQR.'*O@.0]3G:(3U.D,-N!1('32SM<_T_3DM%T^TCL)!+9);Q1VLH97#PQHJ
M*V\$@\J<^JG*GD5N8%C1(DA.Z,(JHV<[E'&[@<=NWI6YOX+)6?E^&UVZ!T-S
M67$E6)O!K]E<9 4^HT!O).NNS*:SCB<YX-D*/;!S2ADMCF]@D8E&N@)@DDSE
M[#[*O;ZQ_/I6T[JM6TZ4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*5K;Y4^'O1
M\M]X0/<YIKZI< +B)<E'30TZMTE>\!F?=GS*FZF4@<4@<Z7<&SFM@CD'^I5H
M\8Q?NFS0*NS@8'W_ #[_ (?A]]:!?B/Y@&3N@[K#.1M%9C4FIY^XSK<K3YX&
M(FSB(R_ O&Y!EC;33EPP.JR@M#5#5E?,+)(DX9QPTS51!B^8UW09M2N+:^M+
MB.&[MXIK?;.K&)H92KY5TR\<BR*"=JD.HP2!Q6%<VIF>.6,@21JZDMG&QL]@
M >=VW)_HY'VXK[+\XN-O\M<XS.NVY>9[K1>*LM5#3.:W7YZS[<,%75M3:GG1
M-A$N[?$E-,N)[%KPJ*Q>1)*DU?5>OK9:-IOT5IT%GU>LZ-+++)M"HTT\KS2]
M)!PD>]SL'';)QGB:UAZ$*QDC.TLQ7A=S-EMH/9=W('SXK85V+7_((_>MVK9H
M8(BTPQ^WY))O]%'=XRSJLSHL[V]\WQ5F"#IL'!#1T<J@Z/0'%W21Q_E9+61O
M#\LIBE?M.Q&/O_#_ "_.:FP,$^OH,?/OFMO_ !!\."DX7[OK+N4RFHK7U!E;
M65S:8ZC275E0/R&KI-+'::&%XXY4UKHRLAJG'M$;\U/5%"S C/&!,E8YS]P^
MSY_?5=WEQC\_+^/W_&MGO5:MITI3I2OB2-DK'Q2L9)'(US)(Y&H]CV.16N8]
MCD5KFN:JHYKD5%1514\=*5$%WQE7# 7)%:?].:T8LL'U"MEEKBFQ220-'(]U
M/ S9T8UL*COF]I$8R7WTBFC4JO\ 'ORGT@1\SIEO'UX\MDXMD<<CG2_MLTHL
M<2>Q$+.2YT[HHW/EA62&$I_F(=K5*J>5Y#P.ZFN1\3N,AL)\Z6P#00Y?24U_
M+1G2(]T8=O'5&%OK2I&QR.9 8D,KTC>K6JC'>,JYL+ZR$37EG=6@G4O";FWE
M@$R#&6B,J+U%&Y<E<@;A\16':ZA87QE6RO;2\:!@DXM;F&X,+'.%E$3N8V.U
ML!\$[3\#5X=8M9E8[\DU5D_71F0SO&%F"!:U_K1C/5ZYA)Y$>JHJ.B:]GNHG
MED<;VO5J.D1RJ5U'\@WU7#3TD,3*T<,(8>0QZPS&%RM:V-DDK2H)8A8I?3([
MVV0RRK(STI*SRL+:=OS^3CG[O4TJ=\X<58TXAA?Z4LK7^F;VO8^:B8]S(BO9
M15;&A#&I(GH7VY&JDT2-BD8QM:57.E*=*4Z4ITI3I2G2E.E*=*5ASWF=JD'=
MGF.)\P;8T0E;QSS-G^4[&MT%0ZVK]*)4YO6Y>>AFC171PM?!K9K6%\PQ43["
MJ 8^.-BNGB54'%>=?XZO" 7;CVM=BG#>9.+L\UD]/S?/96!361*=J]-+F];;
M&P#QHJ!A&7M]JRJT!\I,E>#/"$\PQT#B9;'[#[:O0\G[ONQV%:$NV6@.T7(6
MJ# $F+E$[?NZBVD9 USG1P5?;1RP9+,[T_@R/VD\JOV55:W\7(G5B]_L!/?%
M7G^(_/X5CR[QZ5\_AX7S_>\??JT=Q5:][7/'PZHN\#!<&<ARZL++<D#=O.6Q
M%N9HJ7ZZ*!-/04UK27M+!&H\X%QD[XG0',A25GU&6W5&GU2B^LC(Q^?S_"H<
MXSCX_LY^.?W5N#AC2***)$:B1QLC1&-1C$1C4:B,8GV8U/'Z+4^S4\(GX=*M
MKX*_K8C_  $O^C=TI40]OO\ 8>Q?^+6O^OK7I53W^X?N%3+TJE:SC_AT9[0]
MXNX[I--H:^=FCW7#?(=-75=4T71U5KQ!2505=227!#"(THCKS(Y#0'M@176"
M-NJYPP<DHEFQ5<G&/3\_G[OMKR7=[?!\FI[Q>[+<<C;L3$ 7'<_RUE<S&ZF(
MT%K:OJ;6,V N<2,RJ@ H JBUHX%.4PDF219TB!6,59'\KK'B5-,O#8Q64E]<
M);I<RKU$A1(79E0*TBN'E8QN4C "D(V2",'&N+P0'I+$9'""5ER  I/!Y[D@
MDJ!SBK#E#UO;)QSPC-<TKK@EO.7=UQ]8-I',(^L"%8CME!0_,%E!31S$/6P'
MM*AA 37%+"P,X6'WBHV77T%OXHT&*2)Q;QSF*[A:4;%1HV) F  VQ\NC_5 !
MSGMFV58[ZT!#K&)%21&SM 89QG/(&,Y/?'8<UM ^$AR3?;GOFS?&)%3OZ$"L
MX,YHLK8S:UH.:T;H-)%A*J%*2AKAFU.=IP9*FOF"4)DT9]F04:1&DC6,=A>%
M-%CTZ2\O$N;.<W>R#;I\O6MHEMWG<;YLEI+E^H/K#$<0V+GO4=C:"#?+U(Y#
M)M4B-BRX7MD'D-\<XK>-VB?#HJ>TCG'8<E973TYF6OZGDZC!HV4'RU_]+V&S
MP>HQD%M<-E2,F3 5V<T>>BF2.7ZK%HE.A93M:37S=K6>3G]G[L=NP_"MG'2J
M4Z4ITI3I2G2E.E*=*4Z4J@LU&;DN)<['?4\E_#&DLU&RS"?<11.C25LLE8V=
M38XW1.21KWPHU6*CT7TJBK(89A$)S#-T"<";I/T<_#J[=F>_ZWH:@%U;&8VP
MN;<W(&3;]:/K@;0V3#NZ@&U@V=O8@^M8@?$0RX.I[3.2U+T=;FI,S!6;.M*M
MSPZT"SL<V=$>+G7DV! H;3-&B24U.PF3VG79E=ZXY&M<U>;\4:<^IZ)>6T;%
M)@(YXA@'?);NLHAP2 3*%,:Y.U796;(!!]8]C/BF'PA[0]"U:ZM_>;*4W6EW
MOUP;>UU6VEL9+X&-6D"V)F6[F$8ZCV\,L:,K.&&@;L@^(=9<(:#DO#9+,.ML
MKJL[!:TM-H;,MSLMR?314U/:$DR"@Q(36VLUFLDE<J5Q/TBLJ!2;E;"ML#"^
M&\%7SV4UY91Q2"VDA6X$<K$M!=Q=&*?)PN%E9R0N P2.)6+.LCGZ(]OFA6OB
MB#0M<O;ZW?6+.[DT^2[LHHTBU#0;IKV\TXQQJ\I$MLD($LG4:)KJZO)H8X[:
M:UACM3N;YXY?[I(Z*/D+29LTO)$W,N3]NCKZX*J@TS@X[D=\5:%%9QP21U-4
M\;ZB;:&>JOB1&N>5/(GO_L\]HS^#-0OI+NT:^L-1MEAN(K=8Q<0S0LS6\\0G
M:-) HDFB>,RQ[EE$G4)B$<GQ5[4?8Q9^.M+TZ'2+U=,U72[MIH)[Z2X]TNK:
M=8TNK:X,(GDA=FB@GCECMY,-"T)B59NK#(_;9SES1VT92WJ<CM@?;--GM[7,
ML!$N\Z^W+ @!D(B%*5#6%H(%7-4P=]<XMH<?S#_EXFP.UWCWQO+XP\22:O!#
M):V:6UO96UO+L,W0A61FDEV,\:S/<3228C=D1-B;G*LS;KV:^R6R\%>$(="U
M*:#4-2>^NM1O;RU,J1]>X"(D-L[QQRO;QVT%NF;B*/?(990D(=8EZG:[+FA>
MX7BS7<S7IS,]2:6\Y#T-I9"27=U<:\LH6:KL+;20QPG3U(.D&%N"P2V&$!QN
M.DC;- <5+!Y3;:%:)JUI>O+U$CNKJ]8S0JT[WEP%9',Z'_912[B$(([' X%?
M3>L^TK6[GP+K?AZSLUM[V[T>PT&#W.:2'3H-(MA+!=Q6^GN[QQ7%S93M;=2'
M;U%Z>\(L**?5937U)>U =W1VM?;4Q@[2 K.M,', )']/E)8"AY)(7QIX5%5)
M/T7-<UWA6KX] !!&001\00<_A_"ODF6.2!VCF1XI$.'212C*1WW*V",?.HJR
M?<EP)N]L5QQC.6\)J-R&.67/FJ/15]C9*/7R,BL)!V#3/C-0"21C3FAR$/$5
M?)#8T153<W?A_7+"RCU"]TJ^M+*0H$N)[>2*,]09CSN 9!(/J%PH?]4FM!8^
M)O#^I7LFG:?K&GWE[%O#V]O<QRN#'GJ!2I*.T>UMZHS%<'<!@U-J+Y1%_?\
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M@XV7TGI'\U&D4/@_68RJ7*64;/.6%R\\EQ<2*V,J@4&,J7/4_21QR[FXDP9
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MY->7"J[J8HKB)X42=CU(U+64D0W#,<PV[L6=GHN1 LAH,:!J=('F[6L(H9Z
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MMIYY8I&M[T!!875Q$X5K.VF9P\T^T2.K"(02"/$4LA9<XY\DXG.\AYBOG+F
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M-NYGQ:J(U)R(D5 !I?!?A#1?"FI7FHP7%Y.;J'W>WCN=DB:?&7#2K$VTR-U
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ML,QL"0M15W=7ECM"7]$ HCZ,BR.VCD!/4; ; _1@.V89YE$<9;](V(XU8!E
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M$LL\Q\<37$FE$%3*^>:21V,22<DDD^IY-<Z[O(Q>1VD=OK.[%V;  &68DG
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MPM@!:/'TV#^6X?*D]0RRC6WG&I]-R-2&<C8_/KK8AQZRQN>1L!:MK0%B@F.
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M.[;;D]P&!/V#T.<#OCY?=FM^G;)4<=KR72P:1%J;BAST$6/#-*^4D./KI0"
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M605CAW0SPVU_8@$HV4UM95A3DBQ>EPDAA#)U<YL<L4G%ZK*8&E10R8267#J
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MZ\2QOM:>6\$%1Q&/&#E9"TJ2T(LJ'0-/+]0B<L&D89E) ,LDDLFT$':&>0G
MP.%/?<6O7Q[KZP&W4V01H[:)B+-%=UM+6VM("[J079(+9%#/EO,XSM$:QY!\
M0=NO&W!]A;V>$&MX"KO+YS'GK9VLEBQU-E=AR=N*EL;'Q1I&2V^Y=V4I!">7
M3C3@#N1&@L<_.M+"WLV9H X+QI$VYMPVQRW$RX&!@[[F7)]1M'IDZ35-=O\
M6$CCO6B98KFXNDZ<80]6YM=/M)22"<KT=,M0J_JL';]?B0KGCCCS1'2VF@P>
M,O;.=L39[&YR]'9G3-A8V*%LI9H,Y$C8HV,CB1\BI&QC6-\-:B).]O;R,6D@
MA=CC+/$C,<<#)*D\#@5@PW]];H(X+V[AC7)"0W,T: DY)"HZJ,DDG Y)R:HS
MN%>&W_N^)>,W_P#2P>6=_=_75+^O[]6^Z6G]5M__ (8_[M2_2^J_[SU#^VW/
M^)7 [@SA)_[KAWBQW_2X^R2_YZA>J>YV?]5MO_@B_NU=],ZO_O74O[==?XM<
M#N ^"G>?5PMQ*[S^/JXYQZ^?[_FF^_5/<;+^IVO]GB_N54:WK([:OJ8^R_NO
M\6N%W;UP$[]UP=P^[_I<:8M?\]+T]QLOZG:_V>+^Y5?IS6O]\:I_U"[_ ,:N
M)>W/M[=^ZX(X:7^_QAB%_P ]'U3W"Q_J5I_9H?[E5^G=;_WSJO\ U"[_ ,:N
M->VWMU7\> ^%E_O\689?_P 1=4^C[#^HV?\ 9H?[E5^GM<_WUJW_ %&\_P :
MN)>V;MO=^Z[?N$7?W^*<&O\ GH>GT=I_]1L_[-#_ '*K_I!KW^^]7_ZE>?XU
M<:]L/;4OX]O/!J_W^)L"O_X@Z?1VG_U&S_LT/]RJ_P"D.O\ ^_-8_P"IWO\
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MPHEH,04D;SE '2$=_KC@1--/;Q6=YJ8L((K<G0XW"P1+&#)[Q=KNVH%!;:
M>_ KL]*U&XU6R\)2:[?7.H(GCFYC+W]S+<E8A9:*ZQ;YG8B(RMEDR%\S$CDU
MKA_8P^@Y&N.6.Z6 LR\.X_"XQXQ%/>;(3/6BZ@&[MA<B)$Z=SHX28\XFFBA'
MB\*T$>-CD2&(;SC^%!,OO8;(A CVC)(WY8<$^H51]Q^ %=-[:9+:5=";R>^*
M;I20NV0V^R ^<=P!-N(';);'K7L4Z[&O!J=*4Z4ITI7RYR-3RO\ D_?5?WD3
M[>>E*\E'Q%/C[\C<?]R5[P1VLIG:/"\4Z]<IR1RO840&PT>JT-'8.$UU-B*B
MXE=FZ^FIC(C*/ZB>%9G75D'.77SU5<T:<_E=5\026UP+6RC261) LK.&.,'#
M*H!'V;L\'T->V^#/9;:ZIIZ:KXAN;BWANHA+:P6TD<>V)T+QS3R/'(?,N).F
MHXCR793P/25D]WR-?<'<1;+8TS\;MM=QCC]+NJ42!(69O97&;I[*\S[DLGS3
M Q5UH8<''#)),:BBK$^1[H)%DZ>,LT:,X"L44L!V5B 2.?@:\:NTABN[J.V<
MRV\=Q,D$A[R0I(RQ.< #+H%8X Y/85U<]R)IAQ)C9R)=%/#[7_HI7BQ3EM<]
ML3EB7Y:-HZHCED8]\\3'N:QCFR32L@DN]/Y_Y?G[JQZN(GCR_P!,Z"QLR:<.
M8HF4Z0@&6<Q&0$DOGA1C7Q^DF6,1\8[?24T5$:JQN>U(E:[X/\NWP_[4K43\
M1'A;88WDRHY(0DG0834TH&?%+E-BELLW>5 ;OFJ[Z9YB<RKL885MA"@X"HDL
M)SQ3$'EE$<;X_P"/])ODO#J[%IK&06]LKX\MJX1]MNY PHE=9IHV. Q:1<Y4
M9YO5TV3I(\BXF\L2%@&RB@NJJ3EL<N2!@;N<>NDW>\*NLBK>QIA82J^S:R0L
M2!_H) *7TS-EC8YZ-F&<0KGQMC<DC(W(K?=B_;$XZWOMFQ9"0RY"D\AAVQVR
M#COGC//!XK#2;  /<=L]B,=C\#CU^58]S<+3#N)23*6HC$?%%[LK)V,,F>Q\
MC7QK(Q[?"(Q?#FL>.WU-14_2\];,7X./TR,?4#]4?#@C/?Y-\.U9(N#QA_3M
MQZ8&"!^?6O@#C[5Z*]2J H)&QB1 (%"HSHQX8(96"2*YTGMM:K&RR33+^BQ9
MI7SR)Z$=Z:M=0Q1AVD!W;MQSR3C?Z=\]L? 8'/<9%5<[N26S@Y/RX_8,=@,5
MLZX%XSI.-09;HX,N2R@JY&GW$4#1X@X_FH/<B%0F.")HT:1R,]V-SGS3N3U>
MAJ,C3D=2NY+INFA7:7\L9.XL<'!/).3WP< +\>36JN)#*=H*D9^J<GT/?!_[
M_#L:F;'=[%?VY\UEDF<#D;*LIJJG*^HE6Y@>A' .I(+LP_,UZ5IX!LH=.3#,
MPVSD@@E<(6R-]8R*2T=]:^Q7V VFN^$+3QY?ZTBW]\UV='@%J9;2T-M>7&G'
MW@]1'>[N)H7V%%(@C=#$)I&(3S34_:7_ *->)!IGT,NH"W,?O#/<F"=$DA]X
M:YMUZ;Q;8XG+%I 0P5COA4[AZ(N$N7.*^?<17<I<6F"6M/8RSAD32UJ5UY3V
MPS(E/I+T*:-I=?:B,G@=-!(Y\4XI QH<Y5>6(5/G:YH6I^'-1DTS5K<V]U&J
MR#D-'-"^>G/#(.'B?:P!X965XW5)$=%]MT#Q!I7B;38M5T>Y%S:R,T;<%)8)
MX\=2">,\QRQ[E)'*LC))&SQ.CM;_ "+0VH9*S!I.P6PL9#$LH9/1$)/+(LSD
M+_05PQ"3/;&$1$K6OCC9ZW.GB:QVG.?3_+[^_P"[X5NJEG%&VA^>#FN/+S6/
MG'<2OH3YR."5T;"?$?Z"^I$6-9&_HSNC=.S]KE9U6E6#O,(\F,VVCM@PPH9)
M[$GZB\MC(/6]Y$[6.B]^-?=G>OLJP>.6-SV^W[A*-E6A'[/Y8_C\#2K(R\2Z
M"R JTNK*LK#!O8-!JB5^8),#1UB),\^5LDT<,,;)F2P1L9!ZYFHOS#E>Z%\.
M1]GY]/\ +T[JE*3B_,K*2783&$OF'EA]<Q?RS86O9Z7SJZ!(G33HW[J\I\T7
MV_X%$ZMD3J(T>6!D5DRN0PW @$,.589RI&"#R.:H<;6R<#:<G.,#')SZ8[Y]
M*\L/)V$K*"]W>!@U&9V^>#N+.JK-AE;(.UJ+D!K?2&2DP<Y3(#P8$B2R@E*G
M^5M BV1E%#M2>3Y]\1Z#JGA;6I=-U*WN;6:)$NHA<QO#-/:7&'MI]DB(V)HW
M4-Y2"P;!Y%<)#=6=UUIK"\M[ZWAGFMVN;6=)X>M%M,B-)&2N] V6 8E2.3WK
M O?\;ZH"A;F;(_229026<B*NK;"QFHRAY9U,C+96>_,#!,TOR0])H%=%.]\K
M%<KVO=+;ZD[QG8PV-@F%F.$.,[@FY0%).<D=\<G-;-9L9&2,=PW;(.#QGCG\
MGO41B4MSGOHI,>DV(P&?<4?4 0VEM7/"D+'>]_RGME1?3IC&2M:9- R.4@5\
MC6O7[-ZV"W[NH6-B-H8<,V%+##%,-Y2?Y@]JD$[]E()_X<G&?UL9X'[#G[#5
M:HC>2>0;Q\<&GW99&@-"MC(!=!;QQ&'#R00PGE.::R%)88*X&-L\B.>**&'X
MD:@T2QVR7CVT*[KB08&3NE(=\CU+,,D!1CC(VC&>*O>;I+DOD\#ZW=AVX/?&
M#CY]JVS<&\9Z*CS"G:^YL]+;3S3RL+,NI28J^M8Y6R0+9DE*;+&A3%16-(8R
M1C&-A5L+'NDX?5;_ -ZN%(=VVH(P969F=5X R<9!/(&,? =\Z:ZN6E<>4G@>
M8@X[=LD_@,FMP_:'QYR-8<6V\I%AGW9ZRL76>91"I5LY)IX6(<RQ)!(+B45R
MQC2@P'C1&0R2DO<KQR&/Z]K]G]EK-AI3PZE8-86DSBYL1.K17<JS(N^7I,BD
M6TFU7@>0]7ZP\\?39>@T*1I+5F'2,6\]-HY4D)) +[MF=GIY6)<?\NVLNJRF
MV>(K);&M%KGN'@>PRLL24\VDCW1L B!EK%E9%,I+O:0@])%C^8<C6>B29W7?
M8Q_'^/P_/I6[JSG4UOI;D9@;!)K2,>(XMZE10I*U_MM*)B(<0^<IR.D]"R)%
M&OHF1ZPQN6&6-SQ\?7X?GY_'Y$TK(S-5,]-6(*3*V29\SB'LCEFFBA<]D;71
M12S^)9&JZ-97/<UGF6614:B>/-:5<'2E.E*=*4Z4KCDFBB8Z662.*-C7/?)(
M]L;&,:GJ<][GJB-:UJ*YSG*B(GW5?'2J$@ DD #))/  '<DG& !Z]O7M6@;N
M*F#T'Q(N&]S43"W7'P?)?#+;7>5I(YV(I[BB@LHIZBXU(\TE+57<)0X+(JL\
MT<\B8^NC&&ED,@;)XGJLUL?:SI,PO;$!;&"-E-U#U=QBOCQ'NW' YQ]Y(%>Q
MZ+XL\/CV,ZWI/TG:^_/JDY6/J!@ZM)8E2C@E.&5U<[L*1@X(YVQ<!5UB!R)W
M@&G5YP0=]W(T]O1EEAD##7-4WM?[;*EUG4SS1,CL:]MK5V=8XT-TPZ6%:>$L
MB$ADQ1^MV(83:HQ!"OJ"NC$$!T^CM/7>I/UEW*RY&1N5AG(->>:U+')8>%E2
M1':'P_)',J.KM%(?$7B"81R!22CF*6.38V&V2(V-K*3DWUL:T%.E*=*4Z4IT
MI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E
M*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E:?\ XBNHY3X5SG>_SY@ZZUKI:SL%
MQF5RNUB">\&NULG*G+PMK+7E.AF%DN\G2:X#3?+RLDC&:\ DIB#2*[K17G6@
MO+^\1&V)HR*DF#L,T<]U(4SSRJLK$ 9P1\:[K0DLM1L?#FCSRH7F\93O<6X;
M$HM)[/2(1)@$,JRM%-$C@C+*P'(K4K^QG.=MOI=OW(\.'MKUQ(.$P.]%C J@
MJ]H>JK28\02=/,'%"I5CI:*.L=;%%^\38%9YA\TKBYCIB-=X7N)&%W"Y!1>G
M*IP!@ON0CCX[ <GN<_.NZ]LUG; Z)J$:A+AEN+*0AG(DBB"31L0[-AE:23D8
MRKJ#G:"?75UUU>%TZ4ITI3I2O*K\<#XOO,G '+:]HW:_HV8#1Y^AIKOE_E >
MN"/TH)FIKX[BBQ&22W#+ J/1FS*R]N]' *39R.NZT"F-I9ZNTD-YG7=9FLR;
M6S"^\;%=G8!C&K9^HI!!8J,@GMD#!S7L'LY\!V.N6YUC6BSV32R0V=HKO&)S
M$"CSRM&5D,*S_HU567<T<A)P!F[?A&?"8X,W6)XY[\NX7%;*\Y7W=[8\E8?"
M;RYB/R-6&MLXG+<BVE$M)6V-]?Z2>";9UC])96E,X&VI[:.K>8@Y4-=&TM#%
M%?W<;-=RYE\[9";F)5MN  Q&'YSM)XQBK/'WC>Y]]O?#NA30VVBVB0V>^V5Q
M-((K>.*: 3O(Y$*D&$F-8WD1<.Q!.?3VC6HU&^/T43QX7[_;^[Y_'KI:\BK&
MG4!:"VULTH,R3%R'O @#:GI:(,//***CO2USVM]GWSYW*JM8J2$*K(9(E2G/
MY[C[/3XY/.?3TI61=:'].K@0$D6;Y(,87W7)Z72_+PLB]Q4\KX5_H]2IZE\*
MOCROX]5I7DYW0G=_WF]U]Z$[*[4;<5.J(S0.>T<!N=Q?#V-#L+&:5EPQ:0A
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M-?= 0Z65,$$:K9[C*HEG:U8M&T\IZ89_*$CC2.-453NV08#XJ'/7MD"[SBS
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MM!392V@9H\+GJU8 LDT.FIZN1K*80_ID_'X_MX/XC@_&K1HZ!2HN)5.V500
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MG]GB_N4_J?78K_S.^VC_ +E./?Z Z4^C=/\ ZC:?V>+^Y3^I]=BO_,[[:/\
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MM:YKV@L(F%E$;&3*(81$P6-?94,9(H(XO;EB:SPQC7-];'N]QRO_ $O5X77
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MN/J/-Z\?(]_F/37.>J[NF A<8!&=H'ZV&R.%)\O/H,CTRSX?[O.X2HDHK/\
M*T'38N!T@#\AI:.NDFBK!(_1!!%HJYL5P+9P1Q^(2C+2W",A;%*H<+E<*S=P
M^([^RV1/_K"(0/TN,[,_5WA>IN5>%+$C(Y!KL-.\:Z[IQB@>9;ZW@ B6.X5
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MCN$/XVH&P/=$6!*TBPC)&:OF.84H1QZ.56/1%5S$DCE8CO3)X6-_6'-?7J8
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M$]3X"982FQD(JM<\>3VW>6KX@"X(WC&X!E] 0<\C\/B!6+TRSGWA6!>,,N[
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ML+*<O);4G9]_1B!9I&E!:=EE$L;Q2)AI3TXV61_+'M()!#>50,=;-0NWJ.0
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M1E/3=T25F9T59 +S<RE2V%GQG:H)@>241W#.CHMU!,REBNW>J.T8 5BR$V^
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MEU_2"U@53;.\N55- $I:J >5556Q@CHOGT>5C,\Q.3(V>F\6<_\ ER%F=/\
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A4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g686907image4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image4.jpg
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M&)47(90*&58C.7B6M]0B.%5WF+.TM=4D)C$R-D=7=78E-#5!0E1TAL:V_\0
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MV]Q15[5K8^K=1XOKLA1=,JZ.-F-EVK!XB9W:[Y3<-HZ6D#%"2/TE-<9V3V'
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MK5=O0USMMZ.OX8_'/X?CS1E,D4E/K*9F?]<SO.OK"EBE2TAOP4L%AO.\\5C
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M$7-GVSU^X@L^W(NU'['1Y'5 *+]AN<.%4%5G\:\MYW1LN=8[;:^U?C6%2I:
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M6*[.,NX[-8_F@77L=9PF+&S:W96LT5F0:C0-XB-(-NO5?5F;AUJF91!2=58
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M63SJLMKG51+K\DIK^&R"&V/QTWO=33.=5UM<YUI+7.44LYN3*F]0VO\ FO\
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M1T^%;[C^87K/_56E]N^/D?>^LU/\7>ZT^Z=Z0^P>I/8QG\1T^%;[C^87K/\
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M8_JT^+>J#R863\VXO]'<?-5:^V*_YHSWVGR@5]79[8_JT^+>J#R863\VXO\
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M8_JT^+>J#R863\VXO]'<?-5:^V*_YHSWVGR@5]79[8_JT^+>J#R863\VXO\
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M,1498>E1IJA8DA[166*@X*"CT9WU$-*R0D4*\A(QVD@$B)6_<$!(H)DAM/*
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MQJ'>LV,A;R,%6?%1UBZI*E,373=5,316@5UALLL!/(VF$E)"7@Y%0SMX<N(
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M9JTG),0,<N$6%9&%J@.T0DLFDGMF,"/<G>(+N PY[<^J1,9*(B"GRWU&5O\
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M2_=:?"=])?,-VG_<ZE^UO'SI9G[/QGLVOWG3XAJ_C;'M+]UI\)WTE\PW:?\
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M=S:2#)963"$\@88Q.NW;XGLF@LH2@]=51B62F3=B^OM'1H69BUW,#$);7-0
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M89;L]4%1^D[0/2.-QJ@I@W@]T/IF!%QET_B*5<'55=9"X/)LF.&C15T/=O\
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M*+W??T+JZVBTXETOH&+2:*#ZQ?V%856ZU)(I<Z>;PMQ899JJ 2:'V\'.S@I
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M1&5FEB8?7ZES/5 +A5SLS>S=&KC[2"B;O.:BU5%F@(.'"PCECVCL,9^3^&M
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M:R(Y*F(%@,88CM)L[<"HHF9Y:Z<70O8_&7*W3E#*W5X;I5"<<JY?K+LU'QF
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M3C33C33C33C33C33C33C33C33C33C33C37RSHC_[*1C_ .G@O_=K;GY)O?\
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M\$)$<K#=ZE#(BSM, YG<1+K%\-[MX=H;O?,.M5CV],;@ZY=]VK3LWTCNBPI
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MUQC76 ]LM==<8QKKB^$<8QC&/PQC&,6E^&,8Q_+&,?RQCFM^+.HOQ5W\X_\
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MYXS,3 >?FP#WYMWF(C<9Y3.T?//\H+.=!V>GL116I-[J)M:I=P#:$@@L7B+
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M=>%R2I<#R2!ZBZ1^$C6$E.2ZW'EK66GV>/=FQW:$!=:,HL!..1*51N8C24-
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MTI/M5,8&U"U#1]*VYNE6D,.EK/BM!3*3RR'O8X1/NR#>LCQ-I,Y+%9,Z2&3
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M\W?]:/\ PR=?T8^ [_HLZ4_]'EO_ ']E-?0TZD?\5/K)_H]TO_LXC?/IE/\
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M,C?RCCK<W>D<#BBLV*5NU=J7<7U!:Q3"94(G4L#C/#9%S1.FR &[G?%HI-5
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M0 RZ'0O=2-?:)@D+D.((0R!(EI@29"F 8\2CT9C8Q\XF=]A*8VF(Q75=:_\
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M?-Q[F3F*'-E <)K",[AG1DTG74N(5QVRH3L.YU0K^,TM#8M5M?R@+6,N!HP
M('FCN-OCK% E,IV@Z>%1_/1C+4[295RD04/&9GM'*KE:S/WL*ZP2HQ28]H89
MQDHW-F\S'VJ>ONGEDT:R<VE3[F2LPT4IF_4#(]*YWI\9*_9S%RSD[]9V3J.F
M^YM,+"T&2Z=*1!)R?*>CUZGGDDG0LO2\<F,RS=Q<G!<9<2:!1DA:5P=)YAI'
MXD:EE4F&.5W\2ZMR\D0LLM4JSV-7'8;6?B*Z-Y&*(9F/'V"DV"2!8SQ!2O\
M"6$N=0/BLC24>85#*6DG<'MAD*+;6MJ]:81 5Z+4YBQ3J1A4JN^C6O6%XO$]
M9U._:35RBCXKM]3U%KQRLJ(6<1CSH-R".[!:T0OX>5]%(9;@?)^K%35N1SNQ
M%'"QN=SD^K&&7:>DJ?B $UO)W%9-GLN,1V>U6X2DC? "'L",;DR\D#>[GS!.
M"N(IQEB5O'DF2>&0"9)C"D(N5T )<^S$F0L3/..*XD#DAVF.W-U77V#5;Q+8
M1DQ3B;/1EL132I(&R?3&:RUMZ8K#DB"JFQ0R8S6+OVS78K#6=W%G-T9'N[HO
M()%6ME:#WH9H8-VAW3M4L3A818I/"\;OZ@+FK./Q\*S53 8D4N:O9C#,/ 1"
M1!1!)O'46+>1(J-AJVDUC'D2F[2,$3KSI(!W9(6:STB(Q/'F<2Q>XD0Q,#M!
M1M&M?A>MD5\CCI8#C2C&]'8Q2[CX5159P6>P^2>]QCW_  ]0PIW(%ZZ[FKFP
M3"KS!,&9"Z;BY[*9SV@LZ456(J8980ZF8C&V N&V5!&9=U (,>%EBGN>VZWJ
M2>NT&VIX0+;E'U>B!J+5@E%PSV0H1=0Z_DHBPSMM-(HAHH 8A;5Q,K60E/%R
MD,G;E$1,J&-HX#)0'*:'5[*-:ETWC*V3;E64#R]NPQMS'7B4-^ZAJE=W%9'*
MT0DI2UA*"^UA&967!7*S"%U^D'AI3K6!55"8T0KM9HPZ8U9U/L4;F8SFO8T&
M)P?VQ6161&V,*A[@S8*<N=F57):.NSU/GGKJ%0@BC8 @@GLX$UCQ3.VE82O:
M**:;8YL6(RO?DT( ))G.2WD9)!S*UE#(F-QWZ/A&HS?REVRN^)LZPR?5./;X
M.E?LN7=XQ7QUD[EL4T/" F!38%&60 W;JRH.7/%N1LOP_+XM673C8S.ZZC\9
M/D^WZ(HT!?D&RB4=[(5Y8\-BVRE41VLX4$;2.-[2:+IV8?-V3/)):SD::E6L
MHB;EZE&]O6XVPYC-V*$"*[Q(9F/1M+: _>12L8(9,.Z1-83MB/D$SQU#C>N\
M'BZM+LT<@^RA?24M2]8%$V.G<ACK=J(REC)7'%7L^&M3C4)QU*MBQ:FKX6V(
M39UNEP=/[WN$7)'^8EU;K:0RRO;]JUX&A)68;-&0FV.O8JIP4R+SO^%88A.C
MH0['Q31&.KP2)-0%?>S"F,G-O ;=$G(ZC8=!3PIJ,UV4R*Y/:!=5A(G+.R,L
M(2 8@96$"KT8,I&.53$=683$.KA%OJ;(UJM_!9,&W55((VXO/LRKZ:J/QHY=
M%#DO<96!O6S??DFG62#R)7.M?P_)59)F_P!HC800/ +#KF3J5I&?8RBVL5NZ
MTH]!8I;9\ZW2P@W5AQX'50E)KH*6P:=[W1?>I%)/0N+V<G8PVE9B&B*V*/LC
ML7H6' L'$7T=LA2.T#Z7W^SOMN.^&*Z\K8Y&!*:#FW\?D*T9*S!K'Q6&QEB[
M:Q2$%.Y1<0[*.DB;'9",/@NW,]IL#-=&=<)O!X%V&82O\LB9;>3UVYPS$6#-
M;-8LE$JP"5X.)'YG*(I ]RQ9SH'1U<*!*UC"3"/, (9?,C>"MC#JQ7JL6JR)
M\8.Q,SM#6.B/O(JB288+Y3/'_14.PP(^G(\IT^;ZAI7;^ .KXEM3"  \FT*>
M-,XG)/R#%HIUK5Z%*&7%(P[(V9.P;W#X<&]H8;Z<=+9_0<ZKN6&HW3M9-(-U
M^5IB5LJCL*Q[#6NTSJY@"X292U.;P6O1,.TB:L4D[L0,##)$27<SXFAM(60Y
MDLT,0T:+:[%&0H5"ZW8.$M:WQ!;JXL/N+7 <.!R(C!S,MGTHB-BVW5W6-#.4
MLC538RV2.]GXS-4\K0Q^/C#)D;POJ59I7K[;<VHM5@<US*ZX&@HO#FPX)7BL
MWI/:4_C5WU6AFC6D2LB97I8X:XC+21'+D]YW$Q=Y3@;L*G'AH^,@A^[_ $@1
MZ:#; DKZ1TR#8P5.#B57^2@GQU!S0L)_D\ T[#1>4&3]WQ/WN1XQ #&_;,X8
M<F@87VXWY1[C>LL91LX7*%\=%:QU3"8]V)05=&([6(,-[P.FPT[+SA<WD4V4
M*P5\P\[\W6POM-C\YX?%N2V,6-EX7KV+2BQ6%T-'K#-B6)935)U/>OT=IB-%
MBLS-P:'Y,$4W ))4PJ*K>):#XLR !]=)21%;EG<4XQQ"V9)8&V'1,=UKH^^5
M@0)$PEKY3N/GQ4&P0(^G([SL$]>XJI9Q_!-^U6Q[,.:S^+\?CBD*.>L9BRI=
M1-VYV5R+YA(MR-ON6C>[>JMW:"Q=.=8K.KCLU++/5>0,/6!5Y>A1(&&/G)<_
M-E;CL0'/<$A0"<0=8Y2;Y1V/<O[,8P6ZI)7]GRWU$FTKB'93$#XW:14:JV;M
MUBF?$3 B1')$]HLW@6+DJ\[Q,MA5@EN/8^TOT8#GLOU)C<ATW5QL#>=DE!A%
MD]R$U 2K$8]U'M-?2NPC,K@6"&-.]AJ^0QE3>M\8VXES+-_.;+7"Z<::<::<
M::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<
M::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<
M::<::<::<::<::<::<::<::<::<::<::<::<::<::UXK$8J=+QR0&XT ,'H<
MZ?/HD:*"![\K%WI1CN,).X\0=-U789R0'**,'JXY5NJZ9[[MEMMT=LZ9C-*6
M,4TU+-B9*4L(!(U28\3E93$R$F/HEQF.4>4^6I@L/4MR5N:M5B AZ@88K="R
MYKAH#,"R /T@@XF!+SC:=;#R34.N S'I,G!1RFHNIN6?)D%]5M\;IHJI#!PK
M5)KKC77*2&41J*VR>V=\Y<K.5?2QA3&FCR\MA$9_TIC?<YWGTBWF8Y0/$/1@
M8X@/EON4Q+4*S<<24R]L-*"G>!*$J1L$?Z(\4B4QY^F1%].T<_C4NG&FG&FG
M&FG&FG&FG&FO4/\ &G\7[NYTH[J.:3H.9PT% 4JK@4KT8G*\C4E?8,']S>"2
MV295LJZRBIABW]6AG?U:7H[>AC'I9YQ>>S=_'W_#UC6*^RL]B4)SR*2W\Y\_
MHCRU^KO@=^";HSK+HX,SG*EQUZ<G>JR:+]BL'91V>W';7,#O',MR]<_3ZM>R
MSTPLV673U#ZOW!/735]-[1H"HK!E[UBR;C6;N2R^!@CQMRT'-==&S%NL1?N%
M$6C?75%NGMJDGKC33&.=51:=BE4>S:6.K(:<Q&T29K$BF(^B)F9\OHU^=.L,
M;5PW5G4N)HB04L9GLM0J 9DPQK5+ST)$V%Z1E"P&),O,I\Y\YU9?EK7.:<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::<::<::<::<::<::<::<::<::^>E_:6?\Y:]_YB*I_P"LD_/F
MG5?^=?\ ]V3_ ,3U^^?\G3_HY7_MO*?_ -/KW5O#8_S>?1O_ $2NO?\ LJBW
M.\Q7^;,?_P!2J_\ <AK\<?"+_P"7W6O_ -ZL_P#^]+6KK\OZXW3C33C33C37
MAT<-U%5D$UT5%VWJ_:$=%=-E6_KM?32]<GKMG=+UNF,[I^GC7T]<>EK^./Y\
M;_1],:]D2B(*8F!+?C,Q,06WE.T^J=I\IV]6L 3DC<7(XN <:ZZ[2G!Q)DMM
MOC7.SX.R1)^R::Y_]?=8?H1=?AC_ (6$V*FV,9UQOG6,F0)K"?\ SG/:?[QB
M"V_WCRG_ ':G77)M>R\?56[,G&W^@TY7RG^B(9*Q_P!9Q'TQK9>2:KZ<::<:
M:<::C0#=%.RJ4OH-&+8K21S87E;!.'@9W%S$I'9;9SAQA]'QY5P6:9;YUVPM
MAPT3REG7.-_1_#/(1LUS.5!82;(]:Q:LCC;^D(*2CU3]'T:ONQ>3KUQMV,=?
M15/;A9=4L*KGR_!XN-8K+??RV*=_HU)?)M4-=1'>KQ/))T^NY_48*HZ<F3./
M=7"G:(_(K:[3#^NZY$.&F4@B3N!5\-*U-/6,RG3O 31^&%*&P>2>SG=GCV?V
M?#E;67,@55O;%2CB*\V"EMF$;P)2/ -UG!'.V\1O&_JUWO3/1:L_C0R#+^0K
MDW-AA%)H8,LM ,962\;5M@7ZI5JL2W@P^TWAQY>>^T2\"\5+IR^#D'<CFDQA
MAV*5;5%IV;&B]07 15K%M=,(KN=5U#I-(H_ BL2=6%+6%HQ,3%(1'SI>32V3
M.'T9C0LF?$E!K.6,C5F)DB,2%:V,&5-GMPT -8E(A(R9PP8$(F2,MQ&)*)B-
M>WHCJ 6!":]>PI]Z]1I/7D,>$72QUFW6MV$J;:78&H@J-AC[+5+2A(BYQ@HP
M,MK.>)5TYCL)B\Z)6/*<LI89L8 RBHVE+S.6H&*4YZC:WTIK302MR%KP!O5:
M+MDYL%_-H: 'Q5H1%.BKI! P)4>Y3D*H@)RPMBDX@82Z61*MN[R5"Y:$+WCG
M)@,#$Q,SYQO"KH[J!UE]8*:.2%TVD\\EC%T6!D-_B^:V19<&A:F],%%0:UEI
M/(#%<3*S@8T:>)1$G-WR2K5H[&1L5!]BHQ2 J>O)C+7RTT!R/I@AW"_.D8CT
M;JF0-L/V@958)K')#)  MZ''O)$UF.QQ07!B<<7QEQ*XC B\4P?,IYP53Q7(
M1%<QO$>7$BB)&)*"Y;!-N>C[$8U-V'.-S<0_)G5&N@8K,3U%/3_AW.=?5/ F
M1#>\E+6"PQ3-;M0RT'E)^*SU6.UC*Y_3LU3F#N- :(G+<?8L'ONF@\CK6_+8
MC53Q2P(N7/T>7-2R.KG3;T2V)PZ)R02A,!N(O*RD01W(FQ"<E6)9&H^4Q"#V
M,'*@EO:*Q,9),R0[E,1(B4<XXE(^<P#H?.*N)JY"MX<6MRE8CJ6<7D6)N8J@
MZ^^H]:LDM:'0I0F06'I9-<^^A=B>"F3(AX@_4MQ+[)A2-DF%2E4#[+?RPHG5
MENJ0QTI3*S5K; 2$S].";P>S)97CQ\S82J&UQ()5*AI%?W=L'V?(N6Z$WC:W
M)@=R=U]SE/;;PW5MW!!G#@PES,00K(BB?*8WWC6OGI3.Q7IV9IK@+QTP0$W:
M$6!^,8(J#+-6;46:5>V($:+-Q2$&$<X9QD9G06'B-5/-K"Z[0FI@\BEB=R]A
MY_URG>)O&K$I2;TQ,(+U\E?8'=.25A:5?1^9.7A4"%CZ+1B091UJJ+E;0^R*
MO]&FP]S'%Y1F@%01=UYH/F)J-1 @W^DM@">\P([1,#&Q;Q,[;:M'TC?K5,M9
MOL2B<=B:F7K>&=4R5;(U[>61B8E-VC;;6$5M8V2("<4&@E$ 27,=UOCO/3_6
M^U24,MF11V*PR(4>/NFQI6O_ !%,26+,9E<49I*K&C&&1*L)*./L9U-BQL3A
M=*:,I..?!$LMH88"N2IT!FZXI#)%A"( F&L+[Y)#!M%*MA%904&<E'X<%$C^
M#,;S%;%],Y#,4@L4$M?9L9(\=41'A%I>5?'NR5XBL/NI-1U:P*/C-8DF#9WL
MK8(*;O<)[C=?K J"X+TCTKD2==4$1L43<+B0UA:<1EL#*52 0E4Z&F*UE,+#
MV3DF(C3ID:2%LHFZ)%&CYGH):/7:^C;.86D&IKA(NVGG#9);0()6/(XE9!#-
MX':=H&9F)C:)G5:ST_E:E_'XQR%>+R@5&8^%7:-A%H+S916-=Q%EE/@QPDN3
M)X@!"7<(1B9U%5D^(11,;>A(O7TI"3^?&)[UKAN(\NPM4<)1T[,8=2*%IZ2:
M*U-8#-::/*N"R6Q14"4;-B>PI@'7F+R"Q^2#9-R)EY(S K(6')UPX[,V_E'I
M!Z0K..<K@C$/*=H'E("4%J[3Z4RC@8^TAE6J%7,6.]!43.?B;BFQ,H??J%%<
M;K$U#M04AS-D5QM-2:=1E3GBZ]0+:"0@JN7L6 D;/+66I749E].6^D:/5U65
MAL:]*W"268P)T!BU9[K%!LC?RTZ:;1^+1W8VK*RP<C![!'1/!.3JM$)W,)9+
M.V)*;O*UL@);.P<17YP4D4\1'?E,2!P-W(]!Y^@VR$+J6@I!2BVZOD<?*U6[
MM0K88\(*T+7W(A;$A74LG/;"X0M@6:A/LQU\[I]<^T1<P!IN9'#!@1%H_/DQ
MTJK6SZQ=2.N98\)#XO9D&3LZ'1#,_K>0/Q!)F)G<+]^QAVX;>KT)_BX:>T3H
MMHLS,*(IF!$]B6Q?("F8%@=P YK*8F(,-Q\O7ZM:;*].Y;"@MF0KJ6MCW59)
M%RE=A-RN($^G:FE8L>$N*%@$RK9[3Q$M^'D6T:D_$PZ9 E;4TDEGR.*HTY&2
M,VF1"54O>4;%.H2&L0=4IJ900F9K=DQM*)A[(+#HB4D-:+RP2Q)/$%5W6C!3
M5YG"<A5B603"'M#)E)*<,2$,A1$$RN(8(LF!DE\HB9]>WGJX'1W438I2FDE\
MY!P5JXHR.,<<664SOKKV@7<(J+V4P.P";L5V$ S$#SCCKRZ>)1T_4CFTA3GD
MXW=8MYQ1.L!UH3L!FYU;1:1%&P74;0HK^%_\9%]&U?N$9RX-(P;<$C%5-2ZI
M+1O^/X/'U>/+F>_=[/#L/[O<X=R1[/;[L[+].9X;0/GOKR>C\_#>U-6MQ^+X
MRGBOC3%?%T42L34ATY/QOQ=&]N)JPN;7=E\=N DM86MN_<7F_AX._$"D  -
M8PVK6S+#S'B\G.E@B"<%D$LCH=J^E$?@!&2>QR9W'F&ZCD-7!PP.P8]0PCA]
MVU2;OL5W1.A-XA@![;#XR12,<"(8W* DMBD8]03,;^0S,><MSI9];JP>E5-9
M:>5RE4[JT*!DS:2AS)%+;0)Y(%Q1LRXI9]O<W*$ID=EB/B%=:9!9D<HDC,B
M^ZR<[UIH['QU<W,0@ &]F=:(6J;J;%QE*PCU>N9&TB67I,6V?%0Y(PV&OD=!
M+4NR("&607JY,%,G,.Y]HHA;I7#H7W)5W96(<N.\Q$S$S$3Y;Q,1"_I3,JI-
MR85P/'!5G(*:=S'#:;C)N317>G'A=;;%)6.(&0K8"R,9[A+(&%>+ES7-:<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::
M<::<::<::<::^>E_:6?\Y:]_YB*I_P"LD_/FG5?^=?\ ]V3_ ,3U^^?\G3_H
MY7_MO*?_ -/J-J@_M OB#4A5%:TU!R%.:0RJ8+%:[B>A:L\$"FD<AH1E'PVI
M%_[]0]M>ZCV#?#EUZE+UZV-U?5Z>EZ.(4=2Y.NE2%RCMI6"@W5O/%8P([SR\
MYVB-Y^F=;#+? /T%FLID<Q=7EYN92]:R%J59'MJFQ;<;W2L.P7 .XPN([SQC
M:-YVU(OQ*WB8?\IT9\J,?47)?E5EOZU?\C_^5K7_ '.GP<_B\W^E/_E]/B5O
M$P_Y3HSY48^HN/E5EOZU?\C_ /E:?<Z?!S^+S?Z4_P#E]/B5O$P_Y3HSY48^
MHN/E5EOZU?\ (_\ Y6GW.GP<_B\W^E/_ )?3XE;Q,/\ E.C/E1CZBX^566_K
M5_R/_P"5I]SI\'/XO-_I3_Y?4<U=XZ?> 9W1CO:,\J$FA [&8C4MA4Y%0[N/
M1&TH.%.FWX89H':K&%&4^'OY67WB,M8H."(]ZZU8[LB01^9"%HD]0Y"+X6RX
ML(@!+$ ,B#EB12,<8DMF1)SP.(WB9VVD9(2V&3^!+HMG1UCIE$.IK19MY6AE
M[3@L6\7=<A"W,EQ"F#H,755%NH9"M@#S@UN6ER?? MTY*Y%3M2]@X[!YF&D=
M:&8;>A&JCHI/6P-(B3B9>.6I!B$?%NB.'%@!JRG<Q7#QEB\=^W6&"""$W&V5
M,*Z_0;1,*NBV"V0=<PM$B1W;*Y6:["I")G=HH:R1")G=P ,>>TZ_#N-36KY7
M*8-URH^O?7;PR\DALS0*RJTM^-NJ>P5S%%V0IU8.P8!QHN:PAB-QU9J+R>/3
M6. I?$C(^0QB3B6!V/G13A-V-+ARC9-X/(,G*><Z+-G395-5+?&?_5VQC.,;
M8SC%U; : ,60FM@P8&,[B0E&\3$_3$QKGK%=]1[JME1HL5VFEZ6#(L4U92!@
M8SZB$HF)UG>9ZAU7OLUVGHGI_5Q.X.P4^&0.%CU=6355SJL],2$RJDJLTCT7
M!,M%R9\X]T05W18L&ZF4D$EGKU1J/;.G:-2[>JX]$V+;84N)VCZ2,OH!81Z1
ME/\ 1$>4;S,Q$3,;G!8#+=27PQN'J':LG'(MI@%(5$Q!.L..8!2AWC<BG<IF
M!"".1&?5Q[W^.VS[8=&^U(GJ9&[!JIQ&IK3L +S,\6&LIH8JFT5+ 1E,@&"
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M *P97]ZU$,&\)KIK7O;U'MW%:AKV,&XU!HY%:SKB&0.,PVO(')!9"0OC5II
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M&41Y]$)C'2WY,(1R8Q(FNS=OHY(QF\ITU=L=GXX:59+HJMB80Z*$2("0%GQ
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MMM0,^L7>K&TWC(BTFD.BDQQ#3DFA*AU0)/I5.(D#:BEP4F.C3)1V4KHBL1$
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;Z!@BF!'U".T1Y1K>>9ZK:<::<::<::<::__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g686907image6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image6.jpg
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M 0$! 0$!_\  $0@!  )= P$1  (1 0,1 ?_$ !\  0 " @(# 0$
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M;0@$,@&)<NO<KVJJ(WY%K8Z<::<::<::<::<::<::<::<::<::<::WR 3\C
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MR(;J;&JRF*0B:2:01Q%UJJ^89U0>^R;*QC#K+,F6:O>4*R;4AA187#-N,3R
M5&8\HYK6PS")WF/*=N%P_7E3-W:BJ6$ZBG%9%]RMC.HYHI/#7F4>]W3@D6W7
MZM9O8;%2W?HU:UF0F%LWD.6H73T[MRB*8HB\YIM&EXA?HQT1 ,P9)Z^/Q!7
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MHD\>>VJIM);N+FFHV>)6TE61JM  ,>+23+IB"*-CX<9%FWX);><[^6MZ5](
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MA"$6Q]=?!H6$([:.;G7RO3C33C37RW?%G_SE7=7_ )_IQ_VW7GR+,_Z5O_\
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M:R#HW("@;*I1$+JK4#E]V'E"Q6H1DI:,&1KCG,QM);3,:EI=/]%4#@4O6Q^
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MQ_3N%Q3T6<?1"LZMAJ/3]<Q;8/LX?&FUE.D M:80"C<PR;Q[[BF)>UL@''9
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MO6L.?:W/UA[LKEH ;5@8@YHGOA?MWV..8N_4A:1C.G8\;#@]U:,AL>$IS@1
M$T6\1%N$Q0=EH''!V:"8_1E'-0[9X+RL+().QSAPU5E+(7"\3N\O\\%8V=H
M>Z*O)8SQ&.(C$<=@XQ([C.XS,3KT]'=-(^ NWBD__NRVZ_!RQMETT'9&9*XT
M9<\^\QQE+).SWB!L"U4@P1*/V=[>]B))436C#-B;N:W;1Z.0[=@E%X6QDA.%
MPY_DK$(3(+"81QK8<EA45(^B\CL0D$I)QP*NBUW'#&_L;3" LA;*OX4G?>>
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M)+31+3336N1$929S)$4[S,^V9_\ V_P]D:W%>NBJA5:LH$H2 K4I8P(  QM
MC$?^V?;,[S,S,S.L+S'4VG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FILB,1 14
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M'3X5ON/YA>L_]5:7V[X^)][Z34_Q=]EI]T[TA]0]2>YC/XCI\*WW'\PO6?\
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M'3X5ON/YA>L_]5:7V[X^)][Z34_Q=]EI]T[TA]0]2>YC/XCI\*WW'\PO6?\
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M-N+_ $=Q\E5KZXK_ )HS[;3XP*^CL]\?U:?%O5!Y,+)^;<7^CN/DJM?7%?\
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M,26V_L\O;JYW]U" -]_2/52 760E]*[]8L]L(K?&T6% '4DJQ[U];VW'2NP
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M3_=.H/Y=U%IQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIJ_G1O_P!Z'_\ 2?\
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M5Y5QR69KJJ#9KCWRE:Z-=4+0LB,RG<Y:)%,1Y.1#:0A'WN(JK$"/E]YK&3)
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M:20HL8M 5:[D$_DY.ZV<XAH3LR)\Y&8*$+PA*1A12E==U<AYQ!E#R*3,2XS
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MA!C.VC+XA[B%0$P^VE-XVM* $IA:@,RVV$9GRU&/<?Q(9YUD[%CJ:85W4C
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M/HL8KFZ^\$K@Y6M .5:JV&3'!/$MI9_$*X>S1<P5F<Z9S:1D!-(5O<MI@X;
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M>+P6,G'9!61\.PNFV7&XJ\PJF1K.FR$W[2[*X;%*VAI);5D=IC .?"KIUY?
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M7^&KDLN&Q ZS,5E,C[V=B80)2V>&L'&NW?5R8G1$8BG8&I)%(3YA&/A0X>=
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M8VHENDWZF29D?<,M%4B^F=?SB@U48L%=,:XCGK\J[)E-<92VLS1G>9[D1N5
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M=H;O?,.M5CV],;@ZY=]VK3LWTCNBPI _D!!^XE0_=TYK\H<,/'2Z1M%L.<0
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MDJ]UGA7B4LR%BWENG\DH%V"MW;5;&7G6,==8*B*6TK LH,^^;"2N"V%_-VG
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M$S)FX]1SOV:K6J+'!E"2S,*5P/UC#>U&HPJR:I%MGNX5V\:.=-'*;=*,,A#
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M/WJ]J1;F+*E%DG82NZMA[6SN9OLX^Y/<WLE,:0-@0X2PZGIP0XI>\K5UG5P
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M-R:L6ITV\:]&(G.7E-\,!4NGZ/6'56.ZA7P\)6=9R..JIHVE39DWR%>^LQA
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M:=,C20ME$W1(HT?,]!+1Z[7T;9S"T@U-<)%VT\X;)+:!!*QY'$K((9O [3M
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MM1VK<LB3,,F/EMJ]GQ<BC2[XPFW;8V19UC#9.1BT'2:YPJFPT9J/%=U6B7X
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MX=X&P*NH"1 U7P U+7/8%[#[%G@\9B9Q_60E:EAB>]M3-VWT:N,0*/>X29$
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MX%#1UIKGXRU"FI6_!S./NG,B"O9D18B9T]/)#-1!$5EA.;R;R@G8HEI(260
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MN>1<3Y3$]C@,_CL562-BM8993<O.Y"I%@&)NTZ]6!25ILACFI))L:ZM5.Q>
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9(I@1]@CM$>4:WGF>JVG&FG&FG&FG&FO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g686907image7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image7.jpg
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M P$! 0            @%!@<) P0* 0(+_\0 :!    8" 0$"!@D*#PT#"@<
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MV@ , P$  A$#$0 _ /?Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M9E[(AD#$O#H(AAUI6UN"4_6M#%K7C.S0M]G;@XK==H+SP!@# & , 8 P!@#
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M1O>YH!?\\A$=9J?$:X637*^MG1B(-L1ZK1VLX^O=.=4Q!T]@0Y;I$E6I5")
MO2QA2*-Z$HTJ4N1:51*USUK=6F?09K(X2UV1'6R-AE,TVD:N9K[S:(/$>Q]Y
M,L1_M*16PJBQN],NBMPLE\DJMO(( 6!\TU$)@&/1BO1JLP17+NI3[BVZ2X*H
M**D\$#%;^NT^F*D<Y<Z53Q^,4P1GA$9!+4KXB)CDCDL8A3)8UEP>"I)&Z$5O
M#I]+GQJCP@LB]U#(W>)Q)R8PKN)>B)7/=]_MG4GC@@8 P!@# & , 8 P!@#
M& :P;,X62WDCS>E]T6Q)[2KFJJJH6*4[QV44U=$CK>221UL*1.DVY%2.0*H&
M\-SX@:5QD>IR'HV-U, 0[BAJMU&F,( WG#')&J,THBU6JU31D\*\/#E+IV49
M9G%_CN;QNGY&C8W25I6I":$D!K\D?G*4<;!2]=(Z55O@TQQAK<]1J)2!/7BY
MN7%)5>MPH"[Q DJY*I4"%IE3/EW\_"M_5H3LP0, 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M-3"JH7#Z\<VB+DL[<S*'Z.R1]>1#6;-=DT7KX<M^FN14-J>#B, 8 P!@# &
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ME>%[*_\ *#EY=4ATX2ON1LOZ**#)[JO9M8'-<DOZ^@*4R?QA0Q719)@0B\8
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M\R#BO4=J2^]7"HFV]NIFQN;(TV%R2KYMD%<Q=TK)]I"//C])I2V7,ZURVHI
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MO;,ES\&'YW3?>_[5\>P?/RAF0(P!@$(^I-^P*Y9_<1FO^[A9D'J4/[R>!/\
MB'9[_>,GDSW\S3/Z&^_\BFJ_A+^Q*X_?<SCW^PWF1&J/^7;"K^^<W^V,V\$W
MR:6)_=Z7_9$I,LH7#& 08ZD'[$.??SMI;_G;7F9#:E7Y=K%?Z=IOZ2GA9K5
M_)):O?D?]12DVWYN2-8@P!@# & , 8 P!@# & , 8!@AF_;5>DQ]T/EA_P!+
M,USKO_\ !_\ =]Q]W7Q7N\Q_YCUKYUR1@# & , 8 P!@# & , 8 P!@# & ,
M 8 P#'S]6$0D5@U_:2Y$H*G-:HIBSQM\0JSD9XHW/D38GEL4=@%;\6ZQMX<(
M]$I$>UJ@B+!)(;%G<H0#FH(3 ,@X P!@# & 1 M;@[1=SS60S&;BLTU).11(
MRSJ\9+=L6/5/:YD&"D*C&[%K=GD*2,R$M(D;VYK=DVT25)+V1M;V":)Y$R)"
M6\ FOJW-[VWB7^"!@&/JXK&(U6U/C5$42@@,HFTRL23."]6<XN[_ #&>/RR0
MR%Y=7%3L1Z@P:E6%N:TO:!$Q1UN98TRID+$RM;>E R#@# /$QU#.&?+*P>:7
M(>8PCCC=,KBC]8"Y<R2)@KB5.C,[HAI4@0*VYQ1M9R58F$((@A.(-&6+81:T
M+WMY26$C![-[:Q]GIE*)E9UTX@[+04LB'<QG#F#B7<6XF,VB7C*N6F&U1G6H
MQRJ-*J*JJTE$I?L]U&VJMP3X#\%<ULC;A]:!B;QEMIK/W+,JE#,PAO<$9);.
MP#E6WRQ;C%?:_+(K&=8BXK&MM8RX]$AE[0'F[Z*'(#U4S3\SY;K8-M9MK8_N
MCA_)&67XQ'4Z]$VS[FF?20]H#S=]%#D!ZJ9I^9\;!MK-M;']T</Y(?C$=3KT
M3;/N:9])#V@/-WT4.0'JIFGYGQL&VLVUL?W1P_DA^,1U.O1-L^YIGTD7Y7G"
M/F7&GS:]SXI<A@D;3FEZ\14<U.'X0@"#KWM-&M:UVBU]D6O>[>SM[,S U([F
M%P,3VT$PMI.)(S#S)U",0WO7,X>/;57+B8.V\=FKC$^%$NZ7K5,9<U^GC\+[
M;:1ZM;!E8FRF!-Y$/9M(9A&1,>EJG*2"&1T_CI)$,:R^1Y&ZXUK<!$53$9HU
MB)7X54SE[6+E7Z*G)+U-S7\V9GWRPV"[;M>"&\Z/SO\ *!X?N=V+[IO_ $ ]
MK%RK]%3DEZFYK^;,<L-@NV[7@AO.AR@>'[G=B^Z;_P! /:Q<J_14Y)>IN:_F
MS'+#8+MNUX(;SH<H'A^YW8ONF_\ 0%#DO%+EFZ,3D@2\4^1_>%2?Q97C*<FH
M0>%XP OKMZ:A;U[P=_8#OW\IRUV'/!Q.K-S>5P4[8]U1L+K3G76H9V[Q]==M
M_#;]TM8J496^BWEV,!>HUPRX/L+=A;9VA8LJS);/3E(Z8+!3_P!TQ2./<D2Y
M_L7'N-WKK>.]8^#CLW56MQA+7!;FEV:_\U#D)]C7_LFFGYHS5L\P<39IXVTD
MWLO1IMI4_P"..,BJJI_@$1J,\,CV(?O&4LIBO'SUMFL_5%Q6VVFDJGN*Y:+D
M/OM%N:7HH<A/5--/S1G#8WF^V]E_KQQXA\>4PPS:+)_7Z^8CVBW-+T4.0GJF
MFGYHQL;S?;>R_P!>./$'*889M%D_K]?,1[1;FEZ*'(3U333\T8V-YOMO9?Z\
M<>(.4PPS:+)_7Z^8D;;5Z8G/J8R@#NS\4+SVD"V)4F^]5C-B#?'$G*AC^L\@
MC[0^"<#L%H79O?;V?8S._!A;ZR5D[%R:13:=0*1\#!P;A^D-$P[YSCN("#AV
M\1YKK&,FN.6Z+BI5FBYS9!9*R<UDMB[#R&-6$]WR"QMFY',-:B$>.4CI7*H>
M#BD<O,1G7'.O.FM;>8K..S1K%2M#&OFF>H?Z*%U>KB;?-_+@;,-@-NW'9(?R
MY[WO'&\U#]F3B'FF>H?Z*%U>KB;?-_&S#8#;MQV2'\N/>.-YJ'[,G$/-,]0_
MT4+J]7$V^;^-F&P&W;CLD/Y<>\<;S4/V9.(V*=-KAIS!XMWHU6!:?%/D27'D
MA;Z$X4?J&;/"S6W")OC,G\%-Y(2]O:M<$^A_IFO!*V,SW_ WK,)-7M)DU16
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MEGY:Z_R1'^V>DIEZB^!38!G0(& , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@&O\ ZJG[7-S'^X7,?ZL7GH2K\XP?^LSX%.3'
MQDZO@4V 9YYQ& , @'U/BC3N%5EEDEF&F;FO'G>@%@$,>] Y)5$,6]!#K8MZ
M" (A"WK7O!#L6^S6M[SORS\M=_Y(C_;/24R]1? I/S.@0, 8 P!@# & , 8
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M_N+DE2J7HVP)L)8HY(7C:HH T$HE3G#VT*+8#=GJ NS5#IPI&J+,T0$I'MF
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M7N\&@9Z55L_9Q>T9;:L*T466=W[8S1$$AO>W?4H+4Z6Z=(@)7N#5TW1/:E:
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M.<T'>![3";MVN]Z_N*U+ELZ1)4@X)&XI)%HU @KD\LFCO"DR9+HO>P')5;1
MYZ:M/$;V $F-1(2P%[V;I4,6M%;$;_MWT.VSJI8?'0JGYDCS9+-D+A#9&B4.
M+W'@J2S5 6TD,G61%@<1D*R I#%JC<2 8WFGJ"2$KD!*6>K H,3<K36KU!<Y
MAD!CC8%((:59%+*D$S7G+]'$A F/;G:J8(G3)!)Q*#1+2W14< XHDC2 8#QJ
M$PF[-7@]:G7D#I;J9[&GBT&KIYCFNZ^+=7ZTY+&GH7AEE[6>&P-]/RI"#NYN
MS0)O!DAG>RP%F&]R$8(HH1=[)ZRXI6KF*-M+-A##&Y$[[5E -0RF6.<.;@(-
ME'[.4ENK3#)RI-5EG!3%E(A,Y))I1IYPEY(TY9"D-_V[Z')&%4L5M6CIDR1Y
M@>_'G!VWQF4.,M:])@^#W<[3PZ1&%JMGF]H_')_(>BR/!#X"I1X6_  MJ+NE
MN*W31,S@U=Q]E[N<(3A&;3DDN<]*@^#W<G30Z5!"DHB#>T?CE.WL)A'@A\!*
MH\+?@";LU>#UJ?N5.=L(W(!4)A-?2)GVD*&8OE-GR*'.0%VS#M')@-354DX3
M&)2R@IQE+1/)9IQAIQ0D) 2 &J NSUX/6A<4@52Q,RB415DCSU(NU-X+4_RA
MQC3+O0Q TLV)_;XC*UP=D V,2;6HV+O8@@ ;M%H>QEB#@B:R:K4"@R<QZ+QQ
MS"L$!*CBDP=9FA.0:))$!2>XNT(@BA,K$H$H*$B+:U1("2B3]+QC/&G3!O>W
M?4H#.Z6Z?(0)G^#5TV139ZT)CTT6G)'R0 3%DJ!-QH(RLI^/-QARM0%(4M3B
MEA8$!)Z@\A2Y#2EIU87>R>L[<M<;/1*TH()#X+)$(T^Q+5,LL9_A:I.K\8+0
M2$J)HJZ>DK$^R= ,VJ-7H3 F"$5I(((='#$W9Z\'K0K:]5+"XUWIL9(\LF'<
M49GD)=*')NC?E(?B/*"3V5IXBZ.?<DOA*NYN'L-\>N\21X]L;N\F=U$'1B*Z
M?+25HIY&8C&CRS"=-Q<2G#Q-BE90@F;4#6G/%?0$;>84/1022B"'()X1F#&<
MGV6$!H;WMWU*.2Z6X*3;2*(-714.\IGE!?R;3DA\EVS!-,TE7[B8Z?3-@7(X
MG11A[3J9B2IC1F$EO2H!03S@NZN]]]?N*E+U]BH=M_L"BD+DP3=*O*NY;/GN
M$;1;!M/W+2 +/6\_TY:4:$J[UM0)JVCV2GT5I;WDS:0+L_@K]Z%4"JEFXQM6
M-DCP9EY-&;I@#*'$<:\L:+%LM!N6[B('33:(W00#=?87M2 O>S=,Q@@Z*$!2
MH@X60M,7:GD3A4:*+ GVV#B5@/DV,6&"$;WH*XMXK6 !;@$A"1L@9!KF)2(P
MT)A:71(!'A=F\%/O4IRMTMT$ETD0P:NE,/\ **4K;\KM.2(I)II&,G2Y=J*$
MT^O;-N"<L2@25KW,M)E@RB0&NZ'1XS$XF[=KO>O[BM2Y;/$2=&*"1J)R56,X
MP*\B639WA2=,GT#6RC4BEH@,],7'#,[0&$')&\!8-:,"H-%OQ6A&_P"W?0[C
M4JEAT<"J>V2/-TNVF7#$QM<H<7B.Z6%FJ=-I 92KB+&Y"3*R0I#%JO<0":WF
M'J"B$;F%*6<L H42<K16KE!<ZAL"C;:%+L:17%+)D$T6GKO'%!"G4-[O54#(
M2I=D;/-VL+<U9NCBRB-(1 .&H($W9J\'K4ZSZZ6ZG?1IXS!JZ=XUH231;N^6
MG)(Z^"",LK:[8X\@I^3H "3&[. E"&3&:6%EE&FC0B.&20%V[7>]?W%PRQ7,
MD;<2;!V"-2-W$M++/0RJ6ND-;BF_9*@1RHIT:87.E)ZPM0%(46@&T)R323U!
MXG$D:8M,K$'+&E4L5M.CI@R1YA??&GAVVQN4.,K:=$!WKNQFGISB,-5[-.UV
M[/)VPZ GWK6BSU/;VZ MN+NEMK'3Q,T@]=Q]F[N<+RA&+1D<O<^]AV#Q!'DA
MTJ&$I>[F:V9LU5Y:\83L - 2'Z,$(H3=FKP>M3[*72V4;F$J%0BO9"S[2E#$
MOE%H2.'N05NQFZ/3A:6JHYNE$F++T2(I7MY":<,PT T1&B0F'!=GKP>M"XY$
MJEB5FV?$V2//<@\--H+7(90XQAGV 0M:5BV^MT1EJT(B ^%M.#4>%I4+6@F#
M1ZWL01!PQ-7-%K>>;.8_&(XZA6#+3(HK+W29MYS?HA.(M4>YNT)@BA.L&I$J
M*&A+:5))9))"@+B8-28F2AO>W?4L\H-CR9:JCL_K.JC*_<P+T;J878SY,%BU
MOV2?W0I5#7FFV)E7 7'!3%+TBF2Z(2$FGFEF.(DY9"F45651IE595+T5%5%1
M=**EZ$W;M=[U_<5J6N5H(EB8$%AT#DC>--X:Q5*[(?X6L3K/&CUXA,A:*LGA
M*M-XG19G>S7!$;XT8R>Y> 6$\V"+L_@K]Z%<<E4L*C>U30R1Y=+^YHAZ8G&4
M.37'-KS!)].*;<J31%X<M)$H!*A(EWL.V<O$2G">WMNE)@T@>#VW?O.E$5L]
M6D+13R,Q&-*2S2@MY43F[Q-2%1&P"V<8L4.\ @(T!I9F@!*))3.(#@"$,9Y&
MP:+&&][=]2C)W2W128217!JZ(AVG-44!^3VG)%4E$S -.TB7BB9E/I&P+DH)
M"08J:=3,:5(:8:24]+0D@/4";MVN]Z_N*E+W"QD0T&H%%(7)0&!4[=!2V?OD
M)&C&#9'= H0,];3_ $Y!/T)3M0)08U[2[*)T6!9I0,281=G\%?O0JG>I9[&.
M]^1(][,O)OC?('LH<?8UY8\7V]Q]EOL1\I^3?&_6>5?87WGQ?Z9Y&\+]*P"E
MQ!PL9:-?J>Q2%QH!84VVL42G[Y-AK!CV?WL*X#Q6T TVA(T%-M.).8Z;5;-.
MT8!'I. 2D+LW@I]ZE-4.ENADP4B2#5T?#MN:4H;\HM.2)9*%F&:3I:O#$RZ?
M5M@G).2(\Q*T[F8$JLTLHDUZ1!.&>G$W;M=[U_<5F7+9ZB(1"@<9B,E4F&FA
M<"I9-WB%$)2- #LDQ&H:(!/AKS3#-C":2<F;@$@"$8#S]CV6 1O^W?0[K:JE
MAL;TJ=V2/(9?W-:/;$W2AR=(YI>6)1IN3:E2F(L[EM(J %*):N]AVCD CE 2
M&]RTF+&K#P>V[]Y0XDY6@M6*03J'0.-MX$WAHU44LA_FBQ0L\:#7B%*%WJR!
MDI$WB=F&=[*<%IOC0 )[EX!@CR@NS>"GWJ=5[=+<3OXTT=@U=.L7T8CT6\O-
MIR1@?A$C*(VX&#C:*GY&WEF)3Q*2T90948%<440<<<WC4&$)A-V[7>]?W%P2
MQ7-$3>0;!H_&)&ZB6 +4HI5+W2&-Y+?LA0(Q40YM,)G:A0L I"E* A,:4Q)A
M)QZ@3B6-,6F5"-_V[Z'-'54L5,VCY8R1YDD'AJ=":X]*'&3L^@!%O206GUQB
M,26B$>'P=J ;CP=)1;V$L:S6M"$!;D6=+96.8BIK"*]CS/I*:,*^+VA(Y@Y"
M6Z&5HA.)I=:CA"4*8PO9PC5>GD1I(RR@ 1'Z.$82)NS5X/6I\E#I;:-T\3"X
M/7<@9N[DB\H2>T9'$'/O8MC\>1Y(:ZAFR7NY>M%[*5>6O&';&/0TA&BPB-"[
M/7@]:%R255+$C3LZ'LD>?GWQI =-LDE#C%&G9 M[[R9MZ;(C,E>C2==FR"=,
M.P*-[WHP]-V=NQ!Q1-7,EC<<;.&"-1QW"M,+(0Q66NDR;C6_1*<1*HUT=H7!
M5)"PQ0)648@ T*"2B2$YX7$X:DQ,D MYB=+=4/H$\F@U=-$:V)7HQW8[3DDB
M? A 6;M#L$>7T_&$ Q*3=$@5!%)B](RS#32AKA$@)/$W;M=[U_<=J6.5H(EJ
M8N#0Z"2-N&E\-6JE5CO\,6D+?&F!VG3H&FK)V0J2^(T49WPQR1F^-&83W'0"
M@GG""_L 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!AWD%=L4XW4I9=\3I!('.'U
M7%'*8R)OBJ1O7R-6V-8 C4$LR-V=6-M4+AZ%KQ)2UW;R!;[?#4E_9P$ON..Z
MN0M-<>&5F?;AG3?$$\F>-1V)MFD3Q(97,I!W10X"8H5"8LVO<QF3P2W)%;DI
M;(PQ.RU*VI%3@H(*1)CCP"415R(8F6<]^(R"I4-X'W.SBK=?88*C"YI(_,W!
M^0VF,A2JW7#W T$;4SZ.S<I*D-5J8N_1AM>4B4292I1E$+$9AX47O5S9--<A
M=-;<QN,-MQ6QII!;IAB^/T\WF/%LGO*I7#G&L64MJ6OOER?L$S21]_A[&<S-
MKDZ)'J0-C>UK4+8Y*4BL\IO6")"BZ,N3=S7:>H6(OY_<9OJ13^YHG,'"PH[6
M+U7#',V"+LBQLG;,=;$HC\6@S@JB$^]A3HG8G\Z1I7AH?E84[4_,")U<(VJ>
MAHA)Q@B*JTT\53*Y_(N!(G^2M[BDDS;$XD[KXN]6LM:DY=9)9HUD(#W"'#>P
MN!CH2ZDF.*9H(<U3$FB3E+MC@#3)%\^!N,8(I[>WMGR%!DO,/C=&49:PZV(B
M[[/$66G3L#RWN@C#3H2ML0@!ZL"HMK:RQP]&6]'KGEP;FUL2.K <[K&\E_:#
M%@4707(AY.\>'*1BB""Z:W52<,A)B6V,F6-(G'<G4OYD421\"?O/A&.ZV3IW
M"/(4!?A*5KTS2!L2%G+(Z^DMX4706L]\R.-\<03IS>[0CZ!%7Y;@H=C=J JA
MN2)MK*/VX>OC:=#M4H?4IT.D:,UMVC*$<[NB5S:&HE:N0&EX)I7(7(MY1\<V
MXU62ONNMT9Z!UVR+2%,J:R3TKH65)3E"0\DP\)A8D(85-0.9@@Z(:SX5,4KB
M8E4Q5_*;A!F5H>FA_2&+V1R1.R(ER>F8U4@4%*DY;K''A?'GYN&:4(0 K&=]
M:W%I<2-[\8E<$*I*<$)I(PZ JF 1D'RTJ4B=V% URIP:SJQ<61IETE=E$8;(
MLU.+V^PF/DI796LDI+I%Q=[L"/*6HV9M$:(G#;IU<*U-FJ=F<1)Q-%NW?;V[
MY6T?*SC8O5=Q27C61BT*%R<C4FY:TE*4R)G;)&\NARP@Y068B[BTPZ7.2@M6
M$DT"*+2-1XO93(YB3"*%"WS&XY%N:M"KM",-R-(!UUM^<GAJ0,JE:QZ8=/#2
MA&J7%N*UW:5#^2WO*!,VF',3L@<FA[\G.9*=(J$T71[>R&68E;=7SU\?(U"9
M_$I8_1H@A4^M<>?&]V5-J14M7MA"P\*(\[6T9CJTN[1WLH1B<+PSO#2,T+BU
M."9,(,B8 P!@# & >>/GE=CC&.<U^Q64SWGZBAU=\!:<M&MHKPI(N1V)8[,?
M;2Y)M3[,)FU5ZUN=?)=+6V(Q-*6XW6 J"B1LBG:X>T2%R$4.:)<GQ?C-(N-3
M(B,Z;[JKDO-Q'#:7SJP.)?&N;V?,X58MD2NCZR?YY.ZY7M3I!I;+W.(-*J1/
M\9<6$(&):UN3L8J4E*60I.SFB&,;6F2H=D)RAQ6E5IDJM*Y:;I)3! P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M'%(\JY)#*BKJ*3>HI99,L5-"Z5-D@3Q@<N0UX_O$7B:23Z"C:WP;)'6A&OD
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MQX[91TR\165=LLM*K6.RF7&2E#TI91)28P!@# & , 8 P!@# & , 8 P!@#
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M9%72V1)XVE1MFR?91LE>F.:E(*E*Y<U.K>E>IWS;W@XC & , 8 P!@# & ,
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M6#_FG UQYSQOKFN,^;Z2/3#WV=O GBI[V];UV4M"->_K]_L:==NO\&^W7^#
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MO%5EA8AP]<HVJ)5495XRSC*B*BK2M*I7*;*LZ!TA@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & :5^6O):UH69U.K=@4@/9'+AI2E84O52=5X:R+Q:?7)
M&(U;-DWC(8Z</R1)#HO'9Q4IK5I\2J4K$VUQ*TJ8PE!-)02J')$^+7.O>R>&
MN_X).1WB%7W'Z<4G849Y17M%Y/N6E16<[N?D78=JL?*I1)8N^I2X>^PZUYZX
MPQLGRM\+3S:'N=31V-/#%M@7QU@9]0I8N8R0JJUN3J(EU-[@6O5OO-956<_T
MCGU!VJX3[NESI3=]\C+(X/,E-*BYWNM8?#XNV1V.\?[Z9!+&TF @>[.Y%5]:
MD:$^M3B)RD,2Y!5DC6D*"XHG,2B:741+T1&JTX>I14WJ*MUY]Y'\_DL)YZ/]
MQ%7;+F2H.)MSTWQ:F5/(03L5<6!#[!;']#RDN.0Z;VTR#J7.D9O:%,&H79W7
MIW.,I>/%N-*(!A4J/">")=2E5:2J:4ONIOT5.K6^AT^1EEL49Y3]2N9W+3O4
M:NRM*3>Z(.:Y'Q2Y33FJJ]I6,K^+E6R60Z<X;&^8M#*FXO3TXN$XDDJ::YE+
M6T-Y[C(7YX)3I7$LD2B51FBLHJURI6M^:Y>_0F'"I!?%'TCTNK'MBSC+&L"0
M3V&\?+C<VR:AG$?L6O.2;.]%0)S625O+2L4^FT&EK12CAJV$Z$XU_;T=DGM2
MK3=8CDK.'%:*K5$NR[U_#3*G!7)5-Q.#B, 8!JBZA',"8\=KSXHU<V<D./O%
M2#73"^2TEEUL\@:_.L!F"]5 IH4B'Q1C1ZMZGDB%8^E6;)U*LY0]N!QH&A-I
M,B#HH\8AR91%155%6BHE$5$RUW%T%+3\O;465O0<,IGD9QIY87/ROY RNJ:W
MO2%UF[1FC*UBD"J]_M&RI!)X*PW;.G.=OD'8(*^D-K&WVE#]R:3R^*M*PYB;
M6MS<UH42^Y41$K15O6]$RT33HR(I*6O57-&LE]JH+B+@G)J*,M=DS2J);4T8
M;*5L:4SE*)Y \TL]P2967((5M8X!2LBV&V,.;1".A\K*V:5H4 FK4B7B+LU4
M7=O3?KEWTIQ'4X)WS<'(.L[,DMY1.'P6?PKD?>E1JHA!W99(62.ME:S-1'6M
MJ')UJ= .4NJ-,1XEWD:=I94#PX /6-S,W(C"$P 5$1;K\G?1%,5<Q.:\SIVW
MZ#IJEHTPRQT?[^XSQ;D;)W[2P]DJBKKYMQFK*.LJ(*!2EVIMNQ3EKR[1%L4'
M&(F&(1"22F0I@]_A:&2"433H6FZJ7\'W]6FGW]$5?]H_&K^9,Y_WZTY2&%3Y
M,E_?>3?R2T!L-_!I?+M:;^%D^_JFQ1YO<Q6-Y(P!@%58_P!5V_\ QD'_ -\O
MCJ;OEIL3])F?\DF1A7^$0_N;X:_V/(OZND!.O/T/G\VL8 P!@$0W']4G+_*"
MS^L#S2#A[^56U/TIW]DR9QX?/TXEO\/L&G]#2,Z>6=+*# & 1]Y%_K39_P"<
M1'^[73,[-2#^;[1?3(G[&2FR[4;?)3:7^(3[^FY.0YS-0RJ& , S)0-@/M36
MK&+4BY;>;)JS,66!'2G9.:K:C'V&H5$C:"W-*0H1GJ6\;@VIPK$Y*M*:<FV8
M66H(&+1H:,P@0S$9929PCQ6F7<4D/#/&F:(TC#^(=.FE9JBIC(RTJI5%2N5#
MTY0N+',-<RZB%X'#Q2<W*#]$,<].3_'^T^/]DL?'E/!;6C!T3DY\7KN6-<@*
M:U:M*<:)J<%MD.R1(KT-.#P#3VY6#0?"ULG>]ZWK$2>8.)/*I3'3%Q%S!M]"
M.5?.V7K<.KMIIEIE*-HS#LM*E^9I%*B=Q+33;+*LLT6J9]"DMLR6+%# & 1N
MY<_L?9S_ (W!_P#F%%,I.V_Z-1OTJ3_SJ7%98/?TWLS^UH;PJ0XSU#;\, 8
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MC#1C,&+M$,8A;WO=(85/DR7]]Y-_)+0&PW\&E\NUIOX63[^J;%'G!S%8WDC
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M%2'&>H;?A@# & , M&3?JM77W1&/^HN^4Y:'X]G_ -XX#[",+>X1_P UR?\
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MC"_X0'X0?QX \87_  @/P@_CP!XTO^$![WO?^F'\> /&%_P@/P@_CP!XPO\
MA ?A!_'@#QA?\(#\(/X\ ^>-*[>SQA?;^]X8>W_YX!]\87_" _"#^/ 'C"_X
M0'X0?QX \87_  @/P@_CP!XPO^[!^%K\> :^^J[^UO\ ,O[A4P_V!6"4RIOI
MX38/@@8 P#7UU2?V$-H?SSX\_P#4G4.#DQ\9.KX%-@N#B, 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!KQH'J
M#"Y(LM5S.O.&?,@JK[?!''"+VO(&'CRWPI+%Y,>06DF3T2DY'.4Q21Y&E/\
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M61R>40DG;EDNA8%I]$1;+UJ'=([5XRP[<JRC5,J,JJJFBJEN<(DJETNA9:U
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M9A1_(Y3])B?LG9[O\L"6:& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M98Q'3Q%7&5E%KBQ<8YLR^BGD2K40C]TK#*.$5%956W355US%2E':Y%SH;@?
MY=>@_:'K7X[?2KFJ?\6);#YZ,'7U1;+T,7!Y/);T+%\#OQQX'+KT'[0]:_';
MZ5<?BQ+8?/1@Z^J+9>AAR>2WH6+X'?CCP.77H/VAZU^.WTJX_%B6P^>C!U]4
M6R]##D\EO0L7P._'++F=:\M+2-KZ,K.($YBC4DN6F96^O[[95$.+6VQZ&6;&
M)0_*%2!GLEP<U@0M+4KWI,C1*CSQ=A99!HA: *_NIHU$T\P#X697A)G&$^QL
M_@I5([62]97)Y;:=S'Q#^>V;F4GAE<O(Z5N(9E'<1&.WCQ7CUG^S9:HM:(>5
M.K6P,SES^#=.(AVV]5TJ-/$8Q4UMXPVM<5I5O1FB7922'60AK<LZ7G-DADC;
M0)TW1[\:DTG0MB0_PDRUM4F;*4F ("4())1@M"V:#>^SP0[V+>M;SO1MJJ*K
M32HBHJI55R+OEOF4JJ)INX;D[YYOO:-]4+[779OKYXB_3UF2>S=(MJ)MPP?E
MRVO(-&]'07!$^1'M&^J%]KKLWU\\1?IZQLW2+:B;<,'Y<<@T;T=!<$3Y$>T;
MZH7VNNS?7SQ%^GK&S=(MJ)MPP?EQR#1O1T%P1/D2-O+GA9U%VKC_ #-9-^#$
M^@\;VZ5ZC62=SNCC"[(6]4YV7#VUG)/01NYW=X-\J/2MN:2C$S><4F.7%JEP
MTS>2J5$>+:#"W)YQ*G\O<RR9.GCU] O$>/5A581(6/A8MM%Q7RM5:8<-,LW4
MQE9JJ)54]ZR]FXB1VAE$W?Q4.^<R^-=1+QTY1]KKQAVJJK+O7';#&,N;&:93
M2J%$\S?U8O0@D'K_ .)GT\9WMF.1;5S;@@_.C./E@++[4SSL<#YX/,W]6+T(
M)!Z_^)GT\8V8Y%M7-N"#\Z'+ 67VIGG8X'SP>9OZL7H02#U_\3/IXQLQR+:N
M;<$'YT.6 LOM3/.QP/G@\S?U8O0@D'K_ .)GT\8V8Y%M7-N"#\Z'+ 67VIGG
M8X'SP>9OZL7H02#U_P#$SZ>,;,<BVKFW!!^=#E@++[4SSL<#YX4-WZ+G5I<%
ML55$\(GP(&*4MSZI"/D!Q-T(U,C3+B1E$]E[[ULX0E(-AT/80=FA;V+6]:UO
MRIIA4D\<U+%=RZ9L>X9K#1[S'2%^&[<.W[#3#&+$+\-5>HJ8U&:(M52ZM+VK
MPR2"?0<!#0LNFSIN%FT)'MJ_8A49:=.'<0PTPSK<2VN.JOF59JB,T1:JEU<G
M^:5ZK/H+R?XP/$CZ>L]79CD6U<VX(/SHI[9-E'04?P./*CS2O59]!>3_ !@>
M)'T]8V8Y%M7-N"#\Z&R;*.@H_@<>5'FE>JSZ"\G^,#Q(^GK&S'(MJYMP0?G0
MV391T%'\#CRH\TKU6?07D_Q@>)'T]8V8Y%M7-N"#\Z&R;*.@H_@<>5'FE>JS
MZ"\G^,#Q(^GK&S'(MJYMP0?G0V391T%'\#CRIL2Z3?3EY\45SXK&Y[ZXRNE3
MUC$J\M]F=)0Y6S0LOUY6ES VH&-$2RUU:,ND)FU*E(:$:C35W1/KP1*#R@[[
M<H"WMMI?:R'ESF"A(R&6#?1#QXL4CE$:1ZP[991C6GKQ:HK"UQJ94I4HVV-J
MH*T3B"=0KB(<K"O7KQM7Z,4:1XPPRB,XC35Z*RM:TS4J>O7+:%!# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P#7QU7?VM_F7]PJ8?[ K!*94WT\)L'P0,
M 8!KZZI/["&T/YY\>?\ J3J'!R8^,G5\"FP7!Q& , 8 P!@# & , 8 P!@#
'& , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g686907image8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image8.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X7 P:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^:6UA9V4X/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!I;6%G93@N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(Q,#<P,C$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#(Y+4IU;"TR,#$Y(#$S.C$X.C(W)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#(Y+4IU;"TR,#$Y(#$V.C$X.C(W)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,R8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T)B-X
M03LF(WA!.^* HB T-2!H86ER;&EN92!R=6QE<R!C:&%N9V5D('1O(# N,C4N
M)B-X03LF(WA!.^* HB S-R!R=6QE<R!C:&%N9V5D('1O(&MN;V-K;W5T+B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86PM0F]L9$U4)B-X03M!<FEA;$U4
M)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&EM
M86=E."YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C$P-S R,28C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,CDM2G5L+3(P,3D@,3,Z,3@Z
M-#$F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,CDM2G5L+3(P,3D@,38Z
M,3@Z-#$F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XS)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($QI;F4@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H
M="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE
M8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[)B-X03M!<FEA;"U";VQD350F(WA!.T%R:6%L350F(WA!.R8C>$$[
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @:6UA9V4X+F%I)B-X
M03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,3DR,3 T)B-X03M,;V-A;"!4
M:6UE.B @(" @(" @(" @(" S,2U*=6PM,C Q.2 Q-#HP,CHP,R8C>$$[15-4
M(%1I;64Z(" @(" @(" @(" @(" S,2U*=6PM,C Q.2 Q-SHP,CHP,R8C>$$[
M4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!6
M97)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @
M07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O
M;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L
M971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F
M;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R
M:6%L+4)O;&1-5"8C>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S
M8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @
M('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#$Y+3 W+3,Q
M5#$T.C R.C$Q+3 W.C P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \
M>&UP.DUO9&EF>41A=&4^,C Q.2TP-RTS,50Q-#HP,CHQ,2TP-SHP,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$Y+3 W
M+3,Q5#$T.C R.C$Q+3 W.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @
M/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL
M<SX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIW:61T:#XQ-#0\+WAM<$=);6<Z=VED=&@^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FAE:6=H=#XR-38\+WAM<$=);6<Z:&5I9VAT
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP
M1TEM9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E
M/B\Y:B\T04%14VM:2E)G04)!9T5":T%'44%!1"\W44%S54=H=F1'.7IA1SEW
M241-=4U!0311:VQ.02LP04%!04%!0D%":T%!04%!14$F(WA!.T%11U%!04%!
M05%!0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"
M9VM'0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%
M03A/1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"
M05E':%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46="04%#
M44%W15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!
M04%!449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!
M.T%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU2
M0D%!1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II
M.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#
M:&=::$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY
M5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.
M:F\K0VLU4U9L<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V
M;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:
M>&=:17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!
M.S K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R
M4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU
M:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!
M1#A!.55/-DEH9#)#;V]Q>DUA040S2G@F(WA!.U9Y=7)#<6M-2VM60G)U1%%J
M-D1I<E4P554P5'=Y;TI)<$9+4TEW<7)+=V]1465X1TMV36)4.&\O365M3F)2
M-DXU;VMS3D]T-%-P,#8F(WA!.S-I94-+4V5R3TI$=VPT<65D3U(T3GE'>$)W
M<7 V2BM79C5G=#9&,7)8;7EF,5DS1&Y41FUU6C=C1DI#5B]F97)$2V9G4&-K
M,3<P06\F(WA!.W%M;FU$.'1D9#%4>DIB-C%B*UI:-T0P;S=E>FQT-$9L6&Q:
M>$]S<S!9;%=:6E9E855B=GE*-#=B.6-#;T-$.&\O35$P82MS8GIZ4SDF(WA!
M.SE.9E)1<&-08U<T:VIN84LT=4QG:61:2&0K0F$T031X=6XR9#9G:UE64S8U
M+TE855I:2EI)+TU32GIT171H16)-=D5X54%!4TDX-TLF(WA!.S!55DMW>#E&
M3D-E5E!I8E9-<C<X;DQY-3!(5TY-3W-2=DIQ9S R<W(R>$M-,FY%1G!*:SE5
M:#-M-DY39S)(,$MQ=6UF;$106C)K<T0F(WA!.S9N15AA-7,W<4]E0T-71U-T
M<F-*3UDU94TO0U=-2W!I:55P.$,P-FQ2:F%V4V-#=7A6,DMU>%8R2W5X5C)+
M=7A62B].+VQE>#@P*U@F(WA!.TQZ46(V4U-+,'919VME16=/4%1K5U%D45)1
M;$)516)J8D971&%6-5E4>5HK65AL<E-D3#%'.6LP-U9,6%9:3'4P;6QR07I7
M+S%C=W4F(WA!.TE50U)H=TI31V9J>6)U8U9E;S1Q-T9867$W1EA9<3=&6%EQ
M-T9867$W1E5L;#%J>D%U<"]6:S!'4C=0;'@K=6DT9T$T.&=/9D%T>7 F(WA!
M.U$Q<#$Y<W!/4V9&6$1T-W<T>'DU3TMU03$S,D=-95EF4"]M;E1V33DO<%9R
M;W!L<V)A3T8T=%%-3C%+<#E125=::$%K:DUQ;&EL154F(WA!.VUU+U%(3#-*
M4FQT-3,X>79D869B,TAL-F%%,U=O4S)L>$M"2SA3=TLP:7!+:CA&4#)9=WIC
M,55F>3$W2W!&3"MA9FYD439X955,:64F(WA!.UIO5#932DAC<45V2E-O:'1P
M5VMI4F9G<$M*6E5*:C)&1S-X5FMF:T1Z9#5H.'=T<4QA=F]R-E!&0WEV<"]Q
M:5)8;&AD-59$37)Q07 F(WA!.TAP1&%T9#DQ06]70W-V>%8U9CA!;%8U,CAZ
M95IF34=O<F98,%4K:C(X3$,P2#%945-4>7)/635*27ER3T1(15EY=E5K.&Q*
M0S=62W F(WA!.S$U:R\X;78U2B\U9W1A+S1J85E&6G1I<G-69&ER<U9D:7)S
M5F1I<G-69&EQ0698=$=45T4P5G)U36%R2D=:57,V+W9#9W%A,"MJ2BLF(WA!
M.T9,:#1Q.4M/25A343-/:2]M2S-M5F)M1'I(8G@V0GDU3EI'>E%Y0F524' X
M=G1..$Y">C5J+U8X8GAK=SA&1THT=F5W26QF4%II6&XF(WA!.U14=GI2;#@U
M-G!.;R]M5S!S=$1.<$-)3E!L=3%G;%-8;$5'97!H;CE/<'(X5D17=% R='-:
M<U17,7-F>E%I=3E(:G5T9C K4S!J,5<F(WA!.V0W-G!P8S-&=#8P,T-!1E53
M4#1):6Q55D%E438P>%9J>#!J.#=/56I2*V%.3TU0<%A-8GEV8VAT-54Y2U,V
M44Q"2#99='!&5U)9>5@F(WA!.W!Z2SAT:&EQ82]L-S5C+TTK3'I"2F5E62].
M<6%H65=W0694-U(T-4EZ37%V17E3.&\K86<Q16=O=S,R23)X5C9J9U8T=#5*
M+U17;U@F(WA!.V8U9U)E6#E.,$A29DU&<$EB5%-B:3)G<S!M:$5S.'=D8G@W
M4C=H:38K:78R,4%,<C!/2V\W5'10.#8R;C5N*U5V.%4V:D1F4W9A83$F(WA!
M.SE8:FA11&A1,GAD:DE&:35#5&MV1D](=T%5<3%D:7(Q=D%R<U9D:7)S5F1I
M<G-6465Q87IP3VLR>'5D5'9)8D]!5B]E5'5Q03!&84PF(WA!.WE/-3EH:S19
M-5-.4D9O2D$U<UI0-6A83W%65'EN;W0Q<D%/>39H35!Q9&E08U-Z04TY1#)6
M37E0>6]J+T%(:VA(>35L:#1L.&AB6"LF(WA!.T9V3V5S9D8U:#$X,F1U,S)T
M3C!65$%T4$)R<5-S>D1X04%W*TYJ:#E%8C@U9G$U3'=Y4$TO2DXY1#AK959.
M1&1:9$XP>4-+-5=T3'@F(WA!.VPY4S1Q=V\S-S94;$IV,RM,2V-M;VY0;61V
M<UI29T)Y1$1,*U X<68K5F=+3&IZ6$I&<C5L,S!S86M6:3E:<$LK:U)8-$=,
M<4(V4$TF(WA!.V1V:'A'63A.8D]333AH2&AO9DI,=D]6<BM7<2MD.55U.5DQ
M-F)4=%0T,C1U63-J:65'4#1);&IE:S!C<4]R0FQ5.&Q)1$AT=&Q446<F(WA!
M.TQV5G9Y4S!U+W="1VQ(;4,T0FEU,S%#,6IG1"MG<3-C>DLP;$9J5DE9,F53
M:&1+1FPX4FER6CAP+VQ"9E=Z4TAZ4$Y*8E%M3%-:>$4F(WA!.UEO5F%*;R]7
M*W)U25E)*U%L:&=6<$IE=D=/=DE!2$95>3AJ83DK569L1RMU-UA43F9K=3=N
M55EJ8UAS<WE025,Q=3=--T\V>$M68B\F(WA!.T%%;C1K-DQX8EI4>7A6-E8U
M9CA!34]K*UE.3R]33VQ4:31S>DI*17-O0D%,4D]586QF8UE&648K5F5J-F)"
M-7@X,S,Y=G)P,4\O:W4F(WA!.U-U<#)S3FTQ:F)X4W9.2W<U2UI*56MD4W)C
M6%AI4W)&;35C,4E65&YZ2B\U3F9Y5"]W07=7=&8X4G1-5EIT:7)S5F1I<7EA
M94=#2G F(WA!.W U1FEI459E4GE&5E(T:VY965%#95-S575F>DTP3U-D-U11
M66)J>D9E<6%.2' P9G%22V8K3$QH=4U+:C,U2$UK85-66$MO1'HO53$F(WA!
M.RM)3VTV:V)4.'I.82]W0C9B<3(X<U=B9C=O=$%,>3AO97I43T)%=GI28VQX
M65EC9UIN>C)#,4DK4W!$-4PX:39*2BMK3E5:8GDK<'8F(WA!.W%7<U1#-&U0
M>4UX-$MF.$%555I6;#%S<6]K4FHS1%IJ3&=H=DDO3DA(>G9P<WA+-E9B,U=R
M3T\Y<D,S<#$Y-5I/0V9J;4(K6FEF<$(F(WA!.VPW;7(X-44O441,,T0Y2C)A
M*W-E96(S*S9T8E1366HK,6-/,7I-4&-*2'AJ+W=#1WAV3$QO22]A=D9N;'E%
M62LO8R]:=#EQ2C!Z43DF(WA!.U-T-S18=#ER1GAF4T)#:&<T<$1B-VM';VE1
M9%(T:VLU2T=/44YM4E S33AE1U%L>%-K6F994&MI;CAV-D,Y-3ED9E1B5G(P
M16M84F<F(WA!.VI-=%-1>%!0:GDV9TAR;'IK2U=O959V3%=P3SAM;V%883-C
M:G-(9#5O56-L;#152DQ!+S<U5"]G4C19<6Q';2]L5BM8=6YX=TQ&;V0F(WA!
M.W1-.7-X84-A-E@V>DMT6D1+2U-48S)O2&%O1F1S5E1,+T)N;$@P6&<O471L
M-D5K,&1X2D8V169&<&]K16-B;&%5<7%$:5!B1E9&4'DF(WA!.RLX:E)S<DIO
M3F=R3$<P24ET-"\W=#$T=794.6]$9GAX5DYT3S!Z5'1-=$9S.4]T;W)3,5-P
M4T-&06E#=35O<3!'2W9%4'EY:#AW-D4F(WA!.VXU:C)M:'9A87!Q;6Y88U5.
M:D9B=S)V<4TV>E1G*W-)-4EN8C14+W4V4W%K34%$5#1I<64V9'%(;E<X+TTW
M>6HO:6Y466)'5DQ45VHF(WA!.V)V131Q-% Q64]P:4138U)(>%AI+U T=V5I
M,#-6970T1E=4>G=7.$QZ>GE,1$1'0S!K<VA#<7%J8VQM3W='14%N64MW2%=0
M3VUT-C<F(WA!.V)4>&541VIS-TM)9U0K87(W:DAA2U995E="6D9F,5-A8U,S
M2&E0=4]:9WA9.%AQ>D@O3B]8,TY%.&TR>&]D-5,K2%1F2T9X3$<K=38F(WA!
M.VAE961.5U%!=F)X:#=I,5-4.7(P;TE1:T%8+U=R;4Y0=%%$8DAT+U9'+WIA
M4'I'4'9->C5B+V1S>74R=2]->E%,8C90;U9V<%9O;3 F(WA!.U)V2D950F9A
M,W1W,5!L>4=9:'DU6FTV*UI:*TIL;#E-94@K<V8P1#EA<"]H,UAB=F963F5N
M-$AF,$Q"1G162'1Z*T]5:B]:65!#:V8F(WA!.W%K9FAS=F=4;#E5>B]M-V9T
M*S%%,EAK-WDQ6GEE<DA9>'EZ;G)C6$9:-4-F2&Y+6% S6DM/;F=/:D]':WAX
M3C%V,VYC+V%N24%!04$F(WA!.V]"<T%-=6-H,DMU>%8R2W5X5C)+=7A6,DMU
M>%8U>BM84&MZ5V1'.#8K8V19=EE:-U,Q,6$V85,Q4G)Q,W5)8F=.4$TT;3E/
M3T=/5THF(WA!.VM1<49$3S-W=%$Q-&EI<5EE6E O04-A+VMN+VU#,7(O04EJ
M85EQ;6YM4'IX<&5J4R]5;S!K,4172%5'1%1B6E-Z<U=R4W)52W(Y;F8F(WA!
M.W$Q3C9(24A*04=I9C!N-4)X<S)R:&I01'IL,T1C<U!K.'$K9G9..3!T>C5J
M84=X,#571#(K;$Y6-%8X1V5&4U!78V8X5W-"+VLU8BLF(WA!.V%M0E=)8T@Y
M23=Y*T$U0F\O9C5/9V=04&8W4#%N-$UV=&9);6M"54]P4$IQ<VM90V],:R]U
M54$W4G=*>&E19C=(36(X=4-B:U1)*V(F(WA!.V%.2$4W>G5:."\Q8VU147=1
M45)I2T-.66]L,E9%0592.&=-=4%!-4]504)S1BM&3'-69&ER<U9D:7$P>7AI
M4EEI-FE6;$Q,2%5C:7$F(WA!.VM":4(Q;T-W<C@X5EA9<3=&6%EQ-T9867$W
M1EA9<2MF9GI%+TU,54@Q5%-.5#%$4G)Z4UIB5S Q:3-I6FI*1D<U;F4R4D%S
M-TEV>$DF(WA!.TDR.5)E3D1463!92$IW=VI)945N:$(V=&5726Q%9S,X3V)$
M4$QF-6QA:'!'='9.5V%X;'5';#EA-E14;S<T<7%I:4--=D]R8V9K5DHF(WA!
M.W%3,TQB36E2=W=(0D-/=RLS>E!E>C!U1$)I:CE.>4Q)<FHX*U!.,R]!0C4S
M9#5,+T%-6CE+<V]0;C!V<$UR-&]F>F9T8VYJ>"]W03,F(WA!.R]:9G-55R]/
M=CAY>7)02G$R;C)T=7%K=DQ,0E)W44LW2TDU138W8G1I2EDO-78R<4UM3"MA
M9FXK>$50*V)8-6QL;7 U:#!O3#!5<$@F(WA!.T]U,VE1,6A*=CE/1&EH+TXK
M,4AI62\U=C)Q5"]!2FTO;4)+04IV33%U5D<T.4M2;VI8-7)P1TAX22]Z4CEQ
M*TQ$*V%0="]7<"]W1$LF(WA!.WAD9C983W%8,7A**S-*0G)$=U)T-&-6+U)(
M2F1V9DAX4B].:79J:BMB2#AF1F%N-6EY>3%0<C9J3GA*56QF36PT=$-P;U(K
M-S U9"\F(WA!.VYG.%AY:CAL+TUF,%DO2G-E8SE&86XQ;E):3'1E<%=B>D9Q
M:$)0.$%-94YM=2M(>#5E6'E#+VU:95AY1%HX,V54:41Z.&TR:W!06#$F(WA!
M.TYB,4]1;C)*93!.8TAJ>C<Q+TY4-R]S1$Q0>6XQ<GDU<69N-S!T1CAS,G5I
M;4A4-5IP<#!V2EI*;55326Y%43!21U5M4F%K<G14-5DF(WA!.THU6E-&17-:
M-35Y1D4R2'0R5DY4<U9D:7)S5F1I<G-69&EQ565B=$IU=%@X=&%H<'1P-DIU
M3&U,:$=,;4Y*65-A9SA84U):1DE.2V(F(WA!.W%C5E1F1EA9<7@O>C%P;FU4
M52],,#%P-65U64Q855A:85!D27-K3$IV5EA6:VM&3V@V9'-64D]H>C-6;G!7
M;C)E=3-S3#9Y,%%%=%HF(WA!.T4U4TU0-69H:3552%5H0CAS5E1',79B3SAJ
M36QP4$AC4F<X4SA4<39H9T%A5E5N9F9&5D]79C9Z63-$869-:VLS0C%H9$A5
M9U-C87(F(WA!.SA62D9(56164'EX5FDO-61A4C4V,#5B+T%0>%1D451R3TE(
M=%DT3T)+>3!F-G<W<VM-2$QN5DYY0U-15S<P>%9M5TMU>%9G='AO6#4F(WA!
M.VIT*UI!,6%(54QD9DMO0U(O53(Y37IH06=-;$<Y1&YX6F@Y:C%0=%5A=3%-
M5EHQ:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER0V8F(WA!.T\O-59A4C5U
M,3-49%IU-S(U=&)R5$E:-$E&9T5246ED4W!,0U)(<5)Y*U=+<&9Q+S5(95A,
M+U)R8E-O3#8X,#)',6QV6F\S<VI&17@F(WA!.V4O=6MU5TQ5:G!735)#2D0R
M5&)&55(U22]*-U)V2T=Q>&%H66%L9GI#2S(K<7)A>D]N;SAD9T=+;VDO1E)D
M+TAR,GA6;C)+=7A6,DLF(WA!.W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS
M2#@T>F8F(WA!.VU8639T3F9E5UEZ<59M3&%,,&1-;2MR3$%:,FM+>69%9E-N
M+T%,<T$O=T(U>$)0,%EQ:U9X-3,O041H5SA/;C(O;'%#5%5F<7$S4' F(WA!
M.TY'-G=G=$EO2T<U.68P95-O>"M%3G56<E@Y:T95,VYV=GI:;3AL=7-.;D1"
M-7-L:VIJ4F=)5F=H2$ET2SE7;&Y%9T-,=U=Q:F-G,$\F(WA!.RM+;T-,6"]Z
M='5D4G,K96=7.7!94V-*2G=(:35P+W514D1&235M;2\T.#%:,F1%4#)Q059P
M9U9"87!E9FYS5S%"-T<P9$<K<THY6&<F(WA!.T(P*U-.54I9:$E*6#E*,FDK
M>4I(;%1N+T%#9V(X4W%,,&TV+T]L<C9.9%)T;6IH6%5B55--<'-7:64Q3F9R
M;$].2D5H56)X2#1P1"LF(WA!.S$T67%O,D9Z*V1",7EC6&MD,2MJ0G%%=VI-
M86%94CE8.54O5BM)67AT-E!P5CE5;'95<G@T.3A66G(U2&LX>7EA25@X>$-6
M8CAZ4S@F(WA!.U9N5T):0D18.3-Y*W(P:DIP-$0R,W!Y259K1TMU>%8R2W5X
M5C)+=7A6,DMQ1BML-#EJ8W!:3W-6-#!4:3)L8U966E-P0TUW;S)W86XF(WA!
M.V)&6&PP1C<K8FYL6F1-;CAX86Y:86A"9C9N<%=M>5)"3U15=7!$1$\V36EW
M8T-/845C=613<#AC2W9734-U>%8R2W5X5C)+=7A66DXF(WA!.TY$0VAK;6M7
M3D(Q9'E&2#-N05-">E%30GI3934X-BM68F0O5&)5;W!:4#A!9F-"33=F9$5(
M3U93,4=-9%A(;')-43(T:&9L=CEY:B\F(WA!.T%)=&YN,C W4DY1=6EF<W4X
M4S(P6CDK57I**W))*T]4>6I)+UEX+TY%+U1#4BM&9F93-D<V.#8S1C-B<S%H
M6C).:TI".5I74V1P<&HF(WA!.TAV6&IW4E5"*VY#2EI#4G-!16E766MB4D5F
M9EHK-4=A,7)V-DQ%6B]2.35F97 O>7AX97)X,T$K3&-5-C=:3$IL-&5H4'5B
M33)B9S8F(WA!.U-L-VAB1E!-=C5G95I.4#%E>G1T3S!'964P=6)2-V@U2EE:
M=6-C:71)=D9L:40O6D-">6]Q>$A48VI,24=X9DIS:DMX9DIP=GI!.#$F(WA!
M.U(R57-R95A*6EI&;G19-$I)575$1DI&37-*9'5-:U5C>5!75G%!<%%5*TIQ
M-T=42E$Q6#AY=DY';C9T4&)J>7AC,U9N8GI80WET0D8F(WA!.V-T26M-2F5/
M2C8K;#95:&YF,&Y8,#-B:6I(:T)X>%9%95-04%AN2%<Y96MS9%HX=5!P1FMK
M2D%U6D)+2S-5361U6C0Q<79%;TI*,T,F(WA!.TYS1T,O0U=O,4%R4'-6651C
M9FUB1D0U-4AL4G1-:S4X;DPS=G)W.$5H:6E35U-E4D$S2TY&.5%$-#9%.6AI
M<59E9CA!>E0U8C%R5"\F(WA!.T%#-RMI9%5T8C1R-6LP3FE,959*0T$Y,FI+
M84ME-C<T<3E,>%8R2V]B5713<W1.<W!B,CAL159V0W9*,U T065*4%%$27IM
M26EY=WDF(WA!.UI)=VE:4TY!2DI"-7 Q;2MH4UA4=DQT,#!B9T509'E25V]O
M93E#6DA)+S)/54102U@P>%!X,F-A3W!N25A'0BM.1#E:*WAF=S@K6% F(WA!
M.S)P9% P-4-F,D9L=7!!4#EK655W,6Q0.#!F86US-2]M>"M:+U4W+T,K<%0W
M-F@U9W9P9CAI,CE/,%-N:"LW6&PO=T%.:C1-:GIK9F@F(WA!.W-V-6%2*W%C
M=FA1*S=F-U8X4&MB>7-J:5-3>$8Q2T]S;#(W,T)0>CE6;D=%86%!-E=K84Q&
M,48K+V8W,5159&0X;RM7;V%8;#%A85DF(WA!.W1+:4=Q23=$+TIJ6#1M*V=:
M;%ET4$M8,%)B+U1$=4-4+W=#4'13,4MG.',K6&(S555A<%<K=7=,0S%)-TUR
M>D1M-"M36FMF;&A(-C4F(WA!.T%E43-+3TUN:T9S9FPO.$%-4%5D47-,-U9D
M96<P-D<P;E-A5%,Y36EK36-Y2W=:;S5:<$A6;35"869:<'9H3UA&1452:F0Y
M4W9$23@F(WA!.WEM6&TK*S@X5VM54CAR-EIA-FDU<C9W=4IV5$MM;W!X56Q!
M9'8X<UI89VII4#%K:$UZ3&]X5'I8<D@U,G<V=G!384IP1G4Y;$Q:>G0F(WA!
M.W%O:F%/5EDW:&95.4U2=DLX0EDP0T5!,$)/>$E'*U9416(R-4UH-71R<E@U
M,TQP36XK-%,R;G9J8U=O:FQ:-&]#='59<F1R:7-);&TF(WA!.U9N-71+=CA!
M955"1S%25$EP5V%R<C,U,3(S;4-C5V5H>#-M:G<S:&%I*V=N3WE6,E%,1DDP
M+TYP2%(T-41Y:E=H5C%"3S)+;U1Y=F4F(WA!.V8X-4183W978T=U=V%F6397
M=$)F5$-.6F52:F1765)M3U93=G%X:W%R54Y$5V\V2$%R,7)&6&IB,DAK=3@O
M4$A53DA7-3%".55U-% F(WA!.W)E<%)R2EI'>EEF5GA#,75F,U)U,59O=G1+
M2D)H5D8K8V9Y.3AP95<W6'DO4'!6:4DW:'9-5VA2:6%2;FUD5FEU=T%%85%S
M54(Y4GDF(WA!.V5.2SAJ9U8V>FEQ13%85F)(4W)*-WDY:SE/1DM!53-:;5 R
M55)2=7I(<TUH3UEI3$Q8:WEX:$<U8VMK,"]3<B]!1FTX:3%J6%5-554F(WA!
M.U1C.4XP:'5K6#AS<S,X,'9T*WHX.'!H07I01DPT1#EF;30R4$9,2DE4>69#
M4&0U;GHK-6LR6DQM<$9R9FYN>6YO:FU,5614:&IU0G0F(WA!.SE646U7979H
M-E599"]W04UV>#9B2E!K1TUP9V,P<2]X9C5R,5$X9DPS;'%A3TIQ578Y65E7
M8U%R,%E1:FY--B])1$Q007AX*W58=VHF(WA!.W8K>&IX:SAG-R]#4&TS5F0O
M34AM5U=+2FE3,6AO-D,P:D9F,F988FY/-B]3369(>'@K:5!X;'8Y;DIE16YM
M53$P6'E,-5,P850Q<D0F(WA!.U1)5G5A.&ID>6=Z5&QV2#%:4S<O04DU6&LQ
M3U-F33=-:$%"4&-O6D]X5FHS;3-4=D]L,TA%,VQJ5G)F5'!%+W99-VTS17=K
M,T)R>BLF(WA!.TQJ44-L3T)R-UI::DU2.5%T='A39U!Q1G-A.'<V3"M:8C9R
M67):82]#.%5D;3!D-3A8,5 Q6C-E6&EW:4%N-&-K;VET.%9#3U9.<VDF(WA!
M.U-,,F$U144W8D]V=$8O339$5&Y983="0D=,;3%M-5A-=TQP16E22DI%8FA9
M659A375'-59J-5 R6E-C0T9U=&%2*V)55V\S3CE9878F(WA!.V%X5U55='A/
M<3--,4E8:F)M:T-'4#!0,TMW>%-G=6958FTX65!W,4]+<2]K;E$O>D<P-U=M
M=F9-=79286IP3'=I,F=I:F5I:W)(8G@F(WA!.W<S0C5)4&IN9%I76E9);U='
M-U8K14LY03E337E'34U054%$1DLW9T=O0G T8DA&6&PY,6]V;5IF>FYN,2MY
M,$=*-V%/=T5)=C=M-&<F(WA!.S5Z2W$Q<$%K8V]K:7%X-#%L:5E(>%55=W%K
M=78V>BM:5C-&;V-F;7I227)+0G9-5V=M1V%"-#92=CEA<DMP2'%Y338Q0V-7
M04<U3E(F(WA!.U%6>%8V,W)U=3)/:3)*=DQW='A::$A$1V=,4$I+=TI73E%/
M-U5Y<DIK14):86,K94]/3GDO=%-Z4SE'=F(R.5A7.69!1C!L5%EA9'DF(WA!
M.S525VDK2C=.2V4W9'4R5G=X;5(T<#@K9S=V,G173$1+57502GHV1"MB*S-Z
M4R]64%!.>'%%."MJ*U1)4#!P<5E":FTQ145#=W1'3E(F(WA!.WEK;6]W9&PV
M.$9"<FTP:'!H16-75#!J=39L=DTW,FEP5V9K2%AT4G15+WAH-6EU.5%K3S!T
M:EES3$\P27(Y;'924TM35'0Q27=Y,4TF(WA!.UEN.3-%1'I/-5%)13AY>5!2
M9DMV;'I1,30V5' P1F]4<S!K840Q1R\Q<$16,BMK-6HU33 U+U5B6FE)2$I.
M8W%:3WA6,DMU>%8R2W,F(WA!.V,X-"M28D1Z5DA$2&5A:'%6;$A$5VEA9F1Y
M5WEV56AV,VER.$QK8V1U43(W67%K*W0O;$)O;7)24D-F53E413A&;S%L2&1M
M-6%38W@F(WA!.W0V>$IK:VM$=$DQ6C9G=# T<E1&5TLS9B]/3G5N-G!B4U=E
M<BM9=%%L=%5U2EIB4EE7068P6E!4-'!C4$PV,W%S=G W3E%E=V]+67$F(WA!
M.WEI>2]*-U),4#8X2713,4=28C)',VE#>GI,37-:=$QJ-GI%+T=25T0P64MP
M1&=G<4M'=%1I<5<V:"M196=8>F@U9%DQ36-*27!9,%<F(WA!.U-&63!-2E)L
M-%)P17%,=D=".$MI:6A61D%Q-'%Y6'EJ*UAM;"M73E,Q0R]T3'4V=4I.44-Q
M63=H,5I),%9M9%9J5E95041N:7)"<D,F(WA!.T-69BMC:S=X-VTW=5AK8E1Y
M,71A4&(R-&A%2$)2>5=62FI*<S-)0FUI<BMZ6$-R2V9Z5FYG8E103'IR27!2
M9DUE:7-Z0FA103-I3E4F(WA!.VXU8C1Q;'9M>CAW+TQD<#5Q=$1C3S$O0G!W
M2#%3,'-W:WIZ6&LT3D=!-4)E35-I;&$O86(R=UED2E!.;%!334\O=CA!-TA8
M>GE#5V(F(WA!.WEH+W5J*V]F96UN*TA03DAM;VE8>E9+9$TP6G0Q.'4R8V@U
M4TPT6&QW=$,S*V]L0C<U;2M,1$8Y1SAV-7@O44A,-%1,;GDW;5E71VXF(WA!
M.S)/;C)K9&Y9,CAD<F%X0VMC35-H14$Y9TUX2E--:EI.;'-!<$5:1DQS5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)Y1%9,8C8F(WA!.WHK9C=1=W@R
M3%,S1VEM,W58:U<U1G=K16QA=7196DQ6,W(P1$YU=%%C2W!D-74O2UA2+TPR
M;6%3='9F,V,T=CED,%,R=5DU0VE1=7$F(WA!.S-0048T-%9I<68S>DAQ3W=&
M04)I2D5B:FUG:#9J-4PX;S)8;&Y2-')+2DDR=6=#2C=P131S+WA%<4-45G%+
M3FAV:TEC5F5O,E-35#<F(WA!.WDP85A"-%5+-6YQ52]W06LU1'-69&ER<U9D
M:7)S5F1I<G-657!R<3%G84Y:-6MI85IU15-U=U5U>#9+=%1U9FQI<7)I<G-6
M9&ER<U8F(WA!.V1I<G-69&ER>4@X>E!Z0S!393=T3D@Y3V5/-C!B>DIO<E-S
M>4%X=5!R6$TX6$)+<%%23B]E1F5X-D59855*:R\U,G@S:TU%;FPO>3$F(WA!
M.W%7<$Q++T%Y5$),5TE#<$)):W)+1%$K3D(W-60T1F-Y0350-65J57!!235V
M>D$X-B]S*U1L4'HQ:E1X+WAS8TAH>"]N9EE74&AW+VXF(WA!.VHU2#E3;$XK
M669N:$E88V5457%Q:VEM<C),.4(O2W U3CAH:C1C9C5W*S%F0V@O4$AY4#9K
M3EDO;4HK670S6E)3:GEN8GA/83AM;3$F(WA!.T<S:7)U4G1#-45I9C=,130T
M:BM*5&EG1#E1*U)5<"].9C5Z4TE48F%:;U5$16)#938Y46<K2D-4<G0Y3U!"
M1"MD.6DX1U X06YF6BLF(WA!.S%49E5V>G=U2$%&-35D<W<Q2VQ*1TE8+T%)
M3#%J*W9(:'@Y-2M8-U8T8V8X-"],.7%J3%EF;F1/9"]/5VLR9W)8.7@V1"]2
M4U=Y8F(F(WA!.S9C87@K82]U=2M8,F9R4RM8>50K8FLU0FPO36E.04YJ1VMI
M045E-U)W=VXW="]F2#DS+U,K>&)X9C!V<UA0.$%L:#5R=75)=G90>E,F(WA!
M.TLQ4%556&UO8U(X:U,X:54P-V)$1SAF8V9M=D9I-VHX+W=":2]39GE85WHX
M>F%0<7DK65E.5FQS3'1B;&\W9S-4<V50,FEG;'4W<&4F(WA!.V1$54AI2TA%
M>6A83#=633AD2# W*SDW3FQ,43=&6%EQ-T9867$W1EA9<6PK<RM8.40Q<7IE
M>3%E=V=V-U(R5U(T3&E.6D5,<#EL:4,F(WA!.T]O>%9)9CA!;%58-5@O.$%5
M<F%:+W="23!F.$%41EAF.'%I+TLO.$$V;&)44"MK85 K;4MO2%AF>7<O3'%W
M,&$K=G)0>5IP=#=D5W,F(WA!.T5K,$YO3&1&37))<%E)0T99-S W031Q:R]K
M1#AU4'DO,4A2-3%V9DET<G!Z5TYY.7!#3'E)>7EZ4F]Q34I3.'E)-V)U54I0
M9%11:UDF(WA!.W%Y8B]!2E9&*U8O+T%&2S)M9CA!4TY(+T%%>%8S+TMO=GEV
M+T%/<%<P>B]P1VHO<&ER069,6&Q4>51Q2&XS5DY,;2],<3)T-T=-=D4F(WA!
M.W5P4$1+8EIV<7A92UEO-5E),%%N;#A:0BM);&%C9TLT5EHY+WEQ3#AR+SA!
M<59T32]W0VMA4#A!<&=6,R]+;W9Y=CA!*W!7,'HO<$<F(WA!.VHO<&ER1&9/
M;6AE6%!+1W5A5&0K6%!)558U9%=V3SEJ=610:FQG:U-24#-3>&MW=W5R0GA+
M4GA:<58T:V=$9D-R,D1!<G-69&ER<U8F(WA!.V1I<G-69&ER<U9D:7)S5F1I
M<D1V>E,X:C9R-7DP1S$P,U1D6&926C=E.6IU,W551'-84DDU14U20U!(<U1)
M1#$W67%L:T@U638O8E<F(WA!.S)Q3F%E635B8E5D4W4T-V\S4V5U46EX,C51
M>#A8;EDP8319>71U2SE-2W!D-60O2V9Z-W!E='<V;&,K94QI-E@Q<E-3.6A-
M8V@K<U(F(WA!.S)W8C%%679+-$AQ.'5.04M!8CEA649E<31Q-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$F(WA!
M.S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%K=FTO6')Z461#;#%/,71)-S$T
M;FE2;TI::F)I:W-I>#$U<DA0,$QJ8FII<D=$*V1N;&@F(WA!.T)D:#=3.$PR
M17-L=F1&1F@Y35-24U)X3GAD-5DO:$QY:FEZ064Y34Y+<6579GIK.'0K6DY2
M:'1.3W1B<%9L3'(V='HV1G92,&5*3TDF(WA!.U-354\Q9EA";T)88G!G5DQJ
M*V9F;'%.-SE*-T<W<F%3>2MG66=J0V$Q4V%+,VEU9C-J4D5*3DQ-06Q/5W=R
M:'!84V9N:G S;V%:2D8F(WA!.W!Z;#<K965*-'!:2&HT<D)/64%)2E!384LT
M;6-I;VE2+W V171+:$Q0."\W0S0K<6AT35=),TXV8DMP=6=Y5E!$9UDS4TIL
M:UEE<40F(WA!.TM+:%5(-U1D36%6139V.$%N96UN84YO1W!F;VA:5S%S,V]-
M2#%Q;D4R37EW<W-$0TIV6&%1=E=-55=U0E5D669N1' P;'AA<&57.%DF(WA!
M.W0W:3)K=5AN,#9C-FU636-V<&=,1F)21U8Q4#AW6%EG:6UX3T=L6E U33@P
M4F5:.4%I,6E+,V4P5U=7-&DK<GE'<G%B960T9FDR1S4F(WA!.SE0;%1T5VU"
M53=X5C)+=7A6,DMU>%8R2W5X5C5T<6XU<659.4XQ,U5B5V)Y:F54859P.&QW
M1&5W;'%V1&)W97-::#9I2D1X3DM5.5<F(WA!.W9X3%-U*TMV44Y-=C1.4C R
M,#%#,S5#0SAH:G5)9S1O,T-6438Q07)V431Q:5-!975+;U!5=$<P;E4W4C=4
M56)/1S=T6D-'94=:1F0F(WA!.U-186<P238Q>%9%4C(Y=D5Q2DA%:4I'3TUA
M<6]!5E)464%D0CA)>%9D-E56465#,4%!0F].9T151$97:$1#06]#2T%H<6=O
M3FHW94<F(WA!.TMT:4]-56]O,DI98D19;714.'I5-'$P64E#14)J56E/;G Q
M02M';E1J-%EQ,G-C83 T<4)1549!0E%E1TMR9T%"44-G-C=E2C-/2W4F(WA!
M.WA64G5,-GET,VEJ=4QI3T=38SA956MD5DQN655516EV561-5E=R<49G,$IM
M5S5I34E54T=53W9(9U-11S56<%-O3RM+<FUV8DY*5$4F(WA!.S X87ER=T12
M;#%$1#%$>%-O<E@T:G-02$97;SE1<TI*>&)X,TU4>FM-4D5R<5AO<D974$5'
M=7I+469F1E9F1E5L,2]Z<C56.'93<$8F(WA!.W)7<%$R36MI3DMI>6LW>'%A
M33)W3W=/2W1E8S-2+TI/=75H1$DR;3-42W<V14=">41I<F9K;B]L1$Y!+S=:
M,7 O=T%M17A63W-69&DF(WA!.W)S5F1I<G-69&ER<U9D:7%H93,Y:EE7>C-6
M.6-25W1S;$]C.#=R2$=T5%%66FE!36Q'2FMA07-O2G!J6&YF5F9)365M,FLO
M;5<X0S(F(WA!.U9Y1V%Y:VEE8VE1349*6E)B5C5I:DME:$=0-4M763%6,3A'
M:E59.&-X-BM8=E V2&XO-6<S,S504S(O;&$U=CE8=3=F5$IL,4-#=VPF(WA!
M.W1V56M6:VQ-075V5FML1%-X;$M,43E2=E1T9T]!-'934E1::6I%4G%03#4O
M97 S:VXU5'HV2')C;#=Q.35P>G=736-7<6,W94MW;&PF(WA!.U8U-W P45=Y
M=WA2>G-7.5%!2VA!,EE(;#A73%EV.#%J.')',4]16'5S86AB;C8Q84ML>$1$
M2'A7.6%#15)C8F]W;&U-82]6-7I(>DLF(WA!.V=I=D=M=U939GEX<E U22M8
M+T]6=E!P,G!A<&4V>$$P<6]P:&4U5V\Y84=F6D502#%*2&55=%%D9&E&66I&
M6#!,9U8U3"MC*VI8.34F(WA!.W(O;"M586YP;'):<V93=#E0,4LV:W1H8S-W
M;FIE03A59W56;%9#04]*02LP9'@Q=W%I4%!0-70K6&\T3F4X<G1"9%,S-C)L
M,V%Z5%$F(WA!.WA&-'A-3$YP5%)A*W%51S1,:$])4%4T<7IJ>50O=T%O6F](
M+T%'>G)4+VMW;4)5-GA6,DMU>%9X24%*2F]"=5-C5E-$52]0+T%*2S F(WA!
M.W<X8GI78E9:2S Y1T]14WE6-F8S8UA.+W=Y*T=M>5,U4DQ!>FE/<5@O=T1+
M>%9U>G@P5%%D5C%4;"]D5&DS*W)7-V8X.6)K>%5(,%HF(WA!.UHK5G(V<%)J
M.&)0,DDX5'5"82MV9FUN9F=M1%1.33!63VXK;5A%;#5,=C-#,C9O;C-T:G<T
M23AZ2UAU1F9E='E08TAF-$\X,5AT4# F(WA!.W8U=75Y;BLK9$UH:'-10V4S
M<55L:TDK;DAX-$0V640T-W)W2'%7>"M5+VMI5#1R-GIL,4MC+V%U8C(T;FYK
M4'96;F]0;T=0-3-*,$XF(WA!.V4T0F9#:6EF3E9Z8V%.;U5&<G S;' Y9G-)
M,%=*<D=.;S92<$9X15%+4S@R8U8O;%4P<%4U5D$X57)-<4QK67-C6F)%,'<O
M>G1Q,3<F(WA!.THO:&EA-CAH2F94:&)U5T<P=4DQ=5I,5F]40C958V)X0F\T
M,G5!9'585&IU3FIK2FIF;F)'8U%$44YO4S=U>%DK6#<Q8E1Y1%HS:TPF(WA!
M.U=526A7,W,U;&AK0G5B:4YL;&AM9VEM5E92;6-"5EDQ8VXW2C5:1FEQ95HW
M<7E45G U<&9Y+V<Q16XV=D))>'-:2'5F<69O2S!S:%HF(WA!.UE8:%E,03 P
M4U)R25<U3'AO83!65E0X:EAK;'@U=G-O,B],=3,P2S R-#9N.5@Y3U-.;S1:
M+W%N17%N6#9T4E179T):;$IR4E-Q.6@F(WA!.W=+.&$O4&AT1E1Z2C5*;75R
M,F5/.&=V>$Q&63)R8W!P;%-33F=&:&0T-&I6;#0Q-6-I4T%!,U1&6'!(;E)9
M,SAM-C=,=V\U,'DW;U,F(WA!.TM-05E',C,S1TMR+T%#5"]!36]:;T@O8D]T
M4"M40UEQ;E=+<&1R*W8V6&]/;'DV;'%5=G R.&1!<6=695)Z.6U/3F8R;F)S
M4#1:6FDF(WA!.WA3;DMG:55G0EI9:G!/:B]!2FPV,G,Y-7$K=5-A2%E88FU3
M,#!U,FAG3C%$0WI%<DA*33!D5EE,5'!5*TY/;5I5.&U'1S!9.%)(6&4F(WA!
M.VUS0U(U;6MW2#57*U=::4<Q95<K,7511W%T<4XS3DM"+W-&36-F.$%W=5$O
M3U1(,#%(,T)0:&IR=6XK;6589$$P;T0Y1S9D8E=:07 F(WA!.WEG:%-.<61.
M>6]"3U54>7EL>DI,35)!-4IH;&%867$W1EA9<7@O>FQP+VY7.7-5:3AQ871B
M851D1&M:6G)M,BMS.'5H44I6=4MD0T<F(WA!.TI6=&HP>%9J*W5A1BMB.'1H
M<'$V6G(Y9TY3=#0U,78U,F=E1T-D,G5,9&]$-E%-<%AH16MV26AT-C!P4G9H
M5EEZ3F(O05!/5$8R3&HF(WA!.U0T-VY48E)O-#158E5M5E974FYH4'%',D-"
M,G%J='5807%W1D%&<4U66D1P96HO;EI'2DQA+S%R5'!,539D3D1"37-B9E=&
M=F5+<D0F(WA!.TDW.$%R9$-Z349P52]:3S)+;V)59$4O3S93>'5R9E0Y5W1B
M549O5%IE<$ES,'EX5B]F4GE4;3%8:SE+.%A#*TAC1FU+<'8U4C W.#$F(WA!
M.TET9FIU4$Y';S)D>'!+8659,F=T4E)J9D]91UHV96Y(*S=8:$MQ,4YD+V8T
M47%4+T%*<2MB=DY7;&5B=DM7;&%03F(R,6YF,V-8-E$F(WA!.V53-W196EAJ
M339),&%X6$9'8F)O57)88U5R431Q:B]0+W=#6E!K*S$P:E@Y175R>')F55!Q
M;#-B0EI96FM1>6TR6C%54T9/0C5#=D@F(WA!.V9E:'!I<DIV2E X07EH;6=F
M.7,V,"\U34II<4LQ-UAT3C!,4W Y5#%'6#!R84%63DXR9&HY;$58.7!M3W='
M5UES6FY,:$A.17!!0WDF(WA!.WAZ>3EO3W V,7%54&UR>E)&-F,V9D9O;6EN
M9$Q+3G5K:V<O875'2%4O<R]0-T]2;'E#031)9D4Y+W=#>&A'2DIS<WIZ1&)(
M67$W1E@F(WA!.UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EAL4#4U44UD43AL
M,V9P6#@P9&QQ<7I4>#9F871D<S!A=$=E3$MO63=S1C1I;2]Z<&ER2B\F(WA!
M.TYV;&9Y,41O2&U$5UE.370T.51L<TPV5G(P4DMS>&57,EI(67-2>41-;V]F
M8F)&5C)M*UED4#A!3#,U6F%4<3DO=T%J8E=U;5=:6DDF(WA!.RM*9&DP2TM&
M44U60DI*.&-S>%EJ:VM):FU737!53$M".'-A9&0K83=U,S@S-CAN1S)1;#E!
M,%IT,'0Q0DE&>$U$<S W57%/>6IP=C F(WA!.WEC,'AI0GAX-2]X2'8X=F-W
M:4],8W,W>D-B6%EQ-T9867$W1EA9<3=&5D\U=6)A,6=E935L4T-#359K;&M9
M26EJ<'5Z54%X5F1&3$8F(WA!.TQ%:W-4<DI&26]A3U)31U9L659"0D=X0D=+
M<G-69&ER<U9D:7)S5E-F6"]+2&QZ>D)0<#@K<U=3,V-U;'I#-7-'6FY8,'!1
M5EE-3T0F(WA!.TQ89$(Q>%9+4'I'.#!A2' K:39J;SDU8VE'+S%(5&(S-F]J
M2S-&:6QT23-%=E1G<D5),T5%-S!.359E5'(U.%,S=&1,;#AW:4]7,# F(WA!
M.T\P=%)O5VUX3GEH;'504E5#-'5E2EIM84QA:41P=EAJ=FPU,4%J1&=W9WEY
M2#9V-E!K-%IY5&Y-=WAX3352*U$X-49L96QF.#5#858F(WA!.TUI3&574#<P
M9V-J8GEC:50S4$)H.% X07=2>D<T330U=RM2+U<S.$=P03E73R]C9C$P>4)V
M>F@P5#!X2D9P5W%4265P4T=(8F%U+TLF(WA!.UIC9V-O2#%!>#DT64A5:5 Q
M0U5F9D4O94Q#5"]!4$LY-&UK;5=,>3EC<W%T4S-:-31)*V$Q-G9Y3D4K9W1L
M;FE9=C4X5UDQ3T0O5DDF(WA!.V9B*W!49CA!3VYZ2$EP1G0U4V%P*W<U=D5K
M2%@K5TM.:C Y.$AJ-&8U+S)3+U5N.'IG+VXS-V]Y4#9&:2]M1BMB3C!A,FUH
M,E5A:U8F(WA!.T-V0G%->$$V,4IJ441(>#A85&E0*V%V-7)"+W1H.3!#;U-A
M>"ME9#%1<49S-C!R.5AS0SE.-B\X9E!$16%J2"]!1&-N>4-F>E=0.$$F(WA!
M.VU:5#A!4'9,5&%.*V16-D%:=%IV.75Q>#(Q:F$W9%(X4U1P.4\R4&IJ<&IL
M.%I"2#5R=7A4*TUO<4$O3%0X=S4R<F4V=G)%>2]#4V@F(WA!.S%54G!55G)X
M6&I/3R]W1'0T+VU*9$U9+S!Y5'%:.4U59FI-<48U*U%6,6513C9O.5=60GEJ
M935V:DLO36)Q4GAT:T<S8750:C5E:UDF(WA!.V9A:CAZ<4)Y:&E(>E V2'1'
M;#)J5V5M5V1O>$)A,F=J:5EJ;U-I0F1Q0F9$=T=3<SE7>7HQ4D]+=7A6,DMU
M>%8R2W5X5DIF33-K+U$F(WA!.U!-9&Q.8C9N6G=Z4WE7.#%T1F134E)Y4U%R
M3W9%=$=81%5)-FHS>%8U;#5F+TMZ55IB-U=D3V@X,7AV0G P:TYP4390<')Y
M,$9T1W@F(WA!.U=:<#=5:"MU>%9I1#,K2W5316E/<DE4235&;&1P-4$X-C)C
M0S(Y<#4W=6)E0D)225ET33!P14%!<'-Q,C1!=T4S>E%35'I6=CA'9FTF(WA!
M.T0O-6-'.2\W:#)M9CE534-'2RM6-#EB,7973E)T=$XO364T;'5O;FM::6UJ
M5T5,,&AF-G9+2DAK=&PU=6MI-S O6DLT3T5$9$%I0C F(WA!.UI6+V=Z.'=F
M+TQG,W8O8T\P>B]Q:&A3-R]";C5G+SA!;'=B,R]U2&%:+S%1>%9J1W584&U8
M4B]-3FIO.34K6E8Y0E!D1E)W8E)R3G4F(WA!.V9Q;FA(=VQ7,CE-56(W9&5M
M1E=4+W=#1%!Z0B\X=41E+W=$8T\P>B]!2V]91F0O9WHX=V8O3&<S=B]C3S!Z
M+W%H:7%5*V%D3C@U*U@F(WA!.SE&;3%+."]-83EH:51J1VMP,&UW;59:2D1X
M475S5G57-$)J.%=+<S4X=&$Q6C8Q;V1R<59P4#A!5UEP5EI';3E.;W%Y=W59
M<&%X=4$F(WA!.WE%4TEW;V-65%!&6%EQ-T9867$W1EA9<3=&5DM+,71O<%IP
M;V]L4U<T65!026]!6C)646EL:C-O<6=9<7$T<3=&5TXV.6\U,')2=&$F(WA!
M.S%0>6YP9'-V;6%7,FUA,EI);S%A861M95E">65(3&Y+-5DQ3S4V-'%X5'DO
M<68U,50O53=J5DQ+2T525U8P.3=A1TM%97)D>'A2=&(F(WA!.V]S:7I-44I:
M2FY8;TME;C<Q2E9"6$AM=C@O9C!S;VHX<E<O,4=%,T%D5F%/:W=30W-4.&I/
M>D-S=E)246YO4TU66C=A*U=D23%0-F@F(WA!.W)M=6%*84PU:4U&=3EY>DEK
M>E%Z4FIN=U-5:F8P<$=B:6-#<"]I<G-6475P859P;7 R-'1T4G19<GDS1'))
M27 P5U)E84=Q=%)G4E4F(WA!.UEQ=3 W5')$5&)/2WDP*S-J=$Q/14525SA+
M:$57<$Q':6IB8VMN1E52:7)S5F1I<G-69&ER+R]:/"]X;7!'26UG.FEM86=E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@
M(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-
M.DEN<W1A;F-E240^>&UP+FEI9#HS-C<Q0T-!-$0U0C-%.3$Q.#=#-#A#.3 X
M0D(V0D5#1#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O
M8W5M96YT240^>&UP+F1I9#HS-C<Q0T-!-$0U0C-%.3$Q.#=#-#A#.3 X0D(V
M0D5#1#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S
M,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#
M;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HS-3<Q0T-!-$0U0C-%.3$Q.#=#-#A#.3 X0D(V0D5#1#PO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M>&UP+F1I9#HS-3<Q0T-!-$0U0C-%.3$Q.#=#-#A#.3 X0D(V0D5#1#PO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X
M/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S
M<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM
M<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C8Y,D0S0SE",#9",D4Y,3%"03)!0S5%,$,V1C1%,$(X/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 W
M+3(Y5# V.C0Q.C0U+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS-C<Q0T-!-$0U0C-%
M.3$Q.#=#-#A#.3 X0D(V0D5#1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP-RTS,50Q-#HP,CHQ,2TP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O
M,2XP+R(^"B @(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0
M<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP
M1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @
M/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6
M:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54
M<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E
M;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S
M/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO
M<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$
M:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU
M;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @
M/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z
M9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY
M/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT
M.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T
M<FEN9SY697)S:6]N(#4N,C \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O
M;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M
M93YA<FEA;"YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$YA;64^07)I86PM0F]L9$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&
M86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD
M/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-2XR,#PO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6%L8F0N='1F/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @
M(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@
M1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N
M,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.D5X=&5N<VES1F]N=%-E;G-E/2)H='1P.B\O=W=W+F5X=&5N<VES
M+F-O;2]M971A+T9O;G1396YS92\B/@H@(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z<VQU9SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y
M<&4@+2!45#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&86UI;'D^07)I86P\+T5X
M=&5N<VES1F]N=%-E;G-E.D9A;6EL>3X*(" @(" @(" @(" @(" @(" @/$5X
M=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93XP/"]%>'1E;G-I<T9O
M;G1396YS93I/=71L:6YE1FEL95-I>F4^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/DUO;F]T>7!E(%1Y<&]G<F%P:'D\
M+T5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @
M(#Q%>'1E;G-I<T9O;G1396YS93I697)S:6]N/C4N,C \+T5X=&5N<VES1F]N
M=%-E;G-E.E9E<G-I;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O
M;G1396YS93I+97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z
M2V5R;FEN9T-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&
M;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XR,S4V,S0S-#DV/"]%
M>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@(" @
M(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^,C,U
M-C,T,S0Y-CPO17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93Y!
M<FEA;$U4/"]%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^3W!E;E1Y<&4@+2!45#PO17AT
M96YS:7-&;VYT4V5N<V4Z1F]N=$MI;F0^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D^07)I86P\+T5X=&5N<VES1F]N=%-E
M;G-E.D9A;6EL>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E
M;G-E.D]U=&QI;F5&:6QE4VEZ93XP/"]%>'1E;G-I<T9O;G1396YS93I/=71L
M:6YE1FEL95-I>F4^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93I&;W5N9')Y/DUO;F]T>7!E(%1Y<&]G<F%P:'D\+T5X=&5N<VES1F]N
M=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O
M;G1396YS93I697)S:6]N/C4N,C \+T5X=&5N<VES1F]N=%-E;G-E.E9E<G-I
M;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I+97)N
M:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K
M<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]N
M=%-E;G-E7S$N,E]#:&5C:W-U;3XS-C,V,3<Y-S<T/"]%>'1E;G-I<T9O;G13
M96YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/@H@(" @(" @(" @(" @(" @
M(" \17AT96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^,S8S-C$W.3<W-#PO17AT
M96YS:7-&;VYT4V5N<V4Z0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93Y!<FEA;"U";VQD350\
M+T5X=&5N<VES1F]N=%-E;G-E.E!O<W138W)I<'1.86UE/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @
M(" \+T5X=&5N<VES1F]N=%-E;G-E.G-L=6<^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *G 78#
M 1$  A$! Q$!_\0 'P !  (# 0$! 0$!          @)!@<*!00" P$+_\0
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MG7:H^3PRD96K-5K72VJ49X4W5N9<B9EC,S(@+>P;>8:_*2$Q\G$ Q$H"O*7
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M=C@KHGO$4;8N*J>8HN-R6N#>NKUM--M&1('XY"D2K?F(Y&0L>W,*QSTJ0$E
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M,Y.<CXHL1'V$JO)K0EO:(QW9#S(<$VDWR?R@0UQZ=.]:+<&A,P[TP"$I<BG
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MRT-'#&-)9TL*F4H,5I8X!0)Q*0Z2E-;68PQYA"U1%$J.=G9AA*0L$2B"^0R
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M"+QL6@B\>=:%L(?=K6_&_;KS^6L(OUA%_FM:UK6M:UK6ORUK7C6O]&M81?X
M "PZ  (0 #] A '00ZU_)H.M:UK_ ,M81?K"**=L=1H:QZ5YNYK*AYCX]= Q
MF]9NIE*R5,,5981$Z-88J>N/"0];TJF4ADDNG\(CK?&6'85C<S+9#,W(\IJC
M)J=<4XV)SRP/?G/\/L3BSIXKK[GZ/72.%&5R]'RFRZ_F$*U*&J=MT?G-1V+*
M*OF22/3UA(2L<ZBXY%$W!3&Y<TIDR-\9CT:SY1&>,]&01PP<>[Y$9&W38[A2
MLPH6%V1_V=SW^I<I_P#0UV$7([]CS_P>NS/_ !FKG_V0YX7M/[8^B/M*[%L+
MQ3")A$PB81,(F$3")A$PB8107Z+]27C'E[2Y%9MV1M3+$/Q #K^#&;G4X^;+
M\_W"M98[M87'E _&_ACE:Q@2;\?54'W!]V[\/=G/&/$VA]LLM2VE?@BOK1Z#
M1:#^NR:HT&H:.HI63O\ ZO-8:OX@M-MU-J*N,RM_T$)[Z;/@6,SH/^\+!YJF
MZ8>MUT_TD_K:]]/7DJ2/2T0_E_QC+&5?.W]"G4;$$EQ5QF+F$PV%[+WK0M+Y
M3+)&S:UL7S!(=:SL%)V+<,\.0,K^T#BRF@9C5Z'231T,$CF\XVU-2'5E9GEH
MI:6GE_9*U27B^XW!Y@L5KD>>7?2L=,\9Y.,<9$4./VI97L\0O&;/2>]1SM-P
M1RGO[J9=$(^:H+7_ +G+>ZE3=Q0&>?>82BAL54L5.Q$\P(M%EN3*J?3R]A\J
M6XWX0 C]I.U3L[X-C?3<!<+LJZ@-+/QA)$:*-XY!SZNJ;/=ZMHW)CF; #GU9
M!DD4MX9O]W(DO=R=$S(=Z.UPF(/E%$64D1Z:F%Y\0<!6N<Y^D/PQSC\@Y-=3
MIK0F*'X8]36YC4T\<M*2O @*4; I1I(.TJ"3?)J98U15(XD"]F]KC!%@'KEG
M$/:SQOQ%WD<MU=;*-^1Z%9PZACTGFU\[7NK9FD;.9+4OC=OZ@!(6RT'"]FH-
M+FTHJ)6X_/59$SLCJ&$"%ISN"V(.'BK,B224Q)2=.460G(+ 20026$HDDDH.
M@%E%% T$!998 Z    Z" .M!#K6M:UG-B2XESB7.<27.)))).223N23N2=R5
ML(    P!L -@ .0 7],A$PBUU/K>JNJT?S]E6+"H*FV7LPO<IDK0RG*0Z\_H
MHDJY62J7&"WK>@$HR3SC!:]H "%],L:VZ6VVMUW"OI*-N,CTFHBA+OH->X.>
M? ,!)Z!86\<2</\ #\?>WR]VNTLQJ'XPKJ:E<\>$4<LC9)7'HV-KG..P!5?=
MF^KSR7!_F$T46S&UW(KW%EAB,=.;&?XX?\4]YEQC!O:?SKQ\TUH'8 OILH)@
M-^[6D7#M/X9H]3:9]5<I!D#T6 QQ:O!TM48/5_K1LE'@"-UQN^_A(=G5IUQV
M^6Y\0SMR +;1.@IM8Z/J;DZC]3_:4\-2/ .Z16'ZD?;E_#&DY>Y9-;VM4(1)
M,F6L\@G>DVO/M+.W)#R(G!6PT>_TMENI"\D/Z0-#-]FS=ZV>/>+KT=/#O#A9
M&[85#XIZW3X'T@MI:.,G8XD:\#ED\US]W;?VJ<8$Q\ ]G[H*>0EK:^:FK+MH
M')K_ $Y[+=:8'$[XJ&3,&[=3L:E^/WF?J<]&?QM_=$AKE@7?]?C*63F'BT6;
MY_BQPRL"FJ#K@E WL'A7(-&:\Z#[A>XP>H_)3M"OV][OOH$#_;IFU).QZ>B6
MX1T3\<O7GS[\DJ/Y,>WCC;UN,.-19*.;]-01U[GX:>AM=A;3VF;2"1^<K [I
MDY)6^*S]&;G"+[(5V1*)[:K@#V[4)1K2H3&E&]?46_N]@V;(RMCWY\[U,!>
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M-=RQ>Z&M*M.V%/*^)N+40[JG!S*VXJ"G1J( VSJSGEL?X*)/V//_  >NS/\
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MWXTUM#FB*%Y"268$7OU4WLXXANSA+Q'Q(]^X<88WU%<0/V6F=U/#"1_LXI&
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MX$"YW!S-V:J<0R$PGG%RX@K[Q%/(*BGL-B@VJKA754='3,9U]*K971Q[C_\
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MQ1+#7=I/&$X8S!CM=OF-=- P^U#%-,UEKMF/6_-T-)60;Y',JUVDN(N9>?\
M215 :O939&DT 09I*0?BJ7?'#X\JDKL\:4:9C1^-?$+CR=G2B\>?E];WOSO5
MHX0X>LFEU%;HC4-Q_.ZG^<U6H?K-EEU=R3U$#8F_U5WSA7LKX$X.[J2SV&E=
M718(NEP'XPN6L?Z1E14AXI7._6%$RFC/[ 4K\V5=#3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A%A=D?]G<]_J7*?_0UV$7(!]D9D\=A?+?<,JEKXUQN-L5M5\X/#X]+4[<U
MMJ,J$.6AJ%:Q2,LDD'N$$L'N'H1AHP%%Z$8, !>-1404D$M3531T]/"TOEFE
M>UD<;!U<YQ &^ /$D 9) 7E=:^BM=-/<+C5T]#0TD)FJ:NJE9!3P1-)R^260
MM8T9( R<N<0UN7$ WZWMZL',=5M&OP"['79+%:7XZ!GB(C4#"EV/0O@BD$K<
MD>DR  MA%H:9K0OCJ2+0-*6Y,6: [-"O/:7P];HOYE*Z[U+FY9%399"W/+OZ
MF1FE@\6QLFD'ZS&@Y7"N+?PA^!.'Z8"SU#^*KC+'JAI;;JAI(R<Z367">+1"
M"0064\-74-..\AC:X/5#,NNZ]_50Z.BM>L35'':3L33)#&-FC*'2.(UI$C#$
M*I^=Y;+5&URT"=4J0LB%4>K6*SE;T)M0-#,E/7$HQV%QX![7>-N'#Q-=[='P
MYPK#-'+:J>\ROM++I5U.(HS;+?*R6XW&;T;7*VNF@91-I6U+Z:H:U\K'?/=V
MI.UCMVKJ:>>WTEOM](V:2V4<H=;J*"*8QB2?,C9ZZI<]C8LU4X,+MVT;8^]=
M$Z[CE#TJ*8K>(Q]]OV)-5CV[H2X][1*G];(*W;# .JT+66RLPVF-DNQ)K(%M
M,<2Y2W.Y870U<!+KY8"<69*T]F?#=K[E]0)+U4B&G=+)6-[ND;4F&-U2R"C:
M[2^GCJ.\CA=5F5\T36S/B@=(8(^]\#?@\\'V"CI*GB6C9Q%?0P/JO2IGS6:&
M?4<LI*$1TS)X0W2W-QCJ2]VIX9&"UC+6F=E9X\VI&9@:6UC9V\K1"!I9T"5L
M;41 ?U24B%$40E3%!\[\%DE !KS]-9OD4,4$;(8(HX8HQI9%$QL<;&CHQC &
MM'D  N^4U+344$=+1T\%)30M#(:>FAC@@B8.38X8FLCC:.C6M \EZ6>B]TPB
M81,(F$3")A$PB81,(F$3"+XUCBWMQ>SG!>C0$Z_,U8J(2EZ_;]1GC '7T_EW
ME36N<<-:YQ\&@D_4JFL>\X8USCX-:7'Z@5KUUNRF6+W??=N5BS^SS[_O6>Q5
MO]GC\_=\VZD^WQ^WSXRX90UTGZ.CJGYY:*>9V?DPJ\CMEREQW5OKI,\N[I*A
M^?=IC*ULZ]H\=L7N^^NL.:FC8?/N"Y7K5Z$6O'YZV%3*2A>=?R>/.7;+%>Y/
MT=GNC_H6^K=]D)5['PUQ'+^BL%[D^A:JY_\ =@*ULZ>I;Z?K/[OF^QN>3O9Y
M\_==GQA\\^/\G[D7.'O_ */9[O/[,N6<+\1O]FR7(?3I)8_^HUJO8^"N+I?9
MX;O _P!Y03Q?]5C%K=U]8+TUF?W?-]90$[V>?/W4TSA]\^/\G[DBCA[_ .CV
M>[S^SSETS@OBB3V;/4#Z;Z>/_J3,5['V=<:R^SP_5C_>24L7_5J&8^_BM:NO
MKI>F V>X)71BQV,#Y\EM5/W:9YWK]@3EE=HDPO/[-A/V'^G+IG '%;N=L:P>
M+ZV@^QM2X_4KV/LLXY?SLS8QXR7&UCZFUCG?4M;NOV@WTXF_W?*2VU'WV^?'
MW55;V3[_ !_D_?:AF\>?V>_V_P!/C+EG9SQ,[G#21_3JXSC_ +L/^K*O8^R'
MC-_M4]!%_O*^(X_[H2?4M;.OVD7@M![M(H1TR][UY]NV^ 5^G+%O7Y?I.]L-
MHPZW_+LKSK]NLNF=F/$+O:J+5']*HJ2?[%&X?6KV/L7XL?C5562+QUU=8XC_
M +NWO'UK6[I]IEY7)]WW)0'0+AX\^S[TW7+/[OY/=\I,7SV>?V^/?X_IRZ9V
M6W<^W<;<WZ'I+_M@C5['V(WX_I;O:&>/=^FR?WJ:+]RR?G/[0C5/0G2E04B9
M2[W5\7LQ]5Q$^<RR7MKF8@E#JF"3 T1;<VMR=.2E?9#\*/JU"A:;\NH=FY1K
MV)R%8\\;GV<5EMM=;7^G1U<M+&)A3PPN8'0L)-0[4]Q),<690 T9#'C<EJ\+
MSV07"T66XW07.*NGH8FU I:>F>P/@C=FK=K>\DNBAS,T!HU-C>WVBU=$F<V7
M'4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%A=D?]G<]_J7*?\ T-=A
M%PY?9R*_KRT?3K]0F#6=:+!348?+GIK0;"E+NT,S RO;>T;=& #F>^.;.VJD
MR]U1)D V\UQ2GJ]*/:B-+7!3& PG$-D'$5HJK09GP.JNZ[N5C.\+98IF2Q9C
MRWO&N>P-<P.!()TD. (U7M#X/9Q[PQ<N%G5<M"ZXMI3!511&<Q5-+5Q5=/KI
MP^/TB)TL+621!['.:XECVR!CA]W25W<R4;2/[G7-UA1KH2WK63'+9M?*:*/#
M.U5+7AR8*<,%@+=)@B.33N2^5GXEE@$Q#I'V4TUF0[2N*[YAN[3^#]^#?2<.
MU<G%_'%+3U;[7.9K6RL@88340;MJF1.DF9W%*]I?'*0)*FH+ S3#3N%3Q.R]
MAL/9U<APO4T5/Q+VA5U;# V7T6.4VIDX8VEHK=3NGJHXJVHU=_)7N,=0RGE;
MH[F)PD=K/EWU8R>'*3.@W-//S#^ZQ,79I>K-O:S'L;T=)#&AQ(5 AK)"FAL;
MM-43;6@:IG2[.F*Q>8H>W22Z3MCDK2$H>L\:VF7C>]>EW2Y3-M-&V6&UVJE8
M(Q"QX+35S3O<_753O#97X@#6-CCIPY[&%S_OW@?\'BDLE%&;Y=N_K9XM==!;
MX0P,F?$X,C96RO>Z2*ED<2P>BL;*]CG.RV0L%FT0]9SU<)_&6B:0;TY03:'O
MR;:YCE<1HCI20QMZ1:-,($J:7MH?ES8X)]'$FD[/2*CRM'%&%[%[P"#KG$W!
M'!M/*^"?B;N)HSIDAFN-JCE8[ .E\;XVO:<$'#F@X(69J.S;L\I)I*:JXR]%
MJ8G:):>IN]CAFB?@'3)#)"R1AP0<. )!!Y$%9+KU=/6/#O\ C/2[DF];_+0>
M>.H0;\_3]NU0_/\ H\:_TYY_D;P3TXKC_P#>=I/_ ,H5O_)[V<=..H?_ 'Q8
MC]C5_O\ "_>K^7K?Q?2ZE'D/ZV]4#T\ .M?^?O\ 'T_;O>_K_P#PRG\C."^G
M%D/_ +RM*?R=]G9Y<=0?&[6//[E^=^L7ZMA7U/\ 2_DX=>-[UYHWI<K\OSWY
M&0+6]:U^?TUX_EQ^17!QY<5PG_\ 7VO^*G^3GL]Z<=0?^];(?WA:DE_VA7N.
MNM&_NA\60N#_ "VQ?-;E[';T6T3[=_I:-^_%:7X.PZ^@OB;^F_KO7[,?D3P@
M>7%</_CK8?\ YD_DVX"/L\<0;\O_ $C9C]CQE:I*^U$WF\ 5(62D^>SW,:11
M\L)#*)6Y&I#?9L %8T1;X(1Y:8T98QE"V6 ?C18C :'YRXINS[ANJE$=-Q$:
MMX&MT5//02R%C2-1Q&7N:-P"[20"0KNC[*.$*V9L5)Q8^MD [QT%+4VR>4Q-
M(UG3"7O:W< OTD-)'DL5>OM0W33$G1MZRM>66IW+0)?CG2/\=B4+3 EZ*-<-
M-J:QV/9):L\LXP)9.MDEBV(HL0M%Y55<"<(4,ICK^():1[AWC8)JZW4\HC<Y
MP:0R:%TCF^J6A^G!+3URJJWLOX#MLYBN?%,]#(X=ZRFGN%JI9A"YS@PAD].Z
M1[<M<T2:<.+7=05JU;]J"Z^>#]IT"CDAA&/W>T2.*R8LD&O/C_K4CM=Q2ZWK
MS]/B&;\_GXWKSEL>'NSF'V[_ "R>ZOIY/^A2 JU_)#LD@_2<3U$V/_S.EDS_
M .%MXS\%^2_7V]0R7;_Z'Z"Y)C6C?/M^)).:V/1?G7G_ /SJ<G;#XUOZ?%T+
MZZ\;\[\ZV]"[+H?;KY9?^TN3_P#_ %Z<*/Q5V+4_Z2XU,_+_ $EXD\/_ .5I
M6_'XK[B_5@]2^5>-*?4?X[AY1OCR29;7"R3X6A^?'D]J;GI8'V_MV%2(0?.O
M=OSKZ3WO95%[,,DQ\<7PY^$DD;?[*:^Q&#V:6IJ".NGB4Y^$DL3/[(7H%]B=
MZ2[7_2GK3\5QOXOG8OB=75,Q;+^OC?\ _1\*-V#QO\M%?7Q]0:WK(_&_9I%[
M%HEDQ_[-*_E_OZH9^//JH_'G8[ /S?#M5-C_ -AGD)W_ /::T9^)Y<_!?<7*
MNHY1]7[[0YQHR%F;WH8&SU")TW'@^GG?@MGC+(FU]/R]BO0=[_1#OSKQI^57
M9_%^CX8<_'5]KMC@?^\JGGYM4_EIV6P[0\$RRXZR66T.:?C+6R./Q;]9*^\J
MHELG\?C3[1URX=\3QLWW]OR61_K_ )^=/=DLGN_/?N]_L\?X_MQ^7/"L7]'X
M5B'_ .EML/\ <8]/Y2>"8?Z+P+$/#^86F#W?HXI5]Y?#'*\G^LR^T/<H*]F:
MWLX.[D@LD$+7GP+SMYZA:A"^N_S&#7GSY\>-X_E*MT7Z#AF(>'\Y@A]WL4#_
M +[I_*_:H/Z-P5$W'+^=4U/[OT=KDQLO;;O2U]+=6:$Z1>N'S ^G"W_&FH;&
MYZ;C3-_K"\#<+^?Q!WO\_P!+9GCS]?.0[M4GQB*R0L'0.K7O']FEC_<J'=MU
M6!B#AFGC'0.N$CP/#9E%$/L6T6;TJ_1A_B_O;U<JM=?/M\_<W1W*C5[_ '?E
M\/YEU?O;[O\ %\_$_P#/+5_:G=/U+;;V_3=4/^R6-6<G;9?3GNK+:V?[PUDF
M/?IFB6V&;TLO0B(]HU7J/,K\+QY$$SLKE).G%XWX%O0&V*)SPA]WTW_=0O'Y
M>?/URV?VGW]WLTMI9YBGJR?[5:1_95E)VS\6.SIH;)%YBCKG$?%]P</[*VPS
M>FIZ!:78='=4UK(MZ^F].':U8!]^]:\[T+[B>FC?G>OKO0/;XUOSK6M9:/[2
M.)7<I**//+12-/R[Q[U92=KW&;_9DM\7^[H&G'_>ODY>>5M=F]/K[/PC]FQS
M;GM_%KV[T)Q[<<]^_P ^/;Y T70V%"]W[-?#\;\_37CZ9;/[0.*G<KC''G;U
M:*A_^>G>K*3M4XZ?[-U9%_N[;;?MDI)#]:VNS<9>@RV>W[N2\@J_;KSK[QZ4
M*D'G0=^/(OOFVG'WZUOZ;V/W>=_3?URV?QMQ3)[5WF'T(:6/_IP-5E)VC\;R
M9U7^I'CW<%%%_P!*F9A;99N<O14;?9INA_ ZOV[\!^\)'4<@WO8=>=Z%]\OK
MC[]ZU]=^_P!V_'UWEJ_BKB1_M7JX#Z%0^/\ Z9:K&3C?C"3VN(KL,_L5<L7R
M[LLQ\%M=FK?TGVC0-L,&]/9"+7M]AK='><BS=^?U-_')2?%'O?\ BBV,6]_L
MWEJ^_P!]D]N\W5P\'7&K(^1FPK.3B?B:7]+Q!?9!_7NM>X8\@9\ >X86V&91
MP>T>W\/'\CM?MUY!]S&TVB]N@[\>0_(B*\:#OZ>=?EOZ9:ON%PD_25U8_P"G
M4S.^UY5C)=;K+GO;E<)/'O*RI?\ /5(5 2\.G?0ACE\N\=N]\XY5W^A<8FG<
MS'6KF^6RH3FH9F-1#P$2)GA3R0O4A9U#$!JV@=%(DP-)4@=E'IQ$EW$-\O,$
M(IH+K<(J<!X$,=7.V("0ESQH:\-]<N<YPQN7$GFKV#B/B.FIA24UZN\-(&O
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M.8TUO]GY?QMNF_Z?]/\ 1],)B;]II^_DU>>98_V:(?ZO/OJL%?E_>Y90N_\
MS_C;*,_/]O\ ]O&$Q-^TW[_\*^$R>?9JA^?;2'JS$_G_ 'N4<Y;\>?R\?&G)
MOY?L\^?Z?.%.)O%GU_P7P&3#[-D/]6I/5U)_^G).8-^/I^7\=*#?]/\ +Y_;
MX^F$Q-XL^O\ @O@,DGV;H?ZM=>L(5^7][D')>_\ S_C78S\_V_\ V\83$WBS
MZ_X+X#7G[.$9Y]D.]9,CSY_O3YQQOQY_+>OC&'?E^SSYU_+K>$Q-XL^O^"^
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MF4_>3\9_S2.8_P#8)5?_ "IC \!\@F3XGYE/WD_&?\TCF/\ V"57_P J8P/
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MT9R6@G'7KXKT"?6N[(A=8]XK9G$J,FTUYRY:J'IJH)D1SOU!S]"92FL2R&^
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MGDX<8S#QNYT4AZ%:L"F:HY$8^KD,@<D<=B[.RMJAY?7A]<R%[TXJG TA.?\
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M3(-T,NE"JU&!6>,Y&^HI5 &&J5$>(*#HHMLC+1646C4"C;&@ 2B8XPQ-K<B
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ME:^5V_(]Q3Y(&Q.3-CQ&Q6(?O3/6Y[@_CN@KQ#SE7+KOW*(D7(DT7$8TG_\
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M,SB<C&Q'QQG@%XS^R6[<B95I,H9OQM 8B6=']@4*34BY0C;U)21CJ#Y#.WS
M'RRL/L#N!MBTGM9G@7/?05]1N@EH&J]+!J%JK-9&Z_?01IJF;M%VUJFEGPN<
MVE+8S$'UFD4ECM11&<KVXAQ3L!&ETW&&)[)CEN!GE]^GQQ\EEE@=HT[7-S<Z
M4F[ERQ<^=*HESC%Y&V,I&HE"T1B=*&%G6:J=7%K>HJ*TI K#"JZ3@8W)4]3
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MT      8&R^P(XXX8XX88V111,;'%%&UK(XXV-#61QL: UC&- :UK0&M:
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MYK-/-42OFJ)I9YI#JDEFD?+*]WB^1Y<YQ\R25L#&,C:&,:UC6[!K&AK0/
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MJ*Q[*NV62M;@S-&'4T]PIB RFM\+=/H-H:QK'L#75+&P?F*B]8  EA"  0@
M .@  #6@A $.M:"$(=:UH(0ZUK6M:UK6M:UK6O&=C QL-@-@!T7UF      !
M@ ;  <@!T 7ZPI7\5"A.C3GJU9Y*5*E)-4*5*@T!"=.G( (TX\\XT02R222P
MB,--,$$!8 B&,6@ZWO):USW-:UI<YQ#6M:"7.<3@-:!DDDG  W)V"@D $D@
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M<.<6F8PX9&(XRYL;(VBRX^H/M-*O?@Z<2HO0OIO9%G\LH]:_;Y_N)Q)%K_\
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M9 ](KOQSZ)-4JN:^A2KF66ZK>E5[K?W4 )A68;(C%JFQSKY(5&)Q /D>AO\
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MKMZCG$\&Z)E,;21>>!?'^ V*@9V\;5%U$VBP6XYV<(<@4R*4N:>,*27=&%O
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MN2]K2(RM+R 9R2< 8Z9.3G  R/ ]5J.\O4=M^@.*(]?%A<;RQBZHF=OLW/\
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M@19HBH7WX1,(J.NZVCBVLIITU:-K<6UO->BYS 8^94EM=9U+"YYSE;4XB4
MT0"!,%KRMP7PJHG7[T,+C"N"V%)Z(<+'?$(#(^YN292EE"4JAG;?;J =P,^'
MQ\UFOID<SL98C>E;$X\IGFBZ(NHG]65O)Z;H*-\J[M"CYZTU!+'*0SFE(7:M
MQMZ5P(GD67QZ,+I'8+^OVRQXV1,3?&D$T6IG CCT!)&Q.3G??K@=#X#GCHKD
M,*E,(N+;[,K_ (?_ *NG]<T__&JW\*XF]AGWZ+M)PK=,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$7EO+XRQQN4.\A>&MB:4@?>J<WEP2-;<F!_
ME*%JXXA,2'Z;_2,-#KZ?GGK##-42-B@BEGE=LV.&-\DCOHL8'./P"I>]D;2Y
M[FL:.;GN#6CWDD *#UH>J!P-47S!<JZ>K5Q6)O< QM@*]99[AH\/G6TIA%=(
MI.%*H]VO8,*TQ*$D?T4#*UH6];K;.S3CN[:32\-7*-CL$25\;+9'I/ZP=<7T
MNMN-P6!V1[(.0L14<0V:FSWEPIW$?JPN-0[/AB 28/3?&#SPJZ;.^T3<MQW9
MZ2JZFM^T5Y6]A(4NH(]7D=6BWO>B]$+U"^32( 1[\>[YB(D##H6O:68+R'70
M;;^#]Q/4:7W2ZVFV1G!<V(U%PJ&#KJC;'34YQ_5JW ^(&ZP=1QQ;H\BFIJJI
M=T+M$$9]SB9)/G$%HG^%.]5[HK^*YBX8%%V-Q^B.3ND&GDP+3Z,_O.R9U(S8
M-7>A>W>A"VN9S0##K1F@%EZ%YS?\F'9;P_OQ+QMZ3/'[=-%6T-&78]K514XK
MKA[M$S<<LDX5E^47$E=_ZOL_=L/*1T,TN/\ MI##!\V?)05Z(]/;UF>FK !:
M=TU.HFLS6L#:UZ7-U@\\QI.V-"$Y<:WL?W5'YHPMI9B$2M08(P"94>9I2'YE
MP4GZ'HO=^'^/^Q_AN@-LLUT%'1LGDET26_B"I=++(&"2?O9Z.>0A^EH +F@:
M?5C:W&<1763BJOG](JJ8RREC6Y;/0QAK6DZ6:8YF-R,DYP2<[N)Y=C-'1Y[B
M5*4_%)*D$@D<9JVOX\_H1J$RL:)[98FT-KJD$K1GJ4BH2=<F/)$H2J5"8_8-
MF$'FE""8+Y%O=1#5WF[U5,_73U-SKZBG>&N8'PS54LD3PQ[6O;J8YITN:US<
MX<T$$+J-(Q\=+31R#$D=/"QXR#A[8VM<,@D'#@1D$@\P2H2]8>E-RMU],I59
M]C-\P06C(HJGC2.7,DJ<DZ9D-:VDUL8'4F-;-TSKCFD0BE8DJLO:=P&3\)7K
M99@\W/A;M1XHX2HZ6V6^2D?;*>J=4OI)J6-SIA+*):B(U..^8)1E@>PZHP[+
M=P%B;EPY;KI+)43ME%0^(1ME9(X!FEI#'"/.AQ;G.",.Q@J%]9?9Y.48H]K5
M]AV#9UK,Y[4:C2,"D]'"RT+D-6C.+=].49,+7*1DI2%:+2$X7RH]+A'CULY.
M3O6XW+M_XIJH61V^@MMKF;*'OG:U]87QACP8N[J06-!<YC]8]8:-(V<5B:?@
MBVQ/+IYJBI:6X#"1%I=D'5JCPXX (P=M\\P%;NBYWB</YD<^8ZU&?'8D55,H
MJ^*'.RE6^G,Z-^8G5I3*ER@\X"QR^3.<]J#="/ << &R]& WO0M<9NUTK+W<
MJR[5[V/K*^9U14/CC;$QTC@ 2V-N&L&PV&RVVEIXJ."&F@!$4#0R-I<7$-!S
M@N.Y]Y54?,'I67G5=4LW,=POW"4LYZ5<_37F^Q))5/*<MKGJ68P.55>]P#YS
M=T+K<D+25)%:U:V.LD<U<(5DNQ*5:40A0K%"98DQRNBX$Z@"'9S[61SSRT@^
M[=2'Y8X][HJ.6T%'KA[5B<TYTY9@SE (# :OI]TKJ8WBV%Q9-"X0X=*R!XGT
MP97)17K&C3*FQ! 66/$O4C**>GA6+85*5<4.+3G#<$G)WV'NV'/S69M_IS0J
M32?O/5TO[E,JY[2NBK+8_#$+DL_JF21(NL:UKV&(FH^=0&61Z3G&*GN"%O9A
MK,YM*90@5?<[@G6)A*@GDS[/]48WP<[D\B,=?WJ*C_Z&E5,UWT/;=)] =)5X
MV5KT''[MFD,>;FF,Q0/Q,3J=754<;XLY/)ZE_;'])'$D8B"N42AYE3HX5RA>
M(FJ4&:=QK"BG7L1@;@C( ',YZ?8I=]7<?W'.^@*@[#Y2MF!53T?5->3FF')'
M;\ >K'J6T:?G[JRR-9%94U1>7P>6LCE&9:PH)3&GV//X!"5Z5-KLA6(E(!I2
M@$8(.2#@['&",[\CX^2C ]>E#<%VRCFAUZU[<MRT4E!I+OL)4^58ZR>@Y^OZ
M&N>2H1)'N%2J#R73I ZLJVNBW2!P2)(7%8\EIGIVV>\IVAP,9"B:L9P ,XYX
M.P]XP<D G;IR6I8KZ'C\W_N2T?(NI)YOBSGSHR[^D*6@$(D$[A%[QV1V2SH0
MUXSJ+M:),4[)_P!R"7.]I2]KE#26ED4@6V$L*<5!'P#C513KYG U$ 9YCG^R
M01RP/AYKU(MZ(2",RR#0USM%BM?DVMNTGSK6,4[>D77VU)5R2PZ3>8%:-?3*
M33!S<FZ7IWNR' -E-CL]-2HW2I8];=25KNMVZ;*=?7&Y;I)&W78\O 85@'!O
M&3WPRU7/3\:GK?).9G:T'.PN;8 >S*TLIHQ@F6C'2958KD9J]65+(8V2<PQ;
M7ZA000]LS4K5M;LM=0Z1#1E2YVK!QOC<^)\>2GYA4IA$PBYGNL; I6$^J5+)
M7?EYWA!HG7A50.HH0GYBZ\NMBL"+.59&I9%6$#E%+R^44<VU/)#U@E%MQ.S>
M?9#*G>0/#]]SR32=4UJXH58]GD,]#D C?F01GW;J>W#_ %IPX]6KOF3B6!VV
MV1631ZP[ID UU/\ 0%34W6"Z.K:XC144B<>O")PYGB1,VU(3GAFA51-"2'(E
M4:E;TXM+6[OFU3R4'.,DC.PY@D\]]O#'UA6FN4JB[,\QR..\D86J0S$]S2Q%
MA<GAN0O,I4LK:<\O*>.-:I04N?#VEG3J'5S*;"%1B!M(.7*@E)2AFA*E>7$+
M%KZPM/@H#.H;.-1AY4QR2;B$G9)+J/2%%X^<87S;*N6Z:7E)YU\RUK_EUQ'G
M7Q2 ><(N.C[,K_A_^KI_7-/_ ,:K?PKB;V&??HNTG"MTPB81,(F$3")A$PB8
M1,(F$3")A$PB81,(OP88646,TT8"BBP",,,,$$!98 :V(8QC%O00 "'6Q"$+
M>M!UK>][UK62 20 "23@ ;DD\@!U)11/L_N_C6FOF"[%Z6I]D7I/=\RQI)DU
MR23$^SSY^)%HL:]2/6_.MA#K[K\C%K80>X6MZS:;9P/QA>-)M_#EWFC?C3.^
MCEIJ9V?"JJA#3>?Z78$$\PL;47BUTN>_KZ5A'-@F:^3_ +N,N?\ V5719_V@
M/AZ&?,)X(@MJX%H?<%*ICD/)BS <(/GQM0OGKG''M.4/Q^B,F,K#/K^D3K7U
MSH5L[!N-:S2ZNDM5H8<:FU%6ZJG _JQT,51 XCP-2P>:P51QK:(LB$5-4>AC
MB$;#[W3.C<![HS[E$LWUN.U[W,,1\A\&.+L4:8).G>G%LL:X2@!\[!\VI_!;
M-!6=J$']87SKLL1IAZ\'GG@UO6]J'8QP98P'<6\<QQ. #G0QRVZT$]=+?39:
MZ:4'^I$Q[A[(:5C?RMNU8<6RS.=G8/<V>J'F3W3(6-QYN('4D+\?@3[0KTQY
MT^S9IYQC3C]2"]/L!K?:,HW]803:[;YA:Z/8-;\: Y* J0;#Y+#H6]C$].[
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M.42C+;/VF6FN47JMG-4+D<UFB6&NDQ<)!)F-M1,3O#V$U>B4E&W3/QZ>/O\
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M-=4<P2Z[@LKQ5M0V;/+3<E7W)8#,6>L(9(^YRDJ0_(-#(P0IJD,7?]/ Y,D
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M1.BH^<S/+X^IV&XHI!)2G-$M<M,R%[B"XAM2J=>0&K0?-[*H$#H[/B' ;?\
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MC[2XQ[=1&1+ERB'62/<!@:MUK^3A>7^6&.<C$ID\^2.,:,>/NEK+01]D*"N
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M[]%VDX5NN5+ULKP1=<713?!?.; MM&UX=/%ZR2GL"E,8WI)FY-!C8"$$J#!
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M4;^;^;V3G F\B622.LDU>/2%M=(.HG5(D2[8WNV5[<O<8VW_ "F]_,-32-N
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F,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g686907image9b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g686907image9b.jpg
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M@;ZP0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%'7^(XD$Q
MCOQ_ZG<0]5XVV)KU!'Y.\8[*:.&\./71 1AU+;=/_JU9E4W" (GK[_VUAA5X
M@K_VU=L&2E]>/S_)X_$M]IP!!(I456QBKD1[>M(]7<*"UZB*U2T&)PD9&QK.
M+:C]4/\ L_P?[&BQ];^I?]'J7NONOOOGOXX,;WW?5FR, 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M[?1;Q'04>,[9QY]3>^"!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , B;UIVQ0'$L<@4GOTW*Q3&SIRA6\&8PRO)Q9D@D,S<ARAUN%8QR
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M*RFSK-.H1N#0P,V;(N'+TP?+./$T4TD?46;-!\6(K,Q(X@^; DWT]?DNILK
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M)+N'&N]/6T3_ &DB90>&0 JVG!XQ'=<RWW\,9;Z/N73J='>#&, 8 P!@# &
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M!9I*GP@AZ@/1<>#Y((@IGUFNU>:Q=08Z'2 V,DOJ4_\ V_->2_F='V#&, 8
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M^J/RV^W<NEP4& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@%+5)C).P^X75S@^*M$<.*\15>_BCFP)A"Y-'"X+6XSC/<A4PJ+.5R\*
M@6I=J39K1J=)M9.I,&LH.IH>@# 5946?U8[]\MM]NG7_ &_,NEP5& , 8 P!
M@# & , 8 P!@# & , 8 P!@&.RV7Q. QHU,YU)X]"X?&V"Q60RJ5F1T>C@(8
MW\_%P1,&R[EH-&,4//?/573URB@G^/GYM_/Q\P"LA?NB[.JEEH]\V:=:S2'J
MJ[M'O;/0S&2P7EP7IKOZFN\J>,)I#;2Z9?(;).T&R\-9Q.KU7J;?92U%&RGN
MFPMC'5X?AW_/N7YKP->6+0O.W&01KV3W)/;"[GZ;'&1D=J0C8(8::(/[:E+C
M^&A]4<:\Q@_-:[KR52HLDDV"J@196<-T$GYV6V,J&'F"K5^8RWLL)=^-MO-O
M=_EX(D)R+S%9&\\,]I]BZB2W7-C@5 ,;A0M]J<@O(M.O7&A!E1%7O?=?&Q*0
MNM]6Q"Z+/:HHN;"ER/K0?LC#@H1NN#>W*NG5^;\?3P7=ZEC&"HP!@# & , T
M$9ZFYWCT_LJKC=O0L9.Z:JG:[[9!.R?B?^7%5ZJ/-=YA-"?Z?H>.,=$F#I]N
MT*$&Q303HF9V8>"7#=ZJ&'X>7S\#097Z;<:LZ2\Z%#6BO,*P3FYZOB1&,1.4
MJFP$BB5926ZY>E)(F9$A9-'T8U3L/D5FNOW46U=%8FS9NHPU//3\;8F!/*\X
M[_\ ?'Y[>IHOZ!1!1UU=\F[)1G4U]'H]K[Q#2O&Y03[69!0IRQU*>1G3D5^R
M[F5IJP0&; Q91&1I"4X^6*ME@KETX;OVHF/2?_BO_J);;@J, 8 P!@# & ,
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M6BXB[F1/'0:3S22&'#XT6?L$DA*>B(X6C]2>RSB.'W_66?7N]#I?P8Q@# &
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M2AR<!Q\_N$'LT(QZPV49*O6'OLD\R?7OCRY>^^4\_O<EYQ!\\8]4M <4M>@
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M7]7:46G+%'L@\'J[:Z[IQ<!N"AH_WS743'!Z6NJ>OR%W)OKT[ET2^7[9+S!
MP# +/M:LZ3A!RRK?GT0K*OXVV]='9C.9 ,C,=&)?Z^)^.2A9RU:^+N-_/$6C
M7539T]<;:-FB*SA31/8,9V6[.,K[+?X@V@N@N:[HY6Y3U\D$5LL<UALCN>2$
MR\9)2$*E(Q3L^.JFMAHUW)U6!,:UV:$)+<:U6A"(1R3:1X)-/'6FR=Z79]I3
M[5S5+GAVCA%.:I\RYW",\1<E%MQC)I-[/O,L:<UEI?&HMQ3RES8?+SR[EG&>
M7,DGT*3/F7\XJK^J/8_E%B[HG,,K6"TF1N"Q9"T%NI&>*-([-85#FD+CCN3[
MMF,?/%?)]N_1*D1YP0%0'$OX*/OU%EVJ7H7M'K\)W&HZ;/A35-3U6A'3:=.[
MJZE6O:[I58SEV5*E4U"G3KQ?9OFJT::]THR:5!0;JPCI- 6JT+:Y^E+6UM:L
MKENC"WA1@I0<?CG*-"4H/=)1FWVLTLU'+$6_Z)_&'SOY"X"AO\H\R4^!ACMZ
MS1:R>?O]/W^T)OZE[HILK+9Z3U5.$&^[K79XB":K,(N+<*J_L@(6CM^CYYT;
MB4I2W;R38P5& , 8 P!@# .<[I3YA=%6AU1T9<"?'_R;Z2B%ISJ.R. 2KIYS
M:<:N".1P75\"B#N+2+>M*(+CS::4EC9XR.*F9+)36H\NV&[$FXY@/$C1D4L)
M)2FO%))KJ^F9+&WEU)8\&\V]Q<]V.%C$IK+@7FOD$3$;+?E*8XX,V.=<S*YY
M<5KG^69P9_S*IF(N1"$<CT9E0U?6/RUJB54D#78N%+;C1CD4(DT]\RE+*W:2
MVQZOR(P=D7CV30=__2@B$O$E*TXA\II/T'04!CL5\!1*F2C6U+(BXH^D!<%9
M&E.+!!!8SM)CTZ.)):%'&O[,UCXR+C&@O82DFH[?YTF\]4\9_?=XFL(' NE^
MPJ7ZUYYH7I0_<4.I#J6M_P#*6\K/N@X1.FPTVX8CLIDT9_S>CT;F*TF;UST+
M:(68;-WHMX?C(1N1:P.1PNQ(Y6DGB8/"Y6UAM-M8_B:6WHL?GG+SNWMSK4R1
M^H?S.XNE=(RR&O674#J^H/;KJ504O#K-A\=YIOB"G=@\=!'"<OC#EG*9]^WZ
MM9DP$.ETP;UVV1<,G3%TL(BOAF\KHEC?.\HX[L=S[SH!P4& , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & <]_4_P W^D+7ZZZ)N<=R'\ENE8#:
M!JM"%>GNL&$Y#7-%A<4I:NX&? 2 C7O/LB\D35>7Q@\5!OI!,)0291]V)$M7
M(H8Q: 1@R*222YIQ:SG&ZZ]WQ+'V=3>W&O-7?]#3<3&4JQ^</*/,3..VZ</U
M=R-O9$@1GEV2\1!Q5?3>5!YI3=>N&[&'I1-P@4TBTZCSR0CR*;,IJ_\ VT.L
M,$-Q??*3VW:Q^/,_R(+:W3TF+J1]6ES];6(HWDOW/D'*MT]$ #:=.EHW2+2I
M'4Q2CD%*LR+Y.CH>8L(#'(V)0"G?U@X^0KA/WUZ3.NB+X3A9V27P)I8SEYQ\
MWC?\<$AN)8=UWU7$?EQV+*+'0,A8/6TO;V81/RPR%/V(,W+V5#@LS(Q85%7
MN5OI]"_(')&I(3)8 T>%?'9F:M9\'TC(08(>$Y+'^W1XSGQ\<]/%Y/KQ7UH7
MZC^QO4PJ6TA*Z G_ #UQ96U-SR!2V70:</$CJMR&[):OV<AKLL<C#MBY S\/
MYKXS*.MTE]%TUMM%-=DM E'EC%YSS9?Y%_\ @H, 8 P!@# & , 8!7OT1W*I
M%[$<<P<HP+3IOL)=BU=$8&.+;":MH405U]_@9]U!9K9N_8UO'-$?S$!4+:)$
MK2GNB:#&)Q?= @F::B4MLMX7XOT7?Y^!'PG\<J5Z-'+S;Z*R:6=<]$'5FSUS
M/&$PL&GH54C%/U;?RMN=(37LO"^U]6[?QPH@5V*$3TML%XGK(9T;(D=1[<3]
M%K=W=C6C<V5U<6=Q!24*]K6J6]:*G%QFHU:4H3BI1;C)*2YHMIY3*U(TZL'3
MJ4Z=2DVFZ=6$*D9-/*<HSBXMI[K*V?3!9W2U+59SM5T.I:E(4'KRKX",]$1.
M(@]7'\",:*NG!!VINX>KNR)(D3)/'I4R9*O'Q<T7?/2I9\\(O'+E7 VY-RDV
MVVVVWEMO=MM[MM[MOJ2;.WWU3UVWWVUTTTU]WWWW]\UUTUU\]]VVVV]]\\UU
MU\\]]]]]]\\\\\]]]]_#(!SP@O\ $[?,0C:DP@1^0VE#85'/Y@T"7<6A;(W7
M\W<1W5SNIH# P<_*[58(2'1JHK#GDDKP,W.)_E_B-A2KADD[^JI95Z5M1NY.
MW=&M)Q@H7EI5N(M<V.WLZ=>=W;1FHR=.=Q0I0JQ7-3E)--Q%J525)*?/'#EF
ME5C#N6(U90C1J--I25.I-Q>TDF5^=1_XL:*HJKQOC#GHD95>*>,PMF= ^N&6
MA9RKO^BTWAU&0,HK+96W*;;>^A'\@GU?,5G*/C AXT=+?I)_)G]^!G5%][7G
MCN\<M[+\?0I3MJ@?IU]*[IB[OM2<6X7GTP3]D--\CC13#VZ/(J^]33:REK0+
M-\!KKE.KW*:K=L:N&_RL'4W'[ID1*%QDF>[5])=2A!?#AM=9=WIGO?DOP.DO
MYV_X:/F&C/VRT>OXC$KLLC^$]]#4\X<.I=3T \<H^H[;R@@9'B7%V3CQM[YH
M2-$H[$JT:/\ ==:*58-<H-3BHQRJR>R>%OY-I]W[R_,O$Y4X$X[XB3F&O*]"
MPVGUY\Y;.9@2"J'"YLYJQW<*L![@_*2YXVD$'K.W2P^/M'[<&P6<+K-!R*JN
M^VPI*4I8YGG'0F!@J, 8 P!@# & , I?^N5I=.UD<Y'5Y!M$/5=RF9I8B*QB
MY9]7T)Y#=5TS%Q'::)=#-YJLF;D!!)9T ]J]O6J:L[8/596['_E9>OO-Q>&-
M\K*\EF7ECN7GG;'F;0^/TRLF=<I&#EW3>Q+"O?\ SFGC.[93-IG7$[BSZQ46
M$84>ZT6=J9RY@>E#IA5@?\@"PO\ #_M6VQ=D]:HOTG/GH324MMEA87EYYWSX
MEF2T5B[@TZDCB-@5Y$^ ZQ5Z?6#CU33R+ZNW#_6-NBN[?9\X ZOG;M[J'57W
M'^.W3ASXW_664WV%#U\(K^!UE'T(G6\)B-?19JX=NVT:A$;#12/MW3];9R^<
MH!@+)@.2</7&^Z[M9-MJHX6VV56VWWV]V] HE^B</_4^P/Q\GWY-?P:SR<P_
M\_[['==__/UA=)KS3^6=[/1EJVOO[;[[Z=0I<C'6WOG@]W9X4F[910^+Q^I/
MT7S^)>7=Z[YZ/&W01@H, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , IH^OEN="5*VY5>\K6L'J2[#-L'&C [;MB5U .3G4%;AAZL^;=)>3UR@
M^D K1@HP4A(^N]5+%;&_7SV-_E525\W%H)-O/3'=GF_]>[KX[8,L^-=@V797
M,MB2"\;%F5I7RCT1.QEU2TS/*RL.MG4Y0B%=.D4.<351.W4*8T#I$'D57B8%
MKXT)B9$XF")MFB5V=>[A-)/;IC;9IX\\]_CW>!969J>K)''91$)#6E?G8G-R
MRQ^:1<S#8X4CLO.N56:[@U* CT:N-/EG"XX>LL1+-G;Q55BS4W6VW:H>Z"N3
M-!PX>''L! A@S%BA;-J.&#!S5!B/'#V2&C9FQ8,FVB39HS:-DDV[5JW330;H
M)Z))::)Z:Z^ 4!<B1'^6OO=]'2GX(^?SGS;4\C\]2/QXSO[^23B0?XKL0EFS
MY]'%/_1_P_9Y+'JI,[)^:$]8(L+(#Y=)Q=_4A_[+\O)?F_MR=!."@P!@# &
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M,57!DI22!'G,@:/Q30<\%H_5G_XK_P"H]Q<]@J, 8 P!@# & , 8 P!@# &
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M\\\\\\\\\\\\\\\\\_#SSSS_ $\\\\\_T\\\\_\ EYG!FV/G & , 8 P!@#
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MA[,Y3Y75F;"7<P.C8DB/D9UG'8^D/'.#TS5D+<,Q3:, ;@0V5>CQ>+^":_\
M'\)+NSGO\,>?CTR++(MTE%W"J:""*>ZJRRV^J2222>ONVZBBF_NNFB>FOGNV
M^^WOFNNOGOOOOGGF#&?;3?13351/;7?3?77?3?3;S;3?3;SS;7;7;7WWS;7;
MSWSW7;SWWSWSWSWSW\, ^V >I/'P46$$)#)S0F. !+?=V4.'B3,0(&M4_P /
MSN2!(@LW9,V^GX^?G6<+)IZ_CY^.WGXX!_/1^P'8M9=>_1NRI-RV1BUP1&JZ
M%A]&2262V2H,X*^.QV860>D!FKWC4<9\/5NW5E*(V2$-=6K"2EQVQ4(^=@'
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M\-4UZ_H4.)-$YN%].AJ?N-G.\HNZ^F-*5M9:#SVMSRZS3N?=.2X4FNGSG?\
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MEH+B4>+O-=E-=E4DTOS*:B4F^BSCKY>O@0U_S/\ HCU]_P!BCZY;_/RCW_\
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M#A!#9H-'-$_=MMM4&C9)/\VVV_NONVVWOHQYSN]V95@# & , 8 P!@# & ,
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M!N67BHLM;96TE_)_/[5OF'*_:E=])V*]J?ZI?,NT*+ZZIQIL]]NKE9X?/W5
M@K+]77RV:\<582#=1)5*S_*J]_FBG'?0%9M_X?5.7%4?5-V&H../JS33WP]O
MD\Y6?7#\"P&@[IZ?:QU:6<4]54O];*'!^^)$ZQLZ91:J.S8"W3VV02!*VL %
M,83)Y$W\_-LL!O\ JVJY6Z41T3)S[5979?80TLX<7!_/'=W/?['WD:I=_B3J
M\A=R$HA)>-KLB=2P":>5O=\_F,NAS*S:NG PFW 3ABC244;S5&:"8!(%U1AL
M@%LQ D3_ &\BXC((WJDU3>\_<<3Z1;:Y;<.UJ\XZE=4U4I05*;I)R4Y4Z<ZJ
M7+&I4C"4H+==%)Q<H*7K^D>PGVBZY[+-;]L6GZ9:U."M O)VE[<SO[>G?35&
MI;4;J[M;";5:O9V=6[H0N*JY9)NI*E3JPH7$J4Y;-^ILS Q-].('Q%<X" #O
M/S.[C[8G55\"4XV35TWW:+[O+JD#^X%M%]=-E=6[:E%'NZ7Y?4&ZVVWX:] >
M/J/=E9\%F3?IC;\3G$^C/T%[2^A'/TKA%2PZ(WO1D$G$/G-SMN0:"Z0GU.ZQ
MV!GT3#Z.3SJJT=:Z8S#0441$EEXW77.9T.22%O)&ZD7[+']OXGX=3MZMWIU_
M:T*]6UK7%I<4:5Q0_P"]0J5*4X0JTDY4\SA)IQQ4IO/U:D'B:ZW@75M/X=XT
MX4UW5=*T_6].TCB'2-1O='U>3CINIVEG?T*]Q9WW);WCC:W%*$J=9RM;N"A)
M\]I>4^:A4T1\J?CJ[^GQZX;AN-U:?,7/$6(0@'"TJ\CD<8&[:D[EB:_GU]#9
MY*XZ[;QI,"P81@3*2\6C)5A)O"S$&^(.5HT\03TW".EW6D:+1L[R]N;^M&K7
MJ*K=0G3G"$Y?#2A"K4J58TXX;BJC4FYR:A&#BCTG^T3Q[H'M#]INH\2<-\,:
M'PM85;#3;25AH5U;7MK<7-K;\M:_N;FPM+*PK7M;GC2J2LZ4Z$:5O1BZ]>NJ
MU676OSK\3_FOS4-CS6,\X1^QRD8]W5$2*^R!2[7P]\KZGLJ4"A)\Y+0B)DE=
MTDE%',+B<;_,LGHO^7Q;7Q3.G/"7.3SE]>N-L^N.O1=3F;^H?<T #_1:RYQ%
MN4^(9V)X6D4,@WB%BP!603NX7D3CT>DCMF0DD=E8Z/@TXX1*.(=4+1]#9HO'
M)$"47?-E??/8V.Y#6.)WIG$6B:)]$7%W]*<N+^F\0M>UJRH2Y8]C/M.R4.VN
M_P#%H]E;RA/X\\I^C_9Q["H\<^QGVG^U%^T32.'O[BNMS\)7<'*XUQ66GT-2
MI.XK?2-LK+Z2J7$M.X?S8:A](ZO0KVB]U=/M7TQ":&^@?50H8>Z8Z@;\H5U(
M![,G[S[Q Q?![%3'D&Z;]N(L'JRS@ZLZ0,MM7'@\XA4=<5,L@L@LDQD2NWY7
MGO7GYP?*LI++\7_)+/XMY\"67//$G+'*^Y$A2--1>+RT[^?:46:4_<)I<$R6
M5\U_77F=O3=[(K)E2B^^OZN^AR3O6^BF^_J"*.NWNN"&V^K_ *?9T1*C! P"
M-O5U1<P6_3,G'=<QNO"].QEHM+34@L5ZUCS&OO0R6SC^> \\V>B2M=&P>FNR
M[.91XZ"-"O?QV:%$/=O?S"4VGMU\CGF923Z7V!7TF9\M2WJ2Y_EXA)X^B/M8
M^A$XA]-+%ISQH:]F[3E&5SEP"<SZLMM/!'L5M&V ,3Z!E(ASNC69F0N-&4A4
M%\177'-X?Y<_Q8Z/OPLKN:BLHN_^?<WXD-4<SA'#_D8CL&KMXL)EU7HC"T6M
M&O9JXVV].,[NA<Q2:V8(LM^^;N%I"6L1JI(9,]27+*%C*2NA!44><[_UV\GT
MQZ;$[,$# & , 8!SR?8Z1]FU7=/+=@TA>XXA%#4HE(.ON48SRCOT?=,SL[2K
MYBW/22(1+24Q*/S:/ XDY=$S+R:RVNVU8M71DVWE$C_=&$15&2'+NFOGS86/
M/9O\\LD9\0QHX=RK9/J$K_C9"]Z7LIS/JH_\,XCD3_PV3Q..0!@>H[>AP4@E
M(F).6.K)G83M8<?(L#+JQ%2K5=71UZNN*S>6O3;XN;/7O_#'=C!<?@J, HVY
MW#,Q?W2[6=MA9(>J<X]JPF]<OZ)'5"W+.=;.=,/'XN9L1[)?H)CX@R19^VR3
M7)/6SIJYKGQYXU@C=JW%G]6/_MWY\.[N/0?3+[:^<&WX"YXKWG3>^9BS@8"S
MK*?%K-3J\-&XY*"IX='(['5O(7-',AEQ=&-%R2V[IL( !FG[7HJ0(.B#IN)Z
M_A3@?7N,_I/Z$IVT_HJA2K7/O-PJ'-*OVWN]"C\,^:M7]WK<G-R48]F^UJT\
MQYM7J6KV.DJV=[.I'WJI*G2[.GVF.3D[2I4^*/+"':0SCFF^;X82P\;4JR\>
M[OI)74-L^B4HYP)RI9(%C(8[:LLTBMV]<6%&22?ZB1"#P)FN3I.EF)!+U9!H
M=G12TI0CYX@13A E7;377D#:XC%X>9-/==%]O5[Y7=Y,\))S\Z_G-9"PX".G
M_4??4V'>;.VP[]ZZR[YL=!9+S\5SII^NZ<U3"'+=?]118P1I^F&#-+;9!-FF
MW\T\?S_?[_W(S)K&<1^R.WYO[6_,V3_EC]#>P_\ OW?8.OSZHE_^/OM)\ZR8
M7->KI4,W_P!/&EC]+;,5X;4WJ_Z2:K@)0P S(6J+E9JWN+173]3Q^_W^_P"@
MRET7-YM;?9W^67\B':WRR^(\#[+@H)Y8T? 7ZR+QJ=,N4Y1U:J6UG\W#_P (
M=!SF8UG-I08L682@NY8,Y40:OCFXR<NFBYTZ!/:+%EW.SAK6K4M,K:+3U*]A
MI-Q6C<5M.C<559U:T7%JI.@I=FWS0IR>V)3ITYR3E3@XX)6U"=>-Y*VHRN:<
M'3C<NE'M80EG,%4QE+$I);Y2G)+"DT]Y=B_>C@OE1<[$HY/&?1MM!?U&SN#U
M >CSF,@2GFWJ2;";6V4?MZ_ O/'&BJ#F-@R4OL9-5NNDS@3]=/U#W6'T*$GW
M87B_+RZ_R\6B@CH?M/[<_0.(R>10"KI%R=R:R'.2<CG1B0O^2:780OWSS1<U
M+^B+9?5Y<EHAMV;S=HZ7K-*GPZSO35F_@TK:;;Z*#)&,(]6F_!+F;SX+IT]3
M6?SW^.G4W3K[PLFK4M4\RD&;U IU >J)U.)[:K60MET)$IRQ +PB\<C<:%EV
M+Q9 ?T9Y0-0RI3U\H6CTAL[^#])/WY"4TML/.?JYPMO]6&_LR\/9X[[@?G?\
M!YYR!UU7-_6=T-#;&A//#>8(TG'X;!S$:E$F>RB%'*W9FK,<$R[\4&_8XC(2
MFWH&*[DVY>0*,R*Q5DQ8;"WO;<0\>:MQ)H.@\/WM"PI6F@4J5*WJVU&<*]QV
M%M&THRKN56=./);Q2E"A3I0G4;G*.U.-/1V.CVFGWE_>T)5Y5=0E*52-2:E3
MI\U5UIJFE&,GS5'E2J.3C'X4]Y2?39G$FU& , 8 P!@# & , 8 P!@# & ,
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MGGGGGGGGX>>>>>?Z>>>>?Z>>>?Z>>8*GS@# & , 8 P!@# & , 8 P!@# &
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MQ7I65.K"TI5:E.A&;Z,///P_T\_T\\_T\\\_]LV9P8P!@# & , 8 P!@# &
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M+1J#63$BA#B"KW<S,3K>4[1^?2/RY3S?25U=Y(3YD;I"$PB B/*ZQ%C'(_\
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M-&J2KAPNKMJFBBGNIOMKKK[[X'*_&/WX_P!3P(K]8JVG,8CDUAO(GT<E,0F
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M&Q[S9881C+LB?-.';!RR4U=?N3M%?91NIZE@9?\ /YGK*%YQH_F"&.J^H.N
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MW6*T"F0!FK7W-=.@XY6+.R";2PY8,!EBP(8IZ#%0ROV M[(T8V:,%%$W"/\
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M\Y2$51,S5L<%W]\]K&C]J3TQ7B$%CES2(5*8[<@)Z+ALSUE/D0+($_Y@A^R
MD@3:>#T13U7=RZW8"\9)+#[I*7CG":QU7[S\[3N;JA1Y]YWH2A&Y3TXWI&EZ
MMJ% UZCZW],(UK!P4,2*>M]MU-D/2&@75WZCLIOZE^M^3W?;W7\WHH]VWXFZ
M, 8 P!@$.^ZZDGMT<^%8A6]4\Y7E)6<P@$M\J3J<.4*5//141E@PX7 *O!FK
MS2-2MPP:+*0Z3EX_+8\*/I,_#L:?#7#A9H)6SZM==UUZ?O*[UL:.^8_)UD\N
MP[HLI9,6KFIG71'2TRO>.\[TZ;4D58T''#T>BD=90P$9UC4-&DC!%2-+2*4.
MX]%@,=V(DM$!0_31NJJL)DT\8WPL9?5[M^/GMWX+-<%1@# & 0Y^@]%S7IGB
M7J"@:V_9=9_;E-3.!Q%21/E!874T?'^MF?A,DBT?+,F.RWFGKA=-HX]T\U\V
M_1W]U\\P3%XDGX-/[&5?=L_/;KZ:RW:;\Y#:=EI*[/EM)OE]<8VR+ -P5O6(
MZ5'=#K:ZHTZ&0F7>SAF$3.S(:1B?B (FZVV!O6+ASYZZ;MGG_P %U)9WSM+F
M7GCN?AGQW]"[FDZU:4Q3-1T\P(*%F-3UC JU9%%DO$%B32"143%VY!5#S=7Q
M%1XB*T<;I>**>)[*>Z?GW_#\WHQO=M^)L[ & , ^-M==O/PVU\V\_'SW\-O/
M/?/QU]\VU]_#W_3\==O/-O/?_;WSSWS_ %\P"C4)PAT-">4K]KSVGN2^@9?+
M_I#<G6X.G^AO"TBJ^<U)-;G<SH:$T-H"EFL#MI2../=@)T[$YY$X^;TW8F@)
M@>]4>LQ?F3:?Q+$5'*ZY2QX[KYK8E#\PN4;&Y2JJ[FEE J_KLG>W4-K=#@Z)
MJ8NN?K+GR+3]O&6 >J(D9WC\39D=!VL<6/&7 &+QR,_OI\BD##(-4O73P1)Y
MQY)++ZO!95@J, 8 P#G?A/&WT'MSL&\;=[+JJBY/%[:B%R415%@!>@I 5=<@
M\ZV!##\?3#U'2F]6,01NR)H[6%>6I8I.:L3L@:+J#ANX6/LE0A,7S%)8SMAM
M86[VS\6<X\%C\=S87S:X*ZOI>]JKM#IT?4D:&<K?/^-?/BJ4*PG9J=+6T/"V
M4+F1&ZC216&Q#V"MG@*)Q4&.AB^YTCX_7.D7CULE_ M_!,I)II9WES//<\=%
MX]7O^W>]@QC & , YX;&^9G4D@ZNF@,%I5*G(]K_ $=H'Z/RFSWTW,M;2C1&
MGXL$;RFD6M9)Q!=B6<S*8Q8,Y!S=&:M!P*-+/?'PQT553;-1?F6/-1<4N[?.
M^?F\K'7UVZ'L%!@# & , JZ^C'.]M704J.0UWR9Q?UX*BT=N*(GH=U%XYC\R
MA[FS8^%%B995<_=QN?1L4&T=B$_\R8XYA>DAD(]B#\C4E&.FRNR0M%K?+DO3
MOQG9[KY/NWV)(<'<]RSE'CCG'G&=332P9?3M5QN%2&5M]WJHY\2&M]O5F010
MEHB04C@']76/QK=ZW9NM@ L;LNQ8J>[,T!$GF3?3+;^TEK@@8 P!@%3O6@D;
MV9?=!5!1TF DK'^=O?/+?1/4<>/MI+'?8S )%2UOD8WI'C#N.[ IE(#8J7"7
M[4<"*.D&2&CMN8?#'R*;-863PGG_ #1:7VK^A$,O\R^I''5CV/,M*I]Y&-?5
MR%?6=[;"LW,Z6JRE,4@HMB[H;6K/(AL/<?N5A 1)%K-=)RF.:Q'5SZLP4+K^
M"D1;F6%X\O+CYMYSG\,>/DSH>P8Q@# & :#ZKK:07)S!T=4<1_;OYMM&AKAK
MF*[%W.S,7I(YS7<CBX78B]T0<J,V'[B5;^/72;=?=!KZJIJBK[K^GL)6S3\R
MIB\N&>AGO-?%M9".3^&>KS50<8><RS\?T"[?B);6D^(5-!H3Y/JCLE[$9P$=
M05H9CCU271[6$ )F9;,P;N.2=BJJZ;,A;F69/,EF6=L/O;W65^?CXEI?&5'2
M3F?D[G7GV8S+:P933E/P6O#\P\V=[-S12,@68UVJ-]?^>/\ ]E:JH^L 6K[7
M1YJ&:L=72::_BFFHJWEM],MO'@28P0, 8!JN\'=OL:?LES0 B(G;MTAQS2JQ
MD^).A$)6G*S)5&/+2M\Q;NGN@!B041?E&[-+5T^:-E6+==HJYT=(@L96>G?C
MKCOP<YD,^8_=\RY*Z(KZY8/1[#KBP+0HOIQYTV7OV2V<9Z-O"EK-$3,;$+"8
M(5)$VU3U2'BHEU":RB\/T,@($S+Z?H#%]TRS\H,CE'.V>7#7*U]5-8>/B>[^
M62<?,7SCFIUQT5='6K8)!;;Z2Z3F=W;5M5DT6G,>K:*$H=7L%C$/?38A&(OY
M+)"U8P'TH7-CP H:LH62;MFB>S97\1#EC"B]DL9QUW;SC?'7Q^SHKI,%!@#
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8?7J;KP0, 8 P!@# & , 8 P!@# & ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
